,TRIAL_ID,LATITUDE,LONGITUDE,LOCATION,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Study Documents,URL,AGE_LOWER,AGE_UPPER
0,0,55.001251,-115.002136,"Department of Clinical Neurosciences, Heritage Medical Research Clinic, University of Calgary, Calgary, Alberta, Canada",1.0,NCT03981536,A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AP-101,"Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)|Maximum Observed Drug Concentration (Cmax)|Time of Maximum Drug Concentration (Tmax)|Area Under the Concentration Time Curve (AUC)|Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)",AL-S Pharma,All,Phase 1,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AP101-01,September 2019,January 2020,January 2020,"June 11, 2019",,"July 31, 2019",,https://ClinicalTrials.gov/show/NCT03981536,18.0,100.0
1,0,55.001251,-115.002136,"Kaye Edmonton Clinic, University of Alberta, Edmonton, Alberta, Canada",1.0,NCT03981536,A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AP-101,"Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)|Maximum Observed Drug Concentration (Cmax)|Time of Maximum Drug Concentration (Tmax)|Area Under the Concentration Time Curve (AUC)|Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)",AL-S Pharma,All,Phase 1,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AP101-01,September 2019,January 2020,January 2020,"June 11, 2019",,"July 31, 2019",,https://ClinicalTrials.gov/show/NCT03981536,18.0,100.0
2,0,50.000678,-86.000977,"London Health Sciences Centre, University Hospital, London, Ontario, Canada",1.0,NCT03981536,A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AP-101,"Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)|Maximum Observed Drug Concentration (Cmax)|Time of Maximum Drug Concentration (Tmax)|Area Under the Concentration Time Curve (AUC)|Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)",AL-S Pharma,All,Phase 1,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AP101-01,September 2019,January 2020,January 2020,"June 11, 2019",,"July 31, 2019",,https://ClinicalTrials.gov/show/NCT03981536,18.0,100.0
3,0,50.000678,-86.000977,"Sunnybrook Health Sciences Centre, Toronto, Toronto, Ontario, Canada",1.0,NCT03981536,A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AP-101,"Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)|Maximum Observed Drug Concentration (Cmax)|Time of Maximum Drug Concentration (Tmax)|Area Under the Concentration Time Curve (AUC)|Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)",AL-S Pharma,All,Phase 1,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AP101-01,September 2019,January 2020,January 2020,"June 11, 2019",,"July 31, 2019",,https://ClinicalTrials.gov/show/NCT03981536,18.0,100.0
4,0,52.4760892,-71.8258668,"Montreal Neurological Institute & Hospital, Montr√©al, Quebec, Canada",1.0,NCT03981536,A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AP-101,"Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)|Maximum Observed Drug Concentration (Cmax)|Time of Maximum Drug Concentration (Tmax)|Area Under the Concentration Time Curve (AUC)|Pharmacokinetic Concentrations in Cerebrospinal Fluid (CSF)",AL-S Pharma,All,Phase 1,18.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,AP101-01,September 2019,January 2020,January 2020,"June 11, 2019",,"July 31, 2019",,https://ClinicalTrials.gov/show/NCT03981536,18.0,100.0
5,1,33.0000001,119.9999999,"Wujing People's Hospital, Changzhou, Jiangsu, China",2.0,NCT03103815,Trial of Amivita in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Amivita,ALS Functional Rating Scale-Revised (ALSFRS-R) score|Adverse event|Forced vital capacity (FVC)|EQ-5D,"Wujin People's Hospital|Nanjing Bioheng Biotech Co., Ltd.",All,Not Applicable,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WJ2017001,"April 24, 2017","October 20, 2018","October 20, 2018","April 6, 2017",,"April 26, 2017",,https://ClinicalTrials.gov/show/NCT03103815,18.0,70.0
6,2,41.2966556,-7.74678,"Centro Hospitalar Tras-os-Montes e Alto Douro, Vila Real, Portugal",3.0,NCT03073239,Amyotrophic Lateral Sclerosis: a New Paradigm,ALSParadigm,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Genetic: ALS patients genetic characterization|Other: ALS patients epidemiological caracterization,Finding environmental risk factor|Regional prevalence|Finding a genetic marker,"Conde, Bebiana, M.D.",All,,30.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2,December 2016,March 2018,June 2018,"March 8, 2017",,"July 23, 2018",,https://ClinicalTrials.gov/show/NCT03073239,18.0,100.0
7,3,33.8959203,35.47843,"American univeristy of Beirut medical center, Beirut, Lebanon",4.0,NCT03427086,Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Biotin|Drug: Placebo Oral Tablet,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Motor disability measurement|Change in Pulmonary function test parameters ( FEV1- FVC)|Weight changes,American University of Beirut Medical Center,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIO-2017-0270,"January 29, 2018","January 10, 2021","January 10, 2021","February 9, 2018",,"July 2, 2019",,https://ClinicalTrials.gov/show/NCT03427086,18.0,80.0
8,4,45.77958045,10.4258729694612,"AO Spedali Civili, Brescia, BS, Italy",5.0,NCT03293394,Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis,tDCS_MND,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: Anodal bilateral motor cortex and cathodal spinal tDCS|Device: Sham bilateral motor cortex and sham spinal tDCS,Change in muscle strength from baseline|Change in short-interval intracortical inhibition-facilitation (SICI-ICF) from baseline|Decline in the ALSFRS-R score from baseline|Change of quality of life from baseline: ALSAQ-40 scale|Change of quality of life from baseline: EQ-5D-5L scale|Change of quality of life from baseline: EQ-VAS scale|Change in caregiver burden,Azienda Ospedaliera Spedali Civili di Brescia,All,Not Applicable,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NP2743,"October 2, 2017","June 20, 2018","July 1, 2018","September 26, 2017",,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03293394,18.0,85.0
9,5,32.3293809,-83.1137366,"CDC, Atlanta, Georgia, United States",6.0,NCT01772602,The National Amyotrophic Lateral Sclerosis Registry,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,The National Amyotrophic Lateral Sclerosis (ALS) Registry|Risk factors of ALS,Centers for Disease Control and Prevention|US Department of Veterans Affairs|Centers for Medicare and Medicaid Services,All,,17000.0,U.S. Fed,Observational,Observational Model: Other|Time Perspective: Other,CDC-NCEH/ATSDR-5768,October 2010,December 2025,December 2025,"January 21, 2013",,"July 23, 2019",,https://ClinicalTrials.gov/show/NCT01772602,18.0,100.0
10,6,26.5450001,117.842778,"Department of Neurology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China",7.0,NCT04008329,A Registered Cohort Study on Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Age at death|Age of endotracheal intubation or tracheotomy,First Affiliated Hospital of Fujian Medical University,All,,2000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"MRCTA,ECFAH of FMU [2019]191","July 5, 2019",July 2029,July 2059,"July 4, 2019",,"July 9, 2019",,https://ClinicalTrials.gov/show/NCT04008329,18.0,100.0
11,7,51.5073219,-0.1276474,"GSK Investigational Site, London, United Kingdom",8.0,NCT02447952,Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Faros Sensor (FS) and LifeInsight Hub|Device: Fast Fix electrode patch|Procedure: Quantitative Measure of Speech (Core Phase Only),Duration of Day Time Wear Time of the Device,GlaxoSmithKline,All,Not Applicable,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,201283,"June 30, 2015","June 1, 2017","June 1, 2017","May 19, 2015","December 25, 2018","December 25, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02447952/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02447952/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02447952,18.0,80.0
12,7,51.7520131,-1.2578499,"GSK Investigational Site, Oxford, United Kingdom",8.0,NCT02447952,Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Faros Sensor (FS) and LifeInsight Hub|Device: Fast Fix electrode patch|Procedure: Quantitative Measure of Speech (Core Phase Only),Duration of Day Time Wear Time of the Device,GlaxoSmithKline,All,Not Applicable,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,201283,"June 30, 2015","June 1, 2017","June 1, 2017","May 19, 2015","December 25, 2018","December 25, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02447952/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02447952/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02447952,18.0,80.0
13,8,49.1828008,-0.3690815,"University Hospital Center, Caen, France",9.0,NCT01530438,Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis,SLAMEM,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research,"Cognitive, behavioural and emotional changes assesed with Neuropsychological tests.|brain imaging (anatomical MRI, functional MRI, PET using 18FDG)","University Hospital, Caen",All,Not Applicable,90.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),08-067,April 2009,December 2014,May 2015,"February 10, 2012",,"April 9, 2014",,https://ClinicalTrials.gov/show/NCT01530438,18.0,80.0
14,8,49.4404591,1.0939658,"University Hospital Center, Rouen, France",9.0,NCT01530438,Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis,SLAMEM,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research,"Cognitive, behavioural and emotional changes assesed with Neuropsychological tests.|brain imaging (anatomical MRI, functional MRI, PET using 18FDG)","University Hospital, Caen",All,Not Applicable,90.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),08-067,April 2009,December 2014,May 2015,"February 10, 2012",,"April 9, 2014",,https://ClinicalTrials.gov/show/NCT01530438,18.0,80.0
15,9,23.6990775,120.5245511,"China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan",10.0,NCT02383654,Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Autologous Adipose-Tissue Derived Stem Cells,changes of ALS-FRS score|changes of respiratory function|changes of neurologic function|changes of brain structure,China Medical University Hospital,Male,Phase 1,1.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMUH103-REC2-072,January 2015,January 2016,January 2016,"March 9, 2015",,"February 1, 2016",,https://ClinicalTrials.gov/show/NCT02383654,35.0,50.0
16,10,50.0469432,19.9971534358367,"Jagiellonian University Medical College, Department of Neurology, Krak√≥w, Poland",11.0,NCT03892382,Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Device: rTMS,"Apathy Evaluation Scale Clinical Version after rTMS, total score, range 18 to 72 with higher values representing a worse outcome|Apathy Evaluation Scale Clinical Version first follow up, total score, range 18 to 72 with higher values representing a worse outcome|Apathy Evaluation Scale Clinical Version second follow up, total score, range 18 to 72 with higher values representing a worse outcome|Lateral Sclerosis Functional Rating Scale-Revised after rTMS, total score, range 0 to 40 with higher values representing a better outcome|Lateral Sclerosis Functional Rating Scale-Revised first follow up, total score, range 0 to 40 with higher values representing a better outcome|Lateral Sclerosis Functional Rating Scale-Revised second follow up, total score, range 0 to 40 with higher values representing a better outcome|Beck's Depression Inventory ater rTMS, total score, range 0 to 63, with higher values representing a worse outcome|Beck's Depression Inventory first follow up, total score, range 0 to 63, with higher values representing a worse outcome|Beck's Depression Inventory second follow up, total score, range 0 to 63, with higher values representing a worse outcome",Jagiellonian University,All,Not Applicable,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JagiellonianU62,"November 15, 2019","June 30, 2021","December 31, 2021","March 27, 2019",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03892382,18.0,80.0
17,11,41.1257843,16.8620293,"Centro Sla, University of Bari, Bari, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
18,11,45.4667971,9.1904984,"Centro Sla, Istituto Auxologico Italiano, University of Milano, Milano, Milano, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
19,11,45.4667971,9.1904984,"Irccs St. Raffaele Institute of Milano, Milano, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
20,11,44.6458885,10.9255707,"Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena, Modena, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
21,11,40.8359336,14.2487826,"Universit√† della Campania Gianluigi Vanvitelli, Napoli, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
22,11,45.4077172,11.8734455,"Centro Sla, Universita' Di Padova, Padova, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
23,11,45.1860043,9.1546375,"Als Centre, ""C. Mondino"" National Neurological Institute, University of Pavia, Pavia, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
24,11,41.894802,12.4853384,", Neuromuscular Omnicentre Centre, Rome, Catholic University, Rome, Roma, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
25,11,45.0677551,7.6824892,"Centro Sla, Universita' Di Torino, Torino, Italy",12.0,NCT03693781,Colchicine for Amyotrophic Lateral Sclerosis,Co-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Colchicine 1 MG Oral Tablet|Drug: Placebo Oral Tablet,"Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)|Incidence of Treatment-Emergent Adverse Events (safety and tolerability)|Tracheostomy-free survival rate|Changes in Forced Vital Capacity (FVC)|Changes in quality of life|enhancement of autophagy|changes in stress granules size, number and composition|quantification of insoluble species|modifications on extracellular vesicles secretion in blood and CSF|effects on biomarkers of neurodegeneration|effects on biomarkers of inflammation","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|University of Turin, Italy|Istituto Auxologico Italiano|IRCCS National Neurological Institute ""C. Mondino"" Foundation|University of Bari|IRCCS San Raffaele|University of Padova|University of Milan|Istituto Di Ricerche Farmacologiche Mario Negri|University of Campania ""Luigi Vanvitelli""|Catholic University of the Sacred Heart",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Co-ALS,"January 30, 2019","November 1, 2020","November 1, 2020","October 3, 2018",,"January 14, 2019",,https://ClinicalTrials.gov/show/NCT03693781,18.0,80.0
26,12,16.2408636,-61.5334077,"Hospital University Center of Pointe-√†-Pitre, Pointe-√†-Pitre, Guadeloupe",13.0,NCT03367650,Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies,SLA-DOM,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Blood sample and environmental survey,the impact of amyotrophic lateral sclerosis in Guadeloupe and Martinique|Estimate prevalence of the ALS|Clinical criteria of SLA|Study the genetic factors of the ALS,Centre Hospitalier Universitaire de Pointe-a-Pitre,All,Not Applicable,70.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RBM-PAP-2013/55,"May 13, 2014","May 13, 2020","May 13, 2023","December 11, 2017",,"December 11, 2017",,https://ClinicalTrials.gov/show/NCT03367650,18.0,100.0
27,12,14.6367927,-61.0158268506373,"Hospital University Center of Martinique, Fort-de-France, Martinique",13.0,NCT03367650,Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies,SLA-DOM,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Blood sample and environmental survey,the impact of amyotrophic lateral sclerosis in Guadeloupe and Martinique|Estimate prevalence of the ALS|Clinical criteria of SLA|Study the genetic factors of the ALS,Centre Hospitalier Universitaire de Pointe-a-Pitre,All,Not Applicable,70.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RBM-PAP-2013/55,"May 13, 2014","May 13, 2020","May 13, 2023","December 11, 2017",,"December 11, 2017",,https://ClinicalTrials.gov/show/NCT03367650,18.0,100.0
28,13,50.8465573,4.351697,"CHU Brugmann, Brussels, Belgium",14.0,NCT02582385,In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: in-situ cytokine expression,in situ cytokine detection: interleukin 18|in situ cytokine detection: interleukin 1|in situ cytokine detection: interleukin 6|in situ cytokine detection:TNF-a,Brugmann University Hospital,All,,5.0,Other,Observational,Time Perspective: Retrospective,CHUB-ALS,October 2012,February 2015,February 2015,"October 21, 2015",,"October 21, 2015",,https://ClinicalTrials.gov/show/NCT02582385,18.0,100.0
29,14,47.3900474,0.6889268,"Service de chirurgie orthop√©dique et traumatologique, CHRU de TOURS, Tours, France",15.0,NCT02670226,Muscular Biomarkers in Amyotrophic Lateral Sclerosis,METABOMU,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Samples,Metabolic signature of muscle|Metabolic signature of blood|Metabolic signature of satellites cells|Expression levels of targeted genes using transcriptomics,"University Hospital, Tours",All,Not Applicable,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PHAO15-HB-METABOMU|2015-A01629-40|151550B-31|2016-R3,"March 29, 2016","September 29, 2020","September 29, 2020","February 1, 2016",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT02670226,18.0,75.0
30,14,47.3900474,0.6889268,"Service de Neurologie, CHRU de TOURS, Tours, France",15.0,NCT02670226,Muscular Biomarkers in Amyotrophic Lateral Sclerosis,METABOMU,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Samples,Metabolic signature of muscle|Metabolic signature of blood|Metabolic signature of satellites cells|Expression levels of targeted genes using transcriptomics,"University Hospital, Tours",All,Not Applicable,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PHAO15-HB-METABOMU|2015-A01629-40|151550B-31|2016-R3,"March 29, 2016","September 29, 2020","September 29, 2020","February 1, 2016",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT02670226,18.0,75.0
31,15,-23.5506507,-46.6333824,"Escola de Artes,Ciencias e Humanidades da Universidade d Sao Paulo, Sao Paulo, Brazil",16.0,NCT03113630,Virtual Task in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: Acquisition on TouchScreen|Device: Acquisition on Kinect|Device: Acquisition on LeapMotion|Device: Acquisition on TouchScreen Control Group|Device: Acquisition on Kinect Control Group|Device: Acquisition on LeapMotion Control Group,"Motor performance improvement in a virtual Timing Coincident task, comparing performance between LeapMotion, TouchScreen and Kinect.",University of Sao Paulo,All,Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,105/15,"February 2, 2016","August 3, 2016","October 4, 2016","April 13, 2017",,"April 13, 2017",,https://ClinicalTrials.gov/show/NCT03113630,40.0,75.0
32,16,39.5162234,-76.9382069,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",17.0,NCT02437110,HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Darunavir|Drug: Ritonavir|Drug: dolutegravir|Drug: Tenofovir alafenamide (TAF),"To assess whether an antiretroviral regimen of darunavir + ritonavir, dolutegravir, and TAF for 24 weeks will suppress blood levels of HERV-K RNA below the limit of detection (1000 copies/ml) in patients with HERV-K-positive ALS.|To assess the safety of an antiretroviral regimen of darunavir + ritonavir, dolutegravir, and TAF in patients with ALS.",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,Phase 1,200.0,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,150126|15-N-0126,"April 23, 2015","February 1, 2022","February 1, 2022","May 7, 2015",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT02437110,18.0,100.0
33,17,36.7014631,-118.7559974,"Forbes Norris MDA/ALS Center, San Francisco, California, United States",18.0,NCT00302198,Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Behavioral: ALS Registry,,Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,,15000.0,Other,Observational,Time Perspective: Prospective,23.112,January 2006,February 2010,February 2010,"March 14, 2006",,"March 2, 2010",,https://ClinicalTrials.gov/show/NCT00302198,18.0,100.0
34,18,50.0469432,19.9971534358367,"Jagiellonian University Medical College, Department of Neurology, Krak√≥w, Poland",19.0,NCT03892863,Repetitive Transcranial Magnetic Stimulation as Therapy for Depression in Amyotrophic Lateral Sclerosis,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Device: active repetitive transcranial magnetic stimulation|Device: sham repetitive transcranial magnetic stimulation,"Beck's Depression Inventory ater rTMS, total score, range 0 to 63, with higher values representing a worse outcome|Beck's Depression Inventory first follow up, total score, range 0 to 63, with higher values representing a worse outcome|Beck's Depression Inventory second follow up, total score, range 0 to 63, with higher values representing a worse outcome|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised after rTMS, total score, range 0 to 40 with higher values representing a better outcome|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised first follow up, total score, range 0 to 40 with higher values representing a better outcome|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised second follow up, total score, range 0 to 40 with higher values representing a better outcome|Apathy Evaluation Scale Clinical Version ater rTMS, total score, range 18 to 72 with higher values representing a worse outcome|Apathy Evaluation Scale Clinical Version first follow up, total score, range 18 to 72 with higher values representing a worse outcome|AES-C second follow up, total score, range 18 to 72 with higher values representing a worse outcome",Jagiellonian University,All,Not Applicable,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JagiellonianU61,"November 15, 2019","June 30, 2021","December 31, 2021","March 27, 2019",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03892863,18.0,80.0
35,19,19.531932,76.0554568,"Neurogen brain and spine institute, Navi Mumbai, Maharashtra, India",20.0,NCT02242071,Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis,,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Stem Cell,Amyotrophic Lateral Sclerosis Functional rating scale-revised,Neurogen Brain and Spine Institute,All,Phase 1,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NGBSI-10,December 2008,March 2015,September 2016,"September 16, 2014",,"October 25, 2018",,https://ClinicalTrials.gov/show/NCT02242071,18.0,80.0
36,20,34.395342,-111.7632755,"St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics, Phoenix, Arizona, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
37,20,36.7014631,-118.7559974,"Cedars-Sinai Medical Center, Los Angeles, California, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
38,20,36.7014631,-118.7559974,"University of California Irvine, Orange, California, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
39,20,36.7014631,-118.7559974,"Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
40,20,36.7014631,-118.7559974,"Stanford Hospital and Clinics, Stanford, California, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
41,20,38.7251776,-105.6077167,"University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
42,20,41.6500201,-72.7342163,"Hospital for Special Care, New Britain, Connecticut, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
43,20,38.89366125,-76.987883253882,"George Washington University Medical Faculty Associates, Washington, District of Columbia, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
44,20,27.7567667,-81.4639835,"University of Florida, Gainesville, Florida, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
45,20,27.7567667,-81.4639835,"Mayo Clinic, Jacksonville, Florida, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
46,20,27.7567667,-81.4639835,"Carol & Frank Morsani Center for Advanced Healthcare - University of South Florida, Tampa, Florida, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
47,20,32.3293809,-83.1137366,"Emory Clinic, Atlanta, Georgia, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
48,20,40.0796606,-89.4337288,"Duchossois Center for Advanced Medicine, Chicago, Illinois, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
49,20,40.3270127,-86.1746933,"IU Health Neuroscience Center of Excellence, Indianapolis, Indiana, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
50,20,41.9216734,-93.3122705,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
51,20,38.27312,-98.5821872,"University of Kansas Medical Center, Kansas City, Kansas, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
52,20,39.5162234,-76.9382069,"Johns Hopkins University - Outpatient Center, Baltimore, Maryland, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
53,20,42.3788774,-72.032366,"University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, Massachusetts, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
54,20,43.6211955,-84.6824346,"Michigan Medicine, Ann Arbor, Michigan, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
55,20,43.6211955,-84.6824346,"Henry Ford Health System, Detroit, Michigan, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
56,20,45.9896587,-94.6113288,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
57,20,45.9896587,-94.6113288,"Mayo Clinic, Rochester, Minnesota, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
58,20,38.7604815,-92.5617875,"Saint Louis University, Department of Neurology, Saint Louis, Missouri, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
59,20,38.7604815,-92.5617875,"Washington University School of Medicine, Saint Louis, Missouri, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
60,20,41.7370229,-99.5873816,"Neurology Associates, P.C., Lincoln, Nebraska, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
61,20,40.7127281,-74.0060152,"Hospital For Special Surgery, New York, New York, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
62,20,40.7127281,-74.0060152,"Neurological Institute, Columbia University Medical Center, New York, New York, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
63,20,40.7127281,-74.0060152,"SUNY Upstate Medical University, Syracuse, New York, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
64,20,35.6729639,-79.0392919,"Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
65,20,35.6729639,-79.0392919,"Duke Neurological Disorders Clinic, Durham, North Carolina, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
66,20,35.6729639,-79.0392919,"Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
67,20,40.2253569,-82.6881395,"Cleveland Clinic, Cleveland, Ohio, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
68,20,40.2253569,-82.6881395,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
69,20,43.9792797,-120.737257,"Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
70,20,43.9792797,-120.737257,"Oregon Health & Science University, Portland, Oregon, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
71,20,40.9699889,-77.7278831,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
72,20,40.9699889,-77.7278831,"Temple University School of Medicine, Philadelphia, Pennsylvania, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
73,20,35.7730076,-86.2820081,"Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
74,20,31.8160381,-99.5120986,"Texas Neurology, Dallas, Texas, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
75,20,31.8160381,-99.5120986,"Houston Methodist Hospital, Houston, Texas, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
76,20,31.8160381,-99.5120986,"UTHSCSA Medical Arts and Research Center, San Antonio, Texas, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
77,20,44.5990718,-72.5002608,"University of Vermont Medical Center, Burlington, Vermont, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
78,20,37.1232245,-78.4927721,"University of Virginia Health System, Charlottesville, Virginia, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
79,20,37.1232245,-78.4927721,"VCU Health - Ambulatory Care Center (ACC), Richmond, Virginia, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
80,20,38.8950092,-77.0365625,"University of Washington Medical Center, Seattle, Washington, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
81,20,38.4758406,-80.8408415,"West Virginia University, Dept. of Neurology, Morgantown, West Virginia, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
82,20,44.4308975,-89.6884637,"Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
83,20,-31.8759835,147.2869493,"Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
84,20,-31.8759835,147.2869493,"Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
85,20,-21.9182856,144.4588889,"Royal Brisbane and Women's Hospital, Herston, Queensland, Australia",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
86,20,-30.5343665,135.6301212,"Flinders Medical Centre, Bedford Park, South Australia, Australia",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
87,20,-25.2303005,121.0187246,"The Perron Institute for Neurological and Translation Science, Nedlands, Western Australia, Australia",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
88,20,55.001251,-115.002136,"University of Calgary, Heritage Medical Research Center, Calgary, Alberta, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
89,20,55.001251,-115.002136,"Edmonton Kaye Clinic, Edmonton, Alberta, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
90,20,50.000678,-86.000977,"McMaster University Medical Centre, Hamilton, Ontario, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
91,20,50.000678,-86.000977,"London Health Sciences Centre University Hospital, London, Ontario, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
92,20,50.000678,-86.000977,"Sunnybrook Health Science Centre, Toronto, Ontario, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
93,20,52.4760892,-71.8258668,"Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
94,20,52.4760892,-71.8258668,"Centre de recherche du Centre Hospitalier de l'Universite de Montreal, Montr√©al, Quebec, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
95,20,55.5321257,-106.1412243,"Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
96,20,52.4760892,-71.8258668,"CHU de Quebec-Universite Laval, Hopital de l'Enfant Jesus, Quebec, Canada",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
97,20,53.3497645,-6.2602732,"Beaumont Hospital, Dublin, Ireland",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
98,20,52.0809856,5.12768396945229,"University Medical Center Utrecht, Utrecht, Netherlands",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
99,20,40.4167047,-3.7035825,"Hospital San Rafael Servicio de Neurologia, Madrid, Spain",21.0,NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",FORTITUDE-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2127107|Drug: Placebo,Change from baseline to Week 12 in the percent predicted slow vital capacity (SVC)|Slope of change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry from baseline to Week 12|Change from baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R)|Mean plasma concentrations over time of CK-2127107 at Week 12,Cytokinetics|Astellas Pharma Inc,All,Phase 2,458.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5022,"July 24, 2017","March 7, 2019","March 7, 2019","May 19, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03160898,18.0,80.0
100,21,43.6112422,3.8767337,"UH Montpellier, Montpellier, France",22.0,NCT01823380,Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Blood test,Vitamin D blood level,"University Hospital, Montpellier",All,Not Applicable,127.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,8987,September 2012,February 2014,September 2015,"April 4, 2013",,"December 7, 2015",,https://ClinicalTrials.gov/show/NCT01823380,18.0,95.0
101,NULL,NULL,NULL,"Carolinas Medical Center - Dept of Neurology, Charlotte, North Carolina, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
102,23,35.6729639,-79.0392919,"Northwestern University, Chicago, Illinois, United States",24.0,NCT01948102,Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,,Abundance levels of the known messenger RNA transcriptome of skin and adipose tissue samples (measured by gene expression profiling)|Changes in abundance of or post-translational modification of proteins (measured by proteomics),Benjamin Brooks|ALS Therapy Development Institute|Atrium Health,All,,100.0,Other,Observational,Time Perspective: Prospective,CHS-Neurology_ALS_TDI_PEG,July 2008,July 2015,July 2015,"September 23, 2013",,"July 3, 2014",,https://ClinicalTrials.gov/show/NCT01948102,19.0,100.0
103,24,40.0796606,-89.4337288,"Peilin Lee, Taipei, Taiwan",25.0,NCT02039401,Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Genetic: VM202,Number of subjects with serious and non serious adverse events|Hepatocyte Growth Factor (HGF) serum levels|Copies of VM202 in whole blood,"Helixmith Co., Ltd.",All,Phase 1|Phase 2,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VMALS-001 / B,February 2014,September 2015,December 2017,"January 17, 2014",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT02039401,21.0,75.0
104,25,25.0375198,121.5636796,"Osaka, Japan",26.0,NCT00958048,Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: non-invasive ventilation,"Survival|Changes of PtcCO2 and PaCO2, admission or unexpected clinical visiting, and QoL","National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan",All,Not Applicable,70.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200812112R|2011-04-011LA,January 2009,April 2013,April 2013,"August 13, 2009",,"August 16, 2013",,https://ClinicalTrials.gov/show/NCT00958048,18.0,100.0
105,26,34.6937569,135.5014539,"Universidad Cat√≥lica San Antonio de Murcia, Guadalupe, Murcia, Spain",27.0,NCT01492686,Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: MCI-186|Drug: Placebo|Drug: MCI-186 in open label phase,"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks|Number of Participants With Death or a Specified State of Disease Progression|Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks|Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks|Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks|Percentage of Participants With Adverse Events|Percentage of Participants With Adverse Drug Reactions|Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of ""Investigations"" (PT, MedDRA Ver. 17.0)|Percentage of Participants With Abnormal Values in Sensory Examinations",Mitsubishi Tanabe Pharma Corporation,All,Phase 3,137.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI186-19,December 2011,September 2014,October 2014,"December 15, 2011","December 31, 2018","December 31, 2018",,https://ClinicalTrials.gov/show/NCT01492686,20.0,75.0
106,27,37.9923795,-1.1305431,"UT Southwestern, Dallas, Texas, United States",28.0,NCT02507713,Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Measuring muscle thickness.|Measurement muscle strength.|Measurement ALS Functional Rating Scale (ALSFRS-r) scale.|Measurement muscle fasciculations.|Measuring muscle echointensity.|Measuring nerve area.,Universidad Cat√≥lica San Antonio de Murcia,All,,60.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,PMAFI10/14,September 2013,April 2014,,"July 24, 2015",,"July 24, 2015",,https://ClinicalTrials.gov/show/NCT02507713,18.0,100.0
107,28,31.8160381,-99.5120986,"Fondazione Salvatore Maugeri, IRCCS - Scientific Institute of Veruno, Veruno, Italy",29.0,NCT03843710,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS),REPAIR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Gold Nanocrystals,Change in 31P-MRS Redox Ratio (NAD+/NADH),Clene Nanomedicine|University of Texas Southwestern Medical Center,All,Phase 2,24.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CNMAu8.203,"August 30, 2019",July 2020,August 2020,"February 18, 2019",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03843710,35.0,75.0
108,29,45.6906946,8.5307821,"Questcor Investigational Site, Birmingham, Alabama, United States",30.0,NCT01650818,Aerobic Exercise Training in Amyotrophic Lateral Sclerosis,ENDURANCE,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: Aerobic exercise training|Other: Standard physical therapy (Stretching/Range-of-motion),"Change from baseline in peak oxygen consumption (peak VO2)|Aerobic training safety and tolerability|Change from baseline in quality of life|Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score|Change from baseline in lower limbs muscle strength|Change from baseline in upper and lower motor neurons function at the upper and lower limbs level|Change from baseline in ventilatory function|Change from baseline in circulating inflammatory markers, growth factors and descriptors of skeletal muscle damage",Fondazione Salvatore Maugeri,All,Not Applicable,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CEC641,January 2012,June 2014,June 2014,"July 26, 2012",,"September 10, 2013",,https://ClinicalTrials.gov/show/NCT01650818,18.0,80.0
109,30,33.2588817,-86.8295337,"Questcor Investigational Site, Phoenix, Arizona, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
110,30,34.395342,-111.7632755,"Questcor Investigational Site, San Francisco, California, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
111,30,36.7014631,-118.7559974,"Questcor Investigational Site, Stanford, California, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
112,30,36.7014631,-118.7559974,"Questcor Investigational Site, Jacksonville, Florida, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
113,30,27.7567667,-81.4639835,"Questcor Investigational Site, Miami, Florida, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
114,30,27.7567667,-81.4639835,"Questcor Investigational Site, Tampa, Florida, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
115,30,27.7567667,-81.4639835,"Questcor Investigational Site, Atlanta, Georgia, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
116,30,32.3293809,-83.1137366,"Questcor Investigational Site, Kansas City, Kansas, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
117,30,38.27312,-98.5821872,"Questcor Investigational Site, Rochester, Minnesota, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
118,30,45.9896587,-94.6113288,"Questcor Investigational Site, Lincoln, Nebraska, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
119,30,41.7370229,-99.5873816,"Questcor Investigational Site, Hershey, Pennsylvania, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
120,30,40.9699889,-77.7278831,"Questcor Investigational Site, Pittsburgh, Pennsylvania, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
121,30,40.9699889,-77.7278831,"Questcor Investigational Site, Memphis, Tennessee, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
122,30,35.7730076,-86.2820081,"Questcor Investigational Site, Dallas, Texas, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
123,30,31.8160381,-99.5120986,"Questcor Investigational Site, Houston, Texas, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
124,30,31.8160381,-99.5120986,"Questcor Investigational Site, San Antonio, Texas, United States",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
125,30,31.8160381,-99.5120986,"University of Ulm, Ulm, Germany",31.0,NCT01906658,A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Repository corticotropin injection,Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication|Proportion of Subjects With Adverse Events That Required Study Drug Discontinuation|Proportion of Subjects With Adverse Events That Could Not be Controlled by Concomitant Medication|Proportion of Subjects With Treatment Emergent Suicidality,Mallinckrodt,All,Phase 2,43.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QSC01-ALS-01,July 2013,November 2014,December 2014,"July 24, 2013","January 6, 2017","January 6, 2017",,https://ClinicalTrials.gov/show/NCT01906658,18.0,80.0
126,31,48.3974003,9.9934336,"Dept. of Neurology, Klinikum Ludwigshafen, Ludwigshafen, Germany",32.0,NCT03481348,Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Device: Pharyngeal Electrical Stimulation,Penetration Aspiration Scale (PAS) Score|Swallowing-Quality of Life Score (SWAL-QOL)|Schluckbeeintr√§chtigungs-Skala (SBS) Score|Functional Oral Intake Scale (FOIS) Score|Dysphagia Severity Rating Scale (DSRS) Score|Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R)|Frequency of Adverse Events,University of Ulm,All,Phase 1|Phase 2,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PES-ALS,"February 1, 2018","February 1, 2019","August 1, 2019","March 29, 2018",,"March 29, 2018",,https://ClinicalTrials.gov/show/NCT03481348,18.0,100.0
127,32,49.4704113,8.4381568,"Clinica Neurologica, Ospedale Clinicizzato ""SS Annunziata"", Chieti, Italy",33.0,NCT01955369,Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Death|Tracheostomy,Klinikum Ludwigshafen,All,,200.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,837.253.09,October 2009,September 2012,September 2015,"October 7, 2013","April 22, 2015","May 19, 2016",,https://ClinicalTrials.gov/show/NCT01955369,18.0,100.0
128,33,42.3446529,14.1659738,"Azienda Ospedaliero Universitaria Careggi, Firenze, Italy",34.0,NCT03766321,Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,FETR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Fecal microbiota transplantation|Biological: Placebo,Change in Tregs number|Change in T cell subsets frequency in blood and gut tissue samples|Change in heavy neurofilaments levels in CSF|Changes in levels of pro-inflammatory cytokines and cytokines linked to T cell proliferation and differentiation|Changes in microbiota profile|Incidence of Adverse Events|Tracheostomy free survival|Forced vital capacity (FVC)|disease progression|quality of life: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Catholic University of the Sacred Heart|Campus Bio-Medico University|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera di Perugia|University of Chieti|University of Florence,All,Not Applicable,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FeTr-ALS,February 2019,February 2022,February 2022,"December 6, 2018",,"December 6, 2018",,https://ClinicalTrials.gov/show/NCT03766321,18.0,70.0
129,33,43.7698712,11.2555757,"Azienda Ospedaliero Universitaria di Modena, Modena, Italy",34.0,NCT03766321,Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,FETR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Fecal microbiota transplantation|Biological: Placebo,Change in Tregs number|Change in T cell subsets frequency in blood and gut tissue samples|Change in heavy neurofilaments levels in CSF|Changes in levels of pro-inflammatory cytokines and cytokines linked to T cell proliferation and differentiation|Changes in microbiota profile|Incidence of Adverse Events|Tracheostomy free survival|Forced vital capacity (FVC)|disease progression|quality of life: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Catholic University of the Sacred Heart|Campus Bio-Medico University|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera di Perugia|University of Chieti|University of Florence,All,Not Applicable,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FeTr-ALS,February 2019,February 2022,February 2022,"December 6, 2018",,"December 6, 2018",,https://ClinicalTrials.gov/show/NCT03766321,18.0,70.0
130,33,44.6458885,10.9255707,"UO Neurofisiopatologia, Azienda Ospedaliera d√¨ Perugia, Perugia, Italy",34.0,NCT03766321,Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,FETR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Fecal microbiota transplantation|Biological: Placebo,Change in Tregs number|Change in T cell subsets frequency in blood and gut tissue samples|Change in heavy neurofilaments levels in CSF|Changes in levels of pro-inflammatory cytokines and cytokines linked to T cell proliferation and differentiation|Changes in microbiota profile|Incidence of Adverse Events|Tracheostomy free survival|Forced vital capacity (FVC)|disease progression|quality of life: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Catholic University of the Sacred Heart|Campus Bio-Medico University|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera di Perugia|University of Chieti|University of Florence,All,Not Applicable,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FeTr-ALS,February 2019,February 2022,February 2022,"December 6, 2018",,"December 6, 2018",,https://ClinicalTrials.gov/show/NCT03766321,18.0,70.0
131,33,43.1119613,12.3890104,"Institute of Neurology, Policlinico Campus Bio-medico, Roma, Italy",34.0,NCT03766321,Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,FETR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Fecal microbiota transplantation|Biological: Placebo,Change in Tregs number|Change in T cell subsets frequency in blood and gut tissue samples|Change in heavy neurofilaments levels in CSF|Changes in levels of pro-inflammatory cytokines and cytokines linked to T cell proliferation and differentiation|Changes in microbiota profile|Incidence of Adverse Events|Tracheostomy free survival|Forced vital capacity (FVC)|disease progression|quality of life: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Catholic University of the Sacred Heart|Campus Bio-Medico University|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera di Perugia|University of Chieti|University of Florence,All,Not Applicable,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FeTr-ALS,February 2019,February 2022,February 2022,"December 6, 2018",,"December 6, 2018",,https://ClinicalTrials.gov/show/NCT03766321,18.0,70.0
132,33,41.894802,12.4853384,"NEuroMuscular Omnicentre Centre (NeMO), Fondazione Serena Onlus-Fondazione Policlinico A. Gemelli, Roma, Italy",34.0,NCT03766321,Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,FETR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Fecal microbiota transplantation|Biological: Placebo,Change in Tregs number|Change in T cell subsets frequency in blood and gut tissue samples|Change in heavy neurofilaments levels in CSF|Changes in levels of pro-inflammatory cytokines and cytokines linked to T cell proliferation and differentiation|Changes in microbiota profile|Incidence of Adverse Events|Tracheostomy free survival|Forced vital capacity (FVC)|disease progression|quality of life: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Catholic University of the Sacred Heart|Campus Bio-Medico University|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera di Perugia|University of Chieti|University of Florence,All,Not Applicable,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FeTr-ALS,February 2019,February 2022,February 2022,"December 6, 2018",,"December 6, 2018",,https://ClinicalTrials.gov/show/NCT03766321,18.0,70.0
133,33,41.894802,12.4853384,"GSK Investigational Site, Boston, Massachusetts, United States",34.0,NCT03766321,Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients,FETR-ALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Fecal microbiota transplantation|Biological: Placebo,Change in Tregs number|Change in T cell subsets frequency in blood and gut tissue samples|Change in heavy neurofilaments levels in CSF|Changes in levels of pro-inflammatory cytokines and cytokines linked to T cell proliferation and differentiation|Changes in microbiota profile|Incidence of Adverse Events|Tracheostomy free survival|Forced vital capacity (FVC)|disease progression|quality of life: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Catholic University of the Sacred Heart|Campus Bio-Medico University|Azienda Ospedaliero-Universitaria Careggi|Azienda Ospedaliera di Perugia|University of Chieti|University of Florence,All,Not Applicable,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FeTr-ALS,February 2019,February 2022,February 2022,"December 6, 2018",,"December 6, 2018",,https://ClinicalTrials.gov/show/NCT03766321,18.0,70.0
134,34,42.3788774,-72.032366,"GSK Investigational Site, Grand Rapids, Michigan, United States",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
135,34,43.6211955,-84.6824346,"GSK Investigational Site, Syracuse, New York, United States",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
136,34,40.7127281,-74.0060152,"GSK Investigational Site, Columbus, Ohio, United States",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
137,34,40.2253569,-82.6881395,"GSK Investigational Site, Randwick, New South Wales, Australia",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
138,34,-31.8759835,147.2869493,"GSK Investigational Site, Herston, Queensland, Australia",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
139,34,-21.9182856,144.4588889,"GSK Investigational Site, Leuven, Belgium",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
140,34,50.879202,4.7011675,"GSK Investigational Site, Calgary, Alberta, Canada",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
141,34,55.001251,-115.002136,"GSK Investigational Site, London, Ontario, Canada",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
142,34,50.000678,-86.000977,"GSK Investigational Site, Toronto, Ontario, Canada",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
143,34,50.000678,-86.000977,"GSK Investigational Site, Montreal, Quebec, Canada",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
144,34,52.4760892,-71.8258668,"GSK Investigational Site, Montreal, Quebec, Canada",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
145,34,52.4760892,-71.8258668,"GSK Investigational Site, Lille cedex, France",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
146,34,46.603354,1.8883335,"GSK Investigational Site, Limoges cedex, France",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
147,34,46.603354,1.8883335,"GSK Investigational Site, Montpellier cedex 5, France",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
148,34,46.603354,1.8883335,"GSK Investigational Site, Nice cedex 3, France",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
149,34,46.603354,1.8883335,"GSK Investigational Site, Paris cedex 13, France",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
150,34,46.603354,1.8883335,"GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
151,34,48.6296972,9.1949534,"GSK Investigational Site, Muenchen, Bayern, Germany",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
152,34,48.9467562,11.4038717,"GSK Investigational Site, Hannover, Niedersachsen, Germany",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
153,34,52.8398531,9.075962,"GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
154,34,51.4785568,7.5533645,"GSK Investigational Site, Jena, Thueringen, Germany",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
155,34,50.7333163,11.0747905,"GSK Investigational Site, Berlin, Germany",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
156,34,52.5170365,13.3888599,"GSK Investigational Site, Torino, Piemonte, Italy",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
157,34,45.060735,7.923549,"GSK Investigational Site, Verona, Veneto, Italy",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
158,34,45.6476663,11.8665254,"GSK Investigational Site, Kanagawa, Japan",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
159,34,35.4342935,139.374753,"GSK Investigational Site, Miyagi, Japan",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
160,34,38.3880155,140.9761025,"GSK Investigational Site, Osaka, Japan",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
161,34,34.6937569,135.5014539,"GSK Investigational Site, Seoul, Korea, Republic of",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
162,34,42.9629533,47.5133551,"GSK Investigational Site, Seoul, Korea, Republic of",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
163,34,42.9629533,47.5133551,"GSK Investigational Site, Seoul, Korea, Republic of",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
164,34,42.9629533,47.5133551,"GSK Investigational Site, Utrecht, Netherlands",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
165,34,52.0809856,5.12768396945229,"GSK Investigational Site, Preston, Lancashire, United Kingdom",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
166,34,53.86117155,-2.54711154031047,"GSK Investigational Site, Brighton, United Kingdom",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
167,34,50.8220399,-0.1374061,"GSK Investigational Site, Edgbaston,, United Kingdom",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
168,34,52.4603261,-1.9179098,"Coordinated Clinical Research, La Jolla, California, United States",35.0,NCT01753076,Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Ozanezumab|Drug: Placebo,Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival|Change From Baseline in the ALSFRS-R Total Score at Week 48|Rate of Decline Over Week 48 in the ALSFRS-R Total Score|Change From Baseline in Slow Vital Capacity (SVC) at Week 48|Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48|Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48|Overall Survival at Week 48 and Week 60|Progression-free Survival at Week 48|Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48|Change From Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) Total Score at Week 48,GlaxoSmithKline,All,Phase 2,304.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",112264,"December 20, 2012","January 22, 2015","January 22, 2015","December 20, 2012","April 19, 2017","December 21, 2017",,https://ClinicalTrials.gov/show/NCT01753076,18.0,80.0
169,35,36.7014631,-118.7559974,"University of California, Irvine; MDA ALS and Neuromuscular Center,, Orange, California, United States",36.0,NCT00748501,Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SB-509,"To evaluate the effect of SB-509 on progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale -Revised (ALSFRS-R).|To evaluate a) the effect of SB-509 on Forced Vital Capacity, Neurophysiologic Index, Manual Muscle Test, and survival. b) safety and tolerability of SB-509 in ALS. c) stem cell mobilization in subjects with ALS receiving SB-509.",Sangamo Therapeutics,All,Phase 2,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-509-0801,September 2008,June 2010,June 2010,"September 8, 2008",,"November 1, 2012",,https://ClinicalTrials.gov/show/NCT00748501,18.0,85.0
170,35,36.7014631,-118.7559974,"California Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",36.0,NCT00748501,Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SB-509,"To evaluate the effect of SB-509 on progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale -Revised (ALSFRS-R).|To evaluate a) the effect of SB-509 on Forced Vital Capacity, Neurophysiologic Index, Manual Muscle Test, and survival. b) safety and tolerability of SB-509 in ALS. c) stem cell mobilization in subjects with ALS receiving SB-509.",Sangamo Therapeutics,All,Phase 2,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-509-0801,September 2008,June 2010,June 2010,"September 8, 2008",,"November 1, 2012",,https://ClinicalTrials.gov/show/NCT00748501,18.0,85.0
171,35,36.7014631,-118.7559974,"The University of Kansas Medical Center (KU), Kansas City, Kansas, United States",36.0,NCT00748501,Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SB-509,"To evaluate the effect of SB-509 on progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale -Revised (ALSFRS-R).|To evaluate a) the effect of SB-509 on Forced Vital Capacity, Neurophysiologic Index, Manual Muscle Test, and survival. b) safety and tolerability of SB-509 in ALS. c) stem cell mobilization in subjects with ALS receiving SB-509.",Sangamo Therapeutics,All,Phase 2,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-509-0801,September 2008,June 2010,June 2010,"September 8, 2008",,"November 1, 2012",,https://ClinicalTrials.gov/show/NCT00748501,18.0,85.0
172,35,38.27312,-98.5821872,"Johns Hopkins University, Baltimore, Maryland, United States",36.0,NCT00748501,Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SB-509,"To evaluate the effect of SB-509 on progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale -Revised (ALSFRS-R).|To evaluate a) the effect of SB-509 on Forced Vital Capacity, Neurophysiologic Index, Manual Muscle Test, and survival. b) safety and tolerability of SB-509 in ALS. c) stem cell mobilization in subjects with ALS receiving SB-509.",Sangamo Therapeutics,All,Phase 2,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-509-0801,September 2008,June 2010,June 2010,"September 8, 2008",,"November 1, 2012",,https://ClinicalTrials.gov/show/NCT00748501,18.0,85.0
173,35,39.5162234,-76.9382069,"Nerve and Muscle Center of Texas, Houston, Texas, United States",36.0,NCT00748501,Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SB-509,"To evaluate the effect of SB-509 on progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale -Revised (ALSFRS-R).|To evaluate a) the effect of SB-509 on Forced Vital Capacity, Neurophysiologic Index, Manual Muscle Test, and survival. b) safety and tolerability of SB-509 in ALS. c) stem cell mobilization in subjects with ALS receiving SB-509.",Sangamo Therapeutics,All,Phase 2,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-509-0801,September 2008,June 2010,June 2010,"September 8, 2008",,"November 1, 2012",,https://ClinicalTrials.gov/show/NCT00748501,18.0,85.0
174,35,31.8160381,-99.5120986,"Geneva University Hospital, Geneva, Switzerland",36.0,NCT00748501,Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SB-509,"To evaluate the effect of SB-509 on progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale -Revised (ALSFRS-R).|To evaluate a) the effect of SB-509 on Forced Vital Capacity, Neurophysiologic Index, Manual Muscle Test, and survival. b) safety and tolerability of SB-509 in ALS. c) stem cell mobilization in subjects with ALS receiving SB-509.",Sangamo Therapeutics,All,Phase 2,45.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SB-509-0801,September 2008,June 2010,June 2010,"September 8, 2008",,"November 1, 2012",,https://ClinicalTrials.gov/show/NCT00748501,18.0,85.0
175,36,46.2017559,6.1466014,"Novartis, East Hanover, New Jersey, United States",37.0,NCT03536962,Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Other: no intervention,Longitudinal change of the revised Amyotrophic Lateral Sclerosis Functional rating scale in Amyotrophic Lateral Sclerosis patients|Correlation of walking speed measured by Timed Up and Go test and the Amyotrophic Lateral Sclerosis Functional rating scale (ALSFRS-R)|Longitudinal evolution of pulmonary function in ALS patients|Evolution of body mass composition measured by the Body Mass Index in ALS patients|Longitudinal evolution of inspiratory muscle strength in ALS patients,"Ruxandra Iancu Ferfoglia|University Hospital, Geneva",All,,60.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NAC 11-062R,"June 1, 2012","September 1, 2016","October 1, 2018","May 25, 2018",,"May 25, 2018",,https://ClinicalTrials.gov/show/NCT03536962,18.0,100.0
176,NULL,NULL,NULL,"Holy Cross Hospital, Fort Lauderdale, Florida, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
177,38,,,"Massachusetts General Hospital, Boston, Massachusetts, United States",39.0,NCT02881476,Therapeutic Treatment of Amyotrophic Lateral Sclerosis,UwmWjmscAls,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: Biological: Cell-based therapy,Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation.,University of Warmia and Mazury,All,Phase 1,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UWM/ALS-MSC.2015/001,November 2015,April 2018,December 2018,"August 29, 2016",,"August 29, 2016",,https://ClinicalTrials.gov/show/NCT02881476,18.0,65.0
178,39,,,"University of Minnesota, Minneapolis, Minnesota, United States",40.0,NCT03377868,Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Diagnostic Test: Optic coherence tomography|Diagnostic Test: Pulmonary function test,Change in retinal layer thickness parameters over 3 and 6 months in ALS patients|Comparison of changes in retinal layer thickness parameters over 3 and 6 months between ALS patients and their healthy controls|Correlation between changes in retinal layers thickness and ALS-FRS scores in patients with ALS|Correlation between changes in retinal layers thickness and Pulmonary function test parameters in ALS patients over 3 and 6 months,American University of Beirut Medical Center,All,Not Applicable,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IM.AS.01,"January 3, 2018","July 28, 2018","September 28, 2018","December 19, 2017",,"December 19, 2017",,https://ClinicalTrials.gov/show/NCT03377868,18.0,100.0
179,40,27.7567667,-81.4639835,"Hanyang Medical Center, Seoul, Korea, Republic of",41.0,NCT03168711,Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),SURE-ALS2,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Inosine|Drug: Placebo,Safety Will be Assessed by the Occurrence of Adverse Events|Tolerability to Complete the Entire 20 Week Study on Study Drug,Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SURE-ALS2,"October 1, 2017",October 2019,January 2020,"May 30, 2017",,"November 26, 2018",,https://ClinicalTrials.gov/show/NCT03168711,18.0,85.0
180,40,42.3788774,-72.032366,"Piti√©-Salp√™tri√®re Hospital, Paris, France",41.0,NCT03168711,Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),SURE-ALS2,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Inosine|Drug: Placebo,Safety Will be Assessed by the Occurrence of Adverse Events|Tolerability to Complete the Entire 20 Week Study on Study Drug,Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SURE-ALS2,"October 1, 2017",October 2019,January 2020,"May 30, 2017",,"November 26, 2018",,https://ClinicalTrials.gov/show/NCT03168711,18.0,85.0
181,40,45.9896587,-94.6113288,"Mayo Clinic, Jacksonville, Florida, United States",41.0,NCT03168711,Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),SURE-ALS2,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Inosine|Drug: Placebo,Safety Will be Assessed by the Occurrence of Adverse Events|Tolerability to Complete the Entire 20 Week Study on Study Drug,Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SURE-ALS2,"October 1, 2017",October 2019,January 2020,"May 30, 2017",,"November 26, 2018",,https://ClinicalTrials.gov/show/NCT03168711,18.0,85.0
182,41,42.9629533,47.5133551,"Johnny S. Salameh, Beirut, Lebanon",42.0,NCT03835507,"Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: recombinant human erythropoietin(rhEPO),changes of ALSFRS-R score,Hanyang University Seoul Hospital,All,Phase 1|Phase 2,64.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,HYNR-EPO,"June 20, 2016",December 2020,December 2025,"February 8, 2019",,"February 8, 2019",,https://ClinicalTrials.gov/show/NCT03835507,25.0,80.0
183,42,48.8566101,2.3514992,"University of Florida Center for Movement Disorders & Neuroscience, Gainesville, Florida, United States",43.0,NCT00925847,Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis,LISLA,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium,Survival in patients with ALS treated with lithium and riluzole compared to historical cohort (patients treated with riluzole alone )|Functional Assessment Change in ALS Functional Rating Score (ALSFRS-R slope)|Muscle Strength Change in MMT score (MMT slope)|Rate of decline of respiratory function determined as SVC over the 15 month treatment period,Assistance Publique - H√¥pitaux de Paris,All,Phase 2,23.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P080401,June 2009,April 2011,April 2011,"June 22, 2009",,"October 31, 2012",,https://ClinicalTrials.gov/show/NCT00925847,18.0,100.0
184,43,27.7567667,-81.4639835,"Bioclinica, Orlando, Florida, United States",44.0,NCT03793868,Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Perampanel|Other: Placebo,Motor threshold (MT),Mayo Clinic,All,Early Phase 1,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",17-002396,"December 4, 2018","December 1, 2019","December 1, 2019","January 4, 2019",,"January 4, 2019",,https://ClinicalTrials.gov/show/NCT03793868,18.0,70.0
185,44,33.8959203,35.47843,"CHDR, Leiden, South Holland, Netherlands",45.0,NCT03377309,Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Fycompa,Safety and Tolerability: Incidence and severity of drug-related adverse effects|Efficacy: As measured by change in ALSFRS-R score,American University of Beirut Medical Center,All,Phase 2,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM.JS.03,"December 1, 2017","June 1, 2018","July 1, 2018","December 19, 2017",,"December 21, 2017",,https://ClinicalTrials.gov/show/NCT03377309,18.0,80.0
186,45,27.7567667,-81.4639835,"TCA Cellular Therapy, Covington, Louisiana, United States",46.0,NCT03679975,Riluzole Oral Soluble Film Swallowing Safety in Amyotrophic Lateral Sclerosis,ROSF,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole Oral Soluble film (ROSF) 50 mg,Difference from baseline in Penetration Aspiration Scale (PAS),Aquestive Therapeutics|inVentiv Health Clinical|Covance,All,Phase 2,9.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,17MO1R-0012,"April 4, 2018","September 26, 2018","December 21, 2018","September 21, 2018",,"January 21, 2019",,https://ClinicalTrials.gov/show/NCT03679975,18.0,80.0
187,NULL,NULL,NULL,"CHU LImoges, Limoges, France",,,,,,,,,,,,,,,,,,,,,,,,,,,
188,46,51.9966792,4.5597397,"Department of Neurology, University of Ulm, Ulm, Baden-W√ºrttemberg, Germany",47.0,NCT03757351,Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: DNL747|Drug: Placebo,Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Subjects with clinically significant neurological examination abnormalities|Number of Subjects with laboratory test abnormalities|Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL747|Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL747|Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL747|Pharmacokinetic terminal disposition rate constant (Œªz) with the respective t1/2 of DNL747|Pharmacokinetic measure of CSF concentrations of DNL747|Pharmacodynamic measure of pS166 in PBMCs,Denali Therapeutics Inc.,All,Phase 1,16.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DNLI-D-0003,"December 28, 2018",August 2019,August 2019,"November 28, 2018",,"July 3, 2019",,https://ClinicalTrials.gov/show/NCT03757351,21.0,80.0
189,47,30.8703881,-92.007126,"Department of Neurology, Technische Universit√§t M√ºnchen, Muenchen, Bayern, Germany",48.0,NCT01082653,Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis,ALS,Suspended,No Results Available,Amyotrophic Lateral Sclerosis,Biological: autologous bone marrow-derived stem cells,Safety|Efficacy,TCA Cellular Therapy,All,Phase 1,6.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2008-ALS-I,March 2010,May 2014,May 2014,"March 8, 2010",,"May 9, 2014",,https://ClinicalTrials.gov/show/NCT01082653,18.0,80.0
190,48,,,"Department of Neurology, Universty of Regensburg, Regensburg, Bayern, Germany",49.0,NCT00982150,Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALSTAR OL,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Talampanel,"ALSFRS-R|Vital Signs, ECG, Adverse Event Reports",Teva Pharmaceutical Industries,All,Phase 2,446.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALS-TAL-201-OL,September 2009,June 2010,June 2010,"September 23, 2009",,"August 26, 2013",,https://ClinicalTrials.gov/show/NCT00982150,18.0,80.0
191,49,,,"Department of Neurology, University of Wuerzburg, Wuerzburg, Bayern, Germany",50.0,NCT02988297,Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60|Drug: Placebo,ALS functional rating scale-revised (ALSFRS-R) score|Deaths or tracheostomies|Proportion of regulatory T cells (Treg)|Slow vital capacity (SVC)|ALS assessment questionnaire (ALSAQ-40) score|Adverse events (AEs),Revalesio Corporation,All,Phase 2,140.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06.2.1.H6,July 2019,July 2022,July 2022,"December 9, 2016",,"January 9, 2019",,https://ClinicalTrials.gov/show/NCT02988297,18.0,80.0
192,50,45.8354243,1.2644847,"Department of Neurology, Deutsche Klinik f√ºr Diagnostik, Wiesbaden, Hessen, Germany",51.0,NCT03378375,"Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: nutritional assessement,Resting energy expenditure emeasures,"University Hospital, Limoges",All,,315.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,ALS/jesus,November 1996,November 2014,November 2014,"December 19, 2017",,"December 19, 2017",,https://ClinicalTrials.gov/show/NCT03378375,18.0,100.0
193,51,48.6296972,9.1949534,"Department of Neurology, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
194,51,48.9467562,11.4038717,"Department of Neurology, University of Goettingen, Goettingen, Niedersachsen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
195,51,48.9467562,11.4038717,"Department of Neurology, Medical School Hannover, Hannover, Niedersachsen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
196,51,48.9467562,11.4038717,"Neurologische Universit√§tsklinik Bergmannsheil, Bochum, Nordrhein-Westfalen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
197,51,50.6118537,9.1909725,"Department of Neurology, Universty of Muenster, Muenster, Nordrhein-Westfalen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
198,51,53.7735234,12.5755746,"Department of Neurology, Universty of Bonn, Bonn, Nordrhrein-Westfalen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
199,51,52.8398531,9.075962,"Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
200,51,52.8398531,9.075962,"Department of Neurology, TU Dresden, Dresden, Sachsen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
201,51,51.4785568,7.5533645,"Department of Neurology, University of Jena, Jena, Thueringen, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
202,51,51.4785568,7.5533645,"Department of Neurology, Humboldt University, Berlin, Germany",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
203,51,51.0834196,10.4234469,"Sahlgrenska University Hospital, Gothenburg, Sweden",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
204,51,51.908526,11.4939134,"Barrow Neurological Institute, Phoenix, Arizona, United States",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
205,51,50.9295798,13.4585052,"Research Site, Loma Linda, California, United States",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
206,51,50.7333163,11.0747905,"University of California San Diego Medical Center, San Diego, California, United States",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
207,51,52.5170365,13.3888599,"Research Site, Jacksonville, Florida, United States",52.0,NCT01879241,Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rasagiline|Drug: Placebo,"Survival in ALS-Patients with Rasagiline compared to placebo|Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)|Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life|Change of slow vital capacity",University of Ulm,All,Phase 2,252.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAS-ALS|2011-004482-32,June 2013,April 2016,August 2016,"June 17, 2013",,"October 25, 2016",,https://ClinicalTrials.gov/show/NCT01879241,18.0,100.0
208,52,57.7072326,11.9670171,"University of South Florida, Tampa, Florida, United States",53.0,NCT03613571,"A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis",,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ILB,"Frequency, seriousness and intensity of Treatment-emergent Adverse Events (TEAEs)|Change in physical status|Change in vital signs - blood pressure|Change in electrocardiogram (ECG) recordings|Change in vital signs - heart rate|Change in vital signs - body temperatue|Change in safety laboratory measurements - sodium, potassium, chloride, calcium, glucose (non-fasting)|Change in safety laboratory measurements - albumin|Change in safety laboratory measurements - AST, ALT, CK, alkaline phosphatase|Change in safety laboratory measurements - creatinine and total bilirubin|Change in safety laboratory measurements - myoglobin|Change in safety laboratory measurements - CRP|Change in hematology laboratory measurements - Hemoglobin and fibrinogen|Change in hematology laboratory measurements - Red blood cell count|Change in hematology laboratory measurements - WBC, platelets, basophils, eosinophils, lymphocytes, monocytes, neutrophils|Change in hematology laboratory measurements - APTT|Change in hematology laboratory measurements - PK-INR|Change in functional rating with Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Change in functional rating with Norris rating scale|Change in pulmonary function (FVC) from baseline|Change in Quality of Life (QoL) assessed by visual analogue scale (VAS)|Change in functional rating of autonomous and sensory symptoms|Change in maximum plasma concentration (Cmax) of ILB|Change in exposure (Area Under the Curve, AUC) of ILB|Changes in APTT (effect APTT) from day of dosing (day 1)|Change in plasma concentration of hepatocyte growth factor (HGF)",TikoMed AB,All,Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1.3, 2018-08-23","August 15, 2018","June 1, 2019","June 1, 2019","August 3, 2018",,"September 20, 2018",,https://ClinicalTrials.gov/show/NCT03613571,18.0,80.0
209,53,34.395342,-111.7632755,"Research Site, Baltimore, Maryland, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
210,53,36.7014631,-118.7559974,"Research Site, Boston, Massachusetts, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
211,53,36.7014631,-118.7559974,"Research Site, Saint Louis, Missouri, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
212,53,27.7567667,-81.4639835,"Alliance for Multispecialty Research NOCCR/VRG, Knoxville, Tennessee, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
213,53,27.7567667,-81.4639835,"Research Site, La Jolla, California, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
214,53,39.5162234,-76.9382069,"Research Site, Palo Alto, California, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
215,53,42.3788774,-72.032366,"Research Site, Jacksonville, Florida, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
216,53,38.7604815,-92.5617875,"Research Site, Miami, Florida, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
217,53,35.7730076,-86.2820081,"Research Site, Atlanta, Georgia, United States",54.0,NCT03945279,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB100|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100|Maximum Observed Concentration (Cmax) of BIIB100|Time to Reach Cmax (Tmax) of BIIB100|Terminal Elimination Half-life (t1/2) of BIIB100|Apparent Clearance (CL/F) of BIIB100|Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100,Biogen,All,Phase 1,40.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",261AS101,"May 30, 2019","December 31, 2020","December 31, 2020","May 10, 2019",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03945279,18.0,100.0
218,54,36.7014631,-118.7559974,"Research Site, Baltimore, Maryland, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
219,54,36.7014631,-118.7559974,"Research Site, Boston, Massachusetts, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
220,54,27.7567667,-81.4639835,"Research Site, Saint Louis, Missouri, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
221,54,27.7567667,-81.4639835,"Research Site, New York, New York, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
222,54,32.3293809,-83.1137366,"Research Site, Knoxville, Tennessee, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
223,54,39.5162234,-76.9382069,"Research Site, Montreal, Quebec, Canada",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
224,54,42.3788774,-72.032366,"Service ORL Assistance Publique H√¥pitaux de Marseille, Marseille, France",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
225,54,38.7604815,-92.5617875,"H√¥pital Roger Salengro, CHU, Lille, France",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
226,54,40.7127281,-74.0060152,"Neuromuscular Research Center, Phoenix, Arizona, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
227,54,35.7730076,-86.2820081,"Mayo Clinic - Arizona, Scottsdale, Arizona, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
228,54,52.4760892,-71.8258668,"University of California San Diego, La Jolla, California, United States",55.0,NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB078|Drug: Placebo,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2),Biogen,All,Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",245AS101|2017-000294-36,"September 10, 2018","September 27, 2021","September 27, 2021","August 10, 2018",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03626012,18.0,100.0
229,55,43.2961743,5.3699525,"Loma Linda University Health System, Department of Neurology, Loma Linda, California, United States",56.0,NCT02665663,Tongue Strength in Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: medical device,Maximum tongue strength|Tongue contact duration,Assistance Publique Hopitaux De Marseille,All,Not Applicable,60.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2015-18,February 2016,March 2018,July 2018,"January 28, 2016",,"January 28, 2016",,https://ClinicalTrials.gov/show/NCT02665663,18.0,100.0
230,56,50.6365654,3.0635282,"Keck School of Medicine, University of Southern California, Los Angeles, California, United States",57.0,NCT03293069,Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis,FAIR-ALS II,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Deferiprone|Drug: Placebo Oral Tablet,CAFS score (Combined Assessment of Function and Survival)|Changes in ALS Functional Rating Scale-Revised (ALSFRS-R) total score|All-cause and respiratory insufficiency mortality|Changes in muscle strength|Change in the slow vital capacity|Changes in body weight|Change in Quality of life|DSMIV criteria|Fronto-Temporal Dementia (FTD) criteria|Change in Montreal Cognitive Assessment (MoCA)|Change in Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS),"University Hospital, Lille|Ministry of Health, France",All,Phase 2|Phase 3,240.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2016_76|2017-003763-35,"January 30, 2019",March 2022,April 2022,"September 26, 2017",,"May 21, 2019",,https://ClinicalTrials.gov/show/NCT03293069,18.0,75.0
231,57,34.395342,-111.7632755,"University of California Los Angeles, Los Angeles, California, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
232,57,34.395342,-111.7632755,"University of California Irvine Medical Center, Orange, California, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
233,57,36.7014631,-118.7559974,"California Pacific Medical Center, San Francisco, California, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
234,57,36.7014631,-118.7559974,"University of California San Francisco, San Francisco, California, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
235,57,36.7014631,-118.7559974,"Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
236,57,36.7014631,-118.7559974,"Georgetown University, Washington, District of Columbia, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
237,57,36.7014631,-118.7559974,"George Washington University, Washington, District of Columbia, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
238,57,36.7014631,-118.7559974,"University of Florida - McKnight Brain Institute, Gainesville, Florida, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
239,57,36.7014631,-118.7559974,"University of South Florida, Tampa, Florida, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
240,57,38.7251776,-105.6077167,"Emory University, Atlanta, Georgia, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
241,57,38.89366125,-76.987883253882,"Augusta University, Augusta, Georgia, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
242,57,38.89366125,-76.987883253882,"Indiana University-Neuroscience Center of Excellence/Goodman Hall, Indianapolis, Indiana, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
243,57,27.7567667,-81.4639835,"University of Kansas Medical Center, Kansas City, Kansas, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
244,57,27.7567667,-81.4639835,"University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
245,57,32.3293809,-83.1137366,"John Hopkins Outpatient Center, Baltimore, Maryland, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
246,57,32.3293809,-83.1137366,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
247,57,40.3270127,-86.1746933,"Mercy Health- Saint Mary's, Grand Rapids, Michigan, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
248,57,38.27312,-98.5821872,"Neurology Associates, Lincoln, Nebraska, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
249,57,37.5726028,-85.1551411,"University of Nebraska Medical Center - Physicians Clinical Neurosciences Center, Omaha, Nebraska, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
250,57,39.5162234,-76.9382069,"Las Vegas Clinic, Las Vegas, Nevada, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
251,57,42.3788774,-72.032366,"Jersey Shore University Medical Center, Neptune, New Jersey, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
252,57,43.6211955,-84.6824346,"Columbia Presbyterian Hospital, New York, New York, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
253,57,41.7370229,-99.5873816,"Providence ALS Center, Portland, Oregon, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
254,57,41.7370229,-99.5873816,"Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
255,57,39.5158825,-116.8537227,"Temple University School of Medicine, Philadelphia, Pennsylvania, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
256,57,40.0757384,-74.4041622,"Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
257,57,40.7127281,-74.0060152,"Wesley Neurology Clinic, Cordova, Tennessee, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
258,57,43.9792797,-120.737257,"Austin Neuromuscular Center, Austin, Texas, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
259,57,40.9699889,-77.7278831,"Texas Neurology, P.A., Dallas, Texas, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
260,57,40.9699889,-77.7278831,"The Methodist Hospital, Houston, Texas, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
261,57,40.9699889,-77.7278831,"University of Vermont Medical Center, Colchester, Vermont, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
262,57,35.7730076,-86.2820081,"VCU Medical Center, Richmond, Virginia, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
263,57,31.8160381,-99.5120986,"Swedish Neuroscience Institute, Seattle, Washington, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
264,57,31.8160381,-99.5120986,"Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
265,57,31.8160381,-99.5120986,"IADIN, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
266,57,44.5990718,-72.5002608,"STAT Research, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
267,57,37.1232245,-78.4927721,"DIABAID, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
268,57,38.8950092,-77.0365625,"INEBA, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
269,57,44.4308975,-89.6884637,"Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
270,57,-34.6075616,-58.437076,"Hospital Espa√±ol, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
271,57,-34.6075616,-58.437076,"Hospital Brit√°nico de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
272,57,-34.6075616,-58.437076,"ILAIM, Ciudad de C√≥rdoba, C√≥rdoba, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
273,57,-34.6075616,-58.437076,"Fundaci√≥n Scherbovsky, Ciudad de Mendoza, Mendoza, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
274,57,-34.6075616,-58.437076,"Instituto de Neurolog√≠a y Neurorrehabilitaci√≥n del Litoral (INNeL ), Ciudad De Santa Fe, Santa Fe, Argentina",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
275,57,-34.6075616,-58.437076,"Edmonton Kaye Clinic, Edmonton, Alberta, Canada",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
276,57,-34.6075616,-58.437076,"Recherche Sepmus inc, Greenfield Park, Quebec, Canada",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
277,57,-31.4173391,-64.183319,"Centre de recherch√© du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montr√©al, Quebec, Canada",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
278,57,-32.8897294,-68.8442956,"Montreal Neurological Institute & Hospital, Montr√©al, Quebec, Canada",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
279,57,-31.6186951,-60.7019561,"Centro de Trastornos del Movimiento (CETRAM), Santiago, Regi√≥n Metropolitana, Chile",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
280,57,55.001251,-115.002136,"Clinica D√°vila, Santiago, Regi√≥n Metropolitana, Chile",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
281,57,52.4760892,-71.8258668,"Biomedica Research Group AV Salvador 149, oficina 1101, Santiago, Chile",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
282,57,52.4760892,-71.8258668,"Centro de Investigaciones Cl√≠nicas SAS, Cali, Colombia",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
283,57,52.4760892,-71.8258668,"Clinical Research Institute Saltillo S.A. de C.V., Saltillo, Coahuila, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
284,57,-33.8201151,-70.7404378,"Hospital Universitario ""Dr. Jos√© Eleuterio Gonz√°lez"", Monterrey, Nuevo Leon, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
285,57,-33.8201151,-70.7404378,"SMIQ BRCR Global M√©xico, Quer√©taro City, Quer√©taro, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
286,57,-33.4377968,-70.6504451,"Clinical Research Institute S.C., San Lucas Tepetlacalco, Tlalnepantla De Baz, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
287,57,3.4517923,-76.5324943,"Centro Especializado en Investigaci√≥n Cl√≠nica S.C., Boca Del R√≠o, Veracruz, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
288,57,27.3333331,-102.0000001,"Phylasis Clinicas Research, Mexico City, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
289,57,26.2384363,-99.8873,"FAICIC Clinical Researc, Veracruz, Mexico",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
290,57,20.8542575,-99.84756,"Hospital Nivel IV Carlos Alberto Seguin Escobedo, Arequipa, Peru",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
291,57,19.54649025,-99.1899352013895,"Hospital Nacional IV Alberto Sabogal Sologuren, Callao, Peru",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
292,57,19.333333,-96.666667,"Hospital Almenara, Lima, Peru",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
293,57,19.4326009,-99.1333416,"Instituto Neuro Cardiovascular de las Am√©ricas, Lima, Peru",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
294,57,19.333333,-96.666667,"Hospital Nacional Cayetano Heredia, Lima, Peru",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
295,57,-16.3988667,-71.5369607,"Dongsheng Fan, MD; Liping Wang,MD, Beijing, Beijing, China",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
296,NULL,NULL,NULL,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,,,,,,,,,,,,,,,,,,,,,,,,,,
297,57,-12.0621065,-77.0365256,"The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
298,57,-12.0621065,-77.0365256,"University of Florida, Gainesville, Florida, United States",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
299,57,-12.0621065,-77.0365256,"Department of Neurology of Pomeranian Medical University in Szczecin, Szczecin, Poland",58.0,NCT03068754,Study of Acthar¬Æ Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a scale for telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of participants experiencing an adverse event during the Treatment Period|Number of participants experiencing an adverse event by the end of the Trial|Treatment Period: Spirometry (%)|Treatment Period: Scores on a scale for investigator-administered ALSFRS-R|Extension Period: Scores on a scale for investigator-administered ALSFRS-R,Mallinckrodt,All,Phase 2|Phase 3,143.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017",October 2021,October 2021,"March 3, 2017",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03068754,18.0,75.0
300,58,40.190632,116.412144,"University of Michigan Hospital, Ann Arbor, Michigan, United States",59.0,NCT00753571,Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Cistanche Total Glycosides,The mean rate of decline of ALS-FRS score|The mean rate decline of the AARS score,Peking University,All,Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PUTH-1,January 2008,December 2008,October 2010,"September 16, 2008",,"December 30, 2009",,https://ClinicalTrials.gov/show/NCT00753571,18.0,65.0
301,59,,,"UF Health Shands, Gainesville, Florida, United States",60.0,NCT03034317,NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS),PARADIGM,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: NeuRx DPS,Survival|Relationship between survival time and clinical features of ALS|Relationship between survival time and ALS assessment scores|Relationship between survival time and onset of weakness from ALS to treatment|Relationship between survival time and ALS treatment interventions|Relationship between survival time and intraoperative strength of contraction|Characterize change in overall and respiratory function|Characterize change in respiratory function|Types device and procedure-related adverse events|Frequency of device and procedure-related adverse events|Types of respiratory serious adverse events|Frequency of respiratory adverse events,Synapse Biomedical,All,Not Applicable,108.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-1000-51,February 2017,February 2019,August 2019,"January 27, 2017",,"January 27, 2017",,https://ClinicalTrials.gov/show/NCT03034317,21.0,100.0
302,NULL,NULL,NULL,"Diparimento di Scienze Neurologiche, Naples, Italy",,,,,,,,,,,,,,,,,,,,,,,,,,,
303,61,40.9975197,122.9955469,"Istituto Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples, Italy",62.0,NCT03085706,Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: PBMC autotransplantation,adverse events of autologous peripheral blood mononuclear cell mobilization|Functional independence measurement(FIM)|Berg Balance Scale|Dysarthria Assessment Scale,The First Affiliated Hospital of Dalian Medical University,All,Not Applicable,14.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCKY2016-58,October 2010,December 2012,June 2013,"March 21, 2017",,"February 9, 2018",,https://ClinicalTrials.gov/show/NCT03085706,31.0,75.0
304,62,27.7567667,-81.4639835,"CHU de Montpellier - H√¥pital Gui de Chauliac, Montpellier Cedex 5, France",63.0,NCT02710162,Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: Micro Mouth Pressure Meter|Device: Iowa Oral Performance Instrument|Device: Electrical Impedance Myography|Drug: Capsaicin|Procedure: Videofluoroscopic Swallowing Study|Procedure: Pulmonary Function Testing|Other: Swallowing Related Quality of Life Questionnaire|Other: Functional Oral Intake Scale|Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|Other: Eating Assessment Tool-10|Other: Communicative Effectiveness Survey|Other: The Center for Neurologic Studies Bulbar Function Scale,The Penetration-aspiration scale will be used to measure swallowing function|The IOPI will be used to measure Lingual strength and endurance|The oral pneumatograph will be used to measure voluntary cough function|The nebulizer with cough protocol will be used to measure reflexive cough|Global disease progression as confirmed by the ALS Functional Rating Scale-Revised (ALSFRS-R)|Participant perception of swallowing impairment as confirmed by Swallowing Quality of Life Questionnaire (SWAL-QOL)|Dietary intake as confirmed by Functional Oral Intake Scale (FOIS)|Participant perception of swallowing related symptoms as confirmed by The Eating Assessment Tool 10 (EAT-10)|Participant perception of communication abilities as confirmed by Communication Effectiveness Survey|Bulbar function confirmed by the Center for Neurologic Studies Bulbar Function Scale (CNS-BFS),University of Florida,All,Early Phase 1,21.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB201600163,April 2016,"December 19, 2017","December 19, 2017","March 16, 2016",,"December 21, 2017",,https://ClinicalTrials.gov/show/NCT02710162,21.0,85.0
305,63,53.42968095,14.5929126702923,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",64.0,NCT02193893,Biological Treatment of Amyotrophic Lateral Sclerosis,NeuStem-ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: Biological: Cell-based therapeutics|Other: Symptomatic treatment of ALS,Safety of autologous bone marrow stem/progenitor cell infusion in enrolled patients|Efficacy of autologous bone marrow stem/progenitor cell infusion in enrolled patients.,Pomeranian Medical University Szczecin,All,Phase 1,50.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZPO 02|ZPO 02, ALS-BMSC #01",January 2010,July 2017,December 2017,"July 18, 2014",,"July 18, 2014",,https://ClinicalTrials.gov/show/NCT02193893,18.0,65.0
306,64,43.6211955,-84.6824346,"Massachusetts General Hospital, Boston, Massachusetts, United States",65.0,NCT02058732,Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Other: MRI,Changes in spinal cord metabolites in treated ALS subjects and nontreated ALS subjects.,University of Michigan,All,Not Applicable,6.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HUM00078370,November 2013,"September 30, 2015","September 30, 2015","February 10, 2014",,"June 6, 2018",,https://ClinicalTrials.gov/show/NCT02058732,18.0,100.0
307,65,27.7567667,-81.4639835,"Macquarie Neurology, North Ryde, New South Wales, Australia",66.0,NCT02710110,Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: PowerLung trainer|Device: Micro Mouth Pressure Meter|Procedure: Pulmonary Function Testing|Procedure: Videofluoroscopic swallowing study|Other: Swallowing Quality of Life Questionnaire|Device: Iowa Oral Pressure Instrument|Drug: Capsaicin,Maximum Expiratory Pressure will be measured between the groups for a change from baseline to month 3|Maximum Inspiratory Pressure will be measured between the groups for a change from baseline to month 3|Pulmonary function to measure the forced vital capacity (FVC) between the groups for a change from baseline to month 3|Sniff Nasal Inspiratory Pressure will be measured between the groups for a change from baseline to month 3|Pulmonary function to measure the peak expiratory flow (PEF) will be measured between the groups for a change from baseline to month 3|Pulmonary function to measure the forced expiratory volume (FEV1) will be measured between the groups for a change from baseline to month 3|The Penetration-aspiration scale will be used to measure swallowing function|Lingual strength will be measured between the groups for a change from baseline to month 3|Lingual endurance will be measured between the groups for a change from baseline to month 3|Voluntary cough function will be measured between the groups for a change from baseline to month 3|Reflexive cough will be measured between the groups for a change from baseline to month 3,University of Florida|ALS Association,All,Early Phase 1,54.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB201501172,April 2016,"November 30, 2017","February 7, 2019","March 16, 2016",,"February 8, 2019",,https://ClinicalTrials.gov/show/NCT02710110,21.0,85.0
308,66,,,"Westmead Hospital, Parramatta, New South Wales, Australia",67.0,NCT02881489,Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis,UwmBmmscALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: Biological: Cell-based therapy,Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation.,University of Warmia and Mazury,All,Phase 1,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UWM/ALS-MSC.2015/002,November 2015,April 2018,December 2018,"August 29, 2016",,"August 29, 2016",,https://ClinicalTrials.gov/show/NCT02881489,18.0,65.0
309,67,40.8359336,14.2487826,"Brain and Mind Centre, Sydney, New South Wales, Australia",68.0,NCT00635960,Growth Hormone in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Growth Hormone (Somatropin)|Drug: Placebo,Primary endpoint is the N-acetylaspartate/Creatine ratio in the motor cortex assessed with magnetic resonance spectroscopy.|Difference in mortality between groups|Difference in the ALS-FRS score (motor function scale)|Difference in the SF-36 score (quality of life )|Safety and tolerability,"Federico II University|Istituto Biostrutture e Immagini, CNR Naples|Agenzia Italiana del Farmaco",All,Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SLA_GH_1,March 2007,July 2009,May 2010,"March 14, 2008",,"May 27, 2010",,https://ClinicalTrials.gov/show/NCT00635960,40.0,85.0
310,67,40.8359336,14.2487826,"Calvary Health Care Bethlehem, Caulfield South, Victoria, Australia",68.0,NCT00635960,Growth Hormone in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Growth Hormone (Somatropin)|Drug: Placebo,Primary endpoint is the N-acetylaspartate/Creatine ratio in the motor cortex assessed with magnetic resonance spectroscopy.|Difference in mortality between groups|Difference in the ALS-FRS score (motor function scale)|Difference in the SF-36 score (quality of life )|Safety and tolerability,"Federico II University|Istituto Biostrutture e Immagini, CNR Naples|Agenzia Italiana del Farmaco",All,Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SLA_GH_1,March 2007,July 2009,May 2010,"March 14, 2008",,"May 27, 2010",,https://ClinicalTrials.gov/show/NCT00635960,40.0,85.0
311,NULL,NULL,NULL,"Hadassah Medical Organization, Jerusalem, Israel",,,,,,,,,,,,,,,,,,,,,,,,,,,
312,69,43.4849133,-71.6553992,"CHU de SAINT-ETIENNE, Saint-etienne, France",70.0,NCT02872142,Efficacy and Safety of Plasma Exchange With Albutein¬Æ 5% in Patients With Amyotrophic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Biological: Albutein 5%,Changes from baseline in the ALS Functional Rating Scale - Revised|Changes from baseline in forced vital capacity|Changes from baseline in cognitive function determined by the ALS - Cognitive Behavioral Screen test|Changes from baseline in the motor evoked potential in thenar and hypothenar eminence and anterior tibialis muscle determined by electromyography|Evaluation of quality of life using the ALS Assessment Questionnaire 40|Changes from baseline in plasma human apolipoproteins|Changes from baseline in cerebrospinal fluid human apolipoproteins|Changes from baseline in plasma beta-methylamino-L-alanine levels|Changes from baseline in cerebrospinal fluid beta-methylamino-L-alanine levels|Changes from baseline in absolute leukocyte count|Changes from baseline in plasma neurofilament analysis|Changes from baseline in cerebrospinal fluid neurofilament analysis,"Grifols Therapeutics LLC|Grifols Biologicals, LLC",All,Phase 2,12.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBI1501,"August 29, 2016",October 2019,October 2019,"August 19, 2016",,"July 31, 2019",,https://ClinicalTrials.gov/show/NCT02872142,19.0,69.0
313,70,42.3788774,-72.032366,"Dongsheng Fan, Beijing, Beijing, China",71.0,NCT02288091,A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Inosine,Number of Participants Experiencing Adverse Events|Tolerability to Complete the Entire 12 Week Study on Study Drug.|Blood Biomarkers (GSH) at Baseline and Week 12|Neuroimaging Biomarkers at Baseline and Week 12|Blood Biomarkers (FRAP) at Baseline and Week 12,Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund,All,Phase 1,32.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,701,January 2015,March 2016,March 2016,"November 11, 2014","October 2, 2017","November 6, 2017",,https://ClinicalTrials.gov/show/NCT02288091,18.0,100.0
314,71,-31.8759835,147.2869493,"Department of Neurology - Hospital de Santa Maria, Lisbon, Portugal",72.0,NCT02868580,Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).,Lighthouse,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Triumeq,Number of participants with treatment related adverse events as defined CTCAE V4.0.|ALS Functional Rating Scale-Revised (ALSFRS-R) scoring|Number of Participants With Abnormal Laboratory Values for Neurophysiological Index (NI) Related to Treatment.|Number of participants with abnormal Sniff Nasal Inspiratory Pressure (SNIP) Test results|Number of participants with abnormal forced vital capacity (FVC) test results as measured by hand-held spirometry|Number of participants with abnormal quantitative hand muscle testing as measured by dynanometry.|Number of participants with abnormal scores on the Columbia Suicide Severity Score C-SSRS).,"Neuroscience Trials Australia|Macquarie University, Australia|Westmead Hosptial|Calvary Health Care Bethlehem|The University of Sydney - Brain and Mind Centre",All,Phase 2,43.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CUR-101,October 2016,December 2017,December 2018,"August 16, 2016",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT02868580,18.0,75.0
315,NULL,NULL,NULL,"Neurosciences Research Center, Isfahan, Iran, Islamic Republic of",,,,,,,,,,,,,,,,,,,,,,,,,,,
316,71,-31.8759835,147.2869493,"Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain",72.0,NCT02868580,Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).,Lighthouse,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Triumeq,Number of participants with treatment related adverse events as defined CTCAE V4.0.|ALS Functional Rating Scale-Revised (ALSFRS-R) scoring|Number of Participants With Abnormal Laboratory Values for Neurophysiological Index (NI) Related to Treatment.|Number of participants with abnormal Sniff Nasal Inspiratory Pressure (SNIP) Test results|Number of participants with abnormal forced vital capacity (FVC) test results as measured by hand-held spirometry|Number of participants with abnormal quantitative hand muscle testing as measured by dynanometry.|Number of participants with abnormal scores on the Columbia Suicide Severity Score C-SSRS).,"Neuroscience Trials Australia|Macquarie University, Australia|Westmead Hosptial|Calvary Health Care Bethlehem|The University of Sydney - Brain and Mind Centre",All,Phase 2,43.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CUR-101,October 2016,December 2017,December 2018,"August 16, 2016",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT02868580,18.0,75.0
317,71,-36.5986096,144.6780052,"Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain",72.0,NCT02868580,Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).,Lighthouse,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Triumeq,Number of participants with treatment related adverse events as defined CTCAE V4.0.|ALS Functional Rating Scale-Revised (ALSFRS-R) scoring|Number of Participants With Abnormal Laboratory Values for Neurophysiological Index (NI) Related to Treatment.|Number of participants with abnormal Sniff Nasal Inspiratory Pressure (SNIP) Test results|Number of participants with abnormal forced vital capacity (FVC) test results as measured by hand-held spirometry|Number of participants with abnormal quantitative hand muscle testing as measured by dynanometry.|Number of participants with abnormal scores on the Columbia Suicide Severity Score C-SSRS).,"Neuroscience Trials Australia|Macquarie University, Australia|Westmead Hosptial|Calvary Health Care Bethlehem|The University of Sydney - Brain and Mind Centre",All,Phase 2,43.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CUR-101,October 2016,December 2017,December 2018,"August 16, 2016",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT02868580,18.0,75.0
318,72,,,"Department of Neuroscience, S. Anna Hospital, Ferrara, Italy",73.0,NCT02588807,Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis,ALS-PHL,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Spirit1,Tolerability and safety based on the number and severity of adverse events (AE)|Change from baseline in score on the ALS Functional Rating Scale Revised (ALS-FRSr)|Change from baseline in Forced vital capacity (FVC)|Change from baseline in hand grip power using a dynamometer|Change from baseline in walking speed for 10 meters,Herb Spirit|Carmel Medical Center,All,Phase 1,10.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015-14-CMC,July 2017,September 2018,May 2019,"October 28, 2015",,"July 18, 2017",,https://ClinicalTrials.gov/show/NCT02588807,18.0,75.0
319,73,31.778345,35.2250786,"Department of Neuroscience, S.Agostino-Estense Hospital, Modena, Italy",74.0,NCT01777646,"Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,"Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF",Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters,Brainstorm-Cell Therapeutics|Hadassah Medical Organization,All,Phase 2,14.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-NTF-002-HMO-CTIL,December 2012,September 2014,September 2015,"January 29, 2013",,"March 8, 2018",,https://ClinicalTrials.gov/show/NCT01777646,20.0,75.0
320,74,45.4401467,4.3873058,"Department of Neuroscience, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy",75.0,NCT02528071,Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis,SLA,Recruiting,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Other: Diaphragmatic endurance test,Endurance time|Reference values of the diaphragmatic endurance test|Reference values of phrenic nerve activity|Slope of endurance time decrease|Amplitude of phrenic nerve|Latency of phrenic nerve,Centre Hospitalier Universitaire de Saint Etienne,All,,165.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1308188|2014-A00309-38,"September 29, 2014",April 2023,April 2023,"August 19, 2015",,"February 1, 2019",,https://ClinicalTrials.gov/show/NCT02528071,18.0,80.0
321,75,40.190632,116.412144,"University of Kansas Medical Center, Kansas City, Kansas, United States",76.0,NCT00397423,G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Granulocyte Colony Stimulating Factor|Drug: NS,the mean rate of decline of ALS-FRS score|the mean rate decline of the AARS score,Peking University,All,Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",R01-123456-1,December 2006,,August 2007,"November 9, 2006",,"November 28, 2007",,https://ClinicalTrials.gov/show/NCT00397423,18.0,65.0
322,76,38.7077507,-9.1365919,"Massachusetts General Hospital, Boston, Massachusetts, United States",77.0,NCT00353665,Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Memantine (Ebixa)|Drug: riluzole|Drug: Placebo,"ALS-FRS|QoL, depression scale, strength (clinical evaluation), forced vital capacity|neurophysiology (motor unit counting, neurophysiological index)",University of Lisbon|H. Lundbeck A/S,All,Phase 2|Phase 3,63.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",002-04,July 2005,June 2008,January 2009,"July 19, 2006",,"April 1, 2009",,https://ClinicalTrials.gov/show/NCT00353665,20.0,75.0
323,77,,,"University of Massachusetts Medical Center, Worcester, Massachusetts, United States",78.0,NCT02759003,Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Nightime NIV initiation,Adherence as measured by the use of ventilator (hours/month)|Changes in respiratory function as assessed by spirometry|Changes in dyspnea symptoms as assessed by Visual Analogue Scale|Patient's questionnaire of satisfaction|Changes in respiratory function as assessed by Maximal inspiratory pressure/Maximal expiratory pressure|Changes in respiratory function as assessed by blood gas analysis,Fondazione Salvatore Maugeri|Fondazione Don Carlo Gnocchi Onlus,All,Not Applicable,50.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTS 02/2011,March 2011,March 2013,March 2014,"May 3, 2016",,"May 4, 2016",,https://ClinicalTrials.gov/show/NCT02759003,18.0,100.0
324,78,36.2619477,59.6051728,"Washington University at St. Louis, St. Louis, Missouri, United States",79.0,NCT02116634,Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis,,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Biological: mesenchymal stem cell,Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS|ALS-FRS(functional rating scale) score and EMG scale|FVC (forced vital capacity)and DWSE¬±QoL score,"Alzahra Hospital, Iran",All,Phase 1|Phase 2,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,rokhsareh|stem cell injection in ALS,May 2015,May 2017,May 2017,"April 17, 2014",,"January 14, 2016",,https://ClinicalTrials.gov/show/NCT02116634,18.0,60.0
325,79,41.3828939,2.1774322,"SUNY Upstate Medical University, Syracuse, New York, United States",80.0,NCT02479802,Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Albumin,"Evaluate disease progression by changes from baseline in the ALS Functional Rating Scale Revised (ALSFRS-R)|Evaluate disease progression by changes from baseline in Forced Vital Capacity (FVC)|Changes from baseline in ALS cognitive function determined by the ALS-Cognitive Behavioral Screen (ALS-CBS) test|Changes from baseline in electromyography profile by assessing the motor evoked potential in thenar and hypothenar eminence, and anterior tibialis muscle|Evaluation of quality of life using the changes from baseline in ALS assessment questionnaire 40 (ALSAQ40).|Changes from baseline in albumin functional capacity in plasma samples|Changes from baseline in plasma cytokine panel|Changes from baseline in cerebrospinal fluid cytokine panel|Changes from baseline in plasma oxidative stress parameters such as hydroxynonenal, neuroketal, malondialdehyde-lysine and nitrotyrosine|Changes from baseline in cerebrospinal fluid oxidative stress parameters such as glutamic semialdehyde, carboxymethyl lysine, carboxymethyl lysine and malondialdehyde-lysine|Changes from baseline in non-directed metabolome profile in plasma samples|Changes from baseline in non-directed metabolome profile in cerebrospinal fluid samples|Percentage of plasma exchange sessions associated with one adverse event or adverse reaction, including clinically significant changes in vital signs or lab parameters","Instituto Grifols, S.A.|Grifols Biologicals, LLC",All,Phase 2,13.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IG1309,November 2014,June 2016,June 2016,"June 24, 2015",,"February 14, 2018",,https://ClinicalTrials.gov/show/NCT02479802,18.0,70.0
326,80,37.9923795,-1.1305431,"Carolinas Medical Center, Charlotte, North Carolina, United States",81.0,NCT01254539,Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Laminectomy and bone marrow stem cells transplantation|Procedure: Intrathecal infusion of autologous bone marrow stem cells|Procedure: Intrathecal infusion of placebo (saline solution).,"Forced vital capacity|Neurological variables: The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALS-FRS), Medical Research Council (MRC) and Norris scales|Absence of adverse events|Neurophysiological variables: Electromyography, polysomnography, evoked potentials|Neuroradiological variables: Spinal Magnetic Resonance Imaging (MRI)|Respiratory variables: Maximal inspiratory pressure (PIM), Maximal expiratory pressure (PEM), sniff nasal, oxymetry.|Psychological variables: Health Questionnaire (EuroQol-5D), The Profile of Mood States (POMS)",Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Instituto de Salud Carlos III|Hospital Universitario Virgen de la Arrixaca|Hospital General Universitario Morales Meseguer|Di√≥genes Foundation,All,Phase 1|Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Extension CMN/ELA|2006-003096-12|EC07/90762,October 2010,"November 20, 2015","November 20, 2015","December 6, 2010",,"March 30, 2017",,https://ClinicalTrials.gov/show/NCT01254539,18.0,70.0
327,81,44.8372737,11.6186451,"Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States",82.0,NCT02306109,Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS),ermoSla,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Standard motor rehabilitation treatment|Procedure: Intensive motor rehabilitation treatment,"Change from Baseline in ALSFRS R|Rate of complications related to the disease: pressure sores, hospitalizations, infections|Perceived quality of care|Tracheostomy free survival|Time to supporting procedures (NIV and PEG)|Respiratory function: measured by FVC|Quality of Life: measured by McGill and ALSAQ40 scales|Disease symptoms (fatigue) measured with FSS|Depression measured by Beck Inventory Scale",Azienda Unita' Sanitaria Locale Di Modena|University of Modena and Reggio Emilia|Arcispedale Santa Maria Nuova-IRCCS|S. Anna Hospital|Azienda Unit√† Sanitaria Locale Reggio Emilia|Azienda Unit√† Sanitaria Locale Ferrara,All,Not Applicable,65.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,AUSLMO_0001_SLA,January 2015,December 2017,April 2018,"December 3, 2014",,"August 7, 2018",,https://ClinicalTrials.gov/show/NCT02306109,18.0,85.0
328,81,44.6458885,10.9255707,"University of Washington Medical Center, Seattle, Washington, United States",82.0,NCT02306109,Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS),ermoSla,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Standard motor rehabilitation treatment|Procedure: Intensive motor rehabilitation treatment,"Change from Baseline in ALSFRS R|Rate of complications related to the disease: pressure sores, hospitalizations, infections|Perceived quality of care|Tracheostomy free survival|Time to supporting procedures (NIV and PEG)|Respiratory function: measured by FVC|Quality of Life: measured by McGill and ALSAQ40 scales|Disease symptoms (fatigue) measured with FSS|Depression measured by Beck Inventory Scale",Azienda Unita' Sanitaria Locale Di Modena|University of Modena and Reggio Emilia|Arcispedale Santa Maria Nuova-IRCCS|S. Anna Hospital|Azienda Unit√† Sanitaria Locale Reggio Emilia|Azienda Unit√† Sanitaria Locale Ferrara,All,Not Applicable,65.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,AUSLMO_0001_SLA,January 2015,December 2017,April 2018,"December 3, 2014",,"August 7, 2018",,https://ClinicalTrials.gov/show/NCT02306109,18.0,85.0
329,81,44.6978446,10.6304958,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",82.0,NCT02306109,Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS),ermoSla,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Standard motor rehabilitation treatment|Procedure: Intensive motor rehabilitation treatment,"Change from Baseline in ALSFRS R|Rate of complications related to the disease: pressure sores, hospitalizations, infections|Perceived quality of care|Tracheostomy free survival|Time to supporting procedures (NIV and PEG)|Respiratory function: measured by FVC|Quality of Life: measured by McGill and ALSAQ40 scales|Disease symptoms (fatigue) measured with FSS|Depression measured by Beck Inventory Scale",Azienda Unita' Sanitaria Locale Di Modena|University of Modena and Reggio Emilia|Arcispedale Santa Maria Nuova-IRCCS|S. Anna Hospital|Azienda Unit√† Sanitaria Locale Reggio Emilia|Azienda Unit√† Sanitaria Locale Ferrara,All,Not Applicable,65.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,AUSLMO_0001_SLA,January 2015,December 2017,April 2018,"December 3, 2014",,"August 7, 2018",,https://ClinicalTrials.gov/show/NCT02306109,18.0,85.0
330,82,38.27312,-98.5821872,"Neurogen brain and spine institute, Mumbai, Maharashtra, India",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
331,82,42.3788774,-72.032366,"Barrow Neurological Institute, Phoenix, Arizona, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
332,82,42.3788774,-72.032366,"University of California, Irvine, Orange, California, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
333,82,38.7604815,-92.5617875,"Augusta University, Augusta, Georgia, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
334,82,40.7127281,-74.0060152,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
335,82,35.6729639,-79.0392919,"University of Michigan, Ann Arbor, Michigan, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
336,82,40.9699889,-77.7278831,"Columbia Universtiy Medical Center, New York, New York, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
337,82,38.8950092,-77.0365625,"Pennsylvania State Hershey Medical Center, Hershey, Pennsylvania, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
338,82,44.4308975,-89.6884637,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",83.0,NCT01257581,Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS),SDALS-001,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: creatine|Drug: tamoxifen,Change in ALS Functional Rating Scale - Revised (ALSFRS-R)|Vital Capacity/Pulmonary Function Testing|Tracheostomy-free Survival|Dose Adjustments|Lab Abnormal Reports by Treatment Assignment|Hand Held Dynamometry (HHD) Lower Z-score|HHD Lower % Baseline|HHD Upper Z-score|HHD Upper % Baseline|Accurate Test of Limb Isometric Strength (ATLIS) Lower Percentage of Predicted Normal (PPN)|ATLIS Upper Percentage of Predicted Normal (PPN),Nazem Atassi|ALS Therapy Alliance|State University of New York - Upstate Medical University|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDALS-001,March 2011,December 2012,February 2013,"December 9, 2010","December 4, 2014","December 4, 2014",,https://ClinicalTrials.gov/show/NCT01257581,18.0,100.0
339,83,19.531932,76.0554568,"Medical University of South Carolina, Charleston, South Carolina, United States",84.0,NCT01984814,Stem Cell Therapy for Amyotrophic Lateral Sclerosis,,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Stem cell,Duration of survival,Neurogen Brain and Spine Institute,All,Phase 2,0.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NGBSI-04,December 2008,August 2013,August 2013,"November 15, 2013",,"October 25, 2018",,https://ClinicalTrials.gov/show/NCT01984814,26.0,76.0
340,84,34.395342,-111.7632755,"University of Washington, Seattle, Washington, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
341,84,36.7014631,-118.7559974,"University of Miami, Miami, Florida, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
342,84,32.3293809,-83.1137366,"National Hospital Organization Miyagi National Hospital, Watari-gun, Miyagi-ken, Japan",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
343,84,42.3788774,-72.032366,"University of California, Irvine, Orange, California, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
344,84,43.6211955,-84.6824346,"Georgia Regents University, Augusta, Georgia, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
345,84,40.7127281,-74.0060152,"Massachusetts General Hospital, Boston, Massachusetts, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
346,84,40.9699889,-77.7278831,"Methodist Neurological Institute, Houston, Texas, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
347,84,40.9699889,-77.7278831,"Department of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense C, Fyn, Denmark",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
348,84,33.6874388,-80.4363743,"CHRU de Montpellier - H√¥pital Gui de Chauliac, Montpellier, France",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
349,84,38.8950092,-77.0365625,"Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States",85.0,NCT02781454,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis,Mexiletine-2,"Active, not recruiting",No Results Available,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Change in resting motor threshold|Effects on motor evoked potential (MEP)|Effects on strength duration time constant|Effect on frequency and severity of muscle cramps|Effects on cortical silent period|Effects on short-interval intracortical inhibition (SICI)|Effects on threshold electrotonus|Effect on frequency and severity of fasciculations (muscle twitching),University of Washington|Massachusetts General Hospital,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MX-ALS-002,October 2016,"September 30, 2018","December 31, 2018","May 24, 2016",,"August 1, 2018",,https://ClinicalTrials.gov/show/NCT02781454,18.0,100.0
350,85,27.7567667,-81.4639835,"Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States",86.0,NCT01508962,PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis,PRESS-ALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Phenoconversion,University of Miami,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRESS-ALS,November 2013,December 2027,December 2027,"January 12, 2012",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01508962,18.0,100.0
351,86,38.3880155,140.9761025,"University of Miami Miller School of Medicine, Miami, Florida, United States",87.0,NCT00424463,Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: MCI-186|Drug: Placebo of MCI-186,Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks|Number of Participants With Death or a Specified State of Disease Progression|Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks|Percentage of Participants With Adverse Events|Percentage of Participants With Adverse Drug Reactions|Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group|Percentage of Participants With Abnormal Changes in Sensory Examinations,Mitsubishi Tanabe Pharma Corporation,All,Phase 3,181.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI186-17,January 2007,May 2009,May 2009,"January 19, 2007","June 4, 2018","August 23, 2018",,https://ClinicalTrials.gov/show/NCT00424463,20.0,100.0
352,87,36.7014631,-118.7559974,"Bioclinica Research, Orlando, Florida, United States",88.0,NCT01786174,Gilenya in Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Gilenya|Other: Placebo,"ALSFRS-R Total Score at Weeks 0, 2, 4 and 8|Change in Slow Vital Capacity Score (SVC)|Forced Expiratory Volume in 1 Second (FEV1)|Lymphocyte (T-Cell) Subset Trajectories|Forced Expiratory Volume in 1 Second (FEV1) / Slow Vital Capacity (SVC) Ratio",Massachusetts General Hospital|ALS Therapy Development Institute,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013P000313,August 2013,September 2014,May 2015,"February 7, 2013","December 31, 2015","July 1, 2016",,https://ClinicalTrials.gov/show/NCT01786174,18.0,100.0
353,87,32.3293809,-83.1137366,"The Emory ALS Clinic, Atlanta, Georgia, United States",88.0,NCT01786174,Gilenya in Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Gilenya|Other: Placebo,"ALSFRS-R Total Score at Weeks 0, 2, 4 and 8|Change in Slow Vital Capacity Score (SVC)|Forced Expiratory Volume in 1 Second (FEV1)|Lymphocyte (T-Cell) Subset Trajectories|Forced Expiratory Volume in 1 Second (FEV1) / Slow Vital Capacity (SVC) Ratio",Massachusetts General Hospital|ALS Therapy Development Institute,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013P000313,August 2013,September 2014,May 2015,"February 7, 2013","December 31, 2015","July 1, 2016",,https://ClinicalTrials.gov/show/NCT01786174,18.0,100.0
354,87,42.3788774,-72.032366,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",88.0,NCT01786174,Gilenya in Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Gilenya|Other: Placebo,"ALSFRS-R Total Score at Weeks 0, 2, 4 and 8|Change in Slow Vital Capacity Score (SVC)|Forced Expiratory Volume in 1 Second (FEV1)|Lymphocyte (T-Cell) Subset Trajectories|Forced Expiratory Volume in 1 Second (FEV1) / Slow Vital Capacity (SVC) Ratio",Massachusetts General Hospital|ALS Therapy Development Institute,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013P000313,August 2013,September 2014,May 2015,"February 7, 2013","December 31, 2015","July 1, 2016",,https://ClinicalTrials.gov/show/NCT01786174,18.0,100.0
355,87,31.8160381,-99.5120986,"Massachusetts General Hospital, Boston, Massachusetts, United States",88.0,NCT01786174,Gilenya in Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Gilenya|Other: Placebo,"ALSFRS-R Total Score at Weeks 0, 2, 4 and 8|Change in Slow Vital Capacity Score (SVC)|Forced Expiratory Volume in 1 Second (FEV1)|Lymphocyte (T-Cell) Subset Trajectories|Forced Expiratory Volume in 1 Second (FEV1) / Slow Vital Capacity (SVC) Ratio",Massachusetts General Hospital|ALS Therapy Development Institute,All,Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013P000313,August 2013,September 2014,May 2015,"February 7, 2013","December 31, 2015","July 1, 2016",,https://ClinicalTrials.gov/show/NCT01786174,18.0,100.0
356,88,55.32459685,10.347213055567,"Wake Research Associates, Raleigh, North Carolina, United States",89.0,NCT01504009,Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS),ALS-project,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Muscle training,"Improved muscle strength|Physical, social and mental quality of life",University of Southern Denmark|Odense University Hospital,All,Not Applicable,6.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALS-2011.05,May 2011,December 2012,June 2016,"January 4, 2012",,"June 14, 2016",,https://ClinicalTrials.gov/show/NCT01504009,18.0,100.0
357,89,43.6112422,3.8767337,"New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",90.0,NCT02059759,Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2,IMODALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 1.0 MIU IL-2 per day|Drug: 2.0 MIU IL-2 per day,"CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in percentage of total lymphocytes|Presence/absence of specific, pre-defined adverse events.|Presence/absence of abnormal vital signs|MedDRA classification of all adverse events throughout the study|Thyroid function: blood T4|Thyroid function: blood TSH|Presence/absence of clinically significant abnormality on a lung x-ray|Presence/absence of clinically significant abnormality on an electrocardiogram|Presence/absence of a clinically significant abnormality among routine laboratory tests|Vital capacity (% of normal)|The ALSFRS Questionnaire|Tregs (absolute number and % CF4+ cells)|Total lymphocyte number|CD56+(NK), CD19+(B), CD3+, CD4+, CD8+ cell populations: numbers and percentages of total lymphocytes|effector T cells: number and % of CD4 cells|Phosphorylated neurofilament heavy protein (pNfH) levels in serum|Light chain neurofilament levels in serum",Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,36.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LOCAL/2014/WC-01|2014-001327-71,September 2015,December 2015,May 2016,"February 11, 2014",,"June 1, 2016",,https://ClinicalTrials.gov/show/NCT02059759,18.0,75.0
358,90,36.7014631,-118.7559974,"Methodist Neurological Institute, Houston, Texas, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
359,90,27.7567667,-81.4639835,"MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, Canada",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
360,90,27.7567667,-81.4639835,"UMC Utrecht, Utrecht, Netherlands",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
361,90,27.7567667,-81.4639835,"St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
362,90,32.3293809,-83.1137366,"Mayo Clinic Arizona, Scottsdale, Arizona, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
363,90,39.5162234,-76.9382069,"Cedars-Sinai Medical Center, Los Angeles, California, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
364,90,42.3788774,-72.032366,"University of California, Irvine, Department of Neurology, Orange, California, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
365,90,35.6729639,-79.0392919,"Forbes Norris MDA/ALS Research Center, CPMC, San Francisco, California, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
366,90,35.7730076,-86.2820081,"Mayo Clinic Florida, Jacksonville, Florida, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
367,90,31.8160381,-99.5120986,"University of Miami Miller School of Medicine, Miami, Florida, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
368,90,52.4760892,-71.8258668,"Emory University, Department of Neurology, Atlanta, Georgia, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
369,90,52.0809856,5.12768396945229,"University of Kansas Medical Center, Kansas City, Kansas, United States",91.0,NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: GDC-0134|Drug: Placebo|Drug: Rabeprazole|Drug: Midazolam|Drug: Caffeine,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),"Genentech, Inc.",All,Phase 1,82.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GN29823|2017-002931-41,"May 31, 2016","October 30, 2019","October 30, 2019","January 14, 2016",,"August 5, 2019",,https://ClinicalTrials.gov/show/NCT02655614,18.0,100.0
370,91,34.395342,-111.7632755,"University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
371,91,34.395342,-111.7632755,"Massachusetts General Hospital, Boston, Massachusetts, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
372,91,36.7014631,-118.7559974,"Clinical & Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
373,91,36.7014631,-118.7559974,"Washington University School of Medicine, Saint Louis, Missouri, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
374,91,36.7014631,-118.7559974,"Columbia University Medical Center, New York, New York, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
375,91,27.7567667,-81.4639835,"Carolinas Medical Center, Neurosciences Instutite-Neurology, Charlotte, North Carolina, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
376,91,27.7567667,-81.4639835,"Duke Neurological Disorders Clinic at Morreene Road, Durham, North Carolina, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
377,91,32.3293809,-83.1137366,"Cleveland Clinic Foundation-Cleveland Clinic Hospital, Cleveland, Ohio, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
378,91,38.27312,-98.5821872,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
379,91,37.5726028,-85.1551411,"Providence Brain & Spine Institute, ALS Center, Portland, Oregon, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
380,91,42.3788774,-72.032366,"Houston Methodist Neurological Institute, Houston, Texas, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
381,91,45.9896587,-94.6113288,"University of Texas Health Sciences Center San Antonio, San Antonio, Texas, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
382,91,38.7604815,-92.5617875,"Montreal Neurological Institute, Montreal, Quebec, Canada",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
383,91,40.7127281,-74.0060152,"Barrow Neurological Institute, Phoenix, Arizona, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
384,91,35.6729639,-79.0392919,"University of California San Diego Medical Center, La Jolla, California, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
385,91,35.6729639,-79.0392919,"Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
386,91,40.2253569,-82.6881395,"Bioclinica Research, Orlando, Florida, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
387,91,40.2253569,-82.6881395,"Emory University Hospital, Atlanta, Georgia, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
388,91,43.9792797,-120.737257,"Johns Hopkins University, Baltimore, Maryland, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
389,91,31.8160381,-99.5120986,"Massachusetts General Hospital, Boston, Massachusetts, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
390,91,31.8160381,-99.5120986,"Washington University School of Medicine, Saint Louis, Missouri, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
391,91,52.4760892,-71.8258668,"Alliance for Multispecialty Research, Knoxville, Tennessee, United States",92.0,NCT02794857,Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire|Change in pulmonary function as measured by slow vital capacity readings|Time to tracheotomy|Change in levels of blood inflammatory biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,138.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-003,"August 29, 2016","December 12, 2017","December 12, 2017","June 9, 2016",,"May 7, 2018",,https://ClinicalTrials.gov/show/NCT02794857,21.0,80.0
392,92,34.395342,-111.7632755,"Research Site, Leuven, Belgium",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
393,92,36.7014631,-118.7559974,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
394,92,36.7014631,-118.7559974,"Montreal Neurological Institute, Montreal, Quebec, Canada",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
395,92,27.7567667,-81.4639835,"Research Site, Paris, France",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
396,92,32.3293809,-83.1137366,"Research Site, Ulm, Baden Wuerttemberg, Germany",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
397,92,39.5162234,-76.9382069,"Research Site, Bunkyo-Ku, Tokyo-To, Japan",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
398,92,42.3788774,-72.032366,"Research Site, Shinjuku-ku, Tokyo-To, Japan",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
399,92,38.7604815,-92.5617875,"Research Site, Kagoshima City, Japan",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
400,92,35.7730076,-86.2820081,"Research Site, Sheffield, South Yorkshire, United Kingdom",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
401,92,50.879202,4.7011675,"University of Michigan Hospital, Ann Arbor, Michigan, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
402,92,50.000678,-86.000977,"Massachusetts General Hospital, Boston, Massachusetts, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
403,92,52.4760892,-71.8258668,"Houston Methodist Hospital, Houston, Texas, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
404,92,48.8566101,2.3514992,"Barrow Neurological Institute/St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
405,92,48.6296972,9.1949534,"University of California at Irvine, Irvine, California, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
406,92,35.6828387,139.7594549,"California Pacific Medical Center, University of California at San Francisco, San Francisco, California, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
407,92,35.6828387,139.7594549,"Sarasota Memorial Hospital, Sarasota, Florida, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
408,92,31.521587,130.5474077,"Emory University School of Medicine, Atlanta, Georgia, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
409,92,53.48153335,-1.38104220661496,"Neurology Clinical Trials Unit, Massachusetts General Hospital, Boston, Massachusetts, United States",93.0,NCT02623699,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BIIB067|Other: Placebo,Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)|PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)|Slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score|Change From Baseline in CSF Levels of SOD1 Protein.|Combined Assessment of Function and Survival (CAFS) Score|Change From Baseline in ALSFRS-R Score|Change From Baseline in Slow Vital Capacity (SVC)|Ventilation Assistance-free Survival (VAFS)|Overall Survival|Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)|Change From Baseline in ALS Assessment Questionnaire (ALSAQ-5) Score|Change From Baseline in Fatigue Severity Scale (FSS) Score|Change From Baseline in EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) Score|Change From Baseline in Work Productivity and Activity Inventory (WPAI) Score|Change From Baseline in Zarit Burden Interview (ZBI) Score|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score|Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,144.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",233AS101|2015-004098-33,"January 20, 2016","May 29, 2020","May 29, 2020","December 8, 2015",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT02623699,18.0,100.0
410,93,43.6211955,-84.6824346,"Saint Mary's Health Care, Grand Rapids, Michigan, United States",94.0,NCT02000713,Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS),,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Other: MRI|Other: Clinical Exam,Study levels of N-acetylaspartate (NAA)in the cervical spinal cord.|Fractional anisotropy in the cervical spinal cord,University of Michigan,All,Not Applicable,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HUM00069508,October 2013,August 2015,August 2015,"December 4, 2013",,"June 4, 2018",,https://ClinicalTrials.gov/show/NCT02000713,18.0,80.0
411,94,42.3788774,-72.032366,"Columbia Presbyterian Medical Center, New York, New York, United States",95.0,NCT02559869,Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis,TRACK-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: [18F] GE-180,"Measure & localize brain inflammation in people with ALS via [18F] GE-180 PET imaging.|Define anatomical, structural, and functional changes in the brain via MRI of ALS Subjects vs. Healthy Controls at Baseline|Determine systemic inflammatory factors that may modify the progression or other clinical or imaging correlates of ALS.|Determine the longitudinal changes in brain inflammation in people with ALS in correlation with ALS severity and rate of progression.|Determine the longitudinal changes in the anatomical, structural, and functional measures in people with ALS, and build ALS prediction models using the clinical and MRI data.",Massachusetts General Hospital|The Methodist Hospital System|Cedars-Sinai Medical Center|ALS Association,All,,200.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2015P000140,November 2015,January 2020,May 2021,"September 24, 2015",,"March 23, 2018",,https://ClinicalTrials.gov/show/NCT02559869,18.0,80.0
412,94,31.8160381,-99.5120986,"Carolinas Medical Center Neuromuscular/ALS-MDA Center, Charlotte, North Carolina, United States",95.0,NCT02559869,Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis,TRACK-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: [18F] GE-180,"Measure & localize brain inflammation in people with ALS via [18F] GE-180 PET imaging.|Define anatomical, structural, and functional changes in the brain via MRI of ALS Subjects vs. Healthy Controls at Baseline|Determine systemic inflammatory factors that may modify the progression or other clinical or imaging correlates of ALS.|Determine the longitudinal changes in brain inflammation in people with ALS in correlation with ALS severity and rate of progression.|Determine the longitudinal changes in the anatomical, structural, and functional measures in people with ALS, and build ALS prediction models using the clinical and MRI data.",Massachusetts General Hospital|The Methodist Hospital System|Cedars-Sinai Medical Center|ALS Association,All,,200.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2015P000140,November 2015,January 2020,May 2021,"September 24, 2015",,"March 23, 2018",,https://ClinicalTrials.gov/show/NCT02559869,18.0,80.0
413,95,34.395342,-111.7632755,"Oregan Health and Science University, Portland, Oregon, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
414,95,36.7014631,-118.7559974,"Drexel University, Philadelphia, Pennsylvania, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
415,95,36.7014631,-118.7559974,"Methodist Neurological Institute, Houston, Texas, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
416,95,27.7567667,-81.4639835,"University of Vermont, Burlington, Vermont, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
417,95,32.3293809,-83.1137366,"Clinique Neurologique, Service des Maladies du Syst√®me Nerveux et du Muscle, H√¥pital Civil, H√¥pitaux Universitaires, Strasbourg, France",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
418,95,42.3788774,-72.032366,"Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
419,95,43.6211955,-84.6824346,"Mayo Clinic, Scottsdale, Arizona, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
420,95,40.7127281,-74.0060152,"UCLA Neuromuscular Research Center, Los Angeles, California, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
421,95,35.6729639,-79.0392919,"UC Irvine MDA/ALS & Neuromuscular Center, Orange, California, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
422,95,43.9792797,-120.737257,"California Pacific Medical Center, San Francisco, California, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
423,95,40.9699889,-77.7278831,"Kansas University Medical Center, Kansas City, Kansas, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
424,95,31.8160381,-99.5120986,"Washington University Department of Neurology, St. Louis, Missouri, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
425,95,44.5990718,-72.5002608,"Providence ALS Clinic, Portland, Oregon, United States",96.0,NCT00983983,High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Dietary Supplement: Oxepa|Dietary Supplement: Jevity 1.5|Dietary Supplement: Jevity 1.0,Safety Outcomes: Frequency of Adverse Events|Serious Adverse Events|Tolerability|Rate of Change in ALSFRS-R in Units/Month|Biomarkers of Body Composition and Lipid Metabolism,Massachusetts General Hospital|Muscular Dystrophy Association,All,Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA136152|2009-P-001132,October 2009,April 2013,May 2013,"September 24, 2009","February 27, 2015","February 27, 2015",,https://ClinicalTrials.gov/show/NCT00983983,18.0,100.0
426,96,48.584614,7.7507127,"University of Pennsylvania Neurological Institute, Philadelphia, Pennsylvania, United States",97.0,NCT00213824,A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,,,"University Hospital, Strasbourg, France",All,,79.0,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,3142,February 2004,July 2012,July 2012,"September 21, 2005",,"March 27, 2015",,https://ClinicalTrials.gov/show/NCT00213824,18.0,100.0
427,97,37.9923795,-1.1305431,"Methodist Neurological Institute, Houston, Texas, United States",98.0,NCT00855400,Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis,CMN/ELA,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Laminectomy and bone marrow stem cells transplantation|Procedure: Autologous bone marrow cells collection,"Forced vital capacity|ALS-FRS, MRC and Norris scales|Absence of adverse events",Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Carlos III Health Institute|Hospital Universitario Virgen de la Arrixaca|Hospital General Universitario Morales Meseguer|Di√≥genes Foundation,All,Phase 1|Phase 2,11.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMN/ELA|EudraCT number: 2006-003096-12|ISCIII: EC07/90762,February 2007,October 2009,February 2010,"March 4, 2009",,"December 2, 2010",,https://ClinicalTrials.gov/show/NCT00855400,20.0,65.0
428,98,34.395342,-111.7632755,"University of Utah Clinical Neurosciences Center, Salt Lake City, Utah, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
429,98,36.7014631,-118.7559974,"Peking University Third Hospital, Beijing, China",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
430,98,36.7014631,-118.7559974,"Servicio Hematolog√≠a Hospital Universitario, Monterrey, Nuevo Le√≥n, Mexico",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
431,98,36.7014631,-118.7559974,"David Lacomis MD, Pittsburgh, Pennsylvania, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
432,98,38.27312,-98.5821872,"University of Virginia, Charlottesville, Virginia, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
433,NULL,NULL,NULL,"Bruneteau Gaelle, Paris, France",,,,,,,,,,,,,,,,,,,,,,,,,,,
434,98,43.9792797,-120.737257,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
435,98,40.9699889,-77.7278831,"UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles, California, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
436,98,31.8160381,-99.5120986,"The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
437,98,39.4225192,-111.7143584,"University of Miami Miller School of Medicine, Miami, Florida, United States",99.0,NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),Lithium,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: lithium carbonate,ALSFRS-R|Vital Capacity|Safety Labs|Adverse Events|Lithium Level (blood),Forbes Norris MDA/ALS Research Center|Muscular Dystrophy Association,All,Phase 2,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28.013,May 2008,March 2010,July 2010,"November 13, 2008",,"March 12, 2009",,https://ClinicalTrials.gov/show/NCT00790582,21.0,80.0
438,99,40.190632,116.412144,"University of Kansas Medical Center, Kansas City, Kansas, United States",100.0,NCT01935518,A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Fasudil,The slope of decline of the ALS Functional Rating Scale-Revised (ALSFRS-R) score|Survival time,Peking University Third Hospital,All,Phase 2,10.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PUTH-2013121,September 2013,March 2015,May 2015,"September 5, 2013",,"September 6, 2013",,https://ClinicalTrials.gov/show/NCT01935518,18.0,70.0
439,100,26.2384363,-99.8873,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",101.0,NCT01933321,Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Intrathecal autologous stem cell,Evaluation of autologous intrathecal administration of hematopoietic stem cells in patients with ALS.|To evaluate the safety of intrathecal administration of hematopoietic stem cells in patients with ALS.,Hospital Universitario Dr. Jose E. Gonzalez,All,Phase 2|Phase 3,14.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALS and stem cell therapy,September 2012,January 2014,June 2014,"September 2, 2013",,"April 3, 2015",,https://ClinicalTrials.gov/show/NCT01933321,18.0,100.0
440,101,40.9699889,-77.7278831,"Massachusettes General Hospital, Boston, Massachusetts, United States",102.0,NCT00140218,R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: R(+) pramipexole dihydrochloride monohydrate,ALS-FRSr score taken each month for 3 months during lead-in and for 6 months during treatment|FVC taken each month|hand dynamometry taken each month,"Bennett, James P., Jr., M.D., Ph.D.|University of Pittsburgh",All,Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11736,August 2005,January 2007,December 2006,"September 1, 2005",,"January 8, 2008",,https://ClinicalTrials.gov/show/NCT00140218,21.0,85.0
441,101,37.1232245,-78.4927721,"Washington University School of Medicine, Saint Louis, Missouri, United States",102.0,NCT00140218,R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: R(+) pramipexole dihydrochloride monohydrate,ALS-FRSr score taken each month for 3 months during lead-in and for 6 months during treatment|FVC taken each month|hand dynamometry taken each month,"Bennett, James P., Jr., M.D., Ph.D.|University of Pittsburgh",All,Phase 1|Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11736,August 2005,January 2007,December 2006,"September 1, 2005",,"January 8, 2008",,https://ClinicalTrials.gov/show/NCT00140218,21.0,85.0
442,102,,,"Bryan LGH Medical Center East, Lincoln, Nebraska, United States",103.0,NCT02478450,Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells¬Æ) Into Subjects With Amyotrophic Lateral Sclerosis (ALS),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Q-Cells,Safety of human glial restricted progenitor cell transplantation in patients with Amyotrophic Lateral Sclerosis. (adverse events)|Score on the amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Quantitative muscle strength values from a hand held dynamometer (HHD) will be tested bilaterally|Hand grip (bilateral) values from a grip dynamometer|Forced vital capacity (FVC)|Maximum sniff nasal inspiratory pressure (SNIP)|Electrical Impedance Myography (EIM) values on bilateral upper and lower limbs|Pain scores on the Visual Analog Scale (VAS)|Score on the ALS Specific Quality of Life Questionnaire - Revised|Score on the Ashworth Spasticity Scale,"Q Therapeutics, Inc.",All,Phase 1|Phase 2,30.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QALS-101,December 2020,December 2023,December 2023,"June 23, 2015",,"March 18, 2019",,https://ClinicalTrials.gov/show/NCT02478450,18.0,100.0
443,103,48.8566101,2.3514992,"Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States",104.0,NCT00847847,Neuromuscular Transmission in Amyotrophic Lateral Sclerosis,NETALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Anconeus Muscle biopsy,Characterization of the neuromuscular transmission dysfunction in ALS by studying the structural and functional features of NMJs on muscle biopsies|Search for correlations between the results of the structural and functional study of neuromuscular junctions on muscle biopsy and surface-EMG and clinical data,"Assistance Publique - H√¥pitaux de Paris|Association pour la Recherche sur la Scl√©rose Lat√©rale Amyotrophique|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Not Applicable,14.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),P080404,March 2009,April 2012,April 2012,"February 19, 2009",,"November 19, 2012",,https://ClinicalTrials.gov/show/NCT00847847,18.0,75.0
444,104,35.2048883,-92.4479108,"SUNY Upstate Medical University, Syracuse, New York, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
445,104,36.7014631,-118.7559974,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
446,104,36.7014631,-118.7559974,"Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
447,104,27.7567667,-81.4639835,"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
448,104,38.27312,-98.5821872,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
449,104,39.5162234,-76.9382069,"University of Texas Health Sciences Center of San Antonio, San Antonio, Texas, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
450,104,42.3788774,-72.032366,"University of Utah, Salt Lake City, Utah, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
451,104,38.7604815,-92.5617875,"University of Virginia Health System, Charlottesville, Virginia, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
452,104,41.7370229,-99.5873816,"University of Washington, Seattle, Washington, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
453,104,40.7127281,-74.0060152,"Yoshino Neurology Clinic, Tokyo, Japan",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
454,104,40.7127281,-74.0060152,"Centre r√©f√©rent maladies rares SLA, Paris, France",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
455,104,40.9699889,-77.7278831,"Cedars-Sinai Medical Center, Los Angeles, California, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
456,104,40.9699889,-77.7278831,"Johns Hopkins University, Baltimore, Maryland, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
457,104,40.9699889,-77.7278831,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
458,104,35.7730076,-86.2820081,"Carolinas Medical Center, Charlotte, North Carolina, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
459,104,31.8160381,-99.5120986,"Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
460,104,39.4225192,-111.7143584,"Assistance Publique Hopitaux de Marseille, Marseille, France",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
461,NULL,NULL,NULL,"Phoenix Neurological Assoc., 1331 N. 7th Street, Suite 350, Phoenix, Arizona, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
462,104,38.8950092,-77.0365625,"Cedars-Sinai ALS Center, Neurology Specialty Clinic, 8730 Alden Drive, Thalians, E 245, Los Angeles, California, United States",105.0,NCT00931944,"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)",CL211,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily.|The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function.,Knopp Biosciences,All,Phase 2,74.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KNS-760704-CL211,July 2009,July 2013,July 2013,"July 2, 2009",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00931944,21.0,80.0
463,105,35.6828387,139.7594549,"UCSF ALS Center, University of California San Francisco, Neurology, Box 0114, UCSF, San Francisco, California, United States",106.0,NCT00886977,Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: YAM80,ALSFRS-R|Safety|Manual Muscle Testing|Grip/pinch strength|Pulmonary function (forced vital capacity),Yoshino Neurology Clinic,All,Phase 2,25.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YAM80-01,April 2009,December 2010,,"April 23, 2009",,"October 25, 2010",,https://ClinicalTrials.gov/show/NCT00886977,25.0,65.0
464,106,48.8566101,2.3514992,"Mayo Clinic-Jacksonville, Neurology Department, 4500 San Pablo Road, Jacksonville, Florida, United States",107.0,NCT01639391,Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study,ALSCELL,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: skin biopsy,"Success of fibroblast culture, amplification, and freezing pellets|Induced pluripotent Stem Cells generation success|neurones, motoneurones, glial cells obtention from fibroblasts or iPS",Institut Pasteur,All,Not Applicable,19.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2010-33,"November 29, 2012","March 17, 2015","March 17, 2015","July 12, 2012",,"May 1, 2018",,https://ClinicalTrials.gov/show/NCT01639391,18.0,100.0
465,107,36.7014631,-118.7559974,"University of Miami, Miller School of Medicine, 1150 NW 14th Street, Suite 609 (SCs are suite 701), Miami, Florida, United States",108.0,NCT01521728,Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Resistance Exercise|Other: Endurance Exercise|Other: Stretching/Range-of-Motion,Resistance Exercise Tolerability|Endurance Exercise Tolerability|Vital Capacity|ALS Functional Rating Scores|Muscle Strength|Spasticity|Fatigue|Quality of Life,Johns Hopkins University|ALS Association,All,Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,NA_00022650,January 2012,February 2016,February 2016,"January 31, 2012",,"April 19, 2016",,https://ClinicalTrials.gov/show/NCT01521728,18.0,80.0
466,107,39.5162234,-76.9382069,"Indiana University, Department of Neurology, 1050 Wishard Blvd, RG 6, Indianapolis, Indiana, United States",108.0,NCT01521728,Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Resistance Exercise|Other: Endurance Exercise|Other: Stretching/Range-of-Motion,Resistance Exercise Tolerability|Endurance Exercise Tolerability|Vital Capacity|ALS Functional Rating Scores|Muscle Strength|Spasticity|Fatigue|Quality of Life,Johns Hopkins University|ALS Association,All,Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,NA_00022650,January 2012,February 2016,February 2016,"January 31, 2012",,"April 19, 2016",,https://ClinicalTrials.gov/show/NCT01521728,18.0,80.0
467,107,42.3788774,-72.032366,"University of Kentucky Medical Center, BAMC, Department of Neurology, Room A307, 1101 Veteran's Drive, Lexington, Kentucky, United States",108.0,NCT01521728,Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Resistance Exercise|Other: Endurance Exercise|Other: Stretching/Range-of-Motion,Resistance Exercise Tolerability|Endurance Exercise Tolerability|Vital Capacity|ALS Functional Rating Scores|Muscle Strength|Spasticity|Fatigue|Quality of Life,Johns Hopkins University|ALS Association,All,Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,NA_00022650,January 2012,February 2016,February 2016,"January 31, 2012",,"April 19, 2016",,https://ClinicalTrials.gov/show/NCT01521728,18.0,80.0
468,107,35.6729639,-79.0392919,"Johns Hopkins University, Department of Neurology, 600 N. Wolfe St, Meyer 6-181, Baltimore, Maryland, United States",108.0,NCT01521728,Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Resistance Exercise|Other: Endurance Exercise|Other: Stretching/Range-of-Motion,Resistance Exercise Tolerability|Endurance Exercise Tolerability|Vital Capacity|ALS Functional Rating Scores|Muscle Strength|Spasticity|Fatigue|Quality of Life,Johns Hopkins University|ALS Association,All,Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,NA_00022650,January 2012,February 2016,February 2016,"January 31, 2012",,"April 19, 2016",,https://ClinicalTrials.gov/show/NCT01521728,18.0,80.0
469,108,41.3828939,2.1774322,"Massachusetts General Hospital, 149 13th St, Room 2266, Charlestown, Massachusetts, United States",109.0,NCT01641965,Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: Home pressure ventilator model Vivo 40 (BREAS Medical AB),survival until death or tracheostomy|effects from early use of NIV in progression of respiratory muscle weakness,Hospital Universitari de Bellvitge|Fondo de Investigacion Sanitaria,All,Not Applicable,42.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AC 111/11,April 2012,December 2015,December 2015,"July 17, 2012",,"February 22, 2016",,https://ClinicalTrials.gov/show/NCT01641965,18.0,80.0
470,109,43.2961743,5.3699525,"Wayne State University, Department of Neurology, 4201 St. Antoine, 8C UHC, Detroit, Michigan, United States",110.0,NCT01959373,Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis,,Suspended,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: electroencephalograms (EEG)|Procedure: electro-myography (EMG),recording neuronal activities|identify plasticity phenomena,Assistance Publique Hopitaux De Marseille,All,Not Applicable,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2013-A00802-43|2013-22,October 2013,July 2014,,"October 10, 2013",,"August 24, 2015",,https://ClinicalTrials.gov/show/NCT01959373,18.0,100.0
471,110,,,"Hennepin County Medical Center, Dept of Neurology, 701 Part Ave S, P5-200, Minneapolis, Minnesota, United States",111.0,NCT00330681,Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: MCI-186|Drug: Placebo of MCI-186,Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks|Death or a Specified State of Disease Progression|Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks|Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks|Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks|Percentage of Participants With Adverse Events|Percentage of Participants With Adverse Drug Reactions|Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group|Percentage of Participants With Abnormal Changes in Sensory Examinations,Mitsubishi Tanabe Pharma Corporation,All,Phase 3,206.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI186-16,May 2006,September 2008,September 2008,"May 29, 2006","May 17, 2017","May 17, 2017",,https://ClinicalTrials.gov/show/NCT00330681,20.0,75.0
472,111,34.395342,-111.7632755,"Washington University, 660 S. Euclid Ave., Box 8111 Neurology, St. Louis, Missouri, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
473,111,36.7014631,-118.7559974,"Columbia Univ Med Ctr, Eleanor and Lou Gehrig ALS/MDA Center, 710 West 168th St, 9th Floor, New York, New York, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
474,111,36.7014631,-118.7559974,"SUNY Upstate Medical University, 750 E Adams St, 6610UH, Syracuse, New York, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
475,111,27.7567667,-81.4639835,"Duke University Medical Center, Box 3333, Durham, North Carolina, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
476,111,27.7567667,-81.4639835,"Wake Forest University, ALS Center, Paul Sticht Center, Ground Floor, Medical Center Blvd, Winston-Salem, North Carolina, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
477,111,40.3270127,-86.1746933,"Ohio State University, Neuromuscular Division, 1654 Uphan Drive, 417 Means Hall, Columbus, Ohio, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
478,111,37.5726028,-85.1551411,"Penn State Hershey Medical Center, Department of Neurology, H037, Pennsylvania State Hershey Medical Center, Hershey, Pennsylvania, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
479,111,39.5162234,-76.9382069,"Drexel University College of Medicine, 245 North 15th Street, Philadelphia, Pennsylvania, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
480,111,42.3788774,-72.032366,"Texas Neurology, PA, 6301 Gaston Ave, Suite 400 West Tower, Dallas, Texas, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
481,111,43.6211955,-84.6824346,"University of Vermont, Department of Neurology, 89 Beaumont Drive, Given Bldg, Room C-225, Burlington, Vermont, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
482,111,45.9896587,-94.6113288,"University of Virginia, Department of Neurology, 3100 Hospital Drive, Charlottesville, Virginia, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
483,111,38.7604815,-92.5617875,"University of Calgary, Area 3, University of Calgary Medical Clinic, 3350 Hospital Drive NW Foothills Hosp. Grounds, Calgary, Alberta, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
484,111,40.7127281,-74.0060152,"University of Alberta, Division of Neurology, Dept of Medicine, 2E3.17 Walter C. MacKenzie Health Sciences Center, Edmonton, Alberta, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
485,111,40.7127281,-74.0060152,"University of British Columbia, GF Strong Rehab Centre, 4255 Laurel Street, Vancouver, British Columbia, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
486,111,35.6729639,-79.0392919,"University of Manitoba, Winnipeg, Manitoba, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
487,111,35.6729639,-79.0392919,"University of New Brunswick, The Stan Cassidy Centre for Rehabilitation, 800 Priestman St., Fredericton, New Brunswick, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
488,111,40.2253569,-82.6881395,"Dalhousie University, Capital District Health Authority, Queen Elizabeth II Health Sciences Centre, P.O. Box 9000, Summer Street, Halifax, Nova Scotia, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
489,111,40.9699889,-77.7278831,"McMaster University, McMaster University Medical Centre, Hamilton Health Sciences, 1200 Main Street West, Room 4U7, Box 2000, Hamilton, Ontario, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
490,111,40.9699889,-77.7278831,"Queen's University, The Adult Neuromuscular Clinic, PCCC, St. Mary's of the Lake Hospital Site, Department of Physical Medicine and Rehabilitation, 340 Union Street, Postal Bldg 3600, Kingston, Ontario, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
491,111,31.8160381,-99.5120986,"University of Western Ontario, Department of Clinical Neurological Sciences, Motor Neuron Disease Clinic, 339 Windermere Road, Box 5339, London, Ontario, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
492,111,44.5990718,-72.5002608,"University of Ottawa, The Rehabilitation Centre, 505 Smyth Road, Ottawa, Ontario, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
493,111,37.1232245,-78.4927721,"University of Toronto, Sunnybrook Health Sciences Centre, ALS/Neuromuscular Clinic - SCIL, Room UG-35, 2075 Bayview Ave, Toronto, Ontario, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
494,111,55.001251,-115.002136,"University of Montreal, CHUM (Centre Hospitalier de l'Universit√© de Montr√©al) Notre-Dame Hospital 1560,Sherbrooke east street, Montreal, Quebec, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
495,111,55.001251,-115.002136,"McGill University, Montreal Neurological Hospital, 3801 University, Room 205, Montreal, Quebec, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
496,111,55.001251,-125.002441,"Laval University, CHA-Enfant-Jesus Hospital, 1401, 18th Street, Quebec City, Quebec, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
497,111,55.001251,-97.001038,"University of Saskatchewan, Saskatoon City Hospital, 701 Queen Street, Room 7717 - 7th Floor, Saskatoon, Saskatchewan, Canada",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
498,NULL,NULL,NULL,"Centro Regionale Malattie Neuromuscolari, Ospedale Clinicizzato ""SS. Annunziata"", Chieti, Italy",,,,,,,,,,,,,,,,,,,,,,,,,,,
499,111,45.1960403,-63.1653789,"Azienda Policlinico Universit√† Federico II, Napoli, Italy",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
500,111,50.000678,-86.000977,"Policlinico Universitario Agostino Gemelli, Rome, Italy",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
501,111,50.000678,-86.000977,"Department of Allied health Occupations, Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
502,111,50.000678,-86.000977,"Barrow Neurology, Phoenix, Arizona, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
503,111,50.000678,-86.000977,"University of California, San Diego, La Jolla, California, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
504,111,50.000678,-86.000977,"UC Irvine ALS & Neuromuscular Center, Orange, California, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
505,111,52.4760892,-71.8258668,"Coordinated Clinical Research, San Diego, California, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
506,111,52.4760892,-71.8258668,"California Pacific Medical Center Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
507,111,52.4760892,-71.8258668,"Hospital for Special Care, New Britain, Connecticut, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
508,111,55.5321257,-106.1412243,"The George Washington University, Washington, District of Columbia, United States",112.0,NCT00818389,Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS),,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Lithium Carbonate|Drug: Riluzole|Drug: placebo,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R)|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R)|Vital Capacity (VC) (Percent of Predicted Normal),Massachusetts General Hospital|ALS Association|ALS Society of Canada|National Institute of Neurological Disorders and Stroke (NINDS)|University of Toronto|State University of New York - Upstate Medical University|Columbia University|University of Kentucky,All,Phase 2|Phase 3,84.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS049640|3U01NS049640-04S1,January 2009,October 2009,October 2009,"January 7, 2009","April 19, 2011","April 19, 2011",,https://ClinicalTrials.gov/show/NCT00818389,18.0,100.0
509,112,,,"Mayo Clinic Florida Department of Neurology, Jacksonville, Florida, United States",113.0,NCT00415519,Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: MCI-186|Drug: Placebo of MCI-186,Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks|Death or a Specified State of Disease Progression|Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks|Percentage of Participants With Adverse Events|Percentage of Participants With Adverse Drug Reactions|The Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients|Percentage of Participants With Abnormal Changes in Sensory Examinations,Mitsubishi Tanabe Pharma Corporation,All,Phase 3,25.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI186-18,December 2006,July 2008,July 2008,"December 25, 2006","December 20, 2017","December 20, 2017",,https://ClinicalTrials.gov/show/NCT00415519,20.0,75.0
510,113,42.3446529,14.1659738,"Emory University, School of Medicine, Atlanta, Georgia, United States",114.0,NCT01569958,Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: transcranial direct current stimulation|Other: Sham stimulation,Decline of ALSFRS-R (ALS functional rating scale-revised) from baseline to 12 months|Decline of muscle strength from baseline to 12 months|Change of upper motor neuron signs from baseline to 12 months|Decline of forced vital capacity (percent of predicted normal) from baseline to 12 months|Change of quality of life from baseline to 12 months,"Universit√† degli Studi 'G. d'Annunzio' Chieti e Pescara|Catholic University, Italy|Federico II University|Ministero della Salute, Italy",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TDCS2011-01|RF-ABR-2007-631680,July 2012,April 2016,April 2016,"April 3, 2012",,"October 10, 2012",,https://ClinicalTrials.gov/show/NCT01569958,18.0,85.0
511,113,40.8359336,14.2487826,"Georgia Health Sciences University, Augusta, Georgia, United States",114.0,NCT01569958,Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: transcranial direct current stimulation|Other: Sham stimulation,Decline of ALSFRS-R (ALS functional rating scale-revised) from baseline to 12 months|Decline of muscle strength from baseline to 12 months|Change of upper motor neuron signs from baseline to 12 months|Decline of forced vital capacity (percent of predicted normal) from baseline to 12 months|Change of quality of life from baseline to 12 months,"Universit√† degli Studi 'G. d'Annunzio' Chieti e Pescara|Catholic University, Italy|Federico II University|Ministero della Salute, Italy",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TDCS2011-01|RF-ABR-2007-631680,July 2012,April 2016,April 2016,"April 3, 2012",,"October 10, 2012",,https://ClinicalTrials.gov/show/NCT01569958,18.0,85.0
512,113,41.894802,12.4853384,"Indiana University Department of Neurology, Indianapolis, Indiana, United States",114.0,NCT01569958,Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: transcranial direct current stimulation|Other: Sham stimulation,Decline of ALSFRS-R (ALS functional rating scale-revised) from baseline to 12 months|Decline of muscle strength from baseline to 12 months|Change of upper motor neuron signs from baseline to 12 months|Decline of forced vital capacity (percent of predicted normal) from baseline to 12 months|Change of quality of life from baseline to 12 months,"Universit√† degli Studi 'G. d'Annunzio' Chieti e Pescara|Catholic University, Italy|Federico II University|Ministero della Salute, Italy",All,Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TDCS2011-01|RF-ABR-2007-631680,July 2012,April 2016,April 2016,"April 3, 2012",,"October 10, 2012",,https://ClinicalTrials.gov/show/NCT01569958,18.0,85.0
513,114,52.1014041,5.9515701,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",115.0,NCT00160004,The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Behavioral: Intensive Controlled Exercise,Cardiorespiratory fitness measured with Astrand submaximal test|Muscle Strength measured with MVIC (Maximum Voluntary Isometric Contraction)|Functional status measured with ALS-FRS-r Rating scale|Quality of life with ALS-AQ40 Questionnaire|Fatigue measured with CIS Questionnaire|Pulmonary function measured with FVC,Radboud University,All,Phase 1|Phase 2,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,ALSICEJ1,March 2006,,December 2008,"September 12, 2005",,"June 8, 2009",,https://ClinicalTrials.gov/show/NCT00160004,18.0,100.0
514,115,34.395342,-111.7632755,"University of Kansas, Kansas City, Kansas, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
515,115,36.7014631,-118.7559974,"Johns Hopkins University, Baltimore, Maryland, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
516,115,36.7014631,-118.7559974,"Massachusetts General Hospital, Boston, Massachusetts, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
517,115,36.7014631,-118.7559974,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
518,115,36.7014631,-118.7559974,"University of Michigan, Ann Arbor, Michigan, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
519,115,41.6500201,-72.7342163,"Henry Ford Hospital, Detroit, Michigan, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
520,115,38.89366125,-76.987883253882,"St Mary's Healthcare, Grand Rapids, Michigan, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
521,115,27.7567667,-81.4639835,"Hennepin County Medical Center - Berman Center for Research, Minneapolis, Minnesota, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
522,115,32.3293809,-83.1137366,"Saint Louis University, St. Louis, Missouri, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
523,115,32.3293809,-83.1137366,"Washington University, St. Louis, Missouri, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
524,115,40.3270127,-86.1746933,"Neurology Associates, Lincoln, Nebraska, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
525,115,41.9216734,-93.3122705,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
526,115,38.27312,-98.5821872,"Hospital for Special Surgery, New York, New York, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
527,115,39.5162234,-76.9382069,"University of Rochester, Rochester, New York, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
528,115,42.3788774,-72.032366,"SUNY Upstate Medical University, Syracuse, New York, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
529,115,42.3788774,-72.032366,"Carolinas Medical Center Department of Neurology, Charlotte, North Carolina, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
530,115,43.6211955,-84.6824346,"Duke University, Durham, North Carolina, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
531,115,43.6211955,-84.6824346,"Wake Forest University, School of Medicine, Winston-Salem, North Carolina, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
532,115,43.6211955,-84.6824346,"Ohio State University Department of Neurology, Columbus, Ohio, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
533,115,45.9896587,-94.6113288,"Providence ALS Center, Portand, Oregon, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
534,115,38.7604815,-92.5617875,"Oregon Health & Science University, Portland, Oregon, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
535,115,38.7604815,-92.5617875,"Penn State Hershey Neuroscience Clinics, Hershey, Pennsylvania, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
536,115,41.7370229,-99.5873816,"Drexel Neurology, Philadelphia, Pennsylvania, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
537,115,43.4849133,-71.6553992,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
538,115,40.7127281,-74.0060152,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
539,115,40.7127281,-74.0060152,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
540,115,40.7127281,-74.0060152,"Texas Neurology, Dallas, Texas, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
541,115,35.6729639,-79.0392919,"Baylor College of Medicine, Houston, Texas, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
542,115,35.6729639,-79.0392919,"UTHSCSA Department of Neurology, San Antonio, Texas, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
543,115,35.6729639,-79.0392919,"University of Virginia, Charlottesville, Virginia, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
544,115,40.2253569,-82.6881395,"West Virginia University Department of Neurology, Morgantown, West Virginia, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
545,115,43.9792797,-120.737257,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
546,115,43.9792797,-120.737257,"Heritage Medical Research, Calgary, Alberta, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
547,115,40.9699889,-77.7278831,"University of Alberta Hospital, Edmonton, Alberta, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
548,115,40.9699889,-77.7278831,"University of British Columbia, Vancouver, British Columbia, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
549,115,40.9699889,-77.7278831,"Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
550,115,40.9699889,-77.7278831,"QE II Health Sciences Centre, Halifax, Nova Scotia, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
551,115,35.7730076,-86.2820081,"McMaster University Medical Centre, Hamilton, Ontario, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
552,115,31.8160381,-99.5120986,"Queen's University : Kingston General, Kingston, Ontario, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
553,115,31.8160381,-99.5120986,"London Health Sciences, London, Ontario, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
554,115,31.8160381,-99.5120986,"Univ. of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
555,115,37.1232245,-78.4927721,"H√¥pital Notre Dame (CHUM) Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
556,115,38.4758406,-80.8408415,"Montreal Neurological Institute, Montreal, Quebec, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
557,115,44.4308975,-89.6884637,"CHU de Quebec: Hopital l'Enfant-Jesus, Quebec, Canada",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
558,115,55.001251,-115.002136,"CHRU de Lille - H√¥pital Roger Salengro, Lille, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
559,115,55.001251,-115.002136,"CHU de Limoges - H√¥pital Dupuytren, Limoges, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
560,115,55.001251,-125.002441,"H√¥pital La Timone Adulte, Marseille, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
561,115,46.500283,-66.750183,"CHU Montepellier, Montpellier, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
562,115,45.1960403,-63.1653789,"H√¥pital Archet 1, Nice, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
563,115,50.000678,-86.000977,"H√¥pital de la Salp√™tri√®re, Paris, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
564,115,50.000678,-86.000977,"H√¥pital Bretonneau, Tours, France",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
565,115,50.000678,-86.000977,"Charite Universit√§tsmedizin, Berlin, Germany",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
566,115,50.000678,-86.000977,"Hannover Medical School, Hannover, Germany",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
567,115,52.4760892,-71.8258668,"University of Ulm, Ulm, Germany",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
568,115,52.4760892,-71.8258668,"Trinity College, Beaumont Hospital, Dublin, Ireland",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
569,115,52.4760892,-71.8258668,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
570,115,50.6365654,3.0635282,"Hospital Carlos III, Madrid, Spain",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
571,115,45.8354243,1.2644847,"Barts and the London MND & the Centre Royal London Hospital, Whitechapel, London, United Kingdom",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
572,115,43.2961743,5.3699525,"Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
573,115,43.6112422,3.8767337,"Kings College Hospital NHS Foundation Trust, London, United Kingdom",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
574,115,43.7009358,7.2683912,"John Radcliffe Hospital, Oxford, United Kingdom",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
575,115,48.8566101,2.3514992,"Plymouth Hospitals NHS Trust, Plymouth, United Kingdom",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
576,115,47.3900474,0.6889268,"Sheffield Institute for Translational Neuroscience, Sheffield, United Kingdom",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
577,115,52.5170365,13.3888599,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
578,115,52.3744779,9.7385532,"UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles, California, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
579,115,48.3974003,9.9934336,"The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
580,115,53.3497645,-6.2602732,"University of Colorado Health Sciences Center, Aurora, Colorado, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
581,115,52.0809856,5.12768396945229,"University of Miami Miller School of Medicine, Miami, Florida, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
582,115,40.4167047,-3.7035825,"University of Kansas Medical Center, Kansas City, Kansas, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
583,115,51.5073219,-0.1276474,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
584,115,53.407154,-2.991665,"Massachusettes General Hospital, Boston, Massachusetts, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
585,115,51.5073219,-0.1276474,"Washington University School of Medicine, Saint Louis, Missouri, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
586,115,51.7520131,-1.2578499,"Bryan LGH Medical Center East, Lincoln, Nebraska, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
587,115,50.3712659,-4.1425658,"Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
588,115,53.3806626,-1.4702278,"SUNY Upstate Medical University, Syracuse, New York, United States",116.0,NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Other: Placebo tablets|Drug: Riluzole,The change from baseline to the average of the ALS Functional Rating Scale-Revised (ALSFRS-R) total score obtained at Visits 6 and 7|Change in Maximum Voluntary Ventilation (MVV)|Change in Sniff Nasal Inspiratory Pressure (SNIP)|Change in Slow Vital Capacity (SVC)|Change in handgrip strength and fatigability|Change in muscle strength by hand-held dynamometry (HHD),Cytokinetics,All,Phase 2,711.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4026,October 2012,March 2014,March 2014,"October 18, 2012",,"January 9, 2017",,https://ClinicalTrials.gov/show/NCT01709149,18.0,100.0
589,116,35.2048883,-92.4479108,"Oregon Health Sciences University, Portland, Oregon, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
590,116,36.7014631,-118.7559974,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
591,116,36.7014631,-118.7559974,"Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
592,116,38.7251776,-105.6077167,"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
593,116,27.7567667,-81.4639835,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
594,116,38.27312,-98.5821872,"University of Texas Health Sciences Center of San Antonio, San Antonio, Texas, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
595,116,39.5162234,-76.9382069,"University of Utah, Salt Lake City, Utah, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
596,116,42.3788774,-72.032366,"University of Virginia Health System, Charlottesville, Virginia, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
597,116,38.7604815,-92.5617875,"University of Washington, Seattle, Washington, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
598,116,41.7370229,-99.5873816,"Mayo Clinic, Rochester, Minnesota, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
599,116,40.7127281,-74.0060152,"Yihua An, Beijing, China",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
600,116,40.7127281,-74.0060152,"Montreal Chest Institute, Montreal, Quebec, Canada",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
601,116,43.9792797,-120.737257,"The Centre for Incurable Diseases, Toronto, Ontario, Canada",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
602,116,40.9699889,-77.7278831,"VA Medical Center, Durham, North Carolina, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
603,116,40.9699889,-77.7278831,"IRCCS Neuromed, Pozzilli, Italy",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
604,116,40.9699889,-77.7278831,"Emory University, Atlanta, Georgia, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
605,116,35.7730076,-86.2820081,"Massachusetts General Hospital, Boston, Massachusetts, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
606,116,31.8160381,-99.5120986,"University of Michigan, Ann Arbor, Michigan, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
607,116,39.4225192,-111.7143584,"Methodist Neurological Institute, Houston, Texas, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
608,116,37.1232245,-78.4927721,"University of Miami Miller School of Medicine, Miami, Florida, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
609,116,38.8950092,-77.0365625,"Massachusetts General Hospital, Boston, Massachusetts, United States",117.0,NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),CL201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704|Drug: Placebo,Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for 12 weeks in subjects with ALS (Part 1)|Number of subjects experiencing unacceptable safety or tolerability events after oral administration of KNS-760704 compared to placebo for up to 76 weeks in subjects with ALS (Part 2)|Change from Baseline in ALSFRS-R|Change from baseline to Week 12 in upright and supine vital capacity|Changes in cystatin C and neurofilament H,Knopp Biosciences,All,Phase 2,102.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,March 2008,September 2009,October 2009,"March 31, 2008",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT00647296,21.0,80.0
610,117,45.9896587,-94.6113288,"Columbia University Medical Center, New York, New York, United States",118.0,NCT01609283,A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Biological: autologous mesenchymal stem cells,Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF),Mayo Clinic,All,Phase 1,27.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-008415,May 2012,January 2019,January 2019,"May 31, 2012",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT01609283,18.0,100.0
611,118,40.190632,116.412144,"Hospital e Maternidade Dr Christovao da Gama, Santo Andre, Sao Paulo, Brazil",119.0,NCT01494480,The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: stem cell transplantation,Nerve functional evaluation|Forced vital capacity|Blood test|Urinal test|Electrophysiology examination,General Hospital of Chinese Armed Police Forces,All,Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20111207ALS,March 2012,January 2013,April 2015,"December 19, 2011",,"June 20, 2012",,https://ClinicalTrials.gov/show/NCT01494480,20.0,65.0
612,119,52.4760892,-71.8258668,"Instituto de Ensino e Pesquisas - IEP-S√£o Lucas, Sao Paulo, SP, Brazil",120.0,NCT01746381,Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Non-invasive home ventilation,Difference in the number of respiratory therapist interventions required using IVAPS vs BIST mode of ventilation in patients with ALS.|Feasibility of initiating long term home ventilation in ALS patients using the Stellar 150 iVAPS mode during a single daytime trial.|Difference in symptoms with IVAPS vs. BiST in ALS patients|Effectiveness of ventilation by IVAPS vs. BiST on night-time respiratory parameters in ALS patients|Long-term compliance with the use of nocturnal ventilation on IVAPS vs. BiST in ALS patients,Marta Kaminska|ResMed|McGill University Health Center,All,Not Applicable,30.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2902,February 2014,June 2019,July 2019,"December 10, 2012",,"March 7, 2019",,https://ClinicalTrials.gov/show/NCT01746381,18.0,100.0
613,120,50.000678,-86.000977,"Department of Neurology, University of Ulm, Ulm, Baden-W√ºrttemberg, Germany",121.0,NCT00673140,"Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)",,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Radiation: Far Infrared Radiation (5Œºm to 20Œºm wavelength)|Radiation: Far infrared radiation,Therapy for ALS|Rehabilitation of ALS patients,GAAD Medical Research Institute Inc.,All,Phase 1,7.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GAAD-ALS-CTP1,May 2008,May 2010,June 2010,"May 7, 2008",,"August 17, 2009",,https://ClinicalTrials.gov/show/NCT00673140,18.0,100.0
614,121,35.6729639,-79.0392919,"Department of Neurology and Center for Palliative Medicine, University of Munich, Muenchen, Bayern, Germany",122.0,NCT00007722,Amyotrophic Lateral Sclerosis (ALS) Gulf War Study,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Probability of ALS among veterans both deployed and non-deployed to the Gulf Region(8/2/1990-7/31/1991),US Department of Veterans Affairs|United States Department of Defense|Centers for Disease Control and Prevention|Department of Health and Human Services|ALS Association|VA Office of Research and Development,All,,135.0,U.S. Fed|Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,500,July 2000,March 2003,March 2003,"January 1, 2001",,"October 9, 2009",,https://ClinicalTrials.gov/show/NCT00007722,18.0,100.0
615,122,41.511422,14.062517,"Department of Neurology, Universty of Regensburg, Regensburg, Bayern, Germany",123.0,NCT03088839,Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS),,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),,Identification of circulating miR-218 as biomarker for ALS,Neuromed IRCCS,All,,60.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,ADP_01,"December 1, 2017","September 1, 2019","December 1, 2019","March 23, 2017",,"January 31, 2019",,https://ClinicalTrials.gov/show/NCT03088839,20.0,75.0
616,123,32.3293809,-83.1137366,"Department of Neurology, University of Wuerzburg, Wuerzburg, Bayern, Germany",124.0,NCT01730716,Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: Human spinal cord stem cell implantation,To determine the safety of the maximum tolerated dose of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS) assessed by the number and severity of adverse events.|To evaluate neurologic deficits post spinal stem cell transplantation therapy.,Neuralstem Inc.,All,Phase 2,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NS2012-3,May 2013,December 2015,November 2016,"November 21, 2012",,"April 20, 2015",,https://ClinicalTrials.gov/show/NCT01730716,18.0,100.0
617,123,42.3788774,-72.032366,"Department of Neurology, Deutsche Klinik f√ºr Diagnostik, Wiesbaden, Hessen, Germany",124.0,NCT01730716,Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: Human spinal cord stem cell implantation,To determine the safety of the maximum tolerated dose of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS) assessed by the number and severity of adverse events.|To evaluate neurologic deficits post spinal stem cell transplantation therapy.,Neuralstem Inc.,All,Phase 2,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NS2012-3,May 2013,December 2015,November 2016,"November 21, 2012",,"April 20, 2015",,https://ClinicalTrials.gov/show/NCT01730716,18.0,100.0
618,123,43.6211955,-84.6824346,"Department of Neurology, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany",124.0,NCT01730716,Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: Human spinal cord stem cell implantation,To determine the safety of the maximum tolerated dose of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS) assessed by the number and severity of adverse events.|To evaluate neurologic deficits post spinal stem cell transplantation therapy.,Neuralstem Inc.,All,Phase 2,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NS2012-3,May 2013,December 2015,November 2016,"November 21, 2012",,"April 20, 2015",,https://ClinicalTrials.gov/show/NCT01730716,18.0,100.0
619,124,31.8160381,-99.5120986,"Department of Neurology, University of Goettingen, Goettingen, Niedersachsen, Germany",125.0,NCT03241784,T-Regulatory Cells in Amyotrophic Lateral Sclerosis,,"Active, not recruiting",No Results Available,ALS (Amyotrophic Lateral Sclerosis),Biological: Autologous T-regulatory lymphocytes|Biological: Interleukin-2,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|AALS (Appel ALS) Scale|ALSFRS-R (ALS Functional Rating Scale-Revised)|T-Regulatory Cells|Treg Suppression|TH17 and Th1 lymphocytes,"Stanley H. Appel, MD|The Methodist Hospital System",All,Phase 1,4.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00013616,"May 16, 2016",February 2018,March 2018,"August 7, 2017",,"March 26, 2018",,https://ClinicalTrials.gov/show/NCT03241784,18.0,100.0
620,125,27.7567667,-81.4639835,"Department of Neurology, Medical School Hannover, Hannover, Niedersachsen, Germany",126.0,NCT00706147,"Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo,"Time to death, tracheostomy or permanent assisted ventilation will be the primary outcome measure.|Rate of decline of ALSFRS-R (ALS functional rating scale-revised) over a period of up to 12 months.|Disease progression as measured by the rate of decline of FEV6.|Safety and tolerability of arimoclomol will be evaluated by using vital signs and weight, clinical laboratory measures, physical examination, report of adverse events, and the proportion of subjects completing the study on assigned treatment.",University of Miami|Massachusetts General Hospital,All,Phase 2|Phase 3,38.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20100758|3517,January 2009,December 2014,November 2016,"June 27, 2008",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT00706147,18.0,100.0
621,125,42.3788774,-72.032366,"Neurologische Universit√§tsklinik Bergmannsheil, Bochum, Nordrhein-Westfalen, Germany",126.0,NCT00706147,"Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo,"Time to death, tracheostomy or permanent assisted ventilation will be the primary outcome measure.|Rate of decline of ALSFRS-R (ALS functional rating scale-revised) over a period of up to 12 months.|Disease progression as measured by the rate of decline of FEV6.|Safety and tolerability of arimoclomol will be evaluated by using vital signs and weight, clinical laboratory measures, physical examination, report of adverse events, and the proportion of subjects completing the study on assigned treatment.",University of Miami|Massachusetts General Hospital,All,Phase 2|Phase 3,38.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20100758|3517,January 2009,December 2014,November 2016,"June 27, 2008",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT00706147,18.0,100.0
622,126,40.7127281,-74.0060152,"Department of Neurology, Universty of Muenster, Muenster, Nordrhein-Westfalen, Germany",127.0,NCT01363882,Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Other: Sleep study-guided adjustment of NIV|Other: Standard initiation of NIV,"Change from baseline in spirometric, respiratory muscle strength, and gas exchange measures|Duration that the Mental Component Summary (MCS) is maintained above 75% of baseline score for the Medical Outcomes Study Health Survey (SF-12)|Survival|Nocturnal oxygenation and ventilation|Modified Borg dyspnea score (see description)",Columbia University|ALS Association,All,Not Applicable,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",AAAC6753,February 2008,January 2011,,"June 2, 2011",,"June 2, 2011",,https://ClinicalTrials.gov/show/NCT01363882,18.0,80.0
623,127,-23.5506507,-46.6333824,"Department of Neurology, Universty of Bonn, Bonn, Nordrhrein-Westfalen, Germany",128.0,NCT02987413,Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients,,Completed,No Results Available,Motor Neuron Disease,Biological: Autologous Mesenchymal stem cells (MSCs),Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R),Hospital e Maternidade Dr. Christ√≥v√£o da Gama|IEP S√£o Lucas - Instituto de Ensino e Pesquisa|Clinica Jordy Sinapse|TECHLIFE - Centro de Tecnologia Celular,All,Phase 1,3.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HospitalMCG|IEPSaoLucas,"April 28, 2015",March 2016,"April 5, 2017","December 9, 2016",,"August 7, 2017",,https://ClinicalTrials.gov/show/NCT02987413,18.0,100.0
624,127,-10.3333333,-53.2,"Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany",128.0,NCT02987413,Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients,,Completed,No Results Available,Motor Neuron Disease,Biological: Autologous Mesenchymal stem cells (MSCs),Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R),Hospital e Maternidade Dr. Christ√≥v√£o da Gama|IEP S√£o Lucas - Instituto de Ensino e Pesquisa|Clinica Jordy Sinapse|TECHLIFE - Centro de Tecnologia Celular,All,Phase 1,3.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HospitalMCG|IEPSaoLucas,"April 28, 2015",March 2016,"April 5, 2017","December 9, 2016",,"August 7, 2017",,https://ClinicalTrials.gov/show/NCT02987413,18.0,100.0
625,128,48.6296972,9.1949534,"Department of Neurology, TU Dresden, Dresden, Sachsen, Germany",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
626,128,48.9467562,11.4038717,"Department of Neurology, University of Jena, Jena, Thueringen, Germany",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
627,128,48.9467562,11.4038717,"Department of Neurology, Humboldt University, Berlin, Germany",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
628,128,48.9467562,11.4038717,"Nagoya-shi, Aichi, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
629,128,50.6118537,9.1909725,"Aomori-shi, Aomori, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
630,128,53.7735234,12.5755746,"Chiba-shi, Chiba, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
631,128,52.8398531,9.075962,"Touon-shi, Ehime, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
632,128,52.8398531,9.075962,"Fukuoka-shi, Fukuoka, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
633,128,51.4785568,7.5533645,"Kitakyushi-shi, Fukuoka, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
634,128,51.4785568,7.5533645,"Fukushima-shi, Fukushima, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
635,128,51.0834196,10.4234469,"Maebashi-shi, Gunma, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
636,128,51.908526,11.4939134,"Higashihiroshima-shi, Hiroshima, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
637,128,50.9295798,13.4585052,"Miyoshi-shi, Hiroshima, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
638,128,50.7333163,11.0747905,"Otake-shi, Hiroshima, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
639,128,52.5170365,13.3888599,"Sapporo-shi, Hokkaido, Japan",129.0,NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: pioglitazone|Drug: placebo,Survival in patients with ALS treated with pioglitazone compared to placebo|Incidence of tracheotomy or non-invasive ventilation,University of Ulm,All,Phase 2,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GERP ALS|EUDRACT NUMBER 2006-005410-13,May 2008,June 2010,June 2010,"June 4, 2008",,"May 29, 2015",,https://ClinicalTrials.gov/show/NCT00690118,18.0,100.0
640,129,34.9991645,137.254574,"Kanazawa-shi, Ishikawa, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
641,129,40.886943,140.590121,"Ichinoseki-shi, Iwate, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
642,129,35.549399,140.2647303,"Sagamihara-shi, Kanagawa, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
643,129,33.6013646,132.8185275,"Yokohama-shi, Kanagawa, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
644,129,33.6251241,130.6180016,"Nangoku-shi, Kochi, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
645,129,33.6251241,130.6180016,"Kyoto-shi, Kyoto, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
646,129,37.760777,140.4745807,"Tsu-shi, Mie, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
647,129,36.52198,139.033483,"Sendai-shi, Miyagi, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
648,129,34.3916058,132.4518156,"Watari-gun, Miyagi, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
649,129,34.3916058,132.4518156,"Nagano-shi, Nagano, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
650,129,34.3916058,132.4518156,"Higashisonogi-gun, Nagasaki, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
651,129,43.4603175,143.330715792837,"Kashiwazaki-shi, Niigata, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
652,129,36.9888678,136.8163563,"Niigata-shi, Niigata, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
653,129,39.5713763,141.4253574,"Tsukubo-gun, Okayama, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
654,129,35.4342935,139.374753,"Ginowan-shi, Okinawa, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
655,129,35.4342935,139.374753,"Toyonaka-shi, Osaka, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
656,129,33.6569018,133.5606241,"Hasuda-shi, Saitama, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
657,129,35.021041,135.7556075,"Saitama-shi, Saitama, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
658,129,36.5748441,139.2394179,"Hamamatsu-shi, Shizuoka, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
659,129,38.3880155,140.9761025,"Shizuoka-shi, Shizuoka, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
660,129,38.3880155,140.9761025,"Shimotsuke-shi, Tochigi, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
661,129,36.1143945,138.0319015,"Tokushima-shi, Tokushima, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
662,129,33.1154683,129.7874339,"Yoshinogawa-shi, Tokushima, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
663,129,37.6452283,138.7669125,"Bunkyo-ku, Tokyo, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
664,129,37.6452283,138.7669125,"Kodaira-shi, Tokyo, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
665,129,34.8581334,133.7759256,"Ota-ku, Tokyo, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
666,129,26.5707754,128.0255901,"Wakayama-shi, Wakayama, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
667,129,34.6937569,135.5014539,"Yonezawa-shi, Yamagata, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
668,129,35.8616402,139.6457957,"Shimonoseki-shi, Yamaguchi, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
669,129,35.8616402,139.6457957,"Yanai-shi, Yamaguchi, Japan",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
670,129,34.9332488,138.0955398,"Mayo Clinic, Scottsdale, Scottsdale, Arizona, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
671,129,34.9332488,138.0955398,"UC, Irvine, Irvine, California, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
672,129,36.6782167,139.8096549,"UCLA, Los Angeles, California, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
673,129,33.9196418,134.2509634,"California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
674,129,33.9196418,134.2509634,"Mayo Clinic, Jacksonville, Jacksonville, Florida, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
675,129,35.6828387,139.7594549,"The Emory Clinic, Atlanta, Georgia, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
676,129,35.6828387,139.7594549,"University of Kansas Medical Center, Landon Center on Aging, Kansas City, Kansas, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
677,129,35.6828387,139.7594549,"University of Kentucky, Department of Neurology, Lexington, Kentucky, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
678,129,33.8070292,135.5930743,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
679,129,38.4746705,140.083237,"Columbia University, New York, New York, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
680,129,34.2379614,131.5873845,"SUNY Upstate Medical University, Syracuse, Syracuse, New York, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
681,129,34.2379614,131.5873845,"Carolinas Medical Center, Charlotte, North Carolina, United States",130.0,NCT00445172,A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin),Number of participants with Adverse Events as a Measure of safety|Survival rate|Functional rating scale|Percent-predicted forced vital capacity (%FVC.),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,135.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E0302-J081-762,February 2008,"March 31, 2017","March 31, 2017","March 8, 2007",,"August 23, 2017",,https://ClinicalTrials.gov/show/NCT00445172,20.0,100.0
682,130,34.395342,-111.7632755,"Duke University, Dept of Neurology, Durham, North Carolina, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
683,130,36.7014631,-118.7559974,"Cleveland Clinic, Cleveland, Ohio, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
684,130,36.7014631,-118.7559974,"Providence ALS Center, Portland, Oregon, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
685,130,36.7014631,-118.7559974,"Methodist Hospital Research Institute, Methodist Neurologic Institute, Houston, Texas, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
686,130,27.7567667,-81.4639835,"Providence Saint Peter Hospital, Centralia, Washington, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
687,130,32.3293809,-83.1137366,"Phoenix Neurological Associates, Phoenix, Arizona, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
688,130,38.27312,-98.5821872,"UCLA, Los Angeles, California, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
689,130,37.5726028,-85.1551411,"University of California Irvine, Orange, California, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
690,130,42.3788774,-72.032366,"California Pacific Medical Center, San Francisco, California, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
691,130,40.7127281,-74.0060152,"Mayo Clinic Florida, Jacksonville, Florida, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
692,130,40.7127281,-74.0060152,"Medical College of Georgia, Augusta, Georgia, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
693,130,35.6729639,-79.0392919,"University of Illinois, Chicago, Illinois, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
694,130,35.6729639,-79.0392919,"University of Kansas, Kansas City, Kansas, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
695,130,40.2253569,-82.6881395,"Mayo Clinic Rochester, Rochester, Minnesota, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
696,130,43.9792797,-120.737257,"Washington University, St. Louis, Missouri, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
697,130,31.8160381,-99.5120986,"UMDNJ, New Brunswick, New Jersey, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
698,130,38.8950092,-77.0365625,"University of New Mexico, Albuquerque, New Mexico, United States",131.0,NCT01281631,A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,To evaluate the effects of NP001 on measures of clinical function|Safety and tolerability in ALS|Pulmonary function and biomarkers,"Neuraltus Pharmaceuticals, Inc.",All,Phase 2,136.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001-10-002,February 2011,September 2012,September 2012,"January 24, 2011",,"November 22, 2012",,https://ClinicalTrials.gov/show/NCT01281631,21.0,80.0
699,131,34.395342,-111.7632755,"Beth Israel, New York, New York, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
700,131,36.7014631,-118.7559974,"Columbia University, New York, New York, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
701,131,36.7014631,-118.7559974,"Duke University, Durham, North Carolina, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
702,131,36.7014631,-118.7559974,"Oregon Health and Science University, Portland, Oregon, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
703,131,27.7567667,-81.4639835,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
704,131,32.3293809,-83.1137366,"UT Southwestern Medical Center, Dallas, Texas, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
705,131,40.0796606,-89.4337288,"University of Vermont, Burlington, Vermont, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
706,131,38.27312,-98.5821872,"Novartis USA, East Hanover, New Jersey, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
707,131,45.9896587,-94.6113288,"Novartis Belgium, Vilvoorde, Belgium",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
708,131,38.7604815,-92.5617875,"Novartis CANADA, Dorval, Quebec, Canada",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
709,131,40.0757384,-74.4041622,"Novartis France, Rueil-Malmaison, France",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
710,131,34.5708167,-105.993007,"Novartis Germany, Nuernberg, Germany",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
711,131,40.7127281,-74.0060152,"Novartis Italy, Saronno, Italy",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
712,131,40.7127281,-74.0060152,"Novartis Netherlands, Arnhem, Netherlands",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
713,131,35.6729639,-79.0392919,"Novartis Switzerland, Bern, Switzerland",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
714,131,43.9792797,-120.737257,"Novartis UK, Frimley, United Kingdom",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
715,131,40.9699889,-77.7278831,"University of California at San Francisco, Fresno Campus, Central California Neurological Institute, Fresno, California, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
716,131,31.8160381,-99.5120986,"Coordinated Clinical Research, La Jolla, California, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
717,131,44.5990718,-72.5002608,"University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States",132.0,NCT00355576,Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Celecoxib|Drug: Creatine|Drug: Minocycline,"ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.|Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.",Columbia University|ALS Association|Pfizer,All,Phase 2,86.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB6334|ALSA ID#920,July 2006,,May 2007,"July 24, 2006",,"February 1, 2011",,https://ClinicalTrials.gov/show/NCT00355576,21.0,85.0
718,132,40.0757384,-74.4041622,"Hospital for Special Care, New Britain, Connecticut, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
719,132,50.92813655,4.43290525148385,"Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
720,132,52.4760892,-71.8258668,"Washington University, Saint Louis, Missouri, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
721,132,48.87778,2.1802832,"Cornell Faculty, Hospital for Special Surgery, New York, New York, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
722,132,49.453872,11.077298,"Duke University School of Medicine, Division of Neurology, Durham, North Carolina, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
723,132,45.6256764,9.0373283,"Ohio State University, Department of Neurology, Columbus, Ohio, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
724,132,52.0056642,5.87623450776413,"Providence ALS Center, Portland, Oregon, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
725,132,46.9482713,7.4514512,"University of Texas Health Science Center, Department of Neurology, San Antonio, Texas, United States",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
726,132,51.3154908,-0.7353134,"Gold Coast Hospital and Health Service, Gold Coast, Queensland, Australia",133.0,NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Rate of functional decline as defined by the ALS Functional Rating Scale-Revised|Survival time|Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)|Neurocognitive evaluation in a subset of patients(every visit except screening),Novartis Pharmaceuticals|Novartis,All,Phase 2,551.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346A2211,September 2003,December 2004,December 2004,"November 11, 2003",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00072709,21.0,80.0
727,133,36.7014631,-118.7559974,"Phoenix Neurological Associates, LTD, Phoenix, Arizona, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
728,133,36.7014631,-118.7559974,"UCLA, Neuromuscular Research Center, Los Angeles, California, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
729,133,36.7014631,-118.7559974,"University of Iowa, Iowa City, Iowa, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
730,133,41.6500201,-72.7342163,"University of Kansas Medical Center, Kansas City, Kansas, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
731,133,42.3788774,-72.032366,"Massachusetts General Hospital, Boston, Massachusetts, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
732,133,38.7604815,-92.5617875,"University of Massachusetts (Worcester) Memorial Medical Center, Worcester, Massachusetts, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
733,133,40.7127281,-74.0060152,"Washington University Medical School, Saint Louis, Missouri, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
734,133,35.6729639,-79.0392919,"SUNY Upstate Medical Center, Syracuse, New York, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
735,133,40.2253569,-82.6881395,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
736,133,43.9792797,-120.737257,"University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
737,133,31.8160381,-99.5120986,"University of Washington Medical Center, Seattle, Washington, United States",134.0,NCT01486849,Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CK-2017357|Drug: Placebo|Drug: Riluzole 50 MG,Number of participants with adverse events|Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue|Change from baseline in scores on tests of muscle strength|Change from baseline in scores on tests of Timed Up and Go|Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP)|Change from baseline in scores on tests of Slow Vital Capacity (SVC)|Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV)|Change from baseline in Patient Global Assessment|Change from baseline in Investigator Global Assessment|Evaluate the pharmacokinetics of CK-2017357|Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357,Cytokinetics,All,Phase 2,27.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4025,November 2011,March 2012,March 2012,"December 7, 2011",,"May 3, 2019",,https://ClinicalTrials.gov/show/NCT01486849,18.0,100.0
738,134,-21.9182856,144.4588889,"California Pacific Medical Center, San Francisco, California, United States",135.0,NCT03690791,Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: CannTrust CBD Oil (capsule)|Drug: Placebo (capsule),Difference in mean ALS Functional Rating Scale-Revised (ALSFRS-R) total score between groups at end of treatment (Total score: min 0- max 48) [efficacy]|Difference in mean Forced Vital Capacity (FVC) volume between groups at end of treatment [efficacy]|Nature and number of adverse events [safety and tolerability]|Difference in mean Numeric Rating Scale for spasticity total score between groups at end of treatment (Scores 0-100)|Difference in mean Numeric Rating Scale for pain total score between groups at end of treatment (Total score min:1-max:100)|Difference in mean Percentage of Total Weight Loss score between groups at end of treatment (Percentage score min: 0- max: 100)|Difference in mean ALS Specific Quality of Life- Revised (ALSSQOL-R) total score between groups at end of treatment (Total score min:0- max:460),Gold Coast Hospital and Health Service|CannTrust Inc.,All,Phase 3,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCMR0001,"January 9, 2019",December 2020,January 2021,"October 1, 2018",,"February 4, 2019",,https://ClinicalTrials.gov/show/NCT03690791,25.0,75.0
739,135,34.395342,-111.7632755,"Mayo Florida, Jacksonville, Florida, United States",136.0,NCT00919555,Combination Therapy in Amyotrophic Lateral Sclerosis (ALS),PNA,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Pioglitazone and Tretinoin|Drug: Tretinoin and Pioglitazone HCL|Drug: Placebo,To evaluate the safety and efficacy of Tretinoin and Pioglitazone HCL in patients with ALS|To determine if cerebrospinal fluid tau levels decline over the course of treatment and if the level of tau decline correlates with response in treatment measured by ALSFRS,"Phoenix Neurological Associates, LTD",All,Phase 1|Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20071808,June 2008,November 2009,March 2012,"June 12, 2009",,"November 30, 2012",,https://ClinicalTrials.gov/show/NCT00919555,18.0,85.0
740,136,36.7014631,-118.7559974,"University of Kansas, Kansas City, Kansas, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
741,136,41.9216734,-93.3122705,"Johns Hopkins Hospital, Baltimore, Maryland, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
742,136,38.27312,-98.5821872,"Columbia University Medical Center, New York, New York, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
743,136,42.3788774,-72.032366,"SUNY Upstate Medical Center, Syracuse, New York, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
744,136,42.3788774,-72.032366,"Carolinas Neuromuscular ALS-MND Center, Charlotte, North Carolina, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
745,136,38.7604815,-92.5617875,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
746,136,40.7127281,-74.0060152,"Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
747,136,40.9699889,-77.7278831,"Mayo Clinic, Rochester, Minnesota, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
748,136,31.8160381,-99.5120986,"Emory University, Atlanta, Georgia, United States",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
749,136,38.8950092,-77.0365625,"Prof. Maloteaux, UCL Saint-Luc, Brussels, Belgium",137.0,NCT01849770,Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS),MX-ALS-001,Completed,Has Results,Sporadic Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Percentage of Participants That Discontinued Study Drug|Trough Plasma Concentration (Cmin) of Mexiletine|Peak Plasma Concentration (Cmax) of Mexiletine|Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.|Mean Cerebrospinal Fluid (CSF)/Plasma Ratio|Mean Weekly Cramp Frequency|Maximal Pain Severity|Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12|Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12|Mean Pain Severity|Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12,University of Washington,All,Phase 2,75.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",43708-A,July 2013,August 2014,August 2014,"May 8, 2013","October 12, 2015","October 12, 2015",,https://ClinicalTrials.gov/show/NCT01849770,18.0,100.0
750,137,36.7014631,-118.7559974,"Prof. Wim Robberecht, UZ Leuven, Leuven, Belgium",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
751,137,27.7567667,-81.4639835,"Prof. Alain Destee, Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
752,137,38.27312,-98.5821872,"Prof. Philippe Couratier, Hopital Duruytren, Limoges Cedex, France",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
753,137,39.5162234,-76.9382069,"Prof. Jan Pouget, Hopital de la Timone, Marseille, France",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
754,137,40.7127281,-74.0060152,"Prof. William Camu, Hopital de Chauliac, Montpellier cedex 5, France",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
755,137,40.7127281,-74.0060152,"Prof. Claude Desnuelle, Hopital 1-Archet 1, Nice cedex 3, France",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
756,137,35.6729639,-79.0392919,"Prof. Vincent Meininger, Hopital LaPitie Salpetriere, Paris, France",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
757,137,40.9699889,-77.7278831,"Dr. Thomas Meyer, Charite Campus Virchow, ALS Ambulanz, Berlin, Germany",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
758,137,40.9699889,-77.7278831,"Prof. Torsten Grehl, Neurologische Ambulanz Universitatsklinik Bergmannsheil, Bochum, Germany",138.0,NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (Part A)|Drug: CK-2017357 (Part A)|Drug: Riluzole 50 MG (Part B)|Drug: Placebo (Part B)|Drug: CK-2017357 (Part B),Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,Cytokinetics,All,Phase 2,49.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4024,June 2011,March 2012,March 2012,"June 22, 2011",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT01378676,18.0,100.0
759,138,45.9896587,-94.6113288,"Professor Dieter Heuss, Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik, Erlangen, Germany",139.0,NCT01142856,Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: autologous mesenchymal stem cells,Safety|Neurologic disability score,Mayo Clinic,All,Phase 1,1.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-001995,June 2010,April 2011,April 2011,"June 11, 2010",,"May 3, 2012",,https://ClinicalTrials.gov/show/NCT01142856,18.0,100.0
760,139,32.3293809,-83.1137366,"Prof. Stephan Zierz, Martin Luther Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie, Halle, Germany",140.0,NCT01348451,Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis,ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: surgical implantation,The primary objective of this study is to determine the safety of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis.|The Secondary Objectives of the study are to evaluate spinal stem cell transplantation therapy in this patient population.,Neuralstem Inc.,All,Phase 1,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NS2008-1,January 2009,December 2015,December 2016,"May 5, 2011",,"March 10, 2016",,https://ClinicalTrials.gov/show/NCT01348451,18.0,100.0
761,140,50.8465573,4.351697,"Prof. Reinhard Dengler, Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
762,140,50.879202,4.7011675,"Prof Gian Domenico Borasio, Interdisziplinares Zentrum fur Palliativmedizin, Munchen, Germany",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
763,140,46.603354,1.8883335,"Prof. Albert Ludolph, Klinik und Poliklinikfur Neurologie der Universitat Ulm-Univeritatsklinikum Ulm, Ulm, Germany",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
764,140,46.603354,1.8883335,"Dr. Berthold Schrank, Deutsche Klinik fur Diagnostik, Fachbereich Neurologie, Wiesbarden, Germany",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
765,140,43.2961743,5.3699525,"Prof. Vincenzo Silani, Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano, Milano, Italy",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
766,140,46.603354,1.8883335,"Dr. Gabriele Mora, Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
767,140,46.603354,1.8883335,"Prof. Adriano Chio, Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
768,140,48.8566101,2.3514992,"Prof Marianne de Visser, Academic Medical Centre (AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
769,140,52.5170365,13.3888599,"Prof. Leonard H Van Den Berg, University Medical Center Utrecht, Utrecht, Netherlands",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
770,140,51.4818111,7.2196635,"Dr. Markus Weber, Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
771,140,49.5981187,11.003645,"Prof. Nigel Leigh, Academic Neuroscience Centre, London, United Kingdom",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
772,140,51.4825041,11.9705452,"Prof. Douglas Mitchell, Royal Preston Hospital, Preston, United Kingdom",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
773,140,52.3744779,9.7385532,"Dr. Chris McDermott, Royal Hallamshire Hospital, Sheffield, United Kingdom",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
774,140,48.1371079,11.5753822,"Charite University Hospital, Berlin, Germany, Berlin, Germany",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
775,140,48.3974003,9.9934336,"California Pacific Medical Center, San Francisco, California, United States",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
776,140,51.0834196,10.4234469,"University of Kansas Medical Center - Landon Center on Aging, Kansas City, Kansas, United States",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
777,140,45.4667971,9.1904984,"Department of Neurology; University of Kentucky Medical Center, Lexington, Kentucky, United States",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
778,140,45.1860043,9.1546375,"Nagoya-shi, Aichi, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
779,140,45.0677551,7.6824892,"Akita-shi, Akita, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
780,140,52.3745403,4.89797550561798,"Aomori-shi, Aomori, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
781,140,52.0809856,5.12768396945229,"Chiba-shi, Chiba, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
782,140,47.4250593,9.3765878,"Touon-shi, Ehime, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
783,140,51.5073219,-0.1276474,"Fukuoka-shi, Fukuoka, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
784,140,53.7593363,-2.6992717,"Kitakyusyu-shi, Fukuoka, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
785,140,53.3806626,-1.4702278,"Fukushima-shi, Fukushima, Japan",141.0,NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,Ono Pharmaceutical Co. Ltd,All,Phase 2,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONO-2506POE015,June 2008,December 2008,,"June 11, 2008",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00694941,18.0,100.0
786,141,52.5170365,13.3888599,"Maebashi-shi, Gunma, Japan",142.0,NCT00231140,Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS),,Terminated,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Thalidomide (drug),"to evaluate the long-term safety and tolerability of thalidomide|to compare the total number of adverse events (AE), abnormal laboratory tests, and number of patients who completed the study between groups|to evaluate the clinical effect of two oral doses of the thalidomide on the rate of functional decline in ALS patients measured by the ALS Functional Rating Scale-revised (ALS-FRS-R) over a 24 week treatment period|to investigate the effects of thalidomide on pulmonary function (forced vital capacity) over a 24 week treatment period|to evaluate the sleep quality and somnolence using the Epworth Sleeping Scale: ESS ‚â• 18|to evaluate the frequency and severity of sensory neuropathy using the inflammatory neuropathy cause and treatment sensory sum score ‚Äì ISS ‚â• 4|to evaluate the frequency of thrombotic events|to determine the number of patients who require continuous non-invasive ventilation or invasive ventilation|to determine the number of patients who require percutanous endoscopic gastrostomy (PEG)|to evaluate the survival time or the time point until invasive ventilation is started","Charite University, Berlin, Germany",All,Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,THL-ALS01,December 2005,,August 2006,"October 4, 2005",,"January 19, 2007",,https://ClinicalTrials.gov/show/NCT00231140,25.0,80.0
787,142,36.7014631,-118.7559974,"Higashihiroshima-shi, Hiroshima, Japan",143.0,NCT01091142,Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Safety and tolerability of NP001 compared to placebo in subjects with ALS|To explore the effects of NP001 on biomarkers potentially relevant to ALS,"Neuraltus Pharmaceuticals, Inc.",All,Phase 1,56.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001 Single Dose - ALS,July 2010,September 2010,,"March 23, 2010",,"October 6, 2010",,https://ClinicalTrials.gov/show/NCT01091142,21.0,75.0
788,142,38.27312,-98.5821872,"Miyoshi-shi, Hiroshima, Japan",143.0,NCT01091142,Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Safety and tolerability of NP001 compared to placebo in subjects with ALS|To explore the effects of NP001 on biomarkers potentially relevant to ALS,"Neuraltus Pharmaceuticals, Inc.",All,Phase 1,56.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001 Single Dose - ALS,July 2010,September 2010,,"March 23, 2010",,"October 6, 2010",,https://ClinicalTrials.gov/show/NCT01091142,21.0,75.0
789,142,37.5726028,-85.1551411,"Otake-shi, Hiroshima, Japan",143.0,NCT01091142,Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: NP001|Drug: Placebo,Safety and tolerability of NP001 compared to placebo in subjects with ALS|To explore the effects of NP001 on biomarkers potentially relevant to ALS,"Neuraltus Pharmaceuticals, Inc.",All,Phase 1,56.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP001 Single Dose - ALS,July 2010,September 2010,,"March 23, 2010",,"October 6, 2010",,https://ClinicalTrials.gov/show/NCT01091142,21.0,75.0
790,143,34.9991645,137.254574,"Sapporo-shi, Hokkaido, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
791,143,39.6898802,140.342608,"Kanazawa-shi, Ishikawa, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
792,143,40.886943,140.590121,"Ichinoseki-shi, Iwate, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
793,143,35.549399,140.2647303,"Sagamihara-shi, Kanagawa, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
794,143,33.6013646,132.8185275,"Yokohama-shi, Kanagawa, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
795,143,33.6251241,130.6180016,"Nangoku-shi, Kochi, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
796,143,33.6251241,130.6180016,"Kyoto-shi, Kyoto, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
797,143,37.760777,140.4745807,"Tsu-shi, Mie, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
798,143,36.52198,139.033483,"Sendai-shi, Miyagi, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
799,143,34.3916058,132.4518156,"Watari-gun, Miyagi, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
800,143,34.3916058,132.4518156,"Nagano-shi, Nagano, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
801,143,34.3916058,132.4518156,"Higashisonogi-gun, Nagasaki, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
802,143,43.4603175,143.330715792837,"Kashiwazaki-shi, Niigata, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
803,143,36.9888678,136.8163563,"Niigata-shi, Niigata, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
804,143,39.5713763,141.4253574,"Tsukubo-gun, Okayama, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
805,143,35.4342935,139.374753,"Ginowan-shi, Okinawa, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
806,143,35.4342935,139.374753,"Toyonaka-shi, Osaka, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
807,143,33.6569018,133.5606241,"Hasuda-shi, Saitama, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
808,143,35.021041,135.7556075,"Saitama-shi, Saitama, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
809,143,36.5748441,139.2394179,"Otsu-shi, Shiga, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
810,143,38.3880155,140.9761025,"Hamamatsu-shi, Shizuoka, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
811,143,38.3880155,140.9761025,"Shizuoka-shi, Shizuoka, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
812,143,36.1143945,138.0319015,"Shimotsuke-shi, Tochigi, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
813,143,33.1154683,129.7874339,"Tokushima-shi, Tokushima, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
814,143,37.6452283,138.7669125,"Yoshinogawa-shi, Tokushima, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
815,143,37.6452283,138.7669125,"Bunkyo-ku, Tokyo, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
816,143,34.8581334,133.7759256,"Kodaira-shi, Tokyo, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
817,143,26.5707754,128.0255901,"Ota-ku, Tokyo, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
818,143,34.6937569,135.5014539,"Wakayama-shi, Wakayama, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
819,143,35.8616402,139.6457957,"Yonezawa-shi, Yamagata, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
820,143,35.8616402,139.6457957,"Shimonoseki-shi, Yamaguchi, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
821,143,35.247154,136.109385,"Yanai-shi, Yamaguchi, Japan",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
822,143,34.9332488,138.0955398,"Rambam Medical center, Neurology Department, Haifa, Israel",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
823,143,34.9332488,138.0955398,"University Hospital Leuven, Department of Neurology, Leuven, Belgium",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
824,143,36.6782167,139.8096549,"Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
825,143,33.9196418,134.2509634,"University Neurology Associates, Fresno, California, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
826,143,33.9196418,134.2509634,"California Pacific Medical Center, San Francisco, California, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
827,143,35.6828387,139.7594549,"Mayo Clinic Florida, Jacksonville, Florida, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
828,143,35.6828387,139.7594549,"University of Kentucky, Lexington, Kentucky, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
829,143,35.6828387,139.7594549,"Johns Hopkins Hospital, Baltimore, Maryland, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
830,143,33.8070292,135.5930743,"Massachusetts General Hospital, Boston, Massachusetts, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
831,143,38.4746705,140.083237,"Washington University, Saint Louis, Missouri, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
832,143,34.2379614,131.5873845,"SUNY Upstate Medical Center, Syracuse, New York, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
833,143,34.2379614,131.5873845,"Duke University, Durham, North Carolina, United States",144.0,NCT00444613,A Study in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: E0302 (mecobalamin)|Drug: Placebo,Survival rate|Functional rating scale.|Manual Muscle Test (MMT)|Percent-predicted forced vital capacity (%FVC),"Eisai Co., Ltd.|Eisai Inc.",All,Phase 2|Phase 3,373.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E0302-J081-761,April 2007,March 2014,July 2014,"March 8, 2007",,"December 8, 2014",,https://ClinicalTrials.gov/show/NCT00444613,20.0,100.0
834,144,32.8191218,34.9983856,"Providence ALS Center, Portland, Oregon, United States",145.0,NCT00846560,Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS),,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,,,Rambam Health Care Campus,All,,0.0,Other,Observational,Observational Model: Other|Time Perspective: Other,ALS04CTIL,August 2008,July 2009,July 2009,"February 18, 2009",,"October 11, 2017",,https://ClinicalTrials.gov/show/NCT00846560,18.0,100.0
835,145,50.879202,4.7011675,"Drexel University College of Medicine, Dept of Neurology, Philadelphia, Pennsylvania, United States",146.0,NCT01384162,"An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis",,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sNN0029,"Safety and tolerability through assessments of adverse events, vital signs, clinical laboratory tests, MRI of brain, fundus photography and device performance as characterized by catheter tip placement and infusion accuracy|Disease activity as measured by ALS functional rating scale (FRS) - VEGF concentrations in CSF - Possible VEGF antibodies in plasma",Newron Sweden AB|Medtronic|ICON Clinical Research,All,Phase 1|Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,sNN0029-002,June 2009,October 2015,October 2015,"June 28, 2011",,"January 27, 2016",,https://ClinicalTrials.gov/show/NCT01384162,18.0,75.0
836,146,34.395342,-111.7632755,"Penn State, University Park, Pennsylvania, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
837,146,36.7014631,-118.7559974,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
838,146,36.7014631,-118.7559974,"University of Vermont, Burlington, Vermont, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
839,146,27.7567667,-81.4639835,"Institute of neurology Universit√† Cattolica, Rome, Italy",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
840,146,37.5726028,-85.1551411,"University of Michigan, Ann Arbor, Michigan, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
841,146,39.5162234,-76.9382069,"Washington University School of Medicine, Saint Louis, Missouri, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
842,146,42.3788774,-72.032366,"Carolinas ALS Clinical Research Center, Charlotte, North Carolina, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
843,146,38.7604815,-92.5617875,"University of Colorado, Denver, Colorado, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
844,146,40.7127281,-74.0060152,"University of Miami, Miami, Florida, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
845,146,35.6729639,-79.0392919,"University of Kentucky, Lexington, Kentucky, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
846,146,43.9792797,-120.737257,"Henry Ford Hospital, Detroit, Michigan, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
847,146,40.9699889,-77.7278831,"Beth Israel, New York, New York, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
848,146,40.9699889,-77.7278831,"Columbia University, New York, New York, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
849,146,31.8160381,-99.5120986,"SUNY, Syracuse, New York, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
850,146,44.5990718,-72.5002608,"Pennsylvania State University, Hershey, Pennsylvania, United States",147.0,NCT01089010,A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: 250 mg CK-2017357|Drug: 500 mg CK-2017357,"ALSFRS-R|Maximum grip strength|Maximum grip strength fatigability|Shoulder extension fatigue|Slow Vital Capacity (SVC)|Maximum Voluntary Ventilation (MVV)|Sniff Inspiratory Pressure (SNIP)|Maximum Voluntary Muscle Contraction (MVC)|Repeated Sub-Maximum Grip Strength Fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and ALSFRS-R.|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum grip strength fatigability|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and shoulder extension fatigue|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and slow vital capacity|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary ventilation|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and sniff inspiratory pressure|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and maximum voluntary muscle contraction|Characterize the relationship, if any, between the plasma concentration of CK-2017357 and repeated sub-maximum grip strength fatigability|Number of patients with adverse events|Effect of CK-2017357 on patient determined global functional assessment|Effect of CK-2017357 on investigator determined global functional assessment",Cytokinetics,All,Phase 2,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 4021,March 2010,November 2010,November 2010,"March 18, 2010",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT01089010,18.0,100.0
851,147,41.894802,12.4853384,"Drexel University, Philadelphia, Pennsylvania, United States",148.0,NCT00833820,Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis,rTMS-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Real rTMS of the brain|Procedure: Sham rTMS of the brain,Rate of decline of ALSFRS-R score|Rate of decline of manual muscle force testing score,Catholic University of the Sacred Heart,All,Phase 2|Phase 3,20.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",001,May 2007,December 2008,December 2008,"February 2, 2009",,"February 2, 2009",,https://ClinicalTrials.gov/show/NCT00833820,18.0,100.0
852,148,43.6211955,-84.6824346,"University of Texas-San Antonio, San Antonio, Texas, United States",149.0,NCT01119001,A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: P300 Brain Computer Interface Keyboard,Accuracy of Typing With a BCI Keyboard by ALS Patients.,University of Michigan|U.S. Department of Education,All,Not Applicable,13.0,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,H0004,February 2010,August 2010,August 2010,"May 7, 2010","June 12, 2015","June 12, 2015",,https://ClinicalTrials.gov/show/NCT01119001,18.0,100.0
853,149,38.7604815,-92.5617875,"University of Utah, Salt Lake City, Utah, United States",150.0,NCT02414230,F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis,T807ALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Drug: F 18 T807,"F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.",Washington University School of Medicine,All,Phase 2,9.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IND 123119 Protocol B,February 2015,March 2020,September 2020,"April 10, 2015",,"January 25, 2019",,https://ClinicalTrials.gov/show/NCT02414230,18.0,100.0
854,150,35.6729639,-79.0392919,"University of Vermont, Burlington, Vermont, United States",151.0,NCT00956501,Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,SOT equilibrium scores on conditions 1-6.|MSS on conditions 1-6 Weight Symmetry Score on conditions 1-6 DGI score TUG score POMA-B score,Atrium Health,All,,35.0,Other,Observational,Time Perspective: Prospective,IRB# 02-09-12B,February 2009,February 2010,February 2011,"August 11, 2009",,"August 2, 2013",,https://ClinicalTrials.gov/show/NCT00956501,18.0,75.0
855,151,38.7251776,-105.6077167,"Assistance Publique H√¥pitaux de Marseille, Marseille, France",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
856,151,27.7567667,-81.4639835,"Emory University, Atlanta, Georgia, United States",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
857,151,37.5726028,-85.1551411,"Massachusetts General Hospital, Boston, Massachusetts, United States",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
858,151,43.6211955,-84.6824346,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
859,151,40.7127281,-74.0060152,"Johns Hopkins University, Baltimore, Maryland, United States",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
860,151,40.7127281,-74.0060152,"Salp√™tri√®re Hospital, Paris, France",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
861,151,40.7127281,-74.0060152,"Bretonneau Hospital, Tours, France",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
862,151,40.9699889,-77.7278831,"Service de Neurologie, Limoges, France",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
863,151,40.9699889,-77.7278831,"Fondazione IRCCS Istituto neurologico Carlo Besta, Milan, Italy",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
864,151,31.8160381,-99.5120986,"L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien, Wien, Austria",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
865,151,39.4225192,-111.7143584,"UCL Saint-Luc, Brussels, Belgium",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
866,151,44.5990718,-72.5002608,"UZ Leuven, Leuven, Belgium",152.0,NCT00116558,Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Early NIPPV|Device: Standard NIPPV,Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.,Edward Kasaraskis|National Institute of Neurological Disorders and Stroke (NINDS)|University of Kentucky,All,Not Applicable,153.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,R01NS045087,"August 1, 2004",January 2012,January 2012,"June 30, 2005","July 31, 2019","July 31, 2019",,https://ClinicalTrials.gov/show/NCT00116558,18.0,80.0
867,152,43.2961743,5.3699525,"Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France",153.0,NCT02424669,Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Other: ALS Functional rating Scale-revised (ALS FRS-R)|Other: slow vital capacity|Other: Blood sample|Other: Cerebrospinal Fluid (CSF) sample,ALS Functional rating Scale-revised (ALS FRS-R) score,Assistance Publique Hopitaux De Marseille,All,Not Applicable,100.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2014-19|RCAPHM15_0132,May 2015,November 2017,November 2018,"April 23, 2015",,"November 17, 2015",,https://ClinicalTrials.gov/show/NCT02424669,18.0,80.0
868,153,32.3293809,-83.1137366,"Hopital Duruytren, Limoges Cedex, France",154.0,NCT01884571,Immunosuppression in Amyotrophic Lateral Sclerosis (ALS),NIPALS2013,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Basiliximab|Drug: Methylprednisolone|Drug: Prednisone|Drug: Tacrolimus|Drug: Mycophenolate mofetil,Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month|Mean Rate of Change of ALSFRS-R Scores During Treatment Compared to Pre-Treatment|Mean Rate of Change of Slow Vital Capacity (SVC) During Treatment Compared to Pre-Treatment|Mean Rate of Change of Hand-Held Dynamometry (HHD) During Treatment Compared to Pre-Treatment|Mean Rate of Change in Grip Strength Treatment Compared to Pre-Treatment|Mean Rate of Change of T-cell Subsets in Blood Treatment Compared to Pre-Treatment|Collection of Cerebrospinal Fluid for Future Analysis of Cytokine Levels|Collection of Blood for Future Analysis of Peripheral Blood Mononuclear Cells (PBMCs),Emory University|ALS Association,All,Phase 2,31.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00064218|NIP-ALS-2013|2013P000981,October 2013,January 2016,January 2016,"June 24, 2013","July 31, 2017","November 6, 2017",,https://ClinicalTrials.gov/show/NCT01884571,18.0,100.0
869,153,42.3788774,-72.032366,"Hopital de la Timone, Marseille, France",154.0,NCT01884571,Immunosuppression in Amyotrophic Lateral Sclerosis (ALS),NIPALS2013,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Basiliximab|Drug: Methylprednisolone|Drug: Prednisone|Drug: Tacrolimus|Drug: Mycophenolate mofetil,Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month|Mean Rate of Change of ALSFRS-R Scores During Treatment Compared to Pre-Treatment|Mean Rate of Change of Slow Vital Capacity (SVC) During Treatment Compared to Pre-Treatment|Mean Rate of Change of Hand-Held Dynamometry (HHD) During Treatment Compared to Pre-Treatment|Mean Rate of Change in Grip Strength Treatment Compared to Pre-Treatment|Mean Rate of Change of T-cell Subsets in Blood Treatment Compared to Pre-Treatment|Collection of Cerebrospinal Fluid for Future Analysis of Cytokine Levels|Collection of Blood for Future Analysis of Peripheral Blood Mononuclear Cells (PBMCs),Emory University|ALS Association,All,Phase 2,31.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00064218|NIP-ALS-2013|2013P000981,October 2013,January 2016,January 2016,"June 24, 2013","July 31, 2017","November 6, 2017",,https://ClinicalTrials.gov/show/NCT01884571,18.0,100.0
870,153,42.3788774,-72.032366,"Hopital de Chauliac, Montpellier cedex 5, France",154.0,NCT01884571,Immunosuppression in Amyotrophic Lateral Sclerosis (ALS),NIPALS2013,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Basiliximab|Drug: Methylprednisolone|Drug: Prednisone|Drug: Tacrolimus|Drug: Mycophenolate mofetil,Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month|Mean Rate of Change of ALSFRS-R Scores During Treatment Compared to Pre-Treatment|Mean Rate of Change of Slow Vital Capacity (SVC) During Treatment Compared to Pre-Treatment|Mean Rate of Change of Hand-Held Dynamometry (HHD) During Treatment Compared to Pre-Treatment|Mean Rate of Change in Grip Strength Treatment Compared to Pre-Treatment|Mean Rate of Change of T-cell Subsets in Blood Treatment Compared to Pre-Treatment|Collection of Cerebrospinal Fluid for Future Analysis of Cytokine Levels|Collection of Blood for Future Analysis of Peripheral Blood Mononuclear Cells (PBMCs),Emory University|ALS Association,All,Phase 2,31.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00064218|NIP-ALS-2013|2013P000981,October 2013,January 2016,January 2016,"June 24, 2013","July 31, 2017","November 6, 2017",,https://ClinicalTrials.gov/show/NCT01884571,18.0,100.0
871,154,39.5162234,-76.9382069,"Hopital l-Archet 1, Nice cedex 3, France",155.0,NCT01945853,Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS),,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: 7 Tesla MRI,MRI Changes in ALS Patients Vs Healthy Controls|MRI Changes in ALS Patients,Johns Hopkins University,All,Not Applicable,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NA_00080565,July 2013,April 2015,April 2015,"September 19, 2013",,"September 1, 2015",,https://ClinicalTrials.gov/show/NCT01945853,18.0,80.0
872,155,48.8566101,2.3514992,"Hopital LaPitie Salpetriere, Paris, France",156.0,NCT01160263,Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls,DOSERAL,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM,Dopamine transporter binding potential|Serotonin transporter binding potential|Relationships between transporter binding potential and the clinical scores,"Assistance Publique - H√¥pitaux de Paris|Association Fran√ßaise contre les Myopathies (AFM), Paris|ARS (Association pour la Recherche sur la Scl√©rose Lat√©rale Amyotrophique)|Agence G√©n√©rale des Equipements et Produits de Sant√©",All,Phase 3,16.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P080402|AOM 07225,October 2012,October 2014,October 2014,"July 12, 2010",,"May 13, 2015",,https://ClinicalTrials.gov/show/NCT01160263,39.0,66.0
873,155,47.3900474,0.6889268,"Charite Campus Virchow, ALS Ambulanz, Berlin, Germany",156.0,NCT01160263,Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls,DOSERAL,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM,Dopamine transporter binding potential|Serotonin transporter binding potential|Relationships between transporter binding potential and the clinical scores,"Assistance Publique - H√¥pitaux de Paris|Association Fran√ßaise contre les Myopathies (AFM), Paris|ARS (Association pour la Recherche sur la Scl√©rose Lat√©rale Amyotrophique)|Agence G√©n√©rale des Equipements et Produits de Sant√©",All,Phase 3,16.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P080402|AOM 07225,October 2012,October 2014,October 2014,"July 12, 2010",,"May 13, 2015",,https://ClinicalTrials.gov/show/NCT01160263,39.0,66.0
874,156,45.8354243,1.2644847,"Neurologische Universitatsklinik Bergmannsheil, Bochum, Germany",157.0,NCT02152449,Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients,NUTRALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis (ALS),Dietary Supplement: Oral nutritional supplementation,Change in the ALSFRS-R slope between T0 and T0+6 months|Combined assessment of Function and Survival (CAFS)|Body Mass Index and of Fat Mass.,"University Hospital, Limoges|Laboratoires NUTRICIA",All,Not Applicable,229.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I12025,July 2014,July 2019,July 2020,"June 2, 2014",,"July 4, 2019",,https://ClinicalTrials.gov/show/NCT02152449,18.0,100.0
875,157,45.4667971,9.1904984,"Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik, Erlangen, Germany",158.0,NCT00877604,Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis,TUDCA-ALS,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: tauroursodeoxycholic acid (TUDCA)|Drug: Placebo,"The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.|Forced Vital Capacity (FVC) %|SF-36 Quality of Life Rating Scale|Time to Tracheostomy From Starting of Study Medication Dosing (if Appropriate)|Survival Time From Starting of Study Medication Dosing (if Appropriate)|ALSFRS-R at Study End|Incidence and Severity of Adverse Events, and Their Relationship to Treatment|Medical Research Council Scores for Right and Left Muscle Groups",Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|University of Palermo|Federico II University,All,Phase 2,34.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TUDCA200701|EudraCT No.: 2007-001592-10,June 2008,July 2011,April 2012,"April 8, 2009","November 26, 2014","November 26, 2014",,https://ClinicalTrials.gov/show/NCT00877604,18.0,75.0
876,158,48.2083537,16.3725042,"Martin-Luther-Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie, Halle, Germany",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
877,158,50.8465573,4.351697,"Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
878,158,50.879202,4.7011675,"Interdisziplinares Zentrum fur Palliativmedizin, Munchen, Germany",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
879,158,46.603354,1.8883335,"Klinik und Poliklinik fur Neurologie der Universitat Ulm-Universitatsklinikum Ulm, Ulm, Germany",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
880,158,46.603354,1.8883335,"Deutsche Klinik fur Diagnostik, Fachbereich Neurologie, Wiesbaden, Germany",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
881,158,43.2961743,5.3699525,"Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano, Milano, Italy",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
882,158,46.603354,1.8883335,"Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
883,158,46.603354,1.8883335,"Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
884,158,48.8566101,2.3514992,"Academic Medical Centre (AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
885,158,52.5170365,13.3888599,"University Medial Center Utrecht, Utrecht, Netherlands",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
886,158,51.4818111,7.2196635,"Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
887,158,49.5981187,11.003645,"Academic Neuroscience Centre, London, United Kingdom",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
888,158,51.4825041,11.9705452,"Royal Preston Hospital, Preston, United Kingdom",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
889,158,52.3744779,9.7385532,"University of Sheffield - Academic Neurology Unit, Sheffield, United Kingdom",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
890,158,48.1371079,11.5753822,"Phoenix Neurological Associates, Phoenix, Arizona, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
891,158,48.3974003,9.9934336,"University of California - Irvine, Irvine, California, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
892,158,50.0820384,8.2416556,"California Pacific Medical Center, San Francisco, California, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
893,158,45.4667971,9.1904984,"University of Kansas Medical Center, Kansas City, Kansas, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
894,158,45.1860043,9.1546375,"St. Louis University, Saint Louis, Missouri, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
895,158,45.0677551,7.6824892,"University of Nebraska, Omaha, Nebraska, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
896,158,52.3745403,4.89797550561798,"Columbia University, New York, New York, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
897,158,52.0809856,5.12768396945229,"Oregon Health and Science University, Portland, Oregon, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
898,158,47.4250593,9.3765878,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
899,158,51.5073219,-0.1276474,"UT Southwestern Medical Center, Dallas, Texas, United States",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
900,158,53.7593363,-2.6992717,"Hadassah Ein Kerem Medical Center, Jerusalem, Israel",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
901,158,53.3806626,-1.4702278,"Clermont-Ferrand University Hospital, Clermont-Ferrand, France",159.0,NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: ONO-2506PO,Rate of decline of respiratory function determined as SVC over the 12 month treatment period|Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,Ono Pharmaceutical Co. Ltd,All,Phase 2,420.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ONO-2506POE014,November 2006,December 2008,December 2008,"November 23, 2006",,"June 13, 2012",,https://ClinicalTrials.gov/show/NCT00403104,18.0,74.0
902,159,34.395342,-111.7632755,"University of Miami, Miami, Florida, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
903,159,36.7014631,-118.7559974,"University Hospital Leuven, Department of Neurology, Leuven, Belgium",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
904,159,36.7014631,-118.7559974,"Barrow Neurological Institute, Phoenix, Arizona, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
905,159,38.27312,-98.5821872,"Cedars-Sinai Medical Center, Los Angeles, California, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
906,159,38.7604815,-92.5617875,"California Pacific Medical Center, San Diego, California, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
907,159,41.7370229,-99.5873816,"Stanford University, Stanford, California, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
908,159,40.7127281,-74.0060152,"Hospital for Special Care, New Britain, Connecticut, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
909,159,43.9792797,-120.737257,"Mayo Clinic Florida, Jacksonville, Florida, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
910,159,40.9699889,-77.7278831,"University of Florida, Jacksonville, Jacksonville, Florida, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
911,159,31.8160381,-99.5120986,"University of Iowa, Iowa City, Iowa, United States",160.0,NCT01786603,Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Rasagiline|Drug: Placebo,Change in the ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in vital capacity (VC)|Change in quality of life|Number of participants with adverse events|Difference in survival status between study groups|Bcl2Bax expression ratio in RNA samples|Biomarker Assays of Mitochondrial Function|Effect of study drug on apoptosis markers|Effect of study drug on oxidative stress,"Richard Barohn, MD|University of Kansas Medical Center",All,Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12312|R01FD003739,September 2012,August 2017,August 2017,"February 8, 2013",,"June 14, 2017",,https://ClinicalTrials.gov/show/NCT01786603,21.0,80.0
912,160,31.778345,35.2250786,"Massachusetts General Hospital, Boston, Massachusetts, United States",161.0,NCT03482050,"A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)",,Recruiting,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Biological: AstroRx,Number of participants with treatment emergent adverse events as assessed by CTCAE Version 4.03|Change in the ALS functional rating scale|Change in predicted slow vital capacity (%SVC)|Change in muscle strength grading by JAMAR grip strength|Change in muscle strength grading by hand held dynamometer (HHD)|Change in Quality of Life questionnaire (ALSAQ-40),Kadimastem,All,Phase 1|Phase 2,21.0,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASTRO-001-IL,"April 12, 2018",August 2020,August 2020,"March 29, 2018",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT03482050,18.0,70.0
913,161,45.7774551,3.0819427,"Henry Ford Health Systems, Detroit, Michigan, United States",162.0,NCT00337402,Effects of Gastrostomy on Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,,"University Hospital, Clermont-Ferrand|University Hospital, Angers|University Hospital, Bordeaux|University Hospital, Caen|University Hospital, Grenoble|University Hospital, Lille|University Hospital, Limoges|Neurological department of Lyon University Hospital|University Hospital, Marseille|University Hospital, Montpellier|Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Nice|University Hospital, Paris|University Hospital, Strasbourg|University Hospital, Toulouse|University Hospital, Tours",All,,380.0,Other,Observational,Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective,CHU63-0001,January 2002,,June 2005,"June 16, 2006",,"November 22, 2006",,https://ClinicalTrials.gov/show/NCT00337402,18.0,100.0
914,162,27.7567667,-81.4639835,"St Louis University, St Louis, Missouri, United States",163.0,NCT00317616,The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study,Pre-fALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Risk Factors for Progression to familial ALS,University of Miami|ALS Association,All,,500.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pre-fALS,April 2006,December 2027,December 2027,"April 25, 2006",,"August 2, 2019",,https://ClinicalTrials.gov/show/NCT00317616,18.0,100.0
915,163,50.879202,4.7011675,"Neurology Associates P.C., Lincoln, Nebraska, United States",164.0,NCT00800501,A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sNN0029|Drug: Placebo,"Safety and tolerability through assessment of adverse events, ECGs, vital signs, clinical laboratory variables, MRI of brain and spinal cord, CSF sampling, and device performance as characterized by catheter tip placement and infusion accuracy.|Time course of Amyotrophic Lateral Sclerosis Functional Rating Scale, Quality of life as measured by the EQ-5D rating scale",Newron Sweden AB|Medtronic|ICON Clinical Research,All,Phase 1|Phase 2,18.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",sNN0029-001,December 2008,June 2011,June 2011,"December 2, 2008",,"December 6, 2011",,https://ClinicalTrials.gov/show/NCT00800501,18.0,75.0
916,164,34.395342,-111.7632755,"Hospital for Special Surgery, New York, New York, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
917,164,36.7014631,-118.7559974,"SUNY Upstate Medical University, Syracuse, New York, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
918,164,36.7014631,-118.7559974,"Carolinas Health Care, Charlotte, North Carolina, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
919,164,36.7014631,-118.7559974,"Wake Forest University, Winston-Salem, North Carolina, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
920,164,41.6500201,-72.7342163,"Cleveland Clinic, Cleveland, Ohio, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
921,164,27.7567667,-81.4639835,"Ohio State University, Columbus, Ohio, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
922,164,27.7567667,-81.4639835,"Providence ALS Center, Portland, Oregon, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
923,164,41.9216734,-93.3122705,"Drexel University, Philadelphia, Pennsylvania, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
924,164,42.3788774,-72.032366,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
925,164,43.6211955,-84.6824346,"University of Texas Southwestern, Dallas, Texas, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
926,164,38.7604815,-92.5617875,"University of Texas, San Antonio, Texas, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
927,164,41.7370229,-99.5873816,"University of Vermont, Burlington, Vermont, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
928,164,40.7127281,-74.0060152,"Virginia Mason Medical Center, Seattle, Washington, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
929,164,40.7127281,-74.0060152,"Mayo Clinic in Scottsdale, Scottsdale, Arizona, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
930,164,35.6729639,-79.0392919,"California Pacific Medical Center, San Francisco, California, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
931,164,35.6729639,-79.0392919,"Mayo Clinic in Jacksonville, Jacksonville, Florida, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
932,164,40.2253569,-82.6881395,"Emory University, Atlanta, Georgia, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
933,164,40.2253569,-82.6881395,"Indiana University, Indianapolis, Indiana, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
934,164,43.9792797,-120.737257,"University of Michigan Medical Center, Ann Arbor, Michigan, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
935,164,40.9699889,-77.7278831,"Henry Ford Hospital, Detroit, Michigan, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
936,164,40.9699889,-77.7278831,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
937,164,31.8160381,-99.5120986,"Mayo Clinic, Rochester, Minnesota, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
938,164,31.8160381,-99.5120986,"University of Mississippi, Jackson, Mississippi, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
939,164,44.5990718,-72.5002608,"Beth Israel Medical Center, New York, New York, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
940,164,38.8950092,-77.0365625,"University of Rochester Medical Center, Rochester, New York, United States",165.0,NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),DPS in ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx¬Æ Diaphragm Pacing System‚Ñ¢ (DPS),Survival|quality of life,Barrow Neurological Institute|ALS Association|Muscular Dystrophy Association|Synapse Biomedical,All,Phase 2,52.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013P001504,August 2013,January 2017,April 2017,"September 10, 2013",,"December 23, 2016",,https://ClinicalTrials.gov/show/NCT01938495,21.0,100.0
941,165,34.395342,-111.7632755,"University of Cincinnati, Cincinnati, Ohio, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
942,165,36.7014631,-118.7559974,"Cleveland Clinic, Cleveland, Ohio, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
943,165,27.7567667,-81.4639835,"Ohio State University, Columbus, Ohio, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
944,165,32.3293809,-83.1137366,"University of Pennsylvania, Pennsylvania Hospital, Philadelphia, Pennsylvania, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
945,165,40.3270127,-86.1746933,"Methodist Hospital, Houston, Texas, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
946,165,43.6211955,-84.6824346,"West Virginia University, Morgantown, West Virginia, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
947,165,43.6211955,-84.6824346,"Froedtert and Medical College Clinics, Milwaukee, Wisconsin, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
948,165,45.9896587,-94.6113288,"University of Puerto Rico, San Juan, Puerto Rico",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
949,165,45.9896587,-94.6113288,"Forbes Norris - California Pacific Medical Center (CPMC), San Francisco, California, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
950,165,39.548248,-91.153628,"Stanford University Medical Center, Stanford, California, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
951,165,40.7127281,-74.0060152,"Mayo Clinic, Jacksonville, Florida, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
952,165,40.7127281,-74.0060152,"Johns Hopkins University, Baltimore, Maryland, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
953,165,40.2253569,-82.6881395,"Henry Ford Health System, Detroit, Michigan, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
954,165,40.2253569,-82.6881395,"University Hospitals Of Cleveland, Cleveland, Ohio, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
955,165,40.2253569,-82.6881395,"The Methodist Hospital, Houston, Texas, United States",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
956,165,40.9699889,-77.7278831,"Groupe Hospitalier Pitie-Salpetriere, Paris, France",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
957,165,31.8160381,-99.5120986,"Clinical Universitary Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
958,NULL,NULL,NULL,"Royal Brigham & Women's Hospital, Herston, Queensland, Australia",,,,,,,,,,,,,,,,,,,,,,,,,,,
959,165,44.4308975,-89.6884637,"Teva Benelux, Leuven, Belgium",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
960,165,18.465299,-66.116666,"Teva France, Paris, France",166.0,NCT00035815,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Rate of Change in Composite Manual Muscle Testing (MMT) Score|Number of Participants Alive and Tracheostomy-free at 24 Months|Rate of Change in ALS Functional Rating Scale.,Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,All,Phase 3,330.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1461-01|R01NS042759,June 2003,August 2007,December 2007,"May 7, 2002","February 15, 2013","February 15, 2013",,https://ClinicalTrials.gov/show/NCT00035815,18.0,80.0
961,166,36.7014631,-118.7559974,"Teva Germany, Morfelden-Walldorf, Germany",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
962,166,36.7014631,-118.7559974,"Teva Israel, Tel Aviv, Israel",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
963,166,27.7567667,-81.4639835,"Teva Italy, Milano, Italy",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
964,166,39.5162234,-76.9382069,"Teva UK, Aylesbury, United Kingdom",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
965,166,43.6211955,-84.6824346,"Sheffield Institute for Translational Neuroscience, Sheffield, South Yorkshire, United Kingdom",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
966,166,40.2253569,-82.6881395,"California Pacific Medical Center, San Francisco, California, United States",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
967,166,31.8160381,-99.5120986,"Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
968,166,48.8566101,2.3514992,"University of Kansas Medical Center, Kansas City, Kansas, United States",167.0,NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: Intramuscular diaphragm electrodes,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months|Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.",Synapse Biomedical|University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,All,Not Applicable,100.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0005,October 2004,October 2009,October 2009,"January 11, 2007",,"March 18, 2009",,https://ClinicalTrials.gov/show/NCT00420719,18.0,100.0
969,167,37.9923795,-1.1305431,"University of New Mexico - Medical Center, Albuquerque, New Mexico, United States",168.0,NCT02286011,Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis,TCIM/ELA,Unknown status,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Biological: MNC (Mononuclear cells)|Other: Saline,Rate of serious and non-serious adverse events related to the use of bone marrow mononuclear cells in patients with Amyotrophic Lateral Sclerosis.|Estimated number of motor units (MUNE)|Compound muscle action potential (CMAP)|Fiber density (FD)|Muscle force MRC (Medical Research Council) score|Maximum force developed in an isometric contraction of the tibialis anterior (TA) muscle.|Maximum transversal area of the tibialis anterior (TA),"Red de Terapia Celular|Spanish National Health System|Hospital Universitario Virgen de la Arrixaca|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Public Health Service, Murcia|Instituto Murciano de Investigaci√≥n Biosanitaria Virgen de la Arrixaca",All,Phase 1,20.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TCIM/ELA|2011-004801-25,November 2014,December 2017,December 2017,"November 7, 2014",,"March 30, 2017",,https://ClinicalTrials.gov/show/NCT02286011,18.0,70.0
970,168,,,"University of Texas Health and Science Center, San Antonio, Texas, United States",169.0,NCT03828123,Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis,AMSC-ALS-001,Completed,No Results Available,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Biological: Suspension of human autologous MSC 3P in 1.5 ml,Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC),"Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic",All,Phase 1|Phase 2,26.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMSC-ALS-001,January 2012,"August 18, 2017","August 18, 2017","February 4, 2019",,"February 12, 2019",,https://ClinicalTrials.gov/show/NCT03828123,18.0,65.0
971,169,-21.9182856,144.4588889,"University of Virginia Health System, Charlottesville, Virginia, United States",170.0,NCT03474263,IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS),,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Biologic: IC14 (monoclonal antibody against human CD14),"Glial Activation|Serum neurofilament|Urinary p75 neurotrophin receptor|Incidence of Treatment-Emergent Adverse Events (Safety, Tolerability)|Immunogenicity|Peak Plasma Concentration of IC14|Pharmacodynamics",Implicit Bioscience,All,Phase 2,0.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALS02,"September 1, 2019","April 12, 2021","July 12, 2021","March 22, 2018",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT03474263,18.0,80.0
972,170,50.879202,4.7011675,"VA Medical Center, Iowa City, Iowa City, Iowa, United States",171.0,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: 40 mg glatiramer acetate|Drug: Placebo,Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit|Time to Death/Tracheostomy/Permanent Assisted Ventilation,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",All,Phase 2,366.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALS-GA-201,"July 31, 2006","June 30, 2008","July 31, 2008","May 17, 2006",,"February 20, 2018",,https://ClinicalTrials.gov/show/NCT00326625,18.0,70.0
973,170,48.8566101,2.3514992,"VA Medical Center, Lexington, Lexington, Kentucky, United States",171.0,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: 40 mg glatiramer acetate|Drug: Placebo,Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit|Time to Death/Tracheostomy/Permanent Assisted Ventilation,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",All,Phase 2,366.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALS-GA-201,"July 31, 2006","June 30, 2008","July 31, 2008","May 17, 2006",,"February 20, 2018",,https://ClinicalTrials.gov/show/NCT00326625,18.0,70.0
974,170,49.9923836,8.5622468,"VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States",171.0,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: 40 mg glatiramer acetate|Drug: Placebo,Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit|Time to Death/Tracheostomy/Permanent Assisted Ventilation,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",All,Phase 2,366.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALS-GA-201,"July 31, 2006","June 30, 2008","July 31, 2008","May 17, 2006",,"February 20, 2018",,https://ClinicalTrials.gov/show/NCT00326625,18.0,70.0
975,170,32.0804808,34.7805274,"Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Bedford, Massachusetts, United States",171.0,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: 40 mg glatiramer acetate|Drug: Placebo,Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit|Time to Death/Tracheostomy/Permanent Assisted Ventilation,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",All,Phase 2,366.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALS-GA-201,"July 31, 2006","June 30, 2008","July 31, 2008","May 17, 2006",,"February 20, 2018",,https://ClinicalTrials.gov/show/NCT00326625,18.0,70.0
976,170,45.4667971,9.1904984,"VA Medical Center, Jamaica Plain Campus, Boston, Massachusetts, United States",171.0,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: 40 mg glatiramer acetate|Drug: Placebo,Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit|Time to Death/Tracheostomy/Permanent Assisted Ventilation,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",All,Phase 2,366.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALS-GA-201,"July 31, 2006","June 30, 2008","July 31, 2008","May 17, 2006",,"February 20, 2018",,https://ClinicalTrials.gov/show/NCT00326625,18.0,70.0
977,170,51.8161412,-0.8130383,"VA Medical Center, Syracuse, Syracuse, New York, United States",171.0,NCT00326625,Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: 40 mg glatiramer acetate|Drug: Placebo,Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit|Time to Death/Tracheostomy/Permanent Assisted Ventilation,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",All,Phase 2,366.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALS-GA-201,"July 31, 2006","June 30, 2008","July 31, 2008","May 17, 2006",,"February 20, 2018",,https://ClinicalTrials.gov/show/NCT00326625,18.0,70.0
978,171,53.48153335,-1.38104220661496,"VA Medical Center, Durham, Durham, North Carolina, United States",172.0,NCT03081338,A Programme for Amyotrophic Lateral Sclerosis Care in Europe,ALS-CarE,Unknown status,No Results Available,ALS (Amyotrophic Lateral Sclerosis)|MND (Motor Neurone DIsease),,Calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions using the EuroQoL validated EQ-5D-5L questionnaire.,Sheffield Teaching Hospitals NHS Foundation Trust,All,,115.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STH18567,May 2015,"March 31, 2018","March 31, 2018","March 16, 2017",,"August 8, 2017",,https://ClinicalTrials.gov/show/NCT03081338,18.0,100.0
979,172,36.7014631,-118.7559974,"VA Medical Center, Cincinnati, Cincinnati, Ohio, United States",173.0,NCT00070993,Creatine for the Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: creatine monohydrate,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,Phase 2,110.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01AT000967-01,December 2002,,May 2006,"October 13, 2003",,"August 4, 2006",,https://ClinicalTrials.gov/show/NCT00070993,21.0,80.0
980,172,40.0796606,-89.4337288,"VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, United States",173.0,NCT00070993,Creatine for the Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: creatine monohydrate,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,Phase 2,110.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01AT000967-01,December 2002,,May 2006,"October 13, 2003",,"August 4, 2006",,https://ClinicalTrials.gov/show/NCT00070993,21.0,80.0
981,172,38.27312,-98.5821872,"Michael E. DeBakey VA Medical Center (152), Houston, Texas, United States",173.0,NCT00070993,Creatine for the Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: creatine monohydrate,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,Phase 2,110.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01AT000967-01,December 2002,,May 2006,"October 13, 2003",,"August 4, 2006",,https://ClinicalTrials.gov/show/NCT00070993,21.0,80.0
982,172,34.5708167,-105.993007,"Phoenix Neurological Institute, Phoenix, Arizona, United States",173.0,NCT00070993,Creatine for the Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: creatine monohydrate,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,Phase 2,110.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01AT000967-01,December 2002,,May 2006,"October 13, 2003",,"August 4, 2006",,https://ClinicalTrials.gov/show/NCT00070993,21.0,80.0
983,172,31.8160381,-99.5120986,"California Pacific Medical Center, San Francisco, California, United States",173.0,NCT00070993,Creatine for the Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: creatine monohydrate,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,Phase 2,110.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01AT000967-01,December 2002,,May 2006,"October 13, 2003",,"August 4, 2006",,https://ClinicalTrials.gov/show/NCT00070993,21.0,80.0
984,172,37.1232245,-78.4927721,"University of Iowa, Iowa City, Iowa, United States",173.0,NCT00070993,Creatine for the Treatment of Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: creatine monohydrate,,National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,Phase 2,110.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01AT000967-01,December 2002,,May 2006,"October 13, 2003",,"August 4, 2006",,https://ClinicalTrials.gov/show/NCT00070993,21.0,80.0
985,173,41.9216734,-93.3122705,"University Of Kansas Medical Center, Kansas City, Kansas, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
986,173,37.5726028,-85.1551411,"University of Minnesota, Minneapolis, Minnesota, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
987,173,39.5162234,-76.9382069,"University of Nebraska Medical Center, Omaha, Nebraska, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
988,173,42.3788774,-72.032366,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
989,173,42.3788774,-72.032366,"University of Tennessee, Memphis, Tennessee, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
990,173,40.7127281,-74.0060152,"The Methodist Hospital System, Houston, Texas, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
991,173,35.6729639,-79.0392919,"McGill University, Montreal, Quebec, Canada",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
992,173,40.2253569,-82.6881395,"Johns Hopkins University, Baltimore, Maryland, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
993,173,40.9699889,-77.7278831,"Massachusetts General Hospital-East, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
994,173,31.8160381,-99.5120986,"Washington University School of Medicine, St. Louis, Missouri, United States",174.0,NCT00107770,Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sodium phenylbutyrate,"safety and tolerability|The number of side effects at each dosage, including abnormalities in vital signs, physical examination, blood tests and EKGs, change in vital capacity (breathing function) and ALS functional rating scale|Relationship between blood levels and sodium phenylbutyrate dosage",US Department of Veterans Affairs|Muscular Dystrophy Association|VA Office of Research and Development,All,Phase 1|Phase 2,40.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0015,April 2005,November 2006,September 2007,"April 8, 2005",,"January 11, 2010",,https://ClinicalTrials.gov/show/NCT00107770,18.0,100.0
995,174,34.395342,-111.7632755,"Methodist Neurological Institute, Houston, Texas, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
996,174,36.7014631,-118.7559974,"Charit√© University Hospital, Berlin, Germany",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
997,174,41.9216734,-93.3122705,"the Methodist Neurological Institute, Houston, Texas, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
998,174,38.27312,-98.5821872,"Royal Brigham and Women's Hospital, Herston, Queensland, Australia",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
999,174,45.9896587,-94.6113288,"University of California, San Francisco, San Francisco, California, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
1000,174,41.7370229,-99.5873816,"University of Kansas, Kansas City, Kansas, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
1001,174,40.9699889,-77.7278831,"University of New Mexico, Albuquerque, New Mexico, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
1002,174,35.7730076,-86.2820081,"Carolinas Medical Center, Charlotte, North Carolina, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
1003,174,31.8160381,-99.5120986,"Duke University Medical Center, Durham, North Carolina, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
1004,174,52.4760892,-71.8258668,"Oregon Health Sciences University, Portland, Oregon, United States",175.0,NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: rasagiline,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Difference in Time to Treatment Failure,"Yunxia Wang, MD|Western ALS Study Group|University of Kansas Medical Center",All,Phase 2,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11922,December 2011,May 2013,May 2013,"November 2, 2010","May 18, 2018","May 18, 2018",,https://ClinicalTrials.gov/show/NCT01232738,21.0,80.0
1005,175,39.5162234,-76.9382069,"University of Texas Health Science Center, San Antonio, Texas, United States",176.0,NCT01041222,"Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",SOD-1,Completed,No Results Available,Familial Amyotrophic Lateral Sclerosis,Drug: ISIS 333611,"To evaluate the safety, tolerability, and pharmacokinetics of four dose levels of ISIS 333611","Ionis Pharmaceuticals, Inc.|Muscular Dystrophy Association|ALS Association",All,Phase 1,33.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 333611- CS1,January 2010,December 2011,January 2012,"December 31, 2009",,"April 13, 2012",,https://ClinicalTrials.gov/show/NCT01041222,18.0,100.0
1006,175,42.3788774,-72.032366,"University of Virginia Health System, Charlottesville, Virginia, United States",176.0,NCT01041222,"Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",SOD-1,Completed,No Results Available,Familial Amyotrophic Lateral Sclerosis,Drug: ISIS 333611,"To evaluate the safety, tolerability, and pharmacokinetics of four dose levels of ISIS 333611","Ionis Pharmaceuticals, Inc.|Muscular Dystrophy Association|ALS Association",All,Phase 1,33.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 333611- CS1,January 2010,December 2011,January 2012,"December 31, 2009",,"April 13, 2012",,https://ClinicalTrials.gov/show/NCT01041222,18.0,100.0
1007,175,38.7604815,-92.5617875,"Charit√© - Universit√§tsmedizin, Berlin, Germany, Berlin, Germany",176.0,NCT01041222,"Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",SOD-1,Completed,No Results Available,Familial Amyotrophic Lateral Sclerosis,Drug: ISIS 333611,"To evaluate the safety, tolerability, and pharmacokinetics of four dose levels of ISIS 333611","Ionis Pharmaceuticals, Inc.|Muscular Dystrophy Association|ALS Association",All,Phase 1,33.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 333611- CS1,January 2010,December 2011,January 2012,"December 31, 2009",,"April 13, 2012",,https://ClinicalTrials.gov/show/NCT01041222,18.0,100.0
1008,175,31.8160381,-99.5120986,"Neurological Institute, New York, New York, United States",176.0,NCT01041222,"Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",SOD-1,Completed,No Results Available,Familial Amyotrophic Lateral Sclerosis,Drug: ISIS 333611,"To evaluate the safety, tolerability, and pharmacokinetics of four dose levels of ISIS 333611","Ionis Pharmaceuticals, Inc.|Muscular Dystrophy Association|ALS Association",All,Phase 1,33.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 333611- CS1,January 2010,December 2011,January 2012,"December 31, 2009",,"April 13, 2012",,https://ClinicalTrials.gov/show/NCT01041222,18.0,100.0
1009,176,52.5170365,13.3888599,"Eleanor and Lou Gehrig ALS/MDA Center at Columbia University, New York, New York, United States",177.0,NCT01277315,Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Anakinra,Number and Severity of adverse events (AE)|Number and Severity of serious adverse events (SAE)|Number and Severity of adverse drug reactions (ARD)|Number and Severity of unexpected adverse drug reactions (UADR)|Number and Severity of serious adverse drug reactions (SADR)|Number and Severity of suspected unexpected serious adverse reaction (SUSAR)|Pathological laboratory parameters|Long Term Tolerability and Safety of Anakinra in ALS Patients,"Charite University, Berlin, Germany|Max Planck Institute for Infection Biology",All,Phase 2,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANA-ALS01,February 2011,June 2012,,"January 14, 2011",,"February 28, 2011",,https://ClinicalTrials.gov/show/NCT01277315,18.0,80.0
1010,177,31.8160381,-99.5120986,"Eleanor and Lou Gehrig ALS/MDA Center at Columbia University, New York, New York, United States",178.0,NCT01592084,Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,"survial(tracheostomy free,<23 hours on NIPPV, from enrollment)|ALSFRS(measure of disability)",The Methodist Hospital System,All,,267.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB(2)0609-0087,April 2008,September 2011,September 2011,"May 7, 2012",,"May 7, 2012",,https://ClinicalTrials.gov/show/NCT01592084,18.0,100.0
1011,178,-21.9182856,144.4588889,"University of Wisconsin, Madison, Wisconsin, United States",179.0,NCT03508453,IC14 for Treatment of Amyotrophic Lateral Sclerosis,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Biological: IC14|Other: Placebo,"Neurofilament (biomarker)|Urinary p75 neurotrophin receptor (biomarker)|Monocyte CD14 receptor occupancy|Functional status|Respiratory function|Muscle function|Quality of life|Cognitive and behavioural assessment|Maximum plasma concentration (Cmax)|Area under the curve|Immunogenicity|Adverse events (safety, tolerability)",Implicit Bioscience,All,Phase 2,50.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS03,"August 15, 2018","May 15, 2020","December 15, 2020","April 25, 2018",,"July 2, 2018",,https://ClinicalTrials.gov/show/NCT03508453,18.0,75.0
1012,179,36.7014631,-118.7559974,"Carolinas Medical Center - Dept of Neurology, Charlotte, North Carolina, United States",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1013,179,38.27312,-98.5821872,"Royal Brisbane and Women's Hospital, Herston, Queensland, Australia",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1014,179,34.5708167,-105.993007,"Centro Sla, Irccs A.O.U. S.Martino Ist, Genova, Genova, Italy",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1015,179,35.6729639,-79.0392919,"Centro Clinico Nemo, Fondazione Serena Onlus, Milano, Milano, Italy",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1016,179,35.6729639,-79.0392919,"Centro Sla, Irccs Fondazione Salvatore Maugeri, Milano, Milano, Italy",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1017,179,43.9792797,-120.737257,"Centro Sla, Irccs Istituto Carlo Besta, Milano, Milano, Italy",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1018,179,31.8160381,-99.5120986,"Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena, Modena, Italy",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1019,179,37.1232245,-78.4927721,"Centro Sla, A.O.U. Maggiore Della Carita', Novara, Novara, Italy",180.0,NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Creatine Monohydrate,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months|Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,The Avicena Group,All,Phase 3,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AGI-ALS-III-01|Orphan Drug:01-1527,June 2003,,April 2005,"September 23, 2003",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00069186,21.0,80.0
1020,180,52.5170365,13.3888599,"Centro Sla, Universita' Di Padova, Padova, Italy",181.0,NCT00876772,Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS),,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Olanzapine,Self-evaluation of appetite by using the Council on Nutrition appetite questionnaire (CNAQ)|Number and severity of adverse events (AE) and severe adverse events (SAE)|Number of patients who have completed treatment with OLN in combination with RIL in comparison with placebo treatment in combination with RIL|Body Mass Index (BMI) measured in body weight [kg]/(body length [m])2|Number of patients with a BMI <18.5 kg/m2|Median daily oral food intake in [kcal] which will be determined retrospectively and anamnestically by composing a dietary protocol and by conducting a standardized interview|Median daily energy balance [kcal] (difference between actual food intake and target food intake)determined retrospectively and anamnestically by composing a dietary protocol and by conducting a standardized interview,"Charite University, Berlin, Germany",All,Phase 2|Phase 3,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OLN-ALS01,March 2011,July 2012,,"April 7, 2009",,"March 24, 2011",,https://ClinicalTrials.gov/show/NCT00876772,18.0,80.0
1021,181,40.7127281,-74.0060152,"Centro Sla, Universita' Di Torino, Torino, Italy",182.0,NCT00036413,"A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TCH346,Safety of three oral doses of TCH346 versus placebo administered for up to 12 weeks to patients with ALS|Biomarker assessments at week 12,Novartis Pharmaceuticals|Novartis,All,Phase 2,44.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CTCH346 0102,January 2002,October 2002,October 2002,"May 10, 2002",,"November 24, 2011",,https://ClinicalTrials.gov/show/NCT00036413,40.0,75.0
1022,182,40.7127281,-74.0060152,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",183.0,NCT00537446,Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Device: noninvasive positive pressure ventilation,"Difference in pulmonary function and respiratory muscle pressure testing, difference in gas exchange, and difference in subjective dyspnea between baseline and the two different ventilator modes",Columbia University,All,Not Applicable,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,AAAC7394,September 2007,August 2012,,"October 1, 2007",,"October 13, 2011",,https://ClinicalTrials.gov/show/NCT00537446,18.0,80.0
1023,183,40.7127281,-74.0060152,"Groupe Hospitalier Piti√©-Salp√™tri√®re - Charles Foix, Paris, France",184.0,NCT00537641,Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Tolerance of bilevel PAP|Score on Epworth Sleepiness Scale,Columbia University,All,,25.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAC2000,May 2007,July 2010,June 2011,"October 1, 2007",,"July 7, 2015",,https://ClinicalTrials.gov/show/NCT00537641,18.0,80.0
1024,184,44.4308975,-89.6884637,"CHU Pontchaillou, Angers, France",185.0,NCT00214110,Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS],,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tamoxifen,"Stability at 6, 12, 18 and 24 months on of the patient's mean percent predicted arm strength|Vital capacity, raw liters and percent predicted, compared with baseline measured at 3 month intervals.|Individual arm and leg muscle mean percent predicted isometric strength compared with baseline measured at 3 month intervals.|Bulbar, Breathing, arm and leg subscores of ALS Functional Rating Scale - Revised [ALS-FRS-R] compared with baseline measured at 3 month intervals.|Total ALS Functional Rating Scale [ALS-FRS-R] compared with baseline measured at 3 month intervals.","University of Wisconsin, Madison",All,Phase 2,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single,2000-486,January 2001,,January 2005,"September 21, 2005",,"October 5, 2015",,https://ClinicalTrials.gov/show/NCT00214110,18.0,90.0
1025,185,35.6729639,-79.0392919,"CHU Cote de Nacre, Caen, France",186.0,NCT01950910,"Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)",WBC,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,,Levels of ALS biomarkers in CSF|Leves of ALS biomarkers in blood,Benjamin Brooks|Atrium Health,All,,1000.0,Other,Observational,Time Perspective: Prospective,CHS-Neurology-WBC Tissue Bank,June 2007,January 2015,January 2015,"September 26, 2013",,"July 3, 2014",,https://ClinicalTrials.gov/show/NCT01950910,18.0,100.0
1026,186,-21.9182856,144.4588889,"CHU Gabriel Montpied, Clermont-Ferrand, France",187.0,NCT03487263,"Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease",,Completed,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis,Biological: IC14,"Incidence of treatment-emergent adverse events (safety, tolerability)|Treatment-related change in ALSFRS-R functional scale|Respiratory function|Muscle function|Quality of life measured by ALSSQOL|Patient-reported outcome|Maximum Plasma Concentration (Cmax)|Area Under the Curve (AUC)|Monocyte CD14 Receptor Occupancy|Urinary p75 neurotrophin receptor (biomarker)|Neurofilament (biomarker)|Anti-drug antibodies",Implicit Bioscience|Royal Brisbane and Women's Hospital,All,Phase 1,10.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALS01,"October 1, 2017","April 18, 2018","December 30, 2018","April 4, 2018",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT03487263,18.0,75.0
1027,187,44.40726,8.9338624,"CHRU, H√¥pital Salengro, Lille, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1028,187,45.4667971,9.1904984,"H√¥pital Dupuytren, Limoges, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1029,187,45.4667971,9.1904984,"H√¥pital Neurologique Pierre Wertheimer, Lyon, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1030,187,45.4667971,9.1904984,"AP-HM,H√¥pital de la Timone, Marseille, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1031,187,44.6458885,10.9255707,"H√¥pital Gui de Chauliac, Montpellier, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1032,187,45.4464036,8.619655,"H√¥pital de l'Archet 1, CHU, Nice, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1033,187,45.4077172,11.8734455,"H√¥pital La Piti√© (AP-HP), Paris, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1034,187,45.0677551,7.6824892,"Centre Hospitalier, Saint Brieuc, France",188.0,NCT03359538,Rapamycin Treatment for ALS,RAP-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Rapamycin|Drug: Placebo Oral Tablet,"T-reg number|Number of serious adverse events (SAEs) and AEs in placebo and treatment arms|Rapamycin capacity to pass through blood brain barrier|Rapamycin efficacy in inhibiting Mtor pathway|Changes in activation and homing capabilities of different T, B, natural killer (NK) cell subpopulations|Changes in CSF neurofilaments|Changes in blood biomarkers|Rapamycin-induced changes in inflammatory status|Changes in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Tracheostomy-free survival rate|Changes in Forced vital capacity (FVC)|Change in quality of life","Azienda Ospedaliero-Universitaria di Modena|University of Modena and Reggio Emilia|Azienda Ospedaliero Universitaria Maggiore della Carita|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|University of Turin, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Azienda Ospedaliera Niguarda C√† Granda|Fondazione Salvatore Maugeri|University of Padova",All,Phase 2,63.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RAP-ALS,"September 19, 2017","April 19, 2019","September 19, 2019","December 2, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03359538,18.0,75.0
1035,188,43.4849133,-71.6553992,"H√¥pital Nord, Saint Etienne, France",189.0,NCT03580616,Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS),ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Possible Amyotrophic Sclerosis,Drug: L-Serine,Dose tolerability based on subject reporting|Efficacy based on ALS Functional Rating Scale - Revised (ALSFRS-R)|Efficacy based on neurological exam|Efficacy based on pulmonary forced vital capacity,"Elijah W. Stommel|Brain Chemistry Labs, Institute for Ethnomedicine|Dartmouth-Hitchcock Medical Center",All,Phase 2,50.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D18095,"October 24, 2018",June 2022,June 2022,"July 9, 2018",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT03580616,18.0,100.0
1036,189,48.8566101,2.3514992,"CHU Bretonneau, Tours, France",190.0,NCT02590276,Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS),PREV-DEMALS,Recruiting,No Results Available,Frontotemporal Lobar Degeneration|Amyotrophic Lateral Sclerosis,Behavioral: characterization,"Change in behavioral assessment (20 scales)|Change in MRI morphological criteria|Change in cerebral perfusion by SPECT / PET|correlations between behavioral assessment, MRI morphological criteria, Cerebral perfusion and metabolism by SPECT / PET and transcriptome analysis",Assistance Publique - H√¥pitaux de Paris,All,Not Applicable,100.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,P140705 -|IDRCB : 2015-A00856-43,September 2015,October 2019,October 2019,"October 29, 2015",,"September 15, 2016",,https://ClinicalTrials.gov/show/NCT02590276,18.0,100.0
1037,190,47.4739884,-0.5515588,"D√©partement de Neurologie, H√¥pital de l'H√¥tel-Dieu, CHU d'Angers, Angers cedex 9, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1038,190,49.1828008,-0.3690815,"Centre SLA, Groupement Hospitalier Est, H√¥pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1039,190,45.7774551,3.0819427,"Service de Neurologie Vastel, H√¥pital C√¥te de Nacre, CHU de Caen, Caen cedex 9, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1040,190,50.6365654,3.0635282,"Service de Neurologie, H√¥pital Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand cedex 1, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1041,190,45.8354243,1.2644847,"Centre SLA, Service de Neurologie A et pathologies du mouvement, H√¥pital Roger Salengro, CHU de Lille, Lille, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1042,190,45.6963425,4.73594802991681,"Service de Neurologie, H√¥pital Dupuytren, CHU de Limoges, Limoges, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1043,190,43.2961743,5.3699525,"Service de Neurologie, H√¥pital de la Timone, CHU de Marseille, Marseille cedex 5, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1044,190,43.6112422,3.8767337,"Service de Neurologie, H√¥pital Central, CHU de Nancy, Nancy, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1045,190,43.7009358,7.2683912,"Centre de R√©f√©rence maladies Neuromusculaires, Service de M√©decine Physique et R√©adaptation, H√¥pital de l'Archet 1, CHU de Nice, Nice cedex 3, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1046,190,48.8566101,2.3514992,"F√©d√©ration des Maladies du Syst√®me Nerveux, Groupement Hospitalier Piti√© Salp√™tri√®re, AP-HP, Paris cedex 13, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1047,190,48.5141594,-2.7602707,"Service de Neurologie, CHU de Saint-Etienne, Saint-Etienne cedex 2, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1048,190,45.4401467,4.3873058,"D√©partement de Neurologie, H√¥pital de Hautepierre, CHRU de Strasbourg, Strasbourg, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1049,190,47.3900474,0.6889268,"Service d'Explorations Fonctionelles Neuro-Musculaires, H√¥pital Rangueil, CHU de Toulouse, Toulouse, France",191.0,NCT02360891,Study of Predictive Factors of Progression of Motor Neurone Disease,PULSE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Other: biomarkers (composite analysis),Change of biomarkers of survival|Change of biomarkers of disease progression|Clinical endophenotypes according to the survival duration|Genetic endophenotypes,"University Hospital, Lille",All,,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-50|2013-A00969-36,"January 12, 2015",January 2025,January 2025,"February 11, 2015",,"June 27, 2019",,https://ClinicalTrials.gov/show/NCT02360891,18.0,85.0
1050,191,46.603354,1.8883335,"Dr. Lawrence Korngut -South Health Campus, Calgary, Alberta, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1051,191,45.7337532,4.9092352,"Dr. Wendy Johnston, Edmonton, Alberta, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1052,191,46.603354,1.8883335,"Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1053,191,46.603354,1.8883335,"Dr. John Turnbull McMaster University/Hamilton Health Services, Hamilton, Ontario, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1054,191,50.6365654,3.0635282,"Dr. Christen Shoesmith, London, Ontario, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1055,191,45.8354243,1.2644847,"Dr. Lorne Zinman Sunnybrook Research Institute, Toronto, Ontario, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1056,191,46.603354,1.8883335,"Dr. Sandrine Larue - Reserche Sepmus Inc., Greenfield Park, Quebec, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1057,191,48.6937223,6.1834097,"Dr. Genevieve Matte, Montr√©al, Quebec, Canada",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1058,191,46.603354,1.8883335,"Hospital Carlos III, Madrid, Spain",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1059,191,46.603354,1.8883335,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1060,191,46.603354,1.8883335,"Hanyang University Hospital, Seoul, Korea, Republic of",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1061,191,48.584614,7.7507127,"Barrow Neurological Institute - St. Joseph's Hospital, Phoenix, Arizona, United States",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1062,191,43.6044622,1.4442469,"University of California at San Francisco - Fresno, Fresno, California, United States",192.0,NCT01551940,Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea,ALS-TOX,Completed,No Results Available,Sialorrhea|Amyotrophic Lateral Sclerosis,Drug: Botox injection|Drug: Placebo injection,Improvement of the functional embarrassment provoked by sialorrhea|Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver|Improvement of the value of the hypersalivation item in ALSFRS-R scale|Decrease of the score of severity and frequency of the drooling rating scale|Decrease of the cotton roll weight|Decrease of the number of paper handkerchiefs used|Modification of the speech evaluation|Improvement of the quality of life|Description of patient cohort after the first injection,Hospices Civils de Lyon,All,Phase 2,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010.607/11,February 2012,March 2014,March 2014,"March 13, 2012",,"August 14, 2015",,https://ClinicalTrials.gov/show/NCT01551940,18.0,100.0
1063,192,55.001251,-115.002136,"University of California, Irvine, Orange, California, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1064,192,55.001251,-115.002136,"University of California, Davis, Sacramento, California, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1065,192,46.500283,-66.750183,"California Pacific Medical Center, San Francisco, California, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1066,192,50.000678,-86.000977,"Hospital for Special Care, New Britain, Connecticut, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1067,192,50.000678,-86.000977,"Mayo Clinic - Jacksonville, Jacksonville, Florida, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1068,192,50.000678,-86.000977,"University of Miami Miller School of Medicine, Miami, Florida, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1069,192,52.4760892,-71.8258668,"University of South Florida Medical Center, Tampa, Florida, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1070,192,52.4760892,-71.8258668,"Emory University, Atlanta, Georgia, United States",193.0,NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),Pimozide2,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Drug: Placebo Oral Tablet,Change in ALS Functional Rating Scale-Revised (ALSFRS-R)|Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,University of Calgary|ALS Canada|Brain Canada,All,Phase 2,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pimozide2_ALS-002,"October 27, 2017","December 31, 2019","December 31, 2019","September 5, 2017",,"December 19, 2018",,https://ClinicalTrials.gov/show/NCT03272503,18.0,100.0
1071,193,40.4167047,-3.7035825,"Northwestern University, Chicago, Illinois, United States",194.0,NCT02588677,Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Masitinib (4.5)|Drug: Riluzole|Drug: Placebo|Drug: Masitinib (3.0),Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Change of Forced Vital Capacity (FVC)|Progression Free Survival|Overall Survival,AB Science,All,Phase 2|Phase 3,394.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AB10015,April 2013,"December 5, 2016",March 2018,"October 28, 2015",,"December 17, 2018",,https://ClinicalTrials.gov/show/NCT02588677,18.0,100.0
1072,194,45.9896587,-94.6113288,"Indiana University, Indianapolis, Indiana, United States",195.0,NCT03268603,Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS),,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis,Drug: Autologous Adipose-derived Mesenchymal Stromal Cells,Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R),Mayo Clinic|State of Minnesota Regenerative Medicine Minnesota,All,Phase 2,60.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-008008|UL1TR000135,"October 10, 2017",December 2019,December 2019,"August 31, 2017",,"April 11, 2019",,https://ClinicalTrials.gov/show/NCT03268603,18.0,100.0
1073,195,42.9629533,47.5133551,"University of Iowa, Iowa City, Iowa, United States",196.0,NCT01363401,Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Biological: HYNR-CS inj|Other: Control group,The Difference in the Changes of Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Between Treatment Groups and Control Groups.|Change in Appel Scale|Change in Forced Vital Capacity (FVC) (Percent of Predicted Normal)|Change in SF-36 (The Short Form (36) Health Survey is a 36 Item),"Corestem, Inc.",All,Phase 1|Phase 2,72.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HYNR_CS_ALS201,February 2011,May 2013,August 2013,"June 1, 2011","July 20, 2016","October 9, 2018",,https://ClinicalTrials.gov/show/NCT01363401,25.0,75.0
1074,196,34.395342,-111.7632755,"University of Kansas Medical Center, Kansas City, Kansas, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1075,196,36.7014631,-118.7559974,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1076,196,36.7014631,-118.7559974,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1077,196,36.7014631,-118.7559974,"St. Mary's Health Care, Grand Rapids, Michigan, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1078,196,36.7014631,-118.7559974,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1079,196,41.6500201,-72.7342163,"Mayo Clinic - Rochester, Rochester, Minnesota, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1080,196,27.7567667,-81.4639835,"Washington University School of Medicine, Saint Louis, Missouri, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1081,196,27.7567667,-81.4639835,"Neurology Associates, P.C., Lincoln, Nebraska, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1082,196,27.7567667,-81.4639835,"University of Nevada School of Medicine, Las Vegas, Nevada, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1083,196,32.3293809,-83.1137366,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1084,196,40.0796606,-89.4337288,"Columbia University, New York, New York, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1085,196,40.3270127,-86.1746933,"Research Foundation of the State University of New York, Syracuse, New York, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1086,196,41.9216734,-93.3122705,"Carolinas Medical Center, Charlotte, North Carolina, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1087,196,38.27312,-98.5821872,"Duke University Medical Center, Durham, North Carolina, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1088,196,39.5162234,-76.9382069,"Wake Forest University, Winston-Salem, North Carolina, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1089,196,42.3788774,-72.032366,"The Cleveland Clinic Foundation, Cleveland, Ohio, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1090,196,43.6211955,-84.6824346,"Ohio State University, Columbus, Ohio, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1091,196,45.9896587,-94.6113288,"Providence ALS Center, Portland, Oregon, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1092,196,45.9896587,-94.6113288,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1093,196,38.7604815,-92.5617875,"ALS Center at Penn, Philadelphia, Pennsylvania, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1094,196,41.7370229,-99.5873816,"Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1095,196,39.5158825,-116.8537227,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1096,196,43.4849133,-71.6553992,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1097,196,40.7127281,-74.0060152,"Texas Neurology, Dallas, Texas, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1098,196,40.7127281,-74.0060152,"Methodist Neurological Institute, Houston, Texas, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1099,196,35.6729639,-79.0392919,"University of Texas Health Sciences Center, San Antonio, Texas, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1100,196,35.6729639,-79.0392919,"University of Utah, Salt Lake City, Utah, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1101,196,35.6729639,-79.0392919,"University of Virginia Health System, Charlottesville, Virginia, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1102,196,40.2253569,-82.6881395,"University of Washington, Seattle, Washington, United States",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1103,196,40.2253569,-82.6881395,"Prince of Wales Hospital, Randwick, New South Wales, Australia",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1104,196,43.9792797,-120.737257,"Westmead Hospital, Westmead, New South Wales, Australia",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1105,196,40.9699889,-77.7278831,"Royal Brisbane and Women's Hospital, Herston, Queensland, Australia",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1106,196,40.9699889,-77.7278831,"Calvary Health Care Bethlehem, Melbourne, Victoria, Australia",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1107,196,40.9699889,-77.7278831,"AZ St-Lucas, Gent, Belgium",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1108,196,40.9699889,-77.7278831,"UZ Leuven, Leuven, Belgium",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1109,196,35.7730076,-86.2820081,"Univ of Calgary / Foothills MC, Calgary, Alberta, Canada",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1110,196,31.8160381,-99.5120986,"CHUM - Hopital Notre Dame, Montreal, Quebec, Canada",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1111,196,31.8160381,-99.5120986,"Mcgill University, Montreal, Quebec, Canada",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1112,196,31.8160381,-99.5120986,"London Health Sciences Centre, London, Canada",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1113,196,39.4225192,-111.7143584,"Sunnybrook and Women's College and Health Sciences Centre, Toronto, Canada",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1114,196,37.1232245,-78.4927721,"University of British Columbia, Vancouver, Canada",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1115,196,38.8950092,-77.0365625,"CHRU de Lille - H√¥pital Roger Salengro, Lille, France",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1116,196,-31.8759835,147.2869493,"Centre Hospitalier La Timone, Marseille, France",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1117,196,-31.8759835,147.2869493,"CHU Gui de Chauliac, Montpellier, France",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1118,196,-21.9182856,144.4588889,"CHU de Nice - H√¥pital de l'Archet 1, Nice, France",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1119,196,-36.5986096,144.6780052,"H√¥pital La Piti√© Salp√©tri√®re, Paris, France",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1120,196,51.0538286,3.7250121,"Charit√© - Universit√§tsmedizin Berlin, Berlin, Germany",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1121,196,50.879202,4.7011675,"Bergmannsheil Gmbh, Bochum, Germany",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1122,196,55.001251,-115.002136,"Medizinische Hochschule Hannover (MHH), Hannover, Germany",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1123,196,52.4760892,-71.8258668,"Universit√§tsklinikum Jena, Jena, Germany",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1124,196,52.4760892,-71.8258668,"University of Ulm, RKU, Ulm, Germany",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1125,196,42.9537654,-81.2291529,"Beaumont Hospital, Dublin, Ireland",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1126,196,43.653963,-79.387207,"Academisch Medisch Centrum, Amsterdam, Netherlands",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1127,196,49.2608724,-123.1139529,"UMC St. Radboud, Nijmegen, Netherlands",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1128,196,50.6365654,3.0635282,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1129,196,43.2961743,5.3699525,"Hospital Universitario de Bellvitge, Barcelona, Spain",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1130,196,43.6112422,3.8767337,"Hospital Vall d'Hebron, Barcelona, Spain",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1131,196,43.7009358,7.2683912,"Hospital La Paz, Madrid, Spain",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1132,196,48.8566101,2.3514992,"Hospital Carlos III, Madrid, Spain",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1133,196,52.5170365,13.3888599,"Sahlgrenska Universitetssjukhuset, G√∂teborg, Sweden",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1134,196,51.4818111,7.2196635,"Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1135,196,52.3744779,9.7385532,"Queen Elizabeth Hospital, Birmingham, United Kingdom",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1136,196,50.9281717,11.5879359,"Walton Centre for Neurology & Neurosurgery, Liverpool, United Kingdom",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1137,196,48.3974003,9.9934336,"Kings College Hospital NHS Foundation Trust, London, United Kingdom",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1138,196,53.3497645,-6.2602732,"Newcastle University Hospital - Clinical Ageing Research Unit, Newcastle, United Kingdom",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1139,196,52.3745403,4.89797550561798,"John Radcliffe Hospital, Oxford, United Kingdom",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1140,196,51.84257485,5.83896062874823,"Sheffield Institute for Transnational Neuroscience, Sheffield, United Kingdom",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1141,196,52.0809856,5.12768396945229,"Fondazione S.Maugeri, Pavia, Italy",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1142,196,41.3828939,2.1774322,"Respiratory Unit FSM, Pavia, Italy",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1143,196,41.3828939,2.1774322,"Nagoya University Hospital, Nagoya, Aichi, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1144,196,40.4167047,-3.7035825,"Miyoshi Neurological Clinic, Miyoshi, Hiroshima, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1145,196,40.4167047,-3.7035825,"Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1146,196,57.7072326,11.9670171,"Kobe Central Munincipal Medical center, Kobe, Hyogo, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1147,196,59.3251172,18.0710935,"Ioh National Hospital, Kanazawa, Ishikawa, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1148,196,52.4775396,-1.894053,"Kitasato University East Hospital, Sagamihara, Kanagawa, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1149,196,53.407154,-2.991665,"Shiga Medical University Hospital, Otsu, Shiga, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1150,196,51.5073219,-0.1276474,"Chiba University Hospital, Chiba, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1151,196,53.0117627,-2.2273919,"Murakami Karindo Hospital, Fukuoka, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1152,196,51.7520131,-1.2578499,"Okayama University Hospital, Okayama, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1153,196,53.3806626,-1.4702278,"Tokushima University Hospital, Tokushima, Japan",197.0,NCT01622088,Phase 3 Extension Study of Dexpramipexole in ALS,ENVISION,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole,"Incidence of Adverse Events and Serious Adverse Events|Discontinuation of study treatment due to an Adverse Events|Changes in vital signs, clinical laboratory assessments (hematology, blood chemistry, and urinalysis), 12-lead electrocardiogram (ECGs), and body weight|Incidence of laboratory abnormalities|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) score|Decline in sniff nasal inspiratory pressure (SNIP)|Time to death|Time to death or death equivalent (tracheostomy or permanent assisted ventilation (PAV), defined as use of noninvasive ventilation (NIV) for ‚â• 22 hours per day for ‚â• 10 days)",Knopp Biosciences|Biogen,All,Phase 3,616.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223AS304|EUDRA CT #: 2011-006119-70,June 2012,February 2013,February 2013,"June 18, 2012",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01622088,18.0,80.0
1154,197,45.1860043,9.1546375,"Juntendo University Hospital, Tokyo, Japan",198.0,NCT00560287,Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis|Chronic Respiratory Failure,Device: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|Device: Non invasive ventilation,quality of life|tolerance to NIV|number of hours of NIV per day|frequency of hospital admission|frequency of changing the ventilator settings by the operator.|survival|diurnal and nocturnal gas exchange|Pulmonary Function Tests (PFTs).,Fondazione Salvatore Maugeri,All,Phase 4,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",190H09,January 2008,August 2009,August 2010,"November 19, 2007",,"March 29, 2010",,https://ClinicalTrials.gov/show/NCT00560287,20.0,80.0
1155,197,45.1860043,9.1546375,"Toho University Hospital, Tokyo, Japan",198.0,NCT00560287,Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis|Chronic Respiratory Failure,Device: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|Device: Non invasive ventilation,quality of life|tolerance to NIV|number of hours of NIV per day|frequency of hospital admission|frequency of changing the ventilator settings by the operator.|survival|diurnal and nocturnal gas exchange|Pulmonary Function Tests (PFTs).,Fondazione Salvatore Maugeri,All,Phase 4,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",190H09,January 2008,August 2009,August 2010,"November 19, 2007",,"March 29, 2010",,https://ClinicalTrials.gov/show/NCT00560287,20.0,80.0
1156,198,34.9991645,137.254574,"Teikyo University Hospital, Tokyo, Japan",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1157,198,34.3916058,132.4518156,"Tokyo Metropolitan Neurological Hospital, Tokyo, Japan",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1158,198,43.4603175,143.330715792837,"Wakayama Medical University Hospital, Wakayama, Japan",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1159,198,34.914934,134.860666,"Limoges, France",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1160,198,36.9888678,136.8163563,"Iranian Neurology Research Center of Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1161,NULL,NULL,NULL,"Jena University Hospital, Hans Berger Department of Neurology, Jena, Thuringia, Germany",,,,,,,,,,,,,,,,,,,,,,,,,,,
1162,198,35.247154,136.109385,"Aarhus University Hospital, Aarhus, Denmark",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1163,198,35.549399,140.2647303,"Barrow Neuological Institute, Phoenix, Arizona, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1164,198,33.6251241,130.6180016,"Cedars-Sinai, Los Angeles, California, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1165,198,34.8581334,133.7759256,"UC Irvine Medical Center, Orange, California, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1166,198,33.9196418,134.2509634,"Mayo Clinic in Florida, Jacksonville, Florida, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1167,198,35.6828387,139.7594549,"Augusta University (Georgia Regents Medical Center), Augusta, Georgia, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1168,198,35.6828387,139.7594549,"Johns Hopkins Hospital, Baltimore, Maryland, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1169,198,35.6828387,139.7594549,"Massachusetts General Hospital, Boston, Massachusetts, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1170,198,35.6828387,139.7594549,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1171,198,33.8070292,135.5930743,"University of Michigan, Ann Arbor, Michigan, United States",199.0,NCT03548311,Clinical Trial of Ultra-high Dose Methylcobalamin for ALS,JETALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: methylcobalamin|Drug: saline solution,ALSFRS-R|survival|%Functional Vital Capacity (FVC)|homocystein|Manual Muscle Testing (MMT)|Norris scale|Grip Power|40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40),"University of Tokushima|Eisai Co., Ltd.",All,Phase 3,128.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",763,"November 1, 2017","February 28, 2020","March 31, 2020","June 7, 2018",,"June 25, 2018",,https://ClinicalTrials.gov/show/NCT03548311,20.0,100.0
1172,199,45.8354243,1.2644847,"Hospital for Special Surgery, New York, New York, United States",200.0,NCT03382392,Hypermetabolism in ALS Using Six REE Formulas,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.,Measure of REE,"University Hospital, Limoges",All,,449.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,mREE,November 1996,November 2014,November 2014,"December 22, 2017",,"December 22, 2017",,https://ClinicalTrials.gov/show/NCT03382392,18.0,100.0
1173,200,36.2619477,59.6051728,"Duke University Hospital, Durham, North Carolina, United States",201.0,NCT01825551,The Effect of GCSF in the Treatment of ALS Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Granulocyte Colony Stimulating Factor|Drug: Placebo,patient`s function|mobilizing bone marrow stem cells|amplitude of compound muscle action potential in ulnar and peroneal nerve|quality of life|muscle power,Tehran University of Medical Sciences,All,Phase 2|Phase 3,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",91-01-54-17265,November 2012,November 2013,November 2013,"April 5, 2013",,"November 13, 2013",,https://ClinicalTrials.gov/show/NCT01825551,18.0,85.0
1174,201,,,"Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",202.0,NCT03326622,Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: standard care|Other: moderate exercise,Functional decline between start and end of the study|Performance of Cardiopulmonary Exercise testing variables throughout the study|Changes on the Dioxide Carbon output (VCO2) measurement|Changes on the Minute Ventilation (VE) measurement,University of Lisbon,All,Not Applicable,48.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,FCT - SFRH/BD/78413/2011,"July 1, 2013","March 30, 2015","June 30, 2015","October 31, 2017",,"November 1, 2017",,https://ClinicalTrials.gov/show/NCT03326622,18.0,90.0
1175,202,50.7333163,11.0747905,"Dept. of Neurology Aarhus Hospital, N√∏rrebrogade, Aarhus, Denmark",203.0,NCT02572479,Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS),JERN_ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Dietary Habits|Disorder of Fatty Acid Metabolism,,"Clinical neurological examination|Nutrient intake by diet|Fatty acid distribution in erythrocyte lipids|Blood lipids|Inflammatory parameter|Metabolic serum parameters|Clinical neurological examination, part II",University of Jena|Jena University Hospital,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,H01_15,October 2015,October 2018,October 2018,"October 9, 2015",,"March 7, 2019",,https://ClinicalTrials.gov/show/NCT02572479,18.0,90.0
1176,203,56.1496278,10.2134046,"Gildh√∏j Private Hospital, Br√∏ndby, Denmark",204.0,NCT02325375,sCD163 in ALS Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: lumbar puncture for spinal fluid and blood sample,Concentrations of sCD-163 in patients with ALS.|Concentration of sCD163 in newly diagnosed compared with established ALS,University of Aarhus,All,,20.0,Other,Observational,,ALS CD163|1-10-72-348-14,December 2014,February 2016,February 2016,"December 25, 2014",,"May 16, 2016",,https://ClinicalTrials.gov/show/NCT02325375,18.0,100.0
1177,204,34.395342,-111.7632755,"Dept. of Neurology, Bisbebjerg Hospital, Copenhagen NV, Denmark",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1178,204,36.7014631,-118.7559974,"Clinic of Neurosurgery, Rigshospitalet, Copenhagen √ò, Denmark",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1179,204,36.7014631,-118.7559974,"Clinic of neuroanestesiology, Rigshospitalet Glostrup, Copenhagen, Denmark",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1180,204,27.7567667,-81.4639835,"The Dept. og Neurology, Rigshospitalet Glostrup, Glostrup, Denmark",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1181,204,32.3293809,-83.1137366,"Dept. of Neurology, Odense Hospital, Odense C, Denmark",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1182,204,39.5162234,-76.9382069,"The dept. of Neurology, Roskilde Hospital, Roskilde, Denmark",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1183,204,42.3788774,-72.032366,"ALS Clinic, Vanderbilt University Medical Center, Nashville, Tennessee, United States",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1184,204,42.3788774,-72.032366,"Barrow Neurological Institute - St. Joseph's Hospital, Phoenix, Arizona, United States",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1185,204,43.6211955,-84.6824346,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1186,204,40.7127281,-74.0060152,"University of California at San Francisco - Fresno, Fresno, California, United States",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1187,204,35.6729639,-79.0392919,"University of California, Irvine, Orange, California, United States",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1188,204,40.9699889,-77.7278831,"University of California, Davis, Sacramento, California, United States",205.0,NCT02450552,Clinical Trial of Ezogabine (Retigabine) in ALS Subjects,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Ezogabine|Drug: Placebo,Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS)|Change in resting motor evoked potential (MEP) threshold (prespecified secondary outcome of primary importance)|Change in MEP amplitude|Change in duration of cortical silent period|Change in intracortical facilitation|Change in electrotonus|Change in strength duration time constant|Change in recovery cycle|Muscle Cramping Frequency|Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis|Percentage of Days With Fasciculations|Tolerability to study drug,Brian Wainger|ALS Association|GlaxoSmithKline|Harvard University|Massachusetts General Hospital,All,Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014D002776,June 2015,January 2018,February 2018,"May 21, 2015",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02450552,18.0,80.0
1189,205,56.1496278,10.2134046,"California Pacific Medical Center, San Francisco, California, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1190,205,55.644111,12.4217135,"Hospital for Special Care, New Britain, Connecticut, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1191,205,55.683481,12.572832,"Mayo Clinic - Jacksonville, Jacksonville, Florida, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1192,205,55.6867243,12.5700724,"University of Miami Miller School of Medicine, Miami, Florida, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1193,205,55.6867243,12.5700724,"University of South Florida Medical Center, Tampa, Florida, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1194,205,55.6692478,12.3959521,"Emory University, Atlanta, Georgia, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1195,205,55.3997225,10.3852104,"Northwestern University, Chicago, Illinois, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1196,205,55.6433478,12.0819247,"Indiana University, Indianapolis, Indiana, United States",206.0,NCT02869048,Amyotrophic Lateral Sclerosis and the Innate Immune System,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Complement activity|Subcomponents of the complement cascade|Inactivation of the complement system|Indirect profiling of inflammatory proteins present in the blood|Cytokines present in the blood|Acut phase reactants|Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4)|Quantitatively and qualitatively description of ALS muscle fibers.|Regression analysis,"Rigshospitalet, Denmark|Zealand University Hospital|Bispebjerg Hospital|Aarhus University Hospital|Odense University Hospital",All,,375.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,H-16017145,June 2016,June 2026,June 2026,"August 16, 2016",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT02869048,18.0,100.0
1197,206,35.7730076,-86.2820081,"University of Iowa, Iowa City, Iowa, United States",207.0,NCT00838617,Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,"Muscle thickness, as measured by muscle ultrasound, will decrease over time in patients with ALS.|Muscle thickness, as measured by muscle ultrasound, will correlate with decline in strength testing.|Muscle thickness, as measured by muscle ultrasound, will correlate with decline in the ALS-FRS (ALS Functional Rating Scale) over time.|Muscle echogenicity, as measured by muscle ultrasound, will increase in time, and will correlate with loss of muscle strength.",Vanderbilt University,All,,10.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,081243,February 2009,August 2009,August 2009,"February 6, 2009",,"December 11, 2009",,https://ClinicalTrials.gov/show/NCT00838617,18.0,100.0
1198,207,34.395342,-111.7632755,"University of Kansas Medical Center, Kansas City, Kansas, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1199,207,35.2048883,-92.4479108,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1200,207,36.7014631,-118.7559974,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1201,207,36.7014631,-118.7559974,"St. Mary's Health Care, Grand Rapids, Michigan, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1202,207,36.7014631,-118.7559974,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1203,207,36.7014631,-118.7559974,"Mayo Clinic - Rochester, Rochester, Minnesota, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1204,207,41.6500201,-72.7342163,"Washington University School of Medicine, Saint Louis, Missouri, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1205,207,27.7567667,-81.4639835,"Neurology Associates, P.C., Lincoln, Nebraska, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1206,207,27.7567667,-81.4639835,"University of Nevada School of Medicine, Las Vegas, Nevada, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1207,207,27.7567667,-81.4639835,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1208,207,32.3293809,-83.1137366,"Columbia University, New York, New York, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1209,207,40.0796606,-89.4337288,"Research Foundation of the State University of New York, Syracuse, New York, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1210,207,40.3270127,-86.1746933,"Carolinas Medical Center, Charlotte, North Carolina, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1211,207,41.9216734,-93.3122705,"Duke University Medical Center, Durham, North Carolina, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1212,207,38.27312,-98.5821872,"Wake Forest University, Winston-Salem, North Carolina, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1213,207,39.5162234,-76.9382069,"The Cleveland Clinic Foundation, Cleveland, Ohio, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1214,207,42.3788774,-72.032366,"Ohio State University, Columbus, Ohio, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1215,207,43.6211955,-84.6824346,"Providence ALS Center, Portland, Oregon, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1216,207,45.9896587,-94.6113288,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1217,207,45.9896587,-94.6113288,"ALS Center at Penn, Philadelphia, Pennsylvania, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1218,207,38.7604815,-92.5617875,"Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1219,207,41.7370229,-99.5873816,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1220,207,39.5158825,-116.8537227,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1221,207,43.4849133,-71.6553992,"Texas Neurology, Dallas, Texas, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1222,207,40.7127281,-74.0060152,"Methodist Neurological Institute, Houston, Texas, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1223,207,40.7127281,-74.0060152,"University of Texas Health Sciences Center, San Antonio, Texas, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1224,207,35.6729639,-79.0392919,"University of Utah, Salt Lake City, Utah, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1225,207,35.6729639,-79.0392919,"University of Virginia Health System, Charlottesville, Virginia, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1226,207,35.6729639,-79.0392919,"University of Washington, Seattle, Washington, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1227,207,40.2253569,-82.6881395,"Prince of Wales Hospital, Randwick, New South Wales, Australia",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1228,207,40.2253569,-82.6881395,"Westmead Hospital, Westmead, New South Wales, Australia",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1229,207,43.9792797,-120.737257,"Royal Brisbane and Women's Hospital, Herston, Queensland, Australia",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1230,207,40.9699889,-77.7278831,"Calvary Health Care Bethlehem, Melbourne, Victoria, Australia",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1231,207,40.9699889,-77.7278831,"AZ St-Lucas, Gent, Belgium",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1232,207,40.9699889,-77.7278831,"UZ Leuven, Leuven, Belgium",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1233,207,40.9699889,-77.7278831,"Univ of Calgary / Foothills MC, Calgary, Alberta, Canada",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1234,207,35.7730076,-86.2820081,"CHUM - Hopital Notre Dame, Montreal, Quebec, Canada",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1235,207,31.8160381,-99.5120986,"Mcgill University, Montreal, Quebec, Canada",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1236,207,31.8160381,-99.5120986,"London Health Sciences Centre, London, Canada",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1237,207,31.8160381,-99.5120986,"Sunnybrook and Women's College and Health Sciences Centre, Toronto, Canada",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1238,207,39.4225192,-111.7143584,"University of British Columbia, Vancouver, Canada",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1239,207,37.1232245,-78.4927721,"CHRU de Lille - H√¥pital Roger Salengro, Lille, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1240,207,38.8950092,-77.0365625,"CHU de Limoges - H√¥pital Dupuytren, Limoges, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1241,207,-31.8759835,147.2869493,"Centre Hospitalier La Timone, Marseille, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1242,207,-31.8759835,147.2869493,"CHU Gui de Chauliac, Montpellier, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1243,207,-21.9182856,144.4588889,"CHU de Nice - H√¥pital de l'Archet 1, Nice, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1244,207,-36.5986096,144.6780052,"H√¥pital La Piti√© Salp√©tri√®re, Paris, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1245,207,51.0538286,3.7250121,"Charit√© - Universit√§tsmedizin Berlin, Berlin, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1246,207,50.879202,4.7011675,"Bergmannsheil Gmbh, Bochum, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1247,207,55.001251,-115.002136,"Medizinische Hochschule Hannover (MHH), Hannover, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1248,207,52.4760892,-71.8258668,"Universit√§tsklinikum Jena, Jena, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1249,207,52.4760892,-71.8258668,"University of Ulm, RKU, Ulm, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1250,207,42.9537654,-81.2291529,"Beaumont Hospital, Dublin, Ireland",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1251,207,43.653963,-79.387207,"Academisch Medisch Centrum, Amsterdam, Netherlands",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1252,207,49.2608724,-123.1139529,"UMC St. Radboud, Nijmegen, Netherlands",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1253,207,50.6365654,3.0635282,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1254,207,45.8354243,1.2644847,"Hospital Universitario de Bellvitge, Barcelona, Spain",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1255,207,43.2961743,5.3699525,"Hospital Vall d'Hebron, Barcelona, Spain",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1256,207,43.6112422,3.8767337,"Hospital La Paz, Madrid, Spain",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1257,207,43.7009358,7.2683912,"Hospital Carlos III, Madrid, Spain",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1258,207,48.8566101,2.3514992,"Sahlgrenska Universitetssjukhuset, G√∂teborg, Sweden",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1259,207,52.5170365,13.3888599,"Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1260,207,51.4818111,7.2196635,"Queen Elizabeth Hospital, Birmingham, United Kingdom",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1261,207,52.3744779,9.7385532,"Walton Centre for Neurology & Neurosurgery, Liverpool, United Kingdom",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1262,207,50.9281717,11.5879359,"Kings College Hospital NHS Foundation Trust, London, United Kingdom",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1263,207,48.3974003,9.9934336,"Newcastle University Hospital - Clinical Ageing Research Unit, Newcastle, United Kingdom",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1264,207,53.3497645,-6.2602732,"John Radcliffe Hospital, Oxford, United Kingdom",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1265,207,52.3745403,4.89797550561798,"Sheffield Institute for Transnational Neuroscience, Sheffield, United Kingdom",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1266,207,51.84257485,5.83896062874823,"Department of Neurology, University of Ulm, Ulm, Baden-W√ºrttemberg, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1267,207,52.0809856,5.12768396945229,"Department of Neurology, University of Wuerzburg, Wuerzburg, Bayern, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1268,207,41.3828939,2.1774322,"Department of Neurology, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1269,207,41.3828939,2.1774322,"Department of Neurology, Medical School Hannover, Hannover, Niedersachsen, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1270,207,40.4167047,-3.7035825,"Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1271,207,40.4167047,-3.7035825,"Department of Neurology, TU Dresden, Dresden, Sachsen, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1272,207,57.7072326,11.9670171,"Department of Neurology, University of Jena, Jena, Thueringen, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1273,207,59.3251172,18.0710935,"Department of Neurology, Humboldt University, Berlin, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1274,207,52.4775396,-1.894053,"Neurologische Universit√§tsklinik Bergmannsheil, Bochum, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1275,207,53.407154,-2.991665,"Department f√ºr Neurologie - Klinik f√ºr Schlafmedizin und Neuromuskul√§re Erkrankungen Universit√§tsklinikum M√ºnster, M√ºnster, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1276,207,51.5073219,-0.1276474,"Department of Neurology, DKD HELIOS Klinik, Wiesbaden, Germany",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1277,207,53.0117627,-2.2273919,"APHP, GH Piti√© Salp√™tri√®re, Paris, France",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1278,207,51.7520131,-1.2578499,"Massachusetts General Hospital (MGH) Neurological Clinical Research Institute, Boston, Massachusetts, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1279,207,53.3806626,-1.4702278,"Houston Methodist Hospital, Houston, Texas, United States",208.0,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,"A joint rank of functional outcomes adjusted for mortality.|Time to death or respiratory insufficiency|Time to death|Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death|Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD)|Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5)|Population pharmacokinetics.|Incidence of adverse events, serious adverse events.",Knopp Biosciences,All,Phase 3,943.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011",,"December 15, 2017",,https://ClinicalTrials.gov/show/NCT01281189,18.0,80.0
1280,208,48.6296972,9.1949534,"Hopital Gui De Chauliac, Montpellier, France",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1281,NULL,NULL,NULL,"Carolinas Healthcare System, Dept. of Neurology, Charlotte, North Carolina, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
1282,208,53.7735234,12.5755746,"Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1283,208,52.8398531,9.075962,"Mayo Clinic, Scottsdale, Arizona, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1284,208,51.908526,11.4939134,"University of California, Irvine, Irvine, California, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1285,208,50.9295798,13.4585052,"University of California Department of Neurology, Los Angeles, California, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1286,208,50.7333163,11.0747905,"California Pacific Medical Center, San Francisco, California, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1287,208,52.5170365,13.3888599,"Univ. of Colorado Health Sciences Center, Denver, Colorado, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1288,208,51.4818111,7.2196635,"Mayo Clinic, Jacksonville, Florida, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1289,208,51.9501317,7.61330165026119,"University of Illinois, Chicago, Illinois, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1290,208,50.0820384,8.2416556,"Indiana University School of Medicine, Indianapolis, Indiana, United States",209.0,NCT02306590,"Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Calogen|Dietary Supplement: Placebo,"Survival in ALS-patients with study intervention compared to placebo|Change of total ALS functional rating scale revised (ALSFRS-R)|Change of individual quality of life (SEIQoL)|Change of the slow vital capacity (sVC)|Time to tracheostomy or death (combined)|Change of Body Mass Index (BMI)|Change of Appetite-Score, Council of Nutrition appetite questionnaire (CNAQ)",University of Ulm,All,Not Applicable,207.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LIPCAL-ALS,February 2015,January 2018,September 2018,"December 3, 2014",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT02306590,18.0,100.0
1291,209,48.8566101,2.3514992,"University of Iowa, Iowa City, Iowa, United States",210.0,NCT01583088,Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation,RespiStimALS,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Respiratory Insufficiency,Device: phenique nerve stimulation NeurX‚Ñ¢ (Synapse Biomedical)|Device: sham phrenic nerve stimulation,Survival without NIV 2 years after the phrenic nerve implantation.|global survival from onset disease|effects on sleep|Quality of life and daily activities,Assistance Publique - H√¥pitaux de Paris|ARSla (Association pour la recherche sur la SLA)|Fondation Thierry Latran,All,Phase 3,74.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",AOM11046,September 2012,November 2015,November 2015,"April 23, 2012",,"December 22, 2015",,https://ClinicalTrials.gov/show/NCT01583088,18.0,100.0
1292,210,42.3788774,-72.032366,"University of Kansas Medical Center, Kansas City, Kansas, United States",211.0,NCT04055623,T-Regulatory Cells in ALS,Tregs in ALS,Not yet recruiting,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|Other: Monthly placebo infusions + 3 times per week placebo injections,Treg suppressive function change at baseline and week 24.|Treg cell numbers measured in the blood at baseline and week 24.|Appel ALS Score (AALS) score measured at baseline and week 24.|ALS Functional Rating Scale-Revised (ALSFRS-R) score measured at baseline and week 24.|Forced vital capacity (FVC) measured at baseline and week 24.|Maximum inspiratory pressure measured at baseline and week 24.,The Methodist Hospital System|Massachusetts General Hospital|The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston|North East Amyotrophic Lateral Sclerosis Consortium,All,Phase 2,12.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",Pro00022167,"September 1, 2019","September 1, 2023","November 30, 2023","August 14, 2019",,"August 20, 2019",,https://ClinicalTrials.gov/show/NCT04055623,18.0,100.0
1293,210,31.8160381,-99.5120986,"University of Kentucky, Lexington, Kentucky, United States",211.0,NCT04055623,T-Regulatory Cells in ALS,Tregs in ALS,Not yet recruiting,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|Other: Monthly placebo infusions + 3 times per week placebo injections,Treg suppressive function change at baseline and week 24.|Treg cell numbers measured in the blood at baseline and week 24.|Appel ALS Score (AALS) score measured at baseline and week 24.|ALS Functional Rating Scale-Revised (ALSFRS-R) score measured at baseline and week 24.|Forced vital capacity (FVC) measured at baseline and week 24.|Maximum inspiratory pressure measured at baseline and week 24.,The Methodist Hospital System|Massachusetts General Hospital|The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston|North East Amyotrophic Lateral Sclerosis Consortium,All,Phase 2,12.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",Pro00022167,"September 1, 2019","September 1, 2023","November 30, 2023","August 14, 2019",,"August 20, 2019",,https://ClinicalTrials.gov/show/NCT04055623,18.0,100.0
1294,211,43.6112422,3.8767337,"Hennepin County Med Center, Minneapolis, Minnesota, United States",212.0,NCT03114215,Effect of MD1003 in Amyotrophic Lateral Sclerosis,MD1003-ALS,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: MD1003|Drug: Placebo oral capsule,Recording of adverse events|Laboratory testing (haematology and biochemistry panel)|Motor disability|Severity|Slow vital capacity (SVC)|Maximal inspiratory pressure (MIP)|Sniff nasal inspiratory pressure (SNIP)|Weight,MedDay Pharmaceuticals SA,All,Phase 2,30.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",MD1003CT2015-02-ALS,"June 29, 2016","June 12, 2017",December 2017,"April 14, 2017",,"June 4, 2019",,https://ClinicalTrials.gov/show/NCT03114215,25.0,80.0
1295,212,,,"University of Minnesota, Minneapolis, Minnesota, United States",213.0,NCT02548663,Sport Therapy and Osteopathy Manipulative Treatment in ALS,ME_E_SLA,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Sport therapy|Other: Osteopathic treatment,change in the relationship between maximal oxygen consumption (VO2max) and muscle oxygen extraction capacity at 12 weeks|appearance of side effects during the period of intervention administration|change of pain at 12 weeks|change of quality of life at 12 weeks|change of the neurological functional status at 12 weeks,"University of Milano Bicocca|Italian Academy of Osteopathic Medicine (AIMO), Saronno, Italy",All,Not Applicable,30.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ME_E_SLA,June 2014,December 2014,May 2015,"September 14, 2015",,"September 15, 2015",,https://ClinicalTrials.gov/show/NCT02548663,18.0,100.0
1296,213,35.6729639,-79.0392919,"Washington University, St. Louis, Missouri, United States",214.0,NCT02238626,Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS),IBU-ALS-1201,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo (for MN-166)|Drug: MN-166|Drug: riluzole,Evaluate safety and tolerability of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with ALS|The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Functional Activity|The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Respiratory Function|The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Muscle Strength|The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Non-Invasion Ventilation (NIV),MediciNova|Atrium Health,All,Phase 2,71.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MN-166-ALS-1201,September 2014,August 2017,December 2017,"September 12, 2014",,"November 30, 2018",,https://ClinicalTrials.gov/show/NCT02238626,18.0,80.0
1297,214,37.9923795,-1.1305431,"UMDNJ/Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States",215.0,NCT03683875,Ultrasonography of the Neuromuscular Degeneration Behavior in Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Measuring thickness in peripheral muscles.|Measuring echointensity and in peripheral muscles.|Measuring sonoelastography in peripheral muscles.|Thickness Fraction of the Diaphragm in ALS patients and control group.|Diaphragmatic Excursion (quiet and forced) of the Diaphragm in ALS patients and control group|Measurement muscle fasciculations|Measurement muscle strength|Measurement Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-r)|Measuring Forced Vital Capacity|Maximal Inspiratory Pressure (MIP)|Sniff- nasal inspiratory pressure (SNIP)|Peak Cough Flow (PCF)|Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)|Cumulative time percentage with SpO2 under 90% (CT90),Hospital General Universitario Santa Lucia|Universidad de Murcia,All,,40.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,ECO-ELA,"October 1, 2018",October 2019,December 2019,"September 25, 2018",,"September 25, 2018",,https://ClinicalTrials.gov/show/NCT03683875,18.0,100.0
1298,215,34.395342,-111.7632755,"University of New Mexico, Albuquerque, New Mexico, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1299,215,36.7014631,-118.7559974,"Columbia Unversity, Eleanor and Lou Gehrig MDA/ALS Center, New York, New York, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1300,215,36.7014631,-118.7559974,"Carolinas Medical Center, Charlotte, North Carolina, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1301,215,36.7014631,-118.7559974,"Duke University, Durham, North Carolina, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1302,215,38.7251776,-105.6077167,"Wake Forest University, Winston- Salem, North Carolina, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1303,215,27.7567667,-81.4639835,"Metro Health Clinic, Cleveland, Ohio, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1304,215,40.0796606,-89.4337288,"Oregon Health & Science University, Portland, Oregon, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1305,215,40.3270127,-86.1746933,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1306,215,41.9216734,-93.3122705,"Drexel University College of Medicine, Hahnemann Campus, Philadelphia, Pennsylvania, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1307,215,38.27312,-98.5821872,"University of Texas Southwestern, Dallas, Texas, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1308,215,37.5726028,-85.1551411,"Methodist Hospital, Houston, Texas, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1309,215,45.9896587,-94.6113288,"University of Texas Health Sciences Center, San Antonio, Texas, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1310,215,45.9896587,-94.6113288,"University of Utah, Salt Lake City, Utah, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1311,215,38.7604815,-92.5617875,"University of Vermont, Burlington, Vermont, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1312,215,40.0757384,-74.4041622,"Virginia Mason Medical Center, Seattle, Washington, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1313,215,34.5708167,-105.993007,"Azienda Ospedaliera Santa Maria, Terni, Italy",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1314,215,40.7127281,-74.0060152,"Cleveland Clinic Foundation, Cleveland, Ohio, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1315,215,35.6729639,-79.0392919,"Cleveland Clinic Foundation, Cleveland, Ohio, United States",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1316,215,35.6729639,-79.0392919,"Montreal Neurological Institute and Hospital, Montr√©al, Canada",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1317,215,35.6729639,-79.0392919,"University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1318,215,40.2253569,-82.6881395,"HCL H√¥pital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'√©lectromyographie - 59, boulevard Pinel, Bron Cedex, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1319,215,43.9792797,-120.737257,"CHRU de LILLE - H√¥pital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement, Lille, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1320,215,40.9699889,-77.7278831,"Centre SLA Limoges - Service de Neurologie, Limoges, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1321,215,40.9699889,-77.7278831,"H√¥pital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1322,215,31.8160381,-99.5120986,"Clinique du Motoneurone - Sce d'Explorations Neurologiques - H√¥pital Gui de Chauliac, Montpellier, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1323,215,31.8160381,-99.5120986,"CHU de Nice - H√¥pital de l'Archet 1 - Centre de R√©f√©rence pour les Maladies Neuromusculaires et la SLA, Nice, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1324,215,31.8160381,-99.5120986,"Groupe Hospitalier PITIE-SALPETRIERE - F√©d√©ration des Maladies du Syst√®me Nerveux, Paris, France",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1325,215,39.4225192,-111.7143584,"Charit√© Universit√§tsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz f√ºr ALS und andere Motoeneuronenerkrankungen, Berlin, Germany",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1326,215,44.5990718,-72.5002608,"Universit√§tsklinik und Poliklinik f√ºr Neurologie - Martin-Luther-Universit√§t Halle-Wittenberg, Halle, Germany",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1327,215,38.8950092,-77.0365625,"Neurologische Klinik Medizinische Hochschule, Hannover, Germany",216.0,NCT00047723,Minocycline to Treat Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: minocycline,"Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.|Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival",National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,400.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,R01NS045294,January 2003,,January 2007,"October 17, 2002",,"December 21, 2007",,https://ClinicalTrials.gov/show/NCT00047723,21.0,85.0
1328,216,42.5641417,12.6405466,"Universit√§ts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universit√§tsklinik, Ulm, Germany",217.0,NCT01640067,Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS),hNSCALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Human Neural Stem Cells,safety of a microsurgery human neural stem cells transplantation into spinal cord of ALS patients,"Azienda Ospedaliera Santa Maria, Terni, Italy|Azienda Ospedaliero Universitaria Maggiore della Carita|Universit√† di Padova Italy",All,Phase 1,18.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),EudraCT: 2009-014484-39,December 2011,December 2015,December 2015,"July 13, 2012",,"December 30, 2015",,https://ClinicalTrials.gov/show/NCT01640067,20.0,75.0
1329,217,40.2253569,-82.6881395,"Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10, Madrid, Spain",218.0,NCT00204464,Study of the Effects Strengthening Exercises in Individuals With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Exercise,Function - ALSFRS|MVIC|FVC|Fatigue|SF-36,University of Saskatchewan|Washington University School of Medicine|Columbia University,All,Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,ALS_EX|ALSA-CM Grant,,,December 2004,"September 20, 2005",,"November 4, 2005",,https://ClinicalTrials.gov/show/NCT00204464,18.0,80.0
1330,218,40.2253569,-82.6881395,"King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom",219.0,NCT02916966,Population-Based Ohio Amyotrophic Lateral Sclerosis (ALS) Repository and ALS Risk Factors,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Patient Registry,"Questionnaire for Environmental Exposures, Toxins, and Neurological Disease",Dartmouth-Hitchcock Medical Center|The Cleveland Clinic,All,,1000.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,D06019,October 2016,September 2019,October 2019,"September 28, 2016",,"May 20, 2019",,https://ClinicalTrials.gov/show/NCT02916966,18.0,80.0
1331,219,45.4972159,-73.6103642,"Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom",220.0,NCT03127267,Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Masitinib (6.0)|Drug: Riluzole|Drug: Placebo|Drug: Masitinib (4.5),ALSFRS-R|ALSAQ-40|PFS|FVC|HHD,AB Science,All,Phase 3,495.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AB19001,November 2019,May 2021,May 2024,"April 25, 2017",,"June 17, 2019",,https://ClinicalTrials.gov/show/NCT03127267,18.0,81.0
1332,220,50.879202,4.7011675,"Instituto Nacional de Neurologia Y Neurocirugia Mvs, Mexico City, Distrito Federal, Mexico",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1333,220,46.603354,1.8883335,"University of Sao Paulo School of Medicine Clinics Hospital, Sao Paulo, SP, Brazil",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1334,220,50.6365654,3.0635282,"Stony Brook University Medical Center, Stony Brook, New York, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1335,220,45.8354243,1.2644847,"Assistance Publique Hopitaux de Marseille, Masreille, France",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1336,220,43.2961743,5.3699525,"University of Miami Miller School of Medicine, Miami, Florida, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1337,220,43.6112422,3.8767337,"Emory University, Atlanta, Georgia, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1338,220,43.7009358,7.2683912,"Johns Hopkins, Baltimore, Maryland, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1339,220,48.8566101,2.3514992,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1340,220,52.5170365,13.3888599,"Massachusetts General Hospital, Boston, Massachusetts, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1341,220,51.4825041,11.9705452,"Upstate Medical Center, Syracuse, New York, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1342,220,52.3744779,9.7385532,"Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1343,220,48.3974003,9.9934336,"University of Virginia Medical Center, Charlottesville, Virginia, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1344,220,40.4167047,-3.7035825,"St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1345,220,51.5073219,-0.1276474,"Cedars-Sinai Medical Center, Los Angeles, California, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1346,220,53.3806626,-1.4702278,"University of California, Irvine, Orange, California, United States",221.0,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,Phase 3,512.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 28, 2019",,https://ClinicalTrials.gov/show/NCT00868166,18.0,80.0
1347,221,19.4326009,-99.1333416,"UC Davis Medical Center, Sacramento, California, United States",222.0,NCT03204500,Dual Treatment With Lithium and Valproate in ALS.,,"Active, not recruiting",No Results Available,"Amyotrophic Lateral Sclerosis|Amyotrophic Lateral Sclerosis, Sporadic",Combination Product: Active treatment with dual therapy|Drug: Placebos,Changes in ALSFRS-R|Changes in score in ALSAQ-5|Changes from baseline in FA (fractional anisotropy),El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,All,Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CONACYT234154,May 2016,April 2019,July 2019,"July 2, 2017",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT03204500,40.0,70.0
1348,222,-10.3333333,-53.2,"Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",223.0,NCT02917681,Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,AMYOTROPHIC LATERAL SCLEROSIS,Other: Two intrathecal MSC injections,Safety|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)|Change in Handheld dynamometry|Change in Electrical Impedance Myography|Change in Forced Vital Capacity (FVC)|Change in Isometric Strength|Changes in morphometric parameters of MRI of encephalon and spinal cord,University of Sao Paulo General Hospital|Pontif√≠cia Universidade Cat√≥lica do Paran√°,All,Phase 1|Phase 2,28.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,401922/2014-6,September 2016,February 2019,August 2019,"September 28, 2016",,"September 28, 2016",,https://ClinicalTrials.gov/show/NCT02917681,18.0,70.0
1349,223,40.7127281,-74.0060152,"Stanford Hospital and Clinics, Stanford, California, United States",224.0,NCT03020797,A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS),,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Perampanel|Drug: Placebo Oral Tablet,Incidence of treatment-emergent adverse events|Efficacy as measured by change in ALSFRS-R score (ALS functional rating scale-revised);,Stony Brook University|Eisai Inc.,All,Not Applicable,60.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Eisai-01,December 2016,December 2019,,"January 13, 2017",,"September 5, 2018",,https://ClinicalTrials.gov/show/NCT03020797,18.0,80.0
1350,224,46.603354,1.8883335,"University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States",225.0,NCT02874209,Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: sodium MRI,Central conduction time of the potential muscle through transcranial magnetic stimulation,Assistance Publique Hopitaux De Marseille,All,Not Applicable,60.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015-15|2015-A00328-41,September 2015,September 2017,September 2018,"August 22, 2016",,"August 22, 2016",,https://ClinicalTrials.gov/show/NCT02874209,18.0,100.0
1351,225,27.7567667,-81.4639835,"Hospital for Special Care, New Britain, Connecticut, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1352,225,32.3293809,-83.1137366,"George Washington University Medical Center, Washington, District of Columbia, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1353,225,39.5162234,-76.9382069,"Mayo Clinic, Jacksonville, Florida, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1354,225,42.3788774,-72.032366,"University of Miami, Miller School of Medicine, Miami, Florida, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1355,225,42.3788774,-72.032366,"Carol & Frank Morsani Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1356,225,40.7127281,-74.0060152,"The Emory Clinic, Atlanta, Georgia, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1357,225,35.6729639,-79.0392919,"Indiana University, Indianapolis, Indiana, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1358,225,37.1232245,-78.4927721,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",226.0,NCT00620698,Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials,,Completed,Has Results,Amyotrophic Lateral Sclerosis,,Electrical Impedance Myography|ALS Functional Rating Scale|Handheld Dynamometry,Beth Israel Deaconess Medical Center|ALS Association,All,,89.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EIMALS,May 2007,March 2011,March 2012,"February 21, 2008","September 10, 2014","September 25, 2014",,https://ClinicalTrials.gov/show/NCT00620698,18.0,85.0
1359,226,34.395342,-111.7632755,"University of Kansas Medical Center, Kansas City, Kansas, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1360,226,36.7014631,-118.7559974,"Johns Hopkins University, Baltimore, Maryland, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1361,226,36.7014631,-118.7559974,"University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, Massachusetts, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1362,226,36.7014631,-118.7559974,"University of Michigan Health System, Ann Arbor, Michigan, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1363,226,36.7014631,-118.7559974,"Henry Ford Health System, Detroit, Michigan, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1364,226,36.7014631,-118.7559974,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1365,226,38.7251776,-105.6077167,"St. Louis University, Department of Neurology & Psychiatry, Saint Louis, Missouri, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1366,226,41.6500201,-72.7342163,"Barnes-Jewish Hospital, Saint Louis, Missouri, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1367,226,38.89366125,-76.987883253882,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1368,226,27.7567667,-81.4639835,"Hospital for Special Surgery, New York, New York, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1369,226,27.7567667,-81.4639835,"Neurological Institute, New York, New York, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1370,226,27.7567667,-81.4639835,"SUNY Upstate Medical University, Syracuse, New York, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1371,226,32.3293809,-83.1137366,"Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1372,226,40.3270127,-86.1746933,"Duke Neurological Disorders Clinic, Durham, North Carolina, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1373,226,41.9216734,-93.3122705,"Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1374,226,38.27312,-98.5821872,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1375,226,39.5162234,-76.9382069,"Providence Brain and Spine Inst. ALS Center, Portland, Oregon, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1376,226,42.3788774,-72.032366,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1377,226,43.6211955,-84.6824346,"Temple University School of Medicine, Philadelphia, Pennsylvania, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1378,226,43.6211955,-84.6824346,"Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1379,226,45.9896587,-94.6113288,"Texas Neurology, PA, Dallas, Texas, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1380,226,38.7604815,-92.5617875,"UTHSCSA - First Outpatient Research Unit, San Antonio, Texas, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1381,226,38.7604815,-92.5617875,"University of Virginia Health System, Charlottesville, Virginia, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1382,226,43.4849133,-71.6553992,"University of Washington Medical Center, Seattle, Washington, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1383,226,40.7127281,-74.0060152,"West Virginia University Hospitals, Morgantown, West Virginia, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1384,226,40.7127281,-74.0060152,"Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1385,226,40.7127281,-74.0060152,"UZ Leuven, Leuven, Vlaams Brabant, Belgium",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1386,226,35.6729639,-79.0392919,"University of Calgary, Calgary, Alberta, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1387,226,35.6729639,-79.0392919,"University of Alberta, Edmonton, Alberta, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1388,226,35.6729639,-79.0392919,"Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1389,226,40.2253569,-82.6881395,"QE II Health Sciences, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1390,226,43.9792797,-120.737257,"McMaster University Medical Centre, Hamilton, Ontario, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1391,226,40.9699889,-77.7278831,"London Health Sciences Centre, London, Ontario, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1392,226,40.9699889,-77.7278831,"Sunnybrook Health Sciences Center, Toronto, Ontario, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1393,226,35.7730076,-86.2820081,"Hopital Notre-Dame/CHUM, Montreal, Quebec, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1394,226,31.8160381,-99.5120986,"Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1395,226,31.8160381,-99.5120986,"CHU de Quebec - Univerite' Laval, Quebec, Canada",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1396,226,37.1232245,-78.4927721,"Hopital Dupuytren, service de neurologie, Limoges Cedex, France",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1397,226,38.8950092,-77.0365625,"Hopital Gui de chauliac, Montpellier Cedex 5, France",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1398,226,38.4758406,-80.8408415,"CHU de Nice - Hopital Pasteur 2, Nice Cedex 1, France",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1399,226,44.4308975,-89.6884637,"Hopital Bretonneau, Tours cedex 9, France",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1400,226,50.8686516,4.7886108308049,"University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1401,226,55.001251,-115.002136,"Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1402,226,55.001251,-115.002136,"Charite Campus Virchow-Klinikum, Department of Neurology, Berlin, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1403,226,46.500283,-66.750183,"Clinical Research Centre Beaumont Hospital, Dublin, Ireland",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1404,226,45.1960403,-63.1653789,"IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Lombardy, Italy",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1405,226,50.000678,-86.000977,"Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Ospedale Niguarda, Milan, Lombardy, Italy",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1406,226,50.000678,-86.000977,"Dipartimento di Neuroscienze ""Rita Levi Moltalcini"" A.O.U. Citta della Salute e della Scienza di Torino P.O. ""Molinette"", Torino, Piemonte, Italy",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1407,226,50.000678,-86.000977,"University Medical Center Utrecht, Utrecht, Netherlands",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1408,226,52.4760892,-71.8258668,"Hospital Santa Maria - Centro Hospitalar Lisboa Norte, Lisboa, Portugal",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1409,226,52.4760892,-71.8258668,"Hospital San Rafael, Madrid, Spain",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1410,226,52.4760892,-71.8258668,"King's College Hospital NHS Foundation Trust, London, United Kingdom",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1411,226,46.603354,1.8883335,"Charite Universitatsmedizin Berlin, Berlin, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1412,226,46.603354,1.8883335,"Medical School Hannover, Hannover, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1413,226,46.603354,1.8883335,"University Clinical Jena, Jena, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1414,226,46.603354,1.8883335,"University Hospital of Ulm, Ulm, Germany",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1415,226,48.6296972,9.1949534,"Beaumont Hospital, Dublin, Ireland",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1416,226,52.8398531,9.075962,"University Medical Centre Utrecht, Utrecht, Netherlands",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1417,226,52.5170365,13.3888599,"Royal Sussex County Hospital, Brighton, United Kingdom",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1418,226,53.3497645,-6.2602732,"The Walton Centre, Liverpool, United Kingdom",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1419,226,45.6209,9.768893,"London Kings College Hospital, London, United Kingdom",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1420,226,45.6209,9.768893,"Royal London Hospital, London, United Kingdom",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1421,226,45.060735,7.923549,"University of Sheffield, Sheffield, United Kingdom",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1422,226,52.0809856,5.12768396945229,"UMC Utrecht, Utrecht, Netherlands",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1423,226,38.7077507,-9.1365919,"University of California Los Angeles - Tier 2 Site, Pacific Palisades, California, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1424,226,40.4167047,-3.7035825,"University of California - San Francisco - Tier 2 Site, San Francisco, California, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1425,226,51.5073219,-0.1276474,"University of Colorado Health Sciences Center - Tier 2 Site, Denver, Colorado, United States",227.0,NCT02936635,A Study for Patients Who Completed VITALITY-ALS (CY 4031),VIGOR-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: tirasemtiv,Incidence of adverse events (AEs) in patient population|Time to first use of assisted ventilation or death|Time to the first occurrence of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation (NIV) for ‚â•22 hours per day for ‚â•10 consecutive days) or death|Time to death|Decline in percent predicted Slow Vital Capacity (SVC) from baseline|Decline in ALS Functional Rating Scale - Revised (ALSFRS-R) score from baseline|Slope of the change from baseline in percent predicted SVC|Slope of the change from baseline in ALSFRS-R,Cytokinetics,All,Phase 3,280.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CY 4033|2016-002629-13,"October 17, 2016","October 26, 2018","October 26, 2018","October 18, 2016",,"February 18, 2019",,https://ClinicalTrials.gov/show/NCT02936635,18.0,100.0
1426,227,52.5170365,13.3888599,"University of Miami - Tier 2 Site, Miami, Florida, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1427,227,52.3744779,9.7385532,"Emory University - Tier 2 site, Atlanta, Georgia, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1428,227,50.9281717,11.5879359,"Northwestern University, Dept. of Neurology - Tier 2 Site, Chicago, Illinois, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1429,227,48.3974003,9.9934336,"University of Kansas Medical Center - Tier 2 site, Kansas City, Kansas, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1430,227,53.3497645,-6.2602732,"John Hopkins University - Tier 2 Site, Baltimore, Maryland, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1431,227,52.0809856,5.12768396945229,"Massachusetts General Hospital - Tier 1 Site, Boston, Massachusetts, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1432,227,50.8220399,-0.1374061,"Baystate Medical Center - Tier 2 Site, Springfield, Massachusetts, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1433,227,53.407154,-2.991665,"Saint Louis University, Neuromuscular Div. - Tier 2 Site, Saint Louis, Missouri, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1434,227,51.5073219,-0.1276474,"Washington University - Tier 2 Site, St. Louis, Missouri, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1435,227,51.5073219,-0.1276474,"BryanLGH Medical Center - Tier 2 Site, Lincoln, Nebraska, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1436,227,53.3806626,-1.4702278,"Upstate Clinical Research, LLC - Tier 2 Site, Albany, New York, United States",228.0,NCT02487407,Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis,ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ODM-109|Drug: Placebo for ODM-109,"Slow vital capacity SVC|Hand grip strength and submaximal hand grip strength endurance|Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)|Quality of life|Revised ALS Functional Rating Scale ALSFRS-R|Oxygen saturation|The concentrations of ODM-109, OR-1855 and OR-1896|Determination of subject's acetylation status|Sniff nasal pressure SNP|Fatigue assessment","Orion Corporation, Orion Pharma",All,Phase 2,66.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119001,July 2015,May 2017,June 2017,"July 1, 2015",,"November 28, 2017",,https://ClinicalTrials.gov/show/NCT02487407,18.0,100.0
1437,228,52.0809856,5.12768396945229,"Mount Sinai School of Medicine - Tier 2 Site, New York, New York, United States",229.0,NCT00136110,Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Sodium Valproate,Survival|The rate of decline of daily functioning,UMC Utrecht|Princess Beatrix Muscle Foundation,All,Phase 3,165.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,04/182-0,April 2005,,February 2007,"August 26, 2005",,"May 1, 2007",,https://ClinicalTrials.gov/show/NCT00136110,18.0,85.0
1438,229,36.7014631,-118.7559974,"Columbia University Medical Center - Tier 2 site, New York, New York, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1439,229,36.7014631,-118.7559974,"SUNY Downstate Medical Center - Tier 1 Site, Syracuse, New York, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1440,229,38.7251776,-105.6077167,"Duke University Medical Center - Tier 1 Site, Durham, North Carolina, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1441,229,27.7567667,-81.4639835,"Wake Forest University School of Medicine -Tier 2 Site, Winston Salem, North Carolina, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1442,229,32.3293809,-83.1137366,"Cleveland Clinic Foundation -Tier 2 site, Cleveland, Ohio, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1443,229,40.0796606,-89.4337288,"Providence ALS Center - Tier 2 Site, Portland, Oregon, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1444,229,38.27312,-98.5821872,"Pennsylvania State University School of Medicine - Tier 2 Site, Hershey, Pennsylvania, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1445,229,39.5162234,-76.9382069,"Drexel University College of Medicine - Tier 1 Site, Philadelphia, Pennsylvania, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1446,229,42.3788774,-72.032366,"University of Pittsburgh Medical Center - Tier 2 Site, Pittsburgh, Pennsylvania, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1447,229,42.3788774,-72.032366,"Vanderbilt University Medical Center - Tier 2, Nashville, Tennessee, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1448,229,38.7604815,-92.5617875,"Texas Neurology, PA - Tier 2 Site, Dallas, Texas, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1449,229,38.7604815,-92.5617875,"University of Texas Health Science Center - Tier 2 Site, San Antonio, Texas, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1450,229,41.7370229,-99.5873816,"University of Vermont, College of Medicine - Tier 2, Burlington, Vermont, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1451,229,40.7127281,-74.0060152,"University of Virginia - Tier 2 Sites, Charlottesville, Virginia, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1452,229,40.7127281,-74.0060152,"Virginia Mason Clinic - Tier 2 Site, Seattle, Washington, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1453,229,40.7127281,-74.0060152,"Medical College of Wisconsin - Tier 2 Site, Milwaukee, Wisconsin, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1454,229,40.7127281,-74.0060152,"University of British Columbia, Gordon and Leslie Diamond Health Care Centre - Tier 2 Site, Vancouver, British Columbia, Canada",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1455,229,35.6729639,-79.0392919,"London Health Science Center - Tier 2 Site, London, Ontario, Canada",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1456,229,35.6729639,-79.0392919,"University of Toronto, Sunnybrook Health Sciences Centre - Tier 2 Site, Toronto, Ontario, Canada",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1457,229,40.2253569,-82.6881395,"Montreal Neurological Institute - Tier 2, Montreal, Quebec, Canada",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1458,229,43.9792797,-120.737257,"London Health Sciences Centre, London, Ontario, Canada",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1459,229,40.9699889,-77.7278831,"Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders, Seoul, Haengdang-dong, Seongdong-gu, Korea, Republic of",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1460,229,40.9699889,-77.7278831,"University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1461,229,40.9699889,-77.7278831,"University of Kansas Medical Center/Neurology, 1008 Wescoe, Kansas City, Kansas, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1462,229,35.7730076,-86.2820081,"Carolinas MDA Neuromuscular/ALS Center; Carolinas Medical System; 1540 Garden Terrace, Charlotte, North Carolina, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1463,229,31.8160381,-99.5120986,"University of Michigan, Functional MRI Laboratory, Ann Arbor, Michigan, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1464,229,31.8160381,-99.5120986,"Universidad Cat√≥lica de Valencia San Vicente M√†rtir, Valencia, Spain",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1465,229,44.5990718,-72.5002608,"Norwegian National Advisory Unit on Long-term Mechanical Ventilation at Thoracic Department, Haukeland University Hospital, Bergen, Hordaland, Norway",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1466,229,37.1232245,-78.4927721,"Centro Hospitalar Tras-os-Montes e Alto Douro, Vila Real, Portugal",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1467,229,38.8950092,-77.0365625,"H√¥pital de l'Archet I, Nice, France",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1468,229,44.4308975,-89.6884637,"University of Michigan, Ann Arbor, Michigan, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1469,229,55.001251,-125.002441,"Piti√©-Salp√™tri√®re Hospital, Paris, France",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1470,NULL,NULL,NULL,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
1471,229,50.000678,-86.000977,"Hopital Pitie-Salpetriere, Paris, France",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1472,229,52.4760892,-71.8258668,"Phoenix Neurological Associates, LTD, Phoenix, Arizona, United States",230.0,NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS",,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Placebo|Drug: Arimoclomol,ALSFRS-R|Survival|Muscle strength|Pulmonary function|MUNE|Quality of Life,CytRx,All,Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AALS-003,,,,"November 20, 2007",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00561366,18.0,100.0
1473,230,50.000678,-86.000977,"Paris Als Center, Salpetriere Hospital, Paris, France",231.0,NCT00372879,Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: Vitamin E,Reduction in number of muscle cramps experienced in a two week period.|Reduction in the duration of cramps and reduction in the severity of cramps,Lawson Health Research Institute,All,Phase 3,32.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R-06-451|ALSClin-001,December 2006,August 2010,August 2010,"September 7, 2006",,"March 3, 2016",,https://ClinicalTrials.gov/show/NCT00372879,18.0,100.0
1474,NULL,NULL,NULL,"University Hospital Toulouse, Toulouse, France",,,,,,,,,,,,,,,,,,,,,,,,,,,
1475,232,52.5259976,-2.19736029715209,"Chiba University Hospital, Chiba, Japan",233.0,NCT03705390,A Safety and Tolerability Study of ILB in Patients With Amyothrophic Lateral Sclerosis (ALS),ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: ILB,Safety assessed by SAEs and AEs - CTCAE grading|Safety assessed by SAEs and AEs - Relatedness|Safety assessed by SAEs and AEs - admitted event|Safety assessed by SAEs and AEs - expectedness|Safety assessed by SAEs and AEs - sequelae|Tolerability assessed by SAEs|Quantity of study drug administered - total drug administered|Quantity of study drug administered - number of administrations|Quantity of study drug administered - number and length of interruptions|Quantity of study drug administered - number of discontinuations|Revised Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)|Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)|Urinary p75ECD|NfL in plasma,University of Birmingham|TikoMed AB|University Hospital Birmingham|Neuregenix,All,Phase 2,15.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RG_17-250,"March 29, 2019",March 2020,March 2020,"October 15, 2018",,"April 2, 2019",,https://ClinicalTrials.gov/show/NCT03705390,18.0,100.0
1476,NULL,NULL,NULL,"Hadassah Medical Center -Motor Neuron Disease Clinic, Jerusalem, Israel",,,,,,,,,,,,,,,,,,,,,,,,,,,
1477,233,35.6729639,-79.0392919,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",234.0,NCT00125203,Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Sialorrhea,Drug: Botulinum toxin type B (Myobloc)|Procedure: Injection of salivary glands,Global impression of change by subject at eight weeks post injection|Patient's subjective assessment of benefit|Change in volume of saliva produced over five minutes (measured with funnel and tube)|ALS Functional Rating Scale (ALSFRS)|Caregiver's subjective assessment of benefit|Change in anticholinergic medication doses and number of times per day suction is used|SEQOL-DW|Duration of benefit|Assessment of treatment assignment (final visit only)|Global assessment of change by investigator,The University of Texas Health Science Center at San Antonio|ALS Association|University of Kansas|Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System,All,Phase 2|Phase 3,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BB-IND 11090,July 2003,,August 2007,"July 29, 2005",,"March 14, 2012",,https://ClinicalTrials.gov/show/NCT00125203,21.0,85.0
1478,234,43.6211955,-84.6824346,"Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom",235.0,NCT00809224,Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis,,cortical activation patterns,University of Michigan|National Institute of Neurological Disorders and Stroke (NINDS),All,,92.0,Other|NIH,Observational,Observational Model: Case Control,R01NS052514|Hum00000219,May 2008,May 2012,May 2012,"December 17, 2008",,"May 16, 2016",,https://ClinicalTrials.gov/show/NCT00809224,18.0,70.0
1479,235,39.4699014,-0.3759513,"San Raffaele Scientific Institute, Milan, Italy",236.0,NCT03489200,EH301 for the Treatment of ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: EH301|Other: Placebo,ALSFRS-r|MRC|FVC|Electromyogram|Anthropometry,Elysium Health|Fundaci√≥n Universidad Cat√≥lica de Valencia San Vicente M√°rtir|University of Valencia,All,Not Applicable,32.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",H1479983999044,January 2017,June 2017,June 2017,"April 5, 2018",,"May 18, 2018",,https://ClinicalTrials.gov/show/NCT03489200,18.0,100.0
1480,236,60.2570766,6.06249778348651,"Fondazione Salvatore Maugeri IRCCS, Istituto Scientifico, Milan, Italy",237.0,NCT03887338,Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Transnasal Fiberoptic Laryngoscopy,Apnoea-hypopnea index (AHI)|Time of NIV use|NIV Leaks|NIV time of use|NIV compliance|Night-time pulseoximeter|Night-time capnography,Tiina Maarit Andersen|University of Tr√°s-os-Montes and Alto Douro|Universidade do Porto|Haukeland University Hospital,All,Not Applicable,60.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2018/1306|39/2016,"March 21, 2019","December 31, 2021","December 31, 2022","March 22, 2019",,"March 22, 2019",,https://ClinicalTrials.gov/show/NCT03887338,18.0,100.0
1481,236,41.2966556,-7.74678,"NEuroMuscular Omnicentre (NEMO), Fondazione Serena - H C√† granda, Milan, Italy",237.0,NCT03887338,Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Transnasal Fiberoptic Laryngoscopy,Apnoea-hypopnea index (AHI)|Time of NIV use|NIV Leaks|NIV time of use|NIV compliance|Night-time pulseoximeter|Night-time capnography,Tiina Maarit Andersen|University of Tr√°s-os-Montes and Alto Douro|Universidade do Porto|Haukeland University Hospital,All,Not Applicable,60.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2018/1306|39/2016,"March 21, 2019","December 31, 2021","December 31, 2022","March 22, 2019",,"March 22, 2019",,https://ClinicalTrials.gov/show/NCT03887338,18.0,100.0
1482,237,43.7009358,7.2683912,"Universita' Degli Studi Di Padova, Azienda Ospedaliera Di Padova, Neurologic Department;, Padova, Italy",238.0,NCT01897818,Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: communication system P300 Speller,"the full achievement of ""copy spelling"" and ""free spelling"" tests session 1|the full achievement of ""copy spelling"" and ""free spelling"" tests session 2",Centre Hospitalier Universitaire de Nice,All,Not Applicable,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,12-PP-16,July 2013,July 2015,,"July 12, 2013",,"July 12, 2013",,https://ClinicalTrials.gov/show/NCT01897818,18.0,100.0
1483,238,43.6211955,-84.6824346,"Cedars-Sinai Medical Center, Los Angeles, California, United States",239.0,NCT00580593,Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: BiPAP¬Æ S/T System|Other: sham-NIPPV,"NIPPV adherence, as summarized by weekly means and standard deviations of hours of use for the two groups (active-NIPPV and sham-NIPPV). Additionally the patients' belief as to which treatment they believed they had tried will be assessed.|The SF-36 will be measured as a measure of quality of life.|Pulmonary function tests including FVC will be measured.|The ALS FRS will be used as a measure of functional outcome.|The BDI/TDI (baseline and transition dyspnea indexes).|Tolerance to standard NIPPV treatment during the observational phase of the study (after FVC has fallen below 50%) will also be summarized by weekly means and standard deviations of hours of use.",University of Michigan|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1,60.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01NS55200,April 2007,March 2012,March 2012,"December 24, 2007",,"July 10, 2013",,https://ClinicalTrials.gov/show/NCT00580593,18.0,79.0
1484,239,48.8566101,2.3514992,"Sheffield Institute for Translational Neurosciences, Sheffield, United Kingdom",240.0,NCT03573466,Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS,PRE-ALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Muscle biopsy,Quantification of neuromuscular junctions innervation,Assistance Publique - H√¥pitaux de Paris,All,Not Applicable,10.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,P171004J|2018-A00573-52,"April 10, 2019","April 10, 2021","June 1, 2021","June 29, 2018",,"April 29, 2019",,https://ClinicalTrials.gov/show/NCT03573466,30.0,70.0
1485,240,,,"Macquarie University, Sydney, New South Wales, Australia",241.0,NCT00004457,Determinants of Disease Severity in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,,,National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital|Office of Rare Diseases (ORD),All,,75.0,NIH|Other,Observational,Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Prospective,199/13650|MGH-97-7231|MGH-1K08NS01896,March 1998,,,"October 19, 1999",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00004457,18.0,100.0
1486,241,40.9699889,-77.7278831,"Cedars-Sinai Medical Center, Los Angeles, California, United States",242.0,NCT00714805,Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS),GIDysmotility,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,GI Transit Time,Christine Barr|MDA/ALS Center of Hope|Drexel University,All,,41.0,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,Internal-16637,January 2007,November 2016,November 2016,"July 14, 2008",,"January 6, 2017",,https://ClinicalTrials.gov/show/NCT00714805,18.0,89.0
1487,242,48.8566101,2.3514992,"CHU de la C√¥te de Nacre, Caen, France",243.0,NCT03694132,Brain Excitability and Connectivity in Sensory-motor Pathways in ALS,SOM_ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Device: functional MRI|Device: structural MRI|Device: EEG/MEG,Brain activity|Brain connectivity,"Institut National de la Sant√© Et de la Recherche M√©dicale, France",All,Not Applicable,52.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C17-70,"November 26, 2018","December 31, 2019","April 6, 2022","October 3, 2018",,"December 21, 2018",,https://ClinicalTrials.gov/show/NCT03694132,30.0,80.0
1488,243,34.395342,-111.7632755,"Centre Hospitalier Universitaire de Lille, Lille, France",244.0,NCT01020331,Memantine Therapy in Amyotrophic Lateral Sclerosis,TAME,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Memantine,"Standardized assessment of ALS disease progression through the ALS Functional Rating Scale (ALSFRS) and compare the levels of Tau at baseline, 6 and 12 months|Change in muscle strength as measured by quantitative dynamometry (baseline vs 18 months)","Phoenix Neurological Associates, LTD|Forest Laboratories",All,Phase 2,20.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Memantine in ALS,June 2005,July 2009,October 2009,"November 25, 2009",,"November 25, 2009",,https://ClinicalTrials.gov/show/NCT01020331,18.0,85.0
1489,244,48.8566101,2.3514992,"H√¥pital La Timone, Marseille, France",245.0,NCT03150290,Brown Adipose Tissue in ALS,BATALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: Indirect Calorimetry.|Device: 18-FDG-PET,Quantification of depots of functional brown adipose tissue in ALS patients (grams),"Institut National de la Sant√© Et de la Recherche M√©dicale, France",All,Not Applicable,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-83|2016-A01790-51,June 2017,June 2018,June 2018,"May 12, 2017",,"May 12, 2017",,https://ClinicalTrials.gov/show/NCT03150290,18.0,85.0
1490,245,,,"H√¥pital Sainte-Marguerite, Marseille, France",246.0,NCT04057898,Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: MN-166|Drug: placebo,"Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.|Mean change from baseline of muscle strength measured by hand-held dynamometry (HHD)|Mean change from baseline on quality of life assessed by ALSAQ-5 at Month 12|Mean change from baseline of functional activity measured by ALSFRS-R at Month 12|Responders, measured in percent of subjects overall, whose ALSFRS-R total score was stable or improved|Time to survival|Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Changes from Baseline in Laboratory Values",MediciNova,All,Phase 2|Phase 3,230.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MN-166-ALS-2301,October 2019,December 2021,June 2022,"August 15, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04057898,18.0,80.0
1491,246,43.6044622,1.4442469,"H√¥pital Guillaume et Ren√© La√´nnec, Nantes, France",247.0,NCT03452618,Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment,PREDAPP,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Diagnostic Test: diagnosis variables,"Early Surgical Clinical Score|Sensitivity, specificity, negative and positive predictive values|Percentage of decrease|Slope of FVC decline|Quality of life score","University Hospital, Toulouse",All,Not Applicable,100.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RC31/17/0201|2017-A02202-51,"November 30, 2017",November 2019,November 2021,"March 2, 2018",,"March 2, 2018",,https://ClinicalTrials.gov/show/NCT03452618,18.0,100.0
1492,247,35.549399,140.2647303,"H√¥pital de l'Archet, Nice, France",248.0,NCT03186040,Open-label Clinical Trial of Lacosamide in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Lacosamide,Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Frequency of fasciculation|Frequency and extent of muscle cramp|Effects on strength-duration time constant|Effects on 0.2ms threshold change|Effects on threshold electrotonus|Effects on recovery cycle,Chiba University,All,Phase 1|Phase 2,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G29007,"July 13, 2017","April 30, 2020","May 31, 2020","June 14, 2017",,"July 23, 2019",,https://ClinicalTrials.gov/show/NCT03186040,20.0,100.0
1493,248,,,"H√¥pital Piti√©-Salp√™tri√®re - Centre du Langage-Neuropsychologie, Paris, France",249.0,NCT04066244,Study of Safety and of the Mechanism of BLZ945 in ALS Patients,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: BLZ945,Change from Baseline Volume of distribution (Vt) in different brain regions for each [11C]-PBR28 PET scan|Plasma Pharmacokinetics (PK) of BLZ945 - Cmax|Plasma Pharmacokinetics (PK) of BLZ945 - Tmax|Plasma Pharmacokinetics (PK) of BLZ945 - AUC|Plasma Pharmacokinetics (PK) of BLZ945 - T1/2|Renal Clearance (CLR) of BLZ945|CYP2C8 genotyping and BLZ945 plasma PK parameters,Novartis Pharmaceuticals|Novartis,All,Phase 2,20.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBLZ945C12201,"October 23, 2019","February 11, 2021","February 11, 2021","August 23, 2019",,"August 23, 2019",,https://ClinicalTrials.gov/show/NCT04066244,18.0,75.0
1494,249,31.778345,35.2250786,"H√¥pital Piti√©-Salp√™tri√®re - F√©d√©ration de Neurologie, Paris, France",250.0,NCT03652805,A Study of IPL344 in the Treatment of ALS Patients,ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: IPL344,Adverse Events (AEs) and serious adverse events (SAEs) Reporting|Maximum Tolerated Dose (MTD)|Pharmacokinetic (PK) profile - Maximum Plasma Concentration (Cmax)|Pharmacokinetic (PK) profile - Area Under the Curve (AUC)|Pharmacokinetic (PK) profile - time to reach maximum plasma concentration (Tmax)|Pharmacokinetic (PK) profile - apparent terminal exponential half-life (T1/2),Immunity Pharma Ltd.,All,Phase 1|Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,101/ 2,"August 1, 2018","July 15, 2019","August 15, 2019","August 29, 2018",,"February 15, 2019",,https://ClinicalTrials.gov/show/NCT03652805,18.0,80.0
1495,250,39.5162234,-76.9382069,"H√¥pital Piti√©-Salp√™tri√®re, Paris, France",251.0,NCT01925196,Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Lobar Degeneration,,ALS Functional Rating Scale-revised|Frontobehavioral Index|Verbal Fluency Score,National Institute of Neurological Disorders and Stroke (NINDS)|National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,,50.0,NIH,Observational,Time Perspective: Prospective,130188|13-N-0188,"August 15, 2013","November 30, 2020","November 30, 2021","August 19, 2013",,"January 7, 2019",,https://ClinicalTrials.gov/show/NCT01925196,18.0,100.0
1496,251,53.48153335,-1.38104220661496,"H√¥pital Pontchaillou, Rennes, France",252.0,NCT03154450,EncoreAnywhere Use in Motor Neurone Disease,,Completed,No Results Available,Motor Neuron Disease,Device: EncoreAnywhere with data available to review|Device: EncoreAnywhere with no data available to review,Adherence to non-invasive ventilation (NIV)|Effectiveness of non-invasive ventilation (NIV),Sheffield Teaching Hospitals NHS Foundation Trust,All,Not Applicable,19.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,STH19228,"January 21, 2016","April 1, 2017","April 1, 2017","May 16, 2017",,"December 4, 2017",,https://ClinicalTrials.gov/show/NCT03154450,18.0,100.0
1497,252,45.4667971,9.1904984,"H√¥pital Charles Nicolle, Rouen, France",253.0,NCT01776970,Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease,CANALS,Completed,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis (ALS),Drug: Cannabis Sativa extract Oromucosal spray,"modified 5 - points modified Ashworth scale (AS).|Mean weekly spasticity, spasm frequency and sleep disruption Numeric Rating Scale (NRS) score",Ospedale San Raffaele|Fondazione Salvatore Maugeri|Niguarda Hospital|University of Padova,All,Phase 2|Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CANALS,January 2013,December 2015,December 2015,"January 28, 2013",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT01776970,18.0,80.0
1498,252,45.4667971,9.1904984,"Centre Hospitalier, Saint-Brieuc, France",253.0,NCT01776970,Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease,CANALS,Completed,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis (ALS),Drug: Cannabis Sativa extract Oromucosal spray,"modified 5 - points modified Ashworth scale (AS).|Mean weekly spasticity, spasm frequency and sleep disruption Numeric Rating Scale (NRS) score",Ospedale San Raffaele|Fondazione Salvatore Maugeri|Niguarda Hospital|University of Padova,All,Phase 2|Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CANALS,January 2013,December 2015,December 2015,"January 28, 2013",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT01776970,18.0,80.0
1499,252,45.4667971,9.1904984,"H√¥pital Bellevue, Saint-Etienne, France",253.0,NCT01776970,Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease,CANALS,Completed,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis (ALS),Drug: Cannabis Sativa extract Oromucosal spray,"modified 5 - points modified Ashworth scale (AS).|Mean weekly spasticity, spasm frequency and sleep disruption Numeric Rating Scale (NRS) score",Ospedale San Raffaele|Fondazione Salvatore Maugeri|Niguarda Hospital|University of Padova,All,Phase 2|Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CANALS,January 2013,December 2015,December 2015,"January 28, 2013",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT01776970,18.0,80.0
1500,252,45.4077172,11.8734455,"H√¥pital Civil, Strasbourg, France",253.0,NCT01776970,Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease,CANALS,Completed,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis (ALS),Drug: Cannabis Sativa extract Oromucosal spray,"modified 5 - points modified Ashworth scale (AS).|Mean weekly spasticity, spasm frequency and sleep disruption Numeric Rating Scale (NRS) score",Ospedale San Raffaele|Fondazione Salvatore Maugeri|Niguarda Hospital|University of Padova,All,Phase 2|Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CANALS,January 2013,December 2015,December 2015,"January 28, 2013",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT01776970,18.0,80.0
1501,253,36.7014631,-118.7559974,"H√¥pital Purpan, Toulouse, France",254.0,NCT02682030,The Use of Airway Clearance Devices in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: High Frequency Chest Compression Device (HFCC)|Device: Cough Assist,Change in Chest X-Ray between baseline and end of study|Change in Lung Ventilation Scan between baseline and end of study|Change in McGill Single item quality of life question between baseline and end of study|Change in Forced Vital Capacity (FVC) between baseline and end of study|Change in Maximal Inspiratory Pressure (MIP) between baseline and end of study|Change in Diffusion Capacity between baseline and end of study,Cedars-Sinai Medical Center,All,Not Applicable,5.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00039699,March 2016,December 2018,December 2018,"February 15, 2016",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02682030,18.0,100.0
1502,254,53.3806626,-1.4702278,"H√¥pital Roger Salengro, CHRU de Lille, Lille, France",255.0,NCT02464748,Telehealth in Motor Neurone Disease,TiM,Completed,No Results Available,Motor Neuron Disease,Other: TiM telehealth arm,Feasibility and acceptability of using the telehealth system from interviews,Sheffield Teaching Hospitals NHS Foundation Trust|University of Sheffield,All,Not Applicable,77.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17165|26675465|17022,September 2014,April 2016,April 2016,"June 8, 2015",,"April 28, 2017",,https://ClinicalTrials.gov/show/NCT02464748,18.0,100.0
1503,255,-31.8759835,147.2869493,"Michele Vitacca, Lumezzane, Brescia, Italy",256.0,NCT03136809,ALS Treatment Extension Study,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Cu(II)ATSM,Tolerance of extended treatment|Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)|Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score|Treatment-related change in respiratory function by seated forced vital capacity (FVC)|Treatment-related change in quality of life by ALSSQOL-R score|Treatment-related change in respiratory function by sniff nasal pressure (SNP) test,Collaborative Medicinal Development Pty Limited,All,Phase 1|Phase 2,50.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMD-2017-001,"May 8, 2017","May 31, 2019","May 31, 2019","May 2, 2017",,"July 21, 2017",,https://ClinicalTrials.gov/show/NCT03136809,18.0,75.0
1504,256,36.7014631,-118.7559974,"Paolo Banfi, Milan, Italy",257.0,NCT02943850,CNS10-NPC-GDNF for the Treatment of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Biological: Stem cell (HPC) implantation|Device: Stereotactic surgical device,"Safety evaluated by Adverse Events and Serious Adverse Events, post-operative MRI, and clinical laboratory assessments|Compound Motor Action Potential (CMAP)|Force Generation via ATLIS testing|Quantitative Muscle MRI|Electrical Impedance Myography (EIM)|Assessment of glial cell line derived neurotrophic factor (GDNF) in the cerebral spianl fluid (CSF)",Cedars-Sinai Medical Center|California Institute for Regenerative Medicine (CIRM),All,Phase 1,18.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00042350,"April 1, 2017",October 2019,October 2019,"October 25, 2016",,"October 11, 2018",,https://ClinicalTrials.gov/show/NCT02943850,18.0,100.0
1505,257,49.1828008,-0.3690815,"Cedar's Sinai, Los Angeles, California, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1506,257,50.6365654,3.0635282,"California Pacific Medical Center, San Francisco, California, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1507,257,43.2961743,5.3699525,"Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1508,257,43.2961743,5.3699525,"University of California San Diego Medical Center, San Diego, California, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1509,257,47.2186371,-1.5541362,"California Pacific Medical Center, San Francisco, California, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1510,257,43.7009358,7.2683912,"University of South Florida, Tampa, Florida, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1511,257,48.8566101,2.3514992,"The Emory Clinic, Atlanta, Georgia, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1512,257,48.8566101,2.3514992,"Johns Hopkins Hospital, Baltimore, Maryland, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1513,257,48.8566101,2.3514992,"Massachusetts General Hospital, MA, Charlestown, Massachusetts, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1514,257,48.1113387,-1.6800198,"Washington University School of Medicine, Saint Louis, Missouri, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1515,257,49.4404591,1.0939658,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1516,257,48.5141594,-2.7602707,"UZ Leuven, Leuven, Belgium",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1517,257,45.4401467,4.3873058,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1518,257,48.584614,7.7507127,"Montreal Neurological Institute Clinical Research Unit, Montr√©al, Quebec, Canada",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1519,257,43.6044622,1.4442469,"Hopital Gui de Chauliac, Service de Neurologie, Montpellier, H√©rault, France",258.0,NCT00159198,Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Terminated,No Results Available,Frontotemporal Dementia|Amyotrophic Lateral Sclerosis,,,Assistance Publique - H√¥pitaux de Paris,All,,400.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CRC01107|P011023,September 2002,,June 2007,"September 12, 2005",,"September 8, 2008",,https://ClinicalTrials.gov/show/NCT00159198,18.0,90.0
1520,258,50.6365654,3.0635282,"Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France",259.0,NCT02164253,Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients,SAFEFAIRALS,Completed,No Results Available,ALS (Amyotrophic Lateral Sclerosis)|Iron Overload,Drug: Deferiprone,"Evolution of Amyotrophic Lateral Sclerosis Functional Rating Scale|Comparison of the progression of ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale ) score for 3 months without treatment (V0 to V3) in the period of the first three months under treatment (V3 to V6).|The proportion of patients who become non-self-sufficient after 12 months with the appearance of a sub scores ALSFRS-R less than or equal to 2 on swallowing, cut food using utensils or walk.|Number of patients with anemia at 12 months defined by a hemoglobin / dL Hb <12 g|Number of serious and non-serious adverse events|Progression of respiratory vital capacity tests|Values of R2 * in MRI|Oxidative stress markers analyzed blindly in blood and cerebrospinal fluid|No alteration of energy metabolism in aerobic and anaerobic blood and cerebrospinal fluid","University Hospital, Lille|ApoPharma",All,Phase 2,23.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2012_69|2013-001228-21,September 2013,December 2016,December 2016,"June 16, 2014",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT02164253,18.0,85.0
1521,259,45.5398022,10.2200214,"Charite - Campus Virchow-Klinikum, Berlin, Germany",260.0,NCT02537132,"""New Perspectives of Adaptation to NIV in ALS""",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Other: Adaptation and training to Non Invasive Ventilation (NIV),"Change from baseline in adherence NIV in ALS patients at baseline, 2 and 4 months as measured by monthly means and standard deviations of hours of use of Non Invasive Ventilation (NIV)",Fondazione Don Carlo Gnocchi Onlus|Fondazione Salvatore Maugeri,All,Not Applicable,48.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FDG_ALS1H_01,January 2015,April 2016,January 2018,"September 1, 2015",,"August 2, 2018",,https://ClinicalTrials.gov/show/NCT02537132,18.0,100.0
1522,259,45.4667971,9.1904984,"Medizinische Hochschule Hannover, Hannover, Germany",260.0,NCT02537132,"""New Perspectives of Adaptation to NIV in ALS""",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Other: Adaptation and training to Non Invasive Ventilation (NIV),"Change from baseline in adherence NIV in ALS patients at baseline, 2 and 4 months as measured by monthly means and standard deviations of hours of use of Non Invasive Ventilation (NIV)",Fondazione Don Carlo Gnocchi Onlus|Fondazione Salvatore Maugeri,All,Not Applicable,48.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FDG_ALS1H_01,January 2015,April 2016,January 2018,"September 1, 2015",,"August 2, 2018",,https://ClinicalTrials.gov/show/NCT02537132,18.0,100.0
1523,260,36.7014631,-118.7559974,"Universitaetsklinikum Jena, Jena, Germany",261.0,NCT02460679,Safety and Biomarker Study of EPI-589 in Subjects With ALS,EPI-589,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: EPI-589,Effects of EPI-589 on safety as assessed by drug-related AEs|Pharmacokinetics: Drug plasma concentration|Disease progression as assessed by ALS Functional Rating Scale-Revised|Respiratory function assessed by PFTs and capnography|Failure to thrive as measured by body weight|Effect on swallowing as assessed by change in water and solid swallowing test|Muscle function as assessed by handheld dynamometry|Speech as assessed by speech evaluation|Changes in biomarkers,Edison Pharmaceuticals Inc,All,Phase 2,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPI589-15-001,November 2015,July 2018,July 2018,"June 2, 2015",,"August 23, 2018",,https://ClinicalTrials.gov/show/NCT02460679,21.0,70.0
1524,260,36.7014631,-118.7559974,"Universitaetsklinikum Ulm, Ulm, Germany",261.0,NCT02460679,Safety and Biomarker Study of EPI-589 in Subjects With ALS,EPI-589,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: EPI-589,Effects of EPI-589 on safety as assessed by drug-related AEs|Pharmacokinetics: Drug plasma concentration|Disease progression as assessed by ALS Functional Rating Scale-Revised|Respiratory function assessed by PFTs and capnography|Failure to thrive as measured by body weight|Effect on swallowing as assessed by change in water and solid swallowing test|Muscle function as assessed by handheld dynamometry|Speech as assessed by speech evaluation|Changes in biomarkers,Edison Pharmaceuticals Inc,All,Phase 2,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPI589-15-001,November 2015,July 2018,July 2018,"June 2, 2015",,"August 23, 2018",,https://ClinicalTrials.gov/show/NCT02460679,21.0,70.0
1525,260,43.9792797,-120.737257,"Beaumont Hospital, Dublin, Ireland",261.0,NCT02460679,Safety and Biomarker Study of EPI-589 in Subjects With ALS,EPI-589,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: EPI-589,Effects of EPI-589 on safety as assessed by drug-related AEs|Pharmacokinetics: Drug plasma concentration|Disease progression as assessed by ALS Functional Rating Scale-Revised|Respiratory function assessed by PFTs and capnography|Failure to thrive as measured by body weight|Effect on swallowing as assessed by change in water and solid swallowing test|Muscle function as assessed by handheld dynamometry|Speech as assessed by speech evaluation|Changes in biomarkers,Edison Pharmaceuticals Inc,All,Phase 2,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPI589-15-001,November 2015,July 2018,July 2018,"June 2, 2015",,"August 23, 2018",,https://ClinicalTrials.gov/show/NCT02460679,21.0,70.0
1526,261,36.7014631,-118.7559974,"UMC Utrecht, Utrecht, CX, Netherlands",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1527,261,36.7014631,-118.7559974,"Kantonsspital St. Gallen, St. Gallen, Switzerland",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1528,261,27.7567667,-81.4639835,"Royal Hallamshire Hospital, Sheffield, West Midlands, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1529,261,32.3293809,-83.1137366,"CHRU de Lille - H√¥pital Roger Salengro, Lille, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1530,261,39.5162234,-76.9382069,"CHU de Limoges - H√¥pital Dupuytren, Limoges, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1531,261,42.3788774,-72.032366,"HCL - H√¥pital Neurologique P. Wertheimer, Lyon, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1532,261,38.7604815,-92.5617875,"APHM - H√¥pital de la Timone, Marseille, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1533,261,40.9699889,-77.7278831,"CHRU de Montpellier - H√¥pital Gui de Chauliac, Montpellier Cedex 5, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1534,261,50.879202,4.7011675,"CHU de Nice - H√¥pital Pasteur, Nice, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1535,261,50.000678,-86.000977,"APHP - Groupe Hospitalier Piti√©-Salpetri√®re, Paris Cedex 13, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1536,261,52.4760892,-71.8258668,"CENTRE HOSPITALIER DE SAINT BRIEUC - H√¥pital Yves Le Foll, Saint Brieuc, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1537,261,43.5914424,3.35528302489692,"CHU de Strasbourg - H√¥pital de Hautepierre, Strasbourg, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1538,261,48.8566101,2.3514992,"CHRU de Tours - H√¥pital Bretonneau, Tours, France",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1539,261,52.5170365,13.3888599,"Trafford Centre for Biomedical Research, Brighton, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1540,261,52.3744779,9.7385532,"Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1541,261,50.9281717,11.5879359,"North-East London and Essex MND Regional Care Centre, London, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1542,261,48.3974003,9.9934336,"King's MND Care and Research Centre, London, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1543,261,53.3497645,-6.2602732,"Centre for Neuromuscular Diseases - National Hospital of Neurology, London, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1544,261,52.24726925,5.54122345487672,"Salford Royal NHS Foundation Trust, Neurology Dept, Manchester, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1545,261,47.4250593,9.3765878,"Sheffield Care and Research Centre, Sheffield, United Kingdom",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1546,261,52.5259976,-2.19736029715209,"Johns Hopkins ALS Clinic, Baltimore, Maryland, United States",262.0,NCT02611674,Methodology Study of Novel Outcome Measures to Assess Progression of ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,,Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)|Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)|Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)|Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)|Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)|Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM|Within-participant test-retest reliability between the 2 repeated measurements for CMAP|Within-participant test-retest reliability between the 2 repeated measurements for MUNE|Within-participant test-retest reliability between the 2 repeated measurements for MUNIX|Within-participant test-retest reliability between the 2 repeated measurements for HHD|Within-participant test-retest reliability between the 2 repeated measurements for SVC|Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R|Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival|Comparison between 6-month changes for muscle electrophysiological measures|Comparison between 6-month changes for muscle strength measures|Comparison between 6-month changes for functional measures|Comparison of molecular biomarkers with disease progression,Biogen,All,,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,999AS003,"January 6, 2016","August 2, 2019","August 2, 2019","November 23, 2015",,"August 8, 2018",,https://ClinicalTrials.gov/show/NCT02611674,16.0,85.0
1547,262,50.6365654,3.0635282,"GSK Investigational Site, Baltimore, Maryland, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1548,262,45.8354243,1.2644847,"GSK Investigational Site, New York, New York, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1549,262,45.6963425,4.73594802991681,"GSK Investigational Site, Syracuse, New York, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1550,262,43.2961743,5.3699525,"GSK Investigational Site, Charlotte, North Carolina, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1551,262,46.603354,1.8883335,"GSK Investigational Site, Winston-Salem, North Carolina, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1552,262,43.7009358,7.2683912,"GSK Investigational Site, Columbus, Ohio, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1553,262,46.603354,1.8883335,"GSK Investigational Site, Paris, France",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1554,262,48.5141594,-2.7602707,"GSK Investigational Site, Verona, Veneto, Italy",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1555,262,48.584614,7.7507127,"GSK Investigational Site, Birmingham, United Kingdom",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1556,262,47.3900474,0.6889268,"GSK Investigational Site, Cambridge, United Kingdom",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1557,262,50.8220399,-0.1374061,"GSK Investigational Site, London, United Kingdom",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1558,262,55.8611389,-4.2501672,"GSK Investigational Site, London, United Kingdom",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1559,262,51.5073219,-0.1276474,"PEREZ, Lille, France",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1560,262,51.5073219,-0.1276474,"P√¥le des maladies respiratoires et service EFR- Centre hospitalier Regional Universitaire, Lille, France",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1561,NULL,NULL,NULL,"University Hospital, Geneva, Switzerland",,,,,,,,,,,,,,,,,,,,,,,,,,,
1562,262,53.4794892,-2.2451148,"St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1563,262,53.3806626,-1.4702278,"University of California San Diego, La Jolla, California, United States",263.0,NCT03039673,MIROCALS: Modifying Immune Response and OutComes in ALS,MIROCALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole|Drug: IL-2|Drug: 5% glucose water solution,Time to death from date of randomization to date of death,Centre Hospitalier Universitaire de Nƒ´mes,All,Phase 2,216.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H2020/PHRC-N/2014/GB-01|No 633413|PHRC-N, 14-0077, 2014|Leigh/Jul15/971-797","June 19, 2017",June 2021,June 2021,"February 1, 2017",,"January 11, 2019",,https://ClinicalTrials.gov/show/NCT03039673,18.0,75.0
1564,263,39.5162234,-76.9382069,"Cedars-Sinai Medical Center, Los Angeles, California, United States",264.0,NCT01016522,Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS),,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Dietary Supplement: KetoCal,"Study will determine if humans with ALS fed a strictly controlled diet designed to generate large amounts of ketones is safe and well-tolerated without evidence of weight loss or other adverse effect|Evaluate changes in motor function, strength, fatigue, body fat and cognitive function",Johns Hopkins University|Nutricia North America|Cornell University,All,Phase 3,1.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00008855,November 2009,February 2011,January 2012,"November 19, 2009",,"April 1, 2015",,https://ClinicalTrials.gov/show/NCT01016522,18.0,100.0
1565,264,39.5162234,-76.9382069,"University of California, Irvine, Orange, California, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1566,264,40.7127281,-74.0060152,"University of California Davis Medical Center, Sacramento, California, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1567,264,40.7127281,-74.0060152,"Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1568,264,35.6729639,-79.0392919,"Stanford Hospital and Clinics, Stanford, California, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1569,264,35.6729639,-79.0392919,"University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1570,264,40.2253569,-82.6881395,"Hospital for Special Care, New Britain, Connecticut, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1571,264,48.8566101,2.3514992,"George Washington University Medical Center, Washington, District of Columbia, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1572,264,45.6476663,11.8665254,"Mayo Clinic, Jacksonville, Florida, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1573,264,52.4775396,-1.894053,"University of Miami, Miami, Florida, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1574,264,52.2034823,0.1235817,"Carol and Frank Morsini Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1575,264,51.5073219,-0.1276474,"The Emory Clinic, Atlanta, Georgia, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1576,264,51.5073219,-0.1276474,"Georgia Regents University, Augusta, Georgia, United States",265.0,NCT00875446,First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: PLACEBO|Drug: GSK1223249,"Adverse events, vital signs, standard physical examination, ECG and standard clinical laboratory tests (haematology and biochemistry). Evaluation of safety will include any adverse effects on Immunogenicity, ALSFRS-R, SVC, Muscle Strength and MUNE.|GSK1223249: Single dose PK (Part 1): AUC(0-‚àû), AUC(0-t), AUC(0-Week 4), %AUCex, Cmax, tlast, CL, Vss, MRT, Œªz and t¬Ω.Repeat dose PK (Part 2): GSK1223249 AUC(0-Week 4), Cmax and after the second dose, AUC(0-t), AUC(0-‚àû),Œªz and t¬Ω.|Presence of antibodies to GSK1223249 will be assessed in serum samples using immuno-electrochemiluminescent assay.|ALSFRS-R scores, Manual Muscle Strength test and Slow Inspirational Vital Capacity (SVC)|Motor Unit Number Estimation (MUNE)|Muscle biopsies for protein analysis, Immunohistochemistry (IHC), Transcriptomics. Blood for protein analysis and other biomarkers.|Relationships between PK of GSK1223249 and relevant pharmacological endpoints",GlaxoSmithKline,All,Phase 1,76.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111330,"May 13, 2009","September 9, 2011","September 9, 2011","April 3, 2009",,"September 20, 2017",,https://ClinicalTrials.gov/show/NCT00875446,18.0,80.0
1577,265,50.6365654,3.0635282,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",266.0,NCT00879593,Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: PtcCO2,Nocturnal Transcutaneous PCO2|Pulmonary function,"Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche",All,Not Applicable,66.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANTADIR PTcCO2/SLA,April 2009,June 2014,January 2017,"April 10, 2009",,"January 26, 2017",,https://ClinicalTrials.gov/show/NCT00879593,18.0,75.0
1578,265,50.6365654,3.0635282,"Indiana University, Indianapolis, Indiana, United States",266.0,NCT00879593,Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: PtcCO2,Nocturnal Transcutaneous PCO2|Pulmonary function,"Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche",All,Not Applicable,66.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANTADIR PTcCO2/SLA,April 2009,June 2014,January 2017,"April 10, 2009",,"January 26, 2017",,https://ClinicalTrials.gov/show/NCT00879593,18.0,75.0
1579,266,,,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",267.0,NCT00596115,Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day,,Temporarily not available,No Results Available,Amyotrophic Lateral Sclerosis,Drug: R(+) pramipexole dihydrochloride monohydrate,,"Bennett, James P., Jr., M.D., Ph.D.|University of Pittsburgh|University of Nebraska",All,,,Other,Expanded Access,,12316,,,,"January 16, 2008",,"July 25, 2012",,https://ClinicalTrials.gov/show/NCT00596115,30.0,80.0
1580,267,46.2017559,6.1466014,"University of Kansas Medical Center, Kansas City, Kansas, United States",268.0,NCT01772888,Chewing Efficiency Measured by a Two Colour Chewing Gum Test in Amyotrophic Lateral Sclerosis (ALS) Patients?,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis 11,,- Chewing efficiency|Lip force|Bite force|Calorie and protein intakes|Saliva volume,"University Hospital, Geneva",All,,25.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,12-103,October 2012,October 2019,October 2019,"January 21, 2013",,"May 8, 2018",,https://ClinicalTrials.gov/show/NCT01772888,18.0,100.0
1581,268,34.395342,-111.7632755,"Johns Hopkins University, Baltimore, Maryland, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1582,268,36.7014631,-118.7559974,"Massachusetts General Hospital, Boston, Massachusetts, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1583,268,36.7014631,-118.7559974,"University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1584,268,36.7014631,-118.7559974,"University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1585,268,36.7014631,-118.7559974,"Henry Ford Health System, Detroit, Michigan, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1586,268,36.7014631,-118.7559974,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1587,268,36.7014631,-118.7559974,"Saint Louis University, Saint Louis, Missouri, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1588,268,38.7251776,-105.6077167,"Barnes-Jewish Hospital, Saint Louis, Missouri, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1589,268,41.6500201,-72.7342163,"Neurology Associates, Lincoln, Nebraska, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1590,268,38.89366125,-76.987883253882,"Dartmouth Hitchcock Medical Center Dept of Neurology, Lebanon, New Hampshire, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1591,268,27.7567667,-81.4639835,"Hospital for Special Surgery, New York, New York, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1592,268,27.7567667,-81.4639835,"Neurological Institute Columbia University Medical Center, New York, New York, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1593,268,27.7567667,-81.4639835,"SUNY Upstate Medical University, Syracuse, New York, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1594,268,32.3293809,-83.1137366,"Neurosciences Institute: Neurology - Charlotte, Charlotte, North Carolina, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1595,268,32.3293809,-83.1137366,"Duke Neurological Disorders Clinic, Durham, North Carolina, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1596,268,40.0796606,-89.4337288,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1597,268,40.3270127,-86.1746933,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1598,268,41.9216734,-93.3122705,"Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1599,268,38.27312,-98.5821872,"Oregon Health and Science Center, Portland, Oregon, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1600,268,39.5162234,-76.9382069,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1601,268,42.3788774,-72.032366,"The Penn Comprehensive Neuroscience Center, Philadelphia, Pennsylvania, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1602,268,42.3788774,-72.032366,"Temple University School of Medicine, Philadelphia, Pennsylvania, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1603,268,43.6211955,-84.6824346,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1604,268,43.6211955,-84.6824346,"Texas Neurology, Dallas, Texas, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1605,268,45.9896587,-94.6113288,"Baylor College of Medicine, Houston, Texas, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1606,268,38.7604815,-92.5617875,"University of Texas Health Science Center, San Antonio, Texas, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1607,268,38.7604815,-92.5617875,"University of Virgina Health System, Charlottesville, Virginia, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1608,268,41.7370229,-99.5873816,"University of Washington Medical Center, Seattle, Washington, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1609,268,43.4849133,-71.6553992,"West Virginia University Department of Neurology, Morgantown, West Virginia, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1610,268,40.7127281,-74.0060152,"Froedtert Memorial Lutheran Hospital, Department of Neurology, Milwaukee, Wisconsin, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1611,268,40.7127281,-74.0060152,"UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant, Belgium",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1612,268,40.7127281,-74.0060152,"University of Calgary, Calgary, Alberta, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1613,268,35.6729639,-79.0392919,"Edmonton Kaye Clinic, Edmonton, Alberta, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1614,268,35.6729639,-79.0392919,"Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1615,268,35.6729639,-79.0392919,"QE II Health Sciences Centre, NHI Site, Halifax, Nova Scotia, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1616,268,40.2253569,-82.6881395,"McMaster University Medical Centre, Hamilton, Ontario, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1617,268,43.9792797,-120.737257,"London Health Sciences Centre, London, Ontario, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1618,268,43.9792797,-120.737257,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1619,268,40.9699889,-77.7278831,"Notre-Dame Hospital/CHUM, Montreal, Quebec, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1620,268,40.9699889,-77.7278831,"Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1621,268,40.9699889,-77.7278831,"CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus, Quebec, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1622,268,35.7730076,-86.2820081,"Hopital R. Salengro, CHRU Lille, Lille Cedex, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1623,268,31.8160381,-99.5120986,"CHU Dupuytren, Limoges cedex, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1624,268,31.8160381,-99.5120986,"Hopital de la Timone, Marseille, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1625,268,31.8160381,-99.5120986,"Hopital Gui de Chauliac, Montpellier, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1626,268,37.1232245,-78.4927721,"CHU de Nice - Hopital Pasteur 2, Nice Cedex 1, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1627,268,38.8950092,-77.0365625,"Hopital de la Salpetriere, Paris, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1628,268,38.4758406,-80.8408415,"Bretonneau University Hospital, Tours Cedex 9, France",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1629,268,44.4308975,-89.6884637,"University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1630,268,50.8686516,4.7886108308049,"Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1631,268,55.001251,-115.002136,"Charite Campus Virchow-Klinikum, Neurology Department, Berlin, Germany",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1632,268,55.001251,-115.002136,"Clinical Research Centre, Beaumont Hospital, Dublin, Ireland",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1633,268,46.500283,-66.750183,"IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Italy",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1634,268,45.1960403,-63.1653789,"Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1635,268,50.000678,-86.000977,"Dipartimento di Neuroscienze ""Rita Levi Moltalcini"" A.O.U. Citta della Salute e della Scienza di Torino P.O. ""Molinette"", Torino, Italy",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1636,268,50.000678,-86.000977,"University Medical Center Utrecht, Utrecht, Netherlands",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1637,268,50.000678,-86.000977,"Hospital Santa Maria-Centro Hospitalar Lisboa Norte, Lisboa, Portugal",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1638,268,52.4760892,-71.8258668,"Hospital San Rafael, Madrid, Spain",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1639,268,52.4760892,-71.8258668,"Derriford Hospital, Plymouth, Devon, United Kingdom",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1640,268,52.4760892,-71.8258668,"Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1641,268,46.603354,1.8883335,"Clinical Research Centre, Royal London Hospital, London, United Kingdom",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1642,268,46.603354,1.8883335,"Kings College Hospital, London, United Kingdom",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1643,268,43.2961743,5.3699525,"Philip Van Damme, Leuven, Belgium",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1644,268,43.6112422,3.8767337,"Leonard van den Berg, Utrecht, Netherlands",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1645,268,46.603354,1.8883335,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1646,268,48.8566101,2.3514992,"Cedars-Sinai Medical Center, Los Angeles, California, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1647,268,46.603354,1.8883335,"California Pacific Medical Center -- Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1648,268,48.6296972,9.1949534,"University of Colorado Denver, Denver, Colorado, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1649,268,52.8398531,9.075962,"Mayo Clinic, Jacksonville, Florida, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1650,268,52.5170365,13.3888599,"Northwestern University, Chicago, Illinois, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1651,268,53.3497645,-6.2602732,"University of Kansas Medical Center, Kansas City, Kansas, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1652,268,45.4667971,9.1904984,"University of Nebraska Medical Center, Omaha, Nebraska, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1653,268,45.4667971,9.1904984,"Stony Brook University, Stony Brook, New York, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1654,268,45.0677551,7.6824892,"Duke University, Durham, North Carolina, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1655,268,52.0809856,5.12768396945229,"University Hospitals Case Medical Center, Cleveland, Ohio, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1656,268,38.7077507,-9.1365919,"Providence St. Vincent Medical Center, Portland, Oregon, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1657,268,40.4167047,-3.7035825,"Calgary ALS Neuromuscular Clinic, Calgary, Alberta, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1658,268,50.75,-3.75,"University of Alberta ALS Clinic, Edmonton, Alberta, Canada",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1659,268,53.407154,-2.991665,"Washington University School of Medicine, Saint Louis, Missouri, United States",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1660,268,51.5073219,-0.1276474,"Philip Van Damme, Leuven, Belgium",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1661,268,51.5073219,-0.1276474,"Leonard van den Berg, Utrecht, Netherlands",269.0,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: tirasemtiv|Drug: Placebo tablets|Drug: Riluzole 50 MG,"Change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted slow vital capacity (SVC)|Change from baseline in the ALSFRS-R score of the three respiratory items of the ALSFRS-R (i.e., the sum of items 10, 11 and 12) at the end of 48 weeks of double-blind, placebo-controlled treatment|Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline from baseline in percent predicted SVC ‚â•20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Time to the first occurrence of a decline in SVC to ‚â§50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled treatment|Change from baseline in the ALSFRS-R total score to the end of 48 weeks of the double-blind, placebo-controlled treatment|Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo-controlled treatment",Cytokinetics,All,Phase 3,743.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015",,"August 9, 2018",,https://ClinicalTrials.gov/show/NCT02496767,18.0,100.0
1662,269,50.879202,4.7011675,"Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark",270.0,NCT02269436,A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sNN0029 infusion solution,Number Patients with Adverse Events as a measure of Safety and Tolerability,Newron Sweden AB,All,Phase 1,11.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,sNN0029-004|2012-005034-11,January 2015,October 2015,October 2015,"October 21, 2014",,"January 27, 2016",,https://ClinicalTrials.gov/show/NCT02269436,18.0,75.0
1663,269,52.0809856,5.12768396945229,"Department of Neurology, Gazi University Hospital, Ankara, Turkey",270.0,NCT02269436,A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sNN0029 infusion solution,Number Patients with Adverse Events as a measure of Safety and Tolerability,Newron Sweden AB,All,Phase 1,11.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,sNN0029-004|2012-005034-11,January 2015,October 2015,October 2015,"October 21, 2014",,"January 27, 2016",,https://ClinicalTrials.gov/show/NCT02269436,18.0,75.0
1664,270,40.9699889,-77.7278831,"California Pacific Medical Center, San Francisco, California, United States",271.0,NCT00718003,Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Calories Used with and without NIPPV,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,10.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,Internal-15860,May 2005,February 2013,February 2013,"July 18, 2008",,"March 5, 2013",,https://ClinicalTrials.gov/show/NCT00718003,20.0,85.0
1665,271,36.7014631,-118.7559974,"Georgetown University Medical Center, Washington D.C., District of Columbia, United States",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1666,271,36.7014631,-118.7559974,"Saint Mary's Health Care, Grand Rapids, Michigan, United States",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1667,271,38.7251776,-105.6077167,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1668,271,27.7567667,-81.4639835,"Neurology Associates, P.C., Lincoln, Nebraska, United States",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1669,271,40.0796606,-89.4337288,"The Cleveland Clinic, Cleveland, Ohio, United States",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1670,271,38.27312,-98.5821872,"Providence ALS Center, Portland, Oregon, United States",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1671,271,41.7370229,-99.5873816,"University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1672,271,40.7127281,-74.0060152,"HCL H√¥pital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'√©lectromyographie - 59, boulevard Pinel, Bron Cedex, France",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1673,271,35.6729639,-79.0392919,"CHRU de LILLE - H√¥pital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement, Lille, France",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1674,271,40.2253569,-82.6881395,"Centre SLA Limoges - Service de Neurologie, Limoges, France",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1675,271,43.9792797,-120.737257,"H√¥pital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France",272.0,NCT01605006,Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: NeuRx Diaphragm Pacing System (DPS),Safety Outcome Measure -- Occurrence of major device-related (including procedure-related) adverse events as defined below.|Probable Benefit Outcome Measure,Synapse Biomedical,All,Not Applicable,97.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLIN 20-0009-0020,July 2012,September 2017,September 2017,"May 24, 2012",,"April 13, 2016",,https://ClinicalTrials.gov/show/NCT01605006,21.0,100.0
1676,272,55.001251,-115.002136,"Clinique du Motoneurone - Sce d'Explorations Neurologiques - H√¥pital Gui de Chauliac, Montpellier, France",273.0,NCT00409721,The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Memantine,ALS Functional Rating Scale-Revised (ALSFRS-R)|Forced vital capacity (FVC)|Manual Muscle Testing (MMT)|Addenbrooke Cognitive Examination (ACE)|Motor unit number estimates of hand and foot muscles|N-acetylaspartate in the motor cortex,University of Alberta|ALS Association,All,Phase 2,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1204|EB2006ALS,March 2007,December 2010,December 2010,"December 11, 2006",,"March 2, 2011",,https://ClinicalTrials.gov/show/NCT00409721,18.0,80.0
1677,272,55.001251,-115.002136,"CHU de Nice - H√¥pital de l'Archet 1 - Centre de R√©f√©rence pour les Maladies Neuromusculaires et la SLA, Nice, France",273.0,NCT00409721,The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Memantine,ALS Functional Rating Scale-Revised (ALSFRS-R)|Forced vital capacity (FVC)|Manual Muscle Testing (MMT)|Addenbrooke Cognitive Examination (ACE)|Motor unit number estimates of hand and foot muscles|N-acetylaspartate in the motor cortex,University of Alberta|ALS Association,All,Phase 2,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1204|EB2006ALS,March 2007,December 2010,December 2010,"December 11, 2006",,"March 2, 2011",,https://ClinicalTrials.gov/show/NCT00409721,18.0,80.0
1678,273,38.7604815,-92.5617875,"Groupe Hospitalier PITIE-SALPETRIERE - F√©d√©ration des Maladies du Syst√®me Nerveux, Paris, France",274.0,NCT03929068,Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis,ALS and PLS,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: carbidopa-levodopa|Drug: Placebo Oral Tablet,Visual Analog Scale - Change of spasticity severity from baseline with treatment and placebo|Visual Analog Scale - Change of pain severity from baseline with treatment and placebo|Visual Analog Scale - Change of muscle spasm severity from baseline with treatment and placebo|Strength|Spasticity|Upper extremity function|Lower extremity function:10-meter Walk Test|Lower extremity function: Timed Up and Go (TUG) Test,Washington University School of Medicine,All,Phase 1,15.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Sinemet-001,"May 13, 2019",May 2020,May 2020,"April 26, 2019",,"June 26, 2019","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03929068/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03929068,18.0,100.0
1679,274,50.879202,4.7011675,"Charit√© Universit√§tsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz f√ºr ALS und andere Motoeneuronenerkrankungen, Berlin, Germany",275.0,NCT01999803,A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sNN0029|Drug: Placebo,Number of Adverse Events (AEs)|VEGF165 levels in Cerebrospinal Fluid (CSF)|Medical Device performance,Newron Sweden AB,All,Phase 1,15.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",sNN0029-003|2012-001026-10,September 2014,October 2015,October 2015,"December 3, 2013",,"January 27, 2016",,https://ClinicalTrials.gov/show/NCT01999803,18.0,75.0
1680,274,52.0809856,5.12768396945229,"Universit√§tsklinik und Poliklinik f√ºr Neurologie - Martin-Luther-Universit√§t Halle-Wittenberg, Halle, Germany",275.0,NCT01999803,A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis,Drug: sNN0029|Drug: Placebo,Number of Adverse Events (AEs)|VEGF165 levels in Cerebrospinal Fluid (CSF)|Medical Device performance,Newron Sweden AB,All,Phase 1,15.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",sNN0029-003|2012-001026-10,September 2014,October 2015,October 2015,"December 3, 2013",,"January 27, 2016",,https://ClinicalTrials.gov/show/NCT01999803,18.0,75.0
1681,275,56.1496278,10.2134046,"Neurologische Klinik Medizinische Hochschule, Hannover, Germany",276.0,NCT03664206,Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy,,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Cortical Excitability,"Diagnostic Test: MRS, conventional TMS and treshold tracking TMS",short interval intracortical inhibition (SICI) measured by threshold tracking TMS|short interval intracortical inihibition (SICI) measured by conventional TMS|Concentration of GABA and glutamate,S√°ndor Beniczky|Lundbeck Foundation|Aage og Johanne Louis-Hansens Fond|The A.P Moeller Foundation for Advancement of Medical Science|Danish Council for Independent Research|Aarhus University Hospital|Central Denmark Region,All,,60.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,AMND|7025-00066B|18-2B-2454|17-L-0365|3530,"February 16, 2018","August 31, 2019","August 31, 2019","September 10, 2018",,"September 10, 2018",,https://ClinicalTrials.gov/show/NCT03664206,45.0,100.0
1682,275,39.9207774,32.854067,"Universit√§ts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universit√§tsklinik, Ulm, Germany",276.0,NCT03664206,Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy,,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Cortical Excitability,"Diagnostic Test: MRS, conventional TMS and treshold tracking TMS",short interval intracortical inhibition (SICI) measured by threshold tracking TMS|short interval intracortical inihibition (SICI) measured by conventional TMS|Concentration of GABA and glutamate,S√°ndor Beniczky|Lundbeck Foundation|Aage og Johanne Louis-Hansens Fond|The A.P Moeller Foundation for Advancement of Medical Science|Danish Council for Independent Research|Aarhus University Hospital|Central Denmark Region,All,,60.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,AMND|7025-00066B|18-2B-2454|17-L-0365|3530,"February 16, 2018","August 31, 2019","August 31, 2019","September 10, 2018",,"September 10, 2018",,https://ClinicalTrials.gov/show/NCT03664206,45.0,100.0
1683,276,36.7014631,-118.7559974,"Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10, Madrid, Spain",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1684,276,38.89366125,-76.987883253882,"King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1685,276,43.6211955,-84.6824346,"Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1686,276,45.9896587,-94.6113288,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1687,276,41.7370229,-99.5873816,"Kantonsspital St.Gallen, St.Gallen, Switzerland",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1688,276,40.2253569,-82.6881395,"Weill Cornell Medical Center/New York Presbyterian Hospital, New York, New York, United States",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1689,276,43.9792797,-120.737257,"Methodist Neurological Institute, Houston, Texas, United States",277.0,NCT01806857,Clinical Trial Nuedexta in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis (ALS),Drug: Nuedexta|Drug: Matching Placebo,Bulbar Function Scale (CNS-BFS) Total Score|Bulbar Function Scale (CNS-BFS) Sialorrhea Score|Bulbar Function Scale (CNS-BFS) Speech Score|Bulbar Function Scale (CNS-BFS) Swallowing Score|Center for Neurologic Study - Lability Scale (CNS-LS) Total Score|ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score|Visual Analog Scale - Speech Scores|Ashworth Spasticity Scale Score - Right Arm|Timed Reading of Test Paragraph Result|Average Water Swallowing Test (WST)|Visual Analog Scale - Swallowing Score|Visual Analog Scale - Salivation (Sialorrhea) Score|Average Solids Swallowing Test|Ashworth Spasticity Scale Score - Left Arm|Ashworth Spasticity Scale Score - Right Leg|Ashworth Spasticity Scale Score - Left Leg,"Center for Neurologic Study, La Jolla, California,|ALS Association|State University of New York - Upstate Medical University",All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012P001274|3FKVAD,April 2013,March 2015,March 2015,"March 7, 2013","March 24, 2017","March 24, 2017",,https://ClinicalTrials.gov/show/NCT01806857,18.0,100.0
1690,277,50.879202,4.7011675,"Universit√§ts- und Rehabilitationskliniken Ulm, Ulm, Germany",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1691,277,46.603354,1.8883335,"Milano Neurological Institute, Milan, Italy",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1692,277,50.6365654,3.0635282,"Umea University, Umea, Sweden",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1693,277,45.8354243,1.2644847,"University of Michigan, Ann Arbor, Michigan, United States",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1694,277,43.2961743,5.3699525,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1695,277,43.6112422,3.8767337,"University of Miami, Miami, Florida, United States",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1696,277,43.7009358,7.2683912,"Katholieke Universiteit Leuven, Leuven, Belgium",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1697,277,48.8566101,2.3514992,"Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1698,277,52.5170365,13.3888599,"Centre Hospitalier Universitaire Limoges, Limoges, France",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1699,277,51.4825041,11.9705452,"Centre Hospitalier Universitaire de Montpellier, Montpellier, France",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1700,277,52.3744779,9.7385532,"Centre Hospitalier Regional Universitaire de Tours, Tours, France",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1701,277,48.3974003,9.9934336,"Charit√© - Universit√§tsmedizin Berlin, Berlin, Germany",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1702,277,40.4167047,-3.7035825,"Universit√§tsklinikum Carl Gustav Carus Dresden, Dresden, Germany",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1703,277,51.5073219,-0.1276474,"Alfried Krupp Krankenhaus R√ºttenscheid, Essen, Germany",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1704,277,53.3806626,-1.4702278,"Medizinische Hochschule Hannover, Hannover, Germany",278.0,NCT01285583,Safety Extension Study of TRO19622 in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: TRO19622,The primary outcome measure will be the safety assessment.|Secondary Outcome Measures,Hoffmann-La Roche,All,Phase 2|Phase 3,271.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),WN29852|TRO19622 CL E Q 1425-1,October 2010,March 2012,March 2012,"January 28, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01285583,18.0,100.0
1705,278,39.5162234,-76.9382069,"Universit√§tsklinikum Jena, Jena, Germany",279.0,NCT00362362,Collection of Blood Samples for DNA in Motor Neuron Disease,,Completed,No Results Available,Motor Neuron Diseases,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,23.0,NIH,Observational,,060224|06-N-0224,"August 7, 2006",,"September 9, 2013","August 10, 2006",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT00362362,18.0,100.0
1706,279,47.4250593,9.3765878,"Universit√§t Ulm, Ulm, Germany",280.0,NCT00812851,Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Cramps|Amyotrophic Lateral Sclerosis,Drug: Dronabinol,severity of cramps,Cantonal Hospital of St. Gallen|ALS Association,All,Not Applicable,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",THC SG,April 2005,April 2008,April 2008,"December 22, 2008",,"February 19, 2009",,https://ClinicalTrials.gov/show/NCT00812851,18.0,100.0
1707,280,40.7127281,-74.0060152,"Trinity College Dublin, Dublin, Ireland",281.0,NCT01083667,SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Familial Amyotrophic Lateral Sclerosis,Drug: Pyrimethamine,Mean Change in SOD1 CSF|Appel ALS Score,Weill Medical College of Cornell University|Muscular Dystrophy Association,All,Phase 1|Phase 2,32.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0903010259,November 2009,December 2014,May 2016,"March 10, 2010","June 19, 2017","June 19, 2017",,https://ClinicalTrials.gov/show/NCT01083667,18.0,100.0
1708,280,31.8160381,-99.5120986,"IRCCS Istituto Auxologico Italiano, Milano, Italy",281.0,NCT01083667,SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Familial Amyotrophic Lateral Sclerosis,Drug: Pyrimethamine,Mean Change in SOD1 CSF|Appel ALS Score,Weill Medical College of Cornell University|Muscular Dystrophy Association,All,Phase 1|Phase 2,32.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0903010259,November 2009,December 2014,May 2016,"March 10, 2010","June 19, 2017","June 19, 2017",,https://ClinicalTrials.gov/show/NCT01083667,18.0,100.0
1709,280,48.3974003,9.9934336,"NEuroMuscular Omnicentre. Fondazione Serena Onlus, Milano, Italy",281.0,NCT01083667,SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Familial Amyotrophic Lateral Sclerosis,Drug: Pyrimethamine,Mean Change in SOD1 CSF|Appel ALS Score,Weill Medical College of Cornell University|Muscular Dystrophy Association,All,Phase 1|Phase 2,32.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0903010259,November 2009,December 2014,May 2016,"March 10, 2010","June 19, 2017","June 19, 2017",,https://ClinicalTrials.gov/show/NCT01083667,18.0,100.0
1710,280,45.4667971,9.1904984,"AOU Universit√† degli Studi della Campania ""Luigi Vanvitelli"", Napoli, Italy",281.0,NCT01083667,SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Familial Amyotrophic Lateral Sclerosis,Drug: Pyrimethamine,Mean Change in SOD1 CSF|Appel ALS Score,Weill Medical College of Cornell University|Muscular Dystrophy Association,All,Phase 1|Phase 2,32.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0903010259,November 2009,December 2014,May 2016,"March 10, 2010","June 19, 2017","June 19, 2017",,https://ClinicalTrials.gov/show/NCT01083667,18.0,100.0
1711,280,63.8256568,20.2630745,"IRCCS Istituto Clinico Humanitas, Rozzano, Italy",281.0,NCT01083667,SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS),,Completed,Has Results,Familial Amyotrophic Lateral Sclerosis,Drug: Pyrimethamine,Mean Change in SOD1 CSF|Appel ALS Score,Weill Medical College of Cornell University|Muscular Dystrophy Association,All,Phase 1|Phase 2,32.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0903010259,November 2009,December 2014,May 2016,"March 10, 2010","June 19, 2017","June 19, 2017",,https://ClinicalTrials.gov/show/NCT01083667,18.0,100.0
1712,281,43.6211955,-84.6824346,"Azienda Ospedaliera Santa Maria di Terni, Terni, Italy",282.0,NCT01154283,Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients,,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Device: Viasys¬Æ Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)","Hours of NIPPV Usage|Patient Preference (Likert Scale) ""Definitely IPAP-only"" ""Probably IPAP-only"" ""Uncertain"" ""Probably Bi-level"" ""Definitely Bi-level""|Transitional Dyspnea Index|EuroQol Visual Analogue Scale(VAS)",Kirsten Gruis|ALS Association|University of Michigan,All,Not Applicable,28.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ALSA-9611,January 2008,October 2011,October 2011,"June 30, 2010","January 2, 2017","January 2, 2017",,https://ClinicalTrials.gov/show/NCT01154283,19.0,100.0
1713,282,42.3788774,-72.032366,"AOU Citt√† della Salute e della Scienza di Torino, Torino, Italy",283.0,NCT01565395,Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS),Xeomin,Withdrawn,No Results Available,Parkinson Disease|Amyotrophic Lateral Sclerosis,Drug: Incobotulinum Toxin A|Drug: placebo,Change in objectively measured salivary volume between baseline and one month post-injection in the Xeomin group as compared to placebo,Beth Israel Deaconess Medical Center|Merz Pharmaceuticals,All,Phase 2,0.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",2011P000304,March 2012,July 2013,July 2013,"March 28, 2012",,"February 7, 2017",,https://ClinicalTrials.gov/show/NCT01565395,20.0,80.0
1714,283,27.7567667,-81.4639835,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",284.0,NCT00136500,Clinical Research in ALS Study,CRiALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Recruitment,Michael Benatar|ALS Association|ALS Recovery Fund|University of Miami,All,,10000.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,FALS feasibility,February 2005,December 2027,December 2027,"August 29, 2005",,"August 2, 2019",,https://ClinicalTrials.gov/show/NCT00136500,18.0,100.0
1715,284,50.879202,4.7011675,"The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1716,284,44.841225,-0.5800364,"Plymouth Hospitals NHS Trust, Plymouth, United Kingdom",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1717,284,45.8354243,1.2644847,"Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1718,284,43.6112422,3.8767337,"Salford Royal NHS Foundation Trust, Salford, United Kingdom",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1719,284,47.3900474,0.6889268,"University of Sheffield, Sheffield, United Kingdom",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1720,284,52.5170365,13.3888599,"Avera Medical Group Palliative Medicine Sioux Falls, Sioux Falls, South Dakota, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1721,NULL,NULL,NULL,"University of Vermont, Burlington, Vermont, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
1722,284,51.457087,7.011429,"University of Virginia, Charlottesville, Virginia, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1723,284,52.3744779,9.7385532,"Washington University, St. Louis, Missouri, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1724,284,50.9281717,11.5879359,"Cleveland Clinic, Cleveland, Ohio, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1725,284,48.3974003,9.9934336,"APHP - H√¥pital Piti√©-Salp√™triere, Paris, France",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1726,284,53.3497645,-6.2602732,"Johns Hopkins University, Baltimore, Maryland, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1727,284,45.4667971,9.1904984,"Royal Papworth NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1728,284,45.4667971,9.1904984,"South Health Campus, Calgary, Alberta, Canada",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1729,284,40.8359336,14.2487826,"Macquarie University, Sydenham, New South Wales, Australia",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1730,284,45.3832366,9.1541309,"Calvary Health Care Bethlehem, Caulfield, Victoria, Australia",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1731,284,42.5641417,12.6405466,"Duke Medicine / Neurology, Durham, North Carolina, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1732,284,45.0677551,7.6824892,"University Medical Center G√∂ttingen, G√∂ttingen, Germany",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1733,284,52.0809856,5.12768396945229,"Medizinische Hochschule Hannover, Hannover, Germany",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1734,284,53.407154,-2.991665,"University of W√ºrzburg, W√ºrzburg, Germany",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1735,284,50.3712659,-4.1425658,"Honor Health Research Institute, Scottsdale, Arizona, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1736,284,53.7593363,-2.6992717,"Mayo Clinic, Scottsdale, Arizona, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1737,284,53.4877463,-2.2891921,"California Pacific Medical Center, Sacramento, California, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1738,284,53.3806626,-1.4702278,"University of California - Davis, Sacramento, California, United States",285.0,NCT03800524,Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS,TUDCA-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Tauroursodeoxycholic Acid|Drug: Placebo,Number of responder patients|Survival time|ALS disease functional rating scale - revised version (ALSFRS-R)|ALS Assessment Questionnaire‚Äê40 (ALSAQ-40)|Forced Vital Capacity|EuroQol 5‚ÄêDimension-5 Levels (EQ-5D-5L) scale|Medical Research Council (MRC) scale|Neurofilaments levels|MMP-9 levels,"Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital, Tours|KU Leuven|UMC Utrecht|University of Dublin, Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanit√†|Motor Neurone Disease Association|European Commission",All,Phase 3,440.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",755094,"February 22, 2019","June 30, 2021","June 30, 2021","January 11, 2019",,"July 22, 2019",,https://ClinicalTrials.gov/show/NCT03800524,18.0,80.0
1739,285,44.6471761,-100.348761,"University of California San Francisco, San Francisco, California, United States",286.0,NCT03324399,"A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS,Dietary Supplement: probiotic,Evaluate amino acid levels before and after probiotic use.|Measure changes in questionnaires relating to subjective functional assessments.|Measure changes in Quality of Life.|Evaluate pain levels with the Numbered Pain Scale.,Avera McKennan Hospital & University Health Center,All,Not Applicable,5.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AIHG-2017.004-ALS,"June 1, 2017","June 26, 2019","June 26, 2019","October 27, 2017",,"July 2, 2019",,https://ClinicalTrials.gov/show/NCT03324399,18.0,100.0
1740,286,,,"University of Colorado, Aurora, Colorado, United States",287.0,NCT03755167,A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: IPL344,Adverse Events (AEs) and Serious Adverse Events (SAEs) Reporting|Changes from baseline in ALS disease progression,Immunity Pharma Ltd.,All,Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,101/3,December 2018,November 2022,December 2022,"November 27, 2018",,"November 28, 2018",,https://ClinicalTrials.gov/show/NCT03755167,18.0,75.0
1741,287,44.5990718,-72.5002608,"Hospital for Special Care, New Britain, Connecticut, United States",288.0,NCT00005766,Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Creatinine,,National Center for Research Resources (NCRR),All,Phase 2,,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,NCRR-M01RR00109-0750|M01RR000109,,,,"June 2, 2000",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00005766,18.0,80.0
1742,288,37.1232245,-78.4927721,"GW Medical Faculty Associates Inc., Washington, District of Columbia, United States",289.0,NCT00600873,R(+)PPX High Dose Treatment of ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: R(+) pramipexole dihydrochloride monohydrate,decline in ALSFRS score|plasma PPX levels|CSF PPX levels,"Bennett, James P., Jr., M.D., Ph.D.",All,Phase 1|Phase 2,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),13023,August 2007,September 2008,January 2009,"January 25, 2008",,"September 13, 2010",,https://ClinicalTrials.gov/show/NCT00600873,30.0,80.0
1743,289,38.7604815,-92.5617875,"Mayo Clinic, Jacksonville, Florida, United States",290.0,NCT00005674,Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS],,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Creatine,,National Center for Research Resources (NCRR)|Muscular Dystrophy Association,All,Phase 2,,NIH|Other,Interventional,Primary Purpose: Treatment,NCRR-M01RR00036-0745|M01RR000036,,,,"May 29, 2000",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00005674,18.0,80.0
1744,290,40.2253569,-82.6881395,"University of South Florida Health, Tampa, Florida, United States",291.0,NCT02759913,A Study to Evaluate the Performance of a Diagnostic Test in ALS,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Procedure: Lumbar puncture,Biomarker Measurement of phosphorylated neurofilament heavy chain (pNfH) and complement C3 in CSF|ALS Functional Rating Scale (ALSFRS-R),"Iron Horse Diagnostics, Inc.",All,,300.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,IronHorseDx001,January 2015,August 2016,December 2016,"May 3, 2016",,"May 3, 2016",,https://ClinicalTrials.gov/show/NCT02759913,21.0,80.0
1745,291,48.8566101,2.3514992,"Emory University, Atlanta, Georgia, United States",292.0,NCT03560661,Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS),SPEECH-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Kennedy's Disease,,Number of patients in each patterns of dysarthria|Functional scale with the Norris score|Functional scale with the ALS functional rating scale-R (ALS FRS-R)|Severity of the dysarthria|Clinical examination,"Assistance Publique - H√¥pitaux de Paris|Centre National de la Recherche Scientifique, France",All,,80.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,NI17040J|2017-A03151-52,"July 5, 2018",April 2019,April 2019,"June 18, 2018",,"August 14, 2018",,https://ClinicalTrials.gov/show/NCT03560661,18.0,100.0
1746,292,39.5162234,-76.9382069,"Indiana University Neuroscience Center, Indianapolis, Indiana, United States",293.0,NCT02236897,PET Imaging in ALS Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Other: PET Scanning,Glutamate Receptor Distribution,Johns Hopkins University|ALS Association,All,Not Applicable,36.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NA_00073452,August 2013,March 2017,March 2017,"September 11, 2014",,"March 7, 2017",,https://ClinicalTrials.gov/show/NCT02236897,18.0,80.0
1747,293,52.2034823,0.1235817,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",294.0,NCT03764384,Validation Of Tidal/End -Tidal CO2 in ALS,VOTECO2ALS,Recruiting,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis,,"The primary outcome of interest is the degree of agreement between end tidal CO2 measured by the N-Tidal CTM device and PaCO2 from arterial blood gas analysis.|Identify when an MND patient requires additional support with their breathing, in the form of starting NIV as derived from the CO2 measurement (kPA) and Respiratory Rate (RR) per minute from the N-Tidal CTM device.|Identify when an MND patient develops a treatable respiratory condition, such as an infection as derived from the CO2 measurement (kPA) and Respiratory Rate (RR) per minute from the N-Tidal CTM device..",Papworth Hospital NHS Foundation Trust|Motor Neurone Disease Association|Innovate UK|DOCATEF|Cambridge Respiratory Innovations Limited,All,,200.0,Other|Industry,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,P02366,"August 20, 2018","February 20, 2020","February 20, 2020","December 5, 2018",,"December 5, 2018",,https://ClinicalTrials.gov/show/NCT03764384,18.0,100.0
1748,294,55.001251,-115.002136,"University of Kansas Medical Center, Kansas City, Kansas, United States",295.0,NCT02463825,A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Pimozide 2 mg per day|Drug: Pimozide 4 mg per day|Drug: Placebo (Lactose tablet),ALS Functional Rating Scale-Revised (ALSFRS-R)|Slow Vital Capacity (SVC)|Decremental responses on repetitive nerve stimulation (DRRNS)|Adverse Effects,"University of Calgary|Hotchkiss Brain Institute, University of Calgary",All,Phase 2,25.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",REB14-0617,April 2015,August 2016,December 2021,"June 4, 2015",,"October 26, 2016",,https://ClinicalTrials.gov/show/NCT02463825,18.0,100.0
1749,295,-31.8759835,147.2869493,"Johns Hopkins Hospital, Baltimore, Maryland, United States",296.0,NCT02870634,Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: Cu(II)ATSM,"recommended phase 2 dose as determined by the number of participants at each dose level with dose limiting toxicities|Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)|Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score|Treatment-related change in respiratory function by seated forced vital capacity (FCV)|Treatment-related change in quality of life by ALSSQOL-R score|Treatment-related change in disease severity by transcranial magnetic stimulation (TMS) response|Peak Cu(II)ATSM plasma concentration following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Area under the Cu(II)ATSM plasma concentration versus time curve (AUC) following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Treatment-related change in respiratory function by sniff nasal pressure (SNP) test",Collaborative Medicinal Development Pty Limited,All,Phase 1,50.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMD-2016-001,"November 16, 2016","December 30, 2019","March 30, 2020","August 17, 2016",,"June 25, 2019",,https://ClinicalTrials.gov/show/NCT02870634,18.0,75.0
1750,295,-36.5986096,144.6780052,"Lahey Hospital and Medical Center, Burlington, Massachusetts, United States",296.0,NCT02870634,Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Drug: Cu(II)ATSM,"recommended phase 2 dose as determined by the number of participants at each dose level with dose limiting toxicities|Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)|Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score|Treatment-related change in respiratory function by seated forced vital capacity (FCV)|Treatment-related change in quality of life by ALSSQOL-R score|Treatment-related change in disease severity by transcranial magnetic stimulation (TMS) response|Peak Cu(II)ATSM plasma concentration following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Area under the Cu(II)ATSM plasma concentration versus time curve (AUC) following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Treatment-related change in respiratory function by sniff nasal pressure (SNP) test",Collaborative Medicinal Development Pty Limited,All,Phase 1,50.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMD-2016-001,"November 16, 2016","December 30, 2019","March 30, 2020","August 17, 2016",,"June 25, 2019",,https://ClinicalTrials.gov/show/NCT02870634,18.0,75.0
1751,296,35.6729639,-79.0392919,"University of Minnesota, Minneapolis, Minnesota, United States",297.0,NCT02709330,ALS Reversals - Lunasin Regimen,,Completed,Has Results,ALS (Amyotrophic Lateral Sclerosis),Drug: Lunasin Regimen|Other: Historical control,Change in Revised ALS Functional Rating Scale (ALSFRS-R)|Change in H3 Histone Acetylation|Percent Agreement Between the Weights Obtained by Patients and Study Coordinator|Enrollment Rate|Retention Rate|Frequency of ALS Reversals|ALSFRS-R Accuracy,"Richard Bedlack, M.D., Ph.D.|Duke University",All,Phase 2,60.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00063754,April 2016,"September 13, 2017","September 13, 2017","March 16, 2016","December 13, 2018","December 13, 2018","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02709330/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02709330,18.0,100.0
1752,297,51.5327604,9.9352051,"Saint Louis University, Saint Louis, Missouri, United States",298.0,NCT03792490,Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS,ROCK-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Fasudil|Drug: Placebo,Safety (proportion of patients without treatment-related serious adverse events (SAE) up to day 180) and tolerability (proportion of patients without significant drug intolerance during the treatment period)|Survival time|ALS Functional Rating Scale (ALSFRS-R)|ALS Assessment Questionnaire (ALSAQ-5)|Edinburgh Cognitive and Behavioral ALS Screen (ECAS)|Motor Unit Number Index (MUNIX)|slow Vital capacity (VC)|Safety (proportion of patients without treatment-related serious adverse events (SAE) up to end of treatment (day 26 to 30)) and tolerability (proportion of patients without significant drug intolerance during the treatment period),University Medical Center Goettingen,All,Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01742|2017-003676-31|01GM1704A|01GM1704B|00013948,"February 20, 2019",October 2021,October 2021,"January 3, 2019",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT03792490,18.0,100.0
1753,297,52.3744779,9.7385532,"Hospital for Special Surgery, New York, New York, United States",298.0,NCT03792490,Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS,ROCK-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Fasudil|Drug: Placebo,Safety (proportion of patients without treatment-related serious adverse events (SAE) up to day 180) and tolerability (proportion of patients without significant drug intolerance during the treatment period)|Survival time|ALS Functional Rating Scale (ALSFRS-R)|ALS Assessment Questionnaire (ALSAQ-5)|Edinburgh Cognitive and Behavioral ALS Screen (ECAS)|Motor Unit Number Index (MUNIX)|slow Vital capacity (VC)|Safety (proportion of patients without treatment-related serious adverse events (SAE) up to end of treatment (day 26 to 30)) and tolerability (proportion of patients without significant drug intolerance during the treatment period),University Medical Center Goettingen,All,Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01742|2017-003676-31|01GM1704A|01GM1704B|00013948,"February 20, 2019",October 2021,October 2021,"January 3, 2019",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT03792490,18.0,100.0
1754,297,49.79245,9.932966,"Guilford Neurologic Associates, Greensboro, North Carolina, United States",298.0,NCT03792490,Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS,ROCK-ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Fasudil|Drug: Placebo,Safety (proportion of patients without treatment-related serious adverse events (SAE) up to day 180) and tolerability (proportion of patients without significant drug intolerance during the treatment period)|Survival time|ALS Functional Rating Scale (ALSFRS-R)|ALS Assessment Questionnaire (ALSAQ-5)|Edinburgh Cognitive and Behavioral ALS Screen (ECAS)|Motor Unit Number Index (MUNIX)|slow Vital capacity (VC)|Safety (proportion of patients without treatment-related serious adverse events (SAE) up to end of treatment (day 26 to 30)) and tolerability (proportion of patients without significant drug intolerance during the treatment period),University Medical Center Goettingen,All,Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01742|2017-003676-31|01GM1704A|01GM1704B|00013948,"February 20, 2019",October 2021,October 2021,"January 3, 2019",,"March 14, 2019",,https://ClinicalTrials.gov/show/NCT03792490,18.0,100.0
1755,298,34.395342,-111.7632755,"Wake Forest University, Winston-Salem, North Carolina, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1756,298,34.395342,-111.7632755,"Providence Brain and Spine Institute, Portland, Oregon, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1757,298,36.7014631,-118.7559974,"Oregon Health Sciences University, Portland, Oregon, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1758,298,36.7014631,-118.7559974,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1759,298,36.7014631,-118.7559974,"Temple University, Philadelphia, Pennsylvania, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1760,298,38.7251776,-105.6077167,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1761,298,41.6500201,-72.7342163,"Medical University of South Carolina, Charleston, South Carolina, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1762,298,38.89366125,-76.987883253882,"Austin Neuromuscular Center, Austin, Texas, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1763,298,27.7567667,-81.4639835,"Baylor Scott and White Health, Round Rock, Texas, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1764,298,27.7567667,-81.4639835,"UT Health San Antonio, San Antonio, Texas, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1765,298,32.3293809,-83.1137366,"The University of Utah, Salt Lake City, Utah, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1766,298,40.3270127,-86.1746933,"University of Vermont Medical Center, Burlington, Vermont, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1767,298,41.9216734,-93.3122705,"Virginia Commonwealth University, Richmond, Virginia, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1768,298,38.27312,-98.5821872,"Saint Luke's Rehabilitation Institute, Spokane, Washington, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1769,298,39.5162234,-76.9382069,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1770,298,42.3788774,-72.032366,"Haukeland University Hospital, Bergen, Norway",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1771,298,45.9896587,-94.6113288,"Loma Linda University Dept. of Neurology, Loma Linda, California, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1772,298,38.7604815,-92.5617875,"UCLA School of Medicine Dept. of Neurology, Los Angeles, California, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1773,298,40.7127281,-74.0060152,"University of California, San Francisco, San Francisco, California, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1774,298,35.6729639,-79.0392919,"University of Colorado Health Sciences, Denver, Colorado, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1775,298,35.6729639,-79.0392919,"University of Miami Dept. of Neurology, Miami, Florida, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1776,298,43.9792797,-120.737257,"Northwestern Medical School, Chicago, Illinois, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1777,298,43.9792797,-120.737257,"Johns Hopkins University, Baltimore, Maryland, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1778,298,40.9699889,-77.7278831,"Massachusetts General Hospital, Boston, Massachusetts, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1779,298,40.9699889,-77.7278831,"Columbia-Presbyterian Center Neurological Institute, New York, New York, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1780,298,40.9699889,-77.7278831,"State University of New York, Syracuse, New York, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1781,298,33.6874388,-80.4363743,"Carolinas Medical Center Carolinas Neuromuscular/ALS-MDA Center, Charlotte, North Carolina, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1782,298,31.8160381,-99.5120986,"Wake Forest University, Winston-Salem, North Carolina, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1783,298,31.8160381,-99.5120986,"Cleveland Clinic Foundation, Cleveland, Ohio, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1784,298,31.8160381,-99.5120986,"MCP-Hahnemann University Dept. of Neurology, Philadelphia, Pennsylvania, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1785,298,39.4225192,-111.7143584,"Penn Neurological Institute, Philadelphia, Pennsylvania, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1786,298,44.5990718,-72.5002608,"University of Texas Health Science Center @ San Antonio, San Antonio, Texas, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1787,298,37.1232245,-78.4927721,"University of Wisconsin ALS Clinical Research Center, Madison, Wisconsin, United States",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1788,298,38.8950092,-77.0365625,"Taipei Veterans General Hospital, Taipei, TW, Taiwan",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1789,298,44.4308975,-89.6884637,"Taipei Veterans General Hospital, Taipei, TW, Taiwan",299.0,NCT03196375,A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.,,Terminated,No Results Available,Motor Neuron Disease,Drug: FLX-787-ODT (orally disintegrating tablet)|Drug: Placebo ODT,Cramp frequency,"Flex Pharma, Inc.",All,Phase 2,54.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FLX-787-203,"July 28, 2017","July 27, 2018","July 27, 2018","June 22, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03196375,18.0,100.0
1790,299,60.3943055,5.3259192,"Michigan Medicine, Ann Arbor, Michigan, United States",300.0,NCT03578796,Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Cognitive Impairment,Diagnostic Test: ECAS-N|Diagnostic Test: MoCA|Diagnostic Test: CDR|Other: Questionnaire,Clinical Dementia Rating (CDR)|Ability in car-driving|Working ability|Use of Advanced life-prolonging therapy,Haukeland University Hospital|Western Norway University of Applied Sciences,All,,50.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2016/2187-1,"May 1, 2017","December 31, 2021","December 31, 2021","July 6, 2018",,"August 21, 2019",,https://ClinicalTrials.gov/show/NCT03578796,18.0,100.0
1791,300,36.7014631,-118.7559974,"Haukeland University Hospital, Bergen, Norway",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1792,300,36.7014631,-118.7559974,"University of California, Irvine Medical Center, Irvine, California, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1793,300,36.7014631,-118.7559974,"University of Miami School of Medicine, Miami, Florida, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1794,300,38.7251776,-105.6077167,"University of Kansas Medical Center, Kansas City, Kansas, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1795,300,27.7567667,-81.4639835,"Massachusetts General Hospital, Boston, Massachusetts, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1796,300,40.0796606,-89.4337288,"Hennepin Faculty Associates/Berman Center, Minneapolis, Minnesota, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1797,300,39.5162234,-76.9382069,"SUNY Upstate Medical University, Syracuse, New York, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1798,300,42.3788774,-72.032366,"Duke University, Durham, North Carolina, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1799,300,40.7127281,-74.0060152,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1800,300,40.7127281,-74.0060152,"Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1801,300,35.6729639,-79.0392919,"University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1802,NULL,NULL,NULL,"Service de M√©decine Nucl√©aire et Ultrasons - H√¥pital Bretonneau, Tours, Region Centre, France",,,,,,,,,,,,,,,,,,,,,,,,,,,
1803,300,40.2253569,-82.6881395,"Phoenix Neurological Associates, Phoenix, Arizona, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1804,300,40.9699889,-77.7278831,"UC Irvine, Irvine, California, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1805,300,40.9699889,-77.7278831,"University of Florida, Jacksonville, Florida, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1806,300,31.8160381,-99.5120986,"University of Kansas Medical Center, Kansas City, Kansas, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1807,300,44.4308975,-89.6884637,"University of Kansas School of Medicine - Wichita, Wichita, Kansas, United States",301.0,NCT00021697,Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: AVP-923,,Avanir Pharmaceuticals,All,Phase 3,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,99-AVR-102|AVP-923,January 2001,April 2002,April 2002,"August 3, 2001",,"July 14, 2016",,https://ClinicalTrials.gov/show/NCT00021697,18.0,80.0
1808,301,23.59829785,120.835363138175,"University of Kentucky, Lexington, Kentucky, United States",302.0,NCT03806647,Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 1),,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Amyotrophic Lateral Sclerosis Supportive Care Needs (ALSSCN),"Taipei Veterans General Hospital, Taiwan",All,,20.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2018-09-001A-1,"September 1, 2018","April 1, 2020","September 1, 2020","January 16, 2019",,"January 18, 2019",,https://ClinicalTrials.gov/show/NCT03806647,20.0,100.0
1809,302,23.59829785,120.835363138175,"University of Missouri, Columbia, Missouri, United States",303.0,NCT03806634,Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 2),,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,"System Usability Scale|Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, ALSSQOL-R|Taiwanese Depression Questionnaire, TDQ|Caregiver Burden Scale","Taipei Veterans General Hospital, Taiwan",All,,20.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2018-09-001A-2,"March 1, 2019","July 31, 2020","September 1, 2020","January 16, 2019",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT03806634,20.0,100.0
1810,303,43.6211955,-84.6824346,"Columbia University, New York, New York, United States",304.0,NCT03519880,A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects,,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis,Device: Custom Mask Interface,Average number of hours the custom NIV mask interface is used per night|Leak parameters from device|Tidal volume measurements|Interviews with subjects regarding their experience with the custom mask Qualitative assessment of custom NIV mask efficacy,University of Michigan|ALS Association,All,Not Applicable,40.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,HUM00112433,"March 14, 2017",April 2020,April 2021,"May 9, 2018",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT03519880,18.0,100.0
1811,304,60.3943055,5.3259192,"University of Texas Southwestern, Dallas, Texas, United States",305.0,NCT03579017,Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Validation Study,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Cognitive Impairment,Diagnostic Test: ECAS-N|Diagnostic Test: MoCA,Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen - Norwegian Version (ECAS-N)|Montreal cognitive assessment (MoCA) - Norwegian version|Change from 4 months Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen - Norwegian Version (ECAS-N) at 8 months,Haukeland University Hospital|Western Norway University of Applied Sciences,All,,50.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2016/3166,"May 1, 2017","December 31, 2021","December 31, 2021","July 6, 2018",,"August 21, 2019",,https://ClinicalTrials.gov/show/NCT03579017,35.0,85.0
1812,305,36.7014631,-118.7559974,"Nerve & Muscle Center of Texas, Houston, Texas, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1813,305,27.7567667,-81.4639835,"University of Washington, Seattle, Washington, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1814,NULL,NULL,NULL,"CHU de Bordeaux, Bordeaux, France",,,,,,,,,,,,,,,,,,,,,,,,,,,
1815,305,42.3788774,-72.032366,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1816,305,45.9896587,-94.6113288,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1817,305,40.7127281,-74.0060152,"NIEHS, Research Triangle Park, Research Triangle Park, North Carolina, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1818,305,35.6729639,-79.0392919,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1819,305,40.9699889,-77.7278831,"University Hospital, Tours, France",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1820,305,40.9699889,-77.7278831,"Phoenix Neurological Associates, Phoenix, Arizona, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1821,305,31.8160381,-99.5120986,"University of California, Davis, Davis, California, United States",306.0,NCT00244244,"A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS",,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: arimoclomol,Safety|Pharmacokinetics|ALSFRS-R|Vital Capacity,CytRx,All,Phase 2,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,AALS-001,October 2005,January 2007,January 2007,"October 26, 2005",,"February 9, 2012",,https://ClinicalTrials.gov/show/NCT00244244,18.0,100.0
1822,306,,,"University of California, San Francisco- Fresno, Fresno, California, United States",307.0,NCT03537807,Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS),,No longer available,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: Riluzole,,"Biohaven Pharmaceuticals, Inc.",All,,,Industry,Expanded Access:Treatment IND/Protocol,,BHV0223-401,,,,"May 25, 2018",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT03537807,18.0,100.0
1823,307,40.7112706,-7.7900159,"Loma Linda University School of Medicine (CA), Loma Linda, California, United States",308.0,NCT00563537,Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis|Bulbar Disease|Spinal Disease,Radiation: 18F-X PET SCAN,Quantitative in vivo-imaging of 18F-X microglial binding site as a mesure of disease activity followed up by non invasive quantification of patients using imaging modality.|Evidence of the localisation of benzodiazepine binding site related to microglial activation in ALS|Evidence of the difference of microglial localisation and activation between bulbar and spinal form of amyotrophic lateral sclerosis,"University Hospital, Tours",All,Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHRC05-PC / SLA,January 2007,,December 2010,"November 26, 2007",,"March 19, 2010",,https://ClinicalTrials.gov/show/NCT00563537,40.0,70.0
1824,308,34.395342,-111.7632755,"Cedars-Sinai Medical Center, Los Angeles, California, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1825,308,36.7014631,-118.7559974,"University of California, Los Angeles, Los Angeles, California, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1826,308,27.7567667,-81.4639835,"University of California, Irvine - MDA ALS Neuromuscular Center, Orange, California, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1827,308,38.27312,-98.5821872,"California Pacific Medical Center, San Francisco, California, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1828,308,38.27312,-98.5821872,"University of California, San Francisco, San Francisco, California, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1829,308,37.5726028,-85.1551411,"University of Colorado Health Sciences Center, Aurora, Colorado, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1830,308,38.7604815,-92.5617875,"Hospital for Special Care, New Britain, Connecticut, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1831,308,40.7127281,-74.0060152,"George Washington University, Washington, District of Columbia, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1832,308,31.8160381,-99.5120986,"Mayo Clinic Jacksonville, Jacksonville, Florida, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1833,308,31.8160381,-99.5120986,"University of Miami School of Medicine, Miami, Florida, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1834,308,38.8950092,-77.0365625,"ALS Center at Emory University, Atlanta, Georgia, United States",309.0,NCT02118727,Therapy in Amyotrophic Lateral Sclerosis (TAME),TAME,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontal Temporal Dementia,Drug: Memantine|Drug: Placebo (for Memantine),"Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R)|Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in blood",University of Kansas Medical Center,All,Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAME-ALS FD003937-01|FDA,"November 7, 2018",October 2022,October 2022,"April 21, 2014",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02118727,18.0,85.0
1835,309,,,"Medical College of Georgia, Augusta, Georgia, United States",310.0,NCT03659422,Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis,,Withdrawn,No Results Available,Diet Modification|Amyotrophic Lateral Sclerosis,Other: Modified Paleolithic diet,Change in total body weight from baseline over 12 weeks.|Change in Body Mass Index from baseline over 12 weeks.|change in fat mass (in kilograms) from baseline over 12 weeks|change in fat-free mass (in kilograms) from baseline over 12 weeks|change in motor function over 12 weeks|change in breathing function over 12 weeks|Change in fatigue level,Terry L. Wahls|Muscular Dystrophy Association|University of Iowa,All,Not Applicable,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201802746,"July 1, 2019","July 1, 2021","July 1, 2021","September 6, 2018",,"June 14, 2019",,https://ClinicalTrials.gov/show/NCT03659422,18.0,80.0
1836,310,,,"Northwestern University Medical School, Chicago, Illinois, United States",311.0,NCT03618966,Neuromuscular Magnetic Stimulation in ALS Patients,NMS-ALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: Neuromuscular magnetic stimulation (NMMS),Change from baseline to Week 2 in the muscle strength measured by Medical Research Council Muscle Scale (MRC).|Change from baseline to Week 2 in the muscle strength measured by handgrip dynamometry|Change from baseline to Week 2 in the Compound Muscle Action Potential (CMAP) amplitude from flexor carpi radialis|Change from baseline to Week 2 in the amplitude of the ACh-evoked currents (IACh) for nicotinic acetylcholine receptors|Change from baseline to Week 2 on levels of insulin-like growth factor-1 (IGF-1) and Myostatin|Change from baseline to Week 2 on the diameter size of muscle fibers|Change from baseline to Week 2 on levels of Muscle Atrophy F-box (MAFbx)/Atrogin-1 and Muscle Ring-Finger Protein 1 (MuRF-1),University of Roma La Sapienza,All,Phase 2,22.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2174,"November 1, 2014","May 1, 2016","November 1, 2017","August 7, 2018",,"August 7, 2018",,https://ClinicalTrials.gov/show/NCT03618966,18.0,100.0
1837,311,44.841225,-0.5800364,"Indiana University (Regenstrief Health Center), Indianapolis, Indiana, United States",312.0,NCT01992029,Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis,MIRSLA,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|ALS,Other: Clinical evaluation|Procedure: Muscular biopsy|Procedure: Lumbar puncture|Procedure: Blood sampling|Other: Neurological assessments|Procedure: Neuro-muscular biopsy and lumbar puncture|Procedure: Blood sample|Device: Cervical spinal cord and brain MRI,miRNA expression|miRNA evolution|miRNA expression pattern in different ALS patients compared to control patients predictive of the clinical phenotype and of the progression of the disease.|Difference in diffusivity parameters of MRI,"University Hospital, Bordeaux",All,,5.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHUBX 2012/13,"June 17, 2014",October 2015,"October 22, 2015","November 25, 2013",,"November 5, 2018",,https://ClinicalTrials.gov/show/NCT01992029,45.0,70.0
1838,312,42.3788774,-72.032366,"University of Kansas Medical Center, Kansas City, Kansas, United States",313.0,NCT03334786,Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Fasciculation,Drug: FLX-787-ODT,Change from Baseline of Diastolic Blood Pressure in mmHg|Change from Baseline of Systolic Blood Pressure in mmHg|Change from Baseline in Heart Rate in beats per minute|Change from Baseline in Respiration Rate in breaths per minute|Change from Baseline in Body Temperature in degrees Celsius or Fahrenheit|Change from Baseline of Oral Cavity Examination|Incidence of Treatment-Emergent Adverse Events|Change from Baseline of Fasciculation Frequency|Change from Baseline in Peak Tongue Strength in kPa by Iowa Oral Performance Instrument|Change from Baseline in Speech Assessments|Change from Baseline in Swallowing Assessments,"Flex Pharma, Inc.",All,Phase 1|Phase 2,3.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FLX-787-107,"April 5, 2018","August 23, 2018","August 23, 2018","November 7, 2017",,"August 29, 2018",,https://ClinicalTrials.gov/show/NCT03334786,18.0,100.0
1839,313,35.6729639,-79.0392919,"University of Kentucky Medical Center, Lexington, Kentucky, United States",314.0,NCT03338114,Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS,,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis|Fasciculation,Drug: FLX-787-ODT (orally disintigrating tablet),Change from Baseline of Diastolic Blood Pressure in mmHg|Change from Baseline of Systolic Blood Pressure in mmHg|Change from Baseline in Heart Rate in beats per minute|Change from Baseline in Respiration Rate in breaths per minute|Change from Baseline in Body Temperature in degrees Celsius or Fahrenheit|Change from Baseline of Oral Cavity Examination|Incidence of Treatment-Emergent Adverse Events|Change from Baseline of Fasciculation Frequency,"Flex Pharma, Inc.",All,Phase 1|Phase 2,0.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FLX-787-106,November 2017,August 2018,August 2018,"November 9, 2017",,"January 23, 2018",,https://ClinicalTrials.gov/show/NCT03338114,18.0,100.0
1840,314,35.6729639,-79.0392919,"Massachusetts General Hospital, Boston, Massachusetts, United States",315.0,NCT00339976,Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS,,,National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC),All,,0.0,NIH,Observational,,999902275|02-E-N275,"August 6, 2002",,"April 21, 2008","June 21, 2006",,"July 2, 2017",,https://ClinicalTrials.gov/show/NCT00339976,18.0,100.0
1841,315,39.5162234,-76.9382069,"Lahey Clinic, Burlington, Massachusetts, United States",316.0,NCT01143428,Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study,,Completed,No Results Available,Motor Neuron Disease|Primary Lateral Sclerosis,,Decline in ALSFRS score,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,10.0,NIH,Observational,Time Perspective: Other,100121|10-N-0121,"May 13, 2010",,"August 3, 2015","June 14, 2010",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT01143428,20.0,100.0
1842,316,47.3900474,0.6889268,"Henry Ford Health System, Detroit, Michigan, United States",317.0,NCT02405403,Microglial Activation Role In ALS (MARIA),MARIA,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Drug: [18F]DPA-714 PET,Concentration of cytokines in cerebrospinal fluid (pg/mL)|Fixation and distribution of [18F]DPA-714 (Binding Potential BP),"University Hospital, Tours",All,Early Phase 1,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHAO-13-PC/MARIA,March 2015,September 2016,March 2017,"April 1, 2015",,"May 31, 2017",,https://ClinicalTrials.gov/show/NCT02405403,18.0,100.0
1843,317,34.395342,-111.7632755,"Saint Mary's Healthcare, Grand Rapids, Michigan, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1844,317,36.7014631,-118.7559974,"Hennepin County Medical Center (Berman Center), Minneapolis, Minnesota, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1845,317,36.7014631,-118.7559974,"St. Louis University, St. Louis, Missouri, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1846,317,36.7014631,-118.7559974,"Washington University, St. Louis, Missouri, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1847,317,36.7014631,-118.7559974,"Bryan LGH Medical Center (University of Nebraska), Lincoln, Nebraska, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1848,317,36.7014631,-118.7559974,"UMDNJ- Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1849,317,36.7014631,-118.7559974,"Albany Medical Center, Albany, New York, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1850,317,36.7014631,-118.7559974,"Beth Israel Medical Center (NY), New York, New York, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1851,317,36.7014631,-118.7559974,"Cornell Medical Center, New York, New York, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1852,317,38.7251776,-105.6077167,"Columbia University, New York, New York, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1853,317,41.6500201,-72.7342163,"SUNY Upstate Medical University, Syracuse, New York, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1854,317,38.89366125,-76.987883253882,"Carolinas Medical Center, Charlotte, North Carolina, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1855,317,27.7567667,-81.4639835,"Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1856,317,27.7567667,-81.4639835,"The Cleveland Clinic Foundation, Cleveland, Ohio, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1857,317,32.3293809,-83.1137366,"Ohio State University, Columbus, Ohio, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1858,317,32.3293809,-83.1137366,"Oregon Clinic (Providence Clinic), Portland, Oregon, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1859,317,40.0796606,-89.4337288,"Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1860,317,40.3270127,-86.1746933,"Drexel University College of Medicine (Hahnemann Campus), Philadelphia, Pennsylvania, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1861,317,38.27312,-98.5821872,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1862,317,37.5726028,-85.1551411,"Allegheny Hospital, Pittsburgh, Pennsylvania, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1863,317,42.3788774,-72.032366,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1864,317,42.3788774,-72.032366,"Medical University of South Carolina, Charleston, South Carolina, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1865,317,43.6211955,-84.6824346,"Vanderbilt University, Nashville, Tennessee, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1866,317,43.6211955,-84.6824346,"Texas Neurology, Dallas, Texas, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1867,317,45.9896587,-94.6113288,"Methodist Neurological Institute, Houston, Texas, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1868,317,38.7604815,-92.5617875,"University of Utah Health Sciences Center, Salt Lake City, Utah, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1869,317,38.7604815,-92.5617875,"University of Virginia, Charlottesville, Virginia, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1870,317,41.7370229,-99.5873816,"University of Calgary, Calgary, Alberta, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1871,317,40.0757384,-74.4041622,"Univeristy of Alberta ALS Clinic, Edmonton, Alberta, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1872,317,40.7127281,-74.0060152,"Dalhousie University, Halifax, Nova Scotia, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1873,317,40.7127281,-74.0060152,"London Health Sciences Center, University Campus, London, Ontario, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1874,317,40.7127281,-74.0060152,"University of Toronto, Toronto, Ontario, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1875,317,40.7127281,-74.0060152,"CHUM (Centre Hospitalier de l'Universit√© de Montr√©al), Notre-Dame Hospital, Montreal, Quebec, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1876,317,40.7127281,-74.0060152,"Montreal Neurological Institute (McGill University), Montreal, Quebec, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1877,317,35.6729639,-79.0392919,"Laval University, Quebec City, Quebec, Canada",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1878,317,35.6729639,-79.0392919,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1879,317,40.2253569,-82.6881395,"UZ Leuven, Leuven, Belgium",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1880,317,40.2253569,-82.6881395,"University of Minnesota, Minneapolis, Minnesota, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1881,317,43.9792797,-120.737257,"Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1882,NULL,NULL,NULL,"Center of Functionally Integrative Neuroscience, Aarhus, Denmark",,,,,,,,,,,,,,,,,,,,,,,,,,,
1883,317,40.9699889,-77.7278831,"Phil Smith Neuroscience Institute at Holy Cross Hospital, Fort Lauderdale, Florida, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1884,317,40.9699889,-77.7278831,"University of Florida, Gainesville, Florida, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1885,317,40.9699889,-77.7278831,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1886,317,40.9699889,-77.7278831,"Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City, Taiwan",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1887,317,33.6874388,-80.4363743,"Massachusetts General Hospital, Boston, Massachusetts, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1888,317,35.7730076,-86.2820081,"Columbia Medical Center NY, New York, New York, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1889,317,31.8160381,-99.5120986,"Phoenix Neurological Associates, Phoenix, Arizona, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1890,317,31.8160381,-99.5120986,"Neuromuscular Research Center and Neuromuscular Clinic of Arizona, Phoenix, Arizona, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1891,317,39.4225192,-111.7143584,"University of California San Diego, La Jolla, California, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1892,317,37.1232245,-78.4927721,"Cedars-Sinai Medical Center, Los Angeles, California, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1893,317,55.001251,-115.002136,"University of California Irvine, Orange, California, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1894,317,55.001251,-115.002136,"California Pacific Medical Center, San Francisco, California, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1895,317,45.1960403,-63.1653789,"Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1896,317,50.000678,-86.000977,"Hospital for Special Care, New Britain, Connecticut, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1897,317,50.000678,-86.000977,"Georgetown University, Washington, District of Columbia, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1898,317,52.4760892,-71.8258668,"The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion, Washington, District of Columbia, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1899,317,52.4760892,-71.8258668,"Providence Holy Cross Medical Center, Fort Lauderdale, Florida, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1900,317,52.4760892,-71.8258668,"University of Florida, Gainesville, Florida, United States",318.0,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 3,513.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014",,https://ClinicalTrials.gov/show/NCT00349622,18.0,100.0
1901,318,39.5162234,-76.9382069,"University of Florida Health - Jacksonville, Jacksonville, Florida, United States",319.0,NCT00386464,Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: noninvasive positive pressure ventilation,Decline in forced vital capacity|quality of life|respiratory quality of life,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)",All,Phase 2|Phase 3,60.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HL 67887-03,April 2002,,September 2007,"October 11, 2006",,"November 9, 2007",,https://ClinicalTrials.gov/show/NCT00386464,18.0,100.0
1902,319,50.879202,4.7011675,"Mayo Clinic - Jacksonville, Jacksonville, Florida, United States",320.0,NCT01889043,Monitoring of Non-invasive Ventilation During Sleep in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in transcutaneous carbon dioxide and respiratory events|Change in patient-ventilator asynchronies|Impact of NIV on sympatho-vagal balance|changes in quality of life by patient reported outcomes,Universitaire Ziekenhuizen Leuven,All,,40.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,S53536,January 2012,September 2015,,"June 28, 2013",,"December 14, 2015",,https://ClinicalTrials.gov/show/NCT01889043,18.0,100.0
1903,320,45.9896587,-94.6113288,"University of South Florida, Tampa, Florida, United States",321.0,NCT02567136,Imaging Biomarkers in ALS,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis,,Imaging biomarkers,University of Minnesota - Clinical and Translational Science Institute,All,,30.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,130126,September 2015,September 2025,September 2025,"October 2, 2015",,"May 8, 2019",,https://ClinicalTrials.gov/show/NCT02567136,21.0,75.0
1904,321,41.6500201,-72.7342163,"Emory University School of Medicine, Atlanta, Georgia, United States",322.0,NCT03876002,Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET,,Completed,No Results Available,Healthy Volunteers|Amyotrophic Lateral Sclerosis,Drug: [18F]PBR06,Time-activity data,Molecular NeuroImaging,All,Phase 1,23.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,[18F]PBR06,"June 28, 2016","February 7, 2018","February 7, 2018","March 15, 2019",,"March 26, 2019",,https://ClinicalTrials.gov/show/NCT03876002,18.0,80.0
1905,322,,,"Augusta University, Augusta, Georgia, United States",323.0,NCT04051333,The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2),EAT MORE2,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Device: ALS Nutrition App (MyDataHelps platform),Patient Reported Outcome Measurement Information System Short Form v1.0|ALS Functional Rating Scale-Revised,Massachusetts General Hospital|ALS Association,All,,200.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2019P001649,August 2019,September 2021,December 2021,"August 9, 2019",,"August 9, 2019",,https://ClinicalTrials.gov/show/NCT04051333,18.0,100.0
1906,323,,,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",324.0,NCT03948178,Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension,REFALS-ES,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan,Adverse Events Recording|Pulse/heart rate Assessment|12-lead electrocardiogram Assessments|Disease progression|Slow Vital Capacity (SVC)|Revised ALS Functional Rating Scale (ALSFRS-R)|Need for Respiratory Support Device|Borg Category Ratio 10 Scale (CR 10)|Health care and home care resource use|Subject's status for tracheostomy and survival,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3119003,June 2019,July 2022,July 2022,"May 13, 2019",,"May 13, 2019",,https://ClinicalTrials.gov/show/NCT03948178,18.0,120.0
1907,324,56.1496278,10.2134046,"University of Chicago, Chicago, Illinois, United States",325.0,NCT03900247,Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface,REMAP,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis,Device: REMAP EEG based BCI and SEM-Glove BioServo,Action Research Armtest part b Grip|Grip strength|Bringing glass of water to the mouth,"University of Aarhus|University of Aalborg, Denmark|The Danish National Rehabilitation Center for Neuromuscular Diseases|Bioservo Technologies AB, Sweden|Department of Neurology, Aarhus University Hospital, Denmark",All,Not Applicable,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,6153-00010A,"March 18, 2019","December 31, 2021","December 31, 2022","April 2, 2019",,"April 2, 2019",,https://ClinicalTrials.gov/show/NCT03900247,18.0,90.0
1908,325,27.7567667,-81.4639835,"University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States",326.0,NCT03883581,Impact of Nuedexta on Bulbar Physiology and Function in ALS,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: dextromethorphan HBr and quinidine sulfate,Change in Dynamic Imaging Grade of Swallowing Toxicity|Change in Airway Physiologic Defense Capacity|Change in Speech Intelligibility|Change in maximum isometric lingual strength|Change in Patient-reported outcome: Center for Neurologic Study-Bulbar Function Scale (CNS-BFS),"University of Florida|Holy Cross Hospital, Florida|ALS Association",All,Phase 1|Phase 2,40.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB201802938|OCR20392,August 2019,"December 1, 2020","February 28, 2021","March 21, 2019",,"June 13, 2019",,https://ClinicalTrials.gov/show/NCT03883581,18.0,90.0
1909,325,27.7567667,-81.4639835,"Kentucky Neuroscience Research, Louisville, Kentucky, United States",326.0,NCT03883581,Impact of Nuedexta on Bulbar Physiology and Function in ALS,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: dextromethorphan HBr and quinidine sulfate,Change in Dynamic Imaging Grade of Swallowing Toxicity|Change in Airway Physiologic Defense Capacity|Change in Speech Intelligibility|Change in maximum isometric lingual strength|Change in Patient-reported outcome: Center for Neurologic Study-Bulbar Function Scale (CNS-BFS),"University of Florida|Holy Cross Hospital, Florida|ALS Association",All,Phase 1|Phase 2,40.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB201802938|OCR20392,August 2019,"December 1, 2020","February 28, 2021","March 21, 2019",,"June 13, 2019",,https://ClinicalTrials.gov/show/NCT03883581,18.0,90.0
1910,326,39.5162234,-76.9382069,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",327.0,NCT03225144,Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia,,Recruiting,No Results Available,Frontotemporal Lobar Degeneration|Amytrophic Lateral Sclerosis|Progressive Supranuclear Palsy,,eligibility for research protocols,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,200.0,NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,170131|17-N-0131,"October 11, 2017","October 30, 2025","October 30, 2025","July 21, 2017",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT03225144,18.0,100.0
1911,327,23.99486475,121.604243358312,"Massachusetts General Hospital, Boston, Massachusetts, United States",328.0,NCT03651349,To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers,,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: HK-001|Drug: Placebo control,Maximum Tolerated Dose (MTD)|Dose Limiting Toxicities (DLT),"Everfront Biotech Co., Ltd.",All,Phase 1,56.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",EFBORAZ20141120,January 2020,December 2021,December 2022,"August 29, 2018",,"May 10, 2019",,https://ClinicalTrials.gov/show/NCT03651349,20.0,100.0
1912,328,42.3788774,-72.032366,"University of Michigan, Ann Arbor, Michigan, United States",329.0,NCT01854294,GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS),GALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: GM604|Drug: Placebo comparator,"Efficacy by percent change in biomarker in th CSF at week 12 from baseline|Safety by measuring 1. adverse event frequency and severity, changes in vital signs, clinical laboratory values. 2. Serious adverse event frequency|Tolerability by measuring the ability to complete the first 2 weeks of active treatment in the study|ALSFRS-R (Amyotrophic Laeral Sclerosis Functional Rating Scale - Revised)|Forced Vital Capacity (FVC)|Time Up and Go (TUG)|muscle strength|Biomarker in blood|Mortality rate","Genervon Biopharmaceuticals, LLC|Columbia University|Massachusetts General Hospital",All,Phase 2,12.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GALS 001,August 2013,April 2014,July 2014,"May 15, 2013",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT01854294,18.0,100.0
1913,328,40.7127281,-74.0060152,"Mayo Clinic - Rochester, Rochester, Minnesota, United States",329.0,NCT01854294,GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS),GALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: GM604|Drug: Placebo comparator,"Efficacy by percent change in biomarker in th CSF at week 12 from baseline|Safety by measuring 1. adverse event frequency and severity, changes in vital signs, clinical laboratory values. 2. Serious adverse event frequency|Tolerability by measuring the ability to complete the first 2 weeks of active treatment in the study|ALSFRS-R (Amyotrophic Laeral Sclerosis Functional Rating Scale - Revised)|Forced Vital Capacity (FVC)|Time Up and Go (TUG)|muscle strength|Biomarker in blood|Mortality rate","Genervon Biopharmaceuticals, LLC|Columbia University|Massachusetts General Hospital",All,Phase 2,12.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GALS 001,August 2013,April 2014,July 2014,"May 15, 2013",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT01854294,18.0,100.0
1914,329,34.395342,-111.7632755,"HealthPartners Specialty Center, Saint Paul, Minnesota, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1915,329,34.395342,-111.7632755,"Washington University School of Medicine, Saint Louis, Missouri, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1916,329,36.7014631,-118.7559974,"Neurology Associates, Lincoln, Nebraska, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1917,329,36.7014631,-118.7559974,"Mount Sinai Beth Israel, New York, New York, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1918,329,36.7014631,-118.7559974,"Hospital for Special Surgery, New York, New York, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1919,329,36.7014631,-118.7559974,"Columbia Presbyterian Hospital, New York, New York, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1920,329,38.7251776,-105.6077167,"Neurosciences Institute - Neurology Charlotte, Charlotte, North Carolina, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1921,329,41.6500201,-72.7342163,"Duke University Medical Center, Durham, North Carolina, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1922,329,38.89366125,-76.987883253882,"Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1923,329,38.89366125,-76.987883253882,"The Ohio State University, Columbus, Ohio, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1924,329,27.7567667,-81.4639835,"Oregon Health and Science University, Portland, Oregon, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1925,329,27.7567667,-81.4639835,"Providence Brain and Spine Institute, Portland, Oregon, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1926,329,27.7567667,-81.4639835,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1927,329,27.7567667,-81.4639835,"Temple University School of Medicine, Philadelphia, Pennsylvania, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1928,329,27.7567667,-81.4639835,"Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1929,329,32.3293809,-83.1137366,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1930,329,32.3293809,-83.1137366,"Texas Neurology, Dallas, Texas, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1931,329,40.0796606,-89.4337288,"Nerve and Muscle Center of Texas, Houston, Texas, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1932,329,40.0796606,-89.4337288,"University of Utah - Imaging & Neurosciences Center, Salt Lake City, Utah, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1933,329,37.5726028,-85.1551411,"University of Vermont Medical Center, Burlington, Vermont, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1934,329,37.5726028,-85.1551411,"Swedish Neuroscience Institute, Seattle, Washington, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1935,329,39.5162234,-76.9382069,"University of Washington Medical Center, Seattle, Washington, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1936,329,42.3788774,-72.032366,"Froedtert Hospital, Milwaukee, Wisconsin, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1937,329,43.6211955,-84.6824346,"Brain and Mind Centre, Camperdown, New South Wales, Australia",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1938,329,45.9896587,-94.6113288,"Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1939,329,45.9896587,-94.6113288,"Flinders Medical Centre, Bedford Park, South Australia, Australia",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1940,329,38.7604815,-92.5617875,"Calvary Health Care Bethlehem, Caulfield South, Victoria, Australia",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1941,329,41.7370229,-99.5873816,"Perron Institute for Neurological and Translational Science, Murdoch, Western Australia, Australia",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1942,329,40.7127281,-74.0060152,"Universit√§t Innsbruck, Innsbruck, Tyrol, Austria",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1943,329,40.7127281,-74.0060152,"Salzkammergut-Klinikum V√∂cklabruck, V√∂cklabruck, Upper Austria, Austria",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1944,329,40.7127281,-74.0060152,"Medizinische Universit√§t Wien, Wien, Austria",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1945,329,35.6729639,-79.0392919,"Universitaire Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1946,329,35.6729639,-79.0392919,"Centre Hospitalier R√©gional de la Citadelle, Li√®ge, Liege, Belgium",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1947,329,35.6729639,-79.0392919,"Algemeen Ziekenhuis St. Lucas Gent, Gent, Oost-Vlaanderen, Belgium",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1948,329,40.2253569,-82.6881395,"Alberta Health Services - Neuromuscular Clinic, Calgary, Alberta, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1949,329,43.9792797,-120.737257,"University of Alberta, Edmonton, Alberta, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1950,329,43.9792797,-120.737257,"Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1951,329,40.9699889,-77.7278831,"Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1952,329,40.9699889,-77.7278831,"McMaster University Medical Centre, Hamilton, Ontario, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1953,329,40.9699889,-77.7278831,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1954,329,40.9699889,-77.7278831,"Centre De Recherche Du Centre Hospitalier de l'Universite de Montreal - Hopital Notre-Dame, Montr√©al, Quebec, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1955,329,31.8160381,-99.5120986,"Montreal Neurological Institute and Hospital, Montr√©al, Quebec, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1956,329,31.8160381,-99.5120986,"Centre Hospitalier Affilie Universitaire de Quebec, Qu√©bec, Quebec, Canada",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1957,329,39.4225192,-111.7143584,"Neurologian Poliklinikka - Meilahden Tornisairaala 3, Helsinki, Finland",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1958,329,44.5990718,-72.5002608,"Etel√§-Karjalan keskussairaala, Lappeenranta, Finland",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1959,329,38.8950092,-77.0365625,"Turku University Hospital, Turku, Finland",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1960,329,38.8950092,-77.0365625,"Centre Hospitalier Universitaire de Limoges, Limoges, France",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1961,329,44.4308975,-89.6884637,"H√¥pital Gui de Chauliac, Montpellier, France",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1962,329,-31.8759835,147.2869493,"H√¥pital Pasteur, Nice, France",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1963,329,-21.9182856,144.4588889,"Centre Hospitalier R√©gional et Universitaire de Tours H√¥pital Bretonneau, Tours, France",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1964,329,-30.5343665,135.6301212,"Universit√§tsklinikum Ulm, Ulm, Baden-W√ºrttemberg, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1965,329,-36.5986096,144.6780052,"Deutsche Klinik f√ºr Diagnostik, Wiesbaden, Hessen, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1966,329,-25.2303005,121.0187246,"Universit√§tsmedizin Rostock, Rostock, Mecklenburg-western-pommerania, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1967,329,47.223193,11.5261028,"Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1968,329,48.25,14.0,"Alfried Krupp Krankenhaus R√ºttenscheid, Essen, Nordrhein-westfalen, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1969,329,48.2083537,16.3725042,"Universit√§tsklinikum M√ºnster, M√ºnster, Nordrhein-Westfalen, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1970,329,50.8686516,4.7886108308049,"Universit√§tsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1971,329,50.6451381,5.5734203,"Universit√§tsklinikum Jena, Jena, Thuringen, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1972,329,51.0375423,3.81178301133246,"Charit√© Universit√§tsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1973,329,55.001251,-115.002136,"Beaumont Hospital - Ireland, Dublin, Ireland",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1974,329,55.001251,-115.002136,"Azienda Ospedaliera Universitaria San Martino, Genova, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1975,329,46.500283,-66.750183,"Azienda Ospedaliera Universitaria-Maggiore della Carit√† di Novara, Novara, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1976,329,46.500283,-66.750183,"ICS Maugeri Spa SB, Pavia, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1977,329,50.000678,-86.000977,"Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara, Pisa, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1978,329,50.000678,-86.000977,"Policlinico Umberto I di Roma, Roma, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1979,329,52.4760892,-71.8258668,"Azienda Ospedaliera - Universitaria Citt√† della Salute e della Scienza di Torino, Torino, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1980,329,52.4760892,-71.8258668,"Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1981,329,52.4760892,-71.8258668,"Universitair Medisch Centrum Utrecht - Rudolf Magnus Instituut voor Neurowetenschappen, Utrecht, Netherlands",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1982,329,60.1674086,24.9425683,"Hospital de Basurto, Bilbao, Vizcaya, Spain",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1983,329,61.0582424,28.1875302,"Hospital Universitari de Bellvitge, Barcelona, Spain",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1984,329,60.4517531,22.2670522,"Hospital Universitario Reina Sofia, C√≥rdoba, Spain",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1985,329,45.8354243,1.2644847,"Hospital San Rafael - Madrid, Madrid, Spain",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1986,329,43.6112422,3.8767337,"Hospital Universitario y Polit√©cnico de La Fe, Valencia, Spain",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1987,329,43.7009358,7.2683912,"Norrlands Universitetssjukhus, Ume√•, Vasterbotten, Sweden",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1988,329,47.3900474,0.6889268,"Centralsjukhuset Karlstad, Karlstad, Sweden",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1989,329,48.6296972,9.1949534,"Karolinska Universitetssjukhuset, Stockholm, Sweden",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1990,329,50.6118537,9.1909725,"Barts Health NHS Trust, London, England, United Kingdom",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1991,329,51.0834196,10.4234469,"King's College Hospital NHS Foundation Trust, London, England, United Kingdom",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1992,329,52.8398531,9.075962,"The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1993,329,51.4785568,7.5533645,"James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1994,329,51.4785568,7.5533645,"Medical University of Warsaw, Warsaw, Poland",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1995,329,50.9295798,13.4585052,"Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1996,329,50.7333163,11.0747905,"University of Florida, Gainesville, Florida, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1997,329,52.5170365,13.3888599,"University of Minnesota, Minneapolis, Minnesota, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1998,329,53.3497645,-6.2602732,"University of Kansas Medical Center, Kansas City, Kansas, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
1999,329,44.40726,8.9338624,"James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2000,329,45.4464036,8.619655,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2001,329,45.1860043,9.1546375,"University of Michigan, Ann Arbor, Michigan, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2002,329,43.7159395,10.4018624,"Indiana University, IU Health Physicians Neurology, Indianapolis, Indiana, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2003,329,41.894802,12.4853384,"Barrow Neurological Institute, Phoenix, Arizona, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2004,329,45.0677551,7.6824892,"University of Florida, Gainesville, Florida, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2005,329,52.7212825,4.820665,"University of Florida College of Medicine, Jacksonville, Florida, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2006,329,52.0809856,5.12768396945229,"University of South Florida, Tampa, Florida, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2007,329,43.238482,-2.85163163999482,"Neurology Department, University Hospital, Limoges, Limoges, France",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2008,329,41.3828939,2.1774322,"Neurology Department, University Hospitla, Tours, Tours, France",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2009,329,37.8845813,-4.7760138,"Texas Neurology, P.A., Dallas, Texas, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2010,NULL,NULL,NULL,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2011,329,39.4699014,-0.3759513,"Royan Institute, Tehran, Iran, Islamic Republic of",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2012,329,64.2825306,20.4961141000083,"Cedars-Sinai Medical Center, Los Angeles, California, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2013,329,59.3809146,13.5027631,"Massachusetts General Hospital, Boston, Massachusetts, United States",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2014,329,59.3251172,18.0710935,"Azienda Opsedaliera Universitaria Consorziale Policlinico- Universit√† degli studi di Bari, Bari, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2015,329,52.7954791,-0.540240286617432,"Spedali civili di Brescia, Brescia, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2016,329,52.7954791,-0.540240286617432,"ASST Valle Olona Presidio ospedaliero Gallarate, Gallarate, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2017,329,53.407154,-2.991665,"IRCCS Azienda Ospedaliera Universitaria San Martino IST, Genova, Italy",330.0,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine slow vital capacity SVC|Combined assessment of Revised ALS Functional Rating Scale ALSFRS-R function and survival through 48 weeks|Time to respiratory event through 48 weeks|Clinical Global Impression CGI at 48 weeks|Change from baseline in respiratory function of ALSFRS-R at 48 weeks,"Orion Corporation, Orion Pharma",All,Phase 3,450.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","August 30, 2020","October 30, 2020","April 20, 2018",,"May 14, 2019",,https://ClinicalTrials.gov/show/NCT03505021,18.0,120.0
2018,330,40.7127281,-74.0060152,"Ospedale San Raffaele, Miano, Italy",331.0,NCT03411863,Cervical Electrical Stimulation for ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Device: CES at rest|Device: CES plus active hand or wrist movements,Electromyographic responses (rest)|Electromyographic responses (active),VA Office of Research and Development,All,Not Applicable,50.0,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B2527-P,"January 4, 2018","December 31, 2019","May 29, 2020","January 26, 2018",,"July 11, 2019",,https://ClinicalTrials.gov/show/NCT03411863,21.0,65.0
2019,331,52.2337172,21.0714111288323,"Centro Clinico NEMO - Fondazione Serena Onlus, Milano, Italy",332.0,NCT03296501,Intraspinal Transplantation of Autologous ADRC in ALS Patients,ADIPOSTEM,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients,Functional progression rate|Electrophisiological progression rate,Mossakowski Medical Research Centre Polish Academy of Sciences|Medical University of Warsaw,All,Phase 1,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DPO/014/33/09/2015,"October 13, 2015","October 31, 2018","October 31, 2019","September 28, 2017",,"October 5, 2017",,https://ClinicalTrials.gov/show/NCT03296501,18.0,65.0
2020,332,52.9534161,-1.1492773,"Presidio Ospedaliero Provinciale - Nuovo Ospedale Civile ""S. Agostino Estense"", Modena, Italy",333.0,NCT03237741,Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Reference capsule GDC-0134|Drug: Prototype capsule GDC-0134|Drug: rabeprazole,Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of GDC-0134|Area Under the Plasma Concentration-Time Curve up to Time Tau (AUC0-t) of GDC-0134|Maximum Observed Concentration (Cmax) of GDC-0134|Time to Maximum Concentration (Tmax) of GDC-0134|Apparent Half-Life (t1/2) of GDC-0134|Percentage of Participants with Adverse Events,"Genentech, Inc.|Quotient Clinical",Female,Phase 1,24.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GP39778|2017-000299-27,"August 7, 2017","December 14, 2017","December 14, 2017","August 2, 2017",,"April 18, 2018",,https://ClinicalTrials.gov/show/NCT03237741,30.0,65.0
2021,333,27.7567667,-81.4639835,"Azienda Ospedaliera Universitaria della Seconda Univ. Degli Studi di Napoli (AOU-SUN), Napoli, Italy",334.0,NCT03202017,Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Expiratory Muscle Strength Training (EMST)|Procedure: EMST + Lung Volume Recruitment (LVR),Peak Cough Flow|Maximal Expiratory Pressure|Forced Vital Capacity|Eating Assessment Tool - 10 (EAT-10)|Swallowing Related Quality of Life (SWAL-QOL)|Speech Intelligibility Test (SIT),University of Minnesota - Clinical and Translational Science Institute,All,Not Applicable,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,NEUR-2017-25778,"March 1, 2018",December 2020,December 2021,"June 28, 2017",,"May 8, 2019",,https://ClinicalTrials.gov/show/NCT03202017,18.0,100.0
2022,333,45.9896587,-94.6113288,"Azienda Ospedaliero Universitaria Maggiore della Carit√†, Novara, Italy",334.0,NCT03202017,Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Expiratory Muscle Strength Training (EMST)|Procedure: EMST + Lung Volume Recruitment (LVR),Peak Cough Flow|Maximal Expiratory Pressure|Forced Vital Capacity|Eating Assessment Tool - 10 (EAT-10)|Swallowing Related Quality of Life (SWAL-QOL)|Speech Intelligibility Test (SIT),University of Minnesota - Clinical and Translational Science Institute,All,Not Applicable,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,NEUR-2017-25778,"March 1, 2018",December 2020,December 2021,"June 28, 2017",,"May 8, 2019",,https://ClinicalTrials.gov/show/NCT03202017,18.0,100.0
2023,334,38.27312,-98.5821872,"Azienda Ospedaliera di Padova-Universit√† degli studi di Padova, Padova, Italy",335.0,NCT03201991,ALS Study Determining Various Biomarkers and Strength Comparison After Exercise,ADVANCE,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Other: Resistance Exercise Program,Change in functional muscle strength,University of Kansas Medical Center,All,Not Applicable,7.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00003843,"May 1, 2017","May 1, 2018","May 1, 2018","June 28, 2017",,"June 28, 2017",,https://ClinicalTrials.gov/show/NCT03201991,18.0,100.0
2024,335,27.7567667,-81.4639835,"Azienda Ospedaliera Universitaria Policlinico ""P Giaccone"", Palermo, Italy",336.0,NCT02675075,DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Lung Force Vital Capacity|Change in Speech - as measured by Speech Divergence|Change in Tongue Strength,VA Office of Research and Development|Institute for Human and Machine Cognition,All,,15.0,U.S. Fed|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,N1902-P|I21RX001902,"January 1, 2016","December 31, 2017","December 31, 2017","February 5, 2016",,"April 6, 2018",,https://ClinicalTrials.gov/show/NCT02675075,18.0,100.0
2025,336,40.9699889,-77.7278831,"Istituto Neurologico Nazionale ""C. Mondino"", Pavia, Italy",337.0,NCT03095989,An Online Mindfulness Intervention for People With ALS and Their Caregivers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Behavioral: Mindfulness,Quality of Life|Depression and anxiety|The patient's perception of physical impairment|Physician-assessed physical impairment|Vital capacity (VC)|Cognitive and behavioral function|Caregiver burden (caregivers only),Harvard University|ALS Association|Milton S. Hershey Medical Center|Catholic University of the Sacred Heart,All,Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,IRB14-3695,January 2015,February 2019,February 2019,"March 30, 2017",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT03095989,18.0,100.0
2026,337,43.6211955,-84.6824346,"Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy",338.0,NCT03090932,Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Blood draw,Total number of classical NK (natural killer) cells; total number of CD3+ CD4+ CD8+ cells|Cytokine expression,University of Michigan|University of South Florida,All,,60.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,HUM00107546,"January 18, 2016","December 31, 2019","July 1, 2020","March 27, 2017",,"December 31, 2018",,https://ClinicalTrials.gov/show/NCT03090932,18.0,80.0
2027,338,40.3270127,-86.1746933,"POLICLINICO UMBERTO I - Universit√† di Roma ""La Sapienza"", Roma, Italy",339.0,NCT03049046,CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS,CC100B,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Drug: CC100|Drug: Placebos,"Safety and Tolerability: Adverse events, safety labs, vital signs, and ECGs|Pharmacokinetics (PK)--Peak plasma concentration (Cmax)|Pharmacokinetics (PK)--Area under the plasma concentration versus time curve (AUC)|Pharmacokinetics (PK)--Half life (T 1/2)|Pharmacodynamics (PD)--Monocyte chemotactic protein 1 (MCP-1)|Pharmacodynamics (PD)--Excitotoxicity/oxidative stress biomarkers","Chemigen, LLC",All,Phase 1,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CC100B|1R01FD004790-01A2,"April 7, 2017","January 30, 2018","March 30, 2018","February 9, 2017",,"August 3, 2017",,https://ClinicalTrials.gov/show/NCT03049046,18.0,64.0
2028,339,34.395342,-111.7632755,"IRCCS Casa sollievo della Sofferenza, San Giovanni Rotondo, Italy",340.0,NCT03016897,ALS Testing Through Home-based Outcome Measures,ALS AT HOME,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,"Other: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter",Change in Pulmonary Function|Change in Quantitative Hand Grip|Change in Electrical Impedance Myography (EIM) Measurements|Change in Actigraphy|ALSFRS-R|Change in Patient-reported Experience measures (PREMs)|Adverse Events|Change in Voice/Speech Tracking,Jeremy Shefner|Beth Israel Deaconess Medical Center|Barrow Neurological Institute,All,,144.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,BNI_ALS_001,"February 22, 2017","June 28, 2019",September 2019,"January 11, 2017",,"July 1, 2019",,https://ClinicalTrials.gov/show/NCT03016897,18.0,85.0
2029,340,27.7567667,-81.4639835,"Azienda Ospedaliera Universitaria Senese (AOUS), Siena, Italy",341.0,NCT02962050,Delineating Swallowing Impairment and Decline in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Videofluoroscopic Swallowing Study (VFSS)|Procedure: High Resolution Manometry|Other: DIGEST|Other: Penetration Aspiration Scale|Other: Normalized Residue Ratio Scale|Device: Voluntary Peak Cough Flow Testing|Device: Iowa Oral Performance Instrument|Drug: Capsaicin Challenge|Device: Pulmonary Function Testing|Other: Eating Assessment Tool 10|Other: The Center for Neurologic Study Bulbar Function Scale,Change in Maximum Swallowing Pressure with High Resolution Manometry (HRM)|Change in Rate of Pressure with High Resolution Manometry (HRM)|Change in Mean Pressure with High Resolution Manometry (HRM)|Swallowing Safety (with DIGEST)|Swallowing Efficiency (with DIGEST)|Swallowing Efficiency (with NRRS)|Swallowing Safety (with PAS)|Change in Forced Vital Capacity with Pulmonary Function Testing (with hand-held digital manometer)|Voluntary Peak Cough Flow Testing (with Electronic Peak Cough Flow Meter Device)|Change in Lingual Strength with Lingual Function Testing (with IOPI)|Change in Lingual Physiologic Reserve with Lingual Function Testing (IOPI)|Change in Lingual Swallowing Pressure with Lingual Function Testing (IOPI)|Change in Reflexive Cough Testing (with Urge-to-Cough)|Change in Maximum Expiratory Pressure with Pulmonary Function Testing (with hand-held digital manometer)|Change in Maximum Inspiratory Pressure with Pulmonary Function Testing (with hand-held digital manometer)|Eating Assessment Tool 10|Center for Neurologic Study Bulbar Function Scale|The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R),University of Florida|National Institutes of Health (NIH),All,,110.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB201602098-N|NS100859,"May 31, 2017","June 30, 2022","June 30, 2024","November 11, 2016",,"November 19, 2018",,https://ClinicalTrials.gov/show/NCT02962050,18.0,90.0
2030,340,27.7567667,-81.4639835,"Azienda Ospedaliera ""Santa Maria"" di Terni, Terni, Italy",341.0,NCT02962050,Delineating Swallowing Impairment and Decline in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Videofluoroscopic Swallowing Study (VFSS)|Procedure: High Resolution Manometry|Other: DIGEST|Other: Penetration Aspiration Scale|Other: Normalized Residue Ratio Scale|Device: Voluntary Peak Cough Flow Testing|Device: Iowa Oral Performance Instrument|Drug: Capsaicin Challenge|Device: Pulmonary Function Testing|Other: Eating Assessment Tool 10|Other: The Center for Neurologic Study Bulbar Function Scale,Change in Maximum Swallowing Pressure with High Resolution Manometry (HRM)|Change in Rate of Pressure with High Resolution Manometry (HRM)|Change in Mean Pressure with High Resolution Manometry (HRM)|Swallowing Safety (with DIGEST)|Swallowing Efficiency (with DIGEST)|Swallowing Efficiency (with NRRS)|Swallowing Safety (with PAS)|Change in Forced Vital Capacity with Pulmonary Function Testing (with hand-held digital manometer)|Voluntary Peak Cough Flow Testing (with Electronic Peak Cough Flow Meter Device)|Change in Lingual Strength with Lingual Function Testing (with IOPI)|Change in Lingual Physiologic Reserve with Lingual Function Testing (IOPI)|Change in Lingual Swallowing Pressure with Lingual Function Testing (IOPI)|Change in Reflexive Cough Testing (with Urge-to-Cough)|Change in Maximum Expiratory Pressure with Pulmonary Function Testing (with hand-held digital manometer)|Change in Maximum Inspiratory Pressure with Pulmonary Function Testing (with hand-held digital manometer)|Eating Assessment Tool 10|Center for Neurologic Study Bulbar Function Scale|The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R),University of Florida|National Institutes of Health (NIH),All,,110.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB201602098-N|NS100859,"May 31, 2017","June 30, 2022","June 30, 2024","November 11, 2016",,"November 19, 2018",,https://ClinicalTrials.gov/show/NCT02962050,18.0,90.0
2031,340,27.7567667,-81.4639835,"Azienda Ospedaliero-Universitaria Citt√† della Salute e della Scienza di Torino., Torino, Italy",341.0,NCT02962050,Delineating Swallowing Impairment and Decline in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Videofluoroscopic Swallowing Study (VFSS)|Procedure: High Resolution Manometry|Other: DIGEST|Other: Penetration Aspiration Scale|Other: Normalized Residue Ratio Scale|Device: Voluntary Peak Cough Flow Testing|Device: Iowa Oral Performance Instrument|Drug: Capsaicin Challenge|Device: Pulmonary Function Testing|Other: Eating Assessment Tool 10|Other: The Center for Neurologic Study Bulbar Function Scale,Change in Maximum Swallowing Pressure with High Resolution Manometry (HRM)|Change in Rate of Pressure with High Resolution Manometry (HRM)|Change in Mean Pressure with High Resolution Manometry (HRM)|Swallowing Safety (with DIGEST)|Swallowing Efficiency (with DIGEST)|Swallowing Efficiency (with NRRS)|Swallowing Safety (with PAS)|Change in Forced Vital Capacity with Pulmonary Function Testing (with hand-held digital manometer)|Voluntary Peak Cough Flow Testing (with Electronic Peak Cough Flow Meter Device)|Change in Lingual Strength with Lingual Function Testing (with IOPI)|Change in Lingual Physiologic Reserve with Lingual Function Testing (IOPI)|Change in Lingual Swallowing Pressure with Lingual Function Testing (IOPI)|Change in Reflexive Cough Testing (with Urge-to-Cough)|Change in Maximum Expiratory Pressure with Pulmonary Function Testing (with hand-held digital manometer)|Change in Maximum Inspiratory Pressure with Pulmonary Function Testing (with hand-held digital manometer)|Eating Assessment Tool 10|Center for Neurologic Study Bulbar Function Scale|The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R),University of Florida|National Institutes of Health (NIH),All,,110.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB201602098-N|NS100859,"May 31, 2017","June 30, 2022","June 30, 2024","November 11, 2016",,"November 19, 2018",,https://ClinicalTrials.gov/show/NCT02962050,18.0,90.0
2032,341,45.8354243,1.2644847,"Azienda Ospedaliera ""Card. G. Panico"", Tricase, Italy",342.0,NCT03984708,New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.,METABOCALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Samples|Other: Indirect calorimetry|Other: Electrical bioimpedance,Metabolic signature of fibroblast : concentrations of molecules detected by mass spectrometry|Metabolic signature of blood : concentrations of molecules detected by mass spectrometry|Expression levels of targeted molecules using transcriptomics,"University Hospital, Tours",All,Not Applicable,90.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,DR180135|2019-A00649-48,July 2019,November 2021,November 2021,"June 13, 2019",,"June 13, 2019",,https://ClinicalTrials.gov/show/NCT03984708,18.0,75.0
2033,341,47.3900474,0.6889268,"Groupe Hospitalier Pitie Salpetriere, Paris, France",342.0,NCT03984708,New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.,METABOCALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Other: Samples|Other: Indirect calorimetry|Other: Electrical bioimpedance,Metabolic signature of fibroblast : concentrations of molecules detected by mass spectrometry|Metabolic signature of blood : concentrations of molecules detected by mass spectrometry|Expression levels of targeted molecules using transcriptomics,"University Hospital, Tours",All,Not Applicable,90.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,DR180135|2019-A00649-48,July 2019,November 2021,November 2021,"June 13, 2019",,"June 13, 2019",,https://ClinicalTrials.gov/show/NCT03984708,18.0,75.0
2034,342,31.8160381,-99.5120986,"University of Michigan Hospital, Ann Arbor, Michigan, United States",343.0,NCT03457753,Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis,,Withdrawn,No Results Available,ALS,Drug: Riluzole Oral Soluble Film,Change from baseline in NCI-CTC score at week 12,Aquestive Therapeutics|Inventiv Health|Covance,All,Phase 2,0.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,17MO1R-0016,"March 1, 2018","March 27, 2018","March 27, 2018","March 8, 2018",,"May 13, 2019",,https://ClinicalTrials.gov/show/NCT03457753,18.0,80.0
2035,343,,,"Cedars-Sinai Medical Center, Los Angeles, California, United States",344.0,NCT02645461,Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS,AchALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: endocannabinoid palmitoylethanolamide (PEA)|Drug: Riluzole,Changes from baseline in pulmonary capacity of ALS patients at 6 months.|Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.|Changes from baseline in muscle strength of ALS patients at 6 months.|Changes from baseline in electrophysiological parameters of ALS patients at 6 months,University of Roma La Sapienza,All,Not Applicable,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",3314,January 2014,June 2015,December 2015,"January 1, 2016",,"January 5, 2016",,https://ClinicalTrials.gov/show/NCT02645461,18.0,100.0
2036,344,40.9699889,-77.7278831,"University of Kentucky, Lexington, Kentucky, United States",345.0,NCT00714220,Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS),,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Diseases,,Indirect Calorimetry,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,107.0,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,Internal-16684,November 2006,September 2014,September 2014,"July 14, 2008",,"October 29, 2015",,https://ClinicalTrials.gov/show/NCT00714220,20.0,85.0
2037,345,36.2619477,59.6051728,"Massachusetts General Hospital, Boston, Massachusetts, United States",346.0,NCT02492516,Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: mesenchymal stem cells,fever|Unconsciousness|The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)|FVC,Royan Institute,All,Phase 1,19.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-008,September 2014,March 2017,April 2017,"July 8, 2015",,"April 28, 2017",,https://ClinicalTrials.gov/show/NCT02492516,18.0,55.0
2038,346,36.7014631,-118.7559974,"Washington University, St. Louis, Missouri, United States",347.0,NCT02374606,Accurate Test of Limb Isometric Strength (ATLIS) in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit|Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit,Cedars-Sinai Medical Center,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00038868,March 2015,February 2020,February 2020,"March 2, 2015",,"April 3, 2018",,https://ClinicalTrials.gov/show/NCT02374606,18.0,100.0
2039,347,42.3788774,-72.032366,"Hershey Medical Center, Hershey, Pennsylvania, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2040,347,41.1257843,16.8620293,"H√¥pital Piti√©-Salp√©tri√®re, D√©partement des Maladies du Syst√®me Nerveux 47-83 Boulevard de l'H√¥pital, Paris, France",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2041,347,45.5398022,10.2200214,"Royan Institute, Tehran, Iran, Islamic Republic of",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2042,347,45.6598951,8.7932013,"Royan Institute, Tehran, Iran, Islamic Republic of",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2043,347,44.40726,8.9338624,"Royan Institute, Tehran, Iran, Islamic Republic of",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2044,347,44.4935471,10.1022228,"Research Site, Overland Park, Kansas, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2045,347,45.4667971,9.1904984,"Research Site, Overland Park, Kansas, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2046,347,44.6458885,10.9255707,"Research Site, Overland Park, Kansas, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2047,347,40.8359336,14.2487826,"Research Site, London, United Kingdom",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2048,347,45.4464036,8.619655,"King's College Hospital NHS Foundation Trust, London, United Kingdom",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2049,347,45.4077172,11.8734455,"Phoenix Neurological Associates, Phoenix, Arizona, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2050,347,38.1112268,13.3524434,"University of Michigan, Ann Arbor, Michigan, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2051,347,45.1860043,9.1546375,"Dartmouth Hichcock Medical Center, Lebanon, New Hampshire, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2052,347,43.7159395,10.4018624,"University of Kentucky Medical Center, Lexington, Kentucky, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2053,347,41.894802,12.4853384,"Hadassah Medical Organization - Ein Kerem Campus, Jerusalem, Israel",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2054,347,41.7050554,15.7306463,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2055,347,43.3185536,11.3316533,"Michele Vitacca, Lumezzane, BS, Italy",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2056,347,42.5641417,12.6405466,"Sanofi-Aventis, Laval, Quebec, Canada",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2057,347,45.0677551,7.6824892,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2058,347,39.93042,18.355332,"Pilar Rojas Lozano, Madrid, Spain",348.0,NCT03456882,The Effect of RNS60 on ALS Biomarkers,RNS60,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: RNS60,Pharmacodynamic biomarkers|ALSFRS-R scale|Survival|Forced Vital Capacity (FVC)|Incidence of adverse event (Tolerability) related to RNS60|Quality of life,Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS,All,Phase 2,142.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Other,RNS60,"November 18, 2016","April 30, 2019","April 30, 2019","March 7, 2018",,"June 8, 2018",,https://ClinicalTrials.gov/show/NCT03456882,18.0,70.0
2059,348,48.8566101,2.3514992,"NIEHS, Research Triangle Park, Research Triangle Park, North Carolina, United States",349.0,NCT02313402,A New Eye-based Communication Device for ALS Patients,ELY-SLA,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Device: EOL (Eye On Line),recognition by an outside observer of the digits 0-9 produced by the patient with the device|adverse events,"Assistance Publique - H√¥pitaux de Paris|National Research Agency, France",All,Not Applicable,12.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),P131101,June 2014,April 2015,April 2015,"December 10, 2014",,"November 26, 2015",,https://ClinicalTrials.gov/show/NCT02313402,18.0,65.0
2060,349,43.6211955,-84.6824346,"Columbia University, New York, New York, United States",350.0,NCT01995903,Developing a Discrimination Model to Diagnose ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Diagnostic Test: MRI(magnetic resonance imaging),Developing a Discrimination Model to Diagnose ALS,University of Michigan,All,Not Applicable,50.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HUM00061126,April 2012,October 2015,October 2015,"November 27, 2013",,"June 4, 2018",,https://ClinicalTrials.gov/show/NCT01995903,18.0,80.0
2061,350,36.7014631,-118.7559974,"Clermont-Ferrand University Hospital, Clermont-Ferrand, Auvergne, France",351.0,NCT01911130,Longitudinal Study of Outcomes Measures in ALS Trials,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit|Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit|Change in Slow Vital Capacity (SVC) between each visit,Massachusetts General Hospital|ALS Association,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P000702,July 2013,June 2015,March 2016,"July 30, 2013",,"March 23, 2017",,https://ClinicalTrials.gov/show/NCT01911130,18.0,90.0
2062,350,37.5726028,-85.1551411,"University of Calgary / Heritage Medical Research Clinic, Calgary, Alberta, Canada",351.0,NCT01911130,Longitudinal Study of Outcomes Measures in ALS Trials,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit|Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit|Change in Slow Vital Capacity (SVC) between each visit,Massachusetts General Hospital|ALS Association,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P000702,July 2013,June 2015,March 2016,"July 30, 2013",,"March 23, 2017",,https://ClinicalTrials.gov/show/NCT01911130,18.0,90.0
2063,350,42.3788774,-72.032366,"University of Alberta, Edmonton, Alberta, Canada",351.0,NCT01911130,Longitudinal Study of Outcomes Measures in ALS Trials,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit|Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit|Change in Slow Vital Capacity (SVC) between each visit,Massachusetts General Hospital|ALS Association,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P000702,July 2013,June 2015,March 2016,"July 30, 2013",,"March 23, 2017",,https://ClinicalTrials.gov/show/NCT01911130,18.0,90.0
2064,350,38.7604815,-92.5617875,"University of British Columbia / GF Strong Rehab Centre, Vancouver, British Columbia, Canada",351.0,NCT01911130,Longitudinal Study of Outcomes Measures in ALS Trials,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit|Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit|Change in Slow Vital Capacity (SVC) between each visit,Massachusetts General Hospital|ALS Association,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P000702,July 2013,June 2015,March 2016,"July 30, 2013",,"March 23, 2017",,https://ClinicalTrials.gov/show/NCT01911130,18.0,90.0
2065,350,40.9699889,-77.7278831,"Western University / London Health Sciences Centre, London, Ontario, Canada",351.0,NCT01911130,Longitudinal Study of Outcomes Measures in ALS Trials,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Change in Accurate Test of Limb Isometric Strength (ATLIS) between each visit|Change in ALS Functional Rating Scale - Revised (ALSFRS-R) between each visit|Change in Slow Vital Capacity (SVC) between each visit,Massachusetts General Hospital|ALS Association,All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P000702,July 2013,June 2015,March 2016,"July 30, 2013",,"March 23, 2017",,https://ClinicalTrials.gov/show/NCT01911130,18.0,90.0
2066,351,48.8566101,2.3514992,"University of Toronto / Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",352.0,NCT01874808,From Movement Preparation to Gait Execution in ALS,GAITALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,,Neurophysiological evaluation (braking index)|Evaluation in neuroimaging,"Institut National de la Sant√© Et de la Recherche M√©dicale, France|Universit√© Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement",All,,70.0,Other,Observational,,GAITALS-C12-13|2012-A01247-36,June 2013,May 2015,May 2016,"June 11, 2013",,"August 9, 2013",,https://ClinicalTrials.gov/show/NCT01874808,18.0,75.0
2067,352,36.2619477,59.6051728,"McGill University / Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",353.0,NCT01771640,Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: intrathecal injection,Fever|Unconscious|Vomiting|ALS-FRS|FVC,Royan Institute,All,Phase 1,8.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-006,August 2013,October 2014,December 2014,"January 18, 2013",,"March 7, 2018",,https://ClinicalTrials.gov/show/NCT01771640,18.0,65.0
2068,353,36.2619477,59.6051728,"St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center, Phoenix, Arizona, United States",354.0,NCT01759797,Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: intra venous injection of stem cell,Fever|Unconsciousness|vomiting|ALS-FRS|FVC|EMG-NCV,Royan Institute,All,Phase 1,6.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-005,January 2013,January 2014,March 2014,"January 3, 2013",,"July 6, 2016",,https://ClinicalTrials.gov/show/NCT01759797,18.0,65.0
2069,354,36.2619477,59.6051728,"HonorHealth Neurology, Phoenix, Arizona, United States",355.0,NCT01759784,Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS,,Withdrawn,No Results Available,Amyotrophic Lateral Sclerosis,Biological: Intraventricular injection,fever|unconsciousness|brain hematoma|vomiting|ALS-FRS|EMG-NCV,Royan Institute,All,Phase 1,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Royan-Nerve-004,March 2014,March 2017,,"January 3, 2013",,"January 1, 2016",,https://ClinicalTrials.gov/show/NCT01759784,18.0,70.0
2070,355,38.27312,-98.5821872,"UC Irvine Health ALS and Neuromuscular Center, Orange, California, United States",356.0,NCT01536249,Dexpramipexole and Cimetidine Drug Drug Interaction (DDI),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Cimetidine plus Dexpramipexole,"Determination of the effect of cimetidine on the PK of dexpramipexole parameters including: AUC: Area under the plasma-concentration time curve over a specified time period; Cmax: Maximum observed plasma concentration and CLr: renal clearance|PK parameters of dexpramipexole including, but not limited to, half-life when given with or without cimetidine",Knopp Biosciences,All,Phase 1,14.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,223HV104,March 2012,April 2012,April 2012,"February 22, 2012",,"November 25, 2014",,https://ClinicalTrials.gov/show/NCT01536249,18.0,55.0
2071,356,38.27312,-98.5821872,"University of Miami, Miami, Florida, United States",357.0,NCT01511029,Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Dexpramipexole Placebo|Drug: Moxifloxacin,To evaluate whether a single dose of dexpramipexole prolongs the QTC interval as measured by frequent ECG measurements (using Holter monitoring) of individually corrected QT intervals (QTcI)|Area Under Curve (AUC) of dexpramipexole|Change in ECG measurements|Cmax of dexpramipexole|Tmax of dexpramipexole,Knopp Biosciences,All,Phase 1,68.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",223HV102,January 2012,May 2012,May 2012,"January 18, 2012",,"November 25, 2014",,https://ClinicalTrials.gov/show/NCT01511029,18.0,60.0
2072,357,38.27312,-98.5821872,"University of Kansas Medical Center (KUMC) - Landon Center on Aging, Kansas City, Kansas, United States",358.0,NCT01449578,Dexpramipexole SAD/MAD Study,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Dexpramipexole Placebo,"Safety and tolerability based on medical review of adverse events & results of vital sign measurements, electrocardiogram (ECGs), physical examinations and clinical laboratory tests.|Dexpramipexole pharmacokinetics time frame in plasma",Knopp Biosciences,All,Phase 1,63.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",223HV103,November 2011,January 2012,January 2012,"October 10, 2011",,"November 25, 2014",,https://ClinicalTrials.gov/show/NCT01449578,18.0,55.0
2073,358,51.5073219,-0.1276474,"Hospital for Special Surgery, New York, New York, United States",359.0,NCT01424163,Dexpramipexole Japanese PK Study,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Single dose reduced|Drug: Single dose standard|Drug: Multiple Dose,Cmax of dexpramipexole|AUC of dexpramipexole|Changes in clinical laboratory tests|ECG changes|Vital Sign changes|Adverse Event monitoring,Knopp Biosciences|Biogen,All,Phase 1,56.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,223HV101,August 2011,February 2012,February 2012,"August 26, 2011",,"November 25, 2014",,https://ClinicalTrials.gov/show/NCT01424163,18.0,60.0
2074,359,51.5073219,-0.1276474,"Providence Brain & Spine Institute, Portland, Oregon, United States",360.0,NCT03809845,Serial Fasciculation Measurements in Motor Neurone Disease,,Completed,No Results Available,Motor Neuron Disease|Benign Fasciculation-Cramp Syndrome,Device: High-density surface electromyography,Change in fasciculation frequency over time|Change in fasciculation morphology over time|Change in Functional Rating Scale (FRS) over time|Change in motor unit number index measurements over time|Change in MRC power sum score over time|Change in slow vital capacity over time,King's College Hospital NHS Trust,All,Not Applicable,25.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,KCH17-105,"July 6, 2017","March 1, 2019","March 1, 2019","January 18, 2019",,"August 21, 2019",,https://ClinicalTrials.gov/show/NCT03809845,18.0,80.0
2075,360,34.395342,-111.7632755,"University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center, Philadelphia, Pennsylvania, United States",361.0,NCT01259050,Safety Study of High Doses of Zinc in ALS Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Zinc and Copper,To evaluate the safety of high doses of zinc in patients with ALS|Measure levels of BMAA in blood and urine to determine if there is a decline in these levels over the course of treatment,"Phoenix Neurological Associates, LTD",All,Phase 1|Phase 2,10.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Zinc-ALS,October 2010,January 2012,March 2012,"December 13, 2010",,"March 12, 2012",,https://ClinicalTrials.gov/show/NCT01259050,18.0,85.0
2076,361,43.6211955,-84.6824346,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",362.0,NCT01123200,An In-home Study of Brain Computer Interfaces,,Completed,Has Results,Amyotrophic Lateral Sclerosis,Device: Brain Computer Interface for Wheelchair Tilt Control,Duration of BCI Usage by Persons With ALS.|Changes in Accuracy of BCI for Controlling Devices and Text,University of Michigan,All,Not Applicable,1.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,J0002,January 2010,May 2011,May 2011,"May 14, 2010","March 15, 2017","March 15, 2017",,https://ClinicalTrials.gov/show/NCT01123200,18.0,100.0
2077,362,43.4849133,-71.6553992,"University of Virginia Health System, Charlottesville, Virginia, United States",363.0,NCT00140452,Phase II Study Using Thalidomide for the Treatment of ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS,Drug: Thalidomide,To evaluate the effect of Thalidomide in the rate of progression in ALS at 9 months and hence determine preliminary efficacy in the treatment of ALS|To evaluate 1) toxicity 2) quality of life 3) cytokine profile 4) PFT's 5) sleep questionnaire and 6) survival of thalidomide in the treatment of ALS,Dartmouth-Hitchcock Medical Center|Celgene Corporation,All,Phase 2,24.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALS-001,February 2005,,November 2007,"September 1, 2005",,"November 21, 2007",,https://ClinicalTrials.gov/show/NCT00140452,18.0,80.0
2078,363,37.5726028,-85.1551411,"Catholic University Leuven, Leuven, Belgium",364.0,NCT03707795,Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study,TRANSLATE,Recruiting,No Results Available,Familial Amyotrophic Lateral Sclerosis,"Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone¬Æ Soluspan¬Æ), 30 mg IM once a day for four days",Betamethasone plasma levels|Protein carbonyl plasma levels|Superoxide dismutase plasma levels|Peroxide plasma levels|Glutathione disulfide plasma levels|Glutathione plasma levels,University of Kentucky,All,Early Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17-0159-F6A,"August 21, 2017",November 2019,June 2020,"October 16, 2018",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT03707795,20.0,80.0
2079,364,31.778345,35.2250786,"London Health Sciences Centre, London, Ontario, Canada",365.0,NCT00801333,Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,,Hadassah Medical Organization,All,,25.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,0511-08-HMO,November 2008,December 2025,December 2025,"December 3, 2008",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT00801333,18.0,100.0
2080,365,39.5162234,-76.9382069,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",366.0,NCT00023075,"Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis",,Completed,No Results Available,Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Amyotrophic Lateral Sclerosis,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,55.0,NIH,Observational,,010241|01-N-0241,August 2001,,August 2003,"August 23, 2001",,"March 4, 2008",,https://ClinicalTrials.gov/show/NCT00023075,18.0,100.0
2081,366,45.77958045,10.4258729694612,"Montreal Neurological Institute and Hospital, Montr√©al, Quebec, Canada",367.0,NCT00613899,Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: telesurveillance,To test a possible alternative of care for ALS patients (home vs hospital)|To check patients and caregivers' acceptance,Fondazione Salvatore Maugeri,All,Phase 4,40.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N¬∞83_researchbookFSM2006,October 2007,March 2008,October 2008,"February 13, 2008",,"February 4, 2016",,https://ClinicalTrials.gov/show/NCT00613899,18.0,80.0
2082,367,52.4760892,-71.8258668,"Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac, Montpellier, France",368.0,NCT00542412,CARE Canadian ALS Riluzole Evaluation,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Riluzole,"The primary efficacy endpoint was the time to the occurrence of an ALS-related event (PAV, tracheostomy or ALS-related death)",Sanofi,All,Phase 4,414.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RIL_CA1_401,January 2001,,December 2004,"October 11, 2007",,"October 11, 2007",,https://ClinicalTrials.gov/show/NCT00542412,18.0,75.0
2083,368,40.9699889,-77.7278831,"Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422, Paris, France",369.0,NCT00716131,Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,None Specified,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,205.0,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,Internal-16827,April 2007,November 2016,November 2016,"July 16, 2008",,"January 6, 2017",,https://ClinicalTrials.gov/show/NCT00716131,18.0,100.0
2084,369,40.4167047,-3.7035825,"Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen, Berlin, Germany",370.0,NCT03285204,Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,early biomarker of amyotrophic lateral sclerosis and Friedreich's Ataxia,Jose Luis Urcelay Segura|Hospital General Universitario Gregorio Mara√±on,All,,90.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,ELA-AF-OCT-2014-01,July 2015,January 2020,February 2020,"September 15, 2017",,"February 26, 2019",,https://ClinicalTrials.gov/show/NCT03285204,18.0,100.0
2085,370,35.6729639,-79.0392919,"Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie, Hannover, Germany",371.0,NCT00377351,Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,,National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC),All,,21.0,NIH,Observational,,999906247|06-E-N247,"September 11, 2006",,"August 3, 2010","September 18, 2006",,"July 2, 2017",,https://ClinicalTrials.gov/show/NCT00377351,50.0,80.0
2086,371,40.7127281,-74.0060152,"Universitaetsklinikum Ulm - Klinik fuer Neurologie, Ulm, Germany",372.0,NCT03865420,Amyotrophic Lateral Sclerosis (ALS) Families Project,,Recruiting,No Results Available,ALS,,Time to emergence of symptoms attributable to gene mutations,Columbia University,All,,60.0,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,AAAR7275,"September 11, 2018",September 2021,September 2022,"March 6, 2019",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT03865420,18.0,105.0
2087,372,45.71001315,3.15318029649755,"Instituti Clinica Scientifici Maugeri, Milano, Italy",373.0,NCT00331812,Mitochondrial Functions and Oxidative Stress in ALS Patients,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Procedure: Mitochondrial functions and oxidative stress,relationship between these abnormalities and the metabolic status (hypermetabolism or normometabolism).,"University Hospital, Clermont-Ferrand|University Hospital, Limoges|Institut National de la Recherche Agronomique",All,,40.0,Other,Observational,Time Perspective: Prospective,CHU63-0007,February 2006,,February 2008,"May 31, 2006",,"January 19, 2011",,https://ClinicalTrials.gov/show/NCT00331812,30.0,100.0
2088,373,55.001251,-115.002136,"Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino, Torino, Italy",374.0,NCT02405182,MRI Biomarkers in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS|Motor Neuron Diseases,Other: Magnetic Resonance Imaging,Change in neuronal and white matter integrity measures.|Correlation of neuronal and white matter integrity measures with clinical indices.,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto",All,,145.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0013831,September 2014,March 2019,"April 1, 2019","April 1, 2015",,"May 6, 2019",,https://ClinicalTrials.gov/show/NCT02405182,40.0,100.0
2089,373,55.001251,-115.002136,"University Medical Center Utrecht, Utrecht, Netherlands",374.0,NCT02405182,MRI Biomarkers in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS|Motor Neuron Diseases,Other: Magnetic Resonance Imaging,Change in neuronal and white matter integrity measures.|Correlation of neuronal and white matter integrity measures with clinical indices.,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto",All,,145.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0013831,September 2014,March 2019,"April 1, 2019","April 1, 2015",,"May 6, 2019",,https://ClinicalTrials.gov/show/NCT02405182,40.0,100.0
2090,373,55.001251,-125.002441,"Centrum Medyczne NeuroProtect, Warsaw, Poland",374.0,NCT02405182,MRI Biomarkers in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS|Motor Neuron Diseases,Other: Magnetic Resonance Imaging,Change in neuronal and white matter integrity measures.|Correlation of neuronal and white matter integrity measures with clinical indices.,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto",All,,145.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0013831,September 2014,March 2019,"April 1, 2019","April 1, 2015",,"May 6, 2019",,https://ClinicalTrials.gov/show/NCT02405182,40.0,100.0
2091,373,50.000678,-86.000977,"Citi Clinic, Warsaw, Poland",374.0,NCT02405182,MRI Biomarkers in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS|Motor Neuron Diseases,Other: Magnetic Resonance Imaging,Change in neuronal and white matter integrity measures.|Correlation of neuronal and white matter integrity measures with clinical indices.,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto",All,,145.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0013831,September 2014,March 2019,"April 1, 2019","April 1, 2015",,"May 6, 2019",,https://ClinicalTrials.gov/show/NCT02405182,40.0,100.0
2092,373,50.000678,-86.000977,"Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11, Barcelona, Spain",374.0,NCT02405182,MRI Biomarkers in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS|Motor Neuron Diseases,Other: Magnetic Resonance Imaging,Change in neuronal and white matter integrity measures.|Correlation of neuronal and white matter integrity measures with clinical indices.,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto",All,,145.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0013831,September 2014,March 2019,"April 1, 2019","April 1, 2015",,"May 6, 2019",,https://ClinicalTrials.gov/show/NCT02405182,40.0,100.0
2093,373,52.4760892,-71.8258668,"Hospital Carlos III - Hospital Universitario La Paz, ALS Unit, Madrid, Spain",374.0,NCT02405182,MRI Biomarkers in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|ALS|Motor Neuron Diseases,Other: Magnetic Resonance Imaging,Change in neuronal and white matter integrity measures.|Correlation of neuronal and white matter integrity measures with clinical indices.,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto",All,,145.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0013831,September 2014,March 2019,"April 1, 2019","April 1, 2015",,"May 6, 2019",,https://ClinicalTrials.gov/show/NCT02405182,40.0,100.0
2094,374,34.395342,-111.7632755,"Ume√• University Hospital, Ume√•, Sweden",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2095,374,34.395342,-111.7632755,"Kantonsspital St.Gallen, Muskelzentrum/ALS Clinic, Saint Gallen, Switzerland",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2096,374,36.7014631,-118.7559974,"Leonard Wolfson Experimental Neurology Centre, London, United Kingdom",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2097,374,27.7567667,-81.4639835,"St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center, Phoenix, Arizona, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2098,374,38.27312,-98.5821872,"HonorHealth Neurology, Phoenix, Arizona, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2099,374,40.7127281,-74.0060152,"UC Irvine Health ALS and Neuromuscular Center, Orange, California, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2100,374,43.9792797,-120.737257,"University of Miami, Miami, Florida, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2101,374,40.9699889,-77.7278831,"University of Kansas Medical Center (KUMC) - Landon Center on Aging, Kansas City, Kansas, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2102,374,31.8160381,-99.5120986,"Hospital for Special Surgery, New York, New York, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2103,374,37.1232245,-78.4927721,"Providence Brain & Spine Institute, Portland, Oregon, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2104,374,50.879202,4.7011675,"University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center, Philadelphia, Pennsylvania, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2105,374,50.000678,-86.000977,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2106,374,50.000678,-86.000977,"University of Virginia Health System, Charlottesville, Virginia, United States",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2107,374,52.4760892,-71.8258668,"Catholic University Leuven, Leuven, Belgium",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2108,374,43.6112422,3.8767337,"London Health Sciences Centre, London, Ontario, Canada",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2109,374,48.8566101,2.3514992,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2110,374,52.5170365,13.3888599,"Montreal Neurological Institute and Hospital, Montr√©al, Quebec, Canada",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2111,374,52.3744779,9.7385532,"Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac, Montpellier, France",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2112,374,48.3974003,9.9934336,"Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422, Paris, France",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2113,374,45.4667971,9.1904984,"Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen, Berlin, Germany",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2114,374,45.0677551,7.6824892,"Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie, Hannover, Germany",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2115,374,52.0809856,5.12768396945229,"Universitaetsklinikum Ulm - Klinik fuer Neurologie, Ulm, Germany",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2116,374,52.2337172,21.0714111288323,"Instituti Clinica Scientifici Maugeri - IRCCS, Milano, Italy",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2117,374,52.2337172,21.0714111288323,"Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino, Torino, Italy",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2118,374,41.3828939,2.1774322,"University Medical Center Utrecht, Utrecht, Netherlands",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2119,374,40.4167047,-3.7035825,"Centrum Medyczne NeuroProtect, Warsaw, Poland",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2120,374,63.8256568,20.2630745,"Citi Clinic, Warsaw, Poland",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2121,374,47.1561047,9.338323,"Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11, Barcelona, Spain",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2122,374,51.5073219,-0.1276474,"Hospital Carlos III - Hospital Universitario La Paz, ALS Unit, Madrid, Spain",375.0,NCT03836716,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol,Incidence and severity of Treatment-emergent adverse events (TEAEs)|Mean and change from baseline to week 76 (or end of trial ) in Creatinine - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Bilirubin - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Alanine aminotransferase (ALAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Aspartate aminotransferase (ASAT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lactate dehydrogenase (LDH) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Gamma-glutamyltransferase (GGT) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Sodium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Potassium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Blood urea nitrogen (BUN) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Calcium - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Albumin -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Total protein -(biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Creatine kinase (CK) - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cystatin C - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Glucose - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Lipids - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Cholesterol - (biochemistry)|Mean and change from baseline to week 76 (or end of trial ) in Haemoglobin - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Haematocrit - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Thrombocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Erythrocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Leucocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Eosinophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Neutrophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Basophils - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Monocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in Lymphocytes - (Haematology)|Mean and change from baseline to week 76 (or end of trial ) in urinanalysis|Mean and change from baseline to week 76 (or end of trial ) in body weight|Mean and change from baseline to week 76 (or end of trial ) in blood pressure|Mean and change from baseline to week 76 (or end of trial ) in pulse|Incidence of potentially clinically significant abnormalities in body temperature|Columbia-Suicide Severity Rating Scale (C-SSRS) over a treatment period of 76 weeks|Time to Permanent Assisted Ventilation (PAV)/tracheostomy/death /for subjects entering this trial having completed 76 weeks of randomized treatment in ORARIALS-01|Change in ALS Functional Rating Scale Revised (ALSFRS-R) from Baseline to the end of the trial|Change in Slow Vital Capacity (SVC) from Baseline to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial,Orphazyme,All,Phase 3,231.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ORARIALS-02,"August 15, 2019","August 1, 2022","August 1, 2022","February 11, 2019",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03836716,18.0,100.0
2123,375,34.395342,-111.7632755,"Ume√• University Hospital, Ume√•, Sweden",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2124,375,34.395342,-111.7632755,"Kantonsspital St.Gallen, Muskelzentrum/ALS Clinic, Saint Gallen, Switzerland",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2125,375,36.7014631,-118.7559974,"Leonard Wolfson Experimental Neurology Centre, London, United Kingdom",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2126,375,27.7567667,-81.4639835,"Hadassah Medical Organization, Jerusalem, Israel",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2127,375,38.27312,-98.5821872,"University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2128,375,40.7127281,-74.0060152,"Cedars-Sinai Medical Center, Los Angeles, California, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2129,375,43.9792797,-120.737257,"California Pacific Medical Center, San Francisco, California, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2130,375,40.9699889,-77.7278831,"Massachusetts General Hospital, Boston, Massachusetts, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2131,375,31.8160381,-99.5120986,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2132,375,37.1232245,-78.4927721,"Mayo Clinic, Rochester, Minnesota, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2133,375,50.879202,4.7011675,"VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2134,375,50.000678,-86.000977,"Albany VA Medical Center Samuel S. Stratton, Albany, NY, Albany, New York, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2135,375,50.000678,-86.000977,"Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2136,375,52.4760892,-71.8258668,"VA Medical Center, Cleveland, Cleveland, Ohio, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2137,375,43.6112422,3.8767337,"Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2138,375,48.8566101,2.3514992,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2139,375,52.5170365,13.3888599,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2140,375,52.3744779,9.7385532,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2141,375,48.3974003,9.9934336,"Massachusetts General Hospital, Boston, Massachusetts, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2142,375,45.4667971,9.1904984,"South Shore Neurologic Associates, P.C., Patchogue, New York, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2143,NULL,NULL,NULL,"Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan",,,,,,,,,,,,,,,,,,,,,,,,,,,
2144,375,52.0809856,5.12768396945229,"Hospital Regional Universitario Reina Sof√≠a, Cordoba, Spain",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2145,375,52.2337172,21.0714111288323,"Hospital Regional Universitario de M√°laga, M√°laga, Spain",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2146,375,52.2337172,21.0714111288323,"Hospital Universitario Virgen Macarena, Servicio de Neurolog√≠a, Seville, Spain",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2147,375,41.3828939,2.1774322,"Hospital Universitario Virgen del Roc√≠o, Seville, Spain",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2148,375,40.4167047,-3.7035825,"Massachusetts General Hospital, Boston, Massachusetts, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2149,375,63.8256568,20.2630745,"UMass Medical School, Worcester, Massachusetts, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2150,375,47.1561047,9.338323,"Mayo Clinic, Rochester, Minnesota, United States",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2151,375,51.5073219,-0.1276474,"Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders, Seoul, Haengdang-dong, Seongdong-gu, Korea, Republic of",376.0,NCT03491462,Arimoclomol in Amyotropic Lateral Sclerosis,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo oral capsule,Combined Assessment of Function and Survival (CAFS)|Time to permanent assisted ventilation (PAV)/tracheostomy/death|Change from Baseline to Week 76 (or end-of-trial) in the revised ALS Functional Rating Scale (ALSFRS-R)|Change from Baseline to Week 76 (or end-of-trial) in Slow Vital Capacity,Orphazyme,All,Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORARIALS-01,"July 31, 2018",December 2020,January 2021,"April 9, 2018",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT03491462,18.0,100.0
2152,376,31.778345,35.2250786,"Phoenix Neurological Associates, Phoenix, Arizona, United States",377.0,NCT01051882,"Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Biological: MSC-NTF cells transplantation (IM)|Biological: MSC-NTF cells transplantation (IT),"Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death",Brainstorm-Cell Therapeutics|Hadassah Medical Organization,All,Phase 1|Phase 2,12.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC-NTF-001-HMO-CTIL,June 2011,December 2012,March 2013,"January 20, 2010",,"January 10, 2019",,https://ClinicalTrials.gov/show/NCT01051882,20.0,75.0
2153,377,36.7014631,-118.7559974,"Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",378.0,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn¬Æ in ALS Patients,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn¬Æ (MSC-NTF cells)|Other: Placebo,To evaluate the efficacy and safety of NurOwn¬Æ (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,Phase 3,200.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","July 30, 2019","July 30, 2020","September 12, 2017",,"July 8, 2019",,https://ClinicalTrials.gov/show/NCT03280056,18.0,60.0
2154,377,36.7014631,-118.7559974,"Massachusetts General Hospital, Boston, Massachusetts, United States",378.0,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn¬Æ in ALS Patients,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn¬Æ (MSC-NTF cells)|Other: Placebo,To evaluate the efficacy and safety of NurOwn¬Æ (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,Phase 3,200.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","July 30, 2019","July 30, 2020","September 12, 2017",,"July 8, 2019",,https://ClinicalTrials.gov/show/NCT03280056,18.0,60.0
2155,377,36.7014631,-118.7559974,"Washington University in St. Louis, Saint Louis, Missouri, United States",378.0,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn¬Æ in ALS Patients,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn¬Æ (MSC-NTF cells)|Other: Placebo,To evaluate the efficacy and safety of NurOwn¬Æ (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,Phase 3,200.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","July 30, 2019","July 30, 2020","September 12, 2017",,"July 8, 2019",,https://ClinicalTrials.gov/show/NCT03280056,18.0,60.0
2156,377,42.3788774,-72.032366,"Guys and St Thomas NHS Trust, London, United Kingdom",378.0,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn¬Æ in ALS Patients,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn¬Æ (MSC-NTF cells)|Other: Placebo,To evaluate the efficacy and safety of NurOwn¬Æ (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,Phase 3,200.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","July 30, 2019","July 30, 2020","September 12, 2017",,"July 8, 2019",,https://ClinicalTrials.gov/show/NCT03280056,18.0,60.0
2157,377,42.3788774,-72.032366,"Royal Brompton and Harefield NHS Trust, London, United Kingdom",378.0,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn¬Æ in ALS Patients,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn¬Æ (MSC-NTF cells)|Other: Placebo,To evaluate the efficacy and safety of NurOwn¬Æ (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,Phase 3,200.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","July 30, 2019","July 30, 2020","September 12, 2017",,"July 8, 2019",,https://ClinicalTrials.gov/show/NCT03280056,18.0,60.0
2158,NULL,NULL,NULL,"EMG Department, Alzahra Hospital, Isfahan, Iran, Islamic Republic of",,,,,,,,,,,,,,,,,,,,,,,,,,,
2159,378,41.6500201,-72.7342163,"Monteleone Hall, Saint Louis University, 1438 South Grand Blvd., Saint Louis, Missouri, United States",379.0,NCT00786032,A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,ALS,Completed,Has Results,ALS (Amyotrophic Lateral Sclerosis),Device: BCI Device,BCI System Usage by the ALS Patient|BCI Usage by and Impact on the ALS Patient|Time of BCI Impact on the Significant Other and Systems Operator|Facility Support Speed of Solution,US Department of Veterans Affairs|New York State Department of Health|VA Office of Research and Development,All,,27.0,U.S. Fed|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,567,September 2011,June 2013,August 2014,"November 5, 2008","January 8, 2015","January 8, 2015",,https://ClinicalTrials.gov/show/NCT00786032,18.0,79.0
2160,378,40.7127281,-74.0060152,"Hershey Medical Center ALS Clinic, Hershey, Pennsylvania, United States",379.0,NCT00786032,A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,ALS,Completed,Has Results,ALS (Amyotrophic Lateral Sclerosis),Device: BCI Device,BCI System Usage by the ALS Patient|BCI Usage by and Impact on the ALS Patient|Time of BCI Impact on the Significant Other and Systems Operator|Facility Support Speed of Solution,US Department of Veterans Affairs|New York State Department of Health|VA Office of Research and Development,All,,27.0,U.S. Fed|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,567,September 2011,June 2013,August 2014,"November 5, 2008","January 8, 2015","January 8, 2015",,https://ClinicalTrials.gov/show/NCT00786032,18.0,79.0
2161,378,35.6729639,-79.0392919,"Fundaci√≥ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",379.0,NCT00786032,A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,ALS,Completed,Has Results,ALS (Amyotrophic Lateral Sclerosis),Device: BCI Device,BCI System Usage by the ALS Patient|BCI Usage by and Impact on the ALS Patient|Time of BCI Impact on the Significant Other and Systems Operator|Facility Support Speed of Solution,US Department of Veterans Affairs|New York State Department of Health|VA Office of Research and Development,All,,27.0,U.S. Fed|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,567,September 2011,June 2013,August 2014,"November 5, 2008","January 8, 2015","January 8, 2015",,https://ClinicalTrials.gov/show/NCT00786032,18.0,79.0
2162,378,40.2253569,-82.6881395,"Kitasato University East Hospital, Kanagawa, Japan",379.0,NCT00786032,A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,ALS,Completed,Has Results,ALS (Amyotrophic Lateral Sclerosis),Device: BCI Device,BCI System Usage by the ALS Patient|BCI Usage by and Impact on the ALS Patient|Time of BCI Impact on the Significant Other and Systems Operator|Facility Support Speed of Solution,US Department of Veterans Affairs|New York State Department of Health|VA Office of Research and Development,All,,27.0,U.S. Fed|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,567,September 2011,June 2013,August 2014,"November 5, 2008","January 8, 2015","January 8, 2015",,https://ClinicalTrials.gov/show/NCT00786032,18.0,79.0
2163,378,41.7962409,-71.5992372,"Kumamoto Saishunso National Hospital, Kumamoto, Japan",379.0,NCT00786032,A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients,ALS,Completed,Has Results,ALS (Amyotrophic Lateral Sclerosis),Device: BCI Device,BCI System Usage by the ALS Patient|BCI Usage by and Impact on the ALS Patient|Time of BCI Impact on the Significant Other and Systems Operator|Facility Support Speed of Solution,US Department of Veterans Affairs|New York State Department of Health|VA Office of Research and Development,All,,27.0,U.S. Fed|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,567,September 2011,June 2013,August 2014,"November 5, 2008","January 8, 2015","January 8, 2015",,https://ClinicalTrials.gov/show/NCT00786032,18.0,79.0
2164,379,40.9699889,-77.7278831,"Nagoya University Hospital, Nagoya, Japan",380.0,NCT00718107,Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Patient Satisfaction,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,5.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,Internal-15894,June 2005,February 2012,February 2012,"July 18, 2008",,"March 5, 2013",,https://ClinicalTrials.gov/show/NCT00718107,18.0,90.0
2165,380,40.9699889,-77.7278831,"Okayama University Hospital, Okayama, Japan",381.0,NCT00718458,EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS),BCI,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,BCI Accuracy,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,102.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,Internal-17016,August 2007,December 2016,December 2016,"July 18, 2008",,"March 30, 2017",,https://ClinicalTrials.gov/show/NCT00718458,18.0,90.0
2166,381,40.9699889,-77.7278831,"Hokkaido University Hospital, Sapporo, Japan",382.0,NCT00718016,Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Usability of the Cyberlink System,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,1.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,Internal-903,December 2004,April 2009,April 2009,"July 18, 2008",,"March 5, 2013",,https://ClinicalTrials.gov/show/NCT00718016,18.0,75.0
2167,382,42.3788774,-72.032366,"Tohoku University Hospital, Sendai, Japan",383.0,NCT02714036,A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: ibudilast,To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks|To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers|To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.|To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)|To evaluate the effect of ibudilast on slow vital capacity (SVC)|To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD),MediciNova|Massachusetts General Hospital|South Shore Neurologic Associates,All,Phase 1|Phase 2,35.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MN-166-ALS-1202,March 2016,"September 28, 2019",December 2019,"March 21, 2016",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT02714036,18.0,100.0
2168,382,40.7127281,-74.0060152,"Shiga University of Medical Science Hospital, Shiga, Japan",383.0,NCT02714036,A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS),,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Drug: ibudilast,To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks|To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers|To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.|To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)|To evaluate the effect of ibudilast on slow vital capacity (SVC)|To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD),MediciNova|Massachusetts General Hospital|South Shore Neurologic Associates,All,Phase 1|Phase 2,35.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MN-166-ALS-1202,March 2016,"September 28, 2019",December 2019,"March 21, 2016",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT02714036,18.0,100.0
2169,383,,,"Tokyo Medical University, Tokyo, Japan",384.0,NCT00011154,Exogenous Toxicants and Genetic Susceptibility in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,,National Institute of Environmental Health Sciences (NIEHS),All,,525.0,NIH,Observational,Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Retrospective,8150-CP-001,September 1996,,August 2002,"February 14, 2001",,"March 23, 2006",,https://ClinicalTrials.gov/show/NCT00011154,18.0,100.0
2170,384,25.0375198,121.5636796,"The University of Tokyo Hospital, Tokyo, Japan",385.0,NCT03787420,Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.,,Recruiting,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Other: communication system,Part 1- Amyotrophic Lateral Sclerosis Supportive Care Needs|Part 2 - Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revisedclinical study|Part 2 - Beck Depression Inventoryc|Caregiver Burden Scale,"Taipei Veterans General Hospital, Taiwan",All,Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,107-3011-F-027-002-,"September 1, 2018","August 31, 2019","December 31, 2019","December 25, 2018",,"December 25, 2018",,https://ClinicalTrials.gov/show/NCT03787420,20.0,100.0
2171,385,37.8845813,-4.7760138,"Tokyo Metropolitan Neurological Hospital, Tokyo, Japan",386.0,NCT02290886,A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Other: Intravenous administration of placebo|Drug: Intravenous administration of 1 million of MSC|Drug: Intravenous administration of 2 million of MSC|Drug: Intravenous administration of 4 million of MSC,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation",Andalusian Initiative for Advanced Therapies - Fundaci√≥n P√∫blica Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas,All,Phase 1|Phase 2,52.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CeTMAd/ELA/2011,July 2014,March 2019,July 2021,"November 14, 2014",,"November 28, 2018",,https://ClinicalTrials.gov/show/NCT02290886,18.0,100.0
2172,385,36.7213028,-4.4216366,"University of Tsukuba Hospital, Tsukuba, Japan",386.0,NCT02290886,A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Other: Intravenous administration of placebo|Drug: Intravenous administration of 1 million of MSC|Drug: Intravenous administration of 2 million of MSC|Drug: Intravenous administration of 4 million of MSC,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation",Andalusian Initiative for Advanced Therapies - Fundaci√≥n P√∫blica Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas,All,Phase 1|Phase 2,52.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CeTMAd/ELA/2011,July 2014,March 2019,July 2021,"November 14, 2014",,"November 28, 2018",,https://ClinicalTrials.gov/show/NCT02290886,18.0,100.0
2173,385,37.3886303,-5.9953403,"Yamaguchi University Hospital, Yamaguchi, Japan",386.0,NCT02290886,A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Other: Intravenous administration of placebo|Drug: Intravenous administration of 1 million of MSC|Drug: Intravenous administration of 2 million of MSC|Drug: Intravenous administration of 4 million of MSC,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation",Andalusian Initiative for Advanced Therapies - Fundaci√≥n P√∫blica Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas,All,Phase 1|Phase 2,52.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CeTMAd/ELA/2011,July 2014,March 2019,July 2021,"November 14, 2014",,"November 28, 2018",,https://ClinicalTrials.gov/show/NCT02290886,18.0,100.0
2174,385,37.3886303,-5.9953403,"Cedar Sinai Medical Center, Los Angeles, California, United States",386.0,NCT02290886,A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral,,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis,Other: Intravenous administration of placebo|Drug: Intravenous administration of 1 million of MSC|Drug: Intravenous administration of 2 million of MSC|Drug: Intravenous administration of 4 million of MSC,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation",Andalusian Initiative for Advanced Therapies - Fundaci√≥n P√∫blica Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas,All,Phase 1|Phase 2,52.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CeTMAd/ELA/2011,July 2014,March 2019,July 2021,"November 14, 2014",,"November 28, 2018",,https://ClinicalTrials.gov/show/NCT02290886,18.0,100.0
2175,386,42.3788774,-72.032366,"University of Colorado School of Medicine, Aurora, Colorado, United States",387.0,NCT02017912,"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",NurOwn,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: Autologous MSC-NTF cells|Biological: Placebo,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,Brainstorm-Cell Therapeutics,All,Phase 2,48.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BCT-001-US,May 2014,March 2016,July 2016,"December 23, 2013",,"July 18, 2018",,https://ClinicalTrials.gov/show/NCT02017912,18.0,75.0
2176,386,42.3788774,-72.032366,"Univeristy of Michigan, Ann Arbor, Michigan, United States",387.0,NCT02017912,"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",NurOwn,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: Autologous MSC-NTF cells|Biological: Placebo,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,Brainstorm-Cell Therapeutics,All,Phase 2,48.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BCT-001-US,May 2014,March 2016,July 2016,"December 23, 2013",,"July 18, 2018",,https://ClinicalTrials.gov/show/NCT02017912,18.0,75.0
2177,386,45.9896587,-94.6113288,"University of Minnesota, Minneapolis, Minnesota, United States",387.0,NCT02017912,"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",NurOwn,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: Autologous MSC-NTF cells|Biological: Placebo,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,Brainstorm-Cell Therapeutics,All,Phase 2,48.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BCT-001-US,May 2014,March 2016,July 2016,"December 23, 2013",,"July 18, 2018",,https://ClinicalTrials.gov/show/NCT02017912,18.0,75.0
2178,387,42.9629533,47.5133551,"Washington University, Saint Louis, Missouri, United States",388.0,NCT01758510,Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Disease|Neurodegenerative Disease|Central Nervous System Disease,Genetic: HYNR-CS-Allo,Serious Adverse Events(SAE)|ALS-Functional rating scales(ALS-FRS)|Adverse Events(AE),"Hanyang University Seoul Hospital|Corestem, Inc.",All,Phase 1,6.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HYNR-CS-Allo-01,December 2012,"April 10, 2017","April 10, 2017","January 1, 2013",,"May 16, 2019",,https://ClinicalTrials.gov/show/NCT01758510,25.0,80.0
2179,388,34.395342,-111.7632755,"Columbia University, New York, New York, United States",389.0,NCT01835782,Determining the Safety of L-serine in ALS,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: L-Serine,"Safety of L-Serine|Measure levels of Œ≤-Methylamino-L-alanine (BMAA) in blood, urine and Cerebrospinal fluid (CSF) to determine if there is a decline in levels over the course of treatment","Phoenix Neurological Associates, LTD|Institute for Ethnomedicine",All,Phase 1|Phase 2,20.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",L-Serine2013|IND,January 2013,December 2016,,"April 19, 2013",,"July 30, 2015",,https://ClinicalTrials.gov/show/NCT01835782,18.0,85.0
2180,388,36.7014631,-118.7559974,"Duke University, Durham, North Carolina, United States",389.0,NCT01835782,Determining the Safety of L-serine in ALS,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: L-Serine,"Safety of L-Serine|Measure levels of Œ≤-Methylamino-L-alanine (BMAA) in blood, urine and Cerebrospinal fluid (CSF) to determine if there is a decline in levels over the course of treatment","Phoenix Neurological Associates, LTD|Institute for Ethnomedicine",All,Phase 1|Phase 2,20.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",L-Serine2013|IND,January 2013,December 2016,,"April 19, 2013",,"July 30, 2015",,https://ClinicalTrials.gov/show/NCT01835782,18.0,85.0
2181,389,42.3788774,-72.032366,"Oregon Health & Sciences University, Portland, Oregon, United States",390.0,NCT03449212,SOD1 Kinetics Measurements in ALS Patients,,Recruiting,No Results Available,"Amyotrophic Lateral Sclerosis, Familial|Amyotrophic Lateral Sclerosis, Sporadic",,The primary outcome measurement will be the determination of the SOD1 half-life in the CSF of each subject.|ALS Functional Rating Scale-Revised (ALSFRS-R)|Slow Vital Capacity (SVC),Washington University School of Medicine|Massachusetts General Hospital,All,,86.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,SOD1-001,December 2012,May 2020,May 2020,"February 28, 2018",,"March 28, 2019",,https://ClinicalTrials.gov/show/NCT03449212,18.0,100.0
2182,389,38.7604815,-92.5617875,"Penn State College of Medicine, Hershey, Pennsylvania, United States",390.0,NCT03449212,SOD1 Kinetics Measurements in ALS Patients,,Recruiting,No Results Available,"Amyotrophic Lateral Sclerosis, Familial|Amyotrophic Lateral Sclerosis, Sporadic",,The primary outcome measurement will be the determination of the SOD1 half-life in the CSF of each subject.|ALS Functional Rating Scale-Revised (ALSFRS-R)|Slow Vital Capacity (SVC),Washington University School of Medicine|Massachusetts General Hospital,All,,86.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,SOD1-001,December 2012,May 2020,May 2020,"February 28, 2018",,"March 28, 2019",,https://ClinicalTrials.gov/show/NCT03449212,18.0,100.0
2183,390,51.5073219,-0.1276474,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",391.0,NCT03444428,The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease,,Recruiting,No Results Available,Motor Neurone Disease|Hypoxemia and/or Hypercapnia,Other: Non Invasive Ventilation|Other: Without Non Invasive Ventilation,Comparing the pulse wave velocity between MND patients with hypoxemia and/or hypercapnia to those MND Patients that do not have hypoxemia and/or hypercapnia|Comparison of pulse wave velocity values in MND patients to normal values|Comparison of pulse wave velocity pre-post non invasive ventilation in MND patients,Guy's and St Thomas' NHS Foundation Trust,All,,32.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,210214 16/LO/1560,"February 21, 2017",June 2018,June 2018,"February 23, 2018",,"March 29, 2018",,https://ClinicalTrials.gov/show/NCT03444428,18.0,80.0
2184,390,51.5073219,-0.1276474,"Houston Methodist Neurological Institute, Houston, Texas, United States",391.0,NCT03444428,The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease,,Recruiting,No Results Available,Motor Neurone Disease|Hypoxemia and/or Hypercapnia,Other: Non Invasive Ventilation|Other: Without Non Invasive Ventilation,Comparing the pulse wave velocity between MND patients with hypoxemia and/or hypercapnia to those MND Patients that do not have hypoxemia and/or hypercapnia|Comparison of pulse wave velocity values in MND patients to normal values|Comparison of pulse wave velocity pre-post non invasive ventilation in MND patients,Guy's and St Thomas' NHS Foundation Trust,All,,32.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,210214 16/LO/1560,"February 21, 2017",June 2018,June 2018,"February 23, 2018",,"March 29, 2018",,https://ClinicalTrials.gov/show/NCT03444428,18.0,80.0
2185,391,,,"University of Utah, Salt Lake City, Utah, United States",392.0,NCT02891629,Safety and Feasibility of the EyeControl Device,,Completed,No Results Available,ALS (Amyotrophic Lateral Sclerosis),Device: EyeControl device,Feasibility - Successful performance rate of device features|Safety assessment - number of device related adverse events,Eyefree Assisting Communication Ltd,All,Not Applicable,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EFAC-01,September 2016,"January 28, 2017","February 28, 2017","September 7, 2016",,"July 25, 2018",,https://ClinicalTrials.gov/show/NCT02891629,18.0,65.0
2186,392,36.2619477,59.6051728,"University of Washington, Seattle, Washington, United States",393.0,NCT03272802,Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,Neuromuscular Diseases,Drug: Edaravone|Drug: Riluzole,Functional evaluation of patient's muscle strength.|functional status of the patient.|Quality of life in the patients,Isfahan University of Medical Sciences,All,Phase 2|Phase 3,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Isfahan ALS Registery,"March 16, 2017","March 16, 2019","September 16, 2019","September 6, 2017",,"March 27, 2019",,https://ClinicalTrials.gov/show/NCT03272802,18.0,75.0
2187,393,38.7604815,-92.5617875,"The University of Edinburgh, Edinburgh, United Kingdom",394.0,NCT02851914,SSRIs vs. TCAs for Depression in ALS Patients,,Recruiting,No Results Available,Depression|Amyotrophic Lateral Sclerosis,"Drug: Tricyclic Antidepressants (""TCA"")|Drug: Selective Serotonin Uptake Inhibitors (""SSRI"")",BDI-II|ANCOVA,St. Louis University,All,Early Phase 1,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,22974,"July 21, 2015","December 31, 2019","December 31, 2019","August 2, 2016",,"January 7, 2019",,https://ClinicalTrials.gov/show/NCT02851914,25.0,80.0
2188,394,40.9699889,-77.7278831,"Duke University, Durham, North Carolina, United States",395.0,NCT03214224,Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis,,"Active, not recruiting",Has Results,ALS,Device: remote pulmonary function testing|Device: standard pulmonary function testing,(Part 1) Standard PFT - Forced Vital Capacity|(Part 1) Standard PFT - Maximal Inspiratory Pressure|(Part 1) Remote PFT - Forced Vital Capacity|(Part 1) Remote PFT - Maximal Inspiratory Pressure|(Part 2) Longitudinal Standard PFT - FVC|(Part 2) Longitudinal Standard PFT - MIP|(Part 2) Longitudinal Remote PFT - FVC|(Part 2) Longitudinal Remote PFT - MIP|(Part 1) Patient and Caregiver Reported Outcomes|(Part 1) Therapist Reported Outcomes|(Part 2) Patient-reported Outcome - Short Form 36 (SF-36)|(Part 2) Patient-reported Outcome - Sleep Apnea Quality of Life Index (SAQLI)|(Part 2) Patient-reported Outcome - Motor Neuron Disease Dyspnoea Rating Scale (MDRS-D)|(Part 2) Survival Data,Milton S. Hershey Medical Center,All,Not Applicable,49.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,STUDY00006924,"November 1, 2017","September 30, 2018",October 2019,"July 11, 2017","April 9, 2019","April 9, 2019","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03214224/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03214224/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03214224,18.0,100.0
2189,395,41.3828939,2.1774322,"University of Kansas Medical Center, Kansas City, Kansas, United States",396.0,NCT01090674,Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases,,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: No intervention,"Different measures of diaphragmatic mobility, force and function.|Diaphragmatic MRI usefulness",Fundaci√≥ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,All,,5.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PR01/01/2007,June 2007,July 2013,July 2013,"March 22, 2010",,"February 24, 2014",,https://ClinicalTrials.gov/show/NCT01090674,18.0,100.0
2190,396,35.4342935,139.374753,"Hadassah Medical Organisation, Jerusalem, Israel",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2191,NULL,NULL,NULL,"UNC Neurology ALS clinic, Chapel Hill, North Carolina, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2192,396,35.1851045,136.8998438,"Po-Chih Chen, New Taipei City, Taiwan",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2193,396,34.8581334,133.7759256,"CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center, San Francisco, California, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2194,396,43.0614489,141.354538,"University of Kansas Medical Center - Dept of Neurology, Kansas City, Kansas, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2195,396,38.2677554,140.8691498,"Johns Hopkins OPC - Meyer Bldg, Baltimore, Maryland, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2196,396,35.247154,136.109385,"Massachusetts General Hospital-Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2197,396,35.6828387,139.7594549,"Mayo Clinic, Rochester, Minnesota, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2198,396,35.6828387,139.7594549,"Columbia University - Neurology Institute, New York, New York, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2199,396,35.6828387,139.7594549,"SUNY Upstate Medical University, Syracuse, New York, United States",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2200,396,36.0833877,140.0765098,"Academic Hospital University of Leuven - ALS dept, Leuven, Belgium",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2201,396,34.2379614,131.5873845,"ALS Centre, Vancouver, British Columbia, Canada",397.0,NCT03019419,Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS),,"Active, not recruiting",No Results Available,ALS,Drug: Perampanel|Drug: placebo,Change in ALS Functional rating scale|Manual Muscle Test|Percent-predicted forced vital capacity,Tokyo Medical University,All,Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A2016-J000-001,"April 24, 2017",December 2022,December 2022,"January 12, 2017",,"October 23, 2018",,https://ClinicalTrials.gov/show/NCT03019419,40.0,78.0
2202,397,36.7014631,-118.7559974,"London Health Sciences Centre Motor Neuro Diseases Clinic, London, Ontario, Canada",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2203,397,38.7251776,-105.6077167,"Montreal Neurological Institute, Montreal, Quebec, Canada",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2204,397,43.6211955,-84.6824346,"C.H.U. La Timone - Service de Neurologie, Marseille Cedex 5, France",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2205,397,45.9896587,-94.6113288,"C.H.U. de Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques, Montpellier Cedex 5, France",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2206,397,38.7604815,-92.5617875,"Hopital La Pitie Salpetriere - Federation de Neurologie, Paris, France",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2207,397,40.7127281,-74.0060152,"Universitaetsklinik Berlin-Charite, Campus Virchow Klinikum, Neurologische Klinik, Berlin, Germany",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2208,397,35.6729639,-79.0392919,"Berufsgenossenschaftliche Klinik Bergmannsheil, Neurologische Klinik, Bochum, Germany",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2209,397,43.9792797,-120.737257,"Universitaet Ulm, Ulm, Germany",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2210,397,40.9699889,-77.7278831,"Semmelweis University, Department of Neurology, Budapest, Hungary",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2211,397,40.9699889,-77.7278831,"Sourasky MC -EMG Unit, Tel Aviv, Israel",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2212,397,31.8160381,-99.5120986,"Fondazione ""S.Maugeri"" Clinica della Riabilitazione IRCCS-Istituto Scientifico di Lissone, Lissone (MI), Italy",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2213,397,39.4225192,-111.7143584,"Centro Clinico NEMO, Milano, Italy",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2214,397,38.8950092,-77.0365625,"Azienda Ospedaliero Universitaria San Giovanni Battista di Torino - Dipartimento di Neuroscienze, Torino, Italy",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2215,397,55.9521476,-3.1889908,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",398.0,NCT02795897,Genomic Translation for Amyotrophic Lateral Sclerosis Care,GTAC,Recruiting,No Results Available,ALS,,Correlation of DNA genotype with ALS phenotypes|Correlation of gene expression in blood with ALS phenotypes,Columbia University|ALS Association|Biogen,All,,1500.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ7026,"June 8, 2016",September 2019,November 2020,"June 10, 2016",,"March 13, 2019",,https://ClinicalTrials.gov/show/NCT02795897,18.0,80.0
2216,398,35.6729639,-79.0392919,"Hospital Carlos III, Madrid, Spain",399.0,NCT03506425,A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS),,Completed,No Results Available,ALS,Drug: Triheptanoin,ALSFRS-R slope on treatment compared to pre-treatment|Magnetic Resonance Spectroscopy|Oxidative Stress Markers,"Richard Bedlack, M.D., Ph.D.|Ultragenyx Pharmaceutical Inc|Duke University",All,Phase 1|Phase 2,10.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00092250,"June 21, 2018","March 28, 2019","March 28, 2019","April 24, 2018",,"April 10, 2019",,https://ClinicalTrials.gov/show/NCT03506425,18.0,100.0
2217,399,38.27312,-98.5821872,"University of Miami, Miami, Florida, United States",400.0,NCT03472950,Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis,,Recruiting,No Results Available,ALS,Drug: Ranolazine 500 MG|Drug: Ranolazine 1000 MG,Dose limiting toxicities (DLT)|Cramp Questionnaire|Fasciculation frequency on muscle ultrasound|Cramp potential duration,University of Kansas Medical Center|Gilead Sciences,All,Phase 2,20.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00141491,"June 11, 2018","October 1, 2019","November 1, 2019","March 21, 2018",,"June 13, 2019",,https://ClinicalTrials.gov/show/NCT03472950,18.0,100.0
2218,400,31.778345,35.2250786,"University of Utah, Salt Lake City, Utah, United States",401.0,NCT03366506,Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS),EpidALS,Recruiting,No Results Available,ALS,Other: Observation,Progression rate|Appearance of clinical features of UMN or LMN dysfunction,Hadassah Medical Organization,All,,2000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,0633-08-HMO-CTIL,"March 9, 2009",March 2049,,"December 8, 2017",,"February 22, 2019",,https://ClinicalTrials.gov/show/NCT03366506,12.0,120.0
2219,401,,,"University of Calgary / Heritage Medical Research Clinic, Calgary, Alberta, Canada",402.0,NCT01378026,Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis|Alzheimer Disease|Parkinson's Disease,,,China Medical University Hospital,All,,120.0,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,DMR100-IRB-069,January 2012,,,"June 22, 2011",,"June 22, 2011",,https://ClinicalTrials.gov/show/NCT01378026,32.0,87.0
2220,402,35.6729639,-79.0392919,"University of Alberta, Edmonton, Alberta, Canada",403.0,NCT02228915,Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis,SOD1,Completed,No Results Available,ALS,,Post-translational modifications (PTMs) of Cu/Zn superoxide dismutase 1,"University of North Carolina, Chapel Hill",All,,21.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-1780,August 2014,"October 14, 2018","October 16, 2018","August 29, 2014",,"October 17, 2018",,https://ClinicalTrials.gov/show/NCT02228915,18.0,99.0
2221,403,24.98645525,121.771462702121,"University of British Columbia / GF Strong Rehab Centre, Vancouver, British Columbia, Canada",404.0,NCT02166944,Tamoxifen Treatment in Patients With Motor Neuron Disease,,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis|ALS Functional Ration Scale|TAR-DNA-binding Protein-43|Tamoxifen|mTOR,Drug: tamoxifen 40 mg daily for one year,"Change from Baseline in Amyotrophic Lateral Sclerosis Functional Ration Scales (ALSFRS) at 1, 3, 6,12 months|Change from Baseline in pulmonary function test at 1, 3, 6,12 months",Taipei Medical University Shuang Ho Hospital,All,Phase 1|Phase 2,20.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",201307022,April 2014,May 2016,July 2016,"June 18, 2014",,"June 18, 2014",,https://ClinicalTrials.gov/show/NCT02166944,20.0,80.0
2222,404,36.7014631,-118.7559974,"Western University / London Health Sciences Centre, London, Ontario, Canada",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2223,404,38.27312,-98.5821872,"University of Toronto / Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2224,404,39.5162234,-76.9382069,"McGill University / Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2225,404,42.3788774,-72.032366,"Laval University, Quebec City, Quebec, Canada",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2226,404,45.9896587,-94.6113288,"Convergence Medical Devices, Boston, Massachusetts, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2227,404,40.7127281,-74.0060152,"Cedars Sinai Medical Center, Los Angeles, California, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2228,404,40.7127281,-74.0060152,"Johns Hopkins, Baltimore, Maryland, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2229,404,50.879202,4.7011675,"University of Massachusetts, Amherst, Massachusetts, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2230,404,55.001251,-125.002441,"Massachusetts General Hospital, Boston, Massachusetts, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2231,404,50.000678,-86.000977,"Washington University in St. Louis, Saint Louis, Missouri, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2232,404,52.4760892,-71.8258668,"Columbia University Medical Center, New York, New York, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2233,404,46.603354,1.8883335,"Sentara Health Care / Sentara Neurology Specialists, Virginia Beach, Virginia, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2234,404,46.603354,1.8883335,"UMC Utrecht, Utrecht, Netherlands",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2235,404,48.8566101,2.3514992,"Hopital PITIE SALPETRIERE, Paris, France",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2236,404,52.5170365,13.3888599,"Mayo Clinic Florida, Jacksonville, Florida, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2237,404,51.4818111,7.2196635,"Duke University ALS Clinic - 932 Morreene Road, Durham, North Carolina, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2238,404,48.3974003,9.9934336,"University of Arkansas for Medical Sciences, Department of Neurology, Little Rock, Arkansas, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2239,404,47.4983815,19.0404707,"California Pacific Medical Center, San Francisco, California, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2240,404,32.0804808,34.7805274,"University of California at San Francisco, San Francisco, California, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2241,404,45.6107705,9.2408409,"University of Colorado Health Sciences, Dept of Neurology, Denver, Colorado, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2242,404,45.4667971,9.1904984,"Yale University School of Medicine, Department of Neurology, New Haven, Connecticut, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2243,404,45.0677551,7.6824892,"Northwestern University, Department of Neurology,, Chicago, Illinois, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2244,404,52.0809856,5.12768396945229,"University of Chicago, Department of Neurology, Chicago, Illinois, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2245,404,40.4167047,-3.7035825,"University of Kansas Medical Center, Kansas City, Kansas, United States",405.0,NCT00696332,Talampanel for Amyotrophic Lateral Sclerosis (ALS),ALS,Completed,No Results Available,ALS,Drug: Talampanel|Other: placebo,"Change in ALS Functional Rating Score (ALSFRS-R slope)|Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.",Teva Pharmaceutical Industries,All,Phase 2,559.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALS-TAL-201 (ALSTAR)|ALSTAR,September 2008,April 2010,May 2010,"June 12, 2008",,"October 21, 2011",,https://ClinicalTrials.gov/show/NCT00696332,18.0,80.0
2246,405,27.7567667,-81.4639835,"University of Kentucky, Dept of Neurology, College of Medicine, Lexington, Kentucky, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2247,405,39.4225192,-111.7143584,"Brigham and Women's Hospital , Department of Neurology, Boston, Massachusetts, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2248,405,55.001251,-115.002136,"Baystate Medical Center, Division of Critical Care Research, Springfield,, Massachusetts, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2249,405,55.001251,-115.002136,"Minneapolis Medical Research Foundation, ,, Minneapolis, Minnesota, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2250,405,55.001251,-125.002441,"Washington University in St. Louis School of Medicine, Department of Neurology, St. Louis, Missouri, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2251,405,50.000678,-86.000977,"Columbia Presbyterian Medical Center, The Neurological Institute, New York, New York, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2252,405,50.000678,-86.000977,"State University of New York Upstate Medical, Neurology Department, Syracuse, New York, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2253,405,52.4760892,-71.8258668,"Cleveland Clinic Foundation, Cleveland, Ohio, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2254,405,52.4760892,-71.8258668,"Drexel University, Dept of Neurology, Philadelphia, Pennsylvania, United States",406.0,NCT03362658,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Change in cortical thickness in millimetres.|Change in DTI indices (unitless).,"University of Alberta|University of Calgary|Western University, Canada|McGill University|University of Toronto|University of British Columbia|Laval University|University of Miami|University of Utah",All,,700.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RES0027887,October 2016,December 2020,December 2020,"December 5, 2017",,"May 7, 2019",,https://ClinicalTrials.gov/show/NCT03362658,18.0,100.0
2255,406,42.3788774,-72.032366,"University of Texas, Health Science Center at San Antonio, Division of Neurology, San Antonio, Texas, United States",407.0,NCT01803386,Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography,,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Device: EIM Measurements,Muscle health as captured by EIM measurements,"Skulpt, Inc.|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)",All,,20.0,Industry|NIH,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,EIM-002-2011-4|2R44NS070385-02A1,January 2013,March 2015,March 2015,"March 4, 2013",,"July 22, 2015",,https://ClinicalTrials.gov/show/NCT01803386,21.0,85.0
2256,407,36.7014631,-118.7559974,"University of Vermont, Neurology Department, Burlington, Vermont, United States",408.0,NCT02686268,Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,,Completed,No Results Available,C9ORF72 Amyotrophic Lateral Sclerosis (ALS),,Collection of clinical data and biomarker samples|Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials,"Washington University School of Medicine|Cedars-Sinai Medical Center|UMC Utrecht|Johns Hopkins University|Massachusetts General Hospital|University of Massachusetts, Amherst|Biogen|ALS Association|Columbia University",All,,128.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,14LGCA123,February 2015,"December 31, 2017","October 2, 2018","February 19, 2016",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02686268,18.0,100.0
2257,407,39.5162234,-76.9382069,"Durham VA Medical Center, Durham, North Carolina, United States",408.0,NCT02686268,Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,,Completed,No Results Available,C9ORF72 Amyotrophic Lateral Sclerosis (ALS),,Collection of clinical data and biomarker samples|Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials,"Washington University School of Medicine|Cedars-Sinai Medical Center|UMC Utrecht|Johns Hopkins University|Massachusetts General Hospital|University of Massachusetts, Amherst|Biogen|ALS Association|Columbia University",All,,128.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,14LGCA123,February 2015,"December 31, 2017","October 2, 2018","February 19, 2016",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02686268,18.0,100.0
2258,407,42.3788774,-72.032366,"Carolinas ALS Clinical Resarch Center, Charlotte, North Carolina, United States",408.0,NCT02686268,Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,,Completed,No Results Available,C9ORF72 Amyotrophic Lateral Sclerosis (ALS),,Collection of clinical data and biomarker samples|Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials,"Washington University School of Medicine|Cedars-Sinai Medical Center|UMC Utrecht|Johns Hopkins University|Massachusetts General Hospital|University of Massachusetts, Amherst|Biogen|ALS Association|Columbia University",All,,128.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,14LGCA123,February 2015,"December 31, 2017","October 2, 2018","February 19, 2016",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02686268,18.0,100.0
2259,407,42.3788774,-72.032366,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",408.0,NCT02686268,Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,,Completed,No Results Available,C9ORF72 Amyotrophic Lateral Sclerosis (ALS),,Collection of clinical data and biomarker samples|Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials,"Washington University School of Medicine|Cedars-Sinai Medical Center|UMC Utrecht|Johns Hopkins University|Massachusetts General Hospital|University of Massachusetts, Amherst|Biogen|ALS Association|Columbia University",All,,128.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,14LGCA123,February 2015,"December 31, 2017","October 2, 2018","February 19, 2016",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02686268,18.0,100.0
2260,NULL,NULL,NULL,"Massachusetts General Hospital, Boston, Massachusetts, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2261,407,40.7127281,-74.0060152,"University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States",408.0,NCT02686268,Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,,Completed,No Results Available,C9ORF72 Amyotrophic Lateral Sclerosis (ALS),,Collection of clinical data and biomarker samples|Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials,"Washington University School of Medicine|Cedars-Sinai Medical Center|UMC Utrecht|Johns Hopkins University|Massachusetts General Hospital|University of Massachusetts, Amherst|Biogen|ALS Association|Columbia University",All,,128.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,14LGCA123,February 2015,"December 31, 2017","October 2, 2018","February 19, 2016",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02686268,18.0,100.0
2262,NULL,NULL,NULL,"UCD Telehealth Network - Lake Almanor Clinic, Chester, California, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2263,407,52.0809856,5.12768396945229,"UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program, La Jolla, California, United States",408.0,NCT02686268,Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS,,Completed,No Results Available,C9ORF72 Amyotrophic Lateral Sclerosis (ALS),,Collection of clinical data and biomarker samples|Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials,"Washington University School of Medicine|Cedars-Sinai Medical Center|UMC Utrecht|Johns Hopkins University|Massachusetts General Hospital|University of Massachusetts, Amherst|Biogen|ALS Association|Columbia University",All,,128.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,14LGCA123,February 2015,"December 31, 2017","October 2, 2018","February 19, 2016",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02686268,18.0,100.0
2264,408,48.8566101,2.3514992,"UCLA Neuromuscular Research Program, Los Angeles, California, United States",409.0,NCT03545451,Neurofeedback Rehabilitation Based on Motor Imaging in Patients in the Immobilization Phase,REMINARY,Recruiting,No Results Available,"Healthy Subjects, Patients With Amyotrophic Lateral Sclerosis, Patients With Shoulder Surgery",Device: Videogames,Performance|electroencephalography activity|functional brain MRI,Assistance Publique - H√¥pitaux de Paris,All,Not Applicable,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,K170502J,"October 3, 2018",June 2021,June 2021,"June 4, 2018",,"October 11, 2018",,https://ClinicalTrials.gov/show/NCT03545451,18.0,70.0
2265,409,27.7567667,-81.4639835,"UCD Telehealth Network, Multiple Locations, California, United States",410.0,NCT01699451,"DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida",,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis (ALS),,Repository sample collection,Mayo Clinic,All,,160.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,12-004718,September 2012,December 2019,December 2019,"October 3, 2012",,"June 6, 2019",,https://ClinicalTrials.gov/show/NCT01699451,18.0,100.0
2266,410,35.6729639,-79.0392919,"UC Irvine Health ALS & Neuromuscular Center, Orange, California, United States",411.0,NCT00324454,"Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease",,Completed,No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Progressive Muscular Atrophy,Biological: Levetiracetam,"Safety and tolerability at 9 months of treatment.|Cramps scores, spasticity scores, FVC, ALSFRS, MMT",Duke University|UCB Pharma,All,Phase 2,20.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00005846|8380-06-3R0,May 2006,December 2007,June 2008,"May 11, 2006",,"June 19, 2013",,https://ClinicalTrials.gov/show/NCT00324454,18.0,100.0
2267,411,35.2048883,-92.4479108,"UC, Davis Medical Center ALS Clinic, Sacramento, California, United States",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2268,411,36.7014631,-118.7559974,"Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2269,411,36.7014631,-118.7559974,"Department of neurology, University Hospital of Muenster, Muenster, Nordrhein-Westfalen, Germany",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2270,411,38.7251776,-105.6077167,"CHU de Bordeaux -H√¥pital Haut-L√©v√™que, Bordeaux, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2271,411,41.6500201,-72.7342163,"CHU Cr√©teil - Groupe Hospitalier Henri Mondor, Creteil, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2272,411,40.0796606,-89.4337288,"CHRU Lille - H√¥pital Roger Salengro, Lille, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2273,411,40.0796606,-89.4337288,"CHU de Lyon - H√¥pital Pierre Wertheimer, Lyon, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2274,411,38.27312,-98.5821872,"CHU de Marseille - H√¥pital de La Timone, Marseille, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2275,411,37.5726028,-85.1551411,"CHU de Nice - H√¥pital l'Archet, Nice, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2276,411,42.3788774,-72.032366,"CHU Paris - H√¥pital Piti√© Salp√©tri√®re, Paris, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2277,411,42.3788774,-72.032366,"CHU de Saint Etienne - H√¥pital Nord, Saint Etienne, France",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2278,411,45.9896587,-94.6113288,"Universit√† di Genova - Ospedale San Martino, Genova, Italy",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2279,411,38.7604815,-92.5617875,"IRCCS Istituto Clinico Humanitas, Milan, Italy",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2280,411,40.7127281,-74.0060152,"Universit√† Cattolica del Sacro Cuore, Roma, Italy",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2281,411,40.7127281,-74.0060152,"Azienda Ospedaliero Universitaria San Giovanni Battista, Turin, Italy",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2282,411,40.2253569,-82.6881395,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2283,411,40.9699889,-77.7278831,"Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2284,411,31.8160381,-99.5120986,"Hospital Universitario Virgen del Rocio, Sevilla, Spain",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2285,411,44.5990718,-72.5002608,"Hospital Universitari i Polit√®cnic La Fe, Valencia, Spain",412.0,NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,,Completed,Has Results,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease,Drug: coenzyme Q10|Drug: Placebo,Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.|The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).,Columbia University|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 2,185.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AAAA1536|R01NS048125,April 2005,March 2008,March 2008,"October 25, 2005","March 17, 2011","February 28, 2014",,https://ClinicalTrials.gov/show/NCT00243932,21.0,85.0
2286,412,35.6729639,-79.0392919,"Queen Elizabeth Hospital, Birmingham, United Kingdom",413.0,NCT00076154,National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank,ALS Registry,Completed,No Results Available,ALS,,Help studies using dates and DNA collected to determine possible genetic factor.,US Department of Veterans Affairs|ALS Association|VA Office of Research and Development,All,,2121.0,U.S. Fed|Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,500A,January 2003,September 2007,September 2009,"January 16, 2004",,"April 21, 2014",,https://ClinicalTrials.gov/show/NCT00076154,18.0,100.0
2287,413,35.6729639,-79.0392919,"Southampton General Hospital, Southampton, United Kingdom",414.0,NCT00956488,Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Lou Gehrig's Disease,Behavioral: Treadmill Exercise,Twenty Five Foot Walk Test (25FWT)|The Six-Minute Walk Test (6MWT)|Fatigue severity scale (FSS)|Muscle strength|ALS functional rating scale (ALSFRS-R)|Vital Capacity|Beck Depression Inventory (BDI),Atrium Health,All,Phase 1|Phase 2,9.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,07-08-15E,September 2008,September 2010,September 2010,"August 11, 2009",,"August 2, 2013",,https://ClinicalTrials.gov/show/NCT00956488,25.0,75.0
2288,NULL,NULL,NULL,"Massachusetts General Hospital - East, Charlestown, Massachusetts, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2289,415,,,"Duke University Medical Center, Durham, North Carolina, United States",416.0,NCT02852278,A Patient Centric Motor Neuron Disease Activities of Daily Living Scale,,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|Progressive Muscular Atrophy|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia,Other: Web-based Survey,PADL-ALS Survey,University of South Florida|National Institutes of Health (NIH)|University of Kansas|University of Miami,All,,356.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,CReATe 8003|U01TR001263,December 2016,"June 12, 2019","June 12, 2019","August 2, 2016",,"September 27, 2018",,https://ClinicalTrials.gov/show/NCT02852278,18.0,100.0
2290,416,42.3788774,-72.032366,"University Medical Center Leipzig, Leipzig, Saxony, Germany",417.0,NCT03488524,Open Label Extension Study of AMX0035 in Patients With ALS,CENTAUR-OLE,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|ALS,Drug: AMX0035,Quantity of adverse events and serious adverse events observed in the study|Hospitalizations|Rate of Progression on the Amyotrophic Lateral Sclerosis Rating Scale Revised (ALSFRS-R)|Rate of Progression on ATLIS Strength Measurement|Rate of Progression on Slow Vital Capacity|Gastric Tube Frequency|Permanent Invasive Ventilation,Amylyx Pharmaceuticals Inc.|Massachusetts General Hospital Neurology Clinical Research Institute,All,Phase 2,132.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMX-3500-OLE,"March 29, 2018","January 1, 2020","January 1, 2020","April 5, 2018",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03488524,18.0,100.0
2291,416,42.3788774,-72.032366,"UF Gainsville, Gainesville, Florida, United States",417.0,NCT03488524,Open Label Extension Study of AMX0035 in Patients With ALS,CENTAUR-OLE,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|ALS,Drug: AMX0035,Quantity of adverse events and serious adverse events observed in the study|Hospitalizations|Rate of Progression on the Amyotrophic Lateral Sclerosis Rating Scale Revised (ALSFRS-R)|Rate of Progression on ATLIS Strength Measurement|Rate of Progression on Slow Vital Capacity|Gastric Tube Frequency|Permanent Invasive Ventilation,Amylyx Pharmaceuticals Inc.|Massachusetts General Hospital Neurology Clinical Research Institute,All,Phase 2,132.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMX-3500-OLE,"March 29, 2018","January 1, 2020","January 1, 2020","April 5, 2018",,"August 6, 2019",,https://ClinicalTrials.gov/show/NCT03488524,18.0,100.0
2292,417,,,"MGH, Boston, Massachusetts, United States",418.0,NCT00718393,Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Cerebrospinal Fluid|Neurodegenerative Disease|Motor Neuron Disease,,,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,1.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,Internal-16964,June 2007,October 2015,October 2015,"July 18, 2008",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT00718393,20.0,85.0
2293,418,,,"Hospital for Special Surgery, New York, New York, United States",419.0,NCT01123148,A P300 Brain Computer Interface to Operate Power Wheelchair Tilt,,Completed,Has Results,Healthy|Amyotrophic Lateral Sclerosis,Device: Using a BCI to control wheelchair tilt,The Accuracy of BCI Typing While Tilting in a Power Wheelchair and While Sitting Still in a Power Wheelchair.,University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,Not Applicable,16.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,M0001|R21HD054913,January 2010,August 2010,August 2010,"May 14, 2010","August 1, 2016","August 1, 2016",,https://ClinicalTrials.gov/show/NCT01123148,18.0,99.0
2294,419,36.7014631,-118.7559974,"Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, United States",420.0,NCT01811355,Mexiletine for the Treatment of Muscle Cramps in ALS,,Completed,Has Results,Muscle Cramps in Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Daily Muscle Cramps|Cramp Severity,"Bjorn Oskarsson, MD|University of California, Davis|ALS Association",All,Phase 4,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",378164,May 2013,March 2016,May 2016,"March 14, 2013","June 27, 2017","August 28, 2017",,https://ClinicalTrials.gov/show/NCT01811355,21.0,89.0
2295,419,36.7014631,-118.7559974,"Somnos/Neurology Associates Clinical Research, Lincoln, Nebraska, United States",420.0,NCT01811355,Mexiletine for the Treatment of Muscle Cramps in ALS,,Completed,Has Results,Muscle Cramps in Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Daily Muscle Cramps|Cramp Severity,"Bjorn Oskarsson, MD|University of California, Davis|ALS Association",All,Phase 4,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",378164,May 2013,March 2016,May 2016,"March 14, 2013","June 27, 2017","August 28, 2017",,https://ClinicalTrials.gov/show/NCT01811355,21.0,89.0
2296,419,36.7014631,-118.7559974,"Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States",420.0,NCT01811355,Mexiletine for the Treatment of Muscle Cramps in ALS,,Completed,Has Results,Muscle Cramps in Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Daily Muscle Cramps|Cramp Severity,"Bjorn Oskarsson, MD|University of California, Davis|ALS Association",All,Phase 4,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",378164,May 2013,March 2016,May 2016,"March 14, 2013","June 27, 2017","August 28, 2017",,https://ClinicalTrials.gov/show/NCT01811355,21.0,89.0
2297,419,36.7014631,-118.7559974,"Wesley Neurology Clinic, Cordova, Tennessee, United States",420.0,NCT01811355,Mexiletine for the Treatment of Muscle Cramps in ALS,,Completed,Has Results,Muscle Cramps in Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Daily Muscle Cramps|Cramp Severity,"Bjorn Oskarsson, MD|University of California, Davis|ALS Association",All,Phase 4,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",378164,May 2013,March 2016,May 2016,"March 14, 2013","June 27, 2017","August 28, 2017",,https://ClinicalTrials.gov/show/NCT01811355,21.0,89.0
2298,419,36.7014631,-118.7559974,"Texas Neurology, Dallas, Texas, United States",420.0,NCT01811355,Mexiletine for the Treatment of Muscle Cramps in ALS,,Completed,Has Results,Muscle Cramps in Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Daily Muscle Cramps|Cramp Severity,"Bjorn Oskarsson, MD|University of California, Davis|ALS Association",All,Phase 4,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",378164,May 2013,March 2016,May 2016,"March 14, 2013","June 27, 2017","August 28, 2017",,https://ClinicalTrials.gov/show/NCT01811355,21.0,89.0
2299,419,36.7014631,-118.7559974,"Barrow Neurological Institute, Phoenix, Arizona, United States",420.0,NCT01811355,Mexiletine for the Treatment of Muscle Cramps in ALS,,Completed,Has Results,Muscle Cramps in Amyotrophic Lateral Sclerosis,Drug: Mexiletine|Drug: Placebo,Daily Muscle Cramps|Cramp Severity,"Bjorn Oskarsson, MD|University of California, Davis|ALS Association",All,Phase 4,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",378164,May 2013,March 2016,May 2016,"March 14, 2013","June 27, 2017","August 28, 2017",,https://ClinicalTrials.gov/show/NCT01811355,21.0,89.0
2300,NULL,NULL,NULL,"Research Site, Orlando, Florida, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2301,421,51.4785568,7.5533645,"Research Site, Brooklyn Center, Minnesota, United States",422.0,NCT00298597,Influence of G-CSF and EPO on Associative Learning and Motor Skills,,Completed,No Results Available,Chronic Stroke|Amyotrophic Lateral Sclerosis,Drug: granulocyte - colony stimulating factor (G-CSF)|Drug: erythropoetin (EPO),Learning success in a word learning model|Response time in motor function tests|Response time in a word learning model|Total time and number of keystrokes in motor function tests,University Hospital Muenster,All,Phase 2,180.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,GCSFEPO_01|EudraCT Number 2005-001113-18,March 2006,March 2009,March 2009,"March 2, 2006",,"April 23, 2009",,https://ClinicalTrials.gov/show/NCT00298597,18.0,100.0
2302,422,44.841225,-0.5800364,"University of South Carolina School of Medicine, Columbia, South Carolina, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2303,422,48.7771486,2.4530731,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2304,422,50.6365654,3.0635282,"Neuromuscular Research Center, Scottsdale, Arizona, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2305,422,45.6963425,4.73594802991681,"South Coast Clinical Trials, Anaheim, California, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2306,422,43.2961743,5.3699525,"UCI Medical Center, Irvine, California, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2307,422,43.7009358,7.2683912,"Center for Neurologic Study, La Jolla, California, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2308,422,48.8566101,2.3514992,"UCLA School of Medicine, Los Angeles, California, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2309,422,45.4401467,4.3873058,"The Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2310,422,44.40726,8.9338624,"The ALS Center at UCSF, San Francisco, California, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2311,422,45.4667971,9.1904984,"University of Colorado at Denver & Health Science Center, Aurora, Colorado, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2312,422,41.894802,12.4853384,"Neuroscience Center, Ft. Lauderdale, Florida, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2313,422,45.0677551,7.6824892,"Mayo Clinic, Jacksonville, Florida, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2314,422,41.3828939,2.1774322,"University of Miami, Miami, Florida, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2315,422,42.8804219,-8.5458608,"Suncoast Neuroscience Associates, St. Petersburg, Florida, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2316,422,37.3886303,-5.9953403,"The ALS Center at Emory University, Atlanta, Georgia, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2317,422,39.4699014,-0.3759513,"Neurology Specialists of Decatur of Decatur, Decatur, Georgia, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2318,422,52.4775396,-1.894053,"Northwestern University, Chicago, Illinois, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2319,422,50.9137978,-1.39904048346365,"Consultants in Neurology, Northbrook, Illinois, United States",423.0,NCT01951924,LIME Study (LFB IVIg MMN Efficacy Study),LIME,Completed,No Results Available,Motor Neuron Disease,Drug: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|Drug: Biological: Kiovig¬Æ (Human normal Immunoglobulin for intravenous administration 100mg/mL),Change between I10E and Kiovig¬Æ in the original MMRC 10 sum score described by Cats 2008|Change between I10E and Kiovig¬Æ in: MMRC 10 new sum score (10 slightly different muscles on both sides)|AEs observed and reported TAAEs (temporally associated AE) beginning at infusion or within 72H after infusion|Change between I10E and Kiovig¬Æ in : Rasch built MMRC sum score (Cats 2008)|Change between I10E and Kiovig¬Æ in : INCAT: upper and lower limbs|Change between I10E and Kiovig¬Æ: Grip strength|Change between I10E and Kiovig¬Æ in: MMRC 14 sum score,Laboratoire fran√ßais de Fractionnement et de Biotechnologies|TFS Trial Form Support,All,Phase 3,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",I10E-0901,December 2013,July 2016,July 2016,"September 27, 2013",,"July 19, 2016",,https://ClinicalTrials.gov/show/NCT01951924,18.0,80.0
2320,423,,,"University of Kentucky Health Care - Dept. of Neurology, Lexington, Kentucky, United States",424.0,NCT03067857,Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease,,"Active, not recruiting",No Results Available,Motor Neuron Disease|Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Progressive Muscular Atrophy|Progressive Bulbar Palsies,Biological: Stem Cells,Changes in Functional Rating Scale - via questionnaire|Change in Appel Scale|Change in SF-36 (The Short Form (36) Health Survey is a 36 Item)|Change in Forced Vital Capacity (FVC),Stem Cells Arabia,All,Phase 1|Phase 2,40.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCA-MND1,September 2016,January 2019,August 2019,"March 1, 2017",,"June 5, 2018",,https://ClinicalTrials.gov/show/NCT03067857,24.0,70.0
2321,424,42.3788774,-72.032366,"The John Hopkins Universitiy, Baltimore, Maryland, United States",425.0,NCT00606918,Validation of a New Device to Measure Neuromuscular Disease Progression,ATLIS,Completed,No Results Available,Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders,,isometric strength measures,Massachusetts General Hospital,All,,120.0,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,MDA-4343,January 2008,September 2010,September 2010,"February 5, 2008",,"May 12, 2011",,https://ClinicalTrials.gov/show/NCT00606918,18.0,100.0
2322,425,35.6729639,-79.0392919,"Massachusets General Hospital, Boston, Massachusetts, United States",426.0,NCT02457715,Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis,,Completed,No Results Available,Prostate Cancer|Renal Cancer|Brain Cancer|ALS,,Compliance rate of cancer and ALS patients using the device during a 14 week period.|Number of steps per day in cancer patients.|Karnofsky performance status in cancer patients.,Duke University,All,,40.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00063108,July 2015,October 2017,October 2017,"May 29, 2015",,"December 12, 2017",,https://ClinicalTrials.gov/show/NCT02457715,18.0,100.0
2323,426,50.9295798,13.4585052,"Baystate Medical Center, Springfield, Massachusetts, United States",427.0,NCT03975608,Psychological Therapy for Patients With ALS,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Psychological Stress,"Behavioral: Adaptation of ""CALM""",Response rate|Patient adherence|Patient satisfaction|Level of quality of life|Level of depressive symptomatology|Level of functioning,University of Leipzig,All,Not Applicable,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ALS_Pilot,"February 11, 2019",December 2019,March 2020,"June 5, 2019",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT03975608,18.0,100.0
2324,427,27.7567667,-81.4639835,"University of Michigan, Ann Arbor, Michigan, United States",428.0,NCT02868567,Use of Dalfampridin in Primary Lateral Sclerosis,,Recruiting,No Results Available,"Motor Neuron Disease, Upper",Drug: dalfampridine,consistent improvement in the Timed 25 Foot Walk test|Effect of Dalfampridine on quality of life|Effects of Dalfampridine on functional status,"Weill Medical College of Cornell University|Hospital for Special Surgery, New York",All,Phase 1,35.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-247,March 2016,January 2020,September 2020,"August 16, 2016",,"March 27, 2019",,https://ClinicalTrials.gov/show/NCT02868567,18.0,99.0
2325,427,42.3788774,-72.032366,"Henry Ford Hospital, Detroit, Michigan, United States",428.0,NCT02868567,Use of Dalfampridin in Primary Lateral Sclerosis,,Recruiting,No Results Available,"Motor Neuron Disease, Upper",Drug: dalfampridine,consistent improvement in the Timed 25 Foot Walk test|Effect of Dalfampridine on quality of life|Effects of Dalfampridine on functional status,"Weill Medical College of Cornell University|Hospital for Special Surgery, New York",All,Phase 1,35.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-247,March 2016,January 2020,September 2020,"August 16, 2016",,"March 27, 2019",,https://ClinicalTrials.gov/show/NCT02868567,18.0,99.0
2326,427,40.7127281,-74.0060152,"St.Louis University - Neuromuscular Clinic, St. Louis, Missouri, United States",428.0,NCT02868567,Use of Dalfampridin in Primary Lateral Sclerosis,,Recruiting,No Results Available,"Motor Neuron Disease, Upper",Drug: dalfampridine,consistent improvement in the Timed 25 Foot Walk test|Effect of Dalfampridine on quality of life|Effects of Dalfampridine on functional status,"Weill Medical College of Cornell University|Hospital for Special Surgery, New York",All,Phase 1,35.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-247,March 2016,January 2020,September 2020,"August 16, 2016",,"March 27, 2019",,https://ClinicalTrials.gov/show/NCT02868567,18.0,99.0
2327,428,27.7567667,-81.4639835,"Advanced Neurology Specialists, Great Falls, Montana, United States",429.0,NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",,Completed,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: BHV-0223,"Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|BHV-0223 Concentrations in Blood at Days 1, 29 and 57","Biohaven Pharmaceuticals, Inc.|Cognitive Research Corporation",All,Phase 1,22.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHV0223-103,"February 2, 2018","October 8, 2018","October 8, 2018","May 9, 2018",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03520517,18.0,100.0
2328,428,41.7370229,-99.5873816,"Neurology Associates, Lincoln, Nebraska, United States",429.0,NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",,Completed,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: BHV-0223,"Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|BHV-0223 Concentrations in Blood at Days 1, 29 and 57","Biohaven Pharmaceuticals, Inc.|Cognitive Research Corporation",All,Phase 1,22.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHV0223-103,"February 2, 2018","October 8, 2018","October 8, 2018","May 9, 2018",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03520517,18.0,100.0
2329,428,35.6729639,-79.0392919,"Universitiy of Nevada, Las Vegas, Nevada, United States",429.0,NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",,Completed,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: BHV-0223,"Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|BHV-0223 Concentrations in Blood at Days 1, 29 and 57","Biohaven Pharmaceuticals, Inc.|Cognitive Research Corporation",All,Phase 1,22.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHV0223-103,"February 2, 2018","October 8, 2018","October 8, 2018","May 9, 2018",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03520517,18.0,100.0
2330,428,35.7730076,-86.2820081,"Upstate Clinical Research, Albany, New York, United States",429.0,NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",,Completed,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: BHV-0223,"Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|BHV-0223 Concentrations in Blood at Days 1, 29 and 57","Biohaven Pharmaceuticals, Inc.|Cognitive Research Corporation",All,Phase 1,22.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHV0223-103,"February 2, 2018","October 8, 2018","October 8, 2018","May 9, 2018",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03520517,18.0,100.0
2331,428,31.8160381,-99.5120986,"Jacobs Neurological Institute, Buffalo, New York, United States",429.0,NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",,Completed,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: BHV-0223,"Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|BHV-0223 Concentrations in Blood at Days 1, 29 and 57","Biohaven Pharmaceuticals, Inc.|Cognitive Research Corporation",All,Phase 1,22.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHV0223-103,"February 2, 2018","October 8, 2018","October 8, 2018","May 9, 2018",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03520517,18.0,100.0
2332,429,34.395342,-111.7632755,"Mount Sinai Medical Center, New York, New York, United States",430.0,NCT03868345,Speech Analysis in ALS Patients,,Recruiting,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig Disease,,"Change in ability on Speech and Language Battery|Change in Montreal Cognitive Assessment|Change in ALS Cognitive Behavioral Screen|Change in Vital Capacity|Change in Negative Inspiratory Force|Change in ""ALS Functional Rating Scale- Revised""",Barrow Neurological Institute|Arizona State University,All,,50.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,BNI-ALS-003,"February 18, 2019","August 31, 2019","December 31, 2019","March 11, 2019",,"March 11, 2019",,https://ClinicalTrials.gov/show/NCT03868345,21.0,100.0
2333,430,,,"Neurological Institute - Columbia Presbyterian Center, New York, New York, United States",431.0,NCT03076632,Interactions Between Neurostimulation and Physical Exercise,,Withdrawn,No Results Available,Spinal Cord Injuries|Amyotrophic Lateral Sclerosis,Device: Cervical plus transcranial stimulation|Device: Cervical stimulation plus hand/wrist exercise|Device: Electromyographic (EMG)-triggered (closed-loop) stimulation,Motor evoked potentials (MEP)|Volitional electromyographic (EMG) activity|Response to closed-loop stimulation,Bronx VA Medical Center,All,Not Applicable,0.0,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Device Feasibility,HAR-16-042,"April 1, 2017","September 26, 2017","September 26, 2017","March 10, 2017",,"September 28, 2017",,https://ClinicalTrials.gov/show/NCT03076632,21.0,65.0
2334,431,27.7567667,-81.4639835,"Carolinas Medical Center, Charlotte, North Carolina, United States",432.0,NCT01424176,Dexpramipexole Renal PK Study,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Renal Insufficiency,Drug: Dexpramipexole (dose 1)|Drug: Dexpramipexole (dose 2),AUC after single dose of dexpramipexole|Cmax after single dose of dexpramipexole|Mointoring of Clinical Laboratory tests|ECG Monitoring|Vital Sign monitoring|AE monitoring,Knopp Biosciences,All,Phase 1,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,223RI101,July 2011,January 2012,January 2012,"August 26, 2011",,"November 25, 2014",,https://ClinicalTrials.gov/show/NCT01424176,18.0,75.0
2335,431,45.9896587,-94.6113288,"Duke Universitiy Medical Center, Durham, North Carolina, United States",432.0,NCT01424176,Dexpramipexole Renal PK Study,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Renal Insufficiency,Drug: Dexpramipexole (dose 1)|Drug: Dexpramipexole (dose 2),AUC after single dose of dexpramipexole|Cmax after single dose of dexpramipexole|Mointoring of Clinical Laboratory tests|ECG Monitoring|Vital Sign monitoring|AE monitoring,Knopp Biosciences,All,Phase 1,36.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,223RI101,July 2011,January 2012,January 2012,"August 26, 2011",,"November 25, 2014",,https://ClinicalTrials.gov/show/NCT01424176,18.0,75.0
2336,432,33.6874388,-80.4363743,"Department of Neurology - The Cleveland Clinic Foundation, Cleveland, Ohio, United States",433.0,NCT00965497,Escitalopram (Lexapro) for Depression MS or ALS,,Completed,Has Results,Major Depression|Multiple Sclerosis|Amyotrophic Lateral Sclerosis,Drug: escitalopram,Hamilton Depression Scale (HAM-D 17).|McGill Quality of Life Scale (MQOL),University of South Carolina,All,Phase 3,13.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00003013,July 2009,March 2010,March 2010,"August 25, 2009","September 7, 2011","May 1, 2019",,https://ClinicalTrials.gov/show/NCT00965497,18.0,70.0
2337,433,34.395342,-111.7632755,"Ohio State Universitiy, Columbus, Ohio, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2338,433,34.395342,-111.7632755,"Oregon Health Science University, Portland, Oregon, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2339,433,36.7014631,-118.7559974,"Drexel University - Department of Neurology, Philadelphia, Pennsylvania, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2340,433,36.7014631,-118.7559974,"The ALS Center - Penn Neurological Institute - The University of Pennsylvania, Philadelphia, Pennsylvania, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2341,433,36.7014631,-118.7559974,"Vanderbilt University, Nashville, Tennessee, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2342,433,36.7014631,-118.7559974,"The Methodist Hospital - Baylor College of Medicine, Houston, Texas, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2343,433,36.7014631,-118.7559974,"Department of Neuropsychiatry - Texas Tech University, Lubbock, Texas, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2344,433,36.7014631,-118.7559974,"University of Texas Health Science Center, San Antonio, Texas, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2345,433,38.7251776,-105.6077167,"Universitiy of Vermont, Burlington, Vermont, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2346,433,27.7567667,-81.4639835,"West Virginia University, Morgantown, West Virginia, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2347,433,27.7567667,-81.4639835,"Dean Foundation, Madison, Wisconsin, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2348,433,27.7567667,-81.4639835,"FACENE, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2349,433,27.7567667,-81.4639835,"IADIN, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2350,433,32.3293809,-83.1137366,"Hospital Italiano, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2351,433,32.3293809,-83.1137366,"INEBA, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2352,433,40.0796606,-89.4337288,"Hospital Ramos Mejia, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2353,433,40.0796606,-89.4337288,"Hospital Britanico, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2354,433,37.5726028,-85.1551411,"Policlinico Bancario, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2355,433,39.5162234,-76.9382069,"FLENI, Buenos Aires, Ciudad de Buenos Aires, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2356,433,42.3788774,-72.032366,"Instituto Medico Rodriguez Alfici, Godoy Cruz, Mendoza, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2357,433,42.3788774,-72.032366,"Instituto de Neurociencias Rosario, Rosario, Santa Fe, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2358,433,43.6211955,-84.6824346,"Hospital Militar Regional de Cordoba, Cordoba, Argentina",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2359,433,43.6211955,-84.6824346,"Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, M G, Brazil",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2360,433,38.7604815,-92.5617875,"Hospital da Restaura√ß√£o, Recife, PE, Brazil",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2361,433,47.3752671,-109.6387579,"Hospital de Cl√≠nicas-UFPR, Curitiba, PR, Brazil",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2362,433,41.7370229,-99.5873816,"Hospital Universit√°rio Clementino Fraga Filho, Rio de Janeiro, RJ, Brazil",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2363,433,39.5158825,-116.8537227,"Hospital Moinhos de Vento, Porto Alegre, RS, Brazil",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2364,433,40.7127281,-74.0060152,"Hospital das Cl√≠nicas da Faculdade de Medicina da Universidade S√£o Paulo, Sao Paulo, SP, Brazil",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2365,433,40.7127281,-74.0060152,"H√¥pital Roger Salengro, CHRU de Lille, Lille, France",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2366,433,40.7127281,-74.0060152,"Duke ALS Clinic / DUSOM Dept of Neurology / DUHS, Durham, North Carolina, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2367,433,40.7127281,-74.0060152,"University of Kansas Medical Center, Fairway, Kansas, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2368,433,35.6729639,-79.0392919,"University of Missouri-Columbia, Columbia, Missouri, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2369,433,35.6729639,-79.0392919,"Northwestern, Chicago, Illinois, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2370,433,40.2253569,-82.6881395,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2371,NULL,NULL,NULL,"James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2372,NULL,NULL,NULL,"UF Clinical Research Center, Gainesville, Florida, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2373,433,40.9699889,-77.7278831,"University of Florida, Gainesville, Florida, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2374,433,40.9699889,-77.7278831,"Barrow Neurological Institute, Phoenix, Arizona, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2375,433,35.7730076,-86.2820081,"University of California, Irvine, Dept. of Neurology, Orange, California, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2376,433,31.8160381,-99.5120986,"University of Michigan   Neurology - ALS Clinic, Ann Arbor, Michigan, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2377,433,31.8160381,-99.5120986,"Spectrum Health, Grand Rapids, Michigan, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2378,433,31.8160381,-99.5120986,"Hospital for Special Surgery (HSS), New York, New York, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2379,433,44.5990718,-72.5002608,"Oregon Health & Science University, Portland, Oregon, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2380,433,38.4758406,-80.8408415,"Temple University, Philadelphia, Pennsylvania, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2381,433,44.4308975,-89.6884637,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2382,433,-34.6075616,-58.437076,"Department of Neurosurgery & Neurology   Medical University of South Carolina, Charleston, South Carolina, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2383,433,-34.6075616,-58.437076,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2384,433,-34.6075616,-58.437076,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2385,433,-34.6075616,-58.437076,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2386,433,-34.6075616,-58.437076,"Johns Hopkins University, Baltimore, Maryland, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2387,433,-34.6075616,-58.437076,"Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2388,433,-34.6075616,-58.437076,"University of California Irvine, Orange, California, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2389,433,-34.6075616,-58.437076,"Mayo Clinic Neurology, Jacksonville, Florida, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2390,433,-32.8897294,-68.8442956,"University of Miami, Miami, Florida, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2391,433,-31.6186951,-60.7019561,"Emory University, Atlanta, Georgia, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2392,433,-32.0967361,-63.7940923,"University of Chicago, Chicago, Illinois, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2393,433,-10.3333333,-53.2,"Johns Hopkins University, Baltimore, Maryland, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2394,433,-8.4116316,-37.5919699,"Massachusetts General Hospital, Boston, Massachusetts, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2395,433,-24.4842187,-51.8148872,"Lahey Clinic, Burlington, Massachusetts, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2396,433,-22.2752762,-42.419415,"Saint Mary's Healthcare, Grand Rapids, Michigan, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2397,433,-29.8425284,-53.7680577,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2398,433,-10.3333333,-53.2,"Saint Louis University, Saint Louis, Missouri, United States",434.0,NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,STAR,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted|Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects",Avanir Pharmaceuticals|Syneos Health,All,Phase 3,326.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,December 2007,June 2009,September 2009,"December 14, 2007","July 10, 2013","April 12, 2017",,https://ClinicalTrials.gov/show/NCT00573443,18.0,80.0
2399,434,50.6365654,3.0635282,"Washington University, Saint Louis, Missouri, United States",435.0,NCT02880033,Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes,LymphoEnergy,"Active, not recruiting",No Results Available,Parkinson's Disease|Amyotrophic Lateral Sclerosis|Oxidative Stress|Iron Overload,Drug: deferiprone|Drug: placebo,hydroxyl radical measured|adenosine triphosphate production measured by seahorse|oxygen consumption measured by seahorse|free reactive iron (ferrous iron)|lipid peroxidation measured by Fluorescence-activated cell sorting,"University Hospital, Lille",All,Not Applicable,90.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2010_29|2010-A01216-33,February 2011,December 2019,December 2019,"August 26, 2016",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02880033,18.0,80.0
2400,435,35.6729639,-79.0392919,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",436.0,NCT03464903,Study of ALS Reversals 2: Genetic Analyses,StAR2,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|Progressive Muscular Atrophy,,genetic comparison|factors associated with genes,Duke University|Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium (funded by NIH/NCATS/NINDS),All,,30.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,Pro00091570|8007,"June 25, 2018","August 1, 2020","August 1, 2020","March 14, 2018",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03464903,18.0,100.0
2401,436,38.27312,-98.5821872,"Robert Wood Johnson/UMDNJ, New Brunswick, New Jersey, United States",437.0,NCT03613038,A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Parkinson Disease,Behavioral: Phonetic complexity effects on speech motor performance,Peak movement speed|Range of movement|Duration|Spatiotemporal movement variability (STI)|Inter-articulator coordination,University of Missouri-Columbia|National Institute on Deafness and Other Communication Disorders (NIDCD),All,Not Applicable,150.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1209643|1R15DC016383-01,"July 15, 2017","January 31, 2020","July 14, 2020","August 2, 2018",,"September 3, 2018",,https://ClinicalTrials.gov/show/NCT03613038,19.0,90.0
2402,436,38.7604815,-92.5617875,"Upstate Clinical Research, LLC, Albany, New York, United States",437.0,NCT03613038,A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Parkinson Disease,Behavioral: Phonetic complexity effects on speech motor performance,Peak movement speed|Range of movement|Duration|Spatiotemporal movement variability (STI)|Inter-articulator coordination,University of Missouri-Columbia|National Institute on Deafness and Other Communication Disorders (NIDCD),All,Not Applicable,150.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1209643|1R15DC016383-01,"July 15, 2017","January 31, 2020","July 14, 2020","August 2, 2018",,"September 3, 2018",,https://ClinicalTrials.gov/show/NCT03613038,19.0,90.0
2403,437,40.0796606,-89.4337288,"Beth Israel Medical Center, PACC, New York, New York, United States",438.0,NCT03797677,MN4000 for Treatment of CF and MND Patients in the Home Setting,,Completed,No Results Available,Cystic Fibrosis|Motor Neuron Disease|Airway Clearance Impairment,Device: MN 4000,Patient / Caregiver Satisfaction scores|Mean adherence to prescribed treatment regimen|ALS-Functional Rating Scale (ALS-FRS)|Cystic Fibrosis Questionnaire - Revised (CFQ-R)|Exacerbation of pulmonary disease|FEV1|FVC|FEV1/FVC ratio|SVC|SPO2|Maximal inspiratory pressure (MIP)|PCF,Hill-Rom,All,Not Applicable,10.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR-RR2016-002,"March 9, 2017","November 30, 2017","November 30, 2017","January 9, 2019",,"January 9, 2019","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03797677/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03797677,18.0,100.0
2404,438,39.5162234,-76.9382069,"SUNY Upstate Medical University, Syracuse, New York, United States",439.0,NCT00071435,Brain Function in Primary Lateral Sclerosis,,Completed,No Results Available,Motor Neuron Disease,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,36.0,NIH,Observational,,040017|04-N-0017,October 2003,,February 2006,"October 23, 2003",,"March 4, 2008",,https://ClinicalTrials.gov/show/NCT00071435,18.0,100.0
2405,439,,,"Carolinas Health Care, Charlotte, North Carolina, United States",440.0,NCT00004771,Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease,,Completed,No Results Available,Spinal Muscular Atrophy|Amyotrophic Lateral Sclerosis|Spinobulbar Muscular Atrophy,Drug: leuprolide|Drug: testosterone,,National Center for Research Resources (NCRR)|Ohio State University|Office of Rare Diseases (ORD),Male,Phase 2,40.0,NIH|Other,Interventional,Primary Purpose: Treatment,199/11792|OSU-92H0325,October 1992,,,"February 25, 2000",,"June 24, 2005",,https://ClinicalTrials.gov/show/NCT00004771,18.0,100.0
2406,440,40.7127281,-74.0060152,"Duke University Medical Center, Durham, North Carolina, United States",441.0,NCT02469675,Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS,,Completed,No Results Available,Spinal Cord Injury (SCI)|Amyotrophic Lateral Sclerosis (ALS),Device: Transcranial magnetic stimulation|Device: Median nerve stimulation|Device: Cervical transcutaneous stimulation,Change in motor evoked potential (MEP) amplitude of the abductor pollicis brevis (APB) muscle response to single pulses of TMS|Hand dexterity|Safety and tolerability|Grip strength|Change in the duration of the 'cortical silent period' after TMS stimulation during APB contraction|F-wave responses of the APB muscle,Bronx VA Medical Center,All,Not Applicable,39.0,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,HAR-15-001,June 2015,"July 31, 2018","July 31, 2018","June 11, 2015",,"October 1, 2018",,https://ClinicalTrials.gov/show/NCT02469675,21.0,65.0
2407,441,,,"Wake Forest University, Winston-Salem, North Carolina, United States",442.0,NCT03100110,NeuroCognitive Communicator: Safety Study,NCC-1701,Not yet recruiting,No Results Available,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis|Tetraplegia",Device: NeuroCognitive Communicator,"Rate of adverse events|Change in quality of life as assessed by McGill Quality of Life questionnaire.|Percentage of allotted time spent with each augmentative and assistive communication technology.|Information transfer rate (measured in bits per second) achieved by each participant calculated during closed-loop operation of the neuroprosthetic device, aggregated across trials within a task.|Coefficients of neuronal activity covariance matrix and their dependence on task performance.",Ottawa Hospital Research Institute,All,Not Applicable,2.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,20170100-01H,April 2017,February 2019,May 2020,"April 4, 2017",,"April 4, 2017",,https://ClinicalTrials.gov/show/NCT03100110,18.0,70.0
2408,442,27.7567667,-81.4639835,"OSU Medical Center, Columbus, Ohio, United States",443.0,NCT03645031,Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease,AIH in ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS)|Neuromuscular Diseases,Other: Acute Intermittent Hypoxia|Other: Sham Acute Intermittent Hypoxia,Maximal Respiratory Pressures|Maximal Voluntary Grip Force|Minute Ventilation|Ventilatory Drive|Surface electromyography (EMG),University of Florida,All,Not Applicable,42.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB201801131|OCR18018,"October 1, 2018",March 2020,June 2020,"August 24, 2018",,"June 24, 2019",,https://ClinicalTrials.gov/show/NCT03645031,21.0,75.0
2409,442,27.7567667,-81.4639835,"Providence ALS Clinic, Portland, Oregon, United States",443.0,NCT03645031,Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease,AIH in ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS)|Neuromuscular Diseases,Other: Acute Intermittent Hypoxia|Other: Sham Acute Intermittent Hypoxia,Maximal Respiratory Pressures|Maximal Voluntary Grip Force|Minute Ventilation|Ventilatory Drive|Surface electromyography (EMG),University of Florida,All,Not Applicable,42.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB201801131|OCR18018,"October 1, 2018",March 2020,June 2020,"August 24, 2018",,"June 24, 2019",,https://ClinicalTrials.gov/show/NCT03645031,21.0,75.0
2410,443,34.395342,-111.7632755,"Oregon Health & Science University, Portland, Oregon, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2411,443,36.7014631,-118.7559974,"Pennsylvania State University, Hershey, Pennsylvania, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2412,443,43.6211955,-84.6824346,"Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2413,443,43.6211955,-84.6824346,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2414,443,40.7127281,-74.0060152,"Methodist Neurological Institute, Houston, Texas, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2415,443,43.9792797,-120.737257,"University of Utah, Salt Lake City, Utah, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2416,443,40.9699889,-77.7278831,"Montreal Neurological Institute, Montreal, Quebec, Canada",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2417,443,40.9699889,-77.7278831,"Duke ALS Clinic / DUSOM Dept of Neurology / DUHS, Durham, North Carolina, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2418,443,33.6874388,-80.4363743,"Barrow Neurological Institute, Phoenix, Arizona, United States",444.0,NCT02819765,Deep Phenotyping in Patients With ALS,,Recruiting,No Results Available,ALS|Motor Neuron Disease,,ALS Functional Rating Scale Revised (ALSFRS-R)|Slow vital capacity (SVC)|Hand held dynamometry (HHD)|ALS cognitive behavioral screen (ALS-CBS)|Multipoint incremental motor unit number estimates (MIMUNE)|Paired Pulse Stimulation Using Transcranial Magnetic Stimulation (TMS)|Threshold tracking nerve conduction studies (ttNCS),Barrow Neurological Institute|ALS Association,All,,50.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ALSA-BIO3|PHX16BN016,"February 7, 2017",July 2020,December 2020,"June 30, 2016",,"January 8, 2019",,https://ClinicalTrials.gov/show/NCT02819765,18.0,75.0
2419,444,40.9699889,-77.7278831,"University of Kansas Medical Center, Kansas City, Kansas, United States",445.0,NCT00718497,Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,Time Taken to Complete a Sentence,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,25.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,Internal-17018,August 2007,May 2012,May 2012,"July 18, 2008",,"March 5, 2013",,https://ClinicalTrials.gov/show/NCT00718497,18.0,89.0
2420,445,40.9699889,-77.7278831,"Massachusetts General Hospital, Boston, Massachusetts, United States",446.0,NCT00718445,Pennsylvania Consortium: Clinical Database,,Terminated,No Results Available,Amyotrophic Lateral Sclerosis|Neurodegenerative Disease|Motor Neuron Disease,,None Specified,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,25.0,Other,Observational,Observational Model: Cohort,Internal-17445,March 2008,December 2015,December 2015,"July 18, 2008",,"June 27, 2016",,https://ClinicalTrials.gov/show/NCT00718445,18.0,89.0
2421,446,39.5162234,-76.9382069,"Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States",447.0,NCT01369901,Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy,,Completed,No Results Available,Motor Neuron Disease,Behavioral: A functional exercise program|Behavioral: A stretching exercise program,"Adult Myopathy Assessment Tool (AMAT)|To assess the effect of functional exercise on muscle strength as measured by quantitative muscle analysis (QMA), and the Timed up and go test (TUG), and progressive height sit-to-stand.|Several exploratory biomarkers that may be affected by exercise will be evaluated, including insulin-like growth factor-1 (IGF-1), testosterone, growth hormone, and creatine kinase.|To assess the ability of patients to maintain exercise compliance as measured by accelerometer measurements.|To assess the effect of functional exercise on balance as measured by Computerized Dynamic Posturography (CDP) evaluation.|To assess the effect of functional exercise on adverse outcomes as measured by an adverse event questionnaire.|Beck Depression Inventory (BDI) testing will also be used to determine if the subjects mood is affected by exercise.|To assess the effect of functional exercise on quality of life as measured by the SF36v2.",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),Male,Phase 1|Phase 2,61.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,110171|11-N-0171,"June 8, 2011",,"February 28, 2018","June 9, 2011",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT01369901,18.0,90.0
2422,447,39.5162234,-76.9382069,"Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",448.0,NCT01160367,Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|GI Cancer|Pancreatic Cancer,Other: TAILORED Patient Family Decision Making|Other: standard of care,"family decision-making self-efficacy|family psychological outcomes (depression, caregiver burden, decision making distress)",Johns Hopkins University|University of Chicago|National Institute of Nursing Research (NINR),All,Not Applicable,431.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,NA_00010044|5R01NR010733-02,"August 26, 2010","March 26, 2014","March 26, 2014","July 12, 2010",,"September 5, 2018",,https://ClinicalTrials.gov/show/NCT01160367,18.0,100.0
2423,448,34.395342,-111.7632755,"Barrow Neurological Institute, Phoenix, Arizona, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2424,448,36.7014631,-118.7559974,"UC Irvine Medical Center, Orange, California, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2425,448,27.7567667,-81.4639835,"Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2426,448,27.7567667,-81.4639835,"University of Florida Medical Center, Gainesville, Florida, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2427,448,32.3293809,-83.1137366,"Carol and Frank Morsini Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2428,448,40.0796606,-89.4337288,"Emory University Hospital, Atlanta, Georgia, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2429,448,39.5162234,-76.9382069,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2430,448,42.3788774,-72.032366,"University of Kentucky Medical Center, Lexington, Kentucky, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2431,448,42.3788774,-72.032366,"Ochsner Neuroscience Institute, New Orleans, Louisiana, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2432,448,43.6211955,-84.6824346,"Johns Hopkins Hospital, Baltimore, Maryland, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2433,448,45.9896587,-94.6113288,"Massachusetts General Hospital, Boston, Massachusetts, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2434,448,38.7604815,-92.5617875,"University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2435,448,38.7604815,-92.5617875,"University of Michigan Medical Center, Ann Arbor, Michigan, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2436,448,43.4849133,-71.6553992,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2437,448,40.0757384,-74.4041622,"Washington University Medical Center, Saint Louis, Missouri, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2438,448,40.7127281,-74.0060152,"Neurology Associates P.C., Lincoln, Nebraska, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2439,448,40.7127281,-74.0060152,"Mount Sinai Beth Israel, New York, New York, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2440,448,40.7127281,-74.0060152,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2441,448,35.6729639,-79.0392919,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2442,448,35.6729639,-79.0392919,"Oregon Health & Science University, Portland, Oregon, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2443,448,35.6729639,-79.0392919,"The Penn Comprehensive ALS Center, Philadelphia, Pennsylvania, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2444,448,40.2253569,-82.6881395,"Temple University Hospital, Philadelphia, Pennsylvania, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2445,448,43.9792797,-120.737257,"Texas Neurology, P.A., Dallas, Texas, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2446,448,43.9792797,-120.737257,"University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2447,448,40.9699889,-77.7278831,"ALS Center at the Swedish Neuroscience Institute, Seattle, Washington, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2448,448,40.9699889,-77.7278831,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2449,448,40.9699889,-77.7278831,"INSERM-UPC UMR_S 1158, Service de Pneumologie et R√©animation, GH Piti√©-Salp√™tri√®re, Paris, France",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2450,448,31.8160381,-99.5120986,"ALS Moscow Centre, Moscow, Russian Federation",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2451,448,39.4225192,-111.7143584,"Cambridge Institute for Music Therapy Research (CIMTR), Cambridge, Cambridgeshire, United Kingdom",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2452,448,52.4760892,-71.8258668,"National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States",449.0,NCT00677768,Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS),BIO_ALS-01,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Primary Lateral Sclerosis|Nervous System Diseases|Hereditary Spastic Paraparesis,Other: No intervention,ALS Functional Rating Scale (ALSFRS-R),Massachusetts General Hospital|ALS Association|ALS Therapy Alliance|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,475.0,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,BIO_ALS-01|5RC1NS068179-02,April 2008,November 2015,November 2015,"May 14, 2008",,"June 3, 2016",,https://ClinicalTrials.gov/show/NCT00677768,30.0,80.0
2453,449,35.6729639,-79.0392919,"Barrow Neurological Institute, Phoenix, Arizona, United States",450.0,NCT03706391,Study of ALS Reversals 4: LifeTime Exposures,StARLiTE,Enrolling by invitation,No Results Available,Amyotrophic Lateral Sclerosis|Progressive Muscular Atrophy|Motor Neuron Disease,,Life Time Environmental Exposures,Duke University|National ALS Registry|Centers for Disease Control and Prevention|Agency for Toxic Substances and Disease Registry,All,,30.0,Other|U.S. Fed,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,Pro00100219,"September 26, 2018","August 1, 2020","August 1, 2020","October 16, 2018",,"August 16, 2019",,https://ClinicalTrials.gov/show/NCT03706391,18.0,100.0
2454,450,34.395342,-111.7632755,"Mayo Clinic Jacksonville, Jacksonville, Florida, United States",451.0,NCT02469896,A Trial of Tocilizumab in ALS Subjects,TCZALS-001,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Motor Neuron Disease,Drug: Tocilizumab|Other: Placebo,Safety and Tolerability|Efficacy SVC|Efficacy ALSFRS-R|Efficacy HHD|Target engagement ( change in PBMC pro-inflammatory gene expression)|Target engagement (change in CSF sIL-6 receptor concentrations)|Target engagement (changes in cytokine levels in the serum and CSF)|PBR28 PET,"Barrow Neurological Institute|ALS Association|Barrow Neurological Foundation|Massachusetts General Hospital|Genentech, Inc.",All,Phase 2,22.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015TCZALS-001,November 2015,"July 11, 2018","July 11, 2018","June 12, 2015",,"July 26, 2018",,https://ClinicalTrials.gov/show/NCT02469896,18.0,75.0
2455,450,38.27312,-98.5821872,"Emory University, Atlanta, Georgia, United States",451.0,NCT02469896,A Trial of Tocilizumab in ALS Subjects,TCZALS-001,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Motor Neuron Disease,Drug: Tocilizumab|Other: Placebo,Safety and Tolerability|Efficacy SVC|Efficacy ALSFRS-R|Efficacy HHD|Target engagement ( change in PBMC pro-inflammatory gene expression)|Target engagement (change in CSF sIL-6 receptor concentrations)|Target engagement (changes in cytokine levels in the serum and CSF)|PBR28 PET,"Barrow Neurological Institute|ALS Association|Barrow Neurological Foundation|Massachusetts General Hospital|Genentech, Inc.",All,Phase 2,22.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015TCZALS-001,November 2015,"July 11, 2018","July 11, 2018","June 12, 2015",,"July 26, 2018",,https://ClinicalTrials.gov/show/NCT02469896,18.0,75.0
2456,450,42.3788774,-72.032366,"Massachusetts General Hospital, Boston, Massachusetts, United States",451.0,NCT02469896,A Trial of Tocilizumab in ALS Subjects,TCZALS-001,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Motor Neuron Disease,Drug: Tocilizumab|Other: Placebo,Safety and Tolerability|Efficacy SVC|Efficacy ALSFRS-R|Efficacy HHD|Target engagement ( change in PBMC pro-inflammatory gene expression)|Target engagement (change in CSF sIL-6 receptor concentrations)|Target engagement (changes in cytokine levels in the serum and CSF)|PBR28 PET,"Barrow Neurological Institute|ALS Association|Barrow Neurological Foundation|Massachusetts General Hospital|Genentech, Inc.",All,Phase 2,22.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015TCZALS-001,November 2015,"July 11, 2018","July 11, 2018","June 12, 2015",,"July 26, 2018",,https://ClinicalTrials.gov/show/NCT02469896,18.0,75.0
2457,450,35.6729639,-79.0392919,"University of Massachusetts Medical Center, Worcester, Massachusetts, United States",451.0,NCT02469896,A Trial of Tocilizumab in ALS Subjects,TCZALS-001,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Motor Neuron Disease,Drug: Tocilizumab|Other: Placebo,Safety and Tolerability|Efficacy SVC|Efficacy ALSFRS-R|Efficacy HHD|Target engagement ( change in PBMC pro-inflammatory gene expression)|Target engagement (change in CSF sIL-6 receptor concentrations)|Target engagement (changes in cytokine levels in the serum and CSF)|PBR28 PET,"Barrow Neurological Institute|ALS Association|Barrow Neurological Foundation|Massachusetts General Hospital|Genentech, Inc.",All,Phase 2,22.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015TCZALS-001,November 2015,"July 11, 2018","July 11, 2018","June 12, 2015",,"July 26, 2018",,https://ClinicalTrials.gov/show/NCT02469896,18.0,75.0
2458,450,40.9699889,-77.7278831,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",451.0,NCT02469896,A Trial of Tocilizumab in ALS Subjects,TCZALS-001,Completed,No Results Available,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Motor Neuron Disease,Drug: Tocilizumab|Other: Placebo,Safety and Tolerability|Efficacy SVC|Efficacy ALSFRS-R|Efficacy HHD|Target engagement ( change in PBMC pro-inflammatory gene expression)|Target engagement (change in CSF sIL-6 receptor concentrations)|Target engagement (changes in cytokine levels in the serum and CSF)|PBR28 PET,"Barrow Neurological Institute|ALS Association|Barrow Neurological Foundation|Massachusetts General Hospital|Genentech, Inc.",All,Phase 2,22.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015TCZALS-001,November 2015,"July 11, 2018","July 11, 2018","June 12, 2015",,"July 26, 2018",,https://ClinicalTrials.gov/show/NCT02469896,18.0,75.0
2459,451,34.395342,-111.7632755,"University of Florida, Gainesville, Florida, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2460,451,36.7014631,-118.7559974,"MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2461,NULL,NULL,NULL,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2462,451,27.7567667,-81.4639835,"Hospital Armand Trousseau, Pediatric Pulmonology Department and INSERM UMR S-893, Paris, France",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2463,451,27.7567667,-81.4639835,"Carolinas Medical Center - Dept of Neurology, Charlotte, North Carolina, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2464,451,32.3293809,-83.1137366,"SENTA Clinic, San Diego, California, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2465,451,41.9216734,-93.3122705,"Johns Hopkins Medicine, Baltimore, Maryland, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2466,451,37.5726028,-85.1551411,"Lowenstain hospital rehabilitation center, Ra`anana, Israel",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2467,451,30.8703881,-92.007126,"Miami, Florida, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2468,451,39.5162234,-76.9382069,"Prague, Czech Republic",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2469,451,42.3788774,-72.032366,"Szeged, Hungary",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2470,451,42.3788774,-72.032366,"Warsaw, Poland",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2471,451,43.6211955,-84.6824346,"St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2472,451,45.9896587,-94.6113288,"University of Miami Miller School of Medicine, Miami, Florida, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2473,451,38.7604815,-92.5617875,"Massachusetts General Hospital, Boston, Massachusetts, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2474,451,41.7370229,-99.5873816,"Skulpt, Inc, Boston, Massachusetts, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2475,451,40.7127281,-74.0060152,"SUNY Upstate Medical University, Syracuse, New York, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2476,451,35.6729639,-79.0392919,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2477,451,40.2253569,-82.6881395,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2478,451,43.9792797,-120.737257,"Massachusetts General Hospital, Boston, Massachusetts, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2479,451,40.9699889,-77.7278831,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2480,451,40.9699889,-77.7278831,"Massachusetts General Hospital, Boston, Massachusetts, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2481,451,31.8160381,-99.5120986,"IRCCS Neuromed, Pozzilli, Isernia, Italy",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2482,451,31.8160381,-99.5120986,"California Pacific Medical Center, San Francisco, California, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2483,451,38.8950092,-77.0365625,"University of Miami, Miami, Florida, United States",452.0,NCT03127514,AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS),CENTAUR,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Diseases|Neurodegenerative Diseases|Spinal Cord Diseases|TDP-43 Proteinopathies|Nervous System Diseases|Central Nervous System Diseases,Drug: AMX0035|Other: Placebo,"ALSFRS-R Slope|Incidence of Adverse Events|Proportion of subjects in each group able to remain on study drug until planned discontinuation|Accurate Testing of Limb Isometric Strength (ATLIS)|Blood-based Biomarkers|Slow Vital Capacity|Survival, tracheostomy and hospitalizations|Imaging Biomarkers",Amylyx Pharmaceuticals Inc.|ALS Finding a Cure Foundation|ALS Association|Northeast ALS Consortium|Massachusetts General Hospital Neurology Clinical Research Institute|Leandro P. Rizzuto Foundation,All,Phase 2,132.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMX-3500,"June 22, 2017",October 2019,December 2019,"April 25, 2017",,"March 5, 2019",,https://ClinicalTrials.gov/show/NCT03127514,18.0,80.0
2484,452,39.5162234,-76.9382069,"CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of",453.0,NCT02124057,Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy,,Recruiting,No Results Available,Liver|Motor Neuron Disease,,"Liver MRI Spectroscopy|Liver Ultrasound|Blood testing, Livery Biopsy and Beck's Depression Inventory",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,75.0,NIH,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,140099|14-N-0099,"April 25, 2014","September 5, 2019","November 1, 2019","April 28, 2014",,"April 3, 2019",,https://ClinicalTrials.gov/show/NCT02124057,18.0,100.0
2485,453,48.8566101,2.3514992,"Duke University Medical Center, Durham, North Carolina, United States",454.0,NCT03095729,Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY),VENTIPSY,Recruiting,No Results Available,Ondine Syndrome|Healthy|Amyotrophic Lateral Sclerosis,Other: Neuropsychological tests,Score at PASAT (Paced Auditory Serial Addition Test)|Oxygen saturation changes,Association pour le D√©veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|Association Fran√ßaise du Syndrome d'Ondine|Fonds de Recherche en Sant√© Respiratoire,All,,82.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,ADOREPS_2017_9,"April 26, 2017",October 2020,October 2020,"March 30, 2017",,"May 21, 2018",,https://ClinicalTrials.gov/show/NCT03095729,18.0,100.0
2486,454,55.7504461,37.6174943,"Policlinic Hospital, Bari, Italy",455.0,NCT03604822,Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS,,"Active, not recruiting",No Results Available,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis|ALS (Amyotrophic Lateral Sclerosis)|Dysarthria, Flaccid|Dysarthria, Spastic|Dysarthria, Mixed|Dysphagia|Dyspnea|Aspiration Pneumonia|Hypernasality|Breathlessness",Procedure: Music therapy,"Change of Forced Vital Capacity (FVC) from baseline at Week 6, Week 12, Week 16|Change of Maximal Inspiratory Pressure (MIP) from baseline at Week 6, Week 12, Week 16|Change of Maximal Expiratory Pressure (MEP) from baseline at Week 6, Week 12, Week 16|Change of Peak Cough Flow (PCF) from baseline at Week 6, Week 12, Week 16|Change of Center for Neurologic Study Bulbar Function Scale (CNS-BFS) Swallowing subscore from baseline at Week 6, Week 12, Week 16|Change of Center for Neurologic Study Bulbar Function Scale (CNS-BFS) Speech subscore from baseline at Week 6, Week 12, Week 16|Change in video fluoroscopic swallowing study (VFSS) results from baseline at Week 6, Week 12|Change in acoustic assessment parameters of recorded voice from baseline at Week 6, Week 12, Week 16|Change in Visual Analogue Scale for current perceived ease of respiration from pre-treatment to post-treatment|Change of Visual Analogue Scale for current perceived ease of speech from pre-treatment to post-treatment|Phenomenological analysis of participant semi-structured interviews pre-treatment|Phenomenological analysis of caregiver semi-structured interview pre-treatment|Phenomenological analysis of treatment sessions documentation|Phenomenological analysis of participant semi-structured interviews post-treatment|Phenomenological analysis of caregiver semi-structured interview post-treatment",Alisa Apreleva|ALS Centre Moscow|Anglia Ruskin University,All,Not Applicable,8.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,ALSMT01,"September 27, 2017","July 31, 2018","January 1, 2020","July 30, 2018",,"July 30, 2018",,https://ClinicalTrials.gov/show/NCT03604822,18.0,100.0
2487,454,52.333333,0.083333,"Barrow Neurological Institute, Phoenix, Arizona, United States",455.0,NCT03604822,Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS,,"Active, not recruiting",No Results Available,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis|ALS (Amyotrophic Lateral Sclerosis)|Dysarthria, Flaccid|Dysarthria, Spastic|Dysarthria, Mixed|Dysphagia|Dyspnea|Aspiration Pneumonia|Hypernasality|Breathlessness",Procedure: Music therapy,"Change of Forced Vital Capacity (FVC) from baseline at Week 6, Week 12, Week 16|Change of Maximal Inspiratory Pressure (MIP) from baseline at Week 6, Week 12, Week 16|Change of Maximal Expiratory Pressure (MEP) from baseline at Week 6, Week 12, Week 16|Change of Peak Cough Flow (PCF) from baseline at Week 6, Week 12, Week 16|Change of Center for Neurologic Study Bulbar Function Scale (CNS-BFS) Swallowing subscore from baseline at Week 6, Week 12, Week 16|Change of Center for Neurologic Study Bulbar Function Scale (CNS-BFS) Speech subscore from baseline at Week 6, Week 12, Week 16|Change in video fluoroscopic swallowing study (VFSS) results from baseline at Week 6, Week 12|Change in acoustic assessment parameters of recorded voice from baseline at Week 6, Week 12, Week 16|Change in Visual Analogue Scale for current perceived ease of respiration from pre-treatment to post-treatment|Change of Visual Analogue Scale for current perceived ease of speech from pre-treatment to post-treatment|Phenomenological analysis of participant semi-structured interviews pre-treatment|Phenomenological analysis of caregiver semi-structured interview pre-treatment|Phenomenological analysis of treatment sessions documentation|Phenomenological analysis of participant semi-structured interviews post-treatment|Phenomenological analysis of caregiver semi-structured interview post-treatment",Alisa Apreleva|ALS Centre Moscow|Anglia Ruskin University,All,Not Applicable,8.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,ALSMT01,"September 27, 2017","July 31, 2018","January 1, 2020","July 30, 2018",,"July 30, 2018",,https://ClinicalTrials.gov/show/NCT03604822,18.0,100.0
2488,455,39.5162234,-76.9382069,"University of California San Diego Medical Center, La Jolla, California, United States",456.0,NCT00001220,Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders,,Completed,No Results Available,Deglutition Disorder|Motor Neuron Disease,,,National Institutes of Health Clinical Center (CC),All,,750.0,NIH,Observational,,870160|87-CC-0160,October 1987,,November 2005,"November 4, 1999",,"March 4, 2008",,https://ClinicalTrials.gov/show/NCT00001220,18.0,100.0
2489,456,34.395342,-111.7632755,"California Pacific Medical Center, San Francisco, California, United States",457.0,NCT01495390,A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Nervous System Diseases|Sclerosis|Motor Neuron Disease|Spinal Cord Diseases|Central Nervous System Diseases|Neurodegenerative Diseases|Neuromuscular Diseases|ALS,,ALS Functional Rating Scale|Vital Capacity (VC)|Hand Held Dynamometry (HHD)|Ashworth Spasticity Scale|Fronto-Temporal Dementia (FTD) Assessment|ALS Cognitive Behavioral Screen (ALS CBS),Massachusetts General Hospital|ALS Association|ALS Finding a Cure,All,,139.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BIO-ALS-02,November 2011,"December 31, 2016","December 31, 2016","December 20, 2011",,"May 30, 2017",,https://ClinicalTrials.gov/show/NCT01495390,18.0,100.0
2490,456,27.7567667,-81.4639835,"Bioclinica Orlando, Orlando, Florida, United States",457.0,NCT01495390,A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Nervous System Diseases|Sclerosis|Motor Neuron Disease|Spinal Cord Diseases|Central Nervous System Diseases|Neurodegenerative Diseases|Neuromuscular Diseases|ALS,,ALS Functional Rating Scale|Vital Capacity (VC)|Hand Held Dynamometry (HHD)|Ashworth Spasticity Scale|Fronto-Temporal Dementia (FTD) Assessment|ALS Cognitive Behavioral Screen (ALS CBS),Massachusetts General Hospital|ALS Association|ALS Finding a Cure,All,,139.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BIO-ALS-02,November 2011,"December 31, 2016","December 31, 2016","December 20, 2011",,"May 30, 2017",,https://ClinicalTrials.gov/show/NCT01495390,18.0,100.0
2491,456,32.3293809,-83.1137366,"The Emory Clinic, Atlanta, Georgia, United States",457.0,NCT01495390,A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Nervous System Diseases|Sclerosis|Motor Neuron Disease|Spinal Cord Diseases|Central Nervous System Diseases|Neurodegenerative Diseases|Neuromuscular Diseases|ALS,,ALS Functional Rating Scale|Vital Capacity (VC)|Hand Held Dynamometry (HHD)|Ashworth Spasticity Scale|Fronto-Temporal Dementia (FTD) Assessment|ALS Cognitive Behavioral Screen (ALS CBS),Massachusetts General Hospital|ALS Association|ALS Finding a Cure,All,,139.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BIO-ALS-02,November 2011,"December 31, 2016","December 31, 2016","December 20, 2011",,"May 30, 2017",,https://ClinicalTrials.gov/show/NCT01495390,18.0,100.0
2492,456,42.3788774,-72.032366,"Johns Hopkins Hospital, Baltimore, Maryland, United States",457.0,NCT01495390,A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Nervous System Diseases|Sclerosis|Motor Neuron Disease|Spinal Cord Diseases|Central Nervous System Diseases|Neurodegenerative Diseases|Neuromuscular Diseases|ALS,,ALS Functional Rating Scale|Vital Capacity (VC)|Hand Held Dynamometry (HHD)|Ashworth Spasticity Scale|Fronto-Temporal Dementia (FTD) Assessment|ALS Cognitive Behavioral Screen (ALS CBS),Massachusetts General Hospital|ALS Association|ALS Finding a Cure,All,,139.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BIO-ALS-02,November 2011,"December 31, 2016","December 31, 2016","December 20, 2011",,"May 30, 2017",,https://ClinicalTrials.gov/show/NCT01495390,18.0,100.0
2493,456,42.3788774,-72.032366,"Massachusetts General Hospita, Boston, Massachusetts, United States",457.0,NCT01495390,A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Nervous System Diseases|Sclerosis|Motor Neuron Disease|Spinal Cord Diseases|Central Nervous System Diseases|Neurodegenerative Diseases|Neuromuscular Diseases|ALS,,ALS Functional Rating Scale|Vital Capacity (VC)|Hand Held Dynamometry (HHD)|Ashworth Spasticity Scale|Fronto-Temporal Dementia (FTD) Assessment|ALS Cognitive Behavioral Screen (ALS CBS),Massachusetts General Hospital|ALS Association|ALS Finding a Cure,All,,139.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BIO-ALS-02,November 2011,"December 31, 2016","December 31, 2016","December 20, 2011",,"May 30, 2017",,https://ClinicalTrials.gov/show/NCT01495390,18.0,100.0
2494,456,40.9699889,-77.7278831,"Washington University, Saint Louis, Missouri, United States",457.0,NCT01495390,A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Nervous System Diseases|Sclerosis|Motor Neuron Disease|Spinal Cord Diseases|Central Nervous System Diseases|Neurodegenerative Diseases|Neuromuscular Diseases|ALS,,ALS Functional Rating Scale|Vital Capacity (VC)|Hand Held Dynamometry (HHD)|Ashworth Spasticity Scale|Fronto-Temporal Dementia (FTD) Assessment|ALS Cognitive Behavioral Screen (ALS CBS),Massachusetts General Hospital|ALS Association|ALS Finding a Cure,All,,139.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BIO-ALS-02,November 2011,"December 31, 2016","December 31, 2016","December 20, 2011",,"May 30, 2017",,https://ClinicalTrials.gov/show/NCT01495390,18.0,100.0
2495,457,27.7567667,-81.4639835,"New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",458.0,NCT03192358,Physiological Flow of Liquids Used in Dysphagia Management,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Parkinson Disease|Dysphagia,Diagnostic Test: Videofluoroscopic Swallowing Examination|Other: Tongue Strength Measurement,Penetration-Aspiration Scale (Swallow Safety)|Normalized Residue Ratio Scale (Swallow Efficiency)|Number of Swallows per Bolus (Swallow Efficiency)|Pharyngeal Transit Duration (Bolus Flow)|Time to Laryngeal Vestibule Closure (Swallow Kinematics)|Hyoid Bone Range of Movement (Swallow Kinematics)|Hyoid Speed/Velocity (Swallow Kinematics)|Change in Anterior Maximum Tongue Pressure (IOPI)|Change in Posterior Maximum Tongue Pressure (IOPI)|Change in Saliva Swallow Tongue Pressure (IOPI),"University Health Network, Toronto|University of Florida|National Institute on Deafness and Other Communication Disorders (NIDCD)",All,,40.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,DC011020|5R01DC011020-05,"November 1, 2017",August 2019,"February 28, 2021","June 20, 2017",,"April 5, 2019",,https://ClinicalTrials.gov/show/NCT03192358,18.0,90.0
2496,458,40.9699889,-77.7278831,"UZ Leuven, Leuven, Belgium",459.0,NCT00714636,Cerebrospinal Fluid Repository,CSF,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Cerebrospinal Fluid|Neurodegenerative Disease|Motor Neuron Disease,,,Drexel University College of Medicine|MDA/ALS Center of Hope|Drexel University,All,,11.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,Internal-16262,October 2006,October 2008,October 2008,"July 14, 2008",,"March 9, 2017",,https://ClinicalTrials.gov/show/NCT00714636,18.0,100.0
2497,459,,,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",460.0,NCT02942953,Diaphragmatic Pacer Placement: Anesthetic Management (DP),DP,Completed,No Results Available,Spinal Cord Injuries|Amyotrophic Lateral Sclerosis|Respiratory Paralysis,Device: Diaphragmatic Pacer,all cause of morbidity|anesthetic technique,Institut Guttmann,All,,16.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,2015209,June 2015,October 2015,October 2015,"October 24, 2016",,"October 24, 2016",,https://ClinicalTrials.gov/show/NCT02942953,18.0,100.0
2498,460,42.3788774,-72.032366,"Montreal Neurological Institute Clinical Research Unit, Montreal, Quebec, Canada",461.0,NCT01459302,"Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders",,Recruiting,No Results Available,"Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|PLS|Motor Neuron Disease|Lou Gehrigs Disease|Familial Disease|Amyotrophic Lateral Sclerosis, Sporadic|Muscular Dystrophy|Miyoshi Myopathy",,identification of new genes that may contribute to ALS,"University of Massachusetts, Worcester|National Institute of Neurological Disorders and Stroke (NINDS)",All,,6000.0,Other|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,H-13019|5RC2NS070342-02,January 2009,October 2020,October 2020,"October 25, 2011",,"September 7, 2018",,https://ClinicalTrials.gov/show/NCT01459302,18.0,100.0
2499,461,48.8566101,2.3514992,"Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg, Germany",462.0,NCT00839033,Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders,Nemucough,Terminated,No Results Available,Duchenne Muscular Dystrophy|Amyotrophic Lateral Sclerosis|Neuromuscular Diseases,Device: mechanical insufflation - exsufflation|Device: Standard respiratory physiotherapy,"Reduction of the number of patients requiring invasive ventilatory support in the group treated with MI-E (MI-E group) compared to the group treated with traditional chest physiotherapy without MI-E (Control group).|Decrease in the length of hospitalization in the intensive care unit (ICU) (if necessary)|Decrease in the total length of hospitalization|Decrease in the incidence of bronchoscopy-assisted aspiration|Decrease in the duration of oxygen therapy|Decrease in the daily length of noninvasive positive pressure ventilation (NPPV)|Improvement in blood gases on room air during hospitalization and improvement of the peak cough flow (PCF)|Improvement of the vital capacity (VC), maximal inspiratory (PImax) and expiratory (PEmax) pressures, sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF) and dyspnea during hospitalization|Decrease in the number of secondary tracheotomies (for weaning of ventilatory support)",Assistance Publique - H√¥pitaux de Paris,All,Phase 3,14.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P080406,June 2009,February 2011,December 2011,"February 9, 2009",,"May 28, 2015",,https://ClinicalTrials.gov/show/NCT00839033,4.0,100.0
2500,462,35.6729639,-79.0392919,"Sheffield Institute for Translational Neuroscience, Sheffield, South Yorkshire, United Kingdom",463.0,NCT01954875,Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases,,Unknown status,No Results Available,Neurodegenerative Diseases|Amyotrophic Lateral Sclerosis|Multiple Sclerosis|Parkinson Disease,,"Create a bank of fecal and blood samples for the future investigation of the microbial etiology and pathophysiology of neurodegenerative diseases, including but not limited to amyotrophic lateral sclerosis, Parkinson's Diseases, and multiple sclerosis.",Benjamin Brooks|Atrium Health,All,,300.0,Other,Observational,Time Perspective: Prospective,CHS-Neurology-ALS stool sample,December 2009,December 2013,,"October 7, 2013",,"October 7, 2013",,https://ClinicalTrials.gov/show/NCT01954875,18.0,100.0
2501,463,36.7014631,-118.7559974,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",464.0,NCT03986671,Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx,,Recruiting,No Results Available,Obstructive Sleep Apnea|Amyotrophic Lateral Sclerosis|Muscular Dystrophies|Healthy,Device: Transmembrane EMG Oropharynx Probe,Proof of Diagnostic Consistency|Neuromuscular function in OSA Participants versus Healthy Participants,Powell Mansfield Inc.,All,Not Applicable,23.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,TM-EMG Pilot Study,"April 30, 2019","July 31, 2019","April 30, 2020","June 14, 2019",,"June 14, 2019",,https://ClinicalTrials.gov/show/NCT03986671,18.0,70.0
2502,464,39.5162234,-76.9382069,"University of Michigan Direct Brain Interface Project, Ann Arbor, Michigan, United States",465.0,NCT03567213,Investigation on the Cortical Communication (CortiCom) System,CortiCom,Recruiting,No Results Available,Tetraplegia|Locked-in Syndrome|Brainstem Stroke|Amyotrophic Lateral Sclerosis,Device: Surgical implantation of CortiCom system,"Time to device explantation|Success rate in controlling the brain computer interface, i.e. ratio of successful trials to total trials.|Speed of brain-computer interface control, i.e. time to complete successful trials (in seconds).",Johns Hopkins University,All,Not Applicable,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,IRB00167247,December 2019,November 2024,November 2024,"June 25, 2018",,"May 30, 2019",,https://ClinicalTrials.gov/show/NCT03567213,22.0,70.0
2503,465,32.1862752,34.8692427,"Wadsworth Center, Albany, New York, United States",466.0,NCT02738242,Evaluation of Usability and Human Factors in the Novus System,,Unknown status,No Results Available,"Drop Foot|Muscle Weakness|Motor Neuron Disease, Upper",Device: Novus system,Questionnaire to evaluate system usability|Patients' Questionnaire to evaluate system ease of use|Patients Questionnaire to compare quality of life with and without the Novus system.|Participation scale questionnaire (a sub-scale of Mayo-Portland Adaptability Inventory 4) for quality of life assessment compared to baseline|Total score of modified Emory Functional Ambulation Profile (mEFAP) with the system compared to without the system.|Total score of modified Emory Functional Ambulation Profile (mEFAP) without the system at baseline compared to without the system after daily use with the system.|Walking velocity assessment using the 2 minute walk test (2MWT) with the system compared to without the system.|walking velocity assessment using the 2 minute walk test (2MWT) without the system at baseline compared to without the system after daily use with the system.,Bioness Neuromodulation|Bioness Inc|Loewenstein Hospital,All,Not Applicable,16.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Novus System Usability,May 2016,January 2017,January 2017,"April 14, 2016",,"April 19, 2016",,https://ClinicalTrials.gov/show/NCT02738242,18.0,80.0
2504,466,27.7567667,-81.4639835,"Sanguine Biosciences, Sherman Oaks, California, United States",467.0,NCT00076687,Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function,,Completed,Has Results,Stroke|Muscle Spasticity|Motor Neuron Disease,Biological: botulinum toxin Type A|Drug: saline,Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Volume (FEV1)|Change From Baseline in FEV1/FVC Ratio|Change From Baseline in Ashworth Scale,Allergan,All,Phase 2,155.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",191622-057,October 2003,August 2009,August 2009,"February 26, 2004","October 3, 2011","October 3, 2011",,https://ClinicalTrials.gov/show/NCT00076687,18.0,100.0
2505,466,50.0874654,14.4212535,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",467.0,NCT00076687,Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function,,Completed,Has Results,Stroke|Muscle Spasticity|Motor Neuron Disease,Biological: botulinum toxin Type A|Drug: saline,Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Volume (FEV1)|Change From Baseline in FEV1/FVC Ratio|Change From Baseline in Ashworth Scale,Allergan,All,Phase 2,155.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",191622-057,October 2003,August 2009,August 2009,"February 26, 2004","October 3, 2011","October 3, 2011",,https://ClinicalTrials.gov/show/NCT00076687,18.0,100.0
2506,466,46.2546312,20.1486016,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",467.0,NCT00076687,Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function,,Completed,Has Results,Stroke|Muscle Spasticity|Motor Neuron Disease,Biological: botulinum toxin Type A|Drug: saline,Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Volume (FEV1)|Change From Baseline in FEV1/FVC Ratio|Change From Baseline in Ashworth Scale,Allergan,All,Phase 2,155.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",191622-057,October 2003,August 2009,August 2009,"February 26, 2004","October 3, 2011","October 3, 2011",,https://ClinicalTrials.gov/show/NCT00076687,18.0,100.0
2507,466,52.2337172,21.0714111288323,"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",467.0,NCT00076687,Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function,,Completed,Has Results,Stroke|Muscle Spasticity|Motor Neuron Disease,Biological: botulinum toxin Type A|Drug: saline,Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Volume (FEV1)|Change From Baseline in FEV1/FVC Ratio|Change From Baseline in Ashworth Scale,Allergan,All,Phase 2,155.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",191622-057,October 2003,August 2009,August 2009,"February 26, 2004","October 3, 2011","October 3, 2011",,https://ClinicalTrials.gov/show/NCT00076687,18.0,100.0
2508,467,34.395342,-111.7632755,"University of Miami, Miami, Florida, United States",468.0,NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,Device: Electrical impedance myography (EIM),Discrimination between Groups|Tracking Progression|Correlation with Outcome Measures,"Skulpt, Inc.",All,,106.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P001505,November 2013,March 2016,March 2016,"December 13, 2013",,"May 11, 2016",,https://ClinicalTrials.gov/show/NCT02011204,35.0,80.0
2509,467,27.7567667,-81.4639835,"AAC Institute Clinic (ICAN Talk Clinic), Carnegie, Pennsylvania, United States",468.0,NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,Device: Electrical impedance myography (EIM),Discrimination between Groups|Tracking Progression|Correlation with Outcome Measures,"Skulpt, Inc.",All,,106.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P001505,November 2013,March 2016,March 2016,"December 13, 2013",,"May 11, 2016",,https://ClinicalTrials.gov/show/NCT02011204,35.0,80.0
2510,467,42.3788774,-72.032366,"University of Pittsburgh, AAC Performance and Testing Laboratory, Pittsburgh, Pennsylvania, United States",468.0,NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,Device: Electrical impedance myography (EIM),Discrimination between Groups|Tracking Progression|Correlation with Outcome Measures,"Skulpt, Inc.",All,,106.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P001505,November 2013,March 2016,March 2016,"December 13, 2013",,"May 11, 2016",,https://ClinicalTrials.gov/show/NCT02011204,35.0,80.0
2511,467,42.3788774,-72.032366,"Cedars-Sinai Medical Center, Los Angeles, California, United States",468.0,NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,Device: Electrical impedance myography (EIM),Discrimination between Groups|Tracking Progression|Correlation with Outcome Measures,"Skulpt, Inc.",All,,106.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P001505,November 2013,March 2016,March 2016,"December 13, 2013",,"May 11, 2016",,https://ClinicalTrials.gov/show/NCT02011204,35.0,80.0
2512,467,40.7127281,-74.0060152,"Emory University, Atlanta, Georgia, United States",468.0,NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,Device: Electrical impedance myography (EIM),Discrimination between Groups|Tracking Progression|Correlation with Outcome Measures,"Skulpt, Inc.",All,,106.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P001505,November 2013,March 2016,March 2016,"December 13, 2013",,"May 11, 2016",,https://ClinicalTrials.gov/show/NCT02011204,35.0,80.0
2513,467,35.6729639,-79.0392919,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",468.0,NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,,Completed,No Results Available,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,Device: Electrical impedance myography (EIM),Discrimination between Groups|Tracking Progression|Correlation with Outcome Measures,"Skulpt, Inc.",All,,106.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013P001505,November 2013,March 2016,March 2016,"December 13, 2013",,"May 11, 2016",,https://ClinicalTrials.gov/show/NCT02011204,35.0,80.0
2514,468,39.5162234,-76.9382069,"Johns Hopkins University, Baltimore, Maryland, United States",469.0,NCT01900132,Electrical Impedance Myography: Exploratory Studies in Healthy People and People With Neuromuscular Disorders,,Recruiting,No Results Available,Neuromuscular Disease|Motor Neuron Disease|Inherited Neuromuscular Conditions|Inherited Neuropathies,,Utility of EIM as outcome measure,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,275.0,NIH,Observational,Observational Model: Other|Time Perspective: Other,130165|13-N-0165,"June 6, 2013","January 1, 2023","January 1, 2023","July 16, 2013",,"August 1, 2019",,https://ClinicalTrials.gov/show/NCT01900132,2.0,120.0
2515,469,42.3788774,-72.032366,"Massachusetts General Hospital, Boston, Massachusetts, United States",470.0,NCT02525471,A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS),,Completed,No Results Available,ALS,Drug: RNS60,"Safety as measured by the Number of Participants Experiencing Adverse Events|Tolerability to Complete the Entire 24 Week Study on Study Drug|Blood biomarkers of inflammation.|Neuroimaging biomarkers ([11C]-PBR28-Positron Emission Tomography (PET)) including both regions of interest and voxel-based analyses.|Clinical outcome: Pulmonary Function, Measured by Slow Vital Capacity (SVC)|Clinical outcome: Strength, Measured by Accurate Test of Limb Isometric Strength (ATLIS)|Clinical outcome: Functional Status, Measured by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)","Sabrina Paganoni, M.D.|Massachusetts General Hospital",All,Phase 1,24.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RNS60-01,October 2015,"June 21, 2017","October 18, 2017","August 17, 2015",,"February 22, 2018",,https://ClinicalTrials.gov/show/NCT02525471,18.0,80.0
2516,470,39.5162234,-76.9382069,"Washington University School of Medicine, Saint Louis, Missouri, United States",471.0,NCT00001185,"Study of ""Post-Polio Syndrome""",,Completed,No Results Available,Poliomyelitis|Postpoliomyelitis Syndrome,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,360.0,NIH,Observational,,820083|82-N-0083,June 1982,,May 2003,"November 4, 1999",,"March 4, 2008",,https://ClinicalTrials.gov/show/NCT00001185,18.0,100.0
2517,471,42.3788774,-72.032366,"Ohio State University Wexner Medical Center, Columbus, Ohio, United States",472.0,NCT03330353,Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy,PMPSP,Recruiting,No Results Available,PSP - Progressive Supranuclear Palsy|PD - Parkinson's Disease|AD - Alzheimer's Disease|ALS (Amyotrophic Lateral Sclerosis),Diagnostic Test: Pupillometry,Maximal Pupil Constriction|Post-illumination pupil response (PIPR),Massachusetts General Hospital|NeurOptics Inc.|University of Toronto,All,,56.0,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017p001603,"November 1, 2017","October 1, 2019","October 1, 2019","November 6, 2017",,"November 7, 2017","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03330353/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03330353/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03330353,55.0,100.0
2518,472,41.600216,14.238217,"Texas Neurology, Dallas, Texas, United States",473.0,NCT03217396,Biomarkers of Synaptic Damage in Multiple Sclerosis,,Recruiting,No Results Available,Multiple Sclerosis|Parkinson Disease|Amyotrophic Lateral Sclerosis|Alzheimer Disease,Procedure: lumbar puncture,Identification of predictive biomarkers of SM using an ex vivo chimeric model|Identification of new therapeutic targets in MS.,Neuromed IRCCS|IRCCS Multimedica,All,,150.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,IRCCS Neuromed,"November 22, 2017","September 1, 2020","September 30, 2020","July 14, 2017",,"March 18, 2019",,https://ClinicalTrials.gov/show/NCT03217396,18.0,65.0
2519,473,36.7014631,-118.7559974,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",474.0,NCT03489278,Clinical Procedures to Support Research,CAPTURE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|ALS-Frontotemporal Dementia|Primary Lateral Sclerosis|Progressive Muscular Atrophy,,Using the ALS Toolkit for collecting and using electronic health record data for research purposes,University of Miami|Muscular Dystrophy Association|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|National Institutes of Health (NIH),All,,1200.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20170785|U54NS092091,"February 15, 2018",January 2021,January 2021,"April 5, 2018",,"August 9, 2019",,https://ClinicalTrials.gov/show/NCT03489278,18.0,100.0
2520,473,27.7567667,-81.4639835,"National Neuroscience Institute, Singapore, Singapore",474.0,NCT03489278,Clinical Procedures to Support Research,CAPTURE,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|ALS-Frontotemporal Dementia|Primary Lateral Sclerosis|Progressive Muscular Atrophy,,Using the ALS Toolkit for collecting and using electronic health record data for research purposes,University of Miami|Muscular Dystrophy Association|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|National Institutes of Health (NIH),All,,1200.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20170785|U54NS092091,"February 15, 2018",January 2021,January 2021,"April 5, 2018",,"August 9, 2019",,https://ClinicalTrials.gov/show/NCT03489278,18.0,100.0
2521,NULL,NULL,NULL,"Melbourne Health, Melbourne, Victoria, Australia",,,,,,,,,,,,,,,,,,,,,,,,,,,
2522,475,35.6729639,-79.0392919,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",476.0,NCT01785550,Neuromuscular Ultrasound in ALS,,Completed,No Results Available,ALS,Other: Ultrasound of nerve and muscle,Abnormalities at onset: Ultrasound vs. Electromyography|Ultrasound Predicting Outcome at 1 year,Duke University,All,,40.0,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,Pro00042025,February 2013,March 2015,March 2015,"February 7, 2013",,"March 11, 2015",,https://ClinicalTrials.gov/show/NCT01785550,18.0,100.0
2523,476,41.1257843,16.8620293,"Stanford University School of Medicine, Stanford, California, United States",477.0,NCT03487536,Nutritional Prognostic Factors in ALS,PEG-ALS,Completed,No Results Available,Nutritional Deficiency|Neuro-Degenerative Disease|Gastrostomy,Other: Nutritional assessment,nutritional assessment|biochemical nutritional assessment|body composition assessment,University of Bari,All,,47.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,"Policlinic Hospital 2, Bari","January 2, 2006","June 30, 2015","July 31, 2016","April 4, 2018",,"April 4, 2018",,https://ClinicalTrials.gov/show/NCT03487536,18.0,100.0
2524,477,34.395342,-111.7632755,"Massachusetts General Hospital, Boston, Massachusetts, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2525,477,36.7014631,-118.7559974,"Case Western Reserve University, Cleveland, Ohio, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2526,477,36.7014631,-118.7559974,"Providence VA Medical Center, Providence, Rhode Island, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2527,477,27.7567667,-81.4639835,"Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, United Kingdom",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2528,477,32.3293809,-83.1137366,"Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2529,477,39.5162234,-76.9382069,"Nemours Children's Specialty Care, Jacksonville, Jacksonville, Florida, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2530,477,42.3788774,-72.032366,"Nemours Children's Hospital, Orlando, Florida, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2531,477,38.7604815,-92.5617875,"Stanford University, Palo Alto, California, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2532,477,35.7730076,-86.2820081,"University of California San Diego (UCSD), San Diego, California, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2533,477,50.879202,4.7011675,"California Pacific Medical Center (CPMC), San Francisco, California, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2534,477,50.000678,-86.000977,"University of Miami, Miami, Florida, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2535,477,52.4760892,-71.8258668,"University of Iowa, Iowa City, Iowa, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2536,477,48.6296972,9.1949534,"Kansas University Medical Center (KUMC), Kansas City, Kansas, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2537,477,53.48153335,-1.38104220661496,"Twin Cities ALS Research Consortium, Minneapolis, Minnesota, United States",478.0,NCT03070119,Long-Term Evaluation of BIIB067,,Enrolling by invitation,No Results Available,ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation,Drug: BIIB067,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)|PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf)|PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast)|PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-Life (t¬Ω)|PK Parameter of BIIB067 in CSF: t¬Ω|Change from Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Score|Change from Baseline in Slow Vital Capacity (SVC)|Change from Baseline in Handheld Dynamometry (HHD) Score|Overall Survival|Ventilation Assistance-Free Survival (VAFS)|PD Parameter of BIIB067 in CSF: Change from Baseline in Total SOD1|PD Parameter of BIIB067 in CSF: Change from Baseline in Total Phosphorylated Axonal Neurofilament Heavy Chain (p-NHF)|PD Parameter of BIIB067 in Plasma: Change from Baseline in Total p-NFH,"Biogen|Ionis Pharmaceuticals, Inc.",All,Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,233AS102|2016-003225-41,"March 8, 2017","February 26, 2021","February 26, 2021","March 3, 2017",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT03070119,18.0,100.0
2538,478,39.5162234,-76.9382069,"Wake Forest University, Winston-Salem, North Carolina, United States",479.0,NCT00004568,Study of Inherited Neurological Disorders,,Recruiting,No Results Available,Motor Neuron Disease|Muscular Disease|Muscular Dystrophy|Peripheral Nervous System Disease,,Genetic disease identification; deep phenotyping of rare genetic neurological disorders; training of fellows and students,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,3500.0,NIH,Observational,Observational Model: Other|Time Perspective: Other,000043|00-N-0043,"February 8, 2000",,,"February 14, 2000",,"August 12, 2019",,https://ClinicalTrials.gov/show/NCT00004568,2.0,110.0
2539,479,43.6211955,-84.6824346,"Cleveland Clinic, Cleveland, Ohio, United States",480.0,NCT00860951,P300 Brain Computer Interface Keyboard to Operate Assistive Technology,,Completed,Has Results,Healthy|Amyotrophic Lateral Sclerosis|Neuromuscular Disease|Spinal Cord Injury|Cerebral Palsy,Device: Brain Computer Interface Keyboard,Accuracy of Typing With BCI Keyboard.,University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|U.S. Department of Education,All,Phase 1|Phase 2,29.0,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,H0002 - AT P300 Keyboard Study|5R21HD054697|H133G090005,September 2008,May 2012,May 2012,"March 13, 2009","June 11, 2015","July 9, 2015",,https://ClinicalTrials.gov/show/NCT00860951,18.0,100.0
2540,479,40.7127281,-74.0060152,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",480.0,NCT00860951,P300 Brain Computer Interface Keyboard to Operate Assistive Technology,,Completed,Has Results,Healthy|Amyotrophic Lateral Sclerosis|Neuromuscular Disease|Spinal Cord Injury|Cerebral Palsy,Device: Brain Computer Interface Keyboard,Accuracy of Typing With BCI Keyboard.,University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|U.S. Department of Education,All,Phase 1|Phase 2,29.0,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,H0002 - AT P300 Keyboard Study|5R21HD054697|H133G090005,September 2008,May 2012,May 2012,"March 13, 2009","June 11, 2015","July 9, 2015",,https://ClinicalTrials.gov/show/NCT00860951,18.0,100.0
2541,480,36.7014631,-118.7559974,"University of Texas Southwestern (UTSW), Dallas, Texas, United States",481.0,NCT01592552,"A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery",,Completed,No Results Available,Alzheimer's Disease|Multiple Sclerosis|Parkinson's Disease|Huntington's Disease|Amyotrophic Lateral Sclerosis (ALS),,Biospecimens & Clinical Data collection from patients with neurological diseases.,Sanguine Biosciences,All,,20.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,SAN-ND-01,November 2011,March 2015,March 2015,"May 7, 2012",,"April 8, 2019",,https://ClinicalTrials.gov/show/NCT01592552,18.0,100.0
2542,481,42.3788774,-72.032366,"University of Texas Health Science Center San Antonio (UTHSCSA), San Antonio, Texas, United States",482.0,NCT02104921,Innovative Ultrasound Technology in Neuromuscular Disease,AQUIRe,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Muscular Dystrophy|Radiculopathy|Myopathy|Polyneuropathy and Mononeuropathies,,"Quantitative ultrasound data, including quantified grayscale data and backscattered acoustic data",Beth Israel Deaconess Medical Center|National Institute of Neurological Disorders and Stroke (NINDS),All,,240.0,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2012P000364|2K24NS060951,December 2013,December 2020,December 2021,"April 7, 2014",,"September 7, 2018",,https://ClinicalTrials.gov/show/NCT02104921,21.0,80.0
2543,482,40.0796606,-89.4337288,"University of Virginia (UVA), Charlottesville, Virginia, United States",483.0,NCT00821132,Genetics of Familial and Sporadic ALS,ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS)|Familial Amyotrophic Lateral Sclerosis|Amyotrophic Lateral Sclerosis With Frontotemporal Dementia|Lou Gehrig's Disease|Motor Neuron Disease|Primary Lateral Sclerosis,Other: Genetic study of ALS families,Identification of genes that increase risk for sporadic ALS or cause inherited ALS.,Northwestern University,All,,15000.0,Other,Observational,Observational Model: Family-Based|Time Perspective: Other,Lab01|RO1N505641-04,January 1991,December 2019,December 2022,"January 13, 2009",,"August 7, 2019",,https://ClinicalTrials.gov/show/NCT00821132,18.0,100.0
2544,483,39.5162234,-76.9382069,"Eberhard Karls University of T√ºbingen, T√ºbingen, Germany",484.0,NCT00001780,Magnetic Stimulation of the Human Nervous System,,Completed,No Results Available,Demyelinating Disease|Healthy|Lysosomal Storage Disease|Motor Neuron Disease|Movement Disorder,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,450.0,NIH,Observational,,980065|98-N-0065,February 1998,,November 2005,"November 4, 1999",,"March 4, 2008",,https://ClinicalTrials.gov/show/NCT00001780,18.0,100.0
2545,484,27.7567667,-81.4639835,"University of Cape Town, Cape Town, South Africa",485.0,NCT03912987,TRIAL READY (Clinical Trial Readiness),,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|ALS-Frontotemporal Dementia|Primary Lateral Sclerosis|Progressive Muscular Atrophy,,Longitudinal trajectories (and variability) of leading biological-fluid biomarker candidates.|Prognostic utility of leading biological-fluid biomarker candidates.,University of Miami|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,,610.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20180908|U01NS107027,"January 22, 2019",January 2022,January 2022,"April 12, 2019",,"April 12, 2019",,https://ClinicalTrials.gov/show/NCT03912987,18.0,100.0
2546,485,40.9699889,-77.7278831,"University of Alabama, Birmingham, Alabama, United States",486.0,NCT04026581,Real World Testing of a Brain-Computer Interface,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Brain Stem Stroke|Cerebral Palsy|Traumatic Brain Injury|Speech Disorders,Behavioral: Speech generating device (SGD) evaluation including BCI access|Behavioral: Training and treatment,Change in daily communication performance|User satisfaction of speech generating device (SGD) for daily communication|User satisfaction of speech generating device (SGD) or daily communication,"University of Pittsburgh|National Institute on Disability, Independent Living, and Rehabilitation Research",All,,20.0,Other|U.S. Fed,Observational,Observational Model: Case-Only|Time Perspective: Prospective,STUDY19010094|90IFDV0002-01-00,"June 5, 2019","August 31, 2022","August 31, 2023","July 19, 2019",,"July 23, 2019",,https://ClinicalTrials.gov/show/NCT04026581,14.0,100.0
2547,485,40.9699889,-77.7278831,"University of California, Los Angeles, Los Angeles, California, United States",486.0,NCT04026581,Real World Testing of a Brain-Computer Interface,,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Brain Stem Stroke|Cerebral Palsy|Traumatic Brain Injury|Speech Disorders,Behavioral: Speech generating device (SGD) evaluation including BCI access|Behavioral: Training and treatment,Change in daily communication performance|User satisfaction of speech generating device (SGD) for daily communication|User satisfaction of speech generating device (SGD) or daily communication,"University of Pittsburgh|National Institute on Disability, Independent Living, and Rehabilitation Research",All,,20.0,Other|U.S. Fed,Observational,Observational Model: Case-Only|Time Perspective: Prospective,STUDY19010094|90IFDV0002-01-00,"June 5, 2019","August 31, 2022","August 31, 2023","July 19, 2019",,"July 23, 2019",,https://ClinicalTrials.gov/show/NCT04026581,14.0,100.0
2548,486,36.7014631,-118.7559974,"University of California, San Diego, San Diego, California, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2549,486,32.3293809,-83.1137366,"University of California, San Francisco, San Francisco, California, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2550,486,40.0796606,-89.4337288,"Mayo Clinic - Jacksonville, Jacksonville, Florida, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2551,486,39.5162234,-76.9382069,"Northwestern University, Chicago, Illinois, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2552,486,42.3788774,-72.032366,"Johns Hopkins University, Baltimore, Maryland, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2553,486,38.7604815,-92.5617875,"Harvard University Massachusetts General Hospital, Charlestown, Massachusetts, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2554,486,40.2253569,-82.6881395,"Mayo Clinic - Rochester, Rochester, Minnesota, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2555,486,31.8160381,-99.5120986,"Washington University, Saint Louis, Missouri, United States",487.0,NCT02574390,Answer ALS: Individualized Initiative for ALS Discovery,AnswerALS,"Active, not recruiting",No Results Available,Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls,,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD),"Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center",All,,1000.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB00082277,December 2015,January 2019,January 2020,"October 12, 2015",,"February 5, 2019",,https://ClinicalTrials.gov/show/NCT02574390,18.0,100.0
2556,487,42.3788774,-72.032366,"Columbia University, New York, New York, United States",488.0,NCT02118805,Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders,QUESST,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis (ALS)|Myasthenia Gravis|Myopathies|Stroke|Parkinson's Disease,,Change in Muscle Health over 18 months by Standard Ultrasound|Change in Score on the Sydney Swallow Questionnaire (over 18 months)|Change in Number of Seconds It takes to Repeat Individual Words Ten Times (over 18 months)|Change in Number of Seconds It Takes to Swallow of 3 ounces of Water (over 18 months)|Change in Score on the Amyotrophic Lateral Sclerosis Rating Scale - Revised (ALSFRS-R) (over 18 months)|Change in Score on the Quantitative Myasthenia Gravis Scale (over 18 months)|Change in Score on the United Parkinson's Disease Rating Scale (UPDRS) (over 18 months)|Change in Muscle Health by Standard Concentric Needle Electromyography (EMG) (over 18 months)|Change in Muscle Health by Specialized Electrical Impedance Arrays,Beth Israel Deaconess Medical Center,All,,200.0,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,2013P000204,October 2013,December 2020,December 2021,"April 21, 2014",,"September 7, 2018",,https://ClinicalTrials.gov/show/NCT02118805,20.0,90.0
2557,488,1.340863,103.830391822121,"University of North Carolina, Chapel Hill, North Carolina, United States",489.0,NCT03811301,[BrainConnexion] - Neurodevice Phase II Trial,,Recruiting,No Results Available,Tetraplegia|Tetraplegia/Tetraparesis|Spinal Cord Injuries|Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Locked-in Syndrome|Muscular Dystrophies,Device: BrainConnexion,The number of serious adverse events (SAEs) and adverse events (AEs) reported per patient 12 months post-implantation.|The signal quality of the electrodes for long-term recording of neural signals.|Decoding accuracy per training session.|Number of successful trials per session|Time taken to complete each trial per session,National Neuroscience Institute|Institute of Microelectronics|Institute of Molecular and Cell Biology|Institute for Infocomm Research|Nanyang Technological University,All,Phase 2,3.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,BrainConnexion,"November 21, 2017","December 31, 2021","December 31, 2021","January 21, 2019",,"January 21, 2019",,https://ClinicalTrials.gov/show/NCT03811301,21.0,70.0
2558,489,,,"Case Western Reserve University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",490.0,NCT03827187,Awareness Detection and Communication in Disorders of Consciousness,,Not yet recruiting,No Results Available,Disorder of Consciousness|Paralysis|Motor Neuron Disease|Stroke|Physical Disability,Other: Motor imagery based EEG-BCI,"Change in performance accuracy of BCI use pre- and post- training|Change in ability to use imagined movements to consistently communicate yes-no responses to closed questions over multiple sessions by participant with Prolonged Disorder of Consciousness|Diagnostic utility of BCI data provided through study completion to clinicians|Changes in Wessex Head Injury Matrix and Coma Recovery Scale Scores due to potential therapeutic benefit of engaging in motor imagery|Change in performance accuracy as a factor of whether feedback was presented as music or broadband noise,|Changes in performance accuracy as a results of time of day of research experimentation","University of Ulster|National Rehabilitation Hospital, Ireland|St Conal‚Äôs Campus Rehabilitation Unit, Letterkenny, Ireland|Belfast Health and Social Care Trust|Western Health and Social Care Trust|South Eastern Health and Social Care Trust|Southern Health and Social Care Trust|Northern Health and Social Care Trust|Barnsley Hospital NHS Foundation Trust|NHS Lothian|Walton Centre NHS Foundation Trust|Hull and East Yorkshire Hospitals NHS Trust|Northern Lincolnshire and Goole Hospitals NHS Foundation Trust|Imperial College Healthcare NHS Trust|Woodland Neuro rehab Center, York (Christchurch Group)|Glenside care, Salisbury|Frenchay Brain Injury Rehabilitation Centre, Bristol|Royal Hospital for Neuro-disability",All,Not Applicable,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,136640,"April 15, 2019","April 15, 2024","April 15, 2024","February 1, 2019",,"March 21, 2019",,https://ClinicalTrials.gov/show/NCT03827187,10.0,80.0
2559,490,-36.5986096,144.6780052,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",491.0,NCT03834857,STENTRODE First in Human Early Feasibility Study,SWITCH,Recruiting,No Results Available,Neurologic Disorder,Device: StentrodeTM,Treatment-Related Adverse Events|High fidelity and stable signals over 12 months,"Synchron Medical, Inc",All,Not Applicable,5.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,S-01-01,"June 15, 2019",June 2020,June 2023,"February 8, 2019",,"April 4, 2019",,https://ClinicalTrials.gov/show/NCT03834857,18.0,75.0
2560,491,39.5162234,-76.9382069,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",492.0,NCT00015444,Screening and Natural History: Primary Lateral Sclerosis and Related Disorders,,Completed,No Results Available,Primary Lateral Sclerosis,,"The primary outcome of this protocol is to document the natural history of clinical progression in PLS, defined as the change in clinical measures of movement speed over time: finger tapping, timed gait, and time to read a standard passage.",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,189.0,NIH,Observational,Observational Model: Cohort|Time Perspective: Other,010145|01-N-0145,"May 1, 2001",,"April 24, 2019","April 19, 2001",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT00015444,18.0,100.0
2561,492,36.7014631,-118.7559974,"University of Washington Harborview Medical Center, Seattle, Washington, United States",493.0,NCT00912041,BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia,BrainGate2,Recruiting,No Results Available,Tetraplegia|Spinal Cord Injuries|Amyotrophic Lateral Sclerosis|Brain Stem Infarctions|Locked in Syndrome|Muscular Dystrophy,Device: Placement of the BrainGate2 sensor(s) into the motor-related cortex,"The primary endpoint of this Study is to determine the safety of the BrainGate2 Neural Interface System.|To investigate the feasibility of BrainGate2 and to establish the parameters for a larger clinical study, such as appropriate neural decoding algorithms, sample size, indices of measurement, success criteria, and endpoints.","Leigh R. Hochberg, MD, PhD.|National Institute on Deafness and Other Communication Disorders (NIDCD)|US Department of Veterans Affairs|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital",All,Not Applicable,15.0,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,MGH-BG2-TP-001|R01DC009899|1UH2NS095548,May 2009,September 2022,December 2022,"June 3, 2009",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT00912041,18.0,75.0
2562,492,42.3788774,-72.032366,"University of British Columbia, Vancouver, British Columbia, Canada",493.0,NCT00912041,BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia,BrainGate2,Recruiting,No Results Available,Tetraplegia|Spinal Cord Injuries|Amyotrophic Lateral Sclerosis|Brain Stem Infarctions|Locked in Syndrome|Muscular Dystrophy,Device: Placement of the BrainGate2 sensor(s) into the motor-related cortex,"The primary endpoint of this Study is to determine the safety of the BrainGate2 Neural Interface System.|To investigate the feasibility of BrainGate2 and to establish the parameters for a larger clinical study, such as appropriate neural decoding algorithms, sample size, indices of measurement, success criteria, and endpoints.","Leigh R. Hochberg, MD, PhD.|National Institute on Deafness and Other Communication Disorders (NIDCD)|US Department of Veterans Affairs|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital",All,Not Applicable,15.0,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,MGH-BG2-TP-001|R01DC009899|1UH2NS095548,May 2009,September 2022,December 2022,"June 3, 2009",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT00912041,18.0,75.0
2563,492,40.2253569,-82.6881395,"University of Toronto, Toronto, Ontario, Canada",493.0,NCT00912041,BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia,BrainGate2,Recruiting,No Results Available,Tetraplegia|Spinal Cord Injuries|Amyotrophic Lateral Sclerosis|Brain Stem Infarctions|Locked in Syndrome|Muscular Dystrophy,Device: Placement of the BrainGate2 sensor(s) into the motor-related cortex,"The primary endpoint of this Study is to determine the safety of the BrainGate2 Neural Interface System.|To investigate the feasibility of BrainGate2 and to establish the parameters for a larger clinical study, such as appropriate neural decoding algorithms, sample size, indices of measurement, success criteria, and endpoints.","Leigh R. Hochberg, MD, PhD.|National Institute on Deafness and Other Communication Disorders (NIDCD)|US Department of Veterans Affairs|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital",All,Not Applicable,15.0,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,MGH-BG2-TP-001|R01DC009899|1UH2NS095548,May 2009,September 2022,December 2022,"June 3, 2009",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT00912041,18.0,75.0
2564,492,41.7962409,-71.5992372,"Massachusetts General Hospital, Boston, Massachusetts, United States",493.0,NCT00912041,BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia,BrainGate2,Recruiting,No Results Available,Tetraplegia|Spinal Cord Injuries|Amyotrophic Lateral Sclerosis|Brain Stem Infarctions|Locked in Syndrome|Muscular Dystrophy,Device: Placement of the BrainGate2 sensor(s) into the motor-related cortex,"The primary endpoint of this Study is to determine the safety of the BrainGate2 Neural Interface System.|To investigate the feasibility of BrainGate2 and to establish the parameters for a larger clinical study, such as appropriate neural decoding algorithms, sample size, indices of measurement, success criteria, and endpoints.","Leigh R. Hochberg, MD, PhD.|National Institute on Deafness and Other Communication Disorders (NIDCD)|US Department of Veterans Affairs|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital",All,Not Applicable,15.0,Other|NIH|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,MGH-BG2-TP-001|R01DC009899|1UH2NS095548,May 2009,September 2022,December 2022,"June 3, 2009",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT00912041,18.0,75.0
2565,493,51.083333,-1.166667,"Avanir Pharmaceuticals, Aliso Viejo, California, United States",494.0,NCT03356288,The General Breathing Record Study,GBRS,Completed,No Results Available,Asthma|Heart Failure|Pneumonia|Motor Neuron Disease|Vocal Cord Dysfunction|Breathlessness,,The tidal breathing carbon dioxide waveform for each of the breathing conditions as measured by the N-Tidal C device|Change in the Tidal Breathing carbon dioxide waveform over time|Disease Control in asthma patients|Disease Improvement in Breathing Pattern Disorder patients|Disease severity in the pneumonia patients|Disease severity in heart failure patients|Hypercapnia in the motor neurone disease patients|Usability of the N-Tidal C device|Acceptability of the N-Tidal C device,Cambridge Respiratory Innovations Limited|Innovate UK,All,,70.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,G002-17_GBRS,"August 9, 2017","July 4, 2018","July 4, 2018","November 29, 2017",,"September 20, 2018",,https://ClinicalTrials.gov/show/NCT03356288,16.0,100.0
2566,494,38.6920451,-75.4013315,"Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada",495.0,NCT02532244,Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases,,Recruiting,No Results Available,Spinal Muscular Atrophy|Charcot-Marie-Tooth Disease|Muscular Dystrophy|Spinal Muscular Atrophy With Respiratory Distress 1|Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Disease|Peroneal Muscular Atrophy|Fragile X Syndrome,Other: sample collection,genetic diagnosis|SMN1 copy number|SMN2 copy number|target gene mRNA levels|target gene protein levels,Nemours Children's Clinic,All,,300.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,764456,June 2015,December 2022,December 2022,"August 25, 2015",,"August 25, 2015",,https://ClinicalTrials.gov/show/NCT02532244,6.0,100.0
2567,494,27.7567667,-81.4639835,"Evergreen Healthcare, Kirkland, Washington, United States",495.0,NCT02532244,Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases,,Recruiting,No Results Available,Spinal Muscular Atrophy|Charcot-Marie-Tooth Disease|Muscular Dystrophy|Spinal Muscular Atrophy With Respiratory Distress 1|Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Disease|Peroneal Muscular Atrophy|Fragile X Syndrome,Other: sample collection,genetic diagnosis|SMN1 copy number|SMN2 copy number|target gene mRNA levels|target gene protein levels,Nemours Children's Clinic,All,,300.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,764456,June 2015,December 2022,December 2022,"August 25, 2015",,"August 25, 2015",,https://ClinicalTrials.gov/show/NCT02532244,6.0,100.0
2568,494,27.7567667,-81.4639835,"Lungen Klinik - Chefarzt Abt. Pneumologie Kliniken der StadtK√∂lng GmbH, Cologne, Germany",495.0,NCT02532244,Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases,,Recruiting,No Results Available,Spinal Muscular Atrophy|Charcot-Marie-Tooth Disease|Muscular Dystrophy|Spinal Muscular Atrophy With Respiratory Distress 1|Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Neuromuscular Disease|Peroneal Muscular Atrophy|Fragile X Syndrome,Other: sample collection,genetic diagnosis|SMN1 copy number|SMN2 copy number|target gene mRNA levels|target gene protein levels,Nemours Children's Clinic,All,,300.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,764456,June 2015,December 2022,December 2022,"August 25, 2015",,"August 25, 2015",,https://ClinicalTrials.gov/show/NCT02532244,6.0,100.0
2569,495,36.7014631,-118.7559974,"OMNI Medical Services, Boca Raton, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2570,495,36.7014631,-118.7559974,"OMNI Medical Services, Bradenton, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2571,495,36.7014631,-118.7559974,"OMNI Medical Services, Fort Lauderdale, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2572,495,27.7567667,-81.4639835,"OMNI Medical Services, Fort Myers, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2573,495,41.9216734,-93.3122705,"OMNI Medical Services, Gainesville, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2574,495,38.27312,-98.5821872,"OMNI Medical Services, Merritt Island, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2575,495,45.9896587,-94.6113288,"OMNI Medical Services, Miami, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2576,495,35.6729639,-79.0392919,"OMNI Medical Services, Ocoee, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2577,495,40.2253569,-82.6881395,"OMNI Medical Services, Pensacola, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2578,495,40.9699889,-77.7278831,"OMNI Medical Services, Pompano Beach, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2579,495,31.8160381,-99.5120986,"OMNI Medical Services, Tampa, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2580,495,31.8160381,-99.5120986,"OMNI Medical Services, Wesley Chapel, Florida, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2581,495,37.1232245,-78.4927721,"OMNI Medical Services, Beechwood, Ohio, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2582,495,48.5236164,9.0535531,"OMNI Medical Services, Bowling Green, Ohio, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2583,495,-33.928992,18.417396,"OMNI Medical Services, Sandusky, Ohio, United States",496.0,NCT02327845,"Phenotype, Genotype & Biomarkers in ALS and Related Disorders",,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Primary Lateral Sclerosis|Hereditary Spastic Paraplegia|Progressive Muscular Atrophy|Multisystem Proteinopathy,,Phenotypic correlates of genotype|Genetic determinants of phenotype,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|National Center for Advancing Translational Science (NCATS)|St. Jude Children's Research Hospital|ALS Association,All,,700.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,20160603|U54NS092091,April 2015,July 2020,July 2020,"December 30, 2014",,"July 12, 2019",,https://ClinicalTrials.gov/show/NCT02327845,18.0,100.0
2584,496,33.2588817,-86.8295337,"OMNI Medical Services, Toledo, Ohio, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2585,496,36.7014631,-118.7559974,"OMNI Medical Services, Toledo, Ohio, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2586,496,36.7014631,-118.7559974,"University of Alabama at Birmingham, Birmingham, Alabama, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2587,496,36.7014631,-118.7559974,"Emory University, Atlanta, Georgia, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2588,496,27.7567667,-81.4639835,"University of South Carolina, Columbia, South Carolina, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2589,496,40.0796606,-89.4337288,"University of Texas Southwestern, Dallas, Texas, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2590,496,39.5162234,-76.9382069,"National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2591,496,42.3788774,-72.032366,"The Healing Institute, Margate, Florida, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2592,496,45.9896587,-94.6113288,"Euro-Arabian Hospital, Dubai, Sharjah, United Arab Emirates",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2593,NULL,NULL,NULL,"Centre d'√©valuation Th√©rapeutique, Dr LACOMBLEZ, Paris, France",,,,,,,,,,,,,,,,,,,,,,,,,,,
2594,496,40.7127281,-74.0060152,"Department of Endocrinology, PGIMER, Chandigarh, India",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2595,496,35.6729639,-79.0392919,"University of Tuebingen, Tubingen, Baden Wuerttemberg, Germany",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2596,496,40.2253569,-82.6881395,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2597,496,40.9699889,-77.7278831,"Stanford University Medical Center, 300 Pasteur Drive, Room A343, Stanford, California, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2598,496,31.8160381,-99.5120986,"Washington University Medical School, Washington University, 660 S. Euclid Avenue, Box 8111, St. Louis, Missouri, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2599,496,38.8950092,-77.0365625,"Columbia University, 180 Fort Washington Avenue, 5th Floor, New York, New York, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2600,496,55.001251,-125.002441,"The Children's Hospital of Philadelphia, Clinical Trials Office, A-230, 34th St. and Civic Center Boulevard, Philadelphia, Pennsylvania, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2601,496,50.000678,-86.000977,"University of Texas Southwestern Medical Center at Dallas, Division of Pediatric Neurology, Children's Medical Center of Dallas, Ambulatory Care Pavilion, 2350 Stemmons Freeway, Suite #5074, Dallas, Texas, United States",497.0,NCT02365922,Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL),ARTFL,Recruiting,No Results Available,FTLD|Progressive Supranuclear Palsy (PSP)|Frontotemporal Dementia (FTD)|Corticobasal Degeneration (CBD)|PPA Syndrome|Behavioral Variant Frontotemporal Dementia (bvFTD)|Semantic Variant Primary Progressive Aphasia (svPPA)|Nonfluent Variant Primary Progressive Aphasia (nfvPPA)|FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)|Amyotrophic Lateral Sclerosis (ALS)|Oligosymptomatic PSP (oPSP)|Corticobasal Syndrome (CBS),,Scores of UDS FTLD Module Tests|Progressive Supranuclear Palsy Rating Scale (PSPRS)|Neuroimaging,"University of California, San Francisco|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|The Bluefield Project|Tau Consortium",All,,1560.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ARTFL8101|1U54NS092089-01,September 2014,September 2020,February 2021,"February 19, 2015",,"June 26, 2019",,https://ClinicalTrials.gov/show/NCT02365922,18.0,85.0
2602,497,42.3788774,-72.032366,"Stanford University Medical Center, 300 Pasteur Drive, Room A343, Stanford, California, United States",498.0,NCT02418546,Electronic-health Application To Measure Outcomes REmotely Clinical Trial,EAT MORE,Completed,No Results Available,Neurodegenerative Disease|Weight Loss|Amyotrophic Lateral Sclerosis|Parkinson's Disease|Huntington's Disease|Cachexia,Behavioral: In-Person Nutritional Counseling by a Registered Dietitian|Behavioral: Nutritional counseling using an e-Health Application,Weight: Measured in the clinic|Calorie intake: Measured using 4 day food records|Safety: Frequency of adverse events|Tolerability: The number of participants who complete the study while complying with at least 80% of the counseling sessions,Massachusetts General Hospital|ALS Association,All,Not Applicable,88.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2015P000258,April 2015,December 2017,March 2018,"April 16, 2015",,"March 29, 2018",,https://ClinicalTrials.gov/show/NCT02418546,18.0,100.0
2603,498,36.7014631,-118.7559974,"Children's Hospital, Boston, 300 Longwood Avenue, Fegan 11, Boston, Massachusetts, United States",499.0,NCT01366027,PRISM Registry: Pseudobulbar Affect Registry Series,,Completed,No Results Available,Alzheimer's Disease|Amyotrophic Lateral Sclerosis (ALS)|Multiple Sclerosis (MS)|Parkinson's Disease|Stroke|Traumatic Brain Injury,,Prevalence of PBA (using CNS-LS),Avanir Pharmaceuticals,All,,5290.0,Industry,Observational,,11-AVR-REG-001,May 2011,September 2012,September 2012,"June 3, 2011",,"April 16, 2014",,https://ClinicalTrials.gov/show/NCT01366027,18.0,100.0
2604,499,50.000678,-86.000977,"Columbia University, 180 Fort Washington Avenue, 5th Floor, New York, New York, United States",500.0,NCT02964637,Diagnosing Frontotemporal Lobar Degeneration,,Recruiting,No Results Available,Corticobasal Syndrome|Progressive Supranuclear Palsy|Behavioral Variant Frontotemporal Dementia|Semantic Dementia|Progressive Nonfluent Aphasia|Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia,Other: Observational Study,Structural and Functional Diffferences between the FTLD groups via MRI of the brain|Differences between the FTLD groups via PET imaging of the brain,"University Health Network, Toronto",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,14-8398-A,August 2015,December 2019,December 2019,"November 16, 2016",,"April 16, 2019",,https://ClinicalTrials.gov/show/NCT02964637,18.0,90.0
2605,500,38.8950092,-77.0365625,"The Children's Hospital of Philadelphia, Clinical Trials Office, A-230, 34th St. and Civic Center Boulevard, Philadelphia, Pennsylvania, United States",501.0,NCT02750982,"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",,Completed,No Results Available,Alzheimer's Disease|Amyotrophic Lateral Sclerosis|Brain Injury|Huntington's Disease|Multiple Sclerosis|Parkinson's Disease|Stroke|Spinal Cord Injury,Other: Laughter Therapy,"Patient Health Questionnaire (PHQ-9, for depression)|Generalized Anxiety Disorder 7-item scale (GAD-7, for anxiety)|The General Self-Efficacy Scale (GSE)","Brown, Theodore R., M.D., MPH",All,Not Applicable,24.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,TRBROWN201601,July 2016,August 2018,August 2018,"April 26, 2016",,"September 26, 2018",,https://ClinicalTrials.gov/show/NCT02750982,18.0,100.0
2606,501,50.938361,6.959974,"University of Texas Southwestern Medical Center at Dallas, Division of Pediatric Neurology, Children's Medical Center of Dallas, Ambulatory Care Pavilion, 2350 Stemmons Freeway, Suite #5074, Dallas, Texas, United States",502.0,NCT02315339,European Home Mechanical Ventilation Registry,EHMVR,Terminated,No Results Available,"Pulmonary Disease, Chronic Obstructive|Amyotrophic Lateral Sclerosis|Spinal Cord Injury|Muscular Dystrophies|Obesity Hypoventilation Syndrome|Kyphoscoliosis|Congenital Central Hypoventilation Syndrome|Duchenne Muscular Dystrophy|Myopathies|Myotonic Dystrophy",,Determine the mortality rate and the number of hospital readmissions|Determine the effects of home mechanical ventilation on health-related quality of life using the EQ-5D and the Severe Respiratory Insufficiency questionnaires quality of life,ResMed|Clinical Trial Center North Hamburg Germany|The Clinical Research Institute Munich Germany,All,,37.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CTC11633,August 2014,January 2019,August 2019,"December 11, 2014",,"October 26, 2016",,https://ClinicalTrials.gov/show/NCT02315339,18.0,100.0
2607,502,27.7567667,-81.4639835,"H√¥pital Amiens Nord, Service de Neurologie, Amiens, France",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2608,502,27.7567667,-81.4639835,"CHRU de Lille, H√¥pital Swyngedhauw, Lille, France",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2609,502,27.7567667,-81.4639835,"H√¥pital S√©bastopol, CHU de Reims, Reims, France",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2610,502,27.7567667,-81.4639835,"Loma Linda, California, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2611,502,27.7567667,-81.4639835,"Los Angeles, California, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2612,502,27.7567667,-81.4639835,"National City, California, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2613,502,27.7567667,-81.4639835,"Aurora, Colorado, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2614,502,27.7567667,-81.4639835,"Washington, District of Columbia, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2615,502,27.7567667,-81.4639835,"Boca Raton, Florida, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2616,502,27.7567667,-81.4639835,"Port Charlotte, Florida, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2617,502,27.7567667,-81.4639835,"Carmel, Indiana, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2618,502,27.7567667,-81.4639835,"Baltimore, Maryland, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2619,502,40.2253569,-82.6881395,"Elkridge, Maryland, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2620,502,40.2253569,-82.6881395,"Detroit, Michigan, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2621,502,40.2253569,-82.6881395,"Saint Louis, Missouri, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2622,502,40.2253569,-82.6881395,"Edison, New Jersey, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2623,502,40.2253569,-82.6881395,"Albany, New York, United States",503.0,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder,"Drug: Cannabis, Medical",Treatment of Symptoms|Monitoring Adverse Events|Cannabis Impact on Quality of Life|Cannabis Route and Dosing,"OMNI Medical Services, LLC",All,,10000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00033337,"December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"June 19, 2019",,https://ClinicalTrials.gov/show/NCT03944447,7.0,100.0
2624,503,33.2588817,-86.8295337,"New York, New York, United States",504.0,NCT03516994,Reducing Disparities in the Quality of Advance Care Planning for Older Adults,EQUALACP,Enrolling by invitation,No Results Available,Metastatic Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Parkinson Disease|Interstitial Lung Disease|Amyotrophic Lateral Sclerosis|End Stage Liver Disease|End Stage Renal Disease|Diabetes Complications,Behavioral: Respecting Choices First Steps|Behavioral: Five Wishes Form,Proportion of African Americans who complete advance care planning|Proportion of Whites who complete advance care planning|Difference in Proportion of Whites versus African Americans who complete advance care planning|Patient Readiness to Engage in Advance Care Planning|Patient Quality of Life,Duke University,All,Not Applicable,800.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00091633|OLC-1609-36381,"January 16, 2019","September 1, 2022","September 1, 2022","May 7, 2018",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT03516994,65.0,100.0
2625,503,32.3293809,-83.1137366,"Cincinnati, Ohio, United States",504.0,NCT03516994,Reducing Disparities in the Quality of Advance Care Planning for Older Adults,EQUALACP,Enrolling by invitation,No Results Available,Metastatic Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Parkinson Disease|Interstitial Lung Disease|Amyotrophic Lateral Sclerosis|End Stage Liver Disease|End Stage Renal Disease|Diabetes Complications,Behavioral: Respecting Choices First Steps|Behavioral: Five Wishes Form,Proportion of African Americans who complete advance care planning|Proportion of Whites who complete advance care planning|Difference in Proportion of Whites versus African Americans who complete advance care planning|Patient Readiness to Engage in Advance Care Planning|Patient Quality of Life,Duke University,All,Not Applicable,800.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00091633|OLC-1609-36381,"January 16, 2019","September 1, 2022","September 1, 2022","May 7, 2018",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT03516994,65.0,100.0
2626,503,33.6874388,-80.4363743,"Tulsa, Oklahoma, United States",504.0,NCT03516994,Reducing Disparities in the Quality of Advance Care Planning for Older Adults,EQUALACP,Enrolling by invitation,No Results Available,Metastatic Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Parkinson Disease|Interstitial Lung Disease|Amyotrophic Lateral Sclerosis|End Stage Liver Disease|End Stage Renal Disease|Diabetes Complications,Behavioral: Respecting Choices First Steps|Behavioral: Five Wishes Form,Proportion of African Americans who complete advance care planning|Proportion of Whites who complete advance care planning|Difference in Proportion of Whites versus African Americans who complete advance care planning|Patient Readiness to Engage in Advance Care Planning|Patient Quality of Life,Duke University,All,Not Applicable,800.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00091633|OLC-1609-36381,"January 16, 2019","September 1, 2022","September 1, 2022","May 7, 2018",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT03516994,65.0,100.0
2627,503,31.8160381,-99.5120986,"Port Royal, South Carolina, United States",504.0,NCT03516994,Reducing Disparities in the Quality of Advance Care Planning for Older Adults,EQUALACP,Enrolling by invitation,No Results Available,Metastatic Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Parkinson Disease|Interstitial Lung Disease|Amyotrophic Lateral Sclerosis|End Stage Liver Disease|End Stage Renal Disease|Diabetes Complications,Behavioral: Respecting Choices First Steps|Behavioral: Five Wishes Form,Proportion of African Americans who complete advance care planning|Proportion of Whites who complete advance care planning|Difference in Proportion of Whites versus African Americans who complete advance care planning|Patient Readiness to Engage in Advance Care Planning|Patient Quality of Life,Duke University,All,Not Applicable,800.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00091633|OLC-1609-36381,"January 16, 2019","September 1, 2022","September 1, 2022","May 7, 2018",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT03516994,65.0,100.0
2628,504,39.5162234,-76.9382069,"Cordova, Tennessee, United States",505.0,NCT02014246,Genetic Characterization of Movement Disorders and Dementias,,Recruiting,No Results Available,"Ataxia|Dystonia|Parkinson's Disease|Amyotrophic Lateral Sclerosis|Corticobasal Degeneration|Multiple System Atrophy|Alzheimer's Disease|Lewy Body Dementia|Parkinson Disease-Dementia|Dentatorubral-pallidoluysian Atrophy|Creutzfeldt-Jakob Disease and Fatal Familial Insomnia|Fragile X-associated Tremor/Ataxia Syndrome|Krabbe's Disease|Niemann-Pick Disease, Type C|Neuronal Ceroid Lipofuscinosis",,"Identify and characterize genetic contributions to etiology for movement disorders, such as dystonia, Parkinson's disease, and dementias, such as Alzheimer's disease, Lewy Body Dementia, frontotemporal dementia.",National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC),All,,12000.0,NIH,Observational,Observational Model: Case-Control|Time Perspective: Other,999903329|03-AG-N329,"February 12, 2003","December 31, 2019","December 31, 2019","December 18, 2013",,"July 9, 2019",,https://ClinicalTrials.gov/show/NCT02014246,18.0,100.0
2629,505,27.7567667,-81.4639835,"Houston, Texas, United States",506.0,NCT02795052,Neurologic Stem Cell Treatment Study,NEST,Recruiting,No Results Available,Neurologic Disorders|Nervous System Diseases|Neurodegenerative Diseases|Neurological Disorders|Stroke|Traumatic Brain Injury|Cadasil|Chronic Traumatic Encephalopathy|Cerebral Infarction|Cerebral Ischemia|Cerebral Stroke|Cerebral Hemorrhage|Parkinson|Multi-System Degeneration|MSA - Multiple System Atrophy|Progressive Supranuclear Palsy|ALS|Amyotrophic Lateral Sclerosis|Neuropathy|Diabetic Neuropathies,Procedure: Intravenous BMSC|Procedure: Intranasal BMSC,Activities of Daily Living (ADL)|Neurologic Functioning,MD Stem Cells|The Healing Institute,All,Not Applicable,300.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDSC-NEST,June 2016,June 2020,June 2021,"June 9, 2016",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT02795052,18.0,100.0
2630,505,25.22972105,55.7822507738703,"San Antonio, Texas, United States",506.0,NCT02795052,Neurologic Stem Cell Treatment Study,NEST,Recruiting,No Results Available,Neurologic Disorders|Nervous System Diseases|Neurodegenerative Diseases|Neurological Disorders|Stroke|Traumatic Brain Injury|Cadasil|Chronic Traumatic Encephalopathy|Cerebral Infarction|Cerebral Ischemia|Cerebral Stroke|Cerebral Hemorrhage|Parkinson|Multi-System Degeneration|MSA - Multiple System Atrophy|Progressive Supranuclear Palsy|ALS|Amyotrophic Lateral Sclerosis|Neuropathy|Diabetic Neuropathies,Procedure: Intravenous BMSC|Procedure: Intranasal BMSC,Activities of Daily Living (ADL)|Neurologic Functioning,MD Stem Cells|The Healing Institute,All,Not Applicable,300.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDSC-NEST,June 2016,June 2020,June 2021,"June 9, 2016",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT02795052,18.0,100.0
2631,506,,,"Salt Lake City, Utah, United States",507.0,NCT04055532,Biomarkers in Neurodegenerative Diseases,,Not yet recruiting,No Results Available,Mild Cognitive Impairment (MCI)|Alzheimer Disease (AD)|Dementia With Lewy Bodies (DLB)|Frontotemporal Lobar Degeneration (FTLD)|Parkinsons Disease With Dementia (PDD)|Transient Epileptic Amnesia (TEA)|Temporal Lobe Epilepsy (TLE)|Spinocerebellar Ataxias (SCA)|HIV Associated Neurocognitive Disorder (HAND)|Amyotrophic Lateral Sclerosis (ALS)|Primary Lateral Sclerosis (PLS),Other: Neuraceq,Performance on Batteries of Cognitive Tests,University of Minnesota - Clinical and Translational Science Institute,All,,200.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STUDY00007108,"October 1, 2019","October 1, 2024","October 1, 2025","August 13, 2019",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT04055532,18.0,100.0
2632,507,48.8566101,2.3514992,"Kirkland, Washington, United States",508.0,NCT01984957,Differential Study of Muscle Transcriptome,TRANE,Completed,No Results Available,ALS|SMA|SBMA,Procedure: Muscle biopsy,Gene expression levels|muscle denervation|Functional evaluation,"Assistance Publique - H√¥pitaux de Paris|Direction G√©n√©rale de l'Offre de Soins|Institut National de la Sant√© Et de la Recherche M√©dicale, France",All,Not Applicable,42.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P110401,January 2013,January 2015,January 2015,"November 15, 2013",,"March 23, 2015",,https://ClinicalTrials.gov/show/NCT01984957,18.0,75.0
2633,508,30.7194022,76.7646552,"Tacoma, Washington, United States",509.0,NCT03289338,Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus,,Completed,No Results Available,Charcot Arthropathy|Diabetes Complications,Drug: Zoledronic Acid|Drug: Methylprednisolone|Drug: Placebos,Time for resolution of active Charcot foot|Time for reduction in levels of inflammatory cytokines (>= 50%)|Time for radiologic resolution/reduction on MRI,Postgraduate Institute of Medical Education and Research,All,Phase 2|Phase 3,36.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ZoleMethCNO,"June 1, 2016","December 31, 2018","December 31, 2018","September 20, 2017",,"July 16, 2019",,https://ClinicalTrials.gov/show/NCT03289338,18.0,70.0
2634,509,48.6296972,9.1949534,"Irkutsk, Irkutsk Region, Russian Federation",510.0,NCT02980380,Brain Computer Interface Complete locked-in State Communication,,Recruiting,No Results Available,Complete Locked-in State,Other: Non-invasive brain computer interface,Brain Computer Interface Based Communication in the Completely Locked-In State patients,University Hospital Tuebingen,All,,15.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,ALS BCI study,June 2014,December 2021,April 2022,"December 2, 2016",,"April 19, 2019",,https://ClinicalTrials.gov/show/NCT02980380,18.0,100.0
2635,510,39.5162234,-76.9382069,"Vsevolozhsk, Leningrad Region, Russian Federation",511.0,NCT00061607,Measuring Levels of SMN in Blood Samples of SMA Patients,,Completed,No Results Available,Spinal Muscular Atrophy,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,73.0,NIH,Observational,,030203|03-N-0203,"May 19, 2003",,"April 4, 2017","May 30, 2003",,"October 6, 2017",,https://ClinicalTrials.gov/show/NCT00061607,2.0,100.0
2636,511,36.7014631,-118.7559974,"St.Petersburg, Petrodvorets, Russian Federation",512.0,NCT00439569,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III,NPTUNE01,Terminated,Has Results,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,9.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE01|HHSN265200423611C,January 2008,August 2008,August 2008,"February 23, 2007","February 12, 2010","September 8, 2010",,https://ClinicalTrials.gov/show/NCT00439569,2.0,11.0
2637,511,38.7604815,-92.5617875,"Krasnoyarsk, Russian Federation",512.0,NCT00439569,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III,NPTUNE01,Terminated,Has Results,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,9.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE01|HHSN265200423611C,January 2008,August 2008,August 2008,"February 23, 2007","February 12, 2010","September 8, 2010",,https://ClinicalTrials.gov/show/NCT00439569,2.0,11.0
2638,511,40.7127281,-74.0060152,"Dnipropetrovsk, Ukraine",512.0,NCT00439569,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III,NPTUNE01,Terminated,Has Results,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,9.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE01|HHSN265200423611C,January 2008,August 2008,August 2008,"February 23, 2007","February 12, 2010","September 8, 2010",,https://ClinicalTrials.gov/show/NCT00439569,2.0,11.0
2639,511,40.9699889,-77.7278831,"Ivano-Frankivsk, Ukraine",512.0,NCT00439569,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III,NPTUNE01,Terminated,Has Results,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,9.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE01|HHSN265200423611C,January 2008,August 2008,August 2008,"February 23, 2007","February 12, 2010","September 8, 2010",,https://ClinicalTrials.gov/show/NCT00439569,2.0,11.0
2640,511,31.8160381,-99.5120986,"Kharkiv, Ukraine",512.0,NCT00439569,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III,NPTUNE01,Terminated,Has Results,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,9.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE01|HHSN265200423611C,January 2008,August 2008,August 2008,"February 23, 2007","February 12, 2010","September 8, 2010",,https://ClinicalTrials.gov/show/NCT00439569,2.0,11.0
2641,512,36.7014631,-118.7559974,"Lviv, Ukraine",513.0,NCT00439218,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I,NPTUNE 02,Terminated,Has Results,Spinal Muscular Atrophy Type I,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Plasma Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,5.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE02|HHSN265200423611C,January 2008,May 2009,May 2009,"February 23, 2007","July 20, 2010","November 9, 2010",,https://ClinicalTrials.gov/show/NCT00439218,2.0,48.0
2642,512,42.3788774,-72.032366,"Rivne, Ukraine",513.0,NCT00439218,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I,NPTUNE 02,Terminated,Has Results,Spinal Muscular Atrophy Type I,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Plasma Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,5.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE02|HHSN265200423611C,January 2008,May 2009,May 2009,"February 23, 2007","July 20, 2010","November 9, 2010",,https://ClinicalTrials.gov/show/NCT00439218,2.0,48.0
2643,512,40.7127281,-74.0060152,"Uzhgorod, Ukraine",513.0,NCT00439218,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I,NPTUNE 02,Terminated,Has Results,Spinal Muscular Atrophy Type I,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Plasma Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,5.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE02|HHSN265200423611C,January 2008,May 2009,May 2009,"February 23, 2007","July 20, 2010","November 9, 2010",,https://ClinicalTrials.gov/show/NCT00439218,2.0,48.0
2644,512,40.9699889,-77.7278831,"UMass Memorial Medical Center, Worcester, Massachusetts, United States",513.0,NCT00439218,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I,NPTUNE 02,Terminated,Has Results,Spinal Muscular Atrophy Type I,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Plasma Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,5.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE02|HHSN265200423611C,January 2008,May 2009,May 2009,"February 23, 2007","July 20, 2010","November 9, 2010",,https://ClinicalTrials.gov/show/NCT00439218,2.0,48.0
2645,512,31.8160381,-99.5120986,"Methodist Hospital Research Institute, Houston, Texas, United States",513.0,NCT00439218,Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I,NPTUNE 02,Terminated,Has Results,Spinal Muscular Atrophy Type I,Drug: sodium phenylbutyrate,Dose Limiting Toxicities (DLT)|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)|Survival Motor Neuron (SMN) Protein|Drug Safety|Pharmacokinetic Parameters (Maximum Plasma Concentration)|Pharmacokinetic Parameters (Time to Maximum Plasma Concentration)|Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Overall Study Drug Compliance,Westat|National Institute of Neurological Disorders and Stroke (NINDS),All,Phase 1|Phase 2,5.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01NS42361_NPTUNE02|HHSN265200423611C,January 2008,May 2009,May 2009,"February 23, 2007","July 20, 2010","November 9, 2010",,https://ClinicalTrials.gov/show/NCT00439218,2.0,48.0
2646,513,49.8941708,2.2956951,"Celerion, Inc, Tempe, Arizona, United States",514.0,NCT02789059,Muscle Oxygenation in Effort in Neuromuscular Diseases,OXYNEMU,Unknown status,No Results Available,Neuromuscular Diseases,Other: muscle oxygenation,muscle oxygenation|Muscle oxygenation|maximal isokinetic strength of the knee extensors|Gas exchange|MFM score|6 Minutes Walking Test (MWT)|Vignos functional scales|Brooke functional scales|Medical Research Council Muscle testing|Mitochondrial phenotype|Mitochondrial H2O2 production|kinetic of Muscle oxygenation,"University Hospital, Lille",Male,Not Applicable,170.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2013_29|2014-A01157-40,"July 2, 2015",July 2017,July 2017,"June 2, 2016",,"May 19, 2017",,https://ClinicalTrials.gov/show/NCT02789059,18.0,70.0
2647,513,50.6365654,3.0635282,"NYU Langone Health, New York, New York, United States",514.0,NCT02789059,Muscle Oxygenation in Effort in Neuromuscular Diseases,OXYNEMU,Unknown status,No Results Available,Neuromuscular Diseases,Other: muscle oxygenation,muscle oxygenation|Muscle oxygenation|maximal isokinetic strength of the knee extensors|Gas exchange|MFM score|6 Minutes Walking Test (MWT)|Vignos functional scales|Brooke functional scales|Medical Research Council Muscle testing|Mitochondrial phenotype|Mitochondrial H2O2 production|kinetic of Muscle oxygenation,"University Hospital, Lille",Male,Not Applicable,170.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2013_29|2014-A01157-40,"July 2, 2015",July 2017,July 2017,"June 2, 2016",,"May 19, 2017",,https://ClinicalTrials.gov/show/NCT02789059,18.0,70.0
2648,513,49.2577886,4.031926,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States",514.0,NCT02789059,Muscle Oxygenation in Effort in Neuromuscular Diseases,OXYNEMU,Unknown status,No Results Available,Neuromuscular Diseases,Other: muscle oxygenation,muscle oxygenation|Muscle oxygenation|maximal isokinetic strength of the knee extensors|Gas exchange|MFM score|6 Minutes Walking Test (MWT)|Vignos functional scales|Brooke functional scales|Medical Research Council Muscle testing|Mitochondrial phenotype|Mitochondrial H2O2 production|kinetic of Muscle oxygenation,"University Hospital, Lille",Male,Not Applicable,170.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2013_29|2014-A01157-40,"July 2, 2015",July 2017,July 2017,"June 2, 2016",,"May 19, 2017",,https://ClinicalTrials.gov/show/NCT02789059,18.0,70.0
2649,514,36.7014631,-118.7559974,"Stanford University Medical Center, Palo Alto, California, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2650,514,36.7014631,-118.7559974,"Children's Hospital Colorado, Aurora, Colorado, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2651,514,36.7014631,-118.7559974,"Nemours Children's Hospital, Orlando, Florida, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2652,514,38.7251776,-105.6077167,"Center for Rare Neurological Diseases, Norcross, Georgia, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2653,514,38.89366125,-76.987883253882,"Ann Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2654,514,27.7567667,-81.4639835,"John Hopkins Pediatric Neurology, David M. Rubenstein Building, Baltimore, Maryland, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2655,514,27.7567667,-81.4639835,"Massachusetts General, Boston, Massachusetts, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2656,514,40.3270127,-86.1746933,"Boston Children's Hospital, Boston, Massachusetts, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2657,514,39.5162234,-76.9382069,"Spectrum Health System, Grand Rapids, Michigan, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2658,514,39.5162234,-76.9382069,"Washington Unviersity School of Medicine, Saint Louis, Missouri, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2659,514,43.6211955,-84.6824346,"Columbia University, New York, New York, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2660,514,38.7604815,-92.5617875,"Duke University, Durham, North Carolina, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2661,514,40.0757384,-74.4041622,"Nationwide Children's Hospital, Columbus, Ohio, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2662,514,40.7127281,-74.0060152,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2663,514,40.7127281,-74.0060152,"Clinic for Special Children, Strasburg, Pennsylvania, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2664,514,40.2253569,-82.6881395,"Children's Med. CTR Ambulatory Care, Dallas, Texas, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2665,514,34.9550817,-97.2684063,"University of Utah, Salt Lake City, Utah, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2666,514,33.6874388,-80.4363743,"Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2667,514,35.7730076,-86.2820081,"Virginia Commonwealth University, Richmond, Virginia, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2668,514,31.8160381,-99.5120986,"University of Wisconsin, Madison, Madison, Wisconsin, United States",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2669,514,31.8160381,-99.5120986,"Sydney Children's Hospital Westmead, Randwick, New South Wales, Australia",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2670,514,39.4225192,-111.7143584,"UZ Gent, Gent, Belgium",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2671,514,38.8950092,-77.0365625,"Neuropediatrie-Centre De Reference Des Maladies, Li√®ge, Belgium",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2672,514,38.8950092,-77.0365625,"Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2673,514,64.6863136,97.7453061,"H√¥pital Armand Trousseau I-Motion - Plateforme d'essais cliniques p√©diatriques, Paris, France",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2674,514,58.8525318,29.307005,"Instituto Gianninia Gaslini, Genova, Italy",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2675,514,59.8798041,29.9260550247574,"University of Milan, Milan, Italy",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2676,514,56.0090968,92.8725147,"Carlo Besta Neurological Research Institute, Milan, Italy",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2677,514,48.4680221,35.0417711,"Ospedale Pediatrico Bambino Ges√π, Roma, Italy",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2678,514,48.9225224,24.7103188,"Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2679,514,49.9902794,36.2303893,"Tokyo Women's Medical University Hospital, Tokyo, Japan",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2680,514,49.841952,24.0315921,"Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-Do, Korea, Republic of",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2681,514,50.6196175,26.2513165,"Hospital Mancha Centro, Alc√°zar De San Juan, Spain",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2682,514,48.6223502,22.3021255,"National Taiwan University Hospital, Taipei, Taiwan",515.0,NCT01994109,Efficacy and Safety Study of MYOBLOC¬Æ Followed by Open-Label Multiple-Treatment With MYOBLOC¬Æ in the Treatment of Troublesome Sialorrhea in Adult Subjects,MYSTICOL,Completed,Has Results,Sialorrhea,Drug: MYOBLOC|Other: PLACEBO,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),US WorldMeds LLC,All,Phase 3,187.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SN-SIAL-301,November 2013,January 2016,January 2017,"November 25, 2013","August 15, 2019","August 15, 2019",,https://ClinicalTrials.gov/show/NCT01994109,18.0,85.0
2683,515,42.3788774,-72.032366,"Great Ormond Street Hospital for Children, London, United Kingdom",516.0,NCT01712087,Long-term Surveillance of the MedStream Programmable Infusion System,,Terminated,No Results Available,Spasticity,Device: MedStream Programmable Infusion System,The primary endpoint is the incidence of MedStream system-related Adverse Events (AE)|MedStream system-related AEs occurring from 24 to 36 months|Device-related AEs occurring with both MedStream and non-MedStream devices used or implanted during the course of the study.|Procedure-related AEs|Drug-related AEs associated with intrathecal Baclofen|Drug-related AEs associated with other intrathecally-administered medications|Disease-related AEs associated with pre-existing conditions|Serious Adverse Events (SAEs)|Unanticipated Adverse Device Effects (UADEs)|The secondary effectiveness endpoints will be long-term effectiveness of MedStream System,Codman & Shurtleff,All,,2.0,Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,NM-PMK-1001,"October 1, 2012","December 17, 2017","December 17, 2017","October 23, 2012",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT01712087,18.0,100.0
2684,515,31.8160381,-99.5120986,"Great North Children's Hospital Research Unit, Newcastle Upon Tyne, United Kingdom",516.0,NCT01712087,Long-term Surveillance of the MedStream Programmable Infusion System,,Terminated,No Results Available,Spasticity,Device: MedStream Programmable Infusion System,The primary endpoint is the incidence of MedStream system-related Adverse Events (AE)|MedStream system-related AEs occurring from 24 to 36 months|Device-related AEs occurring with both MedStream and non-MedStream devices used or implanted during the course of the study.|Procedure-related AEs|Drug-related AEs associated with intrathecal Baclofen|Drug-related AEs associated with other intrathecally-administered medications|Disease-related AEs associated with pre-existing conditions|Serious Adverse Events (SAEs)|Unanticipated Adverse Device Effects (UADEs)|The secondary effectiveness endpoints will be long-term effectiveness of MedStream System,Codman & Shurtleff,All,,2.0,Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,NM-PMK-1001,"October 1, 2012","December 17, 2017","December 17, 2017","October 23, 2012",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT01712087,18.0,100.0
2685,516,34.395342,-111.7632755,"Department of Neurology, First Affiliated Hospital Fujian Medical University, Fuzhou, Fujian, China",517.0,NCT03954600,"A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects",,Recruiting,No Results Available,Healthy Volunteers,Drug: NPT520-34 (125 mg)|Drug: Placebos (125 mg),"Safety/Tolerability of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Maximum observed plasma concentration of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Time to maximum plasma concentration of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable plasma concentration of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Area under the plasma concentration-time curve extrapolated to infinity of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Apparent oral clearance of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Apparent oral volume of distribution during the terminal phase of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Mean residence time of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Terminal elimination half-life of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Safety/Tolerability as measures of hematology, clinical chemistry, FSH, coagulation and urinalysis of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measures of vital signs and physical examination of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measures of continuous telemetry of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measures of suicidal ideation, 12-lead ECG, adverse events and serious adverse events of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measure of continuous ECG of Multiple Ascending Doses (250 mg and 500 mg)|Maximum observed plasma concentration (Cmax) after dosing on Day 1 of Multiple Ascending Doses (250 mg, 500 mg)|Maximum observed concentration at steady-state after dosing on Day 14 of Multiple Ascending Doses (250 mg, 500 mg)|Concentration observed at the end of the dosing interval of Multiple Ascending Doses (250 mg, 500 mg)|Time to max. plasma concentration after dosing on Day 1 of Multiple Ascending Doses (250 mg, 500 mg)|Time to reach Cmax,ss of Multiple Ascending Doses (250 mg, 500 mg)|Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable plasma concentration of Multiple Ascending Doses (250 mg, 500 mg)|Area under the plasma concentration-time curve extrapolated to infinity after dosing of Multiple Ascending Doses (250 mg, 500 mg)|Area under the concentration time curve from 0-24 hours after dosing on Day 1 of Multiple Ascending Doses (250 mg, 500 mg)|The area under the concentration time curve during a dosing interval (tau) at steady state after dosing on Day 14 of Multiple Ascending Doses (250 mg, 500 mg)|Apparent oral clearance of Multiple Ascending Doses (250 mg, 500 mg)|Apparent total plasma clearance after oral administration, calculated as Dose/AUCtau after dosing on Day 14 of Multiple Ascending Doses (250 mg, 500 mg)|Apparent oral volume of distribution during the terminal phase of Multiple Ascending Doses (250 mg, 500 mg)|Mean residence time of Multiple Ascending Doses (250 mg, 500 mg)|Terminal elimination half-life of Multiple Ascending Doses (250 mg, 500 mg)|Maximum Tolerated Dose of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Maximum Tolerated Dose of Multiple Ascending Doses (250 mg and 500 mg)",Neuropore Therapies Inc.|Celerion,All,Phase 1,56.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NPT520-34-001,"May 5, 2019","August 27, 2019","September 19, 2019","May 17, 2019",,"May 17, 2019",,https://ClinicalTrials.gov/show/NCT03954600,18.0,55.0
2686,517,40.7127281,-74.0060152,"Covance Research Unit - Dallas, Dallas, Texas, United States",518.0,NCT04050852,Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments,,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen Treatments,percent improvement Maximum inspiratory pressure (MIP)|percent improvement Maximum expiratory pressure (/MEP),NYU Langone Health|Winthrop University Hospital,All,Early Phase 1,10.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19-00242,"July 17, 2019","July 17, 2020","July 17, 2020","August 8, 2019",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT04050852,5.0,21.0
2687,518,36.7014631,-118.7559974,"Copenhagen Neuromuscular Center, Copenhagen, Denmark",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2688,518,36.7014631,-118.7559974,"Nationwide Children's Hospital, Columbus, Ohio, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2689,518,38.7251776,-105.6077167,"Stanford University, Palo Alto, California, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2690,518,27.7567667,-81.4639835,"Children's Hospital Colorado, Aurora, Colorado, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2691,518,32.3293809,-83.1137366,"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2692,518,40.0796606,-89.4337288,"Boston Children's Hospital, Boston, Massachusetts, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2693,518,39.5162234,-76.9382069,"Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2694,518,42.3788774,-72.032366,"Columbia University, New York, New York, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2695,518,42.3788774,-72.032366,"Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2696,518,43.6211955,-84.6824346,"Oregon Health & Science University, Portland, Oregon, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2697,518,38.7604815,-92.5617875,"Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2698,518,40.7127281,-74.0060152,"Centro Clinico Nemo Pediatrico Policlinico A. Gemelli-Universit√† Cattolica Sacro Cuore, Roma, Italy",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2699,518,35.6729639,-79.0392919,"Hospital Sant Joan de D√©u, Barcelona, Spain",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2700,518,40.2253569,-82.6881395,"Clinical Pharmacology of Miami, Inc., Miami, Florida, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2701,518,40.9699889,-77.7278831,"Orlando Clinical Research Center, Orlando, Florida, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2702,518,40.9699889,-77.7278831,"American Research Corporation Inc., San Antonio, Texas, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2703,518,31.8160381,-99.5120986,"Northwell Health Neuroscience, Great Neck, New York, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2704,518,39.4225192,-111.7143584,"Tokyo Women's Medical University, Tokyo, Japan",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2705,518,37.1232245,-78.4927721,"Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, Korea, Republic of",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2706,518,37.1232245,-78.4927721,"National Taiwan University Hospital, Taipei, Taiwan",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2707,518,44.4308975,-89.6884637,"Neurological Institute Carlo Besta, Milano, Lombardy, Italy",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2708,NULL,NULL,NULL,"Neurological Institute Carlo Besta, Milano, Lombardy, Italy",,,,,,,,,,,,,,,,,,,,,,,,,,,
2709,518,51.0538286,3.7250121,"Nemours Children's Hospital, Orlando, Florida, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2710,518,50.6451381,5.5734203,"Columbia University Medical Center, New York, New York, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2711,518,50.000678,-86.000977,"Sydney Children's Hospital; CENTRE FOR CHILD HEALTH RESEARCH & INNOVATION (CHeRI), Randwick, New South Wales, Australia",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2712,518,48.8566101,2.3514992,"Chr de La Citadelle, Li√®ge, Belgium",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2713,518,44.40726,8.9338624,"Instituto de Puericultura E Pediatria Martag√£o Gesteira, Rio de Janeiro, RJ, Brazil",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2714,518,45.4667971,9.1904984,"Hospital das Clinicas - FMUSP; Neurologia, Sao Paulo, SP, Brazil",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2715,518,45.4667971,9.1904984,"Children's Hospital of Fudan University, Shanghai, China",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2716,518,41.894802,12.4853384,"IRCCS Ospedale Pediatrico Bambino Ges√π; U.O. Malattie Neuromuscolari e Neurodegenerative, Roma, Lazio, Italy",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2717,518,41.894802,12.4853384,"Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology, Gda≈Ñsk, Poland",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2718,518,35.6828387,139.7594549,"The Children's Memorial Health Institute Department of Neurology and Epileptology, Warszawa, Poland",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2719,518,42.9629533,47.5133551,"Russian Children Neuromuscular Center of Veltischev, Moscow, Moskovskaja Oblast, Russian Federation",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2720,518,39.3899806,-3.2101376,"King Faisal Specialist Hospital and Research Centre Building, Riyadh, Saudi Arabia",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2721,518,25.0375198,121.5636796,"Barrow Neurological Institute, Phoenix, Arizona, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2722,518,51.5073219,-0.1276474,"Washington University School of Medicine, Saint Louis, Missouri, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2723,518,54.9738474,-1.6131572,"Houston Methodist Neurological Institute, Houston, Texas, United States",519.0,NCT04042025,Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy Type I|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III,Biological: Onasemnogene Abeparvovec-xioi,Number of participants who reach developmental milestones|Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) score|Number of participants who experience a clinically significant change from baseline in pulmonary assessment results|Number of participants who experience swallowing dysfunction|Number of participants who experience a clinically significant change from baseline in physical examination findings|Number of participants who experience a clinically significant change from baseline in vital signs measurements|Change from baseline in height measurements|Change from baseline in weight measurements|Number of participants who experience a clinically significant change from baseline in clinical laboratory assessments|Number of participants who experience a clinically significant change from baseline in cardiac assessments|Number of participants who experience a clinically significant change from baseline in observational phase questionnaire results|Number of participants who experience at least one serious adverse event (SAE)|Number of participants who experience at least one adverse event of special interest (AESI),"AveXis, Inc.",All,Phase 4,308.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AVXS-101-LT-002,"September 1, 2019","December 31, 2034","December 31, 2034","August 1, 2019",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT04042025,18.0,100.0
2724,519,26.5450001,117.842778,"Children's Hospital of the King's Daughthers, Norfolk, Virginia, United States",520.0,NCT04010604,A Registered Cohort Study on SMA,,Not yet recruiting,No Results Available,Spinal Muscular Atrophy,,The time to death|The correlation of genotype and phenotype,Wan-Jin Chen|First Affiliated Hospital of Fujian Medical University,All,,2000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"MRCTA,ECFAHOFFMU[2019]196",July 2019,"December 31, 2039","December 31, 2049","July 8, 2019",,"July 8, 2019",,https://ClinicalTrials.gov/show/NCT04010604,70.0,100.0
2725,520,31.8160381,-99.5120986,"University of Washington, Seattle, Washington, United States",521.0,NCT03988907,A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants,,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam|Drug: Midazolam,Plasma Concentration of Midazolam Alone and in Combination with Risdiplam|Plasma Concentration of Midazolam Metabolite Alone and in Combination with Risdiplam|Percentage of Participants with Adverse Events After Midazolam Administration Alone and in Combination with Risdiplam|Percentage of Participants with Adverse Events After Administration of Multiple Doses of Risdiplam|Plasma Concentration of Risdiplam Metabolite Following Multiple Oral Doses|Plasma Concentration of Risdiplam Following Multiple Oral Doses,Hoffmann-La Roche,All,Phase 1,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP41361,"June 18, 2019","October 18, 2019","October 18, 2019","June 18, 2019",,"August 12, 2019",,https://ClinicalTrials.gov/show/NCT03988907,18.0,55.0
2726,NULL,NULL,NULL,"RTI International, Research Triangle Park, North Carolina, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
2727,522,40.2253569,-82.6881395,"Takeda Selected Site, Tokyo, Japan",523.0,NCT03955679,AveXis Managed Access Program Cohort for Access to AVXS-101,,Approved for marketing,No Results Available,Spinal Muscular Atrophy,Genetic: AVXS-101,,"United BioSource Corporation|AveXis, Inc.",All,,,Industry,Expanded Access:Treatment IND/Protocol,,AVXS-101-MAP-001,,,,"May 20, 2019",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT03955679,18.0,100.0
2728,523,36.7014631,-118.7559974,"CRMN, H√¥pital La Citadelle, Liege, Wallonia, Belgium",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2729,523,38.7251776,-105.6077167,"Dubowitz Neuromuscular Centre, London, United Kingdom",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2730,523,40.0796606,-89.4337288,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2731,523,42.3788774,-72.032366,"Stanford University, Stanford, California, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2732,523,43.6211955,-84.6824346,"Children's Hospital Colorado, Aurora, Colorado, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2733,523,40.7127281,-74.0060152,"Nemours Children's Hospital, Orlando, Florida, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2734,523,35.6729639,-79.0392919,"Center for Rare Neurological Diseases, Norcross, Georgia, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2735,523,43.9792797,-120.737257,"Massachusetts General Hospital, Boston, Massachusetts, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2736,523,37.1232245,-78.4927721,"Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2737,523,41.894802,12.4853384,"Washington Unviersity School of Medicine, Saint Louis, Missouri, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2738,523,41.3828939,2.1774322,"Columbia University, New York, New York, United States",524.0,NCT03921528,An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy,TOPAZ,Recruiting,No Results Available,"Spinal Muscular Atrophy|Spinal Muscular Atrophy Type 3|Spinal Muscular Atrophy Type 2|SMA|Neuromuscular Diseases|Muscular Atrophy|Atrophy|Muscular Atrophy, Spinal|Neuromuscular Manifestations",Biological: SRK-015,Cohort 1: Change from Baseline in the Revised Hammersmith Scale (RHS)|Cohort 2 and Cohort 3: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE),"Scholar Rock, Inc.",All,Phase 2,55.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SRK-015-002,"April 22, 2019",January 2021,April 2021,"April 19, 2019",,"August 22, 2019",,https://ClinicalTrials.gov/show/NCT03921528,2.0,21.0
2739,524,27.7567667,-81.4639835,"Nationwide Children's Hospital, Columbus, Ohio, United States",525.0,NCT03920865,A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function,,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUCinf) of Risdiplam|Area Under the Plasma Concentration-Time Curve from time 0 to the Last Measurable Concentration (AUClast) of Risdiplam|Maximum Observed Plasma Concentration (Cmax) of Risdiplam|Time of the Maximum Observed Plasma Concentration (Tmax) of Risdiplam|Apparent Plasma Terminal Elimination Half-Life (t1/2) of Risdiplam|Percentage of Area Under the Plasma Concentration-Time Curve Due to Extrapolation (%AUCextrap) of Risdiplam|Terminal Elimination Rate Constant (Œªz) of Risdiplam|Adjusted Coefficient for Determination of Exponential Fit (R2-adjusted) of Risdiplam|Apparent Total Clearance (CL/F) of Risdiplam|Fraction of Drug Unbound|Molecular Weight-Adjusted Metabolite-To-Parent Ratio for AUCinf, Cmax, and AUClast|Percentage of Participants with Adverse Event (AE) or Serious Adverse Event (SAE)",Hoffmann-La Roche,All,Phase 1,32.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP40995,"May 16, 2019","October 4, 2019","October 4, 2019","April 19, 2019",,"August 12, 2019",,https://ClinicalTrials.gov/show/NCT03920865,18.0,70.0
2740,524,27.7567667,-81.4639835,"Clinic for Special Children, Strasburg, Pennsylvania, United States",525.0,NCT03920865,A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function,,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUCinf) of Risdiplam|Area Under the Plasma Concentration-Time Curve from time 0 to the Last Measurable Concentration (AUClast) of Risdiplam|Maximum Observed Plasma Concentration (Cmax) of Risdiplam|Time of the Maximum Observed Plasma Concentration (Tmax) of Risdiplam|Apparent Plasma Terminal Elimination Half-Life (t1/2) of Risdiplam|Percentage of Area Under the Plasma Concentration-Time Curve Due to Extrapolation (%AUCextrap) of Risdiplam|Terminal Elimination Rate Constant (Œªz) of Risdiplam|Adjusted Coefficient for Determination of Exponential Fit (R2-adjusted) of Risdiplam|Apparent Total Clearance (CL/F) of Risdiplam|Fraction of Drug Unbound|Molecular Weight-Adjusted Metabolite-To-Parent Ratio for AUCinf, Cmax, and AUClast|Percentage of Participants with Adverse Event (AE) or Serious Adverse Event (SAE)",Hoffmann-La Roche,All,Phase 1,32.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP40995,"May 16, 2019","October 4, 2019","October 4, 2019","April 19, 2019",,"August 12, 2019",,https://ClinicalTrials.gov/show/NCT03920865,18.0,70.0
2741,524,31.8160381,-99.5120986,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",525.0,NCT03920865,A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function,,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUCinf) of Risdiplam|Area Under the Plasma Concentration-Time Curve from time 0 to the Last Measurable Concentration (AUClast) of Risdiplam|Maximum Observed Plasma Concentration (Cmax) of Risdiplam|Time of the Maximum Observed Plasma Concentration (Tmax) of Risdiplam|Apparent Plasma Terminal Elimination Half-Life (t1/2) of Risdiplam|Percentage of Area Under the Plasma Concentration-Time Curve Due to Extrapolation (%AUCextrap) of Risdiplam|Terminal Elimination Rate Constant (Œªz) of Risdiplam|Adjusted Coefficient for Determination of Exponential Fit (R2-adjusted) of Risdiplam|Apparent Total Clearance (CL/F) of Risdiplam|Fraction of Drug Unbound|Molecular Weight-Adjusted Metabolite-To-Parent Ratio for AUCinf, Cmax, and AUClast|Percentage of Participants with Adverse Event (AE) or Serious Adverse Event (SAE)",Hoffmann-La Roche,All,Phase 1,32.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP40995,"May 16, 2019","October 4, 2019","October 4, 2019","April 19, 2019",,"August 12, 2019",,https://ClinicalTrials.gov/show/NCT03920865,18.0,70.0
2742,525,40.7127281,-74.0060152,"University of Utah, Salt Lake City, Utah, United States",526.0,NCT03878030,Effect of Nusinersen on Adults With Spinal Muscular Atrophy,,Recruiting,No Results Available,Adult Spinal Muscular Atrophy,Drug: nusinersen,Change in quantitative motor function|Change in upper limb motor function|Change in 6 minute walk test in ambulatory patients|Change in pulmonary function by spirometry forced vital capacity (FVC)|Change in 10 meter walk test in ambulatory patients|Change in compound muscle action potential (CMAP) amplitude by nerve conduction velocity (NCV) criteria|Change in pulmonary function by spirometry forced expiratory volume (FEV),Northwell Health,All,,40.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,18-0149,"April 1, 2019","January 1, 2023","January 1, 2023","March 18, 2019",,"May 30, 2019",,https://ClinicalTrials.gov/show/NCT03878030,18.0,60.0
2743,526,35.6828387,139.7594549,"Health Research of Hampton Roads - Norfolk, Inc., Norfolk, Virginia, United States",527.0,NCT03837184,Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies,,Recruiting,No Results Available,Spinal Muscular Atrophy Type I,Biological: Onasemnogene Abeparvovec-xioi,Proportion of Participants Sitting Without Support|Proportion of Participants Surviving,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,6.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-306,"May 15, 2019","April 1, 2021","April 1, 2021","February 12, 2019",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT03837184,6.0,100.0
2744,526,42.9629533,47.5133551,"Virginia Commonwealth University, Richmond, Virginia, United States",527.0,NCT03837184,Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies,,Recruiting,No Results Available,Spinal Muscular Atrophy Type I,Biological: Onasemnogene Abeparvovec-xioi,Proportion of Participants Sitting Without Support|Proportion of Participants Surviving,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,6.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-306,"May 15, 2019","April 1, 2021","April 1, 2021","February 12, 2019",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT03837184,6.0,100.0
2745,526,25.0375198,121.5636796,"University of Wisconsin (Madison), Madison, Wisconsin, United States",527.0,NCT03837184,Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies,,Recruiting,No Results Available,Spinal Muscular Atrophy Type I,Biological: Onasemnogene Abeparvovec-xioi,Proportion of Participants Sitting Without Support|Proportion of Participants Surviving,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,6.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-306,"May 15, 2019","April 1, 2021","April 1, 2021","February 12, 2019",,"August 14, 2019",,https://ClinicalTrials.gov/show/NCT03837184,6.0,100.0
2746,527,45.6209,9.768893,"Sydney Children's Hospitals Network and, Randwick, New South Wales, Australia",528.0,NCT03819660,Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3,SMA3,Enrolling by invitation,No Results Available,Muscle Atrophy,Drug: Amifampridine Phosphate 10 MG Oral Tablet,The number and severity of treatment related adverse events and serious adverse events as assessed by CTCAE v4.0,"Catalyst Pharmaceuticals, Inc.",All,Phase 2,12.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SMA-002,"March 7, 2019","December 31, 2020","April 1, 2021","January 28, 2019",,"March 29, 2019",,https://ClinicalTrials.gov/show/NCT03819660,6.0,50.0
2747,528,,,"Centre Hospitalier R√©gional H√¥pital La Citadelle, Li√®ge, Belgium",529.0,NCT03808233,Reliability and Validity of the ACTIVE-mini for Quantifying Movement in Infants With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Other: ACTIVE mini,ACTIVE mini,University of Texas Southwestern Medical Center,All,,25.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STU 052016-109,"November 5, 2016","June 1, 2018","August 31, 2018","January 17, 2019",,"January 17, 2019",,https://ClinicalTrials.gov/show/NCT03808233,18.0,100.0
2748,529,45.6209,9.768893,"Neurop√©diatrie - Centre de R√©f√©rence des Maladies Neuromusculaires, Li√®ge, Belgium",530.0,NCT03781479,Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients,,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Amifampridine Phosphate|Drug: Placebo Oral Tablet,Change from baseline in the Hammersmith Functional Motor Scale Expanded (HFMSE),"Catalyst Pharmaceuticals, Inc.",All,Phase 2,12.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-001,"January 21, 2019","December 15, 2019","March 15, 2020","December 20, 2018",,"January 25, 2019",,https://ClinicalTrials.gov/show/NCT03781479,6.0,50.0
2749,530,27.7567667,-81.4639835,"Canada Childrens Hospital of Eastern Ontario, Ottawa, Ontario, Canada",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2750,530,40.7127281,-74.0060152,"Dr. Von Haunersches Kinderspital, M√ºnchen, Germany",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2751,530,-31.8759835,147.2869493,"Schneider Children's Medical Center of Israel, Tel Aviv, Israel",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2752,530,50.6451381,5.5734203,"Ospedale Pediatrico Bambino Ges√π, Roma, Italy",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2753,530,-22.2752762,-42.419415,"Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2754,530,-10.3333333,-53.2,"Tokyo Women's Medical University, Tokyo, Japan",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2755,530,31.2322735,121.4691749,"Pusan National University Children's Hospital, Yangsan, Gyeungsangnamdo, Korea, Republic of",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2756,530,41.9808038,12.7662312,"Area Genetica Cl√≠nica y Molecular, Barcelona, Spain",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2757,530,54.36143405,18.6282184755727,"National Taiwan University Hospital, Taipei, Taiwan",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2758,530,52.2337172,21.0714111288323,"Great Ormond Street Hospital for Children, London, United Kingdom",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2759,530,53.2028088,50.1604963,"University Hospital Ghent Neuromuscular reference center, Ghent, Belgium",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2760,530,24.6319692,46.7150648,"Istituto Gianninia Gaslini, Genova, Italy",531.0,NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,Rainbowfish,Recruiting,No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Proportion of participants with two copies of the survival motor neuron (SMN) 2 gene (excluding the known SMN2 gene modifier mutation c.859G> C) and baseline compound muscle action potential (CMAP) >=1.5 millivolt (mV) who are sitting without support.|Proportion of participants developing clinically manifested SMA|Time to permanent ventilation and/or death|Proportion of participants who are alive without permanent ventilation|Proportion of participants who achieve the attainment level of the motor milestones as assessed in the Hammersmith Infant Neurological Examination-2 (HINE-2)|Proportion of participants sitting without support for 5 seconds|Proportion of participants sitting without support for 30 seconds|Proportion of participants standing for at least 3 seconds|Proportion of participants walking (takes at least 3 steps)|Proportion of participants demonstrating the ability to achieve a scaled score on BSID-III Gross Motor Subtests within 1.5 standard deviations of chronological reference standard|Change from baseline score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Proportion of participants who achieve a score of 40 or higher, 50 or higher and 64 in the CHOP INTEND motor function scale|Number and proportion of participants within 3rd percentile of normal range for weight‚Äëfor‚Äëage, length/height‚Äëfor‚Äëage, weight‚Äëfor‚Äëlength/height, and head circumference‚Äëfor‚Äëage|Change from baseline percentiles at each time point for weight-for-age, length/height-for-age, weight-for-length/height, and head circumference-for-age|Change from baseline in chest circumference|Ratio between chest and head circumferences|Proportion of participants with the ability to swallow and level of solid food intake|Change of innervation|Measurement of pharmacodynamic marker levels in blood|Proportion of participants with phase angle of < 20 degrees, as measured by respiratory plethysmography|Proportion of participants with adverse events|Plasma concentration of risdiplam and its metabolites to characterize the PK profile",Hoffmann-La Roche,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN40703,"August 8, 2019","June 21, 2021","June 14, 2025","December 18, 2018",,"August 13, 2019",,https://ClinicalTrials.gov/show/NCT03779334,6.0,100.0
2761,531,34.395342,-111.7632755,"Policlinico ""G. Martino"", Messina, Italy",532.0,NCT03709784,Spinraza in Adult Spinal Muscular Atrophy,SAS,Recruiting,No Results Available,Spinal Muscular Atrophy|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type 3,"Other: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA¬Æ prescribed as part of standard of care",Change from baseline in the 6-Minute Walk Test (6MWT) for ambulatory SMA patients|Change from baseline in Revised Upper Limb Module (RULM) for weak ambulatory and non-ambulatory SMA patients,Washington University School of Medicine,All,,73.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201805187,"August 16, 2018","January 30, 2022","January 30, 2022","October 17, 2018",,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03709784,18.0,70.0
2762,531,38.7604815,-92.5617875,"Carlo Besta Neurological Research Institute, Milan, Italy",532.0,NCT03709784,Spinraza in Adult Spinal Muscular Atrophy,SAS,Recruiting,No Results Available,Spinal Muscular Atrophy|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type 3,"Other: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA¬Æ prescribed as part of standard of care",Change from baseline in the 6-Minute Walk Test (6MWT) for ambulatory SMA patients|Change from baseline in Revised Upper Limb Module (RULM) for weak ambulatory and non-ambulatory SMA patients,Washington University School of Medicine,All,,73.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201805187,"August 16, 2018","January 30, 2022","January 30, 2022","October 17, 2018",,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03709784,18.0,70.0
2763,531,31.8160381,-99.5120986,"University of Milan, Milan, Italy",532.0,NCT03709784,Spinraza in Adult Spinal Muscular Atrophy,SAS,Recruiting,No Results Available,Spinal Muscular Atrophy|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type 3,"Other: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA¬Æ prescribed as part of standard of care",Change from baseline in the 6-Minute Walk Test (6MWT) for ambulatory SMA patients|Change from baseline in Revised Upper Limb Module (RULM) for weak ambulatory and non-ambulatory SMA patients,Washington University School of Medicine,All,,73.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201805187,"August 16, 2018","January 30, 2022","January 30, 2022","October 17, 2018",,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03709784,18.0,70.0
2764,531,37.1232245,-78.4927721,"Policlinico Gemelli, Rome, Italy",532.0,NCT03709784,Spinraza in Adult Spinal Muscular Atrophy,SAS,Recruiting,No Results Available,Spinal Muscular Atrophy|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type 3,"Other: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA¬Æ prescribed as part of standard of care",Change from baseline in the 6-Minute Walk Test (6MWT) for ambulatory SMA patients|Change from baseline in Revised Upper Limb Module (RULM) for weak ambulatory and non-ambulatory SMA patients,Washington University School of Medicine,All,,73.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201805187,"August 16, 2018","January 30, 2022","January 30, 2022","October 17, 2018",,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03709784,18.0,70.0
2765,531,38.8950092,-77.0365625,"Great Ormond Street Hospital for Children, London, United Kingdom",532.0,NCT03709784,Spinraza in Adult Spinal Muscular Atrophy,SAS,Recruiting,No Results Available,Spinal Muscular Atrophy|Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type 3,"Other: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA¬Æ prescribed as part of standard of care",Change from baseline in the 6-Minute Walk Test (6MWT) for ambulatory SMA patients|Change from baseline in Revised Upper Limb Module (RULM) for weak ambulatory and non-ambulatory SMA patients,Washington University School of Medicine,All,,73.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201805187,"August 16, 2018","January 30, 2022","January 30, 2022","October 17, 2018",,"May 22, 2019",,https://ClinicalTrials.gov/show/NCT03709784,18.0,70.0
2766,532,,,"The John Walton Muscular Dystrophy Research Centre MRC Centre for Neuromuscular Diseases at Newcastle, Newcastle Upon Tyne, United Kingdom",533.0,NCT03689660,"Feasibility of Virtual Reality in Children With Neuromuscular Disease, Effectiveness of Virtual Reality and Biofeedback",,Not yet recruiting,No Results Available,Neuromuscular Disease|Duchenne Muscular Dystrophy|Spinal Muscular Atrophy|Virtual Reality|Biofeedback,Other: Virtual Reality Training|Other: Biofeedback Training|Other: Conventional rehabilitation,The Motor Function Measure-32|Pediatric Functional Independence Measure|Biodex Balance System|Vignos Scale|Feasibility of Virtual Reality|Pediatric Motivation Scale|Visual Analog Scale|Pediatric Functional Reaching Test|Fall Frequency|Muscle Strength Test with Hand Held Dinamometer|Timed Up Go Test|Stair Climb Test|T-shirt Wear Remove Test|Stand Up from Supine Position Test,Merve Kurt|Dokuz Eylul University,All,Not Applicable,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Merve Kurt,"February 1, 2019","May 1, 2021","October 1, 2021","September 28, 2018",,"January 23, 2019",,https://ClinicalTrials.gov/show/NCT03689660,6.0,18.0
2767,533,35.6729639,-79.0392919,"Nationwide Children's Hospital, Columbus, Ohio, United States",534.0,NCT03655223,Early Check: Expanded Screening in Newborns,,Enrolling by invitation,No Results Available,Spinal Muscular Atrophy|Fragile X Syndrome|Fragile X - Premutation,Diagnostic Test: Confirmatory Testing,Incidence Rates: Number of newborns who screen positive comparative to the whole sample|Impact of Screening: Semi-structured parent interviews.,"RTI International|University of North Carolina, Chapel Hill|The John Merck Fund|Duke University|Wake Forest University|North Carolina Department of Health and Human Services|National Center for Advancing Translational Science (NCATS)|Cure SMA|The National Fragile X Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Asuragen, Inc.",All,,400000.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,18-0009|U01TR001792-01|HHSN27500003,"October 15, 2018","June 30, 2021",December 2022,"August 31, 2018",,"December 13, 2018",,https://ClinicalTrials.gov/show/NCT03655223,28.0,100.0
2768,534,35.6828387,139.7594549,"Service de p√©diatrie, H√¥pital Raymond Poincar√©, Garches, Hauts-de-Seine, France",535.0,NCT03555578,"Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg ""All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)""",,Recruiting,No Results Available,Spinal and Bulbar Muscular Atrophy,Drug: Leuprorelin Acetate,Percentage of Participants who had One or More Adverse Drug Reactions|Percentage of Participants who had One or More Serious Adverse Events|Percentage of Participants without Death Event|Percentage of Participants without Pneumonia Requiring Hospitalization Event|Percentage of Participants without Composite Events of Death and Pneumonia Requiring Hospitalization|Percentage of Participants without Dysphagia Events,Takeda,All,,300.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Leuprorelin-5004|JapicCTI-183981,"November 2, 2017","August 31, 2025","August 31, 2025","June 13, 2018",,"August 13, 2018",,https://ClinicalTrials.gov/show/NCT03555578,18.0,100.0
2769,535,50.1545331,5.39918216716456,"UCLA, Los Angeles, California, United States",536.0,NCT03554343,Sun May Arise on SMA : Newborn Screening of SMA in Belgium,,Recruiting,No Results Available,Spinal Muscular Atrophy,Diagnostic Test: test for SMN1 exon 7 deletion,Cases detected|Incidence of SMA,"Centre Hospitalier R√©gional de la Citadelle|AveXis, Inc.|Biogen|Roche Pharma AG|Association Belge contre les Maladies neuro Musculaires",All,,180000.0,Other|Industry,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,B412201734396,"March 5, 2018","March 4, 2021","July 31, 2021","June 13, 2018",,"November 20, 2018",,https://ClinicalTrials.gov/show/NCT03554343,7.0,100.0
2770,536,51.5073219,-0.1276474,"Stanford University, Stanford, California, United States",537.0,NCT03520179,Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA),SMA-REACH,Recruiting,No Results Available,Spinal Muscular Atrophy,,"Physiotherapy assessment using The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|Physiotherapy assessment using the Test of Infant Motor Performance Screening Items (TIMPSI)|Patient¬¥s perception about the condition, interventions performed and Standards of Care assessed by patient interviews|Patients perception about the condition, interventions performed and Standards of Care assessed using the Paediatric Outcomes Data Collection Instrument (PODCI)|Patients perception about the condition, interventions performed and Standards of Care assessed using the Egan Klassifikation Scale (EK2)",Great Ormond Street Hospital for Children NHS Foundation Trust,All,,70.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,11DN15,"December 17, 2013","January 31, 2019","January 31, 2019","May 9, 2018",,"May 9, 2018",,https://ClinicalTrials.gov/show/NCT03520179,3.0,99.0
2771,537,36.7014631,-118.7559974,"Nemours Children's Hospital, Orlando, Florida, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2772,537,36.7014631,-118.7559974,"Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2773,537,38.7251776,-105.6077167,"Johns Hopkins, Baltimore, Maryland, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2774,537,27.7567667,-81.4639835,"Boston Children's Hospital, Boston, Massachusetts, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2775,537,32.3293809,-83.1137366,"Washington University, Saint Louis, Missouri, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2776,537,42.3788774,-72.032366,"Nationwide Children's Hospital, Columbus, Ohio, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2777,537,43.6211955,-84.6824346,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2778,537,38.7604815,-92.5617875,"UT Southwestern, Dallas, Texas, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2779,537,40.7127281,-74.0060152,"University of Utah, Salt Lake City, Utah, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2780,537,40.2253569,-82.6881395,"Hopital Morvan - CHU de Brest, Brest, France",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2781,537,40.9699889,-77.7278831,"Service de R√©√©ducation P√©diatrique Infantile "" L'Escale "" - H√¥pital Femme M√®re Enfant, Bron, France",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2782,537,31.8160381,-99.5120986,"H√¥pital le Bocage - CHU Dijon, Dijon, France",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2783,537,39.4225192,-111.7143584,"Maladie Neuromusculaire de l'enfant - Service Maladies infectieuses et neurologie infantile - H√¥pital Roger Salengro, Lille, France",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2784,537,37.1232245,-78.4927721,"I-Motion Institute, Paris, France",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2785,537,37.1232245,-78.4927721,"Unit√© de neurologie p√©diatrique - H√¥pital des enfants, Toulouse, France",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2786,537,44.4308975,-89.6884637,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2787,537,-31.8759835,147.2869493,"Stanford University, Stanford, California, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2788,537,50.6451381,5.5734203,"Children's Hospital Colorado, Aurora, Colorado, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2789,537,50.6451381,5.5734203,"Nemours Children's Hospital, Orlando, Florida, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2790,537,50.000678,-86.000977,"Ann and Robert H Lurie Children's Hospital, Chicago, Illinois, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2791,537,48.1371079,11.5753822,"Johns Hopkins Pediatric Neurology, Baltimore, Maryland, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2792,537,32.0804808,34.7805274,"Boston Children's Hospital, Boston, Massachusetts, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2793,537,41.894802,12.4853384,"Washington Unviersity School of Medicine, Saint Louis, Missouri, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2794,537,41.894802,12.4853384,"Columbia University, New York, New York, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2795,537,35.6828387,139.7594549,"Duke University, Durham, North Carolina, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2796,537,42.9629533,47.5133551,"Nationwide Children's Hospital, Columbus, Ohio, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2797,537,41.3828939,2.1774322,"Oregon Health and Science University, Portland, Oregon, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2798,537,25.0375198,121.5636796,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2799,537,51.5073219,-0.1276474,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",538.0,NCT03505099,Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,SPR1NT,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: onasemnogene abeparvovec-xioi,Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit|Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit|Percentage of participants surviving without permanent ventilation in the absence of acute illness and perioperatively|Percentage of participants achieving the ability to maintain weight at or above the 3rd percentile without non-oral/mechanical feeding support at any visit|Percentage of participants demonstrating the ability to walk alone at any visit,"AveXis, Inc.|PRA Health Sciences",All,Phase 3,27.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-304|2017-004087-35|JapicCTI-184203,"April 10, 2018",October 2020,June 2023,"April 23, 2018",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT03505099,42.0,100.0
2800,538,51.0538286,3.7250121,"University of Utah, Salt Lake City, Utah, United States",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2801,538,44.40726,8.9338624,"University of Wisconsin (Madison), Madison, Wisconsin, United States",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2802,538,38.1937571,15.5542082,"Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2803,538,45.4667971,9.1904984,"Hopital Raymond Poincare, Garches, France",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2804,538,45.4667971,9.1904984,"Hopital Raymond Poincare, Garches, France",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2805,538,41.894802,12.4853384,"Nicolas ROCHE, Md PhD, Garches, France",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2806,538,51.5073219,-0.1276474,"Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2807,538,54.9738474,-1.6131572,"The Hong Kong Polytechnic University, Hung Hom, Hong Kong",539.0,NCT03461289,Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STRIVE-EU,"Active, not recruiting",No Results Available,SMA,Biological: AVXS-101,Sitting without support|Survival,"AveXis, Inc.",All,Phase 3,33.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-302|2017-000266-29,"August 29, 2018",November 2020,November 2020,"March 12, 2018",,"June 3, 2019",,https://ClinicalTrials.gov/show/NCT03461289,6.0,100.0
2808,539,40.2253569,-82.6881395,"Stanford University Medical Center, Palo Alto, California, United States",540.0,NCT03421977,Long-Term Follow-up Study for Patients From AVXS-101-CL-101,START,Enrolling by invitation,No Results Available,Spinal Muscular Atrophy 1,Biological: Onasemnogene Abeparvovec-xioi,Long-Term Safety,"AveXis, Inc.",All,,15.0,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,AVXS-101-LT-001,"August 15, 2017",December 2033,December 2033,"February 5, 2018",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03421977,18.0,100.0
2809,540,48.8401859,2.19864122190608,"Columbia University Medical Center; The Neurological Institute of New York, New York, New York, United States",541.0,NCT03395795,Trial Evaluating the Interest of Noninvasive Ventilation in NAVA Mode in Respiratory Decompensations Children With Infantile Spinal Muscular Atrophy Type II,NAVASI,Recruiting,No Results Available,Infantile Spinal Muscular Atrophy,Device: NAVA,Asynchrony percentage|Feasibility|Efficacy and tolerance|Rate of recourse to intubation,Assistance Publique - H√¥pitaux de Paris,All,Not Applicable,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P160941J|IDRCB 2017-A02785-48,"February 13, 2018",February 2020,February 2020,"January 10, 2018",,"May 13, 2019",,https://ClinicalTrials.gov/show/NCT03395795,1.0,18.0
2810,541,36.7014631,-118.7559974,"UZ Gent, Gent, Belgium",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2811,541,36.7014631,-118.7559974,"UZ Leuven Gasthuisberg, Leuven, Belgium",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2812,541,27.7567667,-81.4639835,"Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE, Bron, France",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2813,541,40.0796606,-89.4337288,"Hopital Roger Salengro, Lille, France",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2814,541,39.5162234,-76.9382069,"H√¥pital Necker-Enfants Malades; Service de neurop√©diatrie, Paris, France",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2815,541,42.3788774,-72.032366,"Hopital des Enfants; Unite de Neurologie Pediatrique, Toulouse, France",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2816,541,38.7604815,-92.5617875,"IRCCS Ospedale Pediatrico Bambino Ges√π; U.O. Malattie Neuromuscolari e Neurodegenerative, Roma, Lazio, Italy",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2817,541,40.2253569,-82.6881395,"Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile, Roma, Lazio, Italy",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2818,541,40.9699889,-77.7278831,"IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative, Genova, Liguria, Italy",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2819,541,31.8160381,-99.5120986,"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unit√† Operativa Complessa di Neurologia, Milano, Lombardia, Italy",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2820,541,39.4225192,-111.7143584,"Azienda Ospedaliera Universitaria Policlinico G.Martino; Dip. Neurologia e Malattie neuromuscolari, Messina, Sicilia, Italy",542.0,NCT03381729,Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy,STRONG,Recruiting,No Results Available,Spinal Muscular Atrophy,Biological: Onasemnogene Abeparvovec-xioi,Incidence of Adverse Events|Determine Optimal Dose|Patients ‚â• 6 months and < 24 months: Standing Milestone|Patients ‚â• 24 months and < 60 months: Change from Baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score|Patients ‚â• 6 months and < 24 months: Walking Milestone|Patients ‚â• 24 months and < 60 months: Walking Milestone|Change from Baseline in Ventilation Support,"AveXis, Inc.",All,Phase 1,51.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-102,"December 14, 2017","June 1, 2021","June 1, 2021","December 22, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03381729,6.0,60.0
2821,542,48.3905283,-4.4860088,"UMC Utrecht; Polkliniek Neuromusculaire ziekten, Utrecht, Netherlands",543.0,NCT03339830,European Registry of Patients With Infantile-onset Spinal Muscular Atrophy,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Change from Baseline in survival|Change from Baseline in psychomotor development|Change from Baseline in the number of lower track infections|Change from Baseline in ventilation use|Change from Baseline in cough assist use|Change from Baseline in Forced Vital Capacity|Change from Baseline in diurnal saturation|Change from Baseline in nocturnal hypercapnia|Change from the beginning of the treatment of psychomotor development|Change from the beginning of the treatment of the number of hospitalizations|Change from the beginning of the treatment of the duration of hospitalizations|Change from Baseline of Clinical Global Impressions - Improvement (CGI-I)|Change from Baseline of the scoliosis occurence|Change from Baseline of the arthrodesis occurence|Change from Baseline of contractures occurrence|Change from Baseline of wheelchair use|Change from Baseline of feeding status|Change from Baseline of speech impairment|Change from Baseline of Hammersmith Infant Neurological Examination (HINE) score|Change from Baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score|Change from Baseline of Motor Function Measure (MFM) score|Change from Baseline of Expanded Hammersmith Functional Motor Scale (HFMSE) score|Change from Baseline of the number of physiotherapy sessions per week|Change from Baseline of the number of balneotherapy sessions per week|Change from Baseline of the number of occupational therapy sessions per week,"Institut de Myologie, France",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IO-SMA-Registry|2017-A02291-52,"October 10, 2017","December 1, 2022","December 1, 2022","November 13, 2017",,"January 24, 2018",,https://ClinicalTrials.gov/show/NCT03339830,18.0,100.0
2822,542,45.7337532,4.9092352,"Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, Poland",543.0,NCT03339830,European Registry of Patients With Infantile-onset Spinal Muscular Atrophy,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Change from Baseline in survival|Change from Baseline in psychomotor development|Change from Baseline in the number of lower track infections|Change from Baseline in ventilation use|Change from Baseline in cough assist use|Change from Baseline in Forced Vital Capacity|Change from Baseline in diurnal saturation|Change from Baseline in nocturnal hypercapnia|Change from the beginning of the treatment of psychomotor development|Change from the beginning of the treatment of the number of hospitalizations|Change from the beginning of the treatment of the duration of hospitalizations|Change from Baseline of Clinical Global Impressions - Improvement (CGI-I)|Change from Baseline of the scoliosis occurence|Change from Baseline of the arthrodesis occurence|Change from Baseline of contractures occurrence|Change from Baseline of wheelchair use|Change from Baseline of feeding status|Change from Baseline of speech impairment|Change from Baseline of Hammersmith Infant Neurological Examination (HINE) score|Change from Baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score|Change from Baseline of Motor Function Measure (MFM) score|Change from Baseline of Expanded Hammersmith Functional Motor Scale (HFMSE) score|Change from Baseline of the number of physiotherapy sessions per week|Change from Baseline of the number of balneotherapy sessions per week|Change from Baseline of the number of occupational therapy sessions per week,"Institut de Myologie, France",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IO-SMA-Registry|2017-A02291-52,"October 10, 2017","December 1, 2022","December 1, 2022","November 13, 2017",,"January 24, 2018",,https://ClinicalTrials.gov/show/NCT03339830,18.0,100.0
2823,542,47.3215806,5.0414701,"Universit√§ts-Kinderspitalbeider Basel_Abteilung f√ºr Neuro- und Entwicklungsp√§diatrie, Basel, Switzerland",543.0,NCT03339830,European Registry of Patients With Infantile-onset Spinal Muscular Atrophy,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Change from Baseline in survival|Change from Baseline in psychomotor development|Change from Baseline in the number of lower track infections|Change from Baseline in ventilation use|Change from Baseline in cough assist use|Change from Baseline in Forced Vital Capacity|Change from Baseline in diurnal saturation|Change from Baseline in nocturnal hypercapnia|Change from the beginning of the treatment of psychomotor development|Change from the beginning of the treatment of the number of hospitalizations|Change from the beginning of the treatment of the duration of hospitalizations|Change from Baseline of Clinical Global Impressions - Improvement (CGI-I)|Change from Baseline of the scoliosis occurence|Change from Baseline of the arthrodesis occurence|Change from Baseline of contractures occurrence|Change from Baseline of wheelchair use|Change from Baseline of feeding status|Change from Baseline of speech impairment|Change from Baseline of Hammersmith Infant Neurological Examination (HINE) score|Change from Baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score|Change from Baseline of Motor Function Measure (MFM) score|Change from Baseline of Expanded Hammersmith Functional Motor Scale (HFMSE) score|Change from Baseline of the number of physiotherapy sessions per week|Change from Baseline of the number of balneotherapy sessions per week|Change from Baseline of the number of occupational therapy sessions per week,"Institut de Myologie, France",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IO-SMA-Registry|2017-A02291-52,"October 10, 2017","December 1, 2022","December 1, 2022","November 13, 2017",,"January 24, 2018",,https://ClinicalTrials.gov/show/NCT03339830,18.0,100.0
2824,542,50.6365654,3.0635282,"UCL Institute of Child Health & Great Ormond Street Hospital for Children, London, United Kingdom",543.0,NCT03339830,European Registry of Patients With Infantile-onset Spinal Muscular Atrophy,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Change from Baseline in survival|Change from Baseline in psychomotor development|Change from Baseline in the number of lower track infections|Change from Baseline in ventilation use|Change from Baseline in cough assist use|Change from Baseline in Forced Vital Capacity|Change from Baseline in diurnal saturation|Change from Baseline in nocturnal hypercapnia|Change from the beginning of the treatment of psychomotor development|Change from the beginning of the treatment of the number of hospitalizations|Change from the beginning of the treatment of the duration of hospitalizations|Change from Baseline of Clinical Global Impressions - Improvement (CGI-I)|Change from Baseline of the scoliosis occurence|Change from Baseline of the arthrodesis occurence|Change from Baseline of contractures occurrence|Change from Baseline of wheelchair use|Change from Baseline of feeding status|Change from Baseline of speech impairment|Change from Baseline of Hammersmith Infant Neurological Examination (HINE) score|Change from Baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score|Change from Baseline of Motor Function Measure (MFM) score|Change from Baseline of Expanded Hammersmith Functional Motor Scale (HFMSE) score|Change from Baseline of the number of physiotherapy sessions per week|Change from Baseline of the number of balneotherapy sessions per week|Change from Baseline of the number of occupational therapy sessions per week,"Institut de Myologie, France",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IO-SMA-Registry|2017-A02291-52,"October 10, 2017","December 1, 2022","December 1, 2022","November 13, 2017",,"January 24, 2018",,https://ClinicalTrials.gov/show/NCT03339830,18.0,100.0
2825,542,48.8566101,2.3514992,"The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom",543.0,NCT03339830,European Registry of Patients With Infantile-onset Spinal Muscular Atrophy,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Change from Baseline in survival|Change from Baseline in psychomotor development|Change from Baseline in the number of lower track infections|Change from Baseline in ventilation use|Change from Baseline in cough assist use|Change from Baseline in Forced Vital Capacity|Change from Baseline in diurnal saturation|Change from Baseline in nocturnal hypercapnia|Change from the beginning of the treatment of psychomotor development|Change from the beginning of the treatment of the number of hospitalizations|Change from the beginning of the treatment of the duration of hospitalizations|Change from Baseline of Clinical Global Impressions - Improvement (CGI-I)|Change from Baseline of the scoliosis occurence|Change from Baseline of the arthrodesis occurence|Change from Baseline of contractures occurrence|Change from Baseline of wheelchair use|Change from Baseline of feeding status|Change from Baseline of speech impairment|Change from Baseline of Hammersmith Infant Neurological Examination (HINE) score|Change from Baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score|Change from Baseline of Motor Function Measure (MFM) score|Change from Baseline of Expanded Hammersmith Functional Motor Scale (HFMSE) score|Change from Baseline of the number of physiotherapy sessions per week|Change from Baseline of the number of balneotherapy sessions per week|Change from Baseline of the number of occupational therapy sessions per week,"Institut de Myologie, France",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IO-SMA-Registry|2017-A02291-52,"October 10, 2017","December 1, 2022","December 1, 2022","November 13, 2017",,"January 24, 2018",,https://ClinicalTrials.gov/show/NCT03339830,18.0,100.0
2826,542,43.6044622,1.4442469,"University Medical Center of Utrecht (UMCU), Utrecht, Netherlands",543.0,NCT03339830,European Registry of Patients With Infantile-onset Spinal Muscular Atrophy,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Change from Baseline in survival|Change from Baseline in psychomotor development|Change from Baseline in the number of lower track infections|Change from Baseline in ventilation use|Change from Baseline in cough assist use|Change from Baseline in Forced Vital Capacity|Change from Baseline in diurnal saturation|Change from Baseline in nocturnal hypercapnia|Change from the beginning of the treatment of psychomotor development|Change from the beginning of the treatment of the number of hospitalizations|Change from the beginning of the treatment of the duration of hospitalizations|Change from Baseline of Clinical Global Impressions - Improvement (CGI-I)|Change from Baseline of the scoliosis occurence|Change from Baseline of the arthrodesis occurence|Change from Baseline of contractures occurrence|Change from Baseline of wheelchair use|Change from Baseline of feeding status|Change from Baseline of speech impairment|Change from Baseline of Hammersmith Infant Neurological Examination (HINE) score|Change from Baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score|Change from Baseline of Motor Function Measure (MFM) score|Change from Baseline of Expanded Hammersmith Functional Motor Scale (HFMSE) score|Change from Baseline of the number of physiotherapy sessions per week|Change from Baseline of the number of balneotherapy sessions per week|Change from Baseline of the number of occupational therapy sessions per week,"Institut de Myologie, France",All,,100.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IO-SMA-Registry|2017-A02291-52,"October 10, 2017","December 1, 2022","December 1, 2022","November 13, 2017",,"January 24, 2018",,https://ClinicalTrials.gov/show/NCT03339830,18.0,100.0
2827,543,36.7014631,-118.7559974,"Stanford University Medical Center, Palo Alto, California, United States",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2828,543,36.7014631,-118.7559974,"Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2829,543,38.7251776,-105.6077167,"Boston Childrens Hospital, Boston, Massachusetts, United States",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2830,543,27.7567667,-81.4639835,"Columbia University Medical Center; The Neurological Institute of New York, New York, New York, United States",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2831,543,40.0796606,-89.4337288,"UZ Gent, Gent, Belgium",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2832,543,39.5162234,-76.9382069,"UZ Leuven Gasthuisberg, Leuven, Belgium",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2833,543,42.3788774,-72.032366,"Chr de La Citadelle, Li√®ge, Belgium",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2834,543,38.7604815,-92.5617875,"Instituto de Puericultura E Pediatria Martag√£o Gesteira, Rio de Janeiro, RJ, Brazil",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2835,543,40.7127281,-74.0060152,"Hospital das Clinicas - FMUSP; Neurologia, Sao Paulo, SP, Brazil",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2836,543,35.6729639,-79.0392919,"Peking University First Hospital, Beijing City, China",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2837,543,40.2253569,-82.6881395,"Children's Hospital of Fudan University, Shanghai, China",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2838,543,43.9792797,-120.737257,"Clinical Medical Center Zagreb; University Hospital Rebro Department of Paediatrics, Zagreb, Croatia",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2839,543,40.9699889,-77.7278831,"Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE, Bron, France",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2840,543,31.8160381,-99.5120986,"Hopital Armand Trousseau, Paris, France",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2841,543,39.4225192,-111.7143584,"IRCCS Ospedale Pediatrico Bambino Ges√π; U.O. Malattie Neuromuscolari e Neurodegenerative, Roma, Lazio, Italy",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2842,543,44.4308975,-89.6884637,"Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile, Roma, Lazio, Italy",544.0,NCT03306277,Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1,STR1VE,"Active, not recruiting",No Results Available,SMA - Spinal Muscular Atrophy|Gene Therapy,Biological: Onasemnogene Abeparvovec-xioi,Achievement of independent sitting for at least 30 seconds|Event-free survival|Ability to thrive|Ventilatory support independence,"AveXis, Inc.",All,Phase 3,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-303,"October 24, 2017","November 12, 2019","November 12, 2019","October 11, 2017",,"August 15, 2019",,https://ClinicalTrials.gov/show/NCT03306277,180.0,100.0
2843,544,22.6203348,120.3120375,"IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative, Genova, Liguria, Italy",545.0,NCT03300869,Natural History of Types 2 and 3 SMA in Taiwan,,Recruiting,No Results Available,Spinal Muscular Atrophy,,Describe the correlation of genotype and phenotype in SMA types 2 and 3|Disease onset in patients with SMA types 2 and 3|Disease mortality in patients with SMA types 2 and 3|Scoliosis in patients with SMA types 2 and 3|BiPAP usage in patients with SMA types 2 and 3,Kaohsiung Medical University Chung-Ho Memorial Hospital|Biogen|National Taiwan University Hospital|Mackay Memorial Hospital|China Medical University Hospital|Changhua Christian Hospital|Chang Gung Memorial Hospital,All,,300.0,Other|Industry,Observational,Observational Model: Other|Time Perspective: Retrospective,SMA_RV,"September 1, 2017",December 2019,December 2019,"October 4, 2017",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT03300869,6.0,70.0
2844,545,48.8437486,2.1853699,"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unit√† Operativa Complessa di Neurologia, Milano, Lombardia, Italy",546.0,NCT03223051,Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy,ExplorASI,Recruiting,No Results Available,"Spinal Muscular Atrophy|Assessment, Self",Other: Motor assessment,Motor Function Measure (MFM)|Tiredness|Motivation|Satisfaction,Centre d'Investigation Clinique et Technologique 805,All,Not Applicable,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2017-A01017-46,"September 7, 2017","September 7, 2017",September 2020,"July 19, 2017",,"January 25, 2018",,https://ClinicalTrials.gov/show/NCT03223051,3.0,16.0
2845,545,48.8437486,2.1853699,"Fondazione IRCCS Istituto Neurologico ""Carlo Besta""; UO di Neurologia dello Sviluppo, Milano, Lombardia, Italy",546.0,NCT03223051,Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy,ExplorASI,Recruiting,No Results Available,"Spinal Muscular Atrophy|Assessment, Self",Other: Motor assessment,Motor Function Measure (MFM)|Tiredness|Motivation|Satisfaction,Centre d'Investigation Clinique et Technologique 805,All,Not Applicable,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2017-A01017-46,"September 7, 2017","September 7, 2017",September 2020,"July 19, 2017",,"January 25, 2018",,https://ClinicalTrials.gov/show/NCT03223051,3.0,16.0
2846,545,48.8437486,2.1853699,"Fukuoka Children's Hospital, Fukuoka, Japan",546.0,NCT03223051,Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy,ExplorASI,Recruiting,No Results Available,"Spinal Muscular Atrophy|Assessment, Self",Other: Motor assessment,Motor Function Measure (MFM)|Tiredness|Motivation|Satisfaction,Centre d'Investigation Clinique et Technologique 805,All,Not Applicable,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2017-A01017-46,"September 7, 2017","September 7, 2017",September 2020,"July 19, 2017",,"January 25, 2018",,https://ClinicalTrials.gov/show/NCT03223051,3.0,16.0
2847,546,22.6203348,120.3120375,"Hiroshima University Hospital, Hiroshima, Japan",547.0,NCT03217578,Neonatal Spinal Muscular Atrophy (SMA) Screening,SMA,Recruiting,No Results Available,Spinal Muscular Atrophy,Other: SMA Newborn Screening,Number of neonates with confirmed the deletion of 2 copies of SMN1 gene|Number of neonates with confirmed SMA,Kaohsiung Medical University Chung-Ho Memorial Hospital|The Chinese Foundation of Health|Taipei Institute of Pathology,All,,250000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SMA-NBS001,"September 1, 2017","December 31, 2019","December 31, 2019","July 14, 2017",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT03217578,2.0,100.0
2848,547,22.3028568,114.18203242951,"Hyogo College of Medicine Hospital, Hyogo, Japan",548.0,NCT03056144,Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy,,Terminated,Has Results,Spinal Muscular Atrophy Type 3,Device: whole body vibration therapy,North Star Ambulatory Assessment|2-minute Walk Test|Segmental Assessment of Trunk Control-static|Pediatric Evaluation of Disability Inventory|Body Height|Body Weight|Body Mass Index|Bone Mineral Content of Femur|Bone Mineral Content of Whole Body (Excluding Head)|Areal Bone Mineral Density of Femur|Areal Bone Mineral Density of Total Body (Excluding Head)|Volumetric Bone Mineral Density of Lumbar Spine|Range of Right Hip Flexion|Range of Left Hip Flexion|Range of Right Hip Extension|Range of Left Hip Extension|Range of Right Hip Abduction|Range of Left Hip Abduction|Range of Right Knee Flexion|Range of Left Knee Flexion|Range of Right Knee Extension|Range of Left Knee Extension|Range of Right Ankle Dorsiflexion|Range of Left Ankle Dorsiflexion|Range of Right Ankle Plantarflexion|Range of Left Ankle Plantarflexion|Muscle Strength of Right Hip Flexors|Muscle Strength of Left Hip Flexors|Muscle Strength of Right Hip Extensors|Muscle Strength of Left Hip Extensors|Muscle Strength of Right Knee Flexors|Muscle Strength of Left Knee Flexors|Muscle Strength of Right Knee Extensors|Muscle Strength of Left Knee Extensors|Muscle Strength of Right Hip Abductors|Muscle Strength of Left Hip Abductors|Muscle Strength of Right Ankle Dorsiflexors|Muscle Strength of Left Ankle Dorsiflexors|Muscle Strength of Right Ankle Plantarflexors|Muscle Strength of Left Ankle Plantarflexors|Segmental Assessment of Trunk Control_active|Segmental Assessment of Trunk Control-reactive|Percentage of Attendance of Participants|Visual Analogue Scale,The Hong Kong Polytechnic University|Manchester Metropolitan University|The University of Hong Kong,All,Not Applicable,1.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YBPA,"August 1, 2017","July 12, 2018","July 12, 2018","February 17, 2017","July 26, 2019","July 26, 2019","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03056144/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03056144,6.0,18.0
2849,548,36.7014631,-118.7559974,"Kagoshima City Hospital, Kagoshima, Japan",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2850,548,40.7127281,-74.0060152,"Shiga Medical Center for Children, Shiga, Japan",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2851,548,51.0538286,3.7250121,"Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2852,548,50.879202,4.7011675,"Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology, Gda≈Ñsk, Poland",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2853,548,45.7337532,4.9092352,"The Children's Memorial Health Institute Department of Neurology and Epileptology, Warszawa, Poland",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2854,548,50.6365654,3.0635282,"Russian Children Neuromuscular Center of Veltischev, Moscow, Moskovskaja Oblast, Russian Federation",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2855,548,48.8566101,2.3514992,"King Faisal Specialist Hospital and Research Centre Building, Riyadh, Saudi Arabia",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2856,548,43.6044622,1.4442469,"Institute for Mother and Child Dr. Vukan Cupic, Belgrade, Serbia",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2857,548,41.9808038,12.7662312,"Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2858,548,41.9808038,12.7662312,"Hospital Universitari Vall d'Hebron; Area Gen√©tica Cl√≠nica y Molecular, Barcelona, Spain",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2859,548,44.4777617,8.7026296,"Hospital Universitario Virgen del Rocio, Sevilla, Spain",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2860,548,45.6209,9.768893,"Universit√§ts-Kinderspitalbeider Basel_Abteilung f√ºr Neuro- und Entwicklungsp√§diatrie, Basel, Switzerland",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2861,548,37.587794,14.155048,"Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit, Ankara, Turkey",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2862,548,52.0809856,5.12768396945229,"Stanford University Medical Center, Palo Alto, California, United States",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2863,548,52.2337172,21.0714111288323,"Columbia University Medical Center; The Neurological Institute of New York, New York, New York, United States",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2864,548,47.5581077,7.5878261,"UZ Gent, Gent, Belgium",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2865,548,51.5073219,-0.1276474,"UZ Leuven Gasthuisberg, Leuven, Belgium",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2866,548,54.9738474,-1.6131572,"Chr de La Citadelle, Li√®ge, Belgium",549.0,NCT03032172,A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy,Jewelfish,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: Risdiplam,"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0|Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years)|Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments|Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments|Tanner Staging Among all Participants Aged From 9 to 17 Years|Mean Plasma Concentration of RO7034067|Maximum Plasma Concentration (Cmax) of RO7034067|Area Under the Plasma Concentration Versus Curve (AUC) of RO7034067|Concentration of RO7034067 at the End of Dosing Interval (Ctrough)|Mean Plasma Concentration of RO7034067 Metabolite|Cmax of RO7034067 Metabolite|AUC of RO7034067 Metabolite|Ctrough of RO7034067 Metabolite|SMN messenger Ribonucleic Acid (mRNA) Level in Blood|SMN Protein Levels in Blood",Hoffmann-La Roche,All,Phase 2,180.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39054|2016-004184-39,"March 3, 2017","December 31, 2021","December 27, 2024","January 26, 2017",,"July 25, 2019",,https://ClinicalTrials.gov/show/NCT03032172,6.0,60.0
2867,549,52.0809856,5.12768396945229,"Instituto de Puericultura E Pediatria Martag√£o Gesteira, Rio de Janeiro, RJ, Brazil",550.0,NCT02941328,"SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4",SPACE,Completed,No Results Available,Spinal Muscular Atrophy|SMA|Kugelberg-Welander Disease,Drug: Pyridostigmine|Drug: Placebo,MFM (Motor Function Measurement).|repeated nine-hole peg test performance|endurance nine hole peg test|endurance box-and-block test|endurance walk test,UMC Utrecht,All,Phase 2,39.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NL38048.041.14,December 2015,January 2018,January 2018,"October 21, 2016",,"February 2, 2018",,https://ClinicalTrials.gov/show/NCT02941328,12.0,100.0
2868,550,36.7014631,-118.7559974,"Alberta Children's Hospital Division of Pediatric Neurology, Calgary, Alberta, Canada",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2869,550,40.0796606,-89.4337288,"London Health Sciences Centre; Children's Hospital; Pediatrics, London, Ontario, Canada",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2870,550,42.3788774,-72.032366,"McGill University Health Center, Montreal, Quebec, Canada",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2871,550,40.7127281,-74.0060152,"Peking University First Hospital, Beijing City, China",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2872,550,51.0538286,3.7250121,"Children's Hospital of Fudan University, Shanghai, China",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2873,550,50.879202,4.7011675,"Clinical Medical Center Zagreb; University Hospital Rebro Department of Paediatrics, Zagreb, Croatia",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2874,550,50.6451381,5.5734203,"Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE, Bron, France",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2875,550,-22.2752762,-42.419415,"Hopital Roger Salengro, Lille, France",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2876,550,-10.3333333,-53.2,"CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie, Montpellier, France",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2877,550,39.9265263,116.3932334,"CHU de Nantes - Hotel Dieu, Nantes, France",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2878,550,31.2322735,121.4691749,"H√¥pital Necker-Enfants Malades; Service de neurop√©diatrie, Paris, France",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2879,550,45.813177,15.977048,"Hopital Armand Trousseau, Paris, France",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2880,550,45.7337532,4.9092352,"Universit√§tsklinikum Freiburg; Klinik f√ºr Neurop√§diatrie und Muskelerkrankungen, Freiburg, Germany",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2881,550,48.8566101,2.3514992,"IRCCS Ospedale Pediatrico Bambino Ges√π; U.O. Malattie Neuromuscolari e Neurodegenerative, Roma, Lazio, Italy",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2882,550,41.9808038,12.7662312,"Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile, Roma, Lazio, Italy",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2883,550,41.9808038,12.7662312,"IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative, Genova, Liguria, Italy",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2884,550,44.4777617,8.7026296,"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unit√† Operativa Complessa di Neurologia, Milano, Lombardia, Italy",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2885,550,45.6209,9.768893,"Fondazione IRCCS Istituto Neurologico ""Carlo Besta""; UO di Neurologia dello Sviluppo, Milano, Lombardia, Italy",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2886,550,45.6209,9.768893,"Azienda Ospedaliera Universitaria Policlinico G.Martino; Dip. Neurologia e Malattie neuromuscolari, Messina, Sicilia, Italy",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2887,550,33.6251241,130.6180016,"Fukuoka Children's Hospital, Fukuoka, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2888,550,34.3916058,132.4518156,"Hiroshima University Hospital, Hiroshima, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2889,550,34.914934,134.860666,"Hyogo College of Medicine Hospital, Hyogo, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2890,550,31.521587,130.5474077,"Minami Kyushu National Hospital, Kagoshima, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2891,550,35.247154,136.109385,"Miyagi Children's Hospital, Miyagi, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2892,550,35.6828387,139.7594549,"Shiga Medical Center for Children, Shiga, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2893,550,54.36143405,18.6282184755727,"Shizuoka Children's Hospital, Shizuoka, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2894,550,52.2337172,21.0714111288323,"Jichi Medical University Hospital, Tochigi, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2895,550,53.2028088,50.1604963,"Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2896,550,24.6319692,46.7150648,"National Center Of Neurology And Psychiatry Hospital, Tokyo, Japan",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2897,550,44.8178131,20.4568974,"Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology, Gda≈Ñsk, Poland",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2898,550,41.3828939,2.1774322,"Szpital Kliniczny im. H. Swiecickiego U.M. w Poznaniu; Od. Kliniczny Neurologii Dzieci i M≈Çodziezy, Pozna≈Ñ, Poland",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2899,550,41.3828939,2.1774322,"Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, Poland",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2900,550,37.3886303,-5.9953403,"Russian Children Neuromuscular Center of Veltischev, Moscow, Moskovskaja Oblast, Russian Federation",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2901,550,47.5581077,7.5878261,"Clinic for Neurology and Psychiatry for Children and Youth, Belgrade, Serbia",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2902,550,39.9207774,32.854067,"Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain",551.0,NCT02913482,"Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",FIREFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Risdiplam,"Recommended Part 2 Dose of Risdiplam|Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)|Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)|Part 1: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1: Area Under the Curve (AUC) of Risdiplam|Part 2: Area Under the Curve (AUC) of Risdiplam|Part 1: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Part 2: Concentration at the end of a Dosing Interval (Ctrough) of Risdiplam|Time to Death|Time to Permanent Ventilation|Survival of Motor Neuron (SMN) Protein Levels in Blood|Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24|Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24|Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale|Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12|Percentage of Infants who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12|Time to Death or Permanent Ventilation, Whichever Occurred First|Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24|Percentage of Infants who are Sitting Without Support for 5 Seconds at 24-months|Percentage of Infants who Stand Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who Walk Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24|Percentage of Infants who are Sitting Without Support for 30 Seconds at 24-months|Percentage of Infants that are Crawling at 24 Months|Proportion of Infants Achieving an Increase of >/= 4 Points from Baseline CHOP-INTEND Score|Proportion of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12)|Proportion of Infants not Requiring Respiratory Support (Invasive or Non-Invasive) at 12 and 24 Months|Proportion of Infants Able to Feed Orally at 12 and 24 Months",Hoffmann-La Roche,All,Phase 2|Phase 3,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP39056|2016-000778-40,"December 24, 2016","November 17, 2023","November 17, 2023","September 23, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02913482,1.0,7.0
2903,551,36.7014631,-118.7559974,"Hospital Universitari Vall d'Hebron; Servicio de Reumatologia, Barcelona, Spain",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2904,551,40.7127281,-74.0060152,"Hospital Universitario La Paz, Madrid, Spain",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2905,551,51.0538286,3.7250121,"Hospital Universitario Virgen del Roc√≠o; Servicio de Neuropediatra, Sevilla, Spain",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2906,551,50.879202,4.7011675,"Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit, Ankara, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2907,551,50.6451381,5.5734203,"Columbia University Medical Center, New York, New York, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2908,551,-22.2752762,-42.419415,"Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2909,551,55.001251,-115.002136,"Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Province OF China, China",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2910,551,50.000678,-86.000977,"National Taiwan University Hospital, Taipei, Taiwan, Province OF China, China",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2911,551,52.4760892,-71.8258668,"Hospital Pablo Tobon Uribe, Medell√≠n, Antioquia, Colombia",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2912,551,39.9265263,116.3932334,"Hospital Pablo Tobon Uribe, Medellin, Colombia",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2913,551,31.2322735,121.4691749,"Hospital Infantil de Mexico Federico Gomez, Mexico city, Mexico",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2914,551,45.813177,15.977048,"Auckland City Hospital, Grafton, Auckland, New Zealand",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2915,551,45.7337532,4.9092352,"Auckland District Health Board ADHB, Grafton, Auckland, New Zealand",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2916,551,50.6365654,3.0635282,"Taipei Veterans General Hospital, Taipei city, Beitou District, Taiwan",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2917,551,43.6112422,3.8767337,"Kaohsiung Medical University Hospital, Kaohsiung, Taiwan",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2918,551,47.2186371,-1.5541362,"National Taiwan University Hospital, Taipei, Taiwan",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2919,551,48.8566101,2.3514992,"Ege Universitesi Tip Fakultesi Cocuk Sagligi, Izmir, Anatolia, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2920,551,48.8566101,2.3514992,"Erciyes University Hospital, Kayseri, Anatolia, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2921,551,47.9960901,7.8494005,"Hacettepe University, Ankara, Central Anatolia, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2922,551,41.9808038,12.7662312,"Marmara Uni. Research & Educational Hospital, Kadƒ±k√∂y, Istanbul, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2923,551,41.9808038,12.7662312,"Medipol University Hospital, Istanbul, Marmara, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2924,551,44.4777617,8.7026296,"Karadeniz Technical University, Trabzon, Turkey",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2925,551,45.6209,9.768893,"Royal Victoria Hospital, Belfast City, Belfast, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2926,551,45.6209,9.768893,"Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2927,551,37.587794,14.155048,"Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2928,551,33.6251241,130.6180016,"Central Manchester University Hospitals NHS Trust, Manchester, The Northwest, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2929,551,34.3916058,132.4518156,"The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne And Wear, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2930,551,34.914934,134.860666,"The Leeds Teaching Hospitals, Leeds, Yorkshire, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2931,551,31.521587,130.5474077,"University Hospital of Wales, Cardiff, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2932,551,38.3880155,140.9761025,"Alder Hey Childrens Hospital, Liverpool, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2933,551,35.247154,136.109385,"Guy's & St Thomas' NHS FT, London, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2934,551,34.9332488,138.0955398,"Great Ormond Street Hospital, London, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2935,551,36.6782167,139.8096549,"Nottingham University Hospital, Nottingham, United Kingdom",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2936,551,35.6828387,139.7594549,"Children's Medical Center, Tehran, Iran, Islamic Republic of",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2937,551,35.6828387,139.7594549,"Massachusetts General Hospital, Boston, Massachusetts, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2938,551,54.36143405,18.6282184755727,"UCLA, Los Angeles, California, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2939,551,52.4006522,16.9197520238885,"University of California Irvine, Orange, California, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2940,551,52.2337172,21.0714111288323,"Pediatric Neuromuscular Clinic Stanford University, Palo Alto, California, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2941,551,53.2028088,50.1604963,"Children's Hospital Colorado, Aurora, Colorado, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2942,551,44.8178131,20.4568974,"Hospital for Special Care, New Britain, Connecticut, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2943,551,41.3828939,2.1774322,"Nemours Childrens Hospital, Orlando, Florida, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2944,551,41.3828939,2.1774322,"Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2945,551,40.4167047,-3.7035825,"University of Kansas Medical Center, Kansas City, Kansas, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2946,551,37.3886303,-5.9953403,"Johns Hopkins Hospital Institute for Clinical and Translational Research Pediatric Clinical Research Unit, Baltimore, Maryland, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2947,551,39.9207774,32.854067,"Boston Children's Hospital, Boston, Massachusetts, United States",552.0,NCT02908685,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",SUNFISH,"Active, not recruiting",No Results Available,"Muscular Atrophy, Spinal",Drug: Placebo|Drug: Risdiplam,Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12|Part 1: Recommended Part 2 Dose of Risdiplam|Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood|Survival of Motor Neuron (SMN) Protein Levels in Blood|Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12|Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12|Percentage of Participants who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM) Score at Month 12|Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12|Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12|Change from Baseline in Forced Vital Capacity (FVC) at Month 12|Change from Baseline in the Peak Cough Flow (PCF) at Month 12|Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12|Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12|Percentage of Participants who Experience at Least One Disease-Related Adverse Event|Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam|Part 1 and 2: Area Under the Curve (AUC) of Risdiplam|Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change from Baseline in the MFM Domain 1 (D1) Score at Month 12|Change from Baseline in the MFM Domain 2 (D2) Score at Month 12|Change from Baseline in the MFM Domain 3 (D3) Score at Month 12|Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12|Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings|Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12|Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12,Hoffmann-La Roche,All,Phase 2|Phase 3,231.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP39055|2016-000750-35,"October 20, 2016","September 30, 2019","September 2, 2023","September 21, 2016",,"June 5, 2019",,https://ClinicalTrials.gov/show/NCT02908685,2.0,25.0
2948,552,40.7127281,-74.0060152,"Washington University School of Medicine, Saint Louis, Missouri, United States",553.0,NCT02895789,Oxidative Capacity and Exercise Tolerance in Ambulatory SMA,,Recruiting,No Results Available,Spinal Muscular Atrophy Type 3|Mitochondrial Myopathy,,Change in NIRS derived index of muscle oxygen extraction|Change in Peak oxygen uptake (V02 max)|Change in Distance walked during the Six Minute Walk Test (6MWT)|Change in Lean body mass assessed with Dual Energy X-ray Absorptiometry (DEXA),Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,,42.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAQ9447|1K01HD084690-01A1,November 2016,July 2019,May 2020,"September 12, 2016",,"May 1, 2018",,https://ClinicalTrials.gov/show/NCT02895789,8.0,55.0
2949,553,50.000678,-86.000977,"Duke University Medical Center, Durham, North Carolina, United States",554.0,NCT02876094,Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy,SMA,Recruiting,No Results Available,Spinal Muscular Atrophy (SMA),Drug: celecoxib,"low-dose oral celecoxib administered to patients with SMA type II and III is associated with an increase in the levels of peripheral leukocyte SMN protein compared to baseline|Safety Profile Measured by Adverse Event Frequency,Type and Severity|Recruitment Plan Measured by Number of Potentially Eligible Subjects|Compliance Measured by Reported Protocol Deviations|Eligibility Measured by Number of Screen Failures|Delivery Time of Shipped Samples Assessed by Viability",Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children's Hospital of Eastern Ontario,All,Phase 2,12.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15/22E,"January 29, 2019",July 2020,July 2020,"August 23, 2016",,"July 30, 2019",,https://ClinicalTrials.gov/show/NCT02876094,2.0,80.0
2950,554,25.7059082,-99.2396385,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2951,554,25.7059082,-99.2396385,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2952,554,7.0000085,-75.5000086,"The University of Utah, Clinical Neurosciences Center, Salt Lake City, Utah, United States",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2953,554,6.2443382,-75.573553,"Alberta Children's Hospital, Calgary, Alberta, Canada",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2954,554,19.4326009,-99.1333416,"Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2955,554,-36.852095,174.7631803,"Children's Hospital - LHSC, London, Ontario, Canada",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2956,554,-36.852095,174.7631803,"Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2957,554,25.1319307,121.4985934,"Pra International Group B.V, Groningen, Netherlands",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2958,554,22.6203348,120.3120375,"UZ Gent, Gent, Belgium",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2959,554,25.0375198,121.5636796,"UZ Leuven Gasthuisberg, Leuven, Belgium",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2960,554,39.0,32.0,"Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE, Bron, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2961,554,39.0,32.0,"H√¥pital Raymond Poincare; Serv. Neurologie et R√©animation p√©diatriques - Centre r√©f. neuromusculaire, Garches, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2962,554,37.0550974,37.3763961,"Hopital Jeanne De Flandre; CIC pediatrique, Lille, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2963,554,41.0096334,28.9651646,"Hopital la Timone Enfants; Service de Pediatrie et Neurologie Pediatrique, Marseille, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2964,554,40.62164065,27.6294272209273,"CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie, Montpellier, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2965,554,41.0058605,39.7180928,"Hopital Armand Trousseau; centre reference Maladies Neuro-musculaires Est parisien Neuropediatrie, Paris Cedex 12, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2966,554,54.5964411,-5.9302761,"Hopital des Enfants; Unite de Neurologie Pediatrique, Toulouse, France",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2967,554,53.48153335,-1.38104220661496,"Universit√§tsklinikum Essen; Neurop√§diatrie, Essen, Germany",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2968,554,52.8246942,-2.00745467233481,"Uniklinikum Freiburg Zentrum f√ºr Kinder- und Jugendmedizin; Neurop√§diatrie und Muskelerkrankungen, Freiburg, Germany",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2969,554,54.7023545,-3.2765753,"Dr. Von Haunersches Kinderspital, M√ºnchen, Germany",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2970,554,54.916667,-1.566667,"Ospedale Pediatrico Bambino Ges√π; Dip. Neuroscienze e Salute Mentale, Roma, Lazio, Italy",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2971,554,55.8606731,-4.2567906,"Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile, Roma, Lazio, Italy",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2972,554,51.4816546,-3.1791934,"IRCCS Istituto G. Gaslini; UOC Neurologia Pediatrica e Malattie Muscolari, Genova, Liguria, Italy",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2973,554,53.407154,-2.991665,"I.R.C.C.S. C√† Granda - Ospedale Maggiore Policlinico; Dip. di Salute Mentale, Milano, Lombardia, Italy",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2974,554,51.5073219,-0.1276474,"ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA;NEMO (NEuroMuscular Omnicentre);Centro clinico - Fonda, Milano, Lombardia, Italy",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2975,554,51.5073219,-0.1276474,"Azienda Ospedaliera Universitaria Policlinico G.Martino; Dip. Neurologia e Malattie neuromuscolari, Messina, Sicilia, Italy",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2976,554,52.9534161,-1.1492773,"UMC Utrecht; Polkliniek Neuromusculaire ziekten, Utrecht, Netherlands",555.0,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: Nusinersen,,Biogen,All,,,Industry,Expanded Access:Treatment IND/Protocol,,232-SM-901,,,,"August 12, 2016",,"June 21, 2019",,https://ClinicalTrials.gov/show/NCT02865109,18.0,100.0
2977,555,36.2619477,59.6051728,"Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie; Klinika Neurologii, Warszawa, Poland",556.0,NCT02855112,Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients,,Unknown status,No Results Available,"Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]",Biological: Adipose derived mesenchymal stem cell,Changes in action potential of muscles on ElectroMyoGram (EMG) test|Changes in Motility on Modified Barthel Index Score,Tehran University of Medical Sciences,All,Phase 1|Phase 2,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,94-01-87-28524,June 2015,December 2016,July 2017,"August 4, 2016",,"August 4, 2016",,https://ClinicalTrials.gov/show/NCT02855112,5.0,12.0
2978,556,42.3788774,-72.032366,"Heart of England NHS Trust, Birmingham, United Kingdom",557.0,NCT02831296,Prospective Evaluation of Infants With Spinal Muscular Atrophy:,SPOTSMA,Recruiting,No Results Available,Spinal Muscular Atrophy,,Time to death and/or full time invasive ventilation or need for > 16 hours/day of bilevel respiratory support|Maximum Ulnar CMAP Amplitude|CHOP-INTEND|WHO Motor Milestones|Hammersmith Functional Motor Scale - Expanded|Hammersmith Infant Neurological Exam (HINE)|Body composition|Bone density|Need for tube feeding|Caregiver Questionnaire total score and subscores,"Massachusetts General Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Utah|University of Massachusetts, Worcester|ARUP Laboratories|Newborn Screening Translational Research Network|American College of Medical Genetics and Genomics|Children's Hospital Medical Center, Cincinnati",All,,200.0,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2015P001934|R01HD069045,February 2016,March 2022,,"July 13, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02831296,18.0,100.0
2979,557,36.7014631,-118.7559974,"National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases, London, United Kingdom",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2980,557,36.7014631,-118.7559974,"Great Ormond Street Hospital, London, United Kingdom",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2981,557,36.7014631,-118.7559974,"Newcastle University & The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2982,557,38.7251776,-105.6077167,"UCLA Medical Center, Los Angeles, California, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2983,557,41.6500201,-72.7342163,"Stanford University School of Medicine, Palo Alto, California, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2984,557,27.7567667,-81.4639835,"Children's Hospital Colorado, Aurora, Colorado, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2985,557,40.0796606,-89.4337288,"Connecticut Children's Medical Center, Hartford, Connecticut, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2986,557,38.27312,-98.5821872,"Nemours Children's Hospital, Orlando, Florida, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2987,557,39.5162234,-76.9382069,"Ann & Robert H Lurie Children's Hospital of Chicago Box 51, Chicago, Illinois, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2988,557,42.3788774,-72.032366,"Boston Children's Hospital, Boston, Massachusetts, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2989,557,38.7604815,-92.5617875,"Gillette Children's Specialty Healthcare, Minneapolis, Minnesota, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2990,557,35.6729639,-79.0392919,"Washington University School of Medicine, Saint Louis, Missouri, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2991,557,40.2253569,-82.6881395,"Columbia University Medical Center, New York, New York, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2992,557,40.9699889,-77.7278831,"Duke University School of Medicine, Durham, North Carolina, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2993,557,39.4225192,-111.7143584,"Doernbecher Children's Hospital, Portland, Oregon, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2994,557,55.001251,-115.002136,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2995,557,55.001251,-125.002441,"UT Southwestern Medical Center/Children's Medical Center, Dallas, Texas, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2996,557,50.000678,-86.000977,"Primary Children's Medical Center (University of Utah), Salt Lake City, Utah, United States",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2997,557,52.4760892,-71.8258668,"Sydney Children's Hospital, Sydney, New South Wales, Australia",558.0,NCT02644668,A Study of CK-2127107 in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: CK-2127107 150 mg|Drug: Placebo|Drug: CK-2127107 450 mg,"Change from baseline and slope of change from baseline in Forced Vital Capacity (FVC)|Change from baseline and slope of change from baseline in Maximum Inspiratory Pressure (MIP)/Maximum Expiratory Pressure (MEP)|Change from baseline and slope of change from baseline in Hand-Held Dynamometry (HHD)|Change from baseline and slope of change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMS-E)|Change from baseline and slope of change from baseline in Revised Upper Limb Module (RULM)|Change from baseline and slope of change from baseline in Timed Up and Go (TUG) test|Change from baseline and slope of change from baseline in 6-Minute Walk Test (6MWT)|Global Assessments|Safety and tolerability of multiple doses of CK-2127107 administered orally to SMA patients (TEAEs, SAEs, discontinuations due to TEAEs, medical history, physical and neurological examinations, ECGs, vital signs, clinical safety labs)|Maximum observed plasma concentration (Cmax) of CK-2127107|Pre-dose plasma concentration (Ctrough) of CK-2127107|Area under the plasma concentration-time curve from pre-dose to the last measurable plasma concentration (AUC0-t) of CK-2127107|Area under the plasma concentration-time curve at steady-state will be the average of AUC0-24 at the end of Weeks 2 and 8 (AUCavg) of CK-2127107","Cytokinetics|Astellas Pharma Global Development, Inc.",All,Phase 2,70.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 5021,December 2015,"May 31, 2018","May 31, 2018","January 1, 2016",,"March 6, 2019",,https://ClinicalTrials.gov/show/NCT02644668,12.0,100.0
2998,558,53.2217925,6.55824533479853,"Royal Children's Hospital, Children's Neuroscience Centre, Parkville, Victoria, Australia",559.0,NCT02633709,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers",,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Itraconazole|Other: Placebo|Drug: Risdiplam,"Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Laboratory Test Abnormalities|Percentage of Participants with Clinically Significant Changes in Safety Measurements, Including Vital Signs and Electrocardiograms (ECGs)|Percentage of Participants with Clinically Significant Changes in Ophthalmological Assessments|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration-Time Curve up to the Last Measurable Concentration (AUClast)|Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)|Area Under the Plasma Concentration-Time Curve up to Time t (AUC0-t)|Apparent Terminal Half-Life (t1/2)|Apparent Oral Clearance (CL/F)|Apparent Oral Volume of Distribution (Vz/F)|Cumulative Amount Excreted Unchanged into Urine (Ae)|Renal Clearance (CLR)|Fraction of Dose Excreted Unchanged Renally (Fe)|Metabolite-to-Parent Ratio (AUCm/AUCp) Corrected for Molecular Weight for AUCInf, AUClast or AUC0-t|Change from In Vivo Baseline in Splicing Modifications of SMN mRNAs, Including SMN1, SMN2 FL, and SMNdelta7 mRNA in Blood Ex Vivo|Change from Baseline in SMN Protein Levels in Blood|Metabolite-to-Parent Ratio (Cmax_m/Cmax_p) for Cmax, Corrected for Molecular Weight|Predose Trough Plasma Concentration (Ctrough) of Itraconazole|Change from Baseline in Splicing Modifications of Survival of Motor Neuron (SMN) Messenger Ribonucleic Acids (mRNAs), Including SMN1, SMN2 FL, and SMNdelta7 mRNA in Blood In Vivo",Hoffmann-La Roche,Male,Phase 1,33.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29840|2015-004605-16,"January 7, 2016","August 4, 2016","August 4, 2016","December 17, 2015",,"October 4, 2018",,https://ClinicalTrials.gov/show/NCT02633709,18.0,45.0
2999,559,51.0538286,3.7250121,"H√¥pital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Belgium",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3000,559,50.879202,4.7011675,"BC Children's Hospital / UBC, Vancouver, British Columbia, Canada",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3001,559,45.7337532,4.9092352,"Western University Clinical Neurological Sciences, London, Ontario, Canada",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3002,559,48.8437486,2.1853699,"McGill University Health Centre, Research Institute, Montreal Children's Hospital-CIM, Montreal, Quebec, Canada",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3003,559,50.6365654,3.0635282,"Institut de Myologie, Paris, France",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3004,559,43.2961743,5.3699525,"LMU-Campus Innenstadt, Munich, Bayern, Germany",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3005,559,43.6112422,3.8767337,"Universit√§tsklinikum Essen, Essen, Germany",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3006,559,46.603354,1.8883335,"Universtatsklinikum Freiburg, Zentrum f√ºr Kinder-und Jugendmedizin, Abteilung Neurop√§diatrie und Muskelerkrankungen, Freiburg, Germany",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3007,559,43.6044622,1.4442469,"The University of Hong Kong, Queen Mary Hospital, Department of Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong SAR, Hong Kong",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3008,559,51.457087,7.011429,"Istituto Giannina Gaslini, Centro Traslazionale di Miologia e Patologie Neurodegenerative, Genova, Italy",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3009,559,47.9960901,7.8494005,"Centro Clinico Nemo, Milan, Italy",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3010,559,48.1371079,11.5753822,"Pediatric Neurology Unit, Catholic University, Rome, Italy",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3011,559,41.9808038,12.7662312,"Aichi Children's Health and Medical Center, Obu, Aichi, Japan",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3012,559,41.9808038,12.7662312,"Hyogo College of Medicine, Nishinomiya, Hyogo, Japan",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3013,559,44.4777617,8.7026296,"Tokyo Women's Medical University Institute of Medical Genetics, Shinjuku-ku, Tokyo, Japan",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3014,559,45.6209,9.768893,"Kumamoto University Hospital, Kumamoto, Japan",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3015,559,45.6209,9.768893,"University of Miyazaki, Miyazaki, Japan",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3016,559,37.587794,14.155048,"Seoul National University Hospital, Seoul, Korea, Korea, Republic of",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3017,559,52.0809856,5.12768396945229,"Hospital Vall d'Hebron, Barcelona, Spain",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3018,559,52.2337172,21.0714111288323,"Hospital Sant Joan de Deu, Barcelona, Spain",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3019,559,52.4775396,-1.894053,"Hospital Universitario La Paz, Pediatric Neurology Department, Madrid, Spain",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3020,559,51.5073219,-0.1276474,"University of Gothenburg, The Queen Silvia Children's Hospital, Gothenburg, Sweden",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3021,559,51.5073219,-0.1276474,"Hacettepe Children's Hospital, Ankara, Turkey",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3022,559,54.9738474,-1.6131572,"UCL Institute of Child Health/Great Ormond Street, London, United Kingdom",560.0,NCT02628743,"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,"Muscular Atrophy, Spinal",Drug: Olesoxime,"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score|Change From Baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score|Plasma Concentrations of Olesoxime|Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL) Generic Core Scale Version 4.0 Score|Change From Baseline in Caregiver PedsQL Generic Core Scales Version 4.0 Score|Change From Baseline in PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in Caregiver PedsQL Neuromuscular Module Version 3.0 Scale Score|Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score - Total Score|Change From Baseline in Caregiver Proxy EQ-5D-5L Questionnaire Index Score - Total Score|Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score|Change From Baseline in Caregiver Proxy EQ-5D-5L VAS Score|Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG) Questionnaire|Change From Baseline in Hours Actually Worked and Work Hours Missed Assessed Using WPAI:CG Questionnaire|Change From Baseline in Work Time Missed, Impairment While Working, Overall Work Impairment and Activity Impairment Assessed Using WPAI:CG Questionnaire Score|Change From Baseline in Degree Patient Caregiving Affected Productivity and Activities Using WPAI:CG Questionnaire|Change From Baseline in Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS): Caregiver|Change From Baseline in SF-36 Domain Scores: Caregiver|Change From Baseline in Revised Utility Index Score (SF-6D_R2): Caregiver|SMA Independence Scale (SMAIS) Score: Patient|SMA Independence Scale (SMAIS) Score: Caregiver",Hoffmann-La Roche,All,Phase 2,131.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BN29854|2015-001589-25,"January 20, 2016","December 18, 2018","December 18, 2018","December 11, 2015","August 9, 2019","August 9, 2019","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02628743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02628743,18.0,100.0
3023,560,36.7014631,-118.7559974,"MRC Centre for Neuromuscular Diseases at Newcastle, Institute of Genetic Medicine New Castle University, Newcastle, United Kingdom",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3024,560,36.7014631,-118.7559974,"Nantes University Hospital, Nantes, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3025,560,38.7251776,-105.6077167,"Rouen University Hospital, Rouen, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3026,560,41.6500201,-72.7342163,"Copenhagen Neuromuscular Center, Copenhagen, Denmark",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3027,NULL,NULL,NULL,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
3028,560,40.0796606,-89.4337288,"Connecticut Childrens Medical, Hartford, Connecticut, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3029,560,42.3788774,-72.032366,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3030,560,45.9896587,-94.6113288,"Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3031,560,38.7604815,-92.5617875,"The University of Texas Southwestern Medical Center, Dallas, Texas, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3032,560,40.7127281,-74.0060152,"Seattle Children's Research Institute, Seattle, Washington, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3033,560,35.6729639,-79.0392919,"LMU-Campus Innenstadt, Muenchen, Germany",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3034,560,43.9792797,-120.737257,"Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3035,560,40.9699889,-77.7278831,"Reference centre for neuromuscular diseases - UZ Leuven - Department of Pediatrics - University Hospitals Leuven, Leuven, Belgium",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3036,560,31.8160381,-99.5120986,"Centre de R√©f√©rence neuromusculaire - CHR La Citadelle, Liege, Belgium",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3037,560,39.4225192,-111.7143584,"Service de R√©√©ducation P√©diatrique Infantile "" L'Escale "" - H√¥pital Femme M√®re Enfant, Bron, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3038,560,-31.8759835,147.2869493,"Maladie Neuromusculaire de l'enfant - Service Maladies infectieuses et neurologie infantile - H√¥pital Roger Salengro, Lille, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3039,560,-36.5986096,144.6780052,"Centre de r√©f√©rence Maladies Neuromusculaires Nantes-Angers - H√¥tel Dieu, Nantes, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3040,560,50.8465573,4.351697,"I-Motion Institute - Trousseau Hospital, Paris, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3041,560,55.001251,-125.002441,"Neurop√©diatrie - Service de P√©diatrie 1 - CHU Hautepierre, Strasbourg, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3042,560,50.000678,-86.000977,"Unit√© de neurologie p√©diatrique - H√¥pital des enfants, Toulouse, France",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3043,560,52.4760892,-71.8258668,"Universit√§tsklinikum Essen (A√∂R) - Klinik f√ºr Kinderheilkunde I - Sozialp√§diatrisches Zentrum, Essen, Germany",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3044,560,48.8566101,2.3514992,"Children's Hospital Colorado, Aurora, Colorado, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3045,560,48.9467562,11.4038717,"Nemours Children's Clinic, Orlando, Florida, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3046,560,51.457087,7.011429,"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3047,560,47.9960901,7.8494005,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3048,560,22.2793278,114.1628131,"Massachusetts General Hospital, Boston, Massachusetts, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3049,560,44.40726,8.9338624,"Columbia University Medical Center, The SMA Clinical Research Center, New York, New York, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3050,560,45.4667971,9.1904984,"Primary Children's Medical Center, Salt Lake City, Utah, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3051,560,41.894802,12.4853384,"Royal Children's Hospital- Melbourne, Parkville, Victoria, Australia",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3052,560,34.9991645,137.254574,"Dept. of Neuropediatrics and Muscle Disorders Universit√§tsklinikum Freiburg, Freiburg, Baden-W√ºrttemberg, Germany",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3053,560,34.914934,134.860666,"Bambino Gesu' Children's Research Hospital, Roma, Lazio, Italy",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3054,560,35.6828387,139.7594549,"Fondazione Serena Onlus - Centro Clinico Nemo, Milano, Italy",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3055,560,32.6450475,130.6341345,"Hamad General Hospital, Doha, Qatar",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3056,560,32.097681,131.294542,"Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3057,560,42.9629533,47.5133551,"National Taiwan University Hospital, Taipei, Taiwan",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3058,560,41.3828939,2.1774322,"Hacettepe University Medical Faculty, Ankara, Sihhiye, Turkey",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3059,560,41.3828939,2.1774322,"Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3060,560,40.4167047,-3.7035825,"UCLA Clinical and Translational Research Center, Los Angeles, California, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3061,560,57.7072326,11.9670171,"Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3062,560,39.9207774,32.854067,"Children's Hospital Colorado, Aurora, Colorado, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3063,560,51.5073219,-0.1276474,"Nemours Children's Hospital, Orlando, Florida, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3064,560,53.0117627,-2.2273919,"Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",561.0,NCT02594124,A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.,SHINE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant coagulation parameter abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)|Time to death or permanent ventilation|Percentage of participants not requiring permanent ventilation|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale|Change from Baseline in Revised Upper Limb Module (RULM)|Change from Baseline in 6-Minute Walk Test (6MWT)|Change from Baseline in Compound Muscular Action Potential (CMAP)|Change from Baseline in body length and/or height (for all participants)|Change from Baseline in head circumference (for participants up to 36 months of age)|Change from Baseline in chest circumference (for participants up to 36 months of age)|Change from Baseline in arm circumference (for participants up to 36 months of age)|Proportion of CMAP responders|Number of participants with motor milestones achieved|Proportion of participants who achieved standing alone|Proportion of participants who achieved walking with assistance|Number of participants with serious respiratory events|Number of participants hospitalized|Duration of hospitalizations|Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine|Change from Baseline in Quality of Life (QOL) Questionnaires|Number of Disease-related hospitalizations and AEs|Overall survival rate,Biogen,All,Phase 3,292.0,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS11|2015-001870-16,"November 4, 2015","August 29, 2023","August 29, 2023","November 2, 2015",,"January 30, 2019",,https://ClinicalTrials.gov/show/NCT02594124,18.0,100.0
3065,561,47.2186371,-1.5541362,"Boston Children's Hospital, Boston, Massachusetts, United States",562.0,NCT02550691,Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene,BADGES,Terminated,No Results Available,Spinal Muscular Atrophy,Procedure: blood sampling,Identification of a genetic signature indicating the presence of one allele with 2 copies in cis of the SMN1 gene.|Specificity of a genetic signature,"University Hospital, Rouen|Society GENOMIC VISION",All,Not Applicable,48.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015/092/HP,"December 15, 2015","July 4, 2016","July 4, 2016","September 15, 2015",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT02550691,18.0,100.0
3066,561,49.4404591,1.0939658,"Washington University School of Medicine, Saint Louis, Missouri, United States",562.0,NCT02550691,Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene,BADGES,Terminated,No Results Available,Spinal Muscular Atrophy,Procedure: blood sampling,Identification of a genetic signature indicating the presence of one allele with 2 copies in cis of the SMN1 gene.|Specificity of a genetic signature,"University Hospital, Rouen|Society GENOMIC VISION",All,Not Applicable,48.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015/092/HP,"December 15, 2015","July 4, 2016","July 4, 2016","September 15, 2015",,"July 24, 2019",,https://ClinicalTrials.gov/show/NCT02550691,18.0,100.0
3067,562,55.6867243,12.5700724,"Columbia University Medical Center, New York, New York, United States",563.0,NCT02501395,MRI in Patients With Kennedy Disease,,Completed,No Results Available,"Bulbo-Spinal Atrophy, X-Linked|Kennedy Disease","Other: No intervention, observational",Muscle fat fraction|Muscle strength|Minimal dataset for data collection in Kennedy disease,"Rigshospitalet, Denmark",Male,,53.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,H-15006316,September 2015,February 2017,May 2018,"July 17, 2015",,"June 4, 2018",,https://ClinicalTrials.gov/show/NCT02501395,18.0,100.0
3068,563,,,"Oregon Health & Science University, Portland, Oregon, United States",564.0,NCT02466529,Natural History of Spinal Muscular Atrophy Type 1 in Taiwan,,Completed,No Results Available,Natural History of Type 1 Spinal Muscular Atrophy (SMA),,Age of death|Age of permanent ventilation,"Kaohsiung Medical University Chung-Ho Memorial Hospital|Biogen|Taipei Medical University WanFang Hospital|Taipei Veterans General Hospital, Taiwan|Mackay Memorial Hospital|Chang Gung Memorial Hospital|China Medical University Hospital|Chung Shan Medical University|Changhua Christian Hospital|Taichung Veterans General Hospital|Chi Mei Medical Hospital|Cathay General Hospital|Shin Kong Wu Ho-Su Memorial Hospital|Kaohsiung Veterans General Hospital.|National Cheng-Kung University Hospital|Buddhist Tzu Chi General Hospital|Kaohsiung Medical University|Taipei Medical University Shuang Ho Hospital|National Taiwan University Hospital|Taipei Medical University Hospital",All,,111.0,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,SMA-NHR10311,June 2015,December 2015,December 2015,"June 9, 2015",,"June 22, 2017",,https://ClinicalTrials.gov/show/NCT02466529,36.0,100.0
3069,564,36.7014631,-118.7559974,"Children's Hospital of Philadelphia - Neurology, Philadelphia, Pennsylvania, United States",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3070,564,41.6500201,-72.7342163,"Children's Medical Center, Dallas, Texas, United States",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3071,564,39.5162234,-76.9382069,"Children's Hospital - London Health Sciences Centre, London, Ontario, Canada",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3072,564,45.9896587,-94.6113288,"McGill University Health Centre-Glen Site-CIM, Montreal, Quebec, Canada",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3073,564,31.8160381,-99.5120986,"Armand Trousseau Hospital, I-Motion, Clinical Trials Platform, Paris, France",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3074,564,38.8950092,-77.0365625,"Universitatsklinikum Essen, Essen, Germany",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3075,564,48.1371079,11.5753822,"University Hospital Freiberg, Center for Paediatrics and Adolescent Medicine, Department of Neuropaediatrics and Muscular Disease, Freiburg, Germany",565.0,NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,EMBRACE,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham Procedure,Number of participants with adverse events and serious adverse events|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examination outcomes|Activated partial thromboplastin time (aPTT)|Partial thromboplastin time (PTT)|International normalized ratio (INR)|Urine total protein|Change from Baseline in Head Circumference|Change from Baseline in Chest Circumference|Change from Baseline in Arm Circumference|Change from Baseline in Weight for Age|Change from Baseline in Weight for Length|Change from Baseline in Head to Chest Circumference Ratio|Change from Baseline in Body Length|Nusinersen plasma concentration|Nusinersen cerebrospinal fluid (CSF) concentration|Nusinersen plasma antibodies,Biogen,All,Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",232SM202|2014-003657-33,"August 19, 2015","September 24, 2018","September 24, 2018","June 4, 2015",,"January 16, 2019",,https://ClinicalTrials.gov/show/NCT02462759,18.0,100.0
3076,565,45.9896587,-94.6113288,"The University of Hong Kong, Queen Mary Hospital, Department of Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong SAR, Hong Kong",566.0,NCT02428673,Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions,,"Active, not recruiting",No Results Available,Osteopenia|Spinal Muscular Atrophy|Cerebral Palsy|Muscular Dystrophy|Spina Bifida|Rett Syndrome,Other: Assisted Standing Treatment Program,Bone Mineral Density (BMD) (measured by DXA)|Bone Architecture (measured by pQCT)|Pediatric Quality of Life Inventory (PedsQL)|Neuromuscular Module of the PedsQL|Change in pulmonary function test|Change in Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD),Gillette Children's Specialty Healthcare,All,Not Applicable,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Truong POSNA,December 2015,"March 31, 2019","March 31, 2020","April 29, 2015",,"July 30, 2019",,https://ClinicalTrials.gov/show/NCT02428673,3.0,14.0
3077,566,50.879202,4.7011675,"AOU Policlinico G. Martino Dipartimento di Neuroscienze e Centro Clinico Nemo Sud, Messina, Italy",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3078,566,50.6451381,5.5734203,"Fondazione Policlinico Universitario Agostino Gemelli-Universita Cattolica de Sacro Cuore-UOC Neuropsichiatre Infantile, Rome, Italy",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3079,566,45.7337532,4.9092352,"Hyogo College of Medicine, Nishinomya-shi, Hyogo, Japan",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3080,566,50.6365654,3.0635282,"Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3081,566,47.2186371,-1.5541362,"Seoul National University Children's Hospital, Seoul, Korea, Korea, Republic of",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3082,566,48.8566101,2.3514992,"Hospital Sant Joan de Deu, Barcelona, Spain",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3083,566,48.584614,7.7507127,"University of Gothenburg, The Queen Silvia Children's Hospital, Gothenburg, Sweden",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3084,566,43.6044622,1.4442469,"Novartis Investigative Site, Gent, Belgium",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3085,566,51.457087,7.011429,"Novartis Investigative Site, Leuven, Belgium",567.0,NCT02391831,Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy,NatHis-SMA,Completed,No Results Available,Type 2 Spinal Muscular Atrophy|Type 3 Spinal Muscular Atrophy,"Other: Strength, function and activity measurements|Other: Muscle MRI|Other: Electrophysiology measurements|Other: Blood sampling for biomarker analysis",Change from baseline of muscle strength|Change from baseline of motor function|Change from baseline of respiratory function|Change from baseline of physical activity of upper limbs movements|Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)|Change from baseline of electrophysiology measurements|Change from baseline of Biomarkers of SMA progression,"Institut de Myologie, France|Institut Roche",All,Not Applicable,81.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NatHis-SMA|IDRCB-2014-A01263-44,May 2015,June 2018,June 2018,"March 18, 2015",,"July 19, 2018",,https://ClinicalTrials.gov/show/NCT02391831,2.0,30.0
3086,567,38.7251776,-105.6077167,"Novartis Investigative Site, Sofia, Bulgaria",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3087,567,27.7567667,-81.4639835,"Novartis Investigative Site, Prague 5, CZE, Czechia",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3088,567,40.0796606,-89.4337288,"Novartis Investigative Site, Copenhagen, Denmark",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3089,567,39.5162234,-76.9382069,"Novartis Investigative Site, Essen, Germany",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3090,567,42.3788774,-72.032366,"Novartis Investigative Site, Freiburg, Germany",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3091,567,40.7127281,-74.0060152,"Novartis Investigative Site, Budapest, Hungary",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3092,567,39.4225192,-111.7143584,"Novartis Investigative Site, Roma, ITA, Italy",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3093,567,-36.5986096,144.6780052,"Novartis Investigative Site, Milano, MI, Italy",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3094,567,48.6296972,9.1949534,"Novartis Investigative Site, Warsaw, Poland",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3095,567,41.9808038,12.7662312,"Novartis Investigative Site, Wroclaw, Poland",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3096,567,45.4667971,9.1904984,"Novartis Investigative Site, Ekaterinburg, Russian Federation",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3097,567,25.2856329,51.5264162,"Novartis Investigative Site, Moscow, Russian Federation",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3098,567,22.6203348,120.3120375,"Novartis Investigative Site, Moscow, Russian Federation",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3099,567,25.0375198,121.5636796,"Novartis Investigative Site, Saint Petersburg, Russian Federation",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3100,567,39.928566,32.8549158,"Novartis Investigative Site, Ufa, Russian Federation",568.0,NCT02386553,A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,NURTURE,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,Drug: Nusinersen,Time to death or respiratory intervention|Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).|Percentage of participants alive|Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)|Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria|Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale|Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)|Change from Baseline in weight for age/length|Change from Baseline in head circumference|Change from Baseline in chest circumference ratio|Change from Baseline in head to chest circumference ratio|Change from Baseline in arm circumference ratio|Incidence of adverse events (AEs) and/or serious adverse events (SAEs)|Change from Baseline in clinical laboratory parameters|Change from Baseline in electrocardiograms (ECGs)|Change from Baseline in vital signs|Change from Baseline in neurological examinations|Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.,Biogen,All,Phase 2,25.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,232SM201|2014-002098-12,"May 20, 2015","January 25, 2022","January 25, 2022","March 12, 2015",,"August 27, 2018",,https://ClinicalTrials.gov/show/NCT02386553,6.0,100.0
3101,568,45.9896587,-94.6113288,"Novartis Investigative Site, Volgograd, Russian Federation",569.0,NCT02341053,Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy,,"Active, not recruiting",No Results Available,Spinal Muscular Dystrophy|Neuromuscular Disability,Other: Assisted Standing Treatment Program,Collection of load magnitude and duration data (Use load-sensing platforms to collect load magnitude and duration during standing treatment program)|Bone Mineral Density,"Gillette Children's Specialty Healthcare|University of Minnesota, MN",All,Not Applicable,6.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1411M55281,September 2015,December 2019,December 2019,"January 19, 2015",,"July 10, 2018",,https://ClinicalTrials.gov/show/NCT02341053,3.0,14.0
3102,569,36.7014631,-118.7559974,"Stanford, California, United States",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3103,569,36.7014631,-118.7559974,"Orlando, Florida, United States",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3104,569,38.7251776,-105.6077167,"Chicago, Illinois, United States",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3105,569,27.7567667,-81.4639835,"Boston, Massachusetts, United States",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3106,569,40.0796606,-89.4337288,"St. Louis, Missouri, United States",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3107,569,42.3788774,-72.032366,"New York, New York, United States",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3108,569,38.7604815,-92.5617875,"Toronto, Ontario, Canada",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3109,569,40.7127281,-74.0060152,"Montreal, Quebec, Canada",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3110,569,43.9792797,-120.737257,"Ch Pitie Salpetriere; Institut de Myologie, Paris, France",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3111,569,40.9699889,-77.7278831,"Paris, France",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3112,569,31.8160381,-99.5120986,"Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile, Roma, Lazio, Italy",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3113,569,50.000678,-86.000977,"Roma, Lazio, Italy",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3114,569,52.4760892,-71.8258668,"Fondazione IRCCS Istituto Neurologico ""Carlo Besta""; UO di Neurologia dello Sviluppo, Milano, Lombardia, Italy",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3115,569,48.8566101,2.3514992,"Milano, Lombardia, Italy",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3116,569,51.457087,7.011429,"UMC Utrecht; Polkliniek Neuromusculaire ziekten, Utrecht, Netherlands",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3117,569,47.9960901,7.8494005,"Utrecht, Netherlands",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3118,569,22.2793278,114.1628131,"Drottning Silvias Barn- och ungdomssjukhus; Kliniken f√∂r barnmedicin, Goeteborg, Sweden",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3119,569,38.1937571,15.5542082,"Goeteborg, Sweden",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3120,569,41.894802,12.4853384,"Universit√§ts-Kinderspitalbeider Basel_Abteilung f√ºr Neuro- und Entwicklungsp√§diatrie, Basel, Switzerland",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3121,569,34.914934,134.860666,"Basel, Switzerland",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3122,569,35.6828387,139.7594549,"Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit, Ankara, Turkey",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3123,569,42.9629533,47.5133551,"Ankara, Turkey",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3124,569,41.3828939,2.1774322,"UCL; GAP Unit, Institute of Child Health, UCL, London, United Kingdom",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3125,569,57.7072326,11.9670171,"London, United Kingdom",570.0,NCT02292537,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),CHERISH,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,"Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15|Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15|Proportion of Participants That Achieved Any New Motor Milestone at Month 15|Number of New Motor Milestones Achieved Per Participant|Change From Baseline in Revised Upper Limb Module (RULM) Test|Proportion of Participants That Achieved Standing Alone|Proportion of Participants That Achieved Walking With Assistance|Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Weight Abnormalities|Number of Participants With Clinically Significant Neurological Examination Abnormalities|Number of Participants With Clinically Significant Physical Examination Abnormalities|Number of Participants With Clinically Significant Laboratory Parameter Abnormalities|Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results|Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure",Biogen,All,Phase 3,126.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS4|2014-001947-18,"November 24, 2014","February 20, 2017","February 20, 2017","November 17, 2014","February 21, 2018","February 21, 2018","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02292537/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02292537,2.0,12.0
3126,570,51.0538286,3.7250121,"MRC Neuromuscular Centre - Institute of Genetic Medicine, Newcastle upon Tyne, United Kingdom",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3127,570,50.879202,4.7011675,"Newcastle upon Tyne, United Kingdom",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3128,570,42.6978634,23.3221789,"SI ""Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine"", Kharkiv, Ukraine",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3129,570,50.049028,14.3137333,"Centre de r√©f√©rence des maladies neuromusculaire, Centre Hospitalier R√©gional de la Citadelle, Li√®ge, Belgium",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3130,570,55.6867243,12.5700724,"Rehabilitation Engineering Research Center, Taipei, Taiwan",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3131,NULL,NULL,NULL,"UCLA Medical Center, Los Angeles, California, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
3132,570,47.9960901,7.8494005,"Children's Hospital Colorado, Aurora, Colorado, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3133,570,47.4983815,19.0404707,"Nemours Children's Hospital, Orlando, Florida, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3134,570,46.0992396,9.27736793963108,"Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3135,570,42.6384261,12.674297,"Boston Children's Hospital, Boston, Massachusetts, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3136,570,52.2337172,21.0714111288323,"Washington University School of Medicine, Saint Louis, Missouri, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3137,570,51.1263106,16.9781963305126,"Columbia University Medical Center, New York, New York, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3138,570,56.839104,60.60825,"Duke Children's Hospital, Durham, North Carolina, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3139,570,55.7504461,37.6174943,"Doernbecher Children's Hospital, Portland, Oregon, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3140,570,55.7504461,37.6174943,"Children's Hospital of Philadelphia - Neurology, Philadelphia, Pennsylvania, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3141,570,59.938732,30.316229,"UT Southwestern Medical Center/Children's Medical Center Dallas, Dallas, Texas, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3142,570,54.726288,55.947727,"Primary Children's Medical Center (University of Utah), Salt Lake City, Utah, United States",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3143,570,48.7081906,44.5153353,"Sydney Children's Hospital, Sydney, New South Wales, Australia",571.0,NCT02268552,An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA),,Recruiting,No Results Available,Spinal Muscular Atrophy,Drug: branaplam,"Number of participants with adverse events (AEs), serious adverse events (SAEs)|Change from baseline in length|Change from baseline in pulse oximetry|Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2|Pharmacokinetic: AUC|In addition to the above for Part 2 - Change from baseline in feeding status|In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline|In addition to the above for Part 2 - Changes from baseline on the ability to site without support|Change from baseline in weight|Change from baseline in head circumference|Change from baseline in chest circumference|Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND)|Change from baseline in respiratory rate|Change from baseline in chest circumference during quiet breathing|Change from baseline in paradoxical breathing|Pharmacokinetic: Cmax",Novartis Pharmaceuticals|Novartis,All,Phase 1|Phase 2,44.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLMI070X2201,"April 2, 2015","July 23, 2020","July 23, 2020","October 20, 2014",,"July 26, 2019",,https://ClinicalTrials.gov/show/NCT02268552,182.0,100.0
3144,571,36.7014631,-118.7559974,"Royal Children's Hospital, Children's Neuroscience Centre, Parkville, Victoria, Australia",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3145,571,27.7567667,-81.4639835,"H√¥pital Universitaire des Enfants Reine FABIOLA (HUDERF), Brussels, Belgium",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3146,571,40.0796606,-89.4337288,"British Columbia Children's Hospital/UBC, Vancouver, British Columbia, Canada",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3147,571,42.3788774,-72.032366,"Hospital for Sick Children, Toronto, Ontario, Canada",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3148,571,38.7604815,-92.5617875,"Institut de Myologie, Paris, France",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3149,571,40.7127281,-74.0060152,"Universitatsklinikum Essen, Essen, Germany",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3150,571,50.000678,-86.000977,"Universtatsklinikum Freiburg, Zentrum fur Kinder-und Jugendmedizin , Abteilung Neuropadiatrie und Muskelerkrankungen, Freiburg, Germany",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3151,571,52.4760892,-71.8258668,"Istituto Giannina Gaslini, Centro Traslazionale di Miologia e Patologie Neurodegenerative, Genova, Italy",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3152,571,48.8566101,2.3514992,"Pediatric Neurology Unit, Catholic University, Rome, Italy",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3153,571,48.8566101,2.3514992,"Hyogo College of Medicine, Nishinomiya, Hyogo, Japan",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3154,571,41.9808038,12.7662312,"Tokyo Women's Medical University, Tokyo, Japan",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3155,571,41.9808038,12.7662312,"Seoul National University Hospital, Seoul, Korea, Republic of",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3156,571,45.6209,9.768893,"Hospital Universitario Vall d'Hebron, Barcelona, Spain",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3157,571,45.6209,9.768893,"Hospital Universitario La Paz, Pediatric Neurology Department, Madrid, Spain",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3158,571,52.0809856,5.12768396945229,"University of Gothenburg, The Queen Silvia Children's Hospital, Gothenburg, Sweden",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3159,571,52.0809856,5.12768396945229,"Hacettepe Children's Hospital, Ankara, Turkey",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3160,571,57.7072326,11.9670171,"UCL Institute of Child Health/Great Ormond Street, London, United Kingdom",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3161,571,57.7072326,11.9670171,"MRC Centre for Neuromuscular Diseases at Newcastle, Institute of Genetic Medicine Newcastle University, Newcastle, United Kingdom",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3162,571,47.5581077,7.5878261,"Neuromuscular Research Unit, Copenhagen, Denmark",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3163,571,47.5581077,7.5878261,"Pediatric Department, Children's Hospital, Faculty of Medicine, Ain Shams University, Cairo, Abassia, Egypt",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3164,571,39.9207774,32.854067,"National Taiwan University Hospital, Taipei, Taiwan,, Taiwan",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3165,571,39.9207774,32.854067,"Nationwide Children's Hospital, Columbus, Ohio, United States",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3166,571,51.5073219,-0.1276474,"Raymond Poincar√© Hospital, Garches, Hauts-de-Seine, France",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3167,571,51.5073219,-0.1276474,"Boston Children's Hospital, Boston, Massachusetts, United States",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3168,571,54.9738474,-1.6131572,"Columbia University Medical Center, New York, New York, United States",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3169,571,54.9738474,-1.6131572,"UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States",572.0,NCT02240355,A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH),,Terminated,No Results Available,"Muscular Atrophy, Spinal",Drug: RO6885247|Drug: placebo,"Safety: Incidence of adverse events (AEs)|Pharmacokinetics: RO6885247 plasma concentrations|Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval)|Pharmacodynamics: SMN protein levels in blood|Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP)|Effect of RO6885247 on Electrical Impedance Myography|Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood",Hoffmann-La Roche,All,Phase 1,9.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP29420|2014-002246-41,November 2014,July 2015,July 2015,"September 15, 2014",,"December 22, 2016",,https://ClinicalTrials.gov/show/NCT02240355,55.0,100.0
3170,572,49.9902794,36.2303893,"University of Utah School of Medicine, Salt Lake City, Utah, United States",573.0,NCT02235090,Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting,,Withdrawn,No Results Available,Spinal Muscular Atrophy|Neuromuscular Disorders,Other: Direct current stimulation of cervical spinal cord,Strength Changes from baseline measured by handheld myometry after spinal cord direct current stimulation of different intensity|Short time fluctuations of Hammersmith Functional Motor Scale indexes,Charitable Foundation Children with Spinal Muscular Atrophy,All,Not Applicable,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",CSMA-INPN-1,October 2016,"September 30, 2017","October 30, 2017","September 9, 2014",,"February 15, 2019",,https://ClinicalTrials.gov/show/NCT02235090,5.0,100.0
3171,573,50.6451381,5.5734203,"Basel, Switzerland",574.0,NCT02227823,Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3,EMOTAS,Unknown status,No Results Available,Spinal Muscular Atrophy Type 3,Drug: Pyridostigmine Bromide,Change from Baseline in the distance walked at 6-minute walk test at 6 months|Change from baseline of decrement at 6 months|Change from baseline of MFM-D1|Change from baseline of Moviplate values at 6 months|Change from baseline of the ratio at 6 minutes walk test at 6 months,Centre Hospitalier R√©gional de la Citadelle,All,Phase 2,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1376,July 2014,July 2017,July 2017,"August 28, 2014",,"August 28, 2014",,https://ClinicalTrials.gov/show/NCT02227823,6.0,100.0
3172,574,25.0375198,121.5636796,"Novartis Investigative Site, Orange, California, United States",575.0,NCT02227407,Reciprocating Gait Orthoses for Paraplegia Patients,UPGO,Unknown status,No Results Available,Myelomeningocele|Spinal Cord Injury|Spinal Muscular Atrophy,Device: RGOs(reciprocating gait orthoses),the difference of joint kinetic data in able-bodied subjects and RGO users|the difference of gait parameter in able-bodied subjects and RGO users|the difference of joint kinematic data in able-bodies subjects and RGO users,"National Taiwan University Hospital|National Science Council, Taiwan",All,Not Applicable,8.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,201305047RINC|200703061R,August 2013,December 2015,January 2016,"August 28, 2014",,"August 28, 2014",,https://ClinicalTrials.gov/show/NCT02227407,18.0,100.0
3173,575,,,"National Institutes of Health, Bethesda, Maryland, United States",576.0,NCT02218593,WREX Outcome Study,,Unknown status,No Results Available,Muscular Dystrophy|Arthrogryposis|Spinal Muscular Atrophy,Device: WREX orthosis,Activities of daily living,Nemours Children's Clinic,All,Not Applicable,42.0,Other,Interventional,Intervention Model: Single Group Assignment,579772-2,July 2014,October 2014,July 2015,"August 18, 2014",,"August 18, 2014",,https://ClinicalTrials.gov/show/NCT02218593,2.0,21.0
3174,576,36.7014631,-118.7559974,"Novartis Investigative Site, Columbus, Ohio, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3175,576,38.7251776,-105.6077167,"Novartis Investigative Site, Copenhagen, Denmark",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3176,576,27.7567667,-81.4639835,"Novartis Investigative Site, Ulm, Germany",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3177,576,40.0796606,-89.4337288,"Novartis Investigative Site, Padova, PD, Italy",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3178,576,42.3788774,-72.032366,"Rigshospitalet, Neuromuscular Research Unit, 3342, Copenhagen E, Denmark",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3179,576,38.7604815,-92.5617875,"University of Essen, Children`s Hospital, Dep. of Pediatric Pulmonology, Essen, NRW, Germany",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3180,576,40.7127281,-74.0060152,"Kalamazoo, Michigan, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3181,576,35.6729639,-79.0392919,"Salt Lake, Utah, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3182,576,43.9792797,-120.737257,"Necker Hospital, Paris, France",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3183,576,40.9699889,-77.7278831,"Stanford University Medical Center, Stanford, California, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3184,576,31.8160381,-99.5120986,"Nemours Children's Hospital, Orlando, Florida, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3185,576,39.4225192,-111.7143584,"Columbia University Medical Center, New York, New York, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3186,576,-31.8759835,147.2869493,"The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3187,576,-36.5986096,144.6780052,"Boston Children's Hospital, Boston, Massachusetts, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3188,576,50.8465573,4.351697,"Columbia University Medical Center, New York, New York, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3189,576,55.001251,-125.002441,"UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3190,576,50.000678,-86.000977,"University of Utah School of Medicine, Salt Lake City, Utah, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3191,576,48.8566101,2.3514992,"Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3192,576,51.457087,7.011429,"Nemours Children's Specialty Care, Jacksonville, Jacksonville, Florida, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3193,576,47.9960901,7.8494005,"Nemours Children's Hospital, Orlando, Florida, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3194,576,44.40726,8.9338624,"University of California - Davis, Davis, California, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3195,576,41.894802,12.4853384,"University of California - Los Angeles, Los Angeles, California, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3196,576,34.914934,134.860666,"Children's Hospital Colorado, Aurora, Colorado, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3197,576,35.6828387,139.7594549,"Children's National Medical Center, Washington, District of Columbia, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3198,576,42.9629533,47.5133551,"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3199,576,41.3828939,2.1774322,"Boston Children's Hospital, Boston, Massachusetts, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3200,576,40.4167047,-3.7035825,"Children's Mercy Hospital, Kansas City, Missouri, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3201,576,57.7072326,11.9670171,"Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3202,576,39.9207774,32.854067,"Columbia University Medical Center, New York, New York, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3203,576,51.5073219,-0.1276474,"State University of New York Upstate Medical Center, Syracuse, New York, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3204,576,53.0117627,-2.2273919,"Nationwide Children's Hospital, Columbus, Ohio, United States",577.0,NCT02193074,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy,ENDEAR,Terminated,Has Results,Spinal Muscular Atrophy,Drug: nusinersen|Procedure: Sham procedure,"Percentage of Motor Milestones Responders|Time to Death or Permanent Ventilation|Percentage of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Responders|Summary of Time to Death|Percentage of Participants Not Requiring Permanent Ventilation|Percentage of Compound Muscular Action Potential (CMAP) Responders|Time to Death or Permanent Ventilation in the Subgroup of Participants Below the Study Median Disease Duration|Time to Death or Permanent Ventilation in the Subgroup of Participants Above the Study Median Disease Duration|Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs) and Discontinuations Due to AEs|Number of Participants With AEs Corresponding to Changes in Hematology Values|Number of Participants With AEs Corresponding to Changes in Blood Chemistry Values|Number of Participants Meeting Selected Vital Sign Criteria Post-Baseline|Summary of Shifts in 12-lead Electrocardiogram (ECG) Results|Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values",Biogen,All,Phase 3,122.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 396443-CS3B|2013-004422-29,"August 19, 2014","November 21, 2016","November 21, 2016","July 17, 2014","July 28, 2017","July 28, 2017",,https://ClinicalTrials.gov/show/NCT02193074,210.0,100.0
3205,577,55.6867243,12.5700724,"Doernbecher Children's Hospital, Portland, Oregon, United States",578.0,NCT02156141,High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy,HIT in Kennedy,Completed,No Results Available,Spinal and Bulbar Muscular Atrophy|Healthy Subjects,Other: Supervised high intensity training|Other: Optional training|Other: Control period|Other: Unsupervised High intensity training,"Incremental test|Functional test|Self-rated muscle fatigue, muscle pain and activity level|Serum concentrations of Creatine Kinase (CK)|Activity level","Karen Brorup Heje Pedersen|Rigshospitalet, Denmark",Male,Not Applicable,10.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,H-4-2014-035,June 2014,June 2016,"June 1, 2016","June 5, 2014",,"February 5, 2018",,https://ClinicalTrials.gov/show/NCT02156141,18.0,70.0
3206,578,26.2540493,29.2675469,"Vanderbilt University, Nashville, Tennessee, United States",579.0,NCT02124616,National Registry for Egyptian Pediatric Neuromuscular Diseases,,Recruiting,No Results Available,Spinal Muscular Atrophy|Muscular Dystrophy|Muscle Diseases|Myasthenic Syndromes|Polyneuropathies,,Functional motor ability|Cardio-pulmonary function,Ain Shams University,All,,200.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,EGYPT PED-NMD 2014,April 2014,April 2020,December 2020,"April 28, 2014",,"April 28, 2014",,https://ClinicalTrials.gov/show/NCT02124616,1.0,18.0
3207,579,23.59829785,120.835363138175,"Children's Medical Center of Dallas, Dallas, Texas, United States",580.0,NCT02123186,Newborn Screening for Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Other: newborn screening test for SMA,numbers of newborn with spinal muscular atrophy,National Taiwan University Hospital,All,,120267.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201308058RIND,October 2013,October 2016,October 2016,"April 25, 2014",,"November 2, 2016",,https://ClinicalTrials.gov/show/NCT02123186,3.0,100.0
3208,580,40.2253569,-82.6881395,"University of Utah Health Sciences Center, Salt Lake City, Utah, United States",581.0,NCT02122952,Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1,,Completed,Has Results,Spinal Muscular Atrophy 1,Biological: AVXS-101,"Number of Participants That Experienced One Grade III or Higher Unanticipated, Treatment-related Toxicity That Presents With Clinical Symptoms and Requires Medical Treatment|Number of Participants Who Experienced (a) Requirement of ‚â•16-hour Respiratory Assistance Per Day Continuously for ‚â•2 Weeks in the Absence of an Acute Reversible Illness, Excluding Perioperative Ventilation, or (b) Death|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)","AveXis, Inc.",All,Phase 1,15.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVXS-101-CL-101,"May 5, 2014","December 15, 2017","December 15, 2017","April 25, 2014","May 10, 2019","May 10, 2019","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02122952/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02122952/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02122952,6.0,100.0
3209,581,48.8401859,2.19864122190608,"Boston Children's Hospital, Boston, Massachusetts, United States",582.0,NCT02061189,Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy (SMA),ExerASI,"Active, not recruiting",No Results Available,Infantile Spinal Muscular Atrophy of Type 2 or 3,Other: Physical exercise in a swimming pool during 6 months,Motor function measurement (MFM)|Hammersmith scale|Questionnaire on post-exercise physical well-being|Non invasive motor capacity assessment,Assistance Publique - H√¥pitaux de Paris,All,Not Applicable,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P120124|2013-A01331-44,March 2014,September 2019,March 2020,"February 12, 2014",,"October 12, 2018",,https://ClinicalTrials.gov/show/NCT02061189,5.0,10.0
3210,582,42.3788774,-72.032366,"Columbia University Medical Center, New York, New York, United States",583.0,NCT02052791,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|PK parameters of nusinersen (ISIS 396443) in CSF levels: Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen in CSF levels: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen in CSF levels: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf),Biogen,All,Phase 1,47.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS12,January 2014,January 2017,January 2017,"February 3, 2014",,"March 24, 2017",,https://ClinicalTrials.gov/show/NCT02052791,18.0,100.0
3211,582,40.7127281,-74.0060152,"UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States",583.0,NCT02052791,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|PK parameters of nusinersen (ISIS 396443) in CSF levels: Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen in CSF levels: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen in CSF levels: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf),Biogen,All,Phase 1,47.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS12,January 2014,January 2017,January 2017,"February 3, 2014",,"March 24, 2017",,https://ClinicalTrials.gov/show/NCT02052791,18.0,100.0
3212,582,31.8160381,-99.5120986,"University of Utah School of Medicine, Salt Lake City, Utah, United States",583.0,NCT02052791,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|PK parameters of nusinersen (ISIS 396443) in CSF levels: Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen in CSF levels: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen in CSF levels: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf),Biogen,All,Phase 1,47.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS12,January 2014,January 2017,January 2017,"February 3, 2014",,"March 24, 2017",,https://ClinicalTrials.gov/show/NCT02052791,18.0,100.0
3213,582,39.4225192,-111.7143584,"All India Institute of Medical Sciences, New Delhi, Delhi, India",583.0,NCT02052791,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Change from Baseline in concomitant medications|PK parameters of nusinersen (ISIS 396443) in CSF levels: Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen in CSF levels: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen in CSF levels: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf),Biogen,All,Phase 1,47.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS12,January 2014,January 2017,January 2017,"February 3, 2014",,"March 24, 2017",,https://ClinicalTrials.gov/show/NCT02052791,18.0,100.0
3214,583,47.5581077,7.5878261,"Natera, Inc, San Carlos, California, United States",584.0,NCT02044029,Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.,,Completed,No Results Available,"Healthy Volunteer, Muscular Atrophy, Spinal",,"Differences in quantitative muscle MRI based on fat content and T2 values|Disease progression, assessed through the Motor Function Measure test|Disease progression, assessed with the 6-minute Walk Test.|Levels of Survival of Motor Neuron (SMN) RNA|Levels of SMN proteins",Hoffmann-La Roche,All,,38.0,Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,BE29037,January 2014,July 2015,July 2015,"January 23, 2014",,"November 2, 2016",,https://ClinicalTrials.gov/show/NCT02044029,10.0,100.0
3215,584,36.7014631,-118.7559974,"Columbia University Medical Center, New York, New York, United States",585.0,NCT02024932,"Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",,Completed,Has Results,Spinal and Bulbar Muscular Atrophy,Drug: BVS857|Drug: Placebo,"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability|Number of Mild, Moderate and Severe Adverse Events as a Measure of Safety and Tolerability|Mean Percent Change From Baseline in Thigh Muscle Volume in Part B, Cohort 5|Mean Change From Baseline in Score on the Adult Myopathy Assessment Tool (AMAT) in Part B, Cohort 5|Mean Change From Baseline in Total Lean Body Mass (LBM) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)|Plasma Pharmacokinetics (PK) of BVS857: The Terminal Elimination Half-life (T1/2)|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf)|Compare Dose Normalized Log-transformed AUCinf Following IV and SC Administrations",Novartis Pharmaceuticals|Novartis,Male,Phase 2,37.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBVS857X2202,"February 4, 2014","April 13, 2016","April 13, 2016","December 31, 2013","August 11, 2017","April 10, 2019",,https://ClinicalTrials.gov/show/NCT02024932,18.0,100.0
3216,NULL,NULL,NULL,"National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville, Bethesda, Maryland, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
3217,NULL,NULL,NULL,"Children's Hospital Boston, Boston, Massachusetts, United States",,,,,,,,,,,,,,,,,,,,,,,,,,,
3218,584,55.6867243,12.5700724,"Columbia University Medical Center, New York, New York, United States",585.0,NCT02024932,"Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",,Completed,Has Results,Spinal and Bulbar Muscular Atrophy,Drug: BVS857|Drug: Placebo,"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability|Number of Mild, Moderate and Severe Adverse Events as a Measure of Safety and Tolerability|Mean Percent Change From Baseline in Thigh Muscle Volume in Part B, Cohort 5|Mean Change From Baseline in Score on the Adult Myopathy Assessment Tool (AMAT) in Part B, Cohort 5|Mean Change From Baseline in Total Lean Body Mass (LBM) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)|Plasma Pharmacokinetics (PK) of BVS857: The Terminal Elimination Half-life (T1/2)|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf)|Compare Dose Normalized Log-transformed AUCinf Following IV and SC Administrations",Novartis Pharmaceuticals|Novartis,Male,Phase 2,37.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBVS857X2202,"February 4, 2014","April 13, 2016","April 13, 2016","December 31, 2013","August 11, 2017","April 10, 2019",,https://ClinicalTrials.gov/show/NCT02024932,18.0,100.0
3219,584,48.3974003,9.9934336,"UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States",585.0,NCT02024932,"Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",,Completed,Has Results,Spinal and Bulbar Muscular Atrophy,Drug: BVS857|Drug: Placebo,"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability|Number of Mild, Moderate and Severe Adverse Events as a Measure of Safety and Tolerability|Mean Percent Change From Baseline in Thigh Muscle Volume in Part B, Cohort 5|Mean Change From Baseline in Score on the Adult Myopathy Assessment Tool (AMAT) in Part B, Cohort 5|Mean Change From Baseline in Total Lean Body Mass (LBM) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)|Plasma Pharmacokinetics (PK) of BVS857: The Terminal Elimination Half-life (T1/2)|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf)|Compare Dose Normalized Log-transformed AUCinf Following IV and SC Administrations",Novartis Pharmaceuticals|Novartis,Male,Phase 2,37.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBVS857X2202,"February 4, 2014","April 13, 2016","April 13, 2016","December 31, 2013","August 11, 2017","April 10, 2019",,https://ClinicalTrials.gov/show/NCT02024932,18.0,100.0
3220,584,45.391408,11.8058486771159,"University of Utah School of Medicine, Salt Lake City, Utah, United States",585.0,NCT02024932,"Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy",,Completed,Has Results,Spinal and Bulbar Muscular Atrophy,Drug: BVS857|Drug: Placebo,"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability|Number of Mild, Moderate and Severe Adverse Events as a Measure of Safety and Tolerability|Mean Percent Change From Baseline in Thigh Muscle Volume in Part B, Cohort 5|Mean Change From Baseline in Score on the Adult Myopathy Assessment Tool (AMAT) in Part B, Cohort 5|Mean Change From Baseline in Total Lean Body Mass (LBM) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 1|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part A, Cohort 2|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Observed Maximum Concentration Following Drug Administration (Cmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857: Time to Reach the Maximum Concentration After Drug Administration (Tmax) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 4|Plasma Pharmacokinetics (PK) of BVS857:The Area Under the Plasma Concentration-time Curve From Zero to 48 Hours (AUC0_48h) in Part B, Cohort 5|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)|Plasma Pharmacokinetics (PK) of BVS857: The Terminal Elimination Half-life (T1/2)|Plasma Pharmacokinetics (PK) of BVS857: The Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUCinf)|Compare Dose Normalized Log-transformed AUCinf Following IV and SC Administrations",Novartis Pharmaceuticals|Novartis,Male,Phase 2,37.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBVS857X2202,"February 4, 2014","April 13, 2016","April 13, 2016","December 31, 2013","August 11, 2017","April 10, 2019",,https://ClinicalTrials.gov/show/NCT02024932,18.0,100.0
3221,585,55.6867243,12.5700724,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",586.0,NCT02003937,Aerobic Training in Patients With Spinal Muscular Atrophy Type III,,Completed,No Results Available,Spinal Muscular Atrophy,Behavioral: Aerobic conditioning,Changes in oxidative capacity with aerobic conditioning in SMAIII patients|Changes in maximal workload capacity with aerobic conditioning in SMAIII patients|Changes in isometric muscle strength with aerobic conditioning in SMAIII patients|Changes in daily function with aerobic conditioning in SMAIII patients,"Rigshospitalet, Denmark",All,Not Applicable,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-KF297836,September 2009,September 2010,September 2010,"December 6, 2013",,"October 29, 2015",,https://ClinicalTrials.gov/show/NCT02003937,18.0,65.0
3222,586,51.4785568,7.5533645,"University Hospitals, Ghent, Belgium",587.0,NCT01981915,Optimum Insufflation Capacity in NMD,,Completed,No Results Available,Duchenne Muscular Dystrophy|Spinal Muscular Atrophy|Chronic Respiratory Insufficiency,Procedure: IPPB|Procedure: LIAM,insufflation capacity|Peak cough flow,Universit√§t Duisburg-Essen|Weinmann Ger√§te f√ºr Medizin GmbH + Co. KG,All,Not Applicable,40.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,OIC2013,January 2011,February 2013,March 2013,"November 13, 2013",,"November 13, 2013",,https://ClinicalTrials.gov/show/NCT01981915,6.0,100.0
3223,587,43.6211955,-84.6824346,"University Hospitals, Leuven, Belgium",588.0,NCT01910168,A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis,,Completed,No Results Available,"Muscular Atrophy, Spinal",,SMN1/SMN2 detection in blood by mRNA assay|SMN protein level in blood/lymphocytes,Hoffmann-La Roche|PTC Therapeutics,All,,36.0,Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,BE29002,August 2013,February 2014,February 2014,"July 29, 2013",,"November 2, 2016",,https://ClinicalTrials.gov/show/NCT01910168,18.0,100.0
3224,587,39.4225192,-111.7143584,"H√¥pital Femme-M√®re-Enfant, Bron, France",588.0,NCT01910168,A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis,,Completed,No Results Available,"Muscular Atrophy, Spinal",,SMN1/SMN2 detection in blood by mRNA assay|SMN protein level in blood/lymphocytes,Hoffmann-La Roche|PTC Therapeutics,All,,36.0,Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,BE29002,August 2013,February 2014,February 2014,"July 29, 2013",,"November 2, 2016",,https://ClinicalTrials.gov/show/NCT01910168,18.0,100.0
3225,588,48.8566101,2.3514992,"H√¥pital Raymond Poincar√©, Garches, France",589.0,NCT01862042,Palliative Care in Spinal Muscular Atrophy (SMA) 1,ASI1,Completed,No Results Available,Spinal Muscular Atrophy 1,Other: Follow-up diary and questionnaire,%O2|Qualitative evaluation of the practices of care|Evaluation of nutritional status|Evaluation of orthopedic facilities|Evaluation of comfort,Assistance Publique - H√¥pitaux de Paris,All,Not Applicable,39.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,P110135|2012-A00024-39,June 2012,"June 11, 2018","June 11, 2018","May 24, 2013",,"July 2, 2019",,https://ClinicalTrials.gov/show/NCT01862042,1.0,100.0
3226,589,36.7014631,-118.7559974,"CHRU H√¥pital R. Salengro, Lille, France",590.0,NCT01839656,"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,Spinal Muscular Atrophy,Drug: nusinersen,Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit|Event-free Survival at the End of Study|Percent of Participants With Improved Motor Function at the Last Visit as Assessed by the CHOP-INTEND Motor Function Scale|Change in Neuromuscular Electrophysiology at the Last Visit as Assessed by the Change From Baseline in CMAP Amplitude|Number of Participants Experiencing Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Concentration of Nusinersen in Cerebrospinal Fluid (CSF)|PK Parameters of Nusinersen in Plasma: Maximum Concentration (Cmax)|PK Parameters of Nusinersen in Plasma: Time to Reach Cmax (Tmax)|PK Parameters of Nusinersen in Plasma: Area Under the Plasma Concentrations Time Curve From the Time of the IT Dose to Four Hours After Dosing (AUC0-4),Biogen,All,Phase 2,21.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS3A|2017-000621-12,"May 8, 2013","August 21, 2017","August 21, 2017","April 25, 2013","October 30, 2018","October 30, 2018","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01839656,210.0,100.0
3227,589,27.7567667,-81.4639835,"H√¥pital La Timone, Marseille, France",590.0,NCT01839656,"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,Spinal Muscular Atrophy,Drug: nusinersen,Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit|Event-free Survival at the End of Study|Percent of Participants With Improved Motor Function at the Last Visit as Assessed by the CHOP-INTEND Motor Function Scale|Change in Neuromuscular Electrophysiology at the Last Visit as Assessed by the Change From Baseline in CMAP Amplitude|Number of Participants Experiencing Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Concentration of Nusinersen in Cerebrospinal Fluid (CSF)|PK Parameters of Nusinersen in Plasma: Maximum Concentration (Cmax)|PK Parameters of Nusinersen in Plasma: Time to Reach Cmax (Tmax)|PK Parameters of Nusinersen in Plasma: Area Under the Plasma Concentrations Time Curve From the Time of the IT Dose to Four Hours After Dosing (AUC0-4),Biogen,All,Phase 2,21.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS3A|2017-000621-12,"May 8, 2013","August 21, 2017","August 21, 2017","April 25, 2013","October 30, 2018","October 30, 2018","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01839656,210.0,100.0
3228,589,40.7127281,-74.0060152,"CHU de Montpellier, H√¥pital Gui de Chauliac, Montpellier, France",590.0,NCT01839656,"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,Spinal Muscular Atrophy,Drug: nusinersen,Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit|Event-free Survival at the End of Study|Percent of Participants With Improved Motor Function at the Last Visit as Assessed by the CHOP-INTEND Motor Function Scale|Change in Neuromuscular Electrophysiology at the Last Visit as Assessed by the Change From Baseline in CMAP Amplitude|Number of Participants Experiencing Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Concentration of Nusinersen in Cerebrospinal Fluid (CSF)|PK Parameters of Nusinersen in Plasma: Maximum Concentration (Cmax)|PK Parameters of Nusinersen in Plasma: Time to Reach Cmax (Tmax)|PK Parameters of Nusinersen in Plasma: Area Under the Plasma Concentrations Time Curve From the Time of the IT Dose to Four Hours After Dosing (AUC0-4),Biogen,All,Phase 2,21.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS3A|2017-000621-12,"May 8, 2013","August 21, 2017","August 21, 2017","April 25, 2013","October 30, 2018","October 30, 2018","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01839656,210.0,100.0
3229,589,50.000678,-86.000977,"Groupe hospitalier Armand-Trousseau, Paris, France",590.0,NCT01839656,"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)",,Completed,Has Results,Spinal Muscular Atrophy,Drug: nusinersen,Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit|Event-free Survival at the End of Study|Percent of Participants With Improved Motor Function at the Last Visit as Assessed by the CHOP-INTEND Motor Function Scale|Change in Neuromuscular Electrophysiology at the Last Visit as Assessed by the Change From Baseline in CMAP Amplitude|Number of Participants Experiencing Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Concentration of Nusinersen in Cerebrospinal Fluid (CSF)|PK Parameters of Nusinersen in Plasma: Maximum Concentration (Cmax)|PK Parameters of Nusinersen in Plasma: Time to Reach Cmax (Tmax)|PK Parameters of Nusinersen in Plasma: Area Under the Plasma Concentrations Time Curve From the Time of the IT Dose to Four Hours After Dosing (AUC0-4),Biogen,All,Phase 2,21.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS3A|2017-000621-12,"May 8, 2013","August 21, 2017","August 21, 2017","April 25, 2013","October 30, 2018","October 30, 2018","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01839656/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01839656,210.0,100.0
3230,590,42.3788774,-72.032366,"University of Essen, Essen, Germany",591.0,NCT01780246,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS10,January 2013,February 2014,February 2014,"January 31, 2013",,"April 4, 2017",,https://ClinicalTrials.gov/show/NCT01780246,2.0,15.0
3231,590,40.7127281,-74.0060152,"Universitat Klinikum Freiburg, Freiburg, Germany",591.0,NCT01780246,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS10,January 2013,February 2014,February 2014,"January 31, 2013",,"April 4, 2017",,https://ClinicalTrials.gov/show/NCT01780246,2.0,15.0
3232,590,31.8160381,-99.5120986,"Friedrich-Baur-Institute, Munchen, Germany",591.0,NCT01780246,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS10,January 2013,February 2014,February 2014,"January 31, 2013",,"April 4, 2017",,https://ClinicalTrials.gov/show/NCT01780246,2.0,15.0
3233,590,39.4225192,-111.7143584,"Istituto Giannina Gaslini, Genova, Italy",591.0,NCT01780246,An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701),,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,18.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443-CS10,January 2013,February 2014,February 2014,"January 31, 2013",,"April 4, 2017",,https://ClinicalTrials.gov/show/NCT01780246,2.0,15.0
3234,591,38.6920451,-75.4013315,"AOU Policlinico, Messina, Italy",592.0,NCT01754441,Mechanisms of Cell Death in Spinal Muscular Atrophy,,Unknown status,No Results Available,Spinal Muscular Atrophy,,SMN localization in SMA fibroblasts|SMN isoform mRNA levels|Protein levels of putative SMA phenotypic modifiers|cell viability in response to DNA damaging agents|SMN protein levels|cell viability in response to cell death-inducing agents|SMN2 copy number,Nemours Children's Clinic,All,,50.0,Other,Observational,Time Perspective: Prospective,82008,May 2008,December 2017,December 2017,"December 21, 2012",,"August 24, 2015",,https://ClinicalTrials.gov/show/NCT01754441,21.0,100.0
3235,591,27.7567667,-81.4639835,"Centro Dino Ferrari, Milano, Milano, Italy",592.0,NCT01754441,Mechanisms of Cell Death in Spinal Muscular Atrophy,,Unknown status,No Results Available,Spinal Muscular Atrophy,,SMN localization in SMA fibroblasts|SMN isoform mRNA levels|Protein levels of putative SMA phenotypic modifiers|cell viability in response to DNA damaging agents|SMN protein levels|cell viability in response to cell death-inducing agents|SMN2 copy number,Nemours Children's Clinic,All,,50.0,Other,Observational,Time Perspective: Prospective,82008,May 2008,December 2017,December 2017,"December 21, 2012",,"August 24, 2015",,https://ClinicalTrials.gov/show/NCT01754441,21.0,100.0
3236,591,27.7567667,-81.4639835,"NEuroMuscular Omnicentre (NEMO), Milano, Italy",592.0,NCT01754441,Mechanisms of Cell Death in Spinal Muscular Atrophy,,Unknown status,No Results Available,Spinal Muscular Atrophy,,SMN localization in SMA fibroblasts|SMN isoform mRNA levels|Protein levels of putative SMA phenotypic modifiers|cell viability in response to DNA damaging agents|SMN protein levels|cell viability in response to cell death-inducing agents|SMN2 copy number,Nemours Children's Clinic,All,,50.0,Other,Observational,Time Perspective: Prospective,82008,May 2008,December 2017,December 2017,"December 21, 2012",,"August 24, 2015",,https://ClinicalTrials.gov/show/NCT01754441,21.0,100.0
3237,592,36.7014631,-118.7559974,"Bambino Gesu' Research Children's Hospital, Roma, Italy",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3238,592,36.7014631,-118.7559974,"Policlinico Universitario ""Agostino Gemelli"",, Roma, Italy",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3239,592,38.7251776,-105.6077167,"University Medical Center, Utrecht, Netherlands",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3240,592,38.89366125,-76.987883253882,"Medical University of Warsaw, Warsaw, Poland",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3241,592,40.0796606,-89.4337288,"Birmingham Heartlands Hospital, Birmingham, United Kingdom",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3242,592,42.3788774,-72.032366,"Dubowitz Neuromuscular Centre, London, United Kingdom",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3243,592,38.7604815,-92.5617875,"Institute of Human Genetics, Newcastle, United Kingdom",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3244,592,38.7604815,-92.5617875,"University of Utah, Salt Lake City, Utah, United States",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3245,592,40.7127281,-74.0060152,"Columbia University SMA Clinical Research Center, New York, New York, United States",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3246,592,40.7127281,-74.0060152,"Hadassah Ein Kerem, Jerusalem, Israel",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3247,592,40.2253569,-82.6881395,"University of Bamako, Faculty of Medicine, Pharmacy and Dentistry (FMPOS), Bamako, Mali",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3248,592,43.9792797,-120.737257,"Section of Neuromuscular Disorders and Service of Child Neurology, Clinics Hospital of the School of Medicine at S√£o Paulo University, Sao PAulo, Brazil",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3249,592,35.7730076,-86.2820081,"Department of Rehabilitation Sciences, Lee Mitchener Tolbert Center for Develompental Disabilities, Oklahoma City, Oklahoma, United States",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3250,592,31.8160381,-99.5120986,"UDGEE Hospital S.Maria Nuova, Reggio Emilia, RE, Italy",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3251,592,39.4225192,-111.7143584,"Medical Genetics and Molecular Medicine Unit,, Department of Medicine, Ramathibodi Hospital, Bangkok, Thailand",593.0,NCT01736553,Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development,,Completed,Has Results,Spinal Muscular Atrophy (SMA),,Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI)|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)|Motor Function Assessments-Alberta Infant Motor Scale (AIMS)|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP)|Molecular Biomarkers- mRNA|Molecular Biomarkers- SMN Protein Levels|Putative Physiological Biomarkers-Weight|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- SMN Protein|Correlation of Biomarkers With Motor Function Tests for SMA Subjects- Weight|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- CMAP|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- mRNA|Correlation of Biomarkers With Motor Function Tests for Healthy Control Subjects- Weight|Biomarker Prediction of Risk of Death|Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) SMN Copy Number =2 Cohort|Motor Function Assessments- The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) SMN Copy Number =2 Cohort|Putative Physiological Biomarker- Compound Motor Action Potential Testing (CMAP) SMN Copy Number = 2 Cohort|Molecular Biomarkers- mRNA SMA Copy Number = 2 Cohort|Molecular Biomarkers- SMN Protein Levels SMA Copy Number = 2|Putative Physiological Biomarkers-Weight SMN Copy Number =2 Cohort|Correlation of CMAP Biomarker With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of mRNA Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Protein Level Biomarkers With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort|Correlation of Biomarkers (Weight) With Motor Function Tests for SMA Subjects SMN Copy Number =2 Cohort,Ohio State University|National Institute of Neurological Disorders and Stroke (NINDS)|Cure SMA|Massachusetts General Hospital|University of Iowa,All,,53.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN101|U01NS079163,December 2012,September 2015,September 2015,"November 29, 2012","May 4, 2018","May 4, 2018",,https://ClinicalTrials.gov/show/NCT01736553,6.0,100.0
3252,593,42.3788774,-72.032366,"University of Alabama at Birmingham, Birmingham, Alabama, United States",594.0,NCT01703988,"An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy",,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen,"Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs|Plasma Pharmacokinetics: Maximal Observed Plasma Drug Concentration (Cmax)|Plasma Pharmacokinetics: Time to Reach Cmax in Plasma|Plasma Pharmacokinetics: Plasma Pharmacokinetics: Area Under the Plasma Concentration Time Curve From the Time of the IT Dose to 6 Hours After Dosing (AUC0-6hr)|Cerebrospinal Fluid (CSF) Pharmacokinetics: Predose CSF Drug Concentrations|Urine Pharmacokinetics: Renal Clearance, Cohort 4",Biogen,All,Phase 1|Phase 2,34.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS2|2017-000327-27,October 2012,January 2015,January 2015,"October 11, 2012","March 13, 2017","March 13, 2017",,https://ClinicalTrials.gov/show/NCT01703988,2.0,15.0
3253,593,40.7127281,-74.0060152,"Stanford University, Stanford, California, United States",594.0,NCT01703988,"An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy",,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen,"Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs|Plasma Pharmacokinetics: Maximal Observed Plasma Drug Concentration (Cmax)|Plasma Pharmacokinetics: Time to Reach Cmax in Plasma|Plasma Pharmacokinetics: Plasma Pharmacokinetics: Area Under the Plasma Concentration Time Curve From the Time of the IT Dose to 6 Hours After Dosing (AUC0-6hr)|Cerebrospinal Fluid (CSF) Pharmacokinetics: Predose CSF Drug Concentrations|Urine Pharmacokinetics: Renal Clearance, Cohort 4",Biogen,All,Phase 1|Phase 2,34.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS2|2017-000327-27,October 2012,January 2015,January 2015,"October 11, 2012","March 13, 2017","March 13, 2017",,https://ClinicalTrials.gov/show/NCT01703988,2.0,15.0
3254,593,31.8160381,-99.5120986,"The Children's Hospital, Aurora, Colorado, United States",594.0,NCT01703988,"An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy",,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen,"Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs|Plasma Pharmacokinetics: Maximal Observed Plasma Drug Concentration (Cmax)|Plasma Pharmacokinetics: Time to Reach Cmax in Plasma|Plasma Pharmacokinetics: Plasma Pharmacokinetics: Area Under the Plasma Concentration Time Curve From the Time of the IT Dose to 6 Hours After Dosing (AUC0-6hr)|Cerebrospinal Fluid (CSF) Pharmacokinetics: Predose CSF Drug Concentrations|Urine Pharmacokinetics: Renal Clearance, Cohort 4",Biogen,All,Phase 1|Phase 2,34.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS2|2017-000327-27,October 2012,January 2015,January 2015,"October 11, 2012","March 13, 2017","March 13, 2017",,https://ClinicalTrials.gov/show/NCT01703988,2.0,15.0
3255,593,39.4225192,-111.7143584,"University of Iowa, Iowa City, Iowa, United States",594.0,NCT01703988,"An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy",,Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen,"Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs|Plasma Pharmacokinetics: Maximal Observed Plasma Drug Concentration (Cmax)|Plasma Pharmacokinetics: Time to Reach Cmax in Plasma|Plasma Pharmacokinetics: Plasma Pharmacokinetics: Area Under the Plasma Concentration Time Curve From the Time of the IT Dose to 6 Hours After Dosing (AUC0-6hr)|Cerebrospinal Fluid (CSF) Pharmacokinetics: Predose CSF Drug Concentrations|Urine Pharmacokinetics: Renal Clearance, Cohort 4",Biogen,All,Phase 1|Phase 2,34.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS2|2017-000327-27,October 2012,January 2015,January 2015,"October 11, 2012","March 13, 2017","March 13, 2017",,https://ClinicalTrials.gov/show/NCT01703988,2.0,15.0
3256,594,28.6517178,77.2219388,"Johns Hopkins Hospital, Baltimore, Maryland, United States",595.0,NCT01671384,Valproate and Levocarnitine in Children With Spinal Muscular Atrophy,,Unknown status,No Results Available,Spinal Muscular Atrophy,"Drug: Valproate, Levocarnitine|Drug: Placebo","Change in muscle power on a 5 point scale as per the principles of manual muscle testing at 12, 24, 36 and 52 weeks|a) Change in functional measure using modified Hammersmith Functional Motor Scale (MHFMS) score at 12, 24, 36 and 52 weeks 12, 24, 36 and 52 weeks.","All India Institute of Medical Sciences, New Delhi",All,Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Valproate and SMA,August 2013,December 2016,December 2016,"August 23, 2012",,"January 1, 2016",,https://ClinicalTrials.gov/show/NCT01671384,2.0,15.0
3257,595,36.7014631,-118.7559974,"Children's Hospital Boston, Boston, Massachusetts, United States",596.0,NCT01663584,Multi-disease Carrier Screening Test Validation,,Withdrawn,No Results Available,Spinal Muscular Atrophy (SMA)|Carrier Screening|Genetic Testing,Procedure: Blood draw,,"Natera, Inc.",All,,0.0,Industry,Observational,,Natera014,August 2012,June 2013,,"August 13, 2012",,"July 16, 2013",,https://ClinicalTrials.gov/show/NCT01663584,18.0,100.0
3258,596,40.7127281,-74.0060152,"Children's Hospital of Michigan, Detroit, Detroit, Michigan, United States",597.0,NCT01645787,Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: 4-aminopyridine|Drug: Placebo,"Six Minute Walk Test (6MWT) with Kinematic Evaluation of Gait|Hammersmith Functional Motor Scale, Expanded (HFMSE)|Manual Muscle Testing (MMT)/Hand Held Dynamometer (HHD)|Change in Motor Unit Number Estimation (MUNE)/Nerve Conduction Study (NCS)",Columbia University,All,Phase 2|Phase 3,11.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAI7400,June 2012,September 2015,September 2015,"July 20, 2012",,"May 18, 2016",,https://ClinicalTrials.gov/show/NCT01645787,18.0,50.0
3259,597,,,"Mayo Clinic Rochester, Rochester, Minnesota, United States",598.0,NCT01611610,Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe),,Completed,No Results Available,Spinal Muscular Atrophy,Other: Functional tests,Change from baseline in total score of Motor Function Measure at one year|Change from baseline of Pediatric Quality of Life Inventory Score at one year,"Institut de Myologie, France",All,Not Applicable,4.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),SMA Europe,May 2011,May 2013,May 2013,"June 5, 2012",,"March 5, 2014",,https://ClinicalTrials.gov/show/NCT01611610,30.0,18.0
3260,598,39.5162234,-76.9382069,"Washington University Medical School, St. Louis, Missouri, United States",599.0,NCT01547871,Infants With Spinal Muscular Atrophy Type I,,Terminated,No Results Available,Spinal Muscular Atrophy,,"The primary outcome of this pilot study is to demonstrate the feasibility of the study design and test the outcome measures in patients with SMA 1.|Secondary outcomes include evaluation for time of events, i.e., time of ventilator support for greater than or equal to 16 hours a day continuously for more than 2 weeks and time of death.",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,4.0,NIH,Observational,Time Perspective: Other,999912067|12-N-N067,"February 7, 2012",,"April 14, 2016","March 8, 2012",,"August 19, 2019",,https://ClinicalTrials.gov/show/NCT01547871,1.0,6.0
3261,599,,,"Columbia University SMA Clinical Research Center, New York, New York, United States",600.0,NCT01522079,Spinal Muscular Atrophy and Cardiac Autonomic Function,,Completed,No Results Available,Spinal Muscular Atrophy,Procedure: Air stacking manuever,Cardiac autonomic function,Centro Universit√°rio Augusto Motta,All,Not Applicable,9.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dias,January 2011,August 2011,October 2011,"January 31, 2012",,"January 31, 2012",,https://ClinicalTrials.gov/show/NCT01522079,5.0,25.0
3262,600,42.3788774,-72.032366,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",601.0,NCT01494701,"An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",SMNRx,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS1,"November 30, 2011","January 31, 2013","January 31, 2013","December 19, 2011",,"April 6, 2017",,https://ClinicalTrials.gov/show/NCT01494701,2.0,14.0
3263,600,40.7127281,-74.0060152,"The Ohio State University, Columbus, Ohio, United States",601.0,NCT01494701,"An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",SMNRx,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS1,"November 30, 2011","January 31, 2013","January 31, 2013","December 19, 2011",,"April 6, 2017",,https://ClinicalTrials.gov/show/NCT01494701,2.0,14.0
3264,600,31.8160381,-99.5120986,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",601.0,NCT01494701,"An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",SMNRx,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS1,"November 30, 2011","January 31, 2013","January 31, 2013","December 19, 2011",,"April 6, 2017",,https://ClinicalTrials.gov/show/NCT01494701,2.0,14.0
3265,600,39.4225192,-111.7143584,"Children's Medical Center - Dallas, Dallas, Texas, United States",601.0,NCT01494701,"An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",SMNRx,Completed,No Results Available,Spinal Muscular Atrophy,Drug: nusinersen,"Number of participants that experience Adverse Events (AEs) and Serious Adverse Events|Number of participants with clinically significant neurological examination abnormalities|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant weight abnormalities|Number of participants with clinically significant laboratory parameters|Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants who use concomitant medications|PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)|PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)|PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)|PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible",Biogen,All,Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISIS 396443 - CS1,"November 30, 2011","January 31, 2013","January 31, 2013","December 19, 2011",,"April 6, 2017",,https://ClinicalTrials.gov/show/NCT01494701,2.0,14.0
3266,601,40.2253569,-82.6881395,"University of Utah, Salt lake City, Utah, United States",602.0,NCT01422200,Flu Vaccine Study in Neuromuscular Patients 2011,,Unknown status,No Results Available,Duchenne Muscular Dystrophy|Spinal Muscular Atrophy|Congenital Muscular Dystrophy,Biological: 2011-2012 seasonal flu vaccine,Immunogenicity|safety,"Children's Hospital Medical Center, Cincinnati",All,Not Applicable,30.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2010-2319,August 2011,December 2011,March 2012,"August 23, 2011",,"August 23, 2011",,https://ClinicalTrials.gov/show/NCT01422200,3.0,35.0
3267,602,51.0538286,3.7250121,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3268,602,50.879202,4.7011675,"Children's Hospital - London Health Sciences Center, London, Ontario, Canada",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3269,602,45.7337532,4.9092352,"The Hospital for Sick Children, Toronto, Ontario, Canada",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3270,602,48.8437486,2.1853699,"CHU Clermont Ferrand, Clermont Ferrand, France",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3271,602,50.6365654,3.0635282,"CHU Grenoble, Grenoble, France",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3272,602,43.2961743,5.3699525,"H√¥pital de la Croix Rousse, Lyon, France",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3273,602,43.6112422,3.8767337,"H√¥pital Nord CHU St Etienne, St Etienne, France",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3274,602,48.8566101,2.3514992,"Johns Hopkins University, Baltimore, Maryland, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3275,602,51.457087,7.011429,"Children's Hospital of Michigan, Detroit, Michigan, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3276,602,47.9960901,7.8494005,"Duke University Medical Center, Durham, North Carolina, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3277,602,48.1371079,11.5753822,"Ohio State University Medical Center, Dept. of Neurology, Columbus, Ohio, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3278,602,44.40726,8.9338624,"University of Utah/Primary Children's Medical Center, Salt Lake City, Utah, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3279,602,38.1937571,15.5542082,"University of Wisconsin Children's Hospital, Madison, Wisconsin, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3280,602,45.4667971,9.1904984,"Hospital Sainte-Justine, Montreal, Quebec, Canada",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3281,602,45.4667971,9.1904984,"Klinikum der Universit√§t zu K√∂ln, Cologne, Germany",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3282,602,41.894802,12.4853384,"Stanford University School of Medicine, Stanford, California, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3283,602,41.894802,12.4853384,"Stanford University School of Medicine, Stanford, California, United States",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3284,602,52.0809856,5.12768396945229,"von Haunersches Kinderspital, Munich, Bavaria, Germany",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3285,602,52.2337172,21.0714111288323,"University Children'S Hospital, G√∂ttingen, Niedersachsen, Germany",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3286,602,52.4775396,-1.894053,"University Children'S Hospital, Essen, Nordrhein-Westfalen, Germany",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3287,602,51.5073219,-0.1276474,"University Children'S Hospital, Mainz, Rheinland Pfalz, Germany",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3288,602,53.0117627,-2.2273919,"University Children'S Hospital, Kiel, Schleswig-Holstein, Germany",603.0,NCT01302600,Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.,,Completed,No Results Available,Spinal Muscular Atrophy Type II|Spinal Muscular Atrophy Type III Non Ambulant,Drug: Olesoxime|Drug: Placebo,"Motor Function Measure|responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety","Hoffmann-La Roche|Association Fran√ßaise contre les Myopathies (AFM), Paris",All,Phase 2,165.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WN29836|TRO19622 CL E Q 1275-1,November 2010,October 2013,October 2013,"February 24, 2011",,"November 22, 2016",,https://ClinicalTrials.gov/show/NCT01302600,3.0,25.0
3289,603,39.4225192,-111.7143584,"Charit√©, Department of Neurpaediatrics, Berlin, Germany",604.0,NCT01233817,Progressive Strength Training in Spinal Muscular Atrophy,,Completed,Has Results,"Muscular Atrophy, Spinal",Other: Progressive strength training,Strength,University of Utah,All,Not Applicable,12.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,39995,June 2010,June 2013,June 2013,"November 3, 2010","March 12, 2013","June 14, 2017",,https://ClinicalTrials.gov/show/NCT01233817,5.0,21.0
3290,604,40.7127281,-74.0060152,"University of Utah, Salt Lake City, Utah, United States",605.0,NCT01166022,Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA),,Completed,No Results Available,Spinal Muscular Atrophy|Neuromuscular Disease,Other: Exercise,Distance walked in the Six Minute Walk Test (6MWT).,Columbia University,All,Not Applicable,14.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AAAE8200|A-15886,December 2010,August 2014,August 2014,"July 20, 2010",,"August 12, 2016",,https://ClinicalTrials.gov/show/NCT01166022,8.0,50.0
3291,605,31.778345,35.2250786,"Kaohsiung Medical University Hospital, Kaohsiung, Taiwan",606.0,NCT00874783,Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases,,Recruiting,No Results Available,Neurodegenerative Disorders,,,Hadassah Medical Organization,All,,120.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,0599-08-HMO-CTIL,April 2009,December 2025,December 2025,"April 3, 2009",,"August 20, 2019",,https://ClinicalTrials.gov/show/NCT00874783,18.0,100.0
3292,606,12.60503275,-7.98651367343936,"Ohio State University Medical Center, Dept. of Neurology, Columbus, Ohio, United States",607.0,NCT01059240,"SMN Copy Number Distribution in Mali, West Africa",,Completed,No Results Available,Spinal Muscular Atrophy,,Primary outcome measure for phase 1 is DNA extraction yield of sufficient quantity and quality for SMN genotyping in at least 90% of samples|Secondary outcome measures for phase 2 are the frequency of SMA carriers (SMN1 deletion heterozygotes) and the SMN1 and SMN2 copy number distribution in Mali.,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,701.0,NIH,Observational,Time Perspective: Prospective,999910033|10-N-N033,"January 21, 2010",,"May 18, 2017","January 29, 2010",,"August 8, 2019",,https://ClinicalTrials.gov/show/NCT01059240,18.0,100.0
3293,607,-23.5506507,-46.6333824,"Indiana University School of Medicine, Indianapolis, Indiana, United States",608.0,NCT01033331,Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy(SMA) Treated With Valproic Acid,,Completed,No Results Available,Spinal Muscular Atrophy,,"Manual Muscle Test (Medical Research Council scale-MRC), the Hammersmith Motor Ability Score|Barthel Index",University of Sao Paulo General Hospital,All,,22.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,290/06|CAPES9030,July 2006,August 2008,December 2008,"December 16, 2009",,"December 16, 2009",,https://ClinicalTrials.gov/show/NCT01033331,2.0,18.0
3294,608,34.9550817,-97.2684063,"Columbia University SMA Clinical Research Center, New York, New York, United States",609.0,NCT01028833,Effects of Power Mobility on Young Children With Severe Motor Impairments,,Completed,No Results Available,Cerebral Palsy|Arthrogryposis|Spinal Muscular Atrophy|Other Central Nervous System or Musculoskeletal Disorders,Other: Power mobility,Merrill-Palmer-Revised|Pediatric Evaluation of Disability Inventory|Child Health Status|Two-position object permanence test|Nonspeech Test|Home Observation Measure of the Environment|Parenting Stress Inventory|Center for Epidemiologic Studies Depression Scale (CES-D)|Hollingshead Scale,University of Oklahoma,All,Phase 2,41.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2480,November 2008,December 2012,December 2012,"December 9, 2009",,"January 14, 2016",,https://ClinicalTrials.gov/show/NCT01028833,14.0,30.0
3295,609,44.608664,10.5947968418927,"University of Utah/Primary Children's Medical Center, Salt Lake City, Utah, United States",610.0,NCT00961103,Motor Development and Orthoses in Spinal Muscular Atrophy (SMA),,Unknown status,No Results Available,Spinal Muscular Atrophy,,"time and percentage of sitting, standing, walking achievement in SMA II and SMA III|characteristics and percentage of orthoses for postural sitting control , standing and walking in SMA II and SMA III",Arcispedale Santa Maria Nuova-IRCCS,All,,70.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,UDGEE-SMA,September 2009,November 2009,December 2009,"August 18, 2009",,"August 18, 2009",,https://ClinicalTrials.gov/show/NCT00961103,18.0,100.0
3296,610,13.7538929,100.8160803,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",611.0,NCT00851461,Effect of Goserelin (Zoladex¬Æ) in Spinal and Bulbar Muscular Atrophy,,Completed,No Results Available,Spinobulbar Muscular Atrophy|Kennedy's Disease,Drug: Goserelin|Procedure: Electrophysiologic study|Procedure: tissue biopsy,muscle power|electrophysiologic study (Nerve conduction and Electromyogram),Ramathibodi Hospital|AstraZeneca,Male,Phase 4,10.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID11-50-17,April 2008,November 2011,November 2013,"February 26, 2009",,"May 21, 2015",,https://ClinicalTrials.gov/show/NCT00851461,20.0,100.0
3297,611,33.2588817,-86.8295337,"Johns Hopkins University, Baltimore, Maryland, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3298,611,36.7014631,-118.7559974,"Children's Hospital of Michigan, Detroit, Michigan, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3299,611,38.7251776,-105.6077167,"Ohio State University, Columbus, Ohio, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3300,611,41.9216734,-93.3122705,"University of Utah/Primary Children's Medical Center, Salt Lake City, Utah, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3301,611,39.5162234,-76.9382069,"University of Wisconsin Children's Hospital, Madison, Wisconsin, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3302,611,42.3788774,-72.032366,"Hospital Sainte-Justine, Montreal, Quebec, Canada",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3303,611,43.6211955,-84.6824346,"Dept of Medical Genetics;National Taiwan University Hospital, Taipei, Taiwan",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3304,611,45.9896587,-94.6113288,"Dept of Medical Genetics;National Taiwan University Hospital, Taipei, Taiwan",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3305,611,38.7604815,-92.5617875,"Merz Clinical Site, LaJolla, California, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3306,611,40.7127281,-74.0060152,"Merz Clinical Site, Sacramento, California, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3307,611,40.2253569,-82.6881395,"Merz Clinical Site, Augusta, Georgia, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3308,611,40.2253569,-82.6881395,"Merz Clinical Site, Boston, Massachusetts, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3309,611,40.9699889,-77.7278831,"Merz Clinical Site, Burlington, Massachusetts, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3310,611,31.8160381,-99.5120986,"Merz Clinical Site 0010334, New York, New York, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3311,611,39.4225192,-111.7143584,"Merz Clinical Site 0010068, New York, New York, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3312,611,44.4308975,-89.6884637,"Merz Clinical Site 0010333, Sleepy Hollow, New York, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3313,611,50.000678,-86.000977,"Merz Clinical Site, Durham, North Carolina, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3314,611,50.000678,-86.000977,"Merz Clinical Site 0010332, Pittsburgh, Pennsylvania, United States",612.0,NCT00756821,A Pilot Study of Biomarkers for Spinal Muscular Atrophy,BforSMA,Completed,No Results Available,Spinal Muscular Atrophy,,"To identify candidate blood and urine biochemical markers that correlate with disease severity as determined by the Modified Hammersmith Functional Motor Scale across a range of type I, type II and type III children with Spinal Muscular Atrophy (SMA)|To determine if there are biomarkers from types I-III SMA patients that correlate with SMA type, age at disease onset, 10-meter Timed Walk Test, pulmonary function, nutritional assessment, SMN protein level, SMN transcript level or SMN2 copy number.|To determine if identified candidate biomarkers are associated with the disease state through comparison of SMA specimens with control volunteer specimens.",New England Research Institutes|The Spinal Muscular Atrophy Foundation,All,,130.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,BforSMA,October 2008,March 2009,March 2009,"September 22, 2008",,"October 24, 2012",,https://ClinicalTrials.gov/show/NCT00756821,2.0,12.0
3315,612,45.7774551,3.0819427,"Merz Clinical Site, Houston, Texas, United States",613.0,NCT02936908,Respiratory Care in Intensive Care Unit for Neuromuscular Patients,,Unknown status,No Results Available,Respiratory Failure,Other: Ventilatory support,Mortality|Definitive long term invasive ventilatory support|Mortality attributable to a respiratory issue|Re-hospitalization in a ICU-Ward,Hospices Civils de Lyon,All,,300.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,69HCL16_0558,August 2016,October 2017,October 2017,"October 18, 2016",,"August 29, 2017",,https://ClinicalTrials.gov/show/NCT02936908,18.0,100.0
3316,612,45.1875602,5.7357819,"Merz Clinical Site, Norfolk, Virginia, United States",613.0,NCT02936908,Respiratory Care in Intensive Care Unit for Neuromuscular Patients,,Unknown status,No Results Available,Respiratory Failure,Other: Ventilatory support,Mortality|Definitive long term invasive ventilatory support|Mortality attributable to a respiratory issue|Re-hospitalization in a ICU-Ward,Hospices Civils de Lyon,All,,300.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,69HCL16_0558,August 2016,October 2017,October 2017,"October 18, 2016",,"August 29, 2017",,https://ClinicalTrials.gov/show/NCT02936908,18.0,100.0
3317,612,45.6963425,4.73594802991681,"Sanguine Biosciences, Los Angeles, California, United States",613.0,NCT02936908,Respiratory Care in Intensive Care Unit for Neuromuscular Patients,,Unknown status,No Results Available,Respiratory Failure,Other: Ventilatory support,Mortality|Definitive long term invasive ventilatory support|Mortality attributable to a respiratory issue|Re-hospitalization in a ICU-Ward,Hospices Civils de Lyon,All,,300.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,69HCL16_0558,August 2016,October 2017,October 2017,"October 18, 2016",,"August 29, 2017",,https://ClinicalTrials.gov/show/NCT02936908,18.0,100.0
3318,612,45.4401467,4.3873058,"University of Wisconsin Madison, Madison, Wisconsin, United States",613.0,NCT02936908,Respiratory Care in Intensive Care Unit for Neuromuscular Patients,,Unknown status,No Results Available,Respiratory Failure,Other: Ventilatory support,Mortality|Definitive long term invasive ventilatory support|Mortality attributable to a respiratory issue|Re-hospitalization in a ICU-Ward,Hospices Civils de Lyon,All,,300.0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,69HCL16_0558,August 2016,October 2017,October 2017,"October 18, 2016",,"August 29, 2017",,https://ClinicalTrials.gov/show/NCT02936908,18.0,100.0
3319,613,39.5162234,-76.9382069,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3320,613,43.6211955,-84.6824346,"Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3321,613,35.6729639,-79.0392919,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3322,613,40.2253569,-82.6881395,"['Ohio', 'United States']",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3323,613,39.4225192,-111.7143584,"['Utah', 'United States']",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3324,613,44.4308975,-89.6884637,"['Wisconsin', 'United States']",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3325,613,52.4760892,-71.8258668,"['Quebec', 'Canada']",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3326,613,50.938361,6.959974,"['Cologne', 'Germany']",614.0,NCT00661453,CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I,,Completed,Has Results,Spinal Muscular Atrophy Type I,Drug: Valproic Acid and Levocarnitine,"Laboratory Safety Data|Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)|Time to Death or Ventilator Dependence (Defined as >16 Hours/Day)|Primary Caregiver Functional Rating Scale for SMA Type I Subjects (PCFRS)|Functional Motor Assessments: TIMPSI Scores|Quantitative SMN mRNA and Protein Measures|Maximum Ulnar CMAP Amplitude/Area and MUNE|Whole Body DEXA Scanning for Lean Body Mass and Total Bone Mineral Density/ Content","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.",All,Phase 1|Phase 2,40.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,25409|IND 79276,April 2008,May 2012,June 2012,"April 18, 2008","June 15, 2015","June 15, 2015",,https://ClinicalTrials.gov/show/NCT00661453,12.0,100.0
3327,614,36.7014631,-118.7559974,"['California', 'United States']",615.0,NCT00568802,A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients,,Unknown status,No Results Available,"Muscular Atrophy, Spinal",Drug: Hydroxyurea,"Efficacy: Functional Motor Testing, including Gross Motor Function Measure (GMFM) and Timed Motor Tests|Safety: Frequency of Adverse Events/Lab Abnormalities|Pulmonary Function Testing|Motor Unit Number Estimation (MUNE)|Biomarker Assays: SMN Protein and SMN mRNA",Stanford University,All,Phase 1|Phase 2,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,SU-11012007-781|79233,January 2004,,,"December 6, 2007",,"December 3, 2008",,https://ClinicalTrials.gov/show/NCT00568802,1.0,10.0
3328,615,36.7014631,-118.7559974,"['California', 'United States']",616.0,NCT00568698,A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: Hydroxyurea,Safety: Frequency of Adverse Events/Lab Abnormalities|Efficacy: Length of survival (LOS) and age of ventilator dependence (AVD)|Motor Unit Number Estimation (MUNE)|Biomarker Assays: SMN Protein and SMN mRNA,Stanford University,All,Phase 1|Phase 2,18.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,SU-11012007-783|78811,January 2004,November 2008,November 2008,"December 6, 2007",,"July 8, 2009",,https://ClinicalTrials.gov/show/NCT00568698,2.0,100.0
3329,616,48.9467562,11.4038717,"['Bavaria', 'Germany']",617.0,NCT00533221,Pilot Study of Growth Hormon to Treat SMA Typ II and III,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: somatotropin|Drug: Placebo,"Primary: sum of strength (hand held myometry)|Functional (time) tests, lung function, quality of life,",University Hospital Freiburg|Novo Nordisk A/S,All,Phase 2,20.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-GH|2005-002822-78,October 2007,February 2010,August 2011,"September 21, 2007",,"December 18, 2013",,https://ClinicalTrials.gov/show/NCT00533221,6.0,35.0
3330,616,52.8398531,9.075962,"['Niedersachsen', 'Germany']",617.0,NCT00533221,Pilot Study of Growth Hormon to Treat SMA Typ II and III,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: somatotropin|Drug: Placebo,"Primary: sum of strength (hand held myometry)|Functional (time) tests, lung function, quality of life,",University Hospital Freiburg|Novo Nordisk A/S,All,Phase 2,20.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-GH|2005-002822-78,October 2007,February 2010,August 2011,"September 21, 2007",,"December 18, 2013",,https://ClinicalTrials.gov/show/NCT00533221,6.0,35.0
3331,616,51.4785568,7.5533645,"['Nordrhein-Westfalen', 'Germany']",617.0,NCT00533221,Pilot Study of Growth Hormon to Treat SMA Typ II and III,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: somatotropin|Drug: Placebo,"Primary: sum of strength (hand held myometry)|Functional (time) tests, lung function, quality of life,",University Hospital Freiburg|Novo Nordisk A/S,All,Phase 2,20.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-GH|2005-002822-78,October 2007,February 2010,August 2011,"September 21, 2007",,"December 18, 2013",,https://ClinicalTrials.gov/show/NCT00533221,6.0,35.0
3332,616,49.7497346,7.4396553,"['Rheinland Pfalz', 'Germany']",617.0,NCT00533221,Pilot Study of Growth Hormon to Treat SMA Typ II and III,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: somatotropin|Drug: Placebo,"Primary: sum of strength (hand held myometry)|Functional (time) tests, lung function, quality of life,",University Hospital Freiburg|Novo Nordisk A/S,All,Phase 2,20.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-GH|2005-002822-78,October 2007,February 2010,August 2011,"September 21, 2007",,"December 18, 2013",,https://ClinicalTrials.gov/show/NCT00533221,6.0,35.0
3333,616,54.1853998,9.8220089,"['Schleswig-Holstein', 'Germany']",617.0,NCT00533221,Pilot Study of Growth Hormon to Treat SMA Typ II and III,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: somatotropin|Drug: Placebo,"Primary: sum of strength (hand held myometry)|Functional (time) tests, lung function, quality of life,",University Hospital Freiburg|Novo Nordisk A/S,All,Phase 2,20.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-GH|2005-002822-78,October 2007,February 2010,August 2011,"September 21, 2007",,"December 18, 2013",,https://ClinicalTrials.gov/show/NCT00533221,6.0,35.0
3334,616,52.5170365,13.3888599,"['Berlin', 'Germany']",617.0,NCT00533221,Pilot Study of Growth Hormon to Treat SMA Typ II and III,,Completed,No Results Available,"Muscular Atrophy, Spinal",Drug: somatotropin|Drug: Placebo,"Primary: sum of strength (hand held myometry)|Functional (time) tests, lung function, quality of life,",University Hospital Freiburg|Novo Nordisk A/S,All,Phase 2,20.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-GH|2005-002822-78,October 2007,February 2010,August 2011,"September 21, 2007",,"December 18, 2013",,https://ClinicalTrials.gov/show/NCT00533221,6.0,35.0
3335,617,39.4225192,-111.7143584,"['Utah', 'United States']",618.0,NCT00528268,Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy,STOPSMA,Completed,Has Results,Spinal Muscular Atrophy,Drug: Sodium phenylbutyrate (NaPB),"The Study Will Assess the Safety, Tolerability and Potential Efficacy of Sodium Phenylbutyrate (NaPB) in Presymptomatic Infants Genetically Confirmed to Have SMA. It Will Also Determine Selected Pharmacokinetic Parameters.|The Study Will Determine Potential Benefit of NaPB on Lean Body Mass; Overall Motor Function; Potential Cellular Response to NaPB; and Drug Compliance.",University of Utah|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,Phase 1|Phase 2,14.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,22183|1R01HD054599-01,July 2007,December 2013,December 2013,"September 12, 2007","July 3, 2015","July 3, 2015",,https://ClinicalTrials.gov/show/NCT00528268,6.0,100.0
3336,618,22.6203348,120.3120375,"['Kaohsiung', 'Taiwan']",619.0,NCT00485511,A Trial of Hydroxyurea in Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Hydroxyurea,,Kaohsiung Medical University Chung-Ho Memorial Hospital,All,Phase 2|Phase 3,,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,DOH96-TD-I-111-TM103,June 2007,June 2009,June 2009,"June 13, 2007",,"February 15, 2010",,https://ClinicalTrials.gov/show/NCT00485511,4.0,100.0
3337,619,40.2253569,-82.6881395,"['Ohio', 'United States']",620.0,NCT00481013,Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy,VALIANTSMA,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Valproic Acid (VPA)|Drug: Placebo,"The primary outcome for the study is change in muscle strength from baseline to six months in muscle strength as assessed by MVICT using a fixed testing system.|Change in SMAFRS|Change in strength assessed by hand-held dynamometer|Change in MUNE and CMAP|SMN2 copy number|Change in PFTs, including forced vital capacity (FVC) and negative inspiratory force (NIF)|Change in lean body mass through DEXA scanning|Change in distance walked in 6 minutes|Change in time to climb four standard stairs|Change in health-related QOL assessed through the modified sickness impact profile (SIP)",University of Utah|Families of Spinal Muscular Atrophy|Abbott,All,Phase 2,33.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2006H0249,July 2007,December 2009,November 2010,"June 1, 2007",,"December 6, 2016",,https://ClinicalTrials.gov/show/NCT00481013,18.0,60.0
3338,620,40.3270127,-86.1746933,"['Indiana', 'United States']",621.0,NCT00466349,International SMA Patient Registry,,Completed,No Results Available,"Muscular Atrophy, Spinal",,Study is a patient registry,Indiana University School of Medicine|Cure SMA|Indiana University,All,,3000.0,Other,Observational,Observational Model: Family-Based|Time Perspective: Other,0202-03,May 1986,January 2018,January 2018,"April 27, 2007",,"August 7, 2018",,https://ClinicalTrials.gov/show/NCT00466349,18.0,100.0
3339,621,40.7127281,-74.0060152,"['New York', 'United States']",622.0,NCT00443066,Clinical Study of Spinal Muscular Atrophy,,"Active, not recruiting",No Results Available,Spinal Muscular Atrophy,,Hammersmith Functional Motor Scale Expanded (HFMSE)|Gross Motor Function Scale (GMFM),Columbia University|The Spinal Muscular Atrophy Foundation,All,,120.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,AAAB1635|CU52029001,May 2005,October 2020,December 2022,"March 5, 2007",,"April 9, 2019",,https://ClinicalTrials.gov/show/NCT00443066,18.0,100.0
3340,622,39.4225192,-111.7143584,"['Utah', 'United States']",623.0,NCT00374075,Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy,,Completed,No Results Available,Spinal Muscular Atrophy,Drug: Valproic Acid,"To assess safety and tolerability of VPA in SMA patients greater than 2 years of age|To look for a potential in vivo effect of VPA on SMN mRNA in patient blood cells at routinely used clinical doses|Measures of gross motor function|Electrophysiologic measures of denervation|DEXA estimates of body composition, bone mineral density and content|Measures of pulmonary function","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 1,42.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11893,September 2003,,February 2006,"September 8, 2006",,"August 23, 2016",,https://ClinicalTrials.gov/show/NCT00374075,2.0,100.0
3341,623,39.5162234,-76.9382069,"['Maryland', 'United States']",624.0,NCT00303446,Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA),,Completed,Has Results,Kennedy's Disease|Spinal and Bulbar Muscular Atrophy,Drug: Dutasteride|Drug: Placebo,"Muscle Strength Change From Baseline|Creatine Kinase, Change From Baseline|Manual Muscle Testing, Change From Baseline.|Adult Myopathy Assessment Tool, Change From Baseline|Timed 2-minute Walk, Change From Baseline|Swallow Score Average, Change From Baseline|Bulbar Rating Scale, Change From Baseline|Sensory Nerve Action Potential Average, Change From Baseline|Median Compound Muscle Action Potential, Change From Baseline|Peroneal Compound Muscle Action Potential, Change From Baseline|Motor Unit Nerve Estimation, Change From Baseline|Activities of Daily Living, Change From Baseline|Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline|Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline|International Index for Erectile Function (IIEF), Change From Baseline",National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),Male,Phase 2,57.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",060113|06-N-0113,March 2006,December 2009,December 2009,"March 16, 2006","June 22, 2010","January 27, 2011",,https://ClinicalTrials.gov/show/NCT00303446,18.0,100.0
3342,624,39.5162234,-76.9382069,"['Maryland', 'United States']",625.0,NCT00227266,Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy,,Completed,Has Results,Spinal Muscular Atrophy,Drug: Valproic Acid and Levocarnitine|Drug: Placebo,"Safety Labs|Efficacy, Measured Through Motor Function Assessments|Modified Hammersmith Change From Baseline to 6 Months|Quantitative Assessment of SMN mRNA From Blood Samples|Peds QL‚Ñ¢ Assessment: Parental Version (All), Child Versions (> 5yrs)|Max CMAP Amplitude (Mean)|Max CMAP Amplitude Median|Ulnar MUNE|Growth and Vital Sign Parameters|Nutritional Status|DEXA|Max CMAP Area (Mean)|Max CMAP Area (Median)","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 2,94.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13698,September 2005,November 2007,November 2007,"September 27, 2005","May 3, 2011","September 26, 2011",,https://ClinicalTrials.gov/show/NCT00227266,2.0,17.0
3343,624,43.6211955,-84.6824346,"['Michigan', 'United States']",625.0,NCT00227266,Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy,,Completed,Has Results,Spinal Muscular Atrophy,Drug: Valproic Acid and Levocarnitine|Drug: Placebo,"Safety Labs|Efficacy, Measured Through Motor Function Assessments|Modified Hammersmith Change From Baseline to 6 Months|Quantitative Assessment of SMN mRNA From Blood Samples|Peds QL‚Ñ¢ Assessment: Parental Version (All), Child Versions (> 5yrs)|Max CMAP Amplitude (Mean)|Max CMAP Amplitude Median|Ulnar MUNE|Growth and Vital Sign Parameters|Nutritional Status|DEXA|Max CMAP Area (Mean)|Max CMAP Area (Median)","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 2,94.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13698,September 2005,November 2007,November 2007,"September 27, 2005","May 3, 2011","September 26, 2011",,https://ClinicalTrials.gov/show/NCT00227266,2.0,17.0
3344,624,40.2253569,-82.6881395,"['Ohio', 'United States']",625.0,NCT00227266,Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy,,Completed,Has Results,Spinal Muscular Atrophy,Drug: Valproic Acid and Levocarnitine|Drug: Placebo,"Safety Labs|Efficacy, Measured Through Motor Function Assessments|Modified Hammersmith Change From Baseline to 6 Months|Quantitative Assessment of SMN mRNA From Blood Samples|Peds QL‚Ñ¢ Assessment: Parental Version (All), Child Versions (> 5yrs)|Max CMAP Amplitude (Mean)|Max CMAP Amplitude Median|Ulnar MUNE|Growth and Vital Sign Parameters|Nutritional Status|DEXA|Max CMAP Area (Mean)|Max CMAP Area (Median)","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 2,94.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13698,September 2005,November 2007,November 2007,"September 27, 2005","May 3, 2011","September 26, 2011",,https://ClinicalTrials.gov/show/NCT00227266,2.0,17.0
3345,624,39.4225192,-111.7143584,"['Utah', 'United States']",625.0,NCT00227266,Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy,,Completed,Has Results,Spinal Muscular Atrophy,Drug: Valproic Acid and Levocarnitine|Drug: Placebo,"Safety Labs|Efficacy, Measured Through Motor Function Assessments|Modified Hammersmith Change From Baseline to 6 Months|Quantitative Assessment of SMN mRNA From Blood Samples|Peds QL‚Ñ¢ Assessment: Parental Version (All), Child Versions (> 5yrs)|Max CMAP Amplitude (Mean)|Max CMAP Amplitude Median|Ulnar MUNE|Growth and Vital Sign Parameters|Nutritional Status|DEXA|Max CMAP Area (Mean)|Max CMAP Area (Median)","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 2,94.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13698,September 2005,November 2007,November 2007,"September 27, 2005","May 3, 2011","September 26, 2011",,https://ClinicalTrials.gov/show/NCT00227266,2.0,17.0
3346,624,44.4308975,-89.6884637,"['Wisconsin', 'United States']",625.0,NCT00227266,Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy,,Completed,Has Results,Spinal Muscular Atrophy,Drug: Valproic Acid and Levocarnitine|Drug: Placebo,"Safety Labs|Efficacy, Measured Through Motor Function Assessments|Modified Hammersmith Change From Baseline to 6 Months|Quantitative Assessment of SMN mRNA From Blood Samples|Peds QL‚Ñ¢ Assessment: Parental Version (All), Child Versions (> 5yrs)|Max CMAP Amplitude (Mean)|Max CMAP Amplitude Median|Ulnar MUNE|Growth and Vital Sign Parameters|Nutritional Status|DEXA|Max CMAP Area (Mean)|Max CMAP Area (Median)","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 2,94.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13698,September 2005,November 2007,November 2007,"September 27, 2005","May 3, 2011","September 26, 2011",,https://ClinicalTrials.gov/show/NCT00227266,2.0,17.0
3347,624,52.4760892,-71.8258668,"['Quebec', 'Canada']",625.0,NCT00227266,Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy,,Completed,Has Results,Spinal Muscular Atrophy,Drug: Valproic Acid and Levocarnitine|Drug: Placebo,"Safety Labs|Efficacy, Measured Through Motor Function Assessments|Modified Hammersmith Change From Baseline to 6 Months|Quantitative Assessment of SMN mRNA From Blood Samples|Peds QL‚Ñ¢ Assessment: Parental Version (All), Child Versions (> 5yrs)|Max CMAP Amplitude (Mean)|Max CMAP Amplitude Median|Ulnar MUNE|Growth and Vital Sign Parameters|Nutritional Status|DEXA|Max CMAP Area (Mean)|Max CMAP Area (Median)","University of Utah|Families of Spinal Muscular Atrophy|Leadiant Biosciences, Inc.|Abbott",All,Phase 2,94.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13698,September 2005,November 2007,November 2007,"September 27, 2005","May 3, 2011","September 26, 2011",,https://ClinicalTrials.gov/show/NCT00227266,2.0,17.0
3348,625,25.0375198,121.5636796,"['Taipei', 'Taiwan']",626.0,NCT00155168,Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System,,Unknown status,No Results Available,Spinal Muscular Atrophy,,,National Taiwan University Hospital,All,,500.0,Other,Observational,Observational Model: Case Control|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective,9361700452,April 2004,,,"September 12, 2005",,"September 12, 2005",,https://ClinicalTrials.gov/show/NCT00155168,18.0,100.0
3349,626,25.0375198,121.5636796,"['Taipei', 'Taiwan']",627.0,NCT00154960,Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.,,Unknown status,No Results Available,Spinal Muscular Atrophy|Neonatal Hyperbilirubinemia|Colon Cancer,,,National Taiwan University Hospital,All,,1000.0,Other,Observational,Observational Model: Case Control|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective,9300005565,June 2004,,,"September 12, 2005",,"November 28, 2005",,https://ClinicalTrials.gov/show/NCT00154960,18.0,100.0
3350,627,36.7014631,-118.7559974,"['California', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3351,627,36.7014631,-118.7559974,"['California', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3352,627,32.3293809,-83.1137366,"['Georgia', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3353,627,42.3788774,-72.032366,"['Massachusetts', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3354,627,42.3788774,-72.032366,"['Massachusetts', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3355,627,40.7127281,-74.0060152,"['New York', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3356,627,40.7127281,-74.0060152,"['New York', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3357,627,40.7127281,-74.0060152,"['New York', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3358,627,35.6729639,-79.0392919,"['North Carolina', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3359,627,40.9699889,-77.7278831,"['Pennsylvania', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3360,627,31.8160381,-99.5120986,"['Texas', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3361,627,37.1232245,-78.4927721,"['Virginia', 'United States']",628.0,NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,StrongVoice,Terminated,No Results Available,Neurogenic Dysphonia|Neurogenic Dysphagia,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment|Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty","Merz North America, Inc.|New England Research Institutes|Cmed Clinical Services",All,,146.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METIS M930901001; WI P150999,June 2015,August 2016,September 2016,"July 9, 2015",,"September 9, 2016",,https://ClinicalTrials.gov/show/NCT02493491,18.0,100.0
3362,628,36.7014631,-118.7559974,"['California', 'United States']",629.0,NCT01931644,"Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)",,Recruiting,No Results Available,All Diagnosed Health Conditions,,Biospecimen & Clinical Data Collection,Sanguine Biosciences,All,,20000.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,SAN-BB-01,July 2013,August 2020,December 2040,"August 29, 2013",,"April 18, 2018",,https://ClinicalTrials.gov/show/NCT01931644,18.0,100.0
3363,629,44.4308975,-89.6884637,"['Wisconsin', 'United States']",630.0,NCT00585572,Wisconsin Brain Donor Program,WBDP,Enrolling by invitation,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,,,"University of Wisconsin, Madison|University of Washington",All,,500.0,Other,Observational,Observational Model: Other|Time Perspective: Other,H-2010-0037|H-2014-1484,March 2007,October 2019,October 2019,"January 3, 2008",,"April 8, 2019",,https://ClinicalTrials.gov/show/NCT00585572,18.0,100.0
3364,630,39.5162234,-76.9382069,"['Maryland', 'United States']",631.0,NCT00132353,Training for Diagnosing Neurological Disorders,,Recruiting,No Results Available,Musculoskeletal Physiology,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,400.0,NIH,Observational,Observational Model: Other|Time Perspective: Other,050223|05-N-0223,"November 4, 2005",,,"August 19, 2005",,"June 10, 2019",,https://ClinicalTrials.gov/show/NCT00132353,18.0,120.0
3365,631,39.5162234,-76.9382069,"['Maryland', 'United States']",632.0,NCT00080600,Brain Physiology in Polio Survivors,,Completed,No Results Available,Postpoliomyelitis,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,90.0,NIH,Observational,,040156|04-N-0156,"April 6, 2004",,"December 10, 2007","April 7, 2004",,"July 2, 2017",,https://ClinicalTrials.gov/show/NCT00080600,21.0,80.0
3366,631,39.5162234,-76.9382069,"['Maryland', 'United States']",632.0,NCT00080600,Brain Physiology in Polio Survivors,,Completed,No Results Available,Postpoliomyelitis,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,,90.0,NIH,Observational,,040156|04-N-0156,"April 6, 2004",,"December 10, 2007","April 7, 2004",,"July 2, 2017",,https://ClinicalTrials.gov/show/NCT00080600,21.0,80.0
